<SEC-DOCUMENT>0001000694-24-000035.txt : 20240808
<SEC-HEADER>0001000694-24-000035.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808073707
ACCESSION NUMBER:		0001000694-24-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		241186085

	BUSINESS ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nvax-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24,d:a1cce1d42cea40b398b487e7aaa3b078-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:nvax="http://www.novavax.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-25">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-28">0001000694</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-29">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-209" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-743">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-257" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-933">246</ix:nonNumeric><ix:nonNumeric contextRef="c-263" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-934">233</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>nvax:segment</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>nvax:security</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="dose"><xbrli:measure>nvax:dose</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>nvax:installment</xbrli:measure></xbrli:unit><xbrli:unit id="reporting_unit"><xbrli:measure>nvax:reporting_unit</xbrli:measure></xbrli:unit><xbrli:unit id="defendant"><xbrli:measure>nvax:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>nvax:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nvax:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nvax:AustraliaRevenueAgencyMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:NewZealandTerminationOfTheAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nvax:NewZealandRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:NewZealandTerminationOfTheAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensedCOVID19ProductsAndRoyaltyPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfEMAApprovalOfTheCOVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:DatabaseLockOfAnExistingPhase23ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CICProductRelatedDevelopmentAndLaunchMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:FirstFourAdjuvantProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:AdjuvantProductsThereafterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:ClinicalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CostReimbursementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesMedicalResearchInstituteArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-04</xbrli:startDate><xbrli:endDate>2023-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-05</xbrli:startDate><xbrli:endDate>2024-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from          to           .</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-26770</ix:nonNumeric></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">NOVAVAX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:23.567%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.271%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">700 Quince Orchard Road,</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Gaithersburg,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" id="f-11">MD</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">20878</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">(240)</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">268-2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric>&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant's Common Stock, $0.01 par value, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">160,093,639</ix:nonFraction> as of July&#160;31, 2024.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.758%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_13">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_16">Unaudited Consolidated Statements of Operations and Unaudited Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_19">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_19">Ju</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_19">ne 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_19">, 2024 (unaudited) and December 31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_22">Unaudited Consolidated Statements of Changes in Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_22">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_22"> for the three and six months ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_28">Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_31">Notes to the Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_88">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_88">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_124">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_124">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_127">42</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_130">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_130">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_133">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_136">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_136">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_142">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_142">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_145">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_145">49</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_148">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia1cce1d42cea40b398b487e7aaa3b078_148">50</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_13"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-30">19,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-31">285,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-32">102,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-33">277,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing, royalties, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-34">395,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-35">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-36">407,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-37">3,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-39">137,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-41">224,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-42">415,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-43">424,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-44">509,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-45">505,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-46">46,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-47">55,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-48">105,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-49">89,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-50">106,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-51">219,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-52">199,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-53">466,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-54">101,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-55">93,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-56">188,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-57">206,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-58">254,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-59">368,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-60">493,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-61">762,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-62">160,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-63">55,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-64">16,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-65">257,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-66">4,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-67">3,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-68">8,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-69">7,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-70">7,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-71">5,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-72">11,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-73">29,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income tax expense (benefit)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-74">164,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-75">57,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-76">19,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-77">234,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-78">2,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-79">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-80">4,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-81">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-82">162,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-83">58,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-84">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-85">235,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-86">1.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-87">0.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-88">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-89">2.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-90">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-91">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-92">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-93">2.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-94">148,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-95">89,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-96">144,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-97">87,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-98">165,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-99">104,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-100">145,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-101">87,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-102">162,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-103">58,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">235,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale marketable securities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-106">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-108">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-110">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-111">5,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-112">13,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-113">1,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-114">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-115">5,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-116">13,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-117">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-118">162,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-119">52,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-120">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-121">237,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia1cce1d42cea40b398b487e7aaa3b078_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share information)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-122">680,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-123">568,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-124">369,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-126">10,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-127">10,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-128">32,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-129">297,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-130">9,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-131">41,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-132">102,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-133">226,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-134">1,203,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-135">1,143,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-136">288,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-137">305,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-138">169,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-139">185,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-140">123,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-141">127,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-142">33,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">35,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-144">1,818,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-145">1,797,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-146">79,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-147">132,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-148">159,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-149">394,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-150">666,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">241,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-152">9,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-153">5,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-154">242,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-155">861,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-156">1,157,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">1,635,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">533,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-159">622,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-160">168,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-161">168,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-162">54,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">55,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">335,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-165">33,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-166">2,250,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">2,514,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 15)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-18" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-168"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-169"/></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-171">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-172"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-173">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-175"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-177">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2024 and December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' deficit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-180"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-181">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-182"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-183">600,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-184">161,267,120</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-185">159,891,014</ix:nonFraction> shares outstanding at June&#160;30, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-186">140,506,093</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-187">139,505,770</ix:nonFraction> shares outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-188">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-189">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-190">4,477,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-191">4,192,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-192">4,806,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-193">4,820,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, cost basis, <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-194">1,376,106</ix:nonFraction> shares at June&#160;30, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-195">1,000,323</ix:nonFraction> shares at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-196">94,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-197">92,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-198">10,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-199">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">431,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">716,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">1,818,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">1,797,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three and Six Months Ended June&#160;30, 2024 and 2023</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:19.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.676%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deficit</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-204">141,700,972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">1,417</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">4,204,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">4,968,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">93,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">10,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">867,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">14,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-212">14,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-213">472,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-214">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-215">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-216">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-217">2,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance cost</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">s of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-218">3,830</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-219">19,093,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-220">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-221">256,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-222">256,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-223">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-224">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-225">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-226">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">162,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">162,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-229">161,267,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">1,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">4,477,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">4,806,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">94,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">10,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">431,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-236">87,139,831</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-237">871</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-238">3,767,733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">4,569,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">91,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">3,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">895,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">20,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-244">20,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-245">95,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-246">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-247">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-248">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-249">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-250">861</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-251">7,947,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-252">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-253">67,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-254">67,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-255">5,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-256">5,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">58,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-258">58,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-259">95,183,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-260">952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">3,855,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">4,511,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">91,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">8,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">754,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_25"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.582%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deficit</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-266">140,506,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-267">1,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">4,192,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">4,820,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">92,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">2,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">716,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-273">25,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-274">25,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-275">1,667,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-276">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-277">3,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-278">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-279">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-280">3,830</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-281">19,093,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-282">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-283">256,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-284">256,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-285">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-286">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-287">13,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-288">13,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-290">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">161,267,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">1,613</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">4,477,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">4,806,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">94,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">10,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">431,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-298">86,806,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-299">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-300">3,737,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-301">4,275,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-302">90,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-303">6,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-304">634,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-305">48,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-306">48,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-307">429,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-308">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-309">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-310">765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-311">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-312">861</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-313">7,947,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-314">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-315">67,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-316">67,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-317">1,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-318">1,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-319">235,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-320">235,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-321">95,183,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-322">952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-323">3,855,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-324">4,511,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-325">91,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-326">8,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-327">754,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_28"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-328">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-329">235,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reconciliation of net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-330">23,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-331">19,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-332">25,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-333">48,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for excess and obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:num-dot-decimal" scale="3" id="f-334">18,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:num-dot-decimal" scale="3" id="f-335">31,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-336">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-337">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-338">2,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-339">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-340">14,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-341">19,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-342">390,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-343">266,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-344">366,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-345">443,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-346">111,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-347">357,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-348">230,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">497,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="f-350">9,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="f-351">26,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of available-for-sale marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-352">369,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForSoftware" scale="3" id="f-354">622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-355">4,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-356">379,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-357">31,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from sales of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-358">263,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-359">61,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from the exercise of stock-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" format="ixt:num-dot-decimal" scale="3" id="f-360">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" scale="3" id="f-361">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-362">726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-363">26,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of 2023 Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-365">325,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of costs related to issuance of 2027 Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-367">3,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-368">264,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-369">293,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">3,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-371">8,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-372">111,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-373">830,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-374">583,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-375">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-376">695,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-377">517,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock under the Sales Agreement not settled at quarter-end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-379">5,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset leases, net of tenant improvement allowance on facility leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-380">8,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-382">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-383">6,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash interest payments, net of amounts capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-384">7,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-385">11,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-386">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-387">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_34"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-388" continuedAt="f-388-1" escape="true">Organization and Business</ix:nonNumeric></span></div><ix:continuation id="f-388-1"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a global company that is advancing protein-based vaccines with its Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> adjuvant. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology, and patented Matrix-M&#8482; adjuvant to enhance the immune response. In May 2024, Novavax entered into a collaboration and licensing agreement (the &#8220;Collaboration and License Agreement&#8221; or &#8220; Sanofi CLA&#8221;) with Sanofi Pasteur Inc. (&#8220;Sanofi&#8221;) to co-commercialize Novavax&#8217;s current standalone COVID-19 vaccines (&#8220;COVID-19 Vaccine&#8221;), including Novavax&#8217;s Nuvaxovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, prototype COVID-19 vaccine (&#8220;NVX-CoV2373,&#8221; or &#8220;prototype vaccine&#8221;) and XBB COVID-19 vaccine  (&#8220;NVX-CoV2601&#8221;), and the Company&#8217;s updated vaccine for the 2024-2025 vaccination season (&#8220;NVX-CoV2705,&#8221; or &#8220;updated vaccine&#8221; and, collectively with NVX-CoV2373 and NVX-CoV2601, the Company&#8217;s &#8220;COVID-19 Vaccine&#8221; or &#8220;COVID-19 Program&#8221;). This agreement is discussed in greater detail in Note 6 of Novavax&#8217;s consolidated financial statements. The partnership with Sanofi allows Novavax to broaden access to its vaccine and adjuvant and refocus on clinical-stage research and development and pipeline expansion beginning in 2025.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through the end of the 2024-2025 vaccination season, Novavax will continue commercialization of its COVID-19 Vaccine.  Local regulatory authorities have also specified nomenclature for the labeling of NVX-CoV2373 and NVX-CoV2601 within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;, &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula),&#8221; respectively, for the U.S., and &#8220;Nuvaxovid&#8482;&#8221; for ex-US territories) collectively referred to as the Company&#8217;s &#8220;COVID-19 Program,&#8221; or &#8220;COVID-19 Vaccine&#8221;). </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, the Company has submitted an amendment to the previously granted October 2023 Emergency Use Authorization (&#8220;EUA&#8221;) to the U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;), filed for a type II variation of the existing Marketing Authorization (&#8220;MA&#8221;) with the European Medicines Agency (&#8220;EMA&#8221;) and the United Kingdom's (&#8220;U.K.&#8221;) Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), and filed for authorization with Health Canada for the Company&#8217;s updated vaccine. Currently, the Company significantly depends on its supply agreement with Serum Institute of India Pvt. Ltd. (&#8220;SII&#8221;) and its subsidiary, Serum Life Sciences Limited (&#8220;SLS&#8221; and together with SII, &#8220;Serum&#8221;), for co-formulation, filling, and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID-19-Influenza Combination (&#8220;CIC&#8221;) and stand-alone influenza vaccine candidates. In addition, Novavax&#8217;s adjuvant is included in the University of Oxford and SII&#8217;s R21/Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">malaria vaccine which has received authorizations in a number of countries with doses administered in 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax&#8217;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#8217;s proprietary Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;2&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-389" continuedAt="f-389-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-390" continuedAt="f-390-1" escape="true"><ix:continuation id="f-389-1" continuedAt="f-389-2"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive income (loss), changes in stockholders&#8217; deficit, and cash flows for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were a $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-391">1.6</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-392">6.7</ix:nonFraction>&#160;million loss, and a $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-393">0.2</ix:nonFraction>&#160;million loss and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-394">16.1</ix:nonFraction>&#160;million gain for the three and six months ended June&#160;30, 2024 and 2023, respectively, which are reflected in Other income (expense).</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-389-2" continuedAt="f-389-3"><ix:continuation id="f-390-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2023. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-395">one</ix:nonFraction> business segment.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="nvax:LiquidityAndGoingConcernPolicyTextBlock" id="f-396" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span id="id646a6b9d9154d26bde005a7bb4415f3_15397"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA and a securities subscription agreement (the &#8220;Subscription Agreement&#8221;) with Sanofi as a result of which, the Company received a total of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="nvax:ProceedsFromCollaborationAndLicenseAgreement" scale="6" id="f-397">568.8</ix:nonFraction> million during the second quarter of 2024 (See Note 6).  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-398">680.2</ix:nonFraction> million in cash and cash equivalents, $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-399">369.4</ix:nonFraction> million in marketable securities, and working capital of $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="nvax:WorkingCapital" scale="6" id="f-400">45.6</ix:nonFraction> million. During the six months ended June&#160;30, 2024, the Company recognized net income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-401">14.8</ix:nonFraction> million, and had net cash flows provided by operating activities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-402">230.7</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Based on the Company&#8217;s current cash and cash equivalents and marketable securities balances and its current cash flow forecast for the one-year going concern look forward period, the Company has concluded that it will have sufficient capital available to fund its operations for the one-year period from the date that these financial statements are issued. As of December 31, 2023, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to significant uncertainty related to its ability to successfully develop, manufacture, distribute, and market its updated vaccine and execute on certain cost-reduction initiatives as described in Note 16. The Sanofi CLA has alleviated the substantial doubt.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Licensing and Transition Services</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s third-party licensing agreements may contain multiple performance obligations, including licenses and transition services. The Company evaluates licensing agreements under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;) to determine the distinct performance obligations. Prior to recognizing revenue, the Company estimates the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-389-3"><ix:continuation id="f-403-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple performance obligation arrangements, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, the Company considers discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, the Company applies judgment in determining the forecasted revenue, expected margins, and the discount rate. These estimates are subjective and require the Company to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset. For performance obligations recognized over time, the Company recognizes revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, the Company considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, and indirect administrative costs. Estimating the total cost at completion of the Company&#8217;s performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on the Company&#8217;s contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. The Company has not experienced any material adjustments as a result of changes in estimates arising from this process.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-404" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="f-405" continuedAt="f-405-1" escape="true"><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-405-1">The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities, and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 for additional information on the severance and employee benefit costs for terminated employees and impairment of assets in connection with the Company&#8217;s Restructuring Plan as defined in Note 16.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-406" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-407" continuedAt="f-407-1" escape="true">Marketable Securities </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-408" escape="true"><ix:continuation id="f-407-1" continuedAt="f-407-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities were classified as available-for-sale as of June&#160;30, 2024 and comprised of (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-409">369,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-411">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-412">369,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-417">369,582</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-419">150</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-420">369,432</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-407-2">As of June&#160;30, 2024, investments in marketable securities, comprising corporate debt securities, were due to mature within one year. Based on the Company&#8217;s policy under the expected credit loss model, including an assessment of unrealized losses on the portfolio as of June 30, 2024, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more-likely-than-not to hold these investments for a period of time sufficient for a recovery of the Company&#8217;s cost basis. As of June&#160;30, 2024, the Company held <ix:nonFraction unitRef="security" contextRef="c-18" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="f-425">no</ix:nonFraction> securities that were in an unrealized loss position for more than 12 months.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_55"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-426" continuedAt="f-426-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-426-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="f-427" continuedAt="f-427-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-428">188,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-431">171,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-435">225,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-438">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-444">45,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-447">601,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-452">188,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-453">826,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-455">171,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-456">245,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-458">5.00</ix:nonFraction>% Convertible notes due 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-460">217,587</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-463">100,909</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as cash and cash equivalents as of June 30, 2024 and December 31, 2023, respectively, on the consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-427-1" continuedAt="f-427-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:continuation id="f-427-2">Includes $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-465">232.0</ix:nonFraction> million classified as Cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-466">369.4</ix:nonFraction>&#160;million classified as marketable securities as of June&#160;30, 2024, on the consolidated balance sheets.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics. Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six&#160;months ended June&#160;30, 2024 and 2023, the Company did not have any transfers between levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-467" continuedAt="f-467-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-467-1" continuedAt="f-467-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-468">29.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-469">286.4</ix:nonFraction> million related to amounts that were billed to customers and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-470">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-471">10.8</ix:nonFraction> million related to amounts which had not yet been billed to customers as of June&#160;30, 2024 and December&#160;31, 2023, respectively. <ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" id="f-472" continuedAt="f-472-1" escape="true">During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#8217;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-472-1" continuedAt="f-472-2"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-473">304,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="f-474">672,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-475">937,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-476">39,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-477">96,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="f-478">793,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-479">486,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-480">402,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-481">7,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-484">7,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-485">13,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-487">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-488">7,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-489">863,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-490">365,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="f-491">28,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-492">1,199,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-493">549,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-494">414,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="f-495">56,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-496">907,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;There was <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="0" id="f-497"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="0" id="f-498"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="0" id="f-499"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:fixed-zero" scale="0" id="f-500">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" scale="6" id="f-501">6.2</ix:nonFraction> million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-472-2">(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="6" id="f-502">2.2</ix:nonFraction>&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-503">225.0</ix:nonFraction>&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties and constrained variable consideration, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-9" name="nvax:RemainingPerformanceObligationAmount" scale="9" id="f-504">2</ix:nonFraction> billion, of which $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="f-505">1.2</ix:nonFraction>&#160;billion was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront and other payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on the timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request the Company&#8217;s updated vaccine under certain of the Company&#8217;s APAs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an APA with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;), entered into in May 2021 (the &#8220;Gavi APA&#8221;), the Company received upfront payments of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentAmount" scale="6" id="f-506">700</ix:nonFraction>&#160;million from Gavi (the &#8220;Advance Payment Amount&#8221;) to be applied against purchases of the Company&#8217;s prototype vaccine by certain countries participating in the COVAX Facility. As of December&#160;31, 2023, the remaining Gavi Advance Payment Amount was $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-507">696.4</ix:nonFraction>&#160;million. In February 2024, the Company entered into a Termination and Settlement Agreement with Gavi (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under, or otherwise in connection with the Gavi APA. On February 22, 2024, the claims and counterclaims were dismissed with prejudice. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-508">75</ix:nonFraction>&#160;million, which the Company paid in February 2024, and (ii) deferred payments, in equal annual amounts of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-509">80</ix:nonFraction>&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments and total $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-510">400</ix:nonFraction>&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-467-2" continuedAt="f-467-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-511">225</ix:nonFraction>&#160;million that may be applied against qualifying sales of any of the Company&#8217;s vaccines for supply to such low-income and lower-middle income countries that exceed the $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-512">80</ix:nonFraction>&#160;million deferred payment amount in any calendar year during the deferred payment term. In total, the Gavi settlement agreement is comprised of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentAmount" scale="6" id="f-513">700</ix:nonFraction> million of potential consideration, consisting of the $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-514">75</ix:nonFraction>&#160;million initial settlement payment, deferred payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-515">400</ix:nonFraction>&#160;million that may be reduced through annual vaccine credits, and the additional credit of up to $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-516">225</ix:nonFraction>&#160;million that may be applied for certain qualifying sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-517">3.6</ix:nonFraction>&#160;million difference between the refund liability recorded as of December&#160;31, 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-518">696.4</ix:nonFraction>&#160;million and the $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentAmount" scale="6" id="f-519">700</ix:nonFraction> million of total consideration under the arrangement as a reduction to revenue during the six months ended June&#160;30, 2024. As of June&#160;30, 2024, the remaining amounts included on the Company&#8217;s consolidated balance sheet were  $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-520">225</ix:nonFraction>&#160;million in non-current Deferred revenue for the additional credit that may be applied against future qualifying sales, $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-521">90</ix:nonFraction>&#160;million in Other current liabilities, and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-522">305</ix:nonFraction>&#160;million in Other non-current liabilities. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SII under the SII R21 Agreement (see Note 6), which will continue for the deferred payment term of the Gavi Settlement Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-523" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:34.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-524">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-526">4,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-528">169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-529">1,518</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-530">90,586</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-531">58,785</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-532">18,128</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-533">283,645</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-534">16,397</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-535">218,921</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-536">19,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-537">285,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-538">102,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-539">277,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). Product sales in the U.S. are recorded net of gross-to-net deductions. During the six months ended June&#160;30, 2024, product sales in North America includes $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-540">4.8</ix:nonFraction>&#160;million of gross-to-net deductions in excess of the WAC, primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales, partially offset by updates to estimated product returns. During the six months ended June&#160;30, 2024, product sales for the rest of the world includes a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-541">3.6</ix:nonFraction>&#160;million reduction to revenue recognized pursuant to the Gavi Settlement Agreement as discussed above. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" id="f-542" continuedAt="f-542-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-543">21,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-544">84,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-545">105,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-546">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-547">21,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-548">36,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits/deductions </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-549">35,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-550">51,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-551">86,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of June&#160;30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-552">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-553">54,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-554">55,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-542-1">(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="6" id="f-555">4.0</ix:nonFraction>&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns.</ix:continuation> </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 <ix:nonFraction unitRef="usd" contextRef="c-143" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-556">no</ix:nonFraction> gross-to-net deductions were included in Accounts receivable. As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-557">2.6</ix:nonFraction> million of gross-to-net deductions were included in Accounts receivable. As of June&#160;30, 2024 and December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-558">55.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-559">103.1</ix:nonFraction> million of gross-to-net deductions were included in Accrued expenses, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the Commonwealth of Australia (&#8220;Australia&#8221;) for the purchase of doses of COVID-19 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-467-3" continuedAt="f-467-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine (the &#8220;Australia APA&#8221;). In March 2024, the Company and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-560">54.0</ix:nonFraction> million, including $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="nvax:SettlementPayment" scale="6" id="f-561">6.0</ix:nonFraction> million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until the Company receives authorization from Therapeutic Goods Administration (&#8220;TGA&#8221;). The Company does not expect approval in time for product delivery in 2024 which could result in a loss or deferral of approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-562">240</ix:nonFraction> million of contract value. The Company plans to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-563">119.1</ix:nonFraction> million was classified as current Deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-564">14.7</ix:nonFraction> million was classified as non-current Deferred revenue with respect to the Australia APA in the Company&#8217;s consolidated balance sheet.  If the Company is unable to satisfy its obligations under the Australia APA, $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-565">92.5</ix:nonFraction> million of deferred revenue may become refundable and approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:CustomerRefundLiabilityCurrent" scale="6" id="f-566">225</ix:nonFraction> million of remaining funds under the contract may no longer be available.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not anticipate achieving regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, the Company plans to seek an amendment to the Canada APA to address possible alternatives, which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-567">452.1</ix:nonFraction>&#160;million was classified as current Deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-568">136.1</ix:nonFraction>&#160;million was classified as non-current Deferred revenue with respect to the Canadian APA in the Company&#8217;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-569">28.0</ix:nonFraction>&#160;million of the deferred revenue would become refundable and approximately $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-570">224</ix:nonFraction>&#160;million of the contract value related to future deliverables would no longer be available. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Pharmaceutical Management Agency (&#8220;Pharmac&#8221;), a New Zealand Crown entity, provided notice of its termination of its APA (the &#8220;New Zealand APA&#8221;). As of June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-571">31.3</ix:nonFraction>&#160;million was classified as current Deferred revenue with respect to such agreement in the Company&#8217;s consolidated balance sheet. New Zealand has requested a refund of certain advanced payments and the Company is in discussion with Pharmac on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both, whether its termination of the New Zealand APA was appropriate under the New Zealand APA, and whether a refund of the advanced payments is appropriate under the New Zealand APA. Ap</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proximately $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-572">125</ix:nonFraction>&#160;million of the contract value related to future deliverables may no longer be available if the APA is terminated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing, Royalties, and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, royalties, and other includes Licensing payments, Transition Services revenue, and Technology Transfer revenue from the Company&#8217;s Collaboration and License Agreement with Sanofi (&#8220;Sanofi CLA&#8221;); royalty milestone payments; sales-based royalties; and Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024, respectively, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-573">386.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-574">390.3</ix:nonFraction>&#160;million in revenue related to license fees and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-575">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-576">10.2</ix:nonFraction>&#160;million in revenue related to Matrix-M&#8482; adjuvant sales, respectively. During the three and six months ended June&#160;30, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-577"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-578">6.6</ix:nonFraction></ix:nonFraction>&#160;million of Transition Services revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June&#160;30, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-579">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-580">3.2</ix:nonFraction>&#160;million in revenue related to Matrix-M&#8482; adjuvant sales. During the three and six months ended June&#160;30, 2023, the Company did not recognize revenue related to license fees or milestone payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-467-4" continuedAt="f-467-5">The Company&#8217;s U.S. government agreement consisted of a Project Agreement (the &#8220;Project Agreement&#8221;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#8220;USG Agreement&#8221;). As of December&#160;31, 2023, the Company recognized the full $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="9" id="f-581">1.8</ix:nonFraction>&#160;billion funding in revenue.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8211; <ix:continuation id="f-467-5" continuedAt="f-467-6">Collaboration, License, and Supply Agreements </ix:continuation></span></div><ix:continuation id="f-467-6" continuedAt="f-467-7"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the Company&#8217;s material collaborations, license and supply agreements were as follows: </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously granted SII exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, NVX-CoV2601, its updated vaccine, and its CIC vaccine candidate. SII agreed to purchase the Company's Matrix-M&#8482; adjuvant and the Company granted SII a non-exclusive license to manufacture the antigen drug substance component of the Company&#8217;s COVID-19 Vaccine in SII&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SII equally split the revenue from SII&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. In May 2024, the Company and SLS entered into a supply agreement (the &#8220;SLS Supply Agreement&#8221;) under which SLS will supply the Company with antigen drug substance and finished COVID-19 Vaccine doses. The SLS Supply Agreement includes the general terms and conditions of supply orders between the Company and SLS. The Company and SLS intend to execute statements of work and firm purchase orders to included specific quantities to be delivered under the SLS Supply Agreement. The Company will supply SLS with all Matrix-M&#8482; adjuvant needed to manufacture  finished COVID-19 Vaccine doses. In March 2020, the Company entered into an agreement with SII that granted SII a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant (&#8220;SII R21 Agreement&#8221;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). In December 2023, R21/Matrix-M&#8482; received prequalification by the World Health Organization (&#8220;WHO&#8221;). Under the SII R21 Agreement, SII purchases the Company's Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of <ix:nonNumeric contextRef="c-15" name="nvax:RoyaltyPeriod" format="ixt-sec:duryear" id="f-582">15</ix:nonNumeric> years after the first commercial sale of the vaccine in each country. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of <ix:nonFraction unitRef="dose" contextRef="c-165" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-583">150</ix:nonFraction>&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA under which the Company granted and Sanofi received the following: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i)&#160;&#160;&#160;&#160;A co-exclusive license to commercialize the Company&#8217;s current stand-alone COVID-19 Vaccine, including the Company&#8217;s prototype vaccine and updated vaccines, that address seasonal variants throughout the world (the &#8220;COVID-19 Vaccine Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)&#160;&#160;&#160;&#160;A sole license to develop and commercialize combination products containing a potential combination of the Company&#8217;s COVID-19 Vaccine and Sanofi&#8217;s seasonal influenza vaccine (&#8220;COVID-19 and influenza Combination Products&#8221; or &#8220;CIC Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize combination products containing both the Company&#8217;s COVID-19 Vaccine and one or more non-influenza vaccines (&#8220;Other Combination Products&#8221; and together with the COVID-19 Vaccine Products, CIC Products, and Other Combination Products, &#8220;Licensed COVID-19 Products&#8221;); and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize other vaccine products selected by Sanofi that include the Company&#8217;s Matrix-M&#8482; adjuvant (as described below, the &#8220;Adjuvant Products&#8221;). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-467-7" continuedAt="f-467-8"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also responsible for performing services related to the technology transfer of its manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; components to Sanofi. Until the successful completion of such transfer, the Company will supply Sanofi with both COVID-19 Vaccine Products and Matrix-M&#8482; intermediary components for Sanofi&#8217;s use and is eligible for reimbursement of such costs from Sanofi. In addition, the Company is responsible for certain research and development and medical affairs services related to the COVID-19 Vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sanofi CLA, the Company will continue to commercialize its updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, Sanofi and the Company will commercialize the COVID-19 Vaccine Products worldwide in accordance with a commercialization plan agreed by the Company and Sanofi, under which the Company will continue to supply its existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, the Company and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sanofi CLA, the Company received a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-584">500</ix:nonFraction>&#160;million in the second quarter of 2024. In addition, the Company will also be eligible to receive development, technology transfer, launch, and sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" scale="6" id="f-585">700</ix:nonFraction> million in the aggregate with respect to the COVID-19 Vaccine Products and royalty payments on Sanofi&#8217;s sales of such licensed products. Milestone payments are comprised of a payment of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-586">175</ix:nonFraction>&#160;million upon the approval of the marketing authorization for a COVID-19 Vaccine Product in a pre-filled syringe from the FDA, $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-587">25</ix:nonFraction>&#160;million upon the transfer of such approval to Sanofi, $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-588">25</ix:nonFraction>&#160;million upon the transfer of EMA approval of a COVID-19 Vaccine Product in a pre-filled syringe to Sanofi, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-589">50</ix:nonFraction>&#160;million upon database lock of an existing Phase 2/3 clinical trial (identifier 2019nCoV-503), $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-590">75</ix:nonFraction>&#160;million upon the completion of the technology transfer of the Company&#8217;s manufacturing process for the COVID-19 Vaccine Products to Sanofi, and up to $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" format="ixt:num-dot-decimal" scale="6" id="f-591">350</ix:nonFraction>&#160;million in CIC Product-related development and launch milestones.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive development, launch, and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" scale="6" id="f-592">200</ix:nonFraction> million for each of the first four Adjuvant Products and $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" scale="6" id="f-593">210</ix:nonFraction> million for each Adjuvant Product thereafter, and royalty payments on Sanofi&#8217;s sales of all such licensed products. In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, a portion of the technology transfer costs and research and development costs incurred by the Company will be reimbursed by Sanofi in accordance with agreed upon plans and budgets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed whether the Sanofi CLA fell within the scope of ASC 808,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) based on whether the arrangement involved joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. The Company determined that the Sanofi CLA did not fall within the scope of ASC 808, as the Company does not share in the significant financial risks of Sanofi's development or commercialization activities. The Company then analyzed the arrangement pursuant to the provisions of ASC 606 and determined that the arrangement represents a contract with a customer and is therefore within the scope of ASC 606.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations in the Sanofi CLA and determined that they were within the scope of ASC 606: delivery of (i) the licenses described above (the COVID-19 Vaccine license, CIC Products license, Other Combination Product license, and Adjuvant Products license) (collectively the &#8220;Sanofi CLA Licenses&#8217;), (ii) research and development transition services that support further regulatory approval and development of the COVID-19 Vaccine, referred to as the Sanofi Transition Services, and (iii) technology transfer of the existing manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; adjuvant, referred to as the &#8220;Sanofi Technology Transfer&#8221;. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Sanofi and therefore are not considered separate performance obligations within the Sanofi CLA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sanofi CLA Licenses performance obligations are considered functional intellectual property and distinct from other promises under the contract as Sanofi can benefit from the licenses on their own or together with other readily available resources. Also, the Sanofi Transition Services provide a distinct benefit to Sanofi within the context of the contract, separate from the licenses, as the services could be provided by Sanofi or another third party without the Company&#8217;s assistance. The Sanofi Technology Transfer obligation is distinct as Sanofi can benefit from the Sanofi CLA Licenses transferred by the Company at the inception of the agreement with other readily available resources. Therefore, each represents a separate performance obligation within the contract with a customer under the scope of ASC 606 at contract inception.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-467-8" continuedAt="f-467-9"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price at inception of the Sanofi CLA to be $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="nvax:CollaborationAgreementInitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-594">620.2</ix:nonFraction>&#160;million, consisting of (i) fixed consideration (the $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentAmount" scale="6" id="f-595">500</ix:nonFraction> million upfront nonrefundable fee), (ii) and $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="nvax:CollaborationAgreementVariableConsideration" format="ixt:num-dot-decimal" scale="6" id="f-596">120.2</ix:nonFraction>&#160;million of variable consideration attributed to a $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-597">50.0</ix:nonFraction>&#160;million clinical milestone and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-598">70.2</ix:nonFraction>&#160;million of estimated cost reimbursement related to Sanofi Transition Services and Sanofi Technology Transfer. Since the clinical milestone allocated to Sanofi Transition Services is entirely within the Company&#8217;s control, and the cost reimbursement variable consideration allocated to Sanofi Transition Services and Sanofi Technology Transfer would be recognized as revenue only as the costs are incurred, the Company determined it is not probable that a significant reversal of cumulative revenue would occur. The Company utilized the expected value method to determine the amount of these payments. The Company excluded certain regulatory and technology transfer milestones from the transaction price that were determined to be inherently uncertain of achievement and are highly susceptible to factors outside of the Company&#8217;s control. Sales-based royalties and launch milestones are related to the license of the intellectual property rights and the Company will recognize revenue for these in the period when subsequent sales are made or sale-based milestones are achieved pursuant to the sales-based royalty exception under ASC 606. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the fixed consideration (i.e., the $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="nvax:CollaborationAgreementUpfrontPaymentAmount" scale="6" id="f-599">500</ix:nonFraction> million nonrefundable upfront fee) to the performance obligations in the Sanofi CLA based on each performance obligation&#8217;s relative standalone selling price, or SSP, as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-600">386.3</ix:nonFraction>&#160;million for the upfront transfer of the licenses; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-601">110.2</ix:nonFraction>&#160;million for Transition Services; and</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-602">3.5</ix:nonFraction>&#160;million for Technology Transfer. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SSP for the licenses were determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. In developing such estimates, the Company applied judgment in determining the forecasted revenues, expected margins, and the discount rate. The SSP for the ongoing Transition Services and Technology Transfer were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue related to the licenses at a point in time upon transfer of the rights and control of the license to Sanofi during the second quarter 2024. The Sanofi Transition Services and Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Technology Transfer for the three and six month period ended June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-603"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-604">6.6</ix:nonFraction></ix:nonFraction>&#160;million. The Company&#8217;s consolidated balance sheet as of June&#160;30, 2024 includes a deferred revenue balance of $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="f-605">109.2</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-606">50.9</ix:nonFraction>&#160;million included in Deferred revenue, current portion and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-607">58.3</ix:nonFraction>&#160;million included in Deferred revenue, non-current portion) related to Transition Services and Technology Transfer.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an asset for $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-608">35.0</ix:nonFraction>&#160;million of direct costs incurred to obtain the Sanofi CLA. These costs are amortized to expense over the expected period of the benefit in a manner that is consistent with the transfer of the related goods and services in the Sanofi CLA. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-609">27.1</ix:nonFraction>&#160;million of amortization expense related to the asset in Selling, general, and administrative expense in the second quarter of 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-610">6,880,481</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-611">0.01</ix:nonFraction> per share at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-612">10.00</ix:nonFraction> per share for aggregate gross proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-613">68.8</ix:nonFraction> million. The opening price of the Company&#8217;s common stock on the date of the sale approximated $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-614">10.00</ix:nonFraction> per share and therefore all gross proceeds were allocated to stockholders&#8217; deficit. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Medical Research Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into a <ix:nonNumeric contextRef="c-186" name="nvax:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-615">three-year</ix:nonNumeric> agreement with the Bill &amp; Melinda Gates Medical Research </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-467-9"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute to provide the Company&#8217;s Matrix-M&#8482; adjuvant for use in preclinical vaccine research. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;) and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;) to resolve disputes regarding amounts that Fujifilm claimed were due under a prior Confidential Settlement Agreement and Release effective September 30, 2022 (the &#8220;CSAR&#8221;) by and between the Company and Fujifilm.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CSAR, the Company agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="nvax:SettlementPayment" scale="6" id="f-616">185.0</ix:nonFraction> million to Fujifilm in connection with the cancellation of manufacturing activity at FDBT. The final <ix:nonFraction unitRef="installment" contextRef="c-122" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-617">two</ix:nonFraction> quarterly installments due to Fujifilm in 2023 under the CSAR, totaling $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="nvax:SettlementPayment" scale="6" id="f-618">68.6</ix:nonFraction> million, were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT. In October 2023, the Company sent Fujifilm a notice of breach and refused to pay the final <ix:nonFraction unitRef="installment" contextRef="c-122" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-619">two</ix:nonFraction> installments based on its contention that Fujifilm had not used commercially reasonable efforts to mitigate losses and should have offset some portion of the final <ix:nonFraction unitRef="installment" contextRef="c-122" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-620">two</ix:nonFraction> payments. In October 2023, Fujifilm filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the full amount (the &#8220;Fujifilm Arbitration&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement, in March 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="nvax:SettlementPayment" scale="6" id="f-621">42.0</ix:nonFraction> million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the CSAR, and Fujifilm agreed to dismiss the Fujifilm Arbitration. This payment is less than amounts previously accrued for and reflected in Research and development expense, and accordingly, the Company recorded a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-622">26.6</ix:nonFraction> million as Research and development expense during the six months ended June&#160;30, 2024 upon the execution of the Settlement Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Program, and in doing so, recognizes that significant costs may be incurred.</span></div></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-623" continuedAt="f-623-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-624" escape="true"><ix:continuation id="f-623-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share data):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-625">162,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-626">58,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-627">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-628">235,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-629">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-630">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAttributableToParentDiluted" format="ixt:num-dot-decimal" scale="3" id="f-631">164,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAttributableToParentDiluted" format="ixt:num-dot-decimal" scale="3" id="f-632">60,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToParentDiluted" format="ixt:num-dot-decimal" scale="3" id="f-633">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToParentDiluted" format="ixt:num-dot-decimal" scale="3" id="f-634">235,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-635">148,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-636">89,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-637">144,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-638">87,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-639">17,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-640">14,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-641">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-643">165,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-644">104,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-645">145,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-646">87,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-647">1.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-648">0.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-649">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-650">2.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-651">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-652">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-653">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-654">2.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities excluded from calculations of diluted net income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-655">4,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-656">6,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-657">21,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-658">23,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="f-659" continuedAt="f-659-1" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-660" escape="true"><ix:continuation id="f-659-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-661">680,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-662">568,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-663">10,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-664">10,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-665">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-666">4,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-667">695,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-668">583,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2024 and December&#160;31, 2023, on the consolidated balance sheets.</span></div></ix:continuation></ix:nonNumeric><div id="ia1cce1d42cea40b398b487e7aaa3b078_58"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-669" continuedAt="f-669-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-670" escape="true"><ix:continuation id="f-669-1" continuedAt="f-669-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:60.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-671">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-672">6,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-673">7,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-674">7,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="f-675">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-676">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-677">9,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-678">41,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-669-2">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments, offset by recoveries of such commitments, are recorded as a component of cost of sales in the Company&#8217;s consolidated statements of operations. For the three and six months ended June&#160;30, 2024, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-679">9.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-680">18.5</ix:nonFraction>&#160;million, respectively, and losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-681"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-682">1.7</ix:nonFraction></ix:nonFraction>&#160;million. For the three and six months ended June&#160;30, 2023, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-683">19.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-684">31.5</ix:nonFraction>&#160;million, respectively, and losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-685">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-686">8.5</ix:nonFraction>&#160;million. In addition, for the three and six months ended June&#160;30, 2023 the Company recorded recoveries on firm purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="nvax:InventoryFirmPurchaseCommitmentRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-687">17.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="nvax:InventoryFirmPurchaseCommitmentRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-688">18.8</ix:nonFraction>&#160;million, respectively, related primarily to negotiated reductions to previously recognized firm purchase commitments</ix:continuation>. </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_61"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-689" continuedAt="f-689-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-689-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reporting_unit" contextRef="c-191" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-690"><ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-691">one</ix:nonFraction></ix:nonFraction> reporting unit, which has a negative carrying amount as of June&#160;30, 2024 and December&#160;31, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-692" continuedAt="f-692-1" escape="true">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2024 was as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-692-1"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-693">127,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-694">4,077</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-695">123,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_67"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-696" continuedAt="f-696-1" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="f-696-1" continuedAt="f-696-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConvertibleDebtTableTextBlock" id="f-697" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-698">5.00</ix:nonFraction>% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-699">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-700">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-701">6,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-702">7,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-703">168,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-704">168,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate of the 2027 Convertible notes is <ix:nonFraction unitRef="number" contextRef="c-192" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-705">6.2</ix:nonFraction>%. During the six months ended June&#160;30, 2023, the Company repaid the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-706">325.0</ix:nonFraction>&#160;million on its <ix:nonFraction unitRef="number" contextRef="c-195" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-707">3.75</ix:nonFraction>% Convertible notes due in 2023, together with accrued </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-696-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but unpaid interest on the maturity date. </span></div><ix:nonNumeric contextRef="c-1" name="nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock" id="f-708" escape="true"><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the convertible notes payable&#160;consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-709">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-710">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-711">4,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-712">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-713">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-714">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-715">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-716">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-717">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-718">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-719">5,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-720">6,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_70"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;12&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-721" continuedAt="f-721-1" escape="true">Stockholders&#8217; Deficit</ix:nonNumeric></span></div><ix:continuation id="f-721-1" continuedAt="f-721-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an At Market Issuance Sales Agreement (the &#8220;August 2023 Sales Agreement&#8221;), which allows it to issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-722">500</ix:nonFraction>&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the three and six months ended June&#160;30, 2024, the Company sold $<ix:nonFraction unitRef="shares" contextRef="c-197" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-723"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-724">12</ix:nonFraction></ix:nonFraction>&#160;million shares of its common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-725">188</ix:nonFraction>&#160;million, under the August 2023 Sales Agreement. As of June&#160;30, 2024, the remaining balance available under the August 2023 Sales Agreement was approximately $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="nvax:SaleOfStockAmountOfRemainingUnissuedShares" format="ixt:num-dot-decimal" scale="6" id="f-726">51</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2023, the Company sold </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="f-727"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="f-728">7.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million shares of its common stock under its June 2021 Sales Agreement resulting in net proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-729"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-730">68</ix:nonFraction></ix:nonFraction>&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="6" id="f-731">6</ix:nonFraction>&#160;million was included in prepaid expenses and other current assets as of June&#160;30, 2023 and received in cash in July 2023.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-721-2">In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="f-732">6,880,481</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-733">0.01</ix:nonFraction> per share at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-734">10.00</ix:nonFraction> per share for aggregate gross proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-735">68.8</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_73"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-736" continuedAt="f-736-1" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><ix:continuation id="f-736-1" continuedAt="f-736-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company established the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-737">1.0</ix:nonFraction>&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of June&#160;30, 2024, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="-5" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-738">0.2</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under the 2023 Inducement Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-739">27.5</ix:nonFraction>&#160;million shares of common stock under equity awards granted under the 2015 Plan. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on April&#160;18, 2034. As of June&#160;30, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="-5" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-740">9.4</ix:nonFraction>&#160;million shares available for issuance under the 2015 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Inducement Plan and the 2015 Plan permit, and the 2005 Plan permitted, the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock units (&#8220;RSUs&#8221;). In addition, under the 2023 Inducement Plan and the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of <ix:nonNumeric contextRef="c-207" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-741">ten years</ix:nonNumeric> and may be or were granted with an exercise price that is no less than <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" scale="-2" id="f-742">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of share-based awards are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:f-743">one</span> to <ix:nonNumeric contextRef="c-210" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-744">four years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-736-2" continuedAt="f-736-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-745" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-746">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-747">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-748">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-749">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-750">6,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-751">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-752">11,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-753">23,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-754">6,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-755">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-756">12,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-757">23,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-758">14,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-759">20,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-760">25,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-761">48,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024 and 2023, there was no stock-based compensation expense capitalized into inventory. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, there was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-762">73</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-763">one year</ix:nonNumeric> and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2024. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2024 and 2023 was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-764"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-765">8</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-766"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-767">2</ix:nonFraction></ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-768" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan, and 2005 Plan for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-223" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-769">422,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-770">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-224" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-771">4,787,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-224" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-772">38.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-225" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-773">58,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-225" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-774">119.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-777">703,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-778">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-783">329,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-784">8.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-228" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-226" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-789">518,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-790">46.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-791">57,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-792">119.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-793">422,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-794">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-795">4,642,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-796">34.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-229" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-797">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-798">108.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-799">124,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-800">11.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-801">3,076,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-802">43.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-229" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="f-803">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-804">108.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-805" continuedAt="f-805-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-736-3"><ix:continuation id="f-805-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-806">14.13</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-807">6.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-808">5.86</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-809">7.24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-810">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-811">3.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-812">3.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-813">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-814">3.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-815">4.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-816">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-817">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-818">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-819">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-820">121.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-821">120.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-822">131.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-823">114.3</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-232" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-824">121.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-825">120.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-826">140.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-827">6.3</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-235" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-828">3.9</ix:nonNumeric>-<ix:nonNumeric contextRef="c-236" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-829">6.4</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-237" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-830">3.9</ix:nonNumeric>-<ix:nonNumeric contextRef="c-238" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-831">6.3</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-239" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-832">3.9</ix:nonNumeric>-<ix:nonNumeric contextRef="c-240" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-833">6.4</ix:nonNumeric></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-834">12.3</ix:nonFraction>&#160;million and <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-835">7.0</ix:nonNumeric> years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-836">3.7</ix:nonFraction>&#160;million and <ix:nonNumeric contextRef="c-227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-837">6.0</ix:nonNumeric> years, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" id="f-838" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-839">363,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-241" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-840">10.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-841">3,714,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-242" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-842">19.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-243" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-845">4,441,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-846">5.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-847">102,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-243" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-848">10.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-849">921,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-850">24.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-243" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-853">605,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-854">18.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-855">261,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-245" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-856">10.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-857">6,629,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-246" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-858">9.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June 2013. The ESPP currently authorizes an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-859">2.2</ix:nonFraction> million shares of common stock to be purchased, and the aggregate number of shares will continue to increase <ix:nonFraction unitRef="number" contextRef="c-248" decimals="2" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" scale="-2" id="f-860">5</ix:nonFraction>% on January 1 of each year up to a maximum of <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-861">3.5</ix:nonFraction> million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of <ix:nonFraction unitRef="number" contextRef="c-248" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-862">15</ix:nonFraction>% of their compensation, at <ix:nonFraction unitRef="number" contextRef="c-249" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-863">85</ix:nonFraction>% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). As of June&#160;30, 2024, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-248" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-864">1.2</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under the ESPP.</span></div></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_76"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-865" continuedAt="f-865-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-865-1" continuedAt="f-865-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. Significant pieces of objective evidence evaluated by the Company were the cumulative loss incurred over the three-year period ended June&#160;30, 2024 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2024, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#8220;NOLs&#8221;) have been used to reduce taxable income. As of June&#160;30, 2024, the Company has $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-866">2.3</ix:nonFraction>&#160;billion of U.S. Federal NOLs carryforward, and all are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), which limits allowable NOL deductions to 80% of federal taxable income. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-865-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-867">2.2</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-868">0.1</ix:nonFraction>)&#160;million of federal, state, and foreign income tax expense (benefit), respectively. During the six months ended June&#160;30, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-869">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-870">1.0</ix:nonFraction>&#160;million of federal, state, and foreign income tax expense, respectively.</span></div></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_79"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-871" continuedAt="f-871-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contingencies</span></ix:nonNumeric></div><ix:continuation id="f-871-1" continuedAt="f-871-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against <ix:nonFraction unitRef="defendant" contextRef="c-251" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="f-872">two</ix:nonFraction> individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within <ix:nonNumeric contextRef="c-251" name="nvax:LossContingencyPeriodToAnswer" format="ixt-sec:durwordsen" id="f-873">fourteen days</ix:nonNumeric>. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-874">47</ix:nonFraction>&#160;million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024. Ahead of the May 23 settlement hearing, on April 11, 2024, Plaintiffs filed a motion seeking the Maryland Court&#8217;s final approval of the settlement. At the May 23 settlement hearing, the Maryland Court granted final approval of the settlement. The Maryland Court closed the Sinnathurai Action on May 24, 2024. Upon the Maryland Court&#8217;s final approval, the Company relieved the $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-875">47</ix:nonFraction>&#160;million estimated settlement liability within Accrued expenses and the $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-876">47</ix:nonFraction>&#160;million estimated insurance recovery within Prepaid expenses and other current assets on the consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, <ix:nonFraction unitRef="lawsuit" contextRef="c-253" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-877">eight</ix:nonFraction> derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Needleman Action was also filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-871-2" continuedAt="f-871-3"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order, and, on April 15, 2024, the court entered a further order extending the stay until June 6, 2024. On June 7, 2024, the court entered another order extending the stay until August 5, 2024. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint. On August 5, 2024, the parties agreed to a further <ix:nonNumeric contextRef="c-254" name="nvax:LossContingencyExtensionPeriod" format="ixt-sec:durwordsen" id="f-878">90-day</ix:nonNumeric> extension to November 4, 2024, which remains subject to court approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, following the ruling on the motion to dismiss the Sinnathurai Action, the Delaware Court entered an order granting the Mesa Action parties&#8217; request to set a briefing schedule in connection with a motion to stay by defendants. On February 28, 2023, the court granted the defendants&#8217; motion and stayed the Mesa Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On August 31, 2023, the Mesa plaintiffs filed a motion to lift the stay in the Mesa Action. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-871-3"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. On May 3, 2024, the plaintiffs filed a consolidated complaint. On May 14, 2024, the parties filed a stipulation staying the action until June 6, 2024. On July 12, 2024, the court entered an order staying the action until August 5, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the above derivative claims is not reasonably estimable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.</span></div></ix:continuation><div id="ia1cce1d42cea40b398b487e7aaa3b078_82"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-879" continuedAt="f-879-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring </span></ix:nonNumeric></div><ix:continuation id="f-879-1" continuedAt="f-879-2"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a global restructuring and cost reduction plan (the &#8220;2023 Restructuring Plan&#8221;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#8217;s global workforce, as well as the consolidation of facilities and infrastructure. In January 2024, the Company announced further reductions to its global workforce which supplemented the 2023 Restructuring Plan and both are jointly referred to as the &#8220;Restructuring Plan.&#8221; </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-880" continuedAt="f-880-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following restructuring charge related to the Restructuring Plan in the consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:41.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-881">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-882">4,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-883">5,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-884">4,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-886">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-887">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-888">10,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-889">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-890">14,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-891">7,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-892">14,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-880-1" continuedAt="f-880-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-893">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-894">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-895">0.3</ix:nonFraction>&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three months ended June&#160;30, 2024. Restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-896">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-897">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-898">4.8</ix:nonFraction>&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the six months ended June&#160;30, 2024. Restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-899"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-900">0.5</ix:nonFraction></ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-901"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-902">2.7</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-903"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-904">11.5</ix:nonFraction></ix:nonFraction>&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-880-2">.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and employee benefit costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the reporting period and had no requirements for future service. The Company paid a total of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nvax:PaymentsForSeveranceAndEmployeeBenefitCosts" format="ixt:num-dot-decimal" scale="6" id="f-905">5.5</ix:nonFraction>&#160;million for the severance and employee benefit costs during the six months ended June&#160;30, 2024 and had <ix:nonFraction unitRef="usd" contextRef="c-255" decimals="INF" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-906">no</ix:nonFraction> remaining liability as of June&#160;30, 2024 or December&#160;31, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The Company performed an impairment evaluation for the applicable long-lived assets, which is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the six months ended June&#160;30, 2024, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-907">1.7</ix:nonFraction>&#160;million related to the impairment of capitalized internal-use software. During the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-908">10.1</ix:nonFraction>&#160;million related to the impairment of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-879-2">long-lived assets, including $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-909">5.9</ix:nonFraction>&#160;million related to ROU assets for facility leases. The Company did not recognize any impairment of assets related restructuring charges during the three months ended June&#160;30, 2024.</ix:continuation> </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_85"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-910" continuedAt="f-910-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></ix:nonNumeric></div><ix:continuation id="f-910-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, Pharmac provided notice of its termination of the New Zealand APA (see Note 5).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statements in the discussion below and elsewhere in this Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) about expectations, beliefs, plans, objectives, assumptions, or future events or performance of Novavax, Inc. (&#8220;Novavax,&#8221; together with its wholly owned subsidiaries, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements about our capabilities, goals, expectations regarding future revenue and expense levels, and capital raising activities; our operating plans and prospects, including our ability to continue as a going concern through one year from the date of our unaudited financial statements for the period ended June 30, 2024 are issued; our global restructuring and cost reduction plan (&#8220;Restructuring Plan&#8221;), which includes a more focused investment in our COVID-19 program (which currently includes our prototype COVID-19 vaccine ("NVX-CoV2373&#8221; or &#8220;prototype vaccine&#8221;) and XBB COVID-19 vaccine (&#8220;NVX-CoV2601&#8221;) and our updated vaccine for the 2024-2025 vaccination season (&#8220;NVX-CoV2705,&#8221; or &#8220;updated vaccine&#8221; and, collectively with NVX-CoV2373 and NVX-CoV2601, our &#8220;COVID-19 Vaccine&#8221; or &#8220;COVID-19 Program&#8221;), local regulatory authorities have also specified nomenclature for the labeling of NVX-CoV2373 and NVX-CoV2601 within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;, &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula),&#8221; respectively, for the U.S., and &#8220;Nuvaxovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for ex-US territories) collectively referred to as our (&#8220;COVID-19 Program,&#8221; or &#8220;COVID-19 Vaccine&#8221;)); our cash flow forecast and projected revenue, including potential royalties and milestones pursuant to our collaboration and license agreement (the &#8220;Sanofi CLA&#8221;) with Sanofi Pasteur Inc. (&#8220;Sanofi&#8221;); potential market sizes and demand for our products and product candidates; the efficacy, safety, and intended utilization of our products and product candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the development of our preclinical product candidates; our expectations related to enrollment in our clinical trials; the conduct, timing, and potential results from clinical trials and other preclinical studies; plans for and potential timing of regulatory filings; our expectation of manufacturing capacity, timing, production, distribution, and delivery for our COVID-19 Vaccine by us and our partners; our expectations with respect to the anticipated ongoing development and commercialization or licensure of the COVID-19 Vaccine, ongoing development of COVID-19 variant strain-containing monovalent or bivalent formulations, including the Phase 2b/3 Hummingbird&#8482; trial, and our COVID-19 Influenza Combination (&#8220;CIC&#8221;) vaccine candidate and our stand-alone influenza vaccine candidate; efforts to expand the COVID-19 Vaccine label worldwide as a booster, and to various age groups and geographic locations; the expected timing, content, and outcomes of regulatory actions; funding under our advance purchase agreements (&#8220;APAs&#8221;) and supply agreements and amendments to, termination of, discussion regarding, or legal disputes relating to any such agreement; our available cash resources and usage and the availability of financing generally; plans regarding partnering activities and business development initiatives; our plans regarding APA amendments; and other matters referenced herein. Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, our ability to successfully and timely manufacture, distribute, or market our  COVID-19 Vaccine including as a single dose vial or pre-filled syringe product presentation for the 2024-2025 vaccination season and our ability to receive a Biologics License Application (&#8220;BLA&#8221;) from the U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;) for the 2024-2025 vaccination season; challenges related to the transition to our new partnership with Sanofi; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation, and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for our product candidates, including our updated vaccine in time for the 2024-2025 vaccination season or for future COVID-19 variant strain changes, our CIC vaccine candidate and our stand-alone influenza vaccine candidate; manufacturing, distribution or export delays or challenges; our substantial dependence on Serum Institute of India Pvt. Ltd. (&#8220;SII&#8221;) and Serum Life Sciences Limited (&#8220;SLS&#8221; and together with SII, &#8220;Serum&#8221;) for co-formulation and filling, and PCI Pharma Services for finishing our COVID-19 Vaccine and the impact of any delays or disruptions in their operations on the delivery of customer orders; difficulty obtaining scarce raw materials and supplies, including for our proprietary adjuvant; resource constraints, including human capital and manufacturing capacity, constraints on our ability to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges in implementing the Restructuring Plan; our ability to timely deliver doses; challenges in obtaining commercial adoption and market acceptance of our COVID-19 Vaccine or any COVID-19 variant strain containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities including requirements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to deliver doses that may require us to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19; and other risks and uncertainties identified in Part I, Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2023, Part II, Item 1A. &#8220;Risk Factors&#8221; of our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 and this Quarterly Report on Form 10-Q, which may be detailed and modified or updated in other documents filed with the SEC from time to time, and are available at www.sec.gov and at www.novavax.com. You are encouraged to read these filings as they are made.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee future results, events, level of activity, performance, or achievement. Any or all of our forward-looking statements in this Quarterly Report may turn out to be inaccurate or materially different from actual results. Further, any forward-looking statement speaks only as of the date when it is made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information in this Quarterly Report includes a financial measure that was not prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), which we refer to as adjusted cost of sales. We are presenting this non-GAAP financial measure to assist an understanding of our business and its performance. Adjusted cost of sales includes an estimate of standard manufacturing costs that were previously expensed to research and development prior to regulatory approvals for our COVID-19 Vaccine that would otherwise have been capitalized to inventory. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP, and may not be comparable to the calculation of similar measures of other companies.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_91"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global company advancing protein-based vaccines with our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address global health needs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are nanostructures of conformationally correct recombinant proteins that mimic those found on pathogens. This technology enables the immune system to recognize target proteins and develop protective immune responses. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or some other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an updated vaccine for individuals aged 12 and older for the upcoming 2024-2025 vaccination season and are seeking authorization of our updated vaccine globally. We submitted an amendment to our previously granted October 2023 Emergency Use Authorization (&#8220;EUA&#8221;) to the U.S. FDA, filed for a type II variation of our existing Marketing Authorization (&#8220;MA&#8221;) with the European Medicines Agency (&#8220;EMA&#8221;), and the United Kingdom's (&#8220;UK&#8221;) Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), and filed for authorization with Health Canada. These submissions follow the guidance from the U.S. FDA, EMA, the World Health Organization (&#8220;WHO&#8221;), and the National Advisory Committee on Immunization on the use of the JN.1 lineage strain for the updated formulation. We intend to ship our updated vaccine upon authorization in these markets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we were notified by the U.S. FDA that our BLA for our prototype vaccine and for NVX-CoV2601 was accepted for review with an action date of April 2025.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we entered into the Sanofi CLA with Sanofi, to co-commercialize our COVID-19 Vaccine, including future updated versions that address seasonal COVID-19 variants. We will continue commercialization of our updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, we and Sanofi will commercialize the COVID-19 Vaccine worldwide in accordance with a commercialization plan agreed by us and Sanofi, under which we will continue to supply its existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, we and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction. Additionally, Sanofi has the right to develop novel influenza-COVID-19 combination vaccines utilizing our COVID-19 Vaccine and Sanofi&#8217;s seasonal influenza vaccine, combination products containing our COVID-19 Vaccine and one or more non-influenza vaccines, and multiple new vaccines utilizing our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. We are eligible to receive royalties and milestones associated with the ongoing sales of our COVID-19 Vaccine and Sanofi&#8217;s influenza-COVID-19 combination vaccine and any other combination vaccines Sanofi may develop, as well as ongoing product royalties for vaccines developed with our Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. This partnership provides the opportunity for us to focus more on research and development and pipeline expansion. We discuss this agreement in further detail in Note 6 to our consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our near-term focus is on developing a CIC vaccine candidate, as well as a stand-alone seasonal influenza vaccine candidate, and we are on track to initiate a Phase 3 trial in the fourth quarter of 2024 for both vaccine candidates. Furthermore, we provide our Matrix-M&#8482; adjuvant for collaborations, including in R21/Matrix-M&#8482; adjuvant malaria vaccine, which is authorized in several countries, as well as other preclinical vaccine research with our Matrix-M&#8482; adjuvant, including through a partnership with the Bill &amp; Melinda Gates Medical Research Institute.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to focus our organization to align our investments and activities with our top priorities of prioritizing the successful transition to our new partnership with Sanofi, executing our Phase 3 programs for the CIC and stand-alone seasonal influenza vaccine candidates, and delivering our updated vaccine. To maximize our opportunities and mitigate the significant risks and uncertainties of the COVID-19 market, we have progressed our cost restructuring measures to reduce spend, extend our cash runway, and operate efficiently to seek the best position for us to deliver longer-term growth. We discuss these cost restructuring strategies in greater detail in Note 2 to our consolidated financial statements. </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_94"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recombinant nanoparticle vaccine technology and our proprietary Matrix-M&#8482; adjuvant are well suited for the development and commercialization of vaccine candidates targeting a broad scope of respiratory and other endemic and emerging infectious diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant Nanoparticle Vaccine Technology</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a target of interest has been identified, the genetic sequence encoding an antigen is selected for developing the vaccine construct. The genetic sequence may be optimized to enhance protein stability or confer resistance to degradation. This genetic construct is inserted into the baculovirus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spodoptera frugiperda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Sf-/BV&#8221;) insect cell-expression system, which enables efficient, large-scale expression of the optimized protein. The Sf-/BV system produces protein-based antigens that are properly folded and modified, which can be critical for functional, protective immunity. Protein antigens are purified and organized around a polysorbate-based nanoparticle core in a configuration that resembles their native presentation. This results in a highly immunogenic nanoparticle that is ready to be formulated with Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matrix-M&#8482; Adjuvant</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary Matrix-M&#8482; adjuvant is a key differentiator within our platform. This adjuvant has enabled potent, well tolerated, and durable efficacy by stimulating the entry of antigen presenting cells (&#8220;APCs&#8221;) into the injection site and enhancing antigen presentation in local lymph nodes. This in turn activates APCs, T-cell and B-cell populations, and plasma cells, which promote the production of high affinity antibodies, an immune boosting response. This potent mechanism of action enables a lower dose of antigen to achieve the desired immune response, thereby contributing to increased vaccine supply and manufacturing capacity. These immune-boosting and dose-sparing capabilities contribute to the adjuvant&#8217;s highly unique profile.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate commercial opportunities for the use of our Matrix-M&#8482; adjuvant alongside vaccine antigens produced by other manufacturers. Matrix-M&#8482; adjuvant is being evaluated in combination with several partner-led malaria vaccine candidates, including for R21/Matrix-M&#8482; adjuvant, a malaria vaccine candidate created by the Jenner Institute, University of Oxford. The R21/Matrix-M&#8482; adjuvant vaccine has been licensed to SII for commercialization, and in December 2023, received prequalification by the WHO. In July 2024, first commercial doses of the R21/Matrix-M&#8482; adjuvant malaria vaccine were administered to children in Cote d&#8217;Ivoire and South Sudan. Additionally, in May 2023, we entered into a three-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year agreement with the Bill &amp; Melinda Gates Medical Research Institute to provide our Matrix-M&#8482; adjuvant for use in preclinical vaccine research. In June 2023, we signed a material transfer agreement with SK bioscience Co., Ltd. (&#8220;SK&#8221;) for use of our Matrix-M&#8482; adjuvant in preclinical vaccine experiments for shingles, influenza, and pan-COVID-19. Our adjuvant technology is also being used by commercial partners as a key component in veterinary vaccines against equine influenza and Strangles, as well as the manufacture of black-widow anti-venom. In May 2024, pursuant to the Sanofi CLA, Sanofi received a non-exclusive license to develop and commercialize other vaccine products that include our Matrix-M&#8482; adjuvant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COVID-19 Vaccine Regulatory and Licensure</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our updated vaccine for the 2024-2025 vaccination season, we submitted an amendment to our previously granted October 2023 EUA to the U.S. FDA, filed for a type II variation of our existing MA with the EMA, and the UK&#8217;s MHRA, and filed for authorization with Health Canada. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the U.S. FDA grants an amended EUA for our updated vaccine, we expect that initial stocking orders of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> our updated vaccine will be available for shipment in pre-filled syringes to customers. In the European Union, we intend to have our updated vaccine available for distribution in unit-dose vials for immediate release post-approval. Additionally, in the U.K., we intend to have our updated vaccine available on the private market and in Canada, in five-dose vials for immediate release post-authorization should Canadian public health programs choose to provide the option for five-dose vials.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to continue to expand our label for primary and re-vaccination in younger children, and to achieve supportive policy recommendations enabling broad market access. We continue to work closely with governments, regulatory authorities, and non-governmental organizations in our commitment to facilitate global access to our COVID-19 vaccine.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_100"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Pipeline</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical pipeline encompasses vaccine candidates for infectious diseases. Our COVID-19 vaccine, partnered with Sanofi, is our most advanced product. We are seeking authorization of our 2024-2025 formulated JN.1 COVID vaccine globally. We will continue to commercialize our JN.1 COVID vaccine through the end of the 2024-2025 vaccination season. Beyond our COVID-19 vaccine, our clinical pipeline includes a CIC vaccine candidate and a stand-alone seasonal influenza vaccine candidate in addition to our Matrix-M&#8482; adjuvant being used for collaboration in R21/Matrix-M&#8482; adjuvant malaria vaccine.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:31.9pt"><img src="nvax-20240630_g1.jpg" alt="10Q Q2 MDA.jpg" style="height:140px;margin-bottom:5pt;vertical-align:text-bottom;width:641px"/></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Novavax continues to optimize preclinical candidates, including an RSV vaccine and a new approach to H5N1 pandemic bird flu vaccination. In addition, we are seeking to expand our core technology to new targets and novel applications including mucosal vaccination and high-density nanoparticles. We continue to evaluate the potential of Matrix-M&#8482; to augment immune responses to new and existing vaccines, including marketed products. We are conducting a prioritization review of our preclinical candidates to inform future early-stage clinical study investments to advance Novavax&#8217;s product pipeline.</span></div><div style="margin-top:2pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax&#8482;; and Nuvaxovid&#8482;, and authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula); Ongoing post-authorization Phase 3 strain change trial.</span></div><div style="padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2) &#160;&#160;&#160;&#160;Commercialized by SII; Granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus Vaccine Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work on our efforts to expand our COVID-19 vaccine label within the adolescent and pediatric indications. Additionally, we continue to evaluate vaccine safety, immunogenicity, and effectiveness through ongoing clinical trials and collaborative evidence-generating real-world studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Strain-Change and Re-vaccination Studies </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 313: In November 2023, we fully enrolled 338 adults aged 18 and older in Part 2 of the study which will evaluate the immunogenicity of a single dose of NVX-CoV2601 in previously unvaccinated individuals. Data from Study 313 are intended to support BLA supplements and similar regulatory submissions in other territories for future variant strain formulations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2b/3 Pediatric Hummingbird&#8482; Study</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we announced topline results from our Phase 2b/3 Hummingbird&#8482; trial that met its primary endpoints in children aged 6 through 11 years demonstrating both tolerability and immunologic responses. This ongoing trial is evaluating the safety, effectiveness (immunogenicity), and efficacy of two doses of our prototype vaccine (NVX-CoV2373), followed by a booster 6 months after the primary vaccination series. The trial completed enrollment in September 2023 and includes three age de-escalation cohorts of 1,200 children each. In consultation with the U.S. FDA, the filing strategy includes filing a supplemental BLA for these cohorts once the initial BLA is approved. We are in discussion with the U.S. FDA regarding additional analyses in light of the progressive increase in the number of children with baseline COVID-19 natural immunity during the enrollment period, which began in August 2022. Therefore, we do not anticipate authorization for these age groups for the 2024-2025 vaccination season.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-Influenza Combination and Stand-alone Influenza Program</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our CIC vaccine candidate, we continue to interact with the U.S. FDA as part of the pre-investigational new drug application (&#8220;IND&#8221;) process and incorporate their recommendations into the Phase 3 design, study endpoints, comparators, and size of licensure enabling safety database. We previously disclosed our plan to modify the study to include a stand-alone influenza vaccine comparative component. We remain on track to initiate the study in the fourth quarter of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our focus remains on the combination product, our development plans will maintain optionality to advance our stand-alone seasonal influenza vaccine, as described above, creating a pathway to potentially seek licensure. For our stand-alone seasonal influenza vaccine, we have generated positive data through our previous Phase 2 and Phase 3 trials. We expect to confirm and expand on these findings in the newly planned Phase 3 trial. We continue to believe this asset may also be attractive from a pandemic preparedness perspective and that similar performance in terms of comparative immunogenicity may be expected for A/H5N1 pandemic strains.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">High-dose COVID-19 Vaccine Study</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 205: In October 2023, we completed enrollment in a Phase 2 trial to evaluate our high-dose COVID-19 vaccine for annual vaccination in 994 adults ages 50 years and older. The trial measured immunogenicity levels of 5 micrograms of NVX-CoV2373 and of 5 micrograms, 35 micrograms, and 50 micrograms of NVX-CoV2601 matched with different levels of Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant. Analysis of the complete dataset is ongoing to determine the utility of pursuing a high dose formulation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R21/Matrix-M&#8482; Adjuvant Malaria Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R21/Matrix-M&#8482; adjuvant malaria vaccine, formulated with our Matrix-M&#8482; adjuvant is developed by our partner, the Jenner Institute, University of Oxford, and manufactured by SII. We have an agreement with SII related to its manufacture of R21/Matrix-M&#8482; adjuvant malaria vaccine under which SII purchases our Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single- to low-double digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023, the WHO announced it prequalified the R21/Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adjuvant malaria vaccine to prevent malaria disease in children caused by the P. falciparum parasite in endemic areas.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, first commercial doses of R21/Matrix-M&#8482; adjuvant malaria vaccine have been administered to children in Cote d&#8217;Ivoire and South Sudan. As part of the WHO malaria program, at their discretion, the vaccine is expected to be included in countries such as Central African Republic, Chad, Democratic Republic of Congo, Mozambique, Nigeria and Uganda.</span></div><div><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_103"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have taken steps to enable a successful operationalization of the collaboration and license agreement (the Sanofi Agreement) with Sanofi. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Effective January 1, 2025, Sanofi will assume primary commercial responsibility for our updated 2024-2025 formula COVID-19 vaccine (NVX-CoV2705) in the U.S., Europe and select major markets not currently subject to our APAs or existing partnership agreements.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Received $500 million upfront payment and an approximately $70 million equity investment from Sanofi</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are eligible to receive up to $700 million in development, regulatory and launch milestones for activities related to commercializing Nuvaxovid&#8482; and advancing Sanofi&#8217;s flu-COVID-19 combination vaccine candidate plus royalties. In addition, we are eligible to receive royalties associated with any other Nuvaxovid&#8482; combination vaccine Sanofi chooses to develop. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">For each additional Sanofi vaccine product developed under the non-exclusive license with our Matrix-M&#8482; adjuvant technology, we are eligible to receive additional launch and sales milestones of up to $210 million per product plus ongoing product royalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continued to leverage our technology platform to drive value creation. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On track to initiate the Phase 3 immunogenicity trial for both CIC and stand-alone influenza vaccine candidates in the fourth quarter of 2024, with data expected by mid-2025.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Conducting pipeline prioritization activities to determine our lead portfolio programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continued to progress our cost reduction program to create a more lean and agile organization and accelerate its focus on Research and Development (&#8220;R&amp;D&#8221;).</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On track with global restructuring and cost reduction plan with an approximately 34% reduction in combined R&amp;D and Selling, General and Administrative (&#8220;SG&amp;A&#8221;) expenses in the second quarter of 2024 compared to the same period for 2023. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Prepared to initiate an additional cost reduction program to reduce R&amp;D plus SG&amp;A expenses, with a portion of expenses to be reimbursed by Sanofi under the Sanofi Agreement. We plan to continue assessing existing capabilities to further refine the shape, size and scope of its organization this year and into 2025.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to deliver our updated 2024-2025 formula COVID-19 vaccine to the market by the start of the season.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">U.S. Market:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Submitted an EUA amendment to the U.S. FDA. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced manufacturing of pre-filled syringe presentation of updated 2024-2025 formula COVID-19 vaccine following FDA strain selection guidance. Expect doses will be ready to ship upon receipt of EUA.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The U.S. FDA accepted the BLA for our COVID-19 vaccine with a Prescription Drug User Fee Act date of April 2025.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced retail pharmacy contract negotiations to enhance access for the 2024-2025 vaccination season.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Global Markets:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">For 2024, made decision to conduct lean and targeted commercial launch in Europe in select key countries including Germany, Italy and Poland.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Submitted marketing authorization amendments to the EMA and expect doses will be ready to ship upon receipt of market authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_106"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into an At Market Issuance Sales Agreement (the &#8220;August 2023 Sales Agreement&#8221;), which allows us to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock, and terminated our then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the three and six months ended June&#160;30, 2024, we sold 12.2 million shares of our common stock resulting in net proceeds of approximately $188&#160;million, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the August 2023 Sales Agreement. As of June&#160;30, 2024, the remaining balance available under the August 2023 Sales Agreement was approximately $51&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June&#160;30, 2023, we sold 7.9 million shares of our common stock under our June 2021 Sales Agreement resulting in net proceeds of approximately $68&#160;million, of which $6.0 million was included in prepaid expenses and other current assets as of June&#160;30, 2023 and received in cash in July 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we also entered into a securities subscription agreement (the &#8220;Subscription Agreement&#8221;) with Sanofi, pursuant to which we sold and issued to Sanofi, in a private placement, 6,880,481 shares of our common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to us of $68.8&#160;million. The opening price of our common stock on the date of the sale approximated $10.00 per share and therefore all gross proceeds were allocated to stockholders&#8217; deficit. </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_109"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements (unaudited) and the accompanying notes, which have been prepared in accordance with generally accepted accounting principles in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, and equity and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Our critical accounting policies and estimates are included under Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC and are updated below to incorporate revenue recognition from licensing and transition services included in Licensing, royalties and other in our consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition, Licensing and Transition Services</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The terms of licensing agreements may contain multiple performance obligations, which may include licenses and transition services. We evaluate licensing agreements under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC 606&#8221;), to determine the distinct performance obligations. Prior to recognizing revenue, we estimate the transaction price, including variable consideration that is subject to a constraint. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple distinct performance obligation arrangements, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, we consider discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, we apply judgment in determining the forecasted revenues, expected margins, and the discount rate. These estimates are subjective and require us any to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset.  For performance obligations recognized over time, we recognize revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, we consider the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total cost at completion of our performance obligation under a contract is subjective and requires us to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on our contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. We have not experienced any material difference as a result of change in estimate arising from this process.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 2&#8213;Summary of Significant Accounting Policies&#8221; included in our Notes to Consolidated Financial Statements (under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of the historical financial condition and results of our operations that should be read in conjunction with the unaudited consolidated financial statements and notes set forth in this Quarterly Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June&#160;30, 2024 and 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing, royalties, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended June&#160;30, 2024 was $415.5 million as compared to $424.4 million for the same period in 2023, an decrease of $8.9 million. Revenue for the three months ended June&#160;30, 2024 was primarily comprised of revenue from licensing and revenue from product sales of COVID-19 Vaccine. Revenue for the three months ended June&#160;30, 2023 was primarily comprised of product sales of COVID-19 Vaccine and services performed under our U.S. government agreement with Advanced Technology International (&#8220;USG Agreement&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. The decrease in revenue is due to a decrease in the quantity of dose sales of COVID-19 Vaccine and a decrease in revenue under the USG Agreement during the three months ended June&#160;30, 2024 because we recognized the full funding in revenue by the end of 2023, partially offset by additional licensing revenue from the Sanofi Collaboration and Licensing Agreement (&#8220;Sanofi CLA&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales for the three months ended June&#160;30, 2024 were $19.9 million as compared to $285.2 million during the three months ended June&#160;30, 2023. Our product sales related to revenue from commercial sales of COVID-19 Vaccine, which commenced in 2022.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of product sales was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265,259)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing, royalties, and other </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, royalties, and other includes licensing payments, Transition Services revenue, and Technology Transfer revenue from the Sanofi CLA; royalty milestone payments; sales-based royalties; and Matrix-M&#8482; adjuvant sales. Licensing, royalties, and other revenue during the three months ended June&#160;30, 2024 was $395.6 million as compared to $2.2 million during the same period in 2023, an increase of $393.4 million. The increase was primarily due to $386.3 million of licensing revenue from the Sanofi CLA, which represents the amount of the $500 million upfront payment recognized at a point-in-time. The remaining amount of the upfront payment will be recognized in revenue as Transition Services and Technology Transfer are performed over time. During the three months ended June&#160;30, 2024, we recognized $6.6 million based on progress completed of Transition Services.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any Grant revenue during the three months ended June&#160;30, 2024, as compared to $137.1 million during the same period in 2023, a decrease of $137.1 million. Grant revenue comprised revenue for services performed under our USG Agreement. As of December 31, 2023, we had recognized the full contract funding under the USG Agreement in revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,483)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $46.2&#160;million for the three months ended June&#160;30, 2024, including expenses of $11.4 million related to excess, obsolete, or expired inventory and losses on certain firm purchase commitments, and $12.9 million related to unutilized manufacturing capacity. Cost of sales was $55.8&#160;million for the three months ended June&#160;30, 2023, including expense of $19.8&#160;million related to excess, obsolete, or expired inventory and losses on firm purchase commitments, partially offset by $17.9 million of negotiated reductions to certain previously recognized firm purchase commitments, and $11.4&#160;million related to unutilized manufacturing capacity. Prior to receiving regulatory approval, we expensed manufacturing costs as research and development expenses. After receiving regulatory approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. During the three months ended June&#160;30, 2024, we did not sell any pre-launch inventory. If inventory sold for the three months ended June&#160;30, 2023 was valued at expected standard cost, adjusted cost of sales for the period would have been approximately $71.7&#160;million, an adjustment of $15.9&#160;million. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer pricing mix or standard costs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $106.9&#160;million for the three months ended June&#160;30, 2024 as compared to $219.5 million for the three months ended June&#160;30, 2023, a decrease of $112.5 million. The decrease was primarily due to a reduction in overall expenditures relating to development activities on coronavirus vaccines, including our COVID-19 Program, and CIC, as summarized in the table below (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronavirus vaccines </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other vaccine development programs </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for coronavirus vaccines for the three months ended June&#160;30, 2024 and 2023 decreased from $139.6 million to $40.8 million primarily as a result of a reduction in manufacturing and support costs due, in part, to a reduction in our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand for, COVID-19 Vaccine, including embedded lease costs, under manufacturing supply agreements with Contract Manufacturing Organizations (&#8220;CMOs&#8221;) and contract manufacturing and development organizations (&#8220;CDMOs&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses were $101.3&#160;million for the three months ended June&#160;30, 2024 as compared to $93.7&#160;million for the same period in 2023, an increase of $7.6&#160;million. Excluding the Sanofi transaction related costs of $29.5&#160;million, the decrease in selling, general, and administrative expenses is primarily due to certain cost containment measures to reduce our operating spend.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remainder of 2024, we expect a reduction in our annual combined research and development, and selling, general, and administrative spend as a result of our Restructuring Plan as discussed in Note 16 to our consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income, net (in thousands):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net was $3.6&#160;million for the three months ended June&#160;30, 2024 as compared to a total other income, net of $2.4&#160;million for the same period in 2023. The increase in other income, net is primarily due to additional interest income from higher Cash and cash equivalents and Marketable securities balances.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2024, we recognized an income tax expense of $2.2&#160;million related to federal, state, and foreign income taxes. During the three months ended June&#160;30, 2023, we recognized an income tax benefit of $0.1&#160;million related to federal, state, and foreign income taxes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (in thousands, except per share information):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, basic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share, dilutive</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, dilutive</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income for the three months ended June&#160;30, 2024 was $162.4&#160;million, or $1.09 per share, basic, as compared to net income of $58.0 million, or $0.65 per share, basic, for the same period in 2023. The increase in net income during the three months ended June&#160;30, 2024, was primarily due to a decrease in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for the three months ended June&#160;30, 2024 was primarily a result of sales of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2024 and 2023</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing, royalties, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the six months ended June&#160;30, 2024 was $509.3&#160;million as compared to $505.4&#160;million for the same period in 2023, an increase of $4.0&#160;million. Revenue for the six months ended June&#160;30, 2024 was primarily comprised of revenue from licensing and product sales of COVID-19 Vaccine. Revenue for the six months ended June&#160;30, 2023 was primarily comprised of revenue from product sales of COVID-19 Vaccine and services performed under our USG Agreement. The increase in revenue is due to $392.9 million of licensing and other revenue from the Sanofi CLA, partially offset by a decrease in revenue under the USG Agreement and in the quantity of dose sales of COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales for the six months ended June&#160;30, 2024 were $102.2&#160;million as compared to $277.7&#160;million during the six months ended June&#160;30, 2023. Our product sales related to revenue from commercial sales of COVID-19 Vaccine, which commenced in 2022. Our product sales primarily related to sales of COVID-19 Vaccine under our APA agreements. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of product sales was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,921</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,478)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, product sales in North America includes $4.8 million of gross-to-net deductions in excess of the wholesaler acquisition costs (&#8220;WAC&#8221;), primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing, royalties, and other </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, royalties, and other includes licensing payments, Transition Services revenue, and Technology Transfer revenue from the Sanofi CLA; royalty milestone payments; sales-based royalties; and Matrix-M&#8482; adjuvant sales. Licensing, royalties, and other revenue during the six months ended June&#160;30, 2024 was $407.1 million as compared to $3.2 million during the same period in 2023, an increase of $403.9 million. The increase was primarily due to $386.3 million of licensing revenue from the Sanofi CLA, which represents the amount of the $500 million upfront payment recognized at a point-in-time. The remaining amount of the upfront payment will be recognized in revenue as Transition Services and Technology Transfer are performed over time. During the six  months ended June&#160;30, 2024, we recognized $6.6 million based on progress completed of Transition Services. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any Grant revenue during the six months ended June&#160;30, 2024 as compared to $224.5&#160;million during the same period in 2023, a decrease of $224.5&#160;million. Grant revenue comprised revenue for services performed under our USG Agreement. As of December 31, 2023, we had recognized the full contract funding under the USG Agreement in revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,516)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $105.5&#160;million for the six months ended June&#160;30, 2024, including expenses of $20.2&#160;million related to excess, obsolete, or expired inventory and losses on certain firm purchase commitments, and $18.8&#160;million related to unutilized manufacturing capacity. Cost of sales was $89.9&#160;million for the six months ended June&#160;30, 2023, including expense of $40.0&#160;million related to excess, obsolete, or expired inventory and losses on firm purchase commitments, and a credit of $18.8&#160;million related to negotiated reductions to certain previously recognized firm purchase commitments, and $15.9&#160;million related to unutilized manufacturing capacity. Prior to receiving regulatory approval, we expensed manufacturing costs as research and development expenses. After receiving regulatory approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. If inventory sold for the six months ended June&#160;30, 2024 was valued at expected standard cost, including expenses related to excess and obsolete inventory, adjusted cost of sales for the period would have been approximately $107.1&#160;million, an adjustment of $1.6&#160;million as compared to cost of sales recognized. If inventory sold for the six months ended June&#160;30, 2023 was valued at expected standard cost, adjusted cost of sales for the period would have been approximately $120.8&#160;million, an adjustment of $30.9&#160;million. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer pricing mix or standard costs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to $199.6&#160;million for the six months ended June&#160;30, 2024 from $466.6 million for the same period in 2023, a decrease of $267.0 million. The decrease was primarily due to a reduction in overall expenditures relating to development activities on coronavirus vaccines, including our COVID-19 Program, and CIC, as summarized in the table below (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronavirus vaccines </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other vaccine development programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for coronavirus vaccines for the six months ended June&#160;30, 2024 and 2023 decreased from $279.9&#160;million to $66.0&#160;million primarily as a result of a reduction in manufacturing and support costs due, in part, to a reduction in our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, COVID-19 Vaccine, including embedded lease costs, under manufacturing supply agreements with CMOs and CDMOs. The decrease was also due to a benefit of $26.6&#160;million for the six months ended June&#160;30, 2024 resulting from the Confidential Settlement Agreement and Release agreement entered into with Fujifilm resulting in a reduction to previously recorded expense (see Note 6 to our consolidated financial statements).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses decreased to $188.1&#160;million for the six months ended June&#160;30, 2024 from $206.2&#160;million for the same period in 2023, a decrease of $18.2&#160;million. Excluding the Sanofi transaction related costs of $30.8&#160;million, the decrease in selling, general, and administrative expenses is primarily due to certain cost containment measures to reduce our operating spend. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income, net (in thousands):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,454&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,323)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net for the six months ended June&#160;30, 2024 was $3.1 million as compared to $22.5 million for the same period in 2023. This is primarily due to a decrease in Other income as a result of the unfavorable impact in 2024 as compared to 2023 of exchange rates on foreign currency denominated balances, including an intercompany loan with Novavax CZ.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, we recognized an income tax expense of $4.5&#160;million related to federal, state, and foreign income taxes. During the six months ended June&#160;30, 2023, we recognized an income tax expense of $1.0&#160;million related to federal, state, and foreign income taxes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income (Loss)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (Loss) (in thousands, except per share information):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss) per share, basic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss) per share, dilutive</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, dilutive</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income for the six months ended June&#160;30, 2024 was $14.8&#160;million, or $0.10 per share, basic, as compared to Net loss of $235.9&#160;million, or $2.69 per share, basic, for the same period in 2023. The increase in net income during the six months ended June&#160;30, 2024, was primarily due to a decrease in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for the six months ended June&#160;30, 2024 is primarily a result of sales of our common stock.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_118"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Matters and Capital Resources </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements depend on numerous factors including, but not limited to, revenue from our product sales, milestone payments, royalties and reimbursements under licensing arrangements with our strategic partners; our projected activities related to the development and commercial support of our COVID-19 Vaccine and our CIC vaccine candidate, including significant commitments under various clinical research organizations, CMO, and CDMO agreements; the progress of preclinical studies and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights; and other manufacturing, sales, and distribution costs. We plan to continue developing other vaccines and product candidates, such as our potential combination vaccines candidates, which are in various stages of development. Our ability to generate revenue from product sales is subject </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to uncertainty specifically as it relates to our ability to successfully develop, manufacture, distribute, and market our updated vaccine and to successfully execute on our APAs, as discussed below. Additionally, our plans include our ongoing restructuring and cost reduction measures (see Note 16 to the consolidated financial statements), and may also include raising additional capital through a combination of additional equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to us on commercially acceptable terms, or at all. If we are unable to obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate some or all of our operations, or further downsize our organization, any of which may have a material adverse effect on our business, financial condition, results of operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we entered into the Sanofi CLA pursuant to which Sanofi received:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i) &#160;&#160;&#160;&#160;A co-exclusive license to commercialize our current stand-alone COVID-19 Vaccine, including our prototype vaccine and updated vaccines, that address seasonal variants throughout the world  (the &#8220;COVID-19 Vaccine Products&#8221;);  </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)&#160;&#160;&#160;&#160;A sole license to develop and commercialize combination products containing a potential combination of our COVID-19 Vaccine and Sanofi&#8217;s seasonal influenza vaccine (&#8220;COVID-19 and influenza Combination Products&#8221; or &#8220;CIC Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize combination products containing both our COVID-19 Vaccine and one or more non-influenza vaccines (&#8220;Other Combination Products&#8221; and together with the COVID-19 Vaccine Products, CIC Products, and Other Combination Products (&#8220;Licensed COVID-19 Products&#8221; ); and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize other vaccine products selected by Sanofi that include our Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sanofi CLA, we received a non-refundable upfront payment of $500 million. In addition, we will also be eligible to receive development, technology transfer, launch, and sales milestone payments totaling up to $700 million in the aggregate with respect to the Licensed COVID-19 Products and royalty payments on Sanofi&#8217;s sales of such licensed products. In addition, we are eligible to receive development, launch, and sales milestone payments of up to $200 million for each of the first four Adjuvant Products and $210 million for each Adjuvant Product thereafter, and royalty payments on Sanofi&#8217;s sales of all such licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing shortly after the effective date of the Sanofi CLA, we commenced activities related to the technology transfer of our manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; components to Sanofi. Until the successful completion of such transfer, we will supply Sanofi with both COVID-19 Vaccine Products and Matrix-M&#8482; intermediary components for Sanofi&#8217;s use and are eligible for reimbursement of such costs from Sanofi. Additionally, Sanofi will reimburse us for our research and development and medical affairs costs related to the COVID-19 Vaccine Products in accordance with agreed upon plans and budgets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sanofi CLA, we will continue to commercialize the updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, we and Sanofi will commercialize the COVID-19 Vaccine Products worldwide in accordance with a commercialization plan agreed by us and Sanofi, under which we will continue to supply our existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, we and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we also entered into the Subscription Agreement, pursuant to which we sold and issued to Sanofi, in a private placement, 6,880,481 shares of our common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to us of $68.8 million. The opening price of our common stock on the date of the sale approximated $10.00 per share and therefore all gross proceeds were allocated to stockholders&#8217; deficit. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into supply agreements, sometimes referred to as APAs, with the EC and various countries globally. As of June&#160;30, 2024, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties under the licensing agreements, was approximately $2 billion, of which $1.2 billion is included in Deferred revenue on our consolidated balance sheet. Failure to timely meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under our APAs may require us to refund portions of upfront or other payments or result in reduced future payments, which could adversely impact our ability to realize revenue from our unsatisfied performance obligations. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand, and the ability of the customer to request variant vaccine under certain of our APAs. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of COVID-19 Vaccine. Such upfront payments generally become non-refundable upon our achievement of certain development, regulatory, and commercial milestones. Additionally, for the remaining APA agreements, our intent is to amicably negotiate or deliver doses or when appropriate, exit agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, NVX-CoV2601 received EUA from the U.S. FDA for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, NVX-CoV2601 has also been included in the recommendations issued by the CDC in September 2023. Doses became available within the U.S. at many major pharmacy retailers, following the Center for Biologics Evaluation and Research release of vaccine batches. We have established reserves for gross-to-net deductions for amounts that we expect to return to our customers. As of June&#160;30, 2024, gross-to-net reserve balances were $54.6 million related to product returns and $0.9 million related to wholesale distributor fees, discounts, and chargebacks and was included in Accrued expenses on our consolidated balance sheet.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement with Fujifilm (see Note 6 to our consolidated financial statements), in March 2024, we paid $42.0 million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the prior confidential settlement agreement and release effective September 30, 2022, and Fujifilm agreed to dismiss its demand for arbitration with the Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;). This payment is less than amounts previously recognized as embedded lease expense and reflected in Research and development expenses from Fujifilm manufacturing activity and accordingly, during the six months ended June&#160;30, 2024, we recorded a benefit of $26.6 million as Research and development expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the Commonwealth of Australia (&#8220;Australia&#8221;) for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In March 2024, we and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $54.0 million, including $6.0 million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until we receive authorization from the Therapeutic Goods Administration (&#8220;TGA&#8221;). We do not expect approval in time for product delivery in 2024 which could result in a loss or deferral of  approximately $240 million of contract value. We plan to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $119.1 million was classified as current Deferred revenue and $14.7 million was classified as non-current Deferred revenue with respect to the Australia APA in our consolidated balance sheet. If we are unable to satisfy our obligations under the Australia APA, $92.5 million of deferred revenue may become refundable and approximately $225 million of remaining funds under the contract may no longer be available. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, the Pharmaceutical Management Agency (&#8220;Pharmac&#8221;), a New Zealand Crown entity, provided notice of its termination of its APA (the &#8220;New Zealand APA&#8221;). As of June 30, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$31.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was classified as current Deferred revenue with respect to the APA in our consolidated balance sheet. New Zealand has requested a refund of certain advanced payments and we are in discussion with Pharmac on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">both, whether its termination of the New Zealand APA was appropriate under the New Zealand APA, and whether a refund of the advanced payments is appropriate under the New Zealand APA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$125 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of the contract value related to future deliverables may no longer be available if the APA is terminated. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). The Canadian government may terminate the Canada APA, as amended, if we fail to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. on or before December 31, 2024. We do not anticipate achieving regulatory approval of our COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. Therefore, we plan to seek an amendment to the Canada APA to address possible alternatives, which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $452.1&#160;million was classified as current Deferred revenue and $136.1&#160;million was classified as non-current Deferred revenue with respect to the Canadian APA in our consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1 million doses and up to an additional 15 million doses (the &#8220;Conditional Doses&#8221;) of our prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (&#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15 million doses of our prototype vaccine, we would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44 million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to our prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15 million doses to 7.5 million doses, which reduced number of Conditional Doses were contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, we repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5 million doses to zero. As of August 2024, we are in discussions with the Authority regarding the treatment of the remaining upfront amount previously received of $112.5&#160;million, which is reflected in Other current liabilities on our consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an APA with the Vaccine Alliance (&#8220;Gavi&#8221;) in May 2021 (the &#8220;Gavi APA&#8221;), pursuant to which we received upfront payments of $700&#160;million from Gavi (the &#8220;Advance Payment Amount&#8221;) to be applied against purchases of our prototype vaccine by certain countries participating in the COVAX Facility. As of December 31, 2023, the remaining Gavi Advance Payment Amount was $696.4&#160;million. In February 2024, we and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under, or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, we are responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which we paid in February 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the second quarter of 2024 and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of our vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. We have the right to price the vaccines offered to such low-income and lower-middle income countries in our discretion, and, when utilized by Gavi, we will credit the actual price per vaccine paid against the applicable credit. We intend to price vaccines offered via the tender process, consistent with our shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, we granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of our vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In total, the Gavi settlement agreement is comprised of $700 million of potential consideration, consisting of the $75&#160;million initial settlement payment, deferred payments of up to $400&#160;million that may be reduced through annual vaccine credits, and the additional credit of up to $225&#160;million that may be applied for certain qualifying sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the $3.6&#160;million difference between the refund liability recorded as of December 31, 2023 of $696.4&#160;million and the $700 million of total consideration under the arrangement as a revenue adjustment during the six months ended June&#160;30, 2024. As of June&#160;30, 2024, the remaining amounts included on our consolidated balance sheet are classified as $225&#160;million in non-current Deferred revenue for the additional credit that may be applied against future qualifying sales, $90&#160;million in Other current liabilities, and $305&#160;million in Other non-current liabilities. In addition, we and Gavi entered into a security agreement pursuant to which we granted Gavi a security interest in accounts receivable from SII under the SII R21 Agreement (see Note 6 to our consolidated financial statements), which will continue for the deferred payment term of the Gavi Settlement Agreement. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreements currently include funding from the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) in the form of one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the CMO network funded by CEPI is sold to one or more third parties (which could include sales credited </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Gavi Settlement Agreement), and such sales cover our costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess our manufacturing needs and modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, COVID-19 Vaccine, and in doing so recognize that significant costs may be incurred. For the 2023-2024 vaccination season, we have depended exclusively on Serum for co-formulation and filling (other than in Europe), and PCI Pharma Services for finishing COVID-19 Vaccine in Europe. For the 2024-2025 vaccination season, we are seeking to expand our supply chain network and introduce new single-dose vial or pre-filled syringe product presentations in certain markets. In May 2024, we and SLS entered into a supply agreement (the &#8220;SLS Supply Agreement&#8221;) under which SLS will supply us antigen drug substance and finished COVID-19 Vaccine doses. The SLS Supply Agreement includes the general terms and conditions of supply orders between us and SLS. We and SLS intend to execute statements of work and firm purchase orders to included specific quantities to be delivered under the SLS Supply Agreement. Pursuant to the SLS Supply Agreement, SLS or its authorized manufacturer is responsible for obtaining and maintaining all necessary permits or other regulatory approvals to manufacture drug substance and drug product. Unless otherwise earlier terminated, the SLS Supply Agreement will expire on the later of June 30, 2028 or two years after the expiration or termination of the last firm purchase order under the SLS Supply Agreement. Either party may terminate the SLS Supply Agreement if the other party commits a material breach of the SLS Supply Agreement that is not timely cured or is not curable. The SLS Supply Agreement contains certain customary representations and warranties of the parties along with certain customary covenants, including confidentiality and indemnity provisions. Any delays or disruptions in these suppliers&#8217; operations could prevent or delay the delivery of customer orders.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had $1.1 billion in cash and cash equivalents, restricted cash and marketable securities as compared to $583.8 million as of December 31, 2023. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded our operations for the six months ended June&#160;30, 2024 primarily with cash and cash equivalents, non-refundable upfront payment under the Sanofi CLA and Subscription Agreement, proceeds from the sale of securities under our August 2023 Sales Agreement, upfront payments under APAs, and revenue from product sales. In May 2023, we announced our plan to restructure our global footprint to reduce our planned expenditures and in January 2024, we announced further reductions in our global workforce. We anticipate our future operations to be funded primarily by milestone payments, royalties and transition services under our Sanofi CLA, revenue from product sales, our cash and cash equivalents and investments in marketable securities, and other potential funding sources including equity financings, which may include at the market offerings, debt financings, collaborations, strategic alliances, asset sales, and marketing, distribution or licensing arrangements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash flows for the six months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect on exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(830,904)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,941&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $230.7 million for the six months ended June&#160;30, 2024, as compared to net cash used in operating activities of $497.5 million for the same period in 2023. The increase in cash provided by operating activities is primarily due to the non-refundable upfront payment under the Sanofi CLA, an increase in amounts received under our APAs and an overall decrease in operating expenses period-over-period, partially offset by the timing of payments to vendors. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $380.0 million for the six months ended June&#160;30, 2024, as compared to $31.3 million for the same period in 2023. The increase in cash used in investing activities is primarily due to our investment in marketable securities, partially offset by lower expenditures on equipment and leasehold improvements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $264.1 million for the six months ended June&#160;30, 2024, as compared to net cash used in financing activities of $293.0 million for the same period in 2023. The increase in cash provided by financing activities is primarily as a result of proceeds from the sale of shares under our August 2023 Sales Agreement of approximately $188&#160;million and Subscription Agreement of $68.8&#160;million in 2024 as compared with the $325 million repayment of our 3.75% Convertible notes and finance lease payments during 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span id="i6770c65cad2c4755af673a07ff040ec4_20516"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to our consolidated financial statements, we evaluated our ability to continue as a going concern and concluded that we will have sufficient capital available to fund our operations for at least one-year from the date that the financial statements were issued. </span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_124"></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flows, and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are headquartered in the U.S. our results of operations, including our foreign subsidiaries&#8217; operations, are subject to foreign currency exchange rate fluctuations, primarily the U.S. dollar against the Euro, Pound Sterling, Swedish Krona, and Czech Koruna. This exchange exposure may have a material effect on our cash and cash equivalents, cash flows, and results of operations, particularly in cases of revenue generated under APAs that include provisions that impact our and our counterparty&#8217;s currency exchange exposure. To date, we have not entered into any foreign currency hedging contracts, although we may do so in the future.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face foreign currency exchange exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. While the financial results of our global activities are reported in U.S. dollars, the functional currency for our foreign subsidiaries is generally their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. A 10% decline in the foreign exchange rates (primarily against the U.S. dollar) relating to our foreign subsidiaries would result in a decline of stockholders&#8217; equity (deficit) of approximately $57.2 million as of June&#160;30, 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Interest Rate Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is preservation of capital, with the secondary objective of maximizing income.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to interest rate risk is primarily confined to our investment portfolio. We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our investment portfolio. Changes in interest rates may affect the investment income we earn on our marketable securities when they mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income is recorded when earned and included in investment income. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in investment income. The specific identification method is used in computing realized gains and losses on the sale of our securities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our convertible senior unsecured notes have a fixed interest rate, and we have no additional material debt. As such, we do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_127"></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the assistance of our chief executive officer and chief financial officer, has reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of June&#160;30, 2024. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving such control objectives. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2024, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our chief executive officer and chief financial officer, have evaluated changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2024, and have concluded that there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_130"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_133"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $47 million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024. Ahead of the May 23 settlement hearing, on April 11, 2024, Plaintiffs filed a motion seeking the Maryland Court&#8217;s final approval of the settlement. At the May 23 settlement hearing, the Maryland Court granted final approval of the settlement. The Maryland Court closed the Sinnathurai Action on May 24, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Needleman Action was also filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order, and, on April 15, 2024, the court entered a further order extending the stay until June 6, 2024. On June 7, 2024, the court entered another order extending the stay until August 5, 2024. On August 5, 2024, the parties agreed to a further 90-day extension to November 4, 2024, which remains subject to court approval. The existing and proposed stays include the deadline for the individual defendants to respond to the consolidated amended complaint. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, following the ruling on the motion to dismiss the Sinnathurai Action, the Delaware Court entered an order granting the Mesa Action parties&#8217; request to set a briefing schedule in connection with a motion to stay by defendants. On February 28, 2023, the court granted the defendants&#8217; motion and stayed the Mesa Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On August 31, 2023, the Mesa plaintiffs filed a motion to lift the stay in the Mesa Action. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023. On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions. On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. On May 3, 2024, the plaintiffs filed a consolidated complaint. On May 14, 2024, the parties filed a stipulation staying the action until June 6, 2024. On July 12, 2024, the court entered an order staying the action until August 5, 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_136"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, which was filed with the SEC on February 28, 2024 and Part II, Item 1A. &#8220;Risk Factors&#8221; of our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, which was filed with the SEC on May 10, 2024. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K, for the fiscal year ended December 31, 2023 and the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, other than as described below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks Related to Product Development and Commercialization </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We must identify vaccines for development with our technologies and establish successful third-party relationships.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The near and long-term viability of our vaccine candidates depend in part on our ability to successfully establish new strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies. Establishing strategic collaborations and obtaining government funding is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position or based on their existing pipelines; government agencies may reject contract or grant applications based on their assessment of public need, the public interest, our products&#8217; ability to address these areas, or other reasons beyond our expectations or control. Collaborators also may seek to modify or terminate relationships, which may be difficult and time-consuming, and ultimately may not be successful and lead to the collaborator rejecting the collaboration. Past success in establishing strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies is no guarantee of future success in entering into new relationships or in performing under existing relationships. Our existing collaborations, including with Sanofi under the Sanofi CLA for the co-commercialization of Nuvaxovid and other vaccines that include Nuvaxovid together with influenza and other antigens, may limit interest in partnering opportunities with respect to our CIC and other products. If we fail to establish a sufficient number of collaborations or government relationships on acceptable terms, or fail to perform under collaborations or relationships to the satisfaction of counter-parties, then we may not be able to commercialize our vaccine candidates or generate sufficient revenue to fund further research and development efforts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The collaborations we have established, including the Sanofi CLA, or may establish, may not result in the successful development or commercialization of any vaccine candidates for several reasons, including the fact that:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">we may not have the ability to control the activities of our partners and cannot provide assurance that they will fulfill their obligations to us, including with respect to the license, development and commercialization of vaccine candidates, in a timely manner or at all;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">such partners may not devote sufficient resources to our vaccine candidates or properly prosecute, maintain or defend our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">our partners could independently develop, or develop with third parties, products that compete directly or indirectly with our vaccine candidates if such partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">any failure on the part of our partners to perform or satisfy their obligations to us could lead to delays in the development or commercialization of our vaccine candidates and affect our ability to realize product revenue, including with respect to Sanofi under the Sanofi CLA, revenue for our only commercial-stage product against COVID-19; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">disagreements, including disputes over the ownership of technology developed with such collaborators, could result in litigation, which would be time consuming and expensive, and may delay or terminate research and development efforts, regulatory approvals and commercialization activities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we or our collaborators fail to maintain our existing agreements or in the event we fail to establish agreements as necessary, then we could be required to undertake research, development, manufacturing and commercialization activities solely at our own expense. These activities would significantly increase our capital requirements and, given our lack of sales, marketing and distribution capabilities, significantly delay the commercialization of our vaccine candidates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing funding and supply agreements or our advance purchase agreements do not assure success of our vaccine candidates or vaccines or that we will be able to fully fund our vaccine candidates or vaccines or our company operations, and if we are unable to satisfy the performance obligations under such agreements the agreements may be terminated, the purchase commitments may be reduced or we may be required to refund advanced payments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d may in the future enter into supply agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(also sometimes referred to as advance purchase agreements) for our COVID-19 Vaccine that include prepayments from the purchasers to help fund our development and manufacture of the vaccine. Under certain supply agreements, if we do not timely achieve requisite regulatory milestones for our COVID-19 Vaccine in the relevant jurisdictions, obtain supportive recommendations from governmental advisory committees, and/or achieve product volume or delivery timing obligations, purchasers may seek to terminate such agreements, reduce their purchase commitments, require us to refund all or some prepayments we have received, or renegotiate such agreements, each of which could have a material and adverse effect on our financial condition. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of prototype vaccine under certain of our supply agreements. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of COVID-19 Vaccine. Such upfront payments generally become non-refundable upon our achievement of certain development, regulatory and commercial milestones. We may not achieve such milestones, which could have a material and adverse effect on our financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in September 2022, following a delay in obtaining regulatory approval in the United Kingdom, we entered into the Amended and Restated UK Supply Agreement, which amended and restated in its entirety the Original UK Supply Agreement, which reduced the volume of vaccine doses that the Authority committed to purchase. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1 million doses and up to an additional 15 million doses (the &#8220;Conditional Doses&#8221;) of our prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the JCVI that is approved by the UK Secretary of State for Health. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15 million doses of our prototype vaccine, we would have to repay up to $225.0 million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority al</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">so has </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the option to purchase up to an additional 44 million doses, in one or more tranches, through 2024. As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to our prototype vaccine, thereby triggering (i) a reduction of the number of Conditional Doses from 15 million doses to 7.5 million doses, which reduced number of Conditional Doses were contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described above, and (ii) an obligation for us to repay $112.5 million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, we repaid the$112.5 million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5 million doses to zero.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the Commonwealth of Australia (&#8220;Australia&#8221;) for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In March 2024, we and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $54.0 million, including $6.0 million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until we receive authorization from the Therapeutic Goods Administration (&#8220;TGA&#8221;). We do not expect approval in time for product delivery in 2024 which could result in a loss or deferral of  approximately $240 million of contract value. We plan to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $119.1 million was classified as current Deferred revenue and $14.7 million was classified as non-current Deferred revenue with respect to the Australia APA in our consolidated balance sheet. If we are unable to satisfy our obligations under the Australia APA, $92.5 million of deferred revenue may become refundable and approximately $225 million of remaining funds under the contract may no longer be available. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). The Canadian government may terminate the Canada APA, as amended, if we fail to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. on or before December 31, 2024. We do not currently anticipate achieving regulatory approval of our COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. Therefore, in parallel, we plan to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable on acceptable terms or at all. As of June 3</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$452.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was classified as current Deferred revenue and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$136.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classified as non-current Deferred revenue with respect to the Canadian APA in our consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0 million of the deferred revenue would become refundable and approximately $224 million of the contract value related to future deliverables would no longer be available.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working with the Canadian Government on an amendment to the APA that addresses regulatory approval and future delivery schedules, which may not be achievable on acceptable terms or at all.</span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_139"></div><div style="text-align:justify"><span><br/></span></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_142"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, certain of our directors and &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-911">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-912">terminated</ix:nonNumeric> contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions and written plans as &#8220;Rule 10b5-1 trading plans&#8221; and each one as a &#8220;Rule 10b5-1 trading plan.&#8221; We describe the material terms of these Rule 10b5-1 trading plans below.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-256" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-913" continuedAt="f-913-1" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John C. Jacobs, President and Chief Executive Officer</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-913-1"><ix:nonNumeric contextRef="c-257" name="ecd:TrdArrAdoptionDate" id="f-914">On May 28, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-257" name="ecd:TrdArrIndName" id="f-915">John C. Jacobs</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-257" name="ecd:TrdArrIndTitle" id="f-916">President and Chief Executive Officer and a member of our board of directors</ix:nonNumeric>, <ix:nonNumeric contextRef="c-257" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-917">entered into a Rule 10b5-1 trading plan</ix:nonNumeric> that provides that Mr. Jacobs, acting through a broker, may sell up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-918">47,526</ix:nonFraction> shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 27, 2024 to April 30, 2025. The plan is scheduled to terminate on <ix:nonNumeric contextRef="c-257" name="ecd:TrdArrExpirationDate" id="f-919">April 30, 2025</ix:nonNumeric>, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Jacobs or the broker, or as otherwise provided in the plan.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-259" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-920" continuedAt="f-920-1" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Trizzino, President and Chief Operating Officer</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-920-1"><ix:nonNumeric contextRef="c-260" name="ecd:TrdArrAdoptionDate" id="f-921">On June 17, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="c-260" name="ecd:TrdArrIndName" id="f-922">John Trizzino</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-260" name="ecd:TrdArrIndTitle" id="f-923">President and Chief Operating Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-260" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-924">entered into a Rule 10b5-1 trading plan</ix:nonNumeric> that provides that Mr. Trizzino, acting through a broker, may sell up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-925">218,669</ix:nonFraction> shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from September 16, 2024 to May 7, 2025. The plan is scheduled to terminate on <ix:nonNumeric contextRef="c-260" name="ecd:TrdArrExpirationDate" id="f-926">May 7, 2025</ix:nonNumeric>, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Trizzino or the broker, or as otherwise provided in the plan.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-262" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-927" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filip Dubovsky, MD, Former President, Research &amp; Development</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-263" name="ecd:TrdArrTerminationDate" id="f-928">May 10, 2024</ix:nonNumeric> , <ix:nonNumeric contextRef="c-263" name="ecd:TrdArrIndName" id="f-929">Filip Dubovsky</ix:nonNumeric>, <ix:nonNumeric contextRef="c-263" name="ecd:TrdArrIndTitle" id="f-930">MD, our former President</ix:nonNumeric>, Research &amp; Development, <ix:nonNumeric contextRef="c-263" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-931">terminated</ix:nonNumeric> a Rule 10b5-1 trading plan that he had originally adopted on December 12, 2023. The plan was for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-932">13,365</ix:nonFraction> shares of our common stock. Sales under the plan were scheduled to occur from March 15, 2024 to June 14, 2024.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on May 9, 2019 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069424000013/nvaxex31xamendedandrestate.htm">Amended and Restated By-Laws of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2024 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000- 26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069424000020/nvax-20240429.htm">Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Appendix A of the Company&#8217;s Definitive Proxy Statement filed on April 29, 2024 in connection with the Annual Meeting held on June 13, 2024 (File No. 000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069424000020/nvax-20240429.htm">Amended and Restated Novavax, Inc. 2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069424000020/nvax-20240429.htm">B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069424000020/nvax-20240429.htm"> of the Company&#8217;s Definitive Proxy Statement filed on April 29, 2024 in connection with the Annual Meeting held on June 13, 2024 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/tm2414089d1_ex10-1.htm">Securities Subscription Agreement, dated May 10, 2024, by and between the Company and Sanofi Pasteur Inc. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed May 13, 2024 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*&#177;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit104.htm">Collaboration and License Agreement, dated May 10, 2024, by and between the Company and Sanofi Pasteur Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit104.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit105.htm">Consulting and Advisory Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit105.htm"> between the Company and Filip Dubovsky, M.D. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit105.htm">May 29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit105.htm">, 2024</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*&#177;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm">Supply Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm">, date</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm">May 6, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xexhibit106.htm">, by and between the Company and Serum Life Sciences Limited</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20240630xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from our Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2024, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Operations for the three and six-month periods ended June&#160;30, 2024 and 2023, (ii) the Consolidated Statements of Comprehensive Income (Loss) for the three and six-month periods ended June&#160;30, 2024 and 2023, (iii) the Consolidated Balance Sheets as of June&#160;30, 2024 and December 31, 2023, (iv) the Consolidated Statements of Changes in Stockholders&#8217; Deficit for the three and six-month periods ended June&#160;30, 2024 and 2023, (v) the Consolidated Statements of Cash Flows for the six-month periods ended June&#160;30, 2024 and 2023, and (vi) the Notes to the Consolidated Financial Statements.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________________</span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed or furnished herewith.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#177;&#160;&#160;&#160;&#160;Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ia1cce1d42cea40b398b487e7aaa3b078_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOVAVAX, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John C. Jacobs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John C. Jacobs<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James P. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James P. Kelly<br/>Executive Vice President, Chief Financial Officer and Treasurer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>nvax-20240630xexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic65efe10465541f1844e49bde32dfd4c_1"></div><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.180%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exhibit 10.4</font></div></td></tr></table></div></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-align:center;text-indent:-0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BETWEEN</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SANOFI PASTEUR INC.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AND</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOVAVAX, INC.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective Date&#58; May 10, 2024</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_4"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div id="ic65efe10465541f1844e49bde32dfd4c_7"></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 1 &#58; DEFINITIONS</a><a href="#ic65efe10465541f1844e49bde32dfd4c_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 2 &#58; LICENSE GRANTS&#59; EXCLUSIVITY</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">31</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Licenses</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">31</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Sublicensing</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">33</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Upstream License Agreements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">35</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Adjuvant Field</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">35</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">No Adjuvant Improvements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">36</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Adjuvant In-Licenses</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">No Implied Licenses&#59; Competing Products&#59; Retained Rights</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 3 &#58; RESEARCH AND DEVELOPMENT</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">General</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.35pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.35pt;text-decoration:none">Collaborative Research and Development of Licensed COVID-19 Components and</a> <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Licensed COVID-19 Mono Products</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">40</a></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.10pt">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.10pt;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.10pt;padding-left:17.3pt;text-decoration:none">Day-to-Day Responsibility</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.10pt;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.10pt;text-decoration:none">42</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Research and Development Diligence</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">42</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Research and Development Reports</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">42</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Transfer of Materials</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">43</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 4 &#58; REGULATORY</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">43</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">General</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">43</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Regulatory Responsible Party</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">44</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Manufacturing Changes</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">45</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Regulatory Diligence</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">45</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Transfer of Regulatory Filings</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Right of Reference&#59; BMF&#59; DMF</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Communications with Regulatory Authorities</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">47</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Compliance&#59; Audit of Records</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">48</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Pharmacovigilance</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 5 &#58; TECHNOLOGY TRANSFER</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:9.5pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">General Technology Transfer and Technical Assistance</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">COVID-19 Manufacturing Technology Transfer</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Adjuvant Technology Transfer</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">51</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Technology Transfer Diligence</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Updates to Technology Transfer Plan for Manufacturing Slots</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Adjuvant Intermediates Technology Escrow</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Other Escrows</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">53</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Escrow Material License</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">54</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Ancillary Agreements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">55</a></font></div><div style="margin-top:9.5pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 6 &#58; MANUFACTURING</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">55</a></font></div><div style="margin-bottom:12pt;margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Novavax Manufacturing</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">55</a></font></div><div style="margin-top:18.15pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Sanofi Manufacturing</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">56</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Supply Agreements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">56</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Quality Agreements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Manufacturing Site Change</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 7 &#58; COMMERCIALIZATION</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">General</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Licensed COVID-19 Mono Product Commercialization Framework</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Existing APAs and Settlement Arrangements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Commercialization Diligence</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">58</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Commercialization Reports</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">59</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Advertising and Promotional Materials</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">59</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Sales and Distribution</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">60</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Training</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Recalls, Market Withdrawals, or Corrective Actions</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Market Access Strategy&#59; Pricing Approvals</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Housemarks</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">64</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 8 &#58; MEDICAL</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">65</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">In General</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">65</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Licensed COVID-19 Mono Product Medical Framework</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">65</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Cooperation</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">65</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 9 &#58; GOVERNANCE</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">General</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Steering Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Research and Development Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Manufacturing and Supply Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Commercialization Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Medical Affairs Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">67</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Finance Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">68</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Joint Patent Committee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">68</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Committee Members</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">69</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Party Non-Member Guests</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">69</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Non-Party Guests</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">69</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Meetings&#59; Quorum</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Committee Decisions</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Information Sharing</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Minutes</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">70</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Expenses</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Limitations of Committee Authority</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Decision Making</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">71</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Disbandment of Committees</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">75</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:none">Alliance Managers</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">75</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 10 &#58; FINANCIAL</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-bottom:12pt;margin-top:9.5pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Up-Front Fee</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:18.15pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Equity Investment</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Licensed COVID-19 Product Milestone Payments</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">76</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Licensed Adjuvanted Product Milestone Payments</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">77</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Royalties</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">79</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Research and Development Plan Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">83</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Regulatory Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">84</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Technology Transfer Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">85</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Manufacturing Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">86</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Commercialization Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">86</a></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Revenues and Expenses&#59; Profits and Losses</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">86</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Medical Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">87</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Patent Costs</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">87</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Other Payment Terms</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">87</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Withholding Tax</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">88</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Financial Records&#59; Audits</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">88</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Late Payment</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">89</a></font></div><div style="margin-top:9.5pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 11 &#58; CONFIDENTIALITY AND NON-DISCLOSURE</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">89</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Confidential Information</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">89</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Confidentiality</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">89</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Exceptions</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">90</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Authorized Disclosure</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">90</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Required Disclosures</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">92</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Public Announcements</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">92</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Scientific COVID-19 Mono Publications</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">93</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 12 &#58; PATENT AND KNOW-HOW MATTERS</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">94</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Ownership</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">94</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Prosecution and Maintenance of Patents</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">95</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Unitary Patent System</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">97</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Patent Term Extension and Supplementary Protection Certificate</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">98</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Patent Listings</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">98</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Patent Enforcement</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">98</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Misappropriation of Know-How</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">101</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Defense of Product Infringement Claims</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">102</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Information Sharing</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">103</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Costs and Recoveries</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">103</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Settlement</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">103</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Common Interest Disclosures</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">104</a></font></div><div style="margin-top:9.5pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 13 &#58; TRADEMARK MATTERS</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">104</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Product Marks</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">104</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Review of Licensed COVID-19 Mono Product Marks</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">104</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Domain Names&#59; Websites</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">104</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">License to Sanofi</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">105</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Trademark and Domain Name Infringement&#59; Enforcement</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">105</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Costs and Expenses</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">105</a></font></div><div style="margin-bottom:12pt;margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Falsified Medicines</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">105</a></font></div><div style="margin-top:18.15pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 14 &#58; REPRESENTATIONS AND WARRANTIES</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">106</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Representations and Warranties of Each Party</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">106</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Representations and Warranties of Novavax</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">107</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Covenants of Each Party</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">110</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Covenants of Novavax</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">111</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Warranty Disclaimer</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">112</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 15 &#58; INDEMNIFICATION&#59; INSURANCE&#59; LIMITATIONS</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">113</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Indemnification</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">113</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Insurance</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">115</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Limitation of Damages</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">116</a></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 16 &#58; TERM&#59; TERMINATION</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">116</a></font></div><div style="margin-top:9.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Term&#59; Expiration</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">116</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Termination of this Agreement</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">116</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Consequences of Termination</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">119</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Bankruptcy</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">121</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Surviving Provisions</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">121</a></font></div><div style="margin-top:9.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">ARTICLE 17 &#58; MISCELLANEOUS</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">122</a></font></div><div style="margin-top:9.55pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Assignment</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">122</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Force Majeure</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">123</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Representation by Legal Counsel</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">123</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Notices</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">124</a></font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Amendment</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Waiver</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Severability</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Descriptive Headings</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt;text-decoration:none">Export Control</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Governing Law</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Jurisdiction&#59; Venue&#59; Service of Process</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">125</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Dispute Resolution</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">126</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Performance by Affiliates</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">127</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Entire Agreement</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">128</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Independent Contractors</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">128</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Interpretation</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">128</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">No Third Party Rights or Obligations</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">128</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Further Actions</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">128</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Counterparts</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">129</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt;text-decoration:none">Language&#59; Translation</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">129</a></font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_10"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:17.1pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SCHEDULES AND EXHIBITS</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Collaboration and License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) is made effective as of May 10, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), by and between Sanofi Pasteur Inc., a corporation organized under the laws of the State of Delaware, having offices located at 1 Discovery Drive, Swiftwater, PA 18370 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), and Novavax, Inc., a corporation organized under the laws of the State of Delaware, having offices located at 700 Quince Orchard, Gaithersburg, MD 20878 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Sanofi and Novavax each may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:0.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, Novavax is a global biopharmaceutical company that has expertise in research, development and commercialization of products directed to pathogenic organisms including SARS-CoV- 2&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">, Sanofi is a global biopharmaceutical company that has expertise in all aspects of the exploitation of pharmaceutical products, including a business unit dedicated to vaccines&#59;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">, the Parties wish to collaborate to further develop, commercialize, and otherwise exploit products referred to herein, in accordance with the terms and conditions set forth herein&#59; and</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">concurrently with the execution of this Agreement, the Parties have executed and delivered a Securities Subscription Agreement.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, in consideration of the respective covenants, representations, warranties, and agreements set forth herein, the Parties hereto agree as follows&#58;</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 1&#58; DEFINITIONS</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For purposes of this Agreement, the following capitalized terms will have the following meanings&#58;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1974 Convention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.10</a> (Governing Law).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024&#47;2025 Season</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the period of time during which (a) Research, Development, Manufacturing, Regulatory Activities, Commercial, or Medical Activities or (b) any decision to be taken hereunder, is performed or taken, in each case ((a) and (b)), with respect to a product Directed To Variant(s) of SARS-CoV-2 recommended by VBRPAC in its annual SARS-CoV-2&#47;COVID-19 strain selection meeting held in 2024.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025&#47;2026 Season</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the period of time during which (a) Research, Development, Manufacturing, Regulatory Activities, Commercial, or Medical Activities to be performed hereunder or (b) any decision to be taken hereunder, is performed or taken, in each case ((a) and (b)), with respect to a product Directed To Variant(s) of SARS-CoV-2 recommended by VBRPAC in its annual SARS-CoV-2&#47;COVID-19 strain selection meeting held in 2025.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a Party or its Affiliate or Sublicensee, GAAP or IFRS, as such Person uses for its financial reporting standards from time to time, in each case, as consistently applied.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Acquired Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.54</a> (Change of Control).</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_13"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, in the context of a Change of Control, a Third Party or its Affiliate that acquires a Party.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.11</a> (Jurisdiction&#59; Venue&#59; Service of Process).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means Matrix-M.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.4.1</a> (Development Milestone).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Adjuvant Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">10.4.1</a> (Development Milestone).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means each Field that is not Unavailable as assessed in accordance with Section</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.4.3</a> (Procedures), excluding all Excluded Adjuvant Fields, unless otherwise agreed in writing by Novavax.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Intermediate Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means that Know-How Controlled by Novavax or its Affiliates as of the Effective Date or during the Term that is actually used for the Manufacture of the Adjuvant Intermediates.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Intermediate Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means (a) the Adjuvant Intermediate Know-How, (b) Materials Controlled by Novavax or its Affiliates as of the Effective Date or at any time during the Term, including raw materials and intermediates, used by or on behalf of Novavax or its Affiliate for the process steps set forth on Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.13</a> for the Manufacture of Adjuvant Intermediates, and</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c) &#91;***&#93;.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Intermediate Escrow Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the failure of Novavax to deliver (in conformance with specifications and all other requirements for delivery under the Adjuvant Supply Agreement), at least (a) &#91;***&#93; of all amounts of Adjuvant Intermediates that Novavax is required to deliver pursuant to the terms of with the Adjuvant Supply Agreement in any &#91;***&#93;, or (b) &#91;***&#93; of all amounts of Adjuvant Intermediates that Novavax is required to deliver pursuant to the terms of the Adjuvant Supply Agreement during any &#91;***&#93; period during the Term.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Intermediate Technology Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an escrow of Adjuvant Intermediate Technology held in confidence by a Third Party escrow agent that is designated by the Parties in accordance with this Agreement, which technology will be released to Sanofi upon the occurrence of an Adjuvant Intermediate Escrow Trigger Event in accordance with the terms of this Agreement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Intermediates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Adjuvant Launch Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">10.4.2</a> (Launch Milestone).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Launch Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.4.2</a> (Launch Milestone).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1.4</a> (Licensed Adjuvanted Products).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Adjuvant Manufacturing Handover Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">5.3</a> (Adjuvant Technology Transfer).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Adjuvant Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">5.3</a> (Adjuvant Technology Transfer).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Manufacturing Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">5.3</a> (Adjuvant Technology Transfer).</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Licensed Adjuvanted Product or Novavax Adjuvant Product.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, on a country-by-country and Licensed Adjuvanted Product-by- Licensed Adjuvanted Product basis, the period beginning upon the First Commercial Sale of a Licensed Adjuvanted Product in a country and terminating upon the later of the date (a) that is twenty (20) years following First Commercial Sale of such Licensed Adjuvanted Product in such country and of (b) expiration of the last Valid Claim of a Novavax Patent that Covers (i) the composition of matter or method of use of the Adjuvant in such Licensed Adjuvanted Product or</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii) the making, having made, using, offering for sale, selling, or importing of the Adjuvant in such Licensed Adjuvanted Product.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3.2</a> (Supply Agreements).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Technology Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an escrow of (a) the Novavax Adjuvant Manufacturing Know-How and (b) Novavax Adjuvant Materials, held in confidence by a Third Party escrow agent that is designated by the Parties in accordance with this Agreement, which technology will be released to Sanofi upon the occurrence of an Other Escrow Trigger Event in accordance with the terms of this Agreement.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Third Party Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.6</a> (Adjuvant In-Licenses).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, as of any point in time and for so long as such relationship continues to exist with respect to any Person, any other Person that controls, is controlled by, or is under common control with such Person. A Person will be regarded as in control of another Person if it (a) owns or controls, directly or indirectly, more than fifty percent (50%) of the equity securities of the subject Person entitled to vote in the election of directors (or, in the case of a Person that is not a corporation, for the election of the corresponding managing authority)&#59; or (b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such Person (whether through ownership of securities or other ownership interests, by contract, or otherwise).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.20.1</a> (Appointment).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Allowable Overruns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to any invoice and a budget agreed by the Parties for any activity to be performed under this Agreement, the amounts in such invoice that are less than or equal to &#91;***&#93; of the amounts set forth in the applicable budget for such activity.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Ancillary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any agreement contemplated under this Agreement to be entered into between the Parties or any of their Affiliates, including &#91;***&#93;.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; mean, with respect to a Licensed Product, the aggregate Net Sales of such Licensed Product invoiced by all Selling Entities in a given Calendar Year.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Antigen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any protein, peptide, or other molecule that induces an adaptive immune response specific to such protein, peptide, or other molecule.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">APA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means each advanced purchase agreement and related ancillary agreements between Novavax and any Third Party for the Manufacture or supply of any Licensed COVID-19 Mono Product for, to or on behalf of such Third Party. All APAs in effect as of the Effective Date are set forth on Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">1.35.</a></font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means all applicable laws, statutes, ordinances, rules, regulations, and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city, or other political subdivision, agency, or other body, domestic or foreign, including any applicable rules, regulations, binding guidelines, or other requirements of the Regulatory Authorities that may be in effect from time to time, including the FD&#38;C Act, GCP, GLP, and GMP, anti-bribery laws, such as the United States Anti-Kickback Statute, the United States Foreign Corrupt Practices Act, and the UK Bribery Act, as well as all applicable data protection and privacy laws, rules, and regulations, including the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act, as amended, and the Health Information Technology for Economic and Clinical Health Act and the EU General Data Protection Regulation 2016&#47;679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95&#47;46&#47;EC, along with other country-level data protection laws, as may be applicable.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.4</a> (Bankruptcy).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.4</a> (Bankruptcy).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Baseball Arbitration Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.5(d)</a> (Budget Status Quo).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Licensed COVID-19 Product in a particular country, a pharmaceutical product that (a) is marketed by a Person other than Sanofi, Novavax, or their respective Affiliates or licensees or Sublicensees for the same Indication as such Licensed COVID-19 Product, and such Person did not purchase such product in a chain of distribution that included any of Sanofi or its Affiliates or Sublicensees, and that (b) (i) has been licensed as a biosimilar, bioequivalent or interchangeable product by the FDA under Section 351(k)</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of the Public Health Service Act (42 U.S.C. &#167; 201 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), as amended, (ii) has been licensed as a similar biological medicinal product by the EMA as described in Directive 2001&#47;83&#47;EC, as may be amended (including by EU Directive 2004&#47;27&#47;EC), or any subsequent or superseding law, statute or regulation, or (iii) has received marketing authorization as a biosimilar, bioequivalent or interchangeable product by a Governmental Authority under any equivalent law, statute, or regulation in such jurisdiction&#59; in each case ((b)(i)-(iii)), where the Licensed COVID-19 Product is the reference product for purposes of such licensure or marketing authorization.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a biologics license application submitted to the FDA as defined in the Public Health Service Act and 21 C.F.R. 601.2 (including all additions, supplements, extensions, and modifications thereto).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">BMF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a biologics master file and all equivalents, and related proprietary dossiers, in any country or jurisdiction in the Territory for a biologic substance submitted (or to be submitted) by a Party to Regulatory Authorities.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Budget Status Quo Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.5(d)(ii)</a> (Budget Status Quo).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a day on which the commercial banks in Gaithersburg, MD, U.S.A. or Swiftwater, Pennsylvania, U.S.A. are open for commercial banking business, other than a Saturday or a Sunday.</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30, or December 31, during the Term, or the applicable part thereof during the first or last calendar quarter of the Term.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any year commencing on January 1 and ending on December 31, or the applicable part thereof during the first or last year of the Term.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Cancellation Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means all monetary consideration received by any Selling Entity resulting from the cancellation of a purchase order or other binding purchase commitment for a Licensed Product by a customer of any Selling Entity.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means that Confidential Disclosure Agreement, by and between Sanofi and Novavax, dated &#91;***&#93;.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">CEPI Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means all contracts existing as of the Effective Date by and between Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), including the Outbreak Response Funding Agreements, COVAX Marketplace User Agreement and any amendments thereof, in each case relating to COVID-19.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">CIC License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.1.2</a> (COVID-19 and Influenza Combination Products).</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CIC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Licensed CIC Product or Novavax CIC Product.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any clinical investigation conducted on human subjects, as that term is defined in FDA regulations at 21 C.F.R. &#167; 312.3, or a similar clinical investigation conducted on human subjects, as defined under Applicable Law outside the United States. Without limiting the foregoing, &#8220;Clinical Trial&#8221; includes any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, and Pivotal Clinical Trial.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means chemistry, manufacturing, and controls.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a contract manufacturing organization.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Co-Exclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to the grant of the COVID-19 Mono License hereunder by Novavax to Sanofi, that Sanofi, its Affiliates, and its Sublicensees shall be the only Persons who may practice the Licensed Novavax Assets to Exploit Licensed COVID-19 Mono Products other than&#58; (a) Novavax and its Affiliates, in the Collaboration COVID-19 Territory and (b) Novavax, its Affiliates, and Third Parties under an Existing Strategic Partner Agreement in the Existing Partner Non-Exclusive Territory during the term of such Existing Strategic Partner Agreement, in each case ((a) and (b)), only as expressly permitted by this Agreement.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Collaboration COVID-19 Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to any Licensed COVID-19 Mono Product, any country or region of the world other than Existing Partner Exclusive Territory.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Collaboration Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the period commencing on the Effective Date and ending upon the earlier of (a) termination of the COVID-19 Mono License under this Agreement, and (b) termination of this Agreement in its entirety.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, in respect of a drug product, to (a) (i) market, advertise, promote, detail, distribute, offer for sale, and sell, and (ii) import, or export, in each case, in connection with the activities described in clause (i) above&#59; (b) conduct activities, other than Development, Medical Activities, and Manufacturing, in preparation for the foregoing activities, including obtaining Pricing Approval and interacting with Regulatory Authorities with respect to the foregoing&#59; (c) conduct Post-Marketing Requirements&#59; or (d) interact with recommending Governmental Authorities, such as local National Immunization Technical Advisory Groups, and supranational health organizations, such as World Health Organization, United Nations International Children&#8217;s Emergency Fund (UNICEF), Pan American Health Organization, Gavi, etc. When used as a noun, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any activities involved in Commercializing. The term &#8220;Commercialize&#8221; does not include Medical Activities, Development activities, Manufacturing activities, or Regulatory Activities.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the JSC and each Subcommittee.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Committee Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.3</a> (Decisions of the JSC).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Committee Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.17</a> (Limitations of Committee Authority).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Disclosing Party, all non-public or proprietary information (including information communicated in oral, written, visual, graphic, or electronic form) that is disclosed or made available by or on behalf of such Party to the other Party pursuant to this Agreement, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221;.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means with respect to a Party, other than pursuant to this Agreement,</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) with respect to Materials, the legal authority or right to physical possession of such materials, with the right to provide such materials to the other Party on the terms set forth herein, and (b) with respect to Patents, Marketing Authorizations, Regulatory Filings, Know-How, or other intellectual property rights, the legal authority or right to grant a license, access or other right to use (as applicable) to the other Party under such Patents, Marketing Authorizations, Regulatory Filings, Know-How, or other intellectual property rights on the terms set forth herein, in each case (a) and (b), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use, licenses, or sublicense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that any Materials, Patents, Marketing Authorizations, Regulatory Filings, Know-How, or other intellectual property, as applicable, that comes into such Party&#8217;s or its Affiliates&#8217; control as a result of a Change of Control of such Party, will not be deemed Controlled by such Party for purposes of this Agreement, except to the extent, and only to the extent, that such Materials, Patents, Marketing Authorizations, Regulatory Filings, Know-How, or other intellectual property, as applicable, are</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i) developed, acquired, or otherwise Controlled by the Acquirer pursuant to or in connection with a license or other agreement between the Acquirer or any of its Affiliates, on the one hand, and such Party, on the other hand, (ii) developed or acquired by the Acquirer following such Change of Control with the use of or access to, or otherwise incorporates, is derived from, or based upon, the subject matter used or made available by the Acquirer under this Agreement, (iii) actually used by such Party or its Affiliates, or the Acquirer, in the performance of activities under this Agreement or (iv) developed, acquired, or otherwise Controlled by the Acquirer in the course of or as a result of performing its Affiliate&#8217;s obligations or exercising its Affiliate&#8217;s rights under this Agreement.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;, or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, in reference to a particular subject matter (such as a composition of matter, method, or process) and a Patent in a particular country or other jurisdiction, that such subject matter meets or practices all elements or limitations of at least one (1) claim (as</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">interpreted under principles of patent law in such country or jurisdiction or, in the case of applications filed under the Patent Cooperation Treaty, in the jurisdiction of the international searching authority) of such Patent.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means coronavirus disease, an infectious disease caused by the SARS-CoV-2 virus.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.3.1</a> (Development Milestone).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">COVID-19 Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">10.3.1</a> (Development Milestone).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">COVID-19 Launch Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">10.3.2</a> (Launch Milestone).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Launch Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.3.2</a> (Launch Milestone).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Manufacturing Handover Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">5.2.1</a> (COVID- 19 Manufacturing Handover).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">5.2.1</a> (General).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.3pt">&#8220;COVID-19 Manufacturing Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.2.1</a> (General).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">COVID-19 Mono License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">2.1.1</a> (Licensed COVID-19 Mono Products).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">COVID-19 Research and Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">3.2.2</a> (COVID-19 Research and Development Budget).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Budget Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.2.2</a> (COVID-19 Research and Development Budget).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Research and Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">3.2.1</a> (COVID-19 Research and Development Plan).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Plan Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means FTE Costs and Out-of-Pocket Costs incurred by or on behalf of a Party or its Affiliates after the Effective Date in the course of performing (a) Research or Development activities or (b) the specific Regulatory Activities or Medical Activities, in each case ((a) and (b)), included in the COVID-19 Research and Development Plan.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, on a country-by-country and Licensed COVID-19 Product- by-Licensed COVID-19 Product basis, the period beginning upon the First Commercial Sale of a Licensed COVID-19 Product in a country and terminating upon the latest of (a) expiration of the last Valid Claim of (i) a Novavax Patent or (ii) a Joint Arising Patent in such country that Covers, in whole or in part, the composition of matter or a method of use (of an Indication that has received Marketing Authorization) of such Licensed COVID-19 Product or the making, having made, using,</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">offering for sale, selling, or importing such Licensed COVID-19 Product&#59; (b) expiration of all Regulatory Exclusivity applicable to such Licensed COVID-19 Product in such country&#59; and (c) ten (10) years following First Commercial Sale of such Licensed COVID-19 Product in such country.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3.1</a> (Supply Agreements).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Technology Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an escrow of (a) the Novavax COVID-19 Manufacturing Know-How and (b) Novavax COVID-19 Materials, held in confidence by a Third Party escrow agent that is designated by the Parties in accordance with this Agreement, which technology will be released to Sanofi upon the occurrence of an Other Escrow Trigger Event in accordance with the terms of this Agreement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means all information and results, whether in raw or aggregate form, including preclinical data, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">in vitro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">data, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">in silico </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">data, clinical data, regulatory, biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, safety, and quality control data.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#91;***&#93;.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to any drug product or drug substance contained therein or raw material or intermediate thereof, all development activities directed towards obtaining and maintaining Marketing Authorization of such drug product, including (a) the conduct of Clinical Trials, including all protocol and investigator brochure development&#59; (b) test and assay method development and qualification&#59; (c) process or formulation development&#59; (d) delivery system development&#59; (e) quality assurance and quality control development&#59; and (f) statistical analysis in connection with any of the foregoing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; does not include any Research activities, Commercialization activities, Medical Activities, Manufacturing activities, or Regulatory Activities. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the act of performing Development and to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means to perform Development.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Directed To</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Directed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to an Antigen and a pathogen, organism, or disease, that such Antigen is designed to (a) in the case of a pathogen or organism, elicit a specific immune response to such pathogen or organism, and (b) in the case of a disease, elicit a prophylactic or therapeutic effect with respect to such disease.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.1</a> (Confidentiality).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a first Licensed Adjuvanted Product and a second Licensed Adjuvanted Product, that such first Licensed Adjuvanted Product is Directed To one (1) or more Antigen(s) from a different species of a pathogen or organism as compared to such second Licensed Adjuvanted Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, that the first Licensed Product and the second Licensed Product do not contain Antigens Directed To identical pathogens, organisms, or diseases). &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Distributor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a Person who distributes, offers for sale, and sells Licensed Products in the Territory (with or without packaging rights), in circumstances where the Person purchases its requirements of Licensed Products from a Party or its Affiliates or Sublicensees pursuant to a written agreement but does not otherwise make any royalty or other payment to such Party or its Affiliates with respect to any proprietary rights in or to such Licensed Product, other than a license to use any trademarks in connection with the distribution, marketing, or sale of the Licensed Products. The term &#8220;packaging rights&#8221; in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.95</a> (Distributor) means the right for the Distributor to package and label Licensed Products supplied in unpackaged bulk form into individual ready-for-sale packs.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">DMF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a drug master file and all equivalents, and related proprietary dossiers, in any country or jurisdiction in the Territory for a drug substance submitted (or to be submitted) by a Party to Regulatory Authorities.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency and any successor entity thereto.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Emergency Use Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">EUA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a conditional Marketing Authorization granted pursuant to Section 564 of the FD&#38;C Act to expedite access to medicines to address public health emergencies.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Enforcement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to any Patent, Know-How, or trademark, any action, including bringing, maintaining, and terminating any suit, claim, or action against any Third Party engaged in any existing, alleged, or threated Infringement (with respect to Patents and trademarks), misappropriation, or other violation.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">European Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the European Commission or any successor entity thereto.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">European Union</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the countries of the European Economic Area, as it is constituted on the Effective date and as it may be modified from time to time after the Effective date.</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Excluded Adjuvant Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means (a) all Fields for (i) Influenza and (ii) SARS-CoV-2, and (b) any other Field that is Unavailable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that during the pendency of a Pandemic declared for a pathogen, organism, or disease that is not SARS-CoV-2, no Field for such pathogen, organism, or disease, regardless of whether Novavax has, as of the commencement of such Pandemic, granted exclusive rights to a Third Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, for any Field that is Unavailable due to operation of clause</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b) of the definition thereof), shall be deemed Excluded Adjuvant Fields. For clarity, nothing in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">1.104</a> (&#8220;Excluded Adjuvant Fields&#8221;) is intended to limit the COVID-19 Mono License, the CIC License, or the OC License.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Novavax Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.203</a> (Novavax Patent).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Partner Exclusive Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any country or region of the world where Novavax has, as of the Effective Date, granted a Third Party exclusive rights to Manufacture and Commercialize the Licensed COVID-19 Mono Product pursuant to an Existing Strategic Partner Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that on the date of termination or expiration of all Existing Strategic Partner Agreements for a particular country in the Existing Partner Exclusive Territory, such country will cease to be included in the Existing Partner Exclusive Territory and such country will become included in the Collaboration COVID-19 Territory. Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.106</a> sets forth all countries and regions in the Existing Partner Exclusive Territory as of the Effective Date.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Partner Non-Exclusive Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any country or region of the world where Novavax has, as of the Effective Date, granted a Third Party non-exclusive rights to Manufacture and Commercialize the Licensed COVID-19 Mono Product pursuant to an Existing Strategic Partner Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that on the effective date of termination or expiration of all Existing Strategic Partner Agreements for a particular country in the Existing Partner Non-Exclusive Territory, such country will cease to be included in the Existing Partner Non-Exclusive Territory. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1.107</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sets forth all countries and regions in the Existing Partner Non-Exclusive Territory as of the Effective Date.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Existing Settlement Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">1.270</a> (Settlement Arrangements).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Existing Strategic Partner Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any legally binding contract between Novavax and a Third Party (each such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Strategic Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) granting Manufacturing and Commercialization rights for Licensed COVID-19 Mono Products in a country or region to such Third Party, but excluding all APAs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">1.109</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> sets forth all Existing Strategic Partner Agreements in effect as of the Effective Date.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Existing Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means all suppliers of Materials for the Manufacturing of Licensed COVID- 19 Mono Products as of the Effective Date and any new suppliers engaged in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">14.4.4</a> (New Arrangements).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Existing Supply Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the contracts between Novavax and Existing Suppliers that are material to the Manufacturing of Licensed COVID-19 Mono Products and for Materials that are not available on commercially available standard terms. The Existing Supply Agreements as of the Effective Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">1.111</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (Existing Supply Agreements).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expert Budget Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(d)(ii)</a> (Budget Status Quo).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a drug product or any drug substance contained therein or raw material or intermediate thereof, to use, have used, Research, have Researched, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import, export, transport, conduct Medical Activities with respect to, or otherwise make full use of such compound or product, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the act of exploiting such compound or product.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Extended Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Falsified Medicine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">13.7</a> (Falsified Medicines).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the United States Food and Drug Administration and any successor entity thereto.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means (a) with respect to a particular pathogen or organism, the treatment, diagnosis, or prevention of disease or medical condition in humans caused by or associated with infection with such pathogen or organism, and (b) in the case of targets other than a pathogen or organism, the treatment, diagnosis, or prevention of a particular Indication associated with such target.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means with respect to a Licensed Product, the first sale of such Licensed Product by Sanofi, its Affiliate, or its Sublicensee to a Third Party, which sale is intended for end use or consumption, that results in Net Sales in a particular country and occurs after all required Marketing Authorizations, and if required for reimbursement in such country, Pricing Approvals, for the Licensed Product has been obtained in such country&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that the following will not constitute a First Commercial Sale&#58; (a) any sale or other disposition of a Licensed Product by Sanofi to any of its Affiliates or Sublicensees&#59; (b) any sale or other disposition of a Licensed Product solely for use in Research or Development&#59; (c) the disposal or transfer of a Licensed Product for a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">charitable purpose or disposition for no profit&#59; or (d) sale or other disposition of a Licensed Product for compassionate use, &#8220;treatment IND sales&#8221;, &#8220;named patient sales&#8221;, &#8220;expanded access sales&#8221;, &#8220;right to try sales&#8221;, or similar, in each case, for no profit.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a condition, the occurrence and continuation of which is beyond the reasonable control of a Party, including an act of God, governmental acts, omissions or restrictions, embargoes, shortages, acts of war or terrorism, civil commotion, labor strike or lock-out, epidemic, pandemic, flood, failure or default of public utilities or common carriers, or destruction of production facilities or materials by fire, earthquake, explosion, storm, or like catastrophe.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93; hours of work per annum devoted to or in support of the Research or other Development activities, Technology Transfer activities, Manufacturing activities, Regulatory Activities, Medical Activities, or Commercialization activities, in each case, that are carried out by one or more qualified scientific or technical employees (excluding Service Providers) of either Party or any of its Affiliates, or its or their Sublicensees, as applicable. Notwithstanding the foregoing, the time of a single individual will not account for more than one (1) FTE for a given Calendar Year.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FTE Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, for any period, the FTE Rate multiplied by the number of FTEs who perform a specified activity under this Agreement. FTEs will be calculated on a prorated basis, if necessary, based on the time spent performing the applicable activity.</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93; per annum, which includes (a) all wages and salaries, employee benefits, bonus, travel and entertainment, supplies, and other direct expenses&#59; and (b) indirect allocations, including all general and administrative expenses, human resources, finance, occupancy, and depreciation, in each case ((a) and (b)), expended in connection with relevant activities. The FTE Rate will be increased on January 1 of each Calendar Year beginning in 2025 in accordance with the percentage year-over- year increase based on the then-current CORE CPI-US-U price index published by the U.S. Bureau of Labor Statistics.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.2</a> (Appointment).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">GAVI Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the Termination and Settlement Agreement by and between Novavax and Gavi Alliance, dated February 16, 2024, and including any agreements with UNICEF and PAHO to effectuate the sales of Licensed COVID-19 Mono Products, Novavax CIC Products, or Novavax OC Products under such Termination and Settlement Agreement.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means good clinical practices, which are the then-current standards for Clinical Trials for pharmaceuticals, as set forth in the FD&#38;C Act, ICH Guideline Q7A, or other Applicable Law, and such standards of good clinical practice as are required by the Regulatory Authorities of the European Union and other organizations and Governmental Authorities in countries for which the applicable Licensed Product is intended to be Developed, to the extent such standards are not less stringent than United States standards or ICH Guidelines.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, or the successor thereto, or comparable regulatory standards in jurisdictions outside of the United States as they may be updated from time to time, to the extent such standards are not less stringent than United States standards.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the then-current Good Manufacturing Practices as specified in Applicable Law, including the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules or regulations of an applicable Regulatory Authority at the time of manufacture.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any court, agency, department, authority, or other instrumentality of any national, federal, state, county, city, or other political subdivision, including any relevant Regulatory Authority.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">HCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a health care practitioner, such as physicians, pharmacists, nurse practitioners, or other health professionals having prescribing or purchasing authority or who is able to influence prescribing or purchasing decisions. Whether a specific individual is considered as an HCP in any jurisdiction shall be determined in accordance with Applicable Law in such jurisdiction.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Investigational New Drug application (including any amendment or supplement thereto) filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto or, if applicable, a comparable application or submission filed with a Regulatory Authority outside the U.S. for the investigation of any product in any other country or group of countries (such as a Clinical Trial Application in the EU).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IND Clearance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Novavax Adjuvant Product, the earlier of (a) in the U.S., the date that is thirty (30) days following the filing of the first IND for such Novavax Adjuvant Product, if Novavax has not received any notice of a clinical hold or any other administrative delay from the FDA during such thirty (30) day period, and if Novavax or its Affiliates or Sublicensee does receive a notice of a clinical hold or there is such other administrative delay, then the date of &#8220;IND Clearance&#8221; for the Novavax Adjuvant Product will be the date on which the FDA lifts such clinical hold or such other administrative delay is otherwise resolved and the FDA first allows the Novavax Adjuvant Product to be administered to a human as described in such IND and (b) in other regulatory jurisdictions outside the U.S., the date on which such Novavax Adjuvant Product is first permitted by the applicable Regulatory Authority of such jurisdiction to be administered to a human</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">pursuant to an IND filing in accordance with Applicable Laws (or, to the extent no IND filing is required under Applicable Law in such regulatory jurisdiction, the date of initiation of the first Clinical Trial in such jurisdiction using such Novavax Adjuvant Product).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.3</a> (Procedure).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.3</a> (Procedure).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a product, a distinct disease, or medical condition in humans that such product is designed to address, such that a Regulatory Authority would approve such disease or medical condition as a discrete claim (as opposed to a variant or subdivision or subset of a claim) in the labeling of such product based on the results of a separate Clinical Trial(s) sufficient to support Marketing Authorization of such claim. The following will each be deemed to be part of the same Indication&#58; (a) different diseases or medical condition with the same etiology, (b) different stages of disease (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, localized vs. systemic for the same disease or medical condition, etc.)&#59; (c) different biomarker status with respect to the same disease or medical condition&#59; (d) variants or subdivisions or subclassifications of such disease or medical condition, including Variants of a pathogen or organism&#59; or (e) treatment, modulation, and prophylaxis of a disease or medical condition in a different patient population or sub-population.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Influenza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means all species of influenza viruses in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">Orthomyxoviridae </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">family, including the A&#47;H1N1 strains, A&#47;H3N2 strains, and B-Victoria lineage and any other strains or Variants thereof.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Invalidity Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a Patent, any action, claim, or demand brought by a Third Party, including a declaratory judgment action, opposition, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">review or other post- grant proceeding, alleging that such Patent is invalid or unenforceable.</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.5.1</a> (Formation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.7.1</a> (Formation).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JMAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.6.1</a> (Formation).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JMSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.4.1</a> (Formation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Joint Arising Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.1.3</a> (Joint Ownership).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.8.1</a> (Formation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.3.1</a> (Formation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.2.1</a> (Formation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means all non-public technical or scientific information, including Data, chemical structures, chemical sequences, formulas, methods, processes, procedures, practices, protocols, techniques, discoveries, inventions, specifications, designs, trade secrets, and supply chain sources, including any of the foregoing included or referenced in Regulatory Filings, and in each case, whether patentable or not, and in any tangible or intangible form whatsoever.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Knowledge Portal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.1.1</a> (Transfer Method).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Licensed Adjuvanted Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a Proposed Adjuvanted Product in any dosage, strength, formulation, or presentation designed to treat any disease or condition that has been confirmed to be in the Adjuvant Field in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.4</a> (Adjuvant Field). For clarity, Licensed Adjuvanted Product excludes Licensed COVID-19 Products and Novavax Products.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Licensed CIC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product Exploited by Sanofi or its Affiliates or Sublicensees in any dosage, strength, formulation, or presentation that contains (a) a Licensed COVID-19 Component, (b) the Adjuvant, and (c) one (1) or more Antigens owned by, or licensed to, Sanofi or its Affiliate or Sublicensee and Directed To Influenza (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the Novavax Influenza Component), with or without any other Antigen Directed To any pathogen(s) other than SARS-CoV-2 and Influenza. For clarity, Licensed CIC Product excludes Licensed COVID-19 Mono Products, Licensed OC Products, Licensed Adjuvanted Products, and all Novavax Products.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Licensed COVID-19 Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means (a) all Antigens Directed To SARS-CoV-2 formulated with any polysorbate to form a nanoparticle, and (b) all derivatives or modifications of the molecules of clause (a) generated by or on behalf of Novavax or Sanofi in the performance of Research and Development activities in accordance with this Agreement.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Licensed COVID-19 Mono Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product in any dosage, strength, formulation, or presentation that contains (a) a Licensed COVID-19 Component and (b) the Adjuvant, and does not include any Antigen Directed To any pathogen or organism other than SARS-CoV-2 and that is not for the prevention or prophylaxis of any disease other than COVID-</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">19. For clarity, Licensed COVID-19 Mono Product excludes Licensed CIC Products, Licensed OC Products and Licensed Adjuvanted Products, and all Novavax Products.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Licensed COVID-19 Mono Product Commercialization Framework</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">7.2</a> (Licensed COVID-19 Mono Product Commercialization Framework).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Licensed COVID-19 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means any Licensed COVID-19 Mono Product, Licensed CIC Product, or Licensed OC Product.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Licensed Novavax Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means collectively the Novavax Patents, Novavax Know-How, and Novavax Materials.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Licensed OC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any pharmaceutical product Exploited by Sanofi or its Affiliates or Sublicensees in any dosage, strength, formulation, or presentation that contains (a) a Licensed COVID-19 Component, (b) the Adjuvant, and (c) at least one (1) Antigen Directed To any pathogen(s) other than SARS-CoV-2 or Influenza. For clarity, Licensed OC Product excludes Licensed COVID-19 Mono Products, Licensed CIC Products, Licensed Adjuvanted Products and all Novavax Products.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means any (a) Licensed Adjuvanted Product or (b) Licensed COVID-19 Product.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Licensed Product Mark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means trademarks, designs, copyrights, domain names, trade dress, trade names, positioning, messages, logo, colors, and other visual branding elements a Party utilizes in connection with the Commercialization of Licensed COVID-19 Mono Product.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Major Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means with respect to a drug product or any drug substance contained therein or raw material or intermediate thereof, those activities directed to making, producing, manufacturing, processing, formulating, filling, finishing, packaging, labeling, conducting quality control testing and quality assurance release activities, supplying, shipping, or storing of such compound or product or any raw material or intermediate thereof. Manufacture excludes all Medical Activities, Commercialization activities, Research activities, Development activities, and Regulatory Activities.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Licensed COVID-19 Mono Product, Licensed COVID-19 Component, Adjuvant, &#91;***&#93; and &#91;***&#93;, or Adjuvant Intermediate, as applicable, including, to the extent applicable, in each case, works-in-progress or components or ingredients thereof, the fully-burdened cost incurred by a Party or any of its Affiliates for Manufacturing or purchasing from a Third Party, as applicable, such Licensed COVID-19 Mono Product, Licensed COVID-19 Component, or Adjuvant (including (a) the costs associated with inventory build-up in advance of launch of any thereof (including validation batches if deemed saleable), but only until technical feasibility is determined and such Licensed COVID-19 Mono Product, Licensed COVID-19 Component, or Adjuvant inventory can be capitalized, and thereafter such Licensed COVID-19 Mono Product, Licensed COVID-19 Component, or Adjuvant inventory will be charged as a cost only at the time such inventory is sold or destroyed&#59; and (b) the cost to Manufacture samples of Licensed COVID-19 Mono Product, Licensed COVID-19 Component, or Adjuvant for distribution), which costs calculated as follows&#58;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.165.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.35pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.165.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.35pt">&#91;***&#93;&#58;</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93;&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#91;***&#93;.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product in a particular country or group of countries, any approval, license, registrations, or authorization, including EUAs, granted by a Governmental Authority necessary for the commercial sale of a product in such country or other regulatory jurisdiction, excluding, in each case, Pricing Approval. For purposes of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.166</a> (Marketing Authorization), &#8220;Governmental Authority&#8221; will include the FDA in the U.S., the EC in the EU, or any governmental health authority in any country or other jurisdiction that is a counterpart to the foregoing agencies, in each case, that has jurisdiction in such country or group of countries to authorize the promotion, sale, and distribution of such Licensed Product for any Indication.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketing Authorization Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product in a particular country or region, an application for Marketing Authorization, examples of which include, (a) with respect to the United States, a BLA&#59; (b) with respect to the European Union, an MAA&#59; and (c) with respect to countries and regions other than the United States and the European Union, equivalents to a BLA or MAA in such other country or region.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means all biological materials, chemical compounds, and other materials provided by or on behalf of a Party to the other Party, its Affiliate, or its Sublicensee, or their Service Providers for use in the conduct of activities pursuant to this Agreement or for incorporation into a Licensed Product, including drug products, drug substance, packaging, cell lines, Antigens, compounds, lipids, assays, viruses, and vectors.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#91;***&#93;.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#91;***&#93;.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Matrix-M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the saponin-based adjuvant developed by Novavax or its Affiliates, (a) as described in Novavax&#8217;s DMF for Matrix-M filed with the FDA in the U.S. in existence as of the Effective Date, as such DMF may be updated with the FDA in the U.S. from time-to-time during the Term, including to reflect any changes to Matrix-M and (b) as described in Novavax&#8217;s or any Affiliate&#8217;s DMF for a saponin-based adjuvant that is a derivative, modification, or improvement of the saponin-based adjuvant in the DMF of the foregoing clause (a).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Medical Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means (a) activities directed to HCPs to provide them with objective, scientific information to educate and inform, including such information provided through congresses and other venues for peer-to-peer scientific discourse&#59; (b) to convene and manage</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">advisory boards and relationships with key opinion leaders&#59; and (c) evidence generation studies that do not include the administration of Licensed Product&#59; in each case of (a)-(c), excluding promotional or other sales-related activities further described in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 7</a> (Commercialization) and excluding any Development activities, Manufacturing activities, or Regulatory Activities.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.173</font><img alt="image_01a.jpg" src="image_01a.jpg" style="height:13px;margin-bottom:5pt;vertical-align:text-bottom;width:1px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Milestone Eligible Licensed COVID-19 Mono Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a Licensed COVID-19 Mono Product that has received Marketing Authorization pursuant to a BLA or MAA and that includes &#91;***&#93;. For purposes of this definition, Emergency Use Authorization by FDA or EC shall not be deemed Marketing Authorization.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.174</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Licensed Product sold in a country during the Adjuvant Royalty Term or COVID-19 Royalty Term, as applicable, for such Licensed Product in such country, the gross amount invoiced by Sanofi or its Affiliates or Sublicensee (each such Person, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Selling Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), in each case, to Distributors or other Third Party purchasers in an arms-length transaction, less the following customary deductions, &#91;***&#93;&#58;</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.43pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.37pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.81pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.81pt">&#91;***&#93;&#59; and</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">in each case (a) through (k), on a country-by-country basis, to the extent consistent with applicable Accounting Standards and consistently and equitably applied across Sanofi&#8217;s pharmaceutical products.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#91;***&#93;&#58;</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.81pt">&#91;***&#93;.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.59pt">&#91;***&#93;.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.37pt">&#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Additionally, for the calculation of Net Sales of any Licensed CIC Product or Licensed OC Product, the following shall apply&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#91;***&#93;.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.35pt">&#91;***&#93;.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:25.35pt">&#91;***&#93;.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NIH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means National Institutes of Health of the United States.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#91;***&#93;.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.4</a> (Bankruptcy).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.179</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Party Guest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.11</a> (Non-Party Guests).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.180</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (Data Safeguards).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Adjuvant Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Know-How Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that is &#91;***&#93; to Exploit the Adjuvant, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">all Adjuvant Intermediate Technology.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.183</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Adjuvant Manufacturing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Novavax Adjuvant Know-How that &#91;***&#93; used to Manufacture the Adjuvant, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">all Adjuvant Intermediate Technology.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.184</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Adjuvant Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Materials Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that are &#91;***&#93; to Exploit the Adjuvant (excluding any Material related to the Manufacture of the Adjuvant Intermediate).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Adjuvant Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Patent Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that is &#91;***&#93; to Exploit the Adjuvant, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">all Joint Arising Patents.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Adjuvant Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any pharmaceutical product Exploited by Novavax or its Affiliates or (sub)licensees in any dosage, strength, formulation, or presentation that contains the Adjuvant. For clarity, Novavax Adjuvant Product excludes Novavax CIC Products, Novavax OC Products, and Licensed Products.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax CIC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any pharmaceutical product Exploited by Novavax or its Affiliates or (sub)licensees in any dosage, strength, formulation, or presentation that contains (a) a Licensed COVID-19 Component and (b) a Novavax Influenza Component, with or without any Antigen Directed To any other pathogen(s) other than SARS-CoV-2 and Influenza. For clarity, Novavax CIC Product excludes Novavax OC Products, Novavax Adjuvant Products, and Licensed Products.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.188</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Novavax Commercialization Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">7.6.2</a> (Novavax Commercialization Reports).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax COVID-19 Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Know-How Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that is &#91;***&#93; to Exploit any Licensed COVID-19 Mono Product or Licensed COVID-19 Component, including all Know-How disclosed by Novavax to Sanofi pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1(a)</a> (Strain Selection Activities), but </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">all Novavax Adjuvant Know-How and Adjuvant Intermediate Technology.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.190</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax COVID-19 Manufacturing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Novavax COVID-19 Know-How that is &#91;***&#93; used to Manufacture any Licensed COVID-19 Mono Product or Licensed COVID-19 Component.</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax COVID-19 Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Materials Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that are &#91;***&#93; to Exploit any Licensed COVID-19 Mono Product or Licensed COVID-19 Component, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any Novavax Adjuvant Material and any Material used for the Manufacture of the Adjuvant Intermediate.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.192</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax COVID-19 Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Patent Controlled by Novavax or any of its Affiliates, as of the Effective Date or at any time during the Term, that is &#91;***&#93; to Exploit a Licensed COVID-19 Mono Product or Licensed COVID-19 Component (alone or in combination with a component Directed To another Antigen), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">all Joint Arising Patents and Novavax Adjuvant Patents.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.193</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Domain Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the domain names set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1.193</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">.</a></font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.194</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax General Combo Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Novavax Patent that Covers (a) Licensed COVID- 19 Component (in combination with a component Directed to an Antigen that is not an Influenza Antigen) and (b) a Licensed OC Product. The Novavax General Combo Patents that exist as of the Effective Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">1.194</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">.</a></font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.196</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Influenza Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an Antigen Directed To Influenza made using Novavax&#8217;s Baculovirus Platform.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means Novavax Adjuvant Know-How, Novavax COVID-19 Know-How, Adjuvant Intermediate Know-How, any Unauthorized Inventions, and Novavax&#8217;s rights, title, and interests in Joint Arising Know-How.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.198</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1.5</a> (License to Novavax).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.199</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Novavax Manufacturing Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means any Novavax Adjuvant Manufacturing Know- How and Novavax COVID-19 Manufacturing Know-How.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Novavax Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the Novavax COVID-19 Material and the Novavax Adjuvant Material.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(a)</a> (Novavax Matters).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.202</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax OC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any pharmaceutical product Exploited by Novavax or its Affiliates or (sub)licensees in any dosage, strength, formulation, or presentation that contains (a) a Licensed COVID-19 Component and (b) at least one (1) Antigen owned by, or licensed to, Novavax or its Affiliate or (sub)licensee and Directed To any other pathogen(s) other than SARS-CoV-2 or Influenza. For clarity, Novavax OC Product excludes Novavax CIC Products, Novavax Adjuvant Products, and Licensed Products.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.203</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Novavax Adjuvant Patent, Novavax COVID-19 Patent, Patent Covering an Unauthorized Invention, and Novavax&#8217;s rights, title, and interests in any Joint Arising Patent. The Novavax Patents that exist as of the Effective Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">14.2.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (such Patents, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Existing Novavax Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;), &#91;***&#93;. For the avoidance of doubt, any Patent that solely Covers a Novavax CIC Product or Novavax Influenza Component is not a Novavax Patent.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Novavax Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means any Novavax Adjuvant Product, Novavax CIC Product, or Novavax OC Product.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.205</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Novavax Research and Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">3.5.1</a> (Novavax Research and Development Reports).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.206</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the trademarks set forth on Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.206.</a></font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.207</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax&#8217;s Baculovirus Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means Novavax&#8217;s proprietary method for the expression of recombinant proteins using a baculovirus&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">Spodoptera frugiperda </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">insect cell system. For clarity, as used in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">1.207,</a> &#8220;proprietary&#8221; means that Novavax owns or is licensed to Patents, Know- How, or Materials necessary to express recombinant proteins using a baculovirus&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">Spodoptera frugiperda </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">insect cell system.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.208</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax&#8217;s Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.209</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OC License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1.3</a> (Other Combination Products).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.210</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Escrow Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; (a) on or after &#91;***&#93;, Sanofi&#8217;s written notice to Novavax, (b) Novavax makes an assignment for the benefit of creditors, appoints, or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy, or insolvency act, or has any such petition filed against it that is not discharged within &#91;***&#93; after the filing thereof, (c) the failure of Novavax to perform the technology transfer in all material respects as set forth in the Adjuvant Manufacturing Technology Transfer Plan or the COVID-19 Manufacturing Technology Transfer Plan or (d) the failure of Novavax to deliver (in conformance with specifications and all other requirements for delivery under the Adjuvant Supply Agreement or COVID-19 Supply Agreement), at least (i) &#91;***&#93; of all amounts of Adjuvant, Licensed COVID- 19 Mono Product or Licensed COVID-19 Component that Novavax is required to deliver pursuant to the terms of the Adjuvant Supply Agreement or COVID-19 Supply Agreement in any &#91;***&#93;, or (ii) &#91;***&#93; of all amounts of Adjuvant, Licensed COVID-19 Mono Product or Licensed COVID-19 Component that Novavax is required to deliver pursuant to the terms of the Adjuvant Supply Agreement or COVID-19 Supply Agreement during any &#91;***&#93; period during the Term.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Out-of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, those costs and expenses actually paid by such Party or its Affiliates to a Third Party, including contract personnel (or payable to Third Parties and accrued in accordance with such Party&#8217;s Accounting Standards) and incurred in the performance of activities under this Agreement. Out-of-Pocket Costs exclude each of the following&#58;</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) costs and expenses of a Party, or its Affiliates paid to its or their employees (excluding contractor personnel, which are included as Out-of-Pocket Costs)&#59; (b) capital expenditures and depreciation of assets purchased pursuant to such capital expenditures&#59; and (c) costs incurred related to a Party&#8217;s or its Affiliates&#8217; use of facilities, utilities, general office, or facility supplies. &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:9.35pt">&#8220;Pandemic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means with respect to a pathogen, organism, or disease, the period of time beginning when the World Health Organization declares a public health emergency of international concern, and ending when the World Health Organization declares that such pathogen, organism, or disease, is no longer a public health emergency of international concern. For example, with respect to COVID-19, the World Health Organization declared a pandemic on January 20, 2020, and declared that COVID-19 was no longer a public health emergency of international concern on May 5, 2023.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Parent Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a Person, any other Person that controls (within the meaning of the second sentence of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">1.26</a> (Affiliate)) such entity.</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.214</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.215</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Party Non-Member Guest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">9.10</a> (Party Non-Member Guests).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.216</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Party Vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.13</a> (Committee Decisions).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Patent Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Governmental Authority responsible for the granting of Patents in any national, federal, regional, supranational, or international jurisdiction in the Territory, including the United States Patent and Trademark Office and the European Patent Office, including any adjudicatory bodies related to such Governmental Authorities such as the Patent Trial and Appeal Board (PTAB) and Unified Patent Court (UPC).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.218</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Patent Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any challenge to the validity or enforceability of a Patent by commencing any opposition proceeding, post-grant review, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">review, or declaratory action, or any foreign equivalent thereof, in any court, arbitration proceeding, or other tribunal, including the United States Patent and Trademark Office and any foreign counterpart thereof.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means (a) all national, regional, and international patents and patent applications, including provisional patent applications&#59; (b) all patent applications filed from any of the foregoing provisional patent applications in clause (a)&#59; (c) all patent applications that claim priority to any patent or patent applications in clause (a) or clause (b), including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications&#59; (d) any and all patents that have issued or in the future issue from any of foregoing patent applications in clause (a), clause (b), or clause (c), including utility models, petty patents, and design patents, and certificates of invention&#59; and (e) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re- examinations, and extensions (including any supplementary protection certificates and the like) of any of the foregoing patents or patent applications in clause (a), clause (b), clause (c), or clause (d). The term &#8220;Patents&#8221; includes Unitary Patents.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.220</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture, or similar entity or organization, including a government or political subdivision or department or agency of a government.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.221</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.9</a> (Pharmacovigilance).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Phase 1 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial (or portion thereof in the case of a Phase 1&#47;2 Clinical Trial) of a product that meets the definition of a Phase 1 study as described in 21 C.F.R.</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#167; 312.21(a), or its successor regulation, or the equivalent regulation in any other country where such Clinical Trial is conducted.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Phase 1 Full Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a Phase 1 Clinical Trial that is (a) conducted under an IND and (b) intended by Sanofi to provide the basis for the conduct of a Phase 2 Clinical Trial or Phase 3 Clinical Trial without any additional Phase 1 Clinical Trials, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any Phase 1 Clinical Trials the main aim of which is to translate the results of Research into clinical practice in humans and includes the study of the biology of the disease to provide solid rationales for the development or improvement of new drugs, the evaluation of the biological effects of the drugs in animals to define how to best use those drugs in humans, and the study of the biological effects of those drugs in humans.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Phase 2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a Clinical Trial (or portion thereof in the case of a Phase 1&#47;2 Clinical Trial or Phase 2&#47;3 Clinical Trial) of a product that meets the definition of a Phase 2 study as described in 21 C.F.R. &#167; 312.21(b), or its successor regulation, or the equivalent regulation in any other country where such Clinical Trial is conducted.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.225</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial (or portion thereof in the case of a Phase 2&#47;3 Clinical Trial) of a product that meets the definition of a Phase 3 study as described in 21 C.F.R.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#167; 312.21(c), or its successor regulation, or the equivalent regulation in any other country where such Clinical Trial is conducted.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.226</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pivotal Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means (a) any Phase 3 Clinical Trial or (b) any other Clinical Trial of a product the results of which, together with prior data and information concerning such product, are</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">intended to be sufficient, or are sufficient, without any additional Clinical Trial, to meet the evidentiary standard for demonstrating the safety, purity, and potency of such product established by a Regulatory Authority in any particular jurisdiction and that is intended to, or does, support the filing of a MAA in such jurisdiction.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.227</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Post-Marketing Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a drug product, any activity that is required by a Regulatory Authority in a country or jurisdiction to be conducted after such Regulatory Authority grants Marketing Authorization for such drug product in such country or jurisdiction, the performance of which are a condition to obtaining or maintaining Marketing Authorization in such country or jurisdiction for such drug product&#59; but expressly excluding those COVID-19 Research and Development activities conducted by or on behalf of a Party at its discretion and not as a condition to obtain or maintain Marketing Authorization in such country or jurisdiction.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.228</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.6</a> (Public Announcements).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.229</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Pricing Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of any government approval, agreement determination, or decision establishing such reimbursement authorization or pricing approval or determination.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative, or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination, or investigation that is, has been, or may in the future be commenced, brought, conducted, or heard at law or in equity or before any Governmental Authority, excluding all administrative proceedings before any patent office.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.231</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Adjuvanted Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.2</a> (Gatekeeper).</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.232</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.233</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.3</a> (Procedures).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.234</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, as between the Parties and with respect to a particular Patent, the Party that has the right to take any action or make any final decision (other than a decision to enter into any settlement) to Prosecute and Maintain such Patent in accordance with the terms of this Agreement.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Prosecuted and Maintained</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">,&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Prosecute and Maintain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with regard to a Patent, the preparing, filing, prosecuting, and maintenance of such Patent, as well as handling re-examinations and reissues with respect to such Patent, together with the conduct of interferences, derivation proceedings, pre- and post-grant opposition proceedings, post- grant patent proceedings (such as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">review and post grant review). &#8220;Prosecution and Maintenance&#8221; or &#8220;Prosecute and Maintain&#8221; does not include any Enforcement Actions taken with respect to a Patent.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.236</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Publication Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.1</a> (Publication Strategy).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.237</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Publishing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.238</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a product, (a) the notification, retrieval, and return of such returned product, (b) replacement of such returned product, and (c) distribution of any replacement of such returned product.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.239</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.1</a> (Confidentiality).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.240</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means each of (a) the United States, (b) Europe (including the United Kingdom and Switzerland), and (c) all countries in the world other than the United States and countries in Europe.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.241</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means activities directed to preparing and filing Regulatory Filings and other documentation for submission to Regulatory Authorities, communicating with Regulatory Authorities, and obtaining and fulfilling regulatory obligations as the holder of such Marketing Authorizations and Pricing Approvals. Regulatory Activities exclude any Medical Activities, Development activities, Manufacturing activities, and Commercialization activities.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.242</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a country in the Territory, any national (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, the FDA), supra-national (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, the European Commission, the Council of the European Union, or the EMA), regional, state, or local regulatory agency, department, bureau, board, commission, council, or other Governmental Authority that holds responsibility for development, commercialization, or manufacturing of, and the granting of Marketing Authorization for, a pharmaceutical product in such country or region.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.243</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Regulatory Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means those FTE Costs and Out-of-Pocket Costs (including filing, user, maintenance, and other fees paid to Regulatory Authorities) incurred by or on behalf of Party or any of its Affiliates in the preparation or maintaining of Regulatory Filings in connection with Marketing Authorizations and Pricing Approvals for a product, including compliance with such Marketing Authorizations and Pricing Approvals.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.244</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a product in a country, any data exclusivity rights, market exclusivity rights, or other exclusive rights, other than a Patent, granted, conferred, or afforded by any Regulatory Authority in such country or otherwise under Applicable Law with respect to such product in such country, that (a) confers exclusive marketing rights with respect to a product that prevents such Regulatory Authority from accepting another Marketing Authorization Application (whether new or abbreviated) from another Person, other than a Party or any of its Affiliates or Sublicensees, for a biosimilar or generic version of such product&#59; or (b) confers data protection for regulatory data submitted by the Parties (directly or through their Affiliates or Sublicensees) relating to such product against unfair commercial use or public release consistent with, or no less stringent than, TRIPS Article 39.3.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.245</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, collectively&#58; (a) applications in connection with any Clinical Trials, including INDs (and all submissions made in connection therewith)&#59; (b) Marketing Authorization Applications&#59; (c) establishment license applications&#59; (d) DMFs or BMFs&#59; (e) applications for designation (including as an &#8220;Orphan Product(s)&#8221; under the United States Orphan Drug Act, as amended, for &#8220;Fast Track&#8221; status under Section 506 of the FD&#38;C Act (21 U.S.C. &#167; 356) or for a Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FD&#38;C Act (21 U.S.C.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#167; 355(b)(4)(B)) and similar counterparts thereof in any country or region in the Territory)&#59; (f) applications for Pricing Approval&#59; (g) any Patent-related filings made to Regulatory Authority&#59; (h) all supplements and amendments to any of (a), (b), (c), (d), (e), (f), or (g)&#59; and (i) communications with any Regulatory Authority in connection with (a), (b), (c), (d), (e), (f), or (g), including confirmed meeting requests, meeting minutes, and correspondence.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.246</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.247</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.1.2</a> (Regulatory Transfer Plan).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.248</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a Party, such Party&#8217;s and each of its Affiliates&#8217; directors, officers, employees, contractors, consultants, attorneys, auditors, agents, or other representatives.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.249</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a compound or product or any raw material or intermediate thereof, those </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(other than in humans), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in silico </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">activities directed to discovering, designing, optimizing, synthesizing, and conducting initial characterization of such compound or product or any raw material or intermediate, including any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(other than in humans) toxicology studies. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Researching</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means to engage in Research. Research excludes any Medical Activities, Commercialization activities, Manufacturing activities, or Regulatory Activities.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.250</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Research License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1.6</a> (Adjuvant Research License).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.251</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.3.5</a> (Reversion License).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.252</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.253</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reviewing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.254</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Royalty Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.6</a> (Royalty Reports and Payments).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.255</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.256</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Sanofi Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">15.1.2</a> (Indemnification by Novavax).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.257</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi Licensed COVID-19 Mono Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means all (a) Sanofi Arising Patents, (b) Sanofi Arising Know-How, and (c) other Know-How Controlled by Sanofi or its Affiliates, in each case</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) or (c) that is actually disclosed by Sanofi, its Affiliates, or Sublicensees to Novavax hereunder, including pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1(a)</a> (Strain Selection Activities)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any Know-How generated by or on behalf of Sanofi in the course of performing Manufacturing of any Licensed Product, other than Data generated through the performance of Strain Selection Activities (which Data, for clarity, will be included in the Sanofi Licensed COVID-19 Mono Assets).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.258</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sanofi Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the Adjuvant License, the COVID-19 Mono License, the CIC License, the Research License, and the OC License.</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.259</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(b)</a> (Sanofi Matters).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.260</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sanofi Research and Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">3.5.2</a> (Sanofi Research and Development Reports).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.261</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">SARS-CoV-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means severe acute respiratory syndrome coronavirus 2, as defined by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">Coronaviridae </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Study Group of the International Committee on Taxonomy of Viruses (Nat. MicroBiol. 2020&#59; 5(4)&#58; 536-544), including any Variants thereof.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.262</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">SARS-CoV-2 Antigen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an Antigen derived from SARS-CoV-2, including the spike protein of the SARS-CoV-2 capsid.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.263</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Scientific COVID-19 Mono Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">11.7.1</a> (Publication Strategy).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">1.264</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:118%">Season</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">&#8221; means, with respect to any product Directed To SARS-CoV-2, the period beginning on the date on which the VRBPAC announces in its annual SARS-CoV-2&#47;COVID-19 strain selection meeting which Strain(s) of SARS-CoV-2 it believes are most immediate concern to public health as of such date and continuing for a period of approximately &#91;***&#93; thereafter.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.265</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Securities Subscription Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the Securities Subscription Agreement, dated as of the date of this Agreement, executed between the Parties.</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.266</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sell-Off Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.3.2</a> (Inventory Sell-Off Period).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.267</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Selling Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.174</a> (Net Sales).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.268</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Senior Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the senior executives or employees appointed by Novavax and Sanofi from time to time for the purpose of, and each of which possess the expertise and authority necessary for, resolving a matter pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives for Expedited Decision) or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">17.12.1</a> (Informal Dispute Resolution&#59; Escalation to Senior Executives).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.269</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2.2(e)</a> (Subcontracting).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.270</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Settlement Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means each settlement or similar agreement between Novavax and any Third Party to settle a dispute arising from (a) an APA or (b) other contract, that provides for supply by Novavax of Licensed COVID-19 Mono Product, including the GAVI Arrangements, (i) entered prior to the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Settlement Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) or (ii) approved by the JCC pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.3</a> (Existing APAs and Settlement Arrangements). All Existing Settlement Arrangements are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">1.270</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">.</a></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.271</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#91;***&#93;.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.272</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sole</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to the grant of the CIC License hereunder by Novavax to Sanofi, that Sanofi, its Affiliates, and its Sublicensees shall be the only Persons other than Novavax, its Affiliates and its licensees solely with respect to Novavax CIC Products, who may practice the Licensed Novavax Assets to Exploit a product that includes the Licensed COVID-19 Component and an Antigen Directed To Influenza, with or without any other Antigen Directed To any pathogen(s) other than SARS-CoV-2 and Influenza.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.273</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means a Person who initiates a clinical investigation and that otherwise meets the definition of a &#8220;sponsor&#8221; as described in 21 C.F.R. &#167; 312.3, or its successor regulation.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.274</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status Quo Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.18.5(d)(i)(6) (In General).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.275</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Strain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.307</a> (Variant).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.276</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Strain Selection Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the activities listed in Part 1 of the COVID-19 Research and Development Plan, as amended from time to time in accordance with the terms of this Agreement.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.277</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Strain Selection Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">5.2</a> (COVID-19 Manufacturing Technology Transfer).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.278</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Strategic Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">1.108</a> (&#8220;Existing Strategic Partner Agreements&#8221;).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.279</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means each committee, working group, or team formed from time to time by or at the direction of the JSC in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.2.3</a> (Subcommittees). Each of the JRDC, JMSC, JCC, JFC, JMAC, and JPC shall be deemed a Subcommittee.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.280</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subcommittee Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.2</a> (Escalation to JSC).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.281</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subcontract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2.2(e)</a> (Subcontracting).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.282</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, directly or indirectly, to sublicense, grant any other right with respect to, or agree not to assert, the rights granted to a Party hereunder. When used as a noun, &#8220;Sublicense&#8221; means any agreement to Sublicense.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.283</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means an Affiliate or Third Party that is not a Distributor to whom a Party (or its Affiliate or Sublicensee) grants a Sublicense under any intellectual property licensed to such Party pursuant to this Agreement in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.2</a> (Sublicensing).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.284</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Successful Completion of Adjuvant Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the date on which the Adjuvant Manufacturing Handover Date has occurred.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.285</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Successful Completion of COVID-19 Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the date on which the COVID-19 Manufacturing Handover Date has occurred.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.286</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, as applicable, the COVID-19 Manufacturing Technology Transfer, the Strain Selection Technology Transfer, or the Adjuvant Manufacturing Technology Transfer.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Technology Transfer Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means the budget included in any Technology Transfer Plan.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.288</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Technology Transfer Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Novavax or its Affiliates in the course of performing Technology Transfer activities in accordance with this Agreement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.289</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Technology Transfer Costs Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.8.2</a> (Reporting Technology Transfer Costs).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.290</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, as applicable, the COVID-19 Manufacturing Technology Transfer Plan or Adjuvant Manufacturing Technology Transfer Plan.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.291</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.1</a> (Term&#59; Expiration).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.292</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Licensed Product with respect to which this Agreement has been terminated pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">16.2</a> (Termination of the Agreement) after the effective date of termination of this Agreement in part as to such Licensed Product, and if this Agreement is terminated in its entirety, then all Licensed Products in the Territory will be Terminated Products.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.293</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Terminated Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means any Region with respect to which this Agreement has been terminated pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">16.2</a> (Termination of the Agreement) after the effective date of termination of this Agreement in part as to such Region, and if this Agreement is terminated in its entirety, then all Regions in the Territory will be the Terminated Territory.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.294</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any and all countries and regions of the world.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.295</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any Person other than Sanofi, Novavax, or their respective Affiliates.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.296</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Third Party License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; has the same meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">0</a> (Royalty Adjustments).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.297</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Third-Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the same meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.298</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means on a country-by-country, region-by-region, or jurisdiction-by-jurisdiction basis for Licensed COVID-19 Mono Products, the date set forth in the Regulatory Transfer Plan for such country, region, or jurisdiction.</font></div><div style="margin-top:9.2pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.299</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Transferred Marks and Domains</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">16.3.4(c)</a> (Licensed Product Marks and Licensed Product Domain Names).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.300</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Transferred Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; has the meaning set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">4.5</a> (Transfer of Regulatory Filings).</font></div><div style="margin-top:8.45pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.301</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#92;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unavailable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Field, that (a) Novavax has exchanged at least &#91;***&#93; with a Third Party to grant an exclusive license, option, or other right in relation to such Field, or pursuant to which Novavax would otherwise be subject to exclusivity obligations or covenants (such as an option to grant an exclusive license or other similar right) in relation to such Field for a Novavax Adjuvant Product that has received IND Clearance, in each case, that preclude the grant of rights to such Field to Sanofi pursuant to this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that Novavax and such Third Party execute a definitive agreement no later than &#91;***&#93; after the date such term sheet was first exchanged&#59; (b) Novavax has granted &#91;***&#93; in relation to such Field for a Novavax Adjuvant Product that has received IND Clearance, or is otherwise subject to exclusivity obligations or covenants (such as an option to grant a license or other right) under a legally binding contract that preclude the grant of rights to such Field to Sanofi pursuant to this Agreement&#59; or (c) (i) Novavax has received IND Clearance for a Novavax Adjuvant Product in such Field and (ii) Novavax, its Affiliates, or its or their licensees or sublicensees have not permanently abandoned or terminated Development of such Novavax Adjuvant Product with respect to such Field. Cognates of the word Unavailable shall have the correlative meaning.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Unitary Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means those European patents that are subject to EU Regulation No 1257&#47;2012 (OJ EU L 361, 31.12.2012, p. 1). A &#8220;Unitary Patent&#8221; may also be referred to as a &#8220;European patent with unitary effect.&#8221;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.303</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">U.S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:123%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the United States of America and its territories, possessions, and military bases.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Upstream License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.305</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%">Upstream Licensors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#8221; means the counterparties to Novavax under the Upstream License Agreements.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.306</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means any claim in (a) any issued and unexpired Patent that has not been held unenforceable, unpatentable, or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, and that has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer, or otherwise&#59; or (b) any Patent application that has not been cancelled, withdrawn, or abandoned, and has not been filed more than five (5) years from the earliest available priority date for said application in the applicable jurisdiction, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if such claim is later issued, then it will from the issuance date forward, if meeting the requirements of the foregoing clause (a), be deemed to be a Valid Claim.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.307</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Variant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means, with respect to a reference pathogen, another pathogen of the same recognized species that contains genetic mutations relative to the genome of such reference pathogen. For purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Strain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; as applied to a pathogen is used synonymously with Variant.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.308</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:9.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">VBRPAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221; means the Vaccines and Related Biological Products Advisory Committee of the FDA.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 2&#58; LICENSE GRANTS&#59; EXCLUSIVITY</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Subject to the terms and conditions of this Agreement, Novavax hereby grants Sanofi a Co-Exclusive, sublicensable (subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2</a> (Sublicensing)), non- transferable (except in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)), royalty- bearing license under the Licensed Novavax Assets to Exploit the Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Mono License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9.2pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Sanofi acknowledges that Novavax is a Party to certain Existing Strategic Partner Agreements under which Novavax has granted to certain Third Parties certain</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">rights to Exploit Licensed COVID-19 Mono Products in the Existing Partner Exclusive Territory and Existing Partner Non-Exclusive Territory and the COVID- 19 Mono License is subject to the non-exclusive rights granted in the Existing Partner Non-Exclusive Territory under such Existing Strategic Partner Agreements. Novavax covenants that it will not amend or modify any Existing Strategic Partner Agreement, in any manner that expands the scope, territory, exclusivity, product volume, or term, in each case, of any such agreement without Sanofi&#8217;s prior written consent, &#91;***&#93;.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">COVID-19 and Influenza Combination Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Novavax hereby grants Sanofi a Sole, sublicensable (subject to Section</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:26pt">(Sublicensing)), non-transferable (except in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">17.1</a> (Assignment)), royalty-bearing license under the Licensed Novavax Assets to Exploit the Licensed CIC Products in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">CIC License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Other Combination Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Novavax hereby grants Sanofi a non-exclusive, sublicensable (subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2</a> (Sublicensing)), non-transferable (except as permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)), royalty-bearing license under the Licensed Novavax Assets to Exploit the Licensed OC Products in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OC License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed Adjuvanted Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Novavax hereby grants Sanofi a non-exclusive, sublicensable (subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2</a> (Sublicensing)), non-transferable (except as permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)), royalty-bearing license under the Novavax Adjuvant Know-How, the Adjuvant Intermediate Know-How, the Novavax Adjuvant Patents, and the Novavax Adjuvant Materials to Exploit the Licensed Adjuvanted Products in the Adjuvant Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">License to Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Sanofi hereby grants Novavax a non-exclusive, non-sublicensable (except as permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2</a> (Sublicensing)), non-transferable (except as permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)), royalty-free, paid-up license under the Sanofi Licensed COVID-19 Mono Assets to Exploit the Licensed COVID-19 Mono Products, and Licensed COVID-19 Components in accordance with this Agreement in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Research License for Selection of Adjuvant Fields</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Novavax hereby grants Sanofi a non-exclusive, non-sublicensable, non- transferable (except as permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)), royalty-free license under the Novavax Adjuvant Know-How, Adjuvant Intermediate Technology, the Novavax Adjuvant Patents, and the Novavax Adjuvant Materials to conduct Research (but not any Development activities) for potential Proposed Adjuvanted Products and Proposed Adjuvanted Products in any Field (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Research License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Sanofi Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi covenants that it will not, and it will not grant any rights to or authorize any Affiliate or Third Party under any of the Sanofi Licenses&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">to Exploit any product that contains (i) the Licensed COVID-19 Component without the Adjuvant, and (ii) except for Licensed Adjuvanted Products in the Adjuvant Field, the Adjuvant without the Licensed COVID-19 Component&#59; or</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">to Manufacture the Adjuvant Intermediates unless and until the occurrence of the Adjuvant Intermediate Escrow Trigger Event.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Novavax Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax covenants that it will not, and it will not grant any rights, or authorize any Affiliate or Third Party to&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">practice under the Licensed Novavax Assets to Exploit the Licensed COVID-19 Mono Products except (i) in the Existing Partner Exclusive Territory or Existing Partner Non-Exclusive Territory, in each case, solely pursuant to the Existing Strategic Partner Agreements during the term thereof, and (ii) in the Collaboration COVID-19 Territory, solely in accordance with the COVID-19 Research and Development Plan, Regulatory Transfer Plan, Technology Transfer Plans, and Licensed COVID-19 Mono Product Commercialization Framework, or as otherwise expressly contemplated by this Agreement&#59; or</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">practice under the Licensed Novavax Assets to Exploit any product that contains the Licensed COVID-19 Component together with any Antigen Directed To Influenza other than the Novavax CIC Product&#59; and</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">grant an exclusive or co-exclusive (between Novavax and a Third Party licensee) license to any Third Party to Exploit a Novavax Adjuvant Product in a Field prior to IND Clearance of such Novavax Adjuvant Product.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Sublicensing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">To Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">Sanofi may grant Sublicenses (through multiple tiers) under any of the Sanofi Licenses to its Affiliates without Novavax&#8217;s consent, but subject to the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">17.13</a> (Performance by Affiliates).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Novavax may grant Sublicenses (through multiple tiers) under the Novavax License to its Affiliates without Sanofi&#8217;s consent, but subject to the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">17.13</a> (Performance by Affiliates).</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">To Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">Sanofi may grant Sublicenses (through multiple tiers) under the COVID-19 Mono License, CIC License, or OC License to one (1) or more Third Parties, including to any Service Provider, without Novavax&#8217;s consent.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">Sanofi may grant Sublicenses (through multiple tiers) under the Adjuvant License without Novavax&#8217;s prior written consent to any (i) Service Provider, or (ii) other Third Party who is granted a license under Patents or Know-How Controlled by Sanofi or its Affiliates to Exploit a Licensed Adjuvanted Product, except in the situation in which such Licensed Adjuvanted Product includes an Antigen that Sanofi or its Affiliate has in-licensed from a Third Party, in which case, unless Novavax otherwise agrees in writing, Sanofi may not grant a Sublicense under the Adjuvant License to such Third Party unless the applicable Licensed Adjuvanted Product also includes one or more Antigens or other pharmaceutically active</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">components that Sanofi or its Affiliate owns or has in-licensed from a different Third Party.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">Novavax may grant Sublicenses (through multiple tiers) under the Novavax License without Sanofi&#8217;s prior written consent to any (i) Service Provider and (ii) other Third Party who is concurrently granted a license to Exploit a Novavax Product.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Notwithstanding the inclusion of &#8220;have used, have Research, have Developed, have Manufactured, or have Commercialized&#8221; in the definition of Exploit, neither Party may grant Sublicenses not expressly permitted under Sections <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.2.2</a>(a) (To Third Parties) through <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.2.2(c)</a> (To Third Parties) without the other Party&#8217;s prior written consent, such consent not to be unreasonably withheld, conditioned, or delayed.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Each Sublicense granted to a Third Party must&#58; (i) be in writing&#59; (ii) be subject to, and consistent with, the relevant terms of this Agreement (including in accordance with the license grants set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1</a> (Licenses), ownership of intellectual property set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 12</a> (Patent and Know-How Matters), and obligations of confidentiality set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure))&#59; and (iii) require such Sublicensee to comply with all applicable terms of this Agreement.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party (or its Affiliates or Sublicensees) may engage one or more Third Parties, including CMOs, to perform activities under this Agreement on behalf of such Party, its Affiliate, or its Sublicensee, as applicable (each such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2.3</a> (Subcontracting). Each Party subcontracting any of its activities hereunder to any Service Provider will&#58; (a) reasonably oversee the performance by each such Service Provider of the subcontracted activities&#59; and</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) remain responsible for the performance of such activities in accordance with this Agreement. All subcontracted activities will be conducted pursuant to a written agreement between the subcontracting Party and the Service Provider (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subcontract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), which agreement will be consistent with the terms and conditions of this Agreement (including the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2.2(e)</a> (To Third Parties) if such Service Provider is also granted a sublicense of any rights granted hereunder to the Party entering into the Subcontract), and contain (i) confidentiality provisions no less restrictive than those set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure), (ii) where applicable to the activities of such Service Provider, a certification that such Third Party and its officers, employees, and agents have not been debarred, and are not subject to debarment, pursuant to Section 306 of the FD&#38;C Act, and are not the subject of a conviction described in such section, and (iii) a present assignment to such subcontracting Party of all of such Service Providers&#8217; rights, title, and interests in and to any deliverables, work product, and any related property rights in such deliverables and work product, in each case arising out of such Subcontract.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Retained Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will, notwithstanding any sublicensing of its rights or any subcontracting of its obligations permitted under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2</a> (Sublicensing), remain liable to the other Party for the performance of its obligations hereunder, and notwithstanding the inclusion of &#8220;have used, have Research, have Developed, have Manufactured, or have Commercialized&#8221; in the definition of Exploit, neither Party may engage any Service Provider except as expressly provided in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.2.3</a> (Subcontracting).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Upstream License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi acknowledges that certain of the Licensed Novavax Assets are sublicensed to Sanofi from Upstream Licensors, and with respect to such sublicensed Licensed Novavax Assets, the Sanofi Licenses are no broader in scope than the rights granted by the applicable Upstream Licensor to Novavax under the applicable Upstream License Agreement. Sanofi will comply with all applicable provisions of the Upstream License Agreements, except that Novavax shall be solely responsible for all payments under such Upstream License Agreements, including all upfront, milestone, royalty, and other payments or consideration to the Upstream Licensors.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Adjuvant Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To ensure that Sanofi can Exploit the Adjuvant under the Adjuvant License while allowing Novavax to continue to Exploit the Adjuvant by itself or with Third Parties, with respect to any pharmaceutical product that contains (a) the Adjuvant and (b) one or more active pharmaceutical ingredients (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Adjuvanted Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) that Sanofi wishes to Develop or Commercialize, prior to conducting any Development activities with respect to any such Proposed Adjuvanted Product in a given Field that has not already been confirmed to be included in the Adjuvant Field, Sanofi must, in accordance with the procedures in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.3</a> (Procedures), confirm that such Field is not Unavailable and therefore included in the Adjuvant Field.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The Parties shall agree upon an individual from a law firm, of whom neither Party is a client, to act as a gatekeeper (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) solely for the purposes of verifying whether or not a particular Field is Unavailable. The Parties shall agree upon and enter into a customary three-way agreement with the Gatekeeper setting forth the procedures described in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.4.3</a> (Procedures). The Parties shall agree on the identity of the Gatekeeper within &#91;***&#93; after the Effective Date. The Gatekeeper may be changed by written agreement of the Parties.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">On an ongoing basis during the Term, promptly, but no later than &#91;***&#93; after a particular Field becomes Unavailable, Novavax shall provide the Gatekeeper with an updated list of the Excluded Adjuvant Fields at such time, together with reasonable documentary evidence to support the basis on which such Field is an Excluded Adjuvant Field. The Gatekeeper shall not disclose to Sanofi the list of Excluded Adjuvant Fields.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">At any time during the Term, prior to Sanofi&#8217;s &#91;***&#93; for a Proposed Adjuvanted Product, Sanofi shall submit to the Gatekeeper in writing the identity of all Fields intended for such Proposed Adjuvanted Product that has not been previously confirmed to be included within the Adjuvant Field (all such Fields for such Proposed Adjuvanted Product, to the extent that such Fields are not already confirmed to be included in the Adjuvant Field, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Gatekeeper will promptly notify Novavax that a request for an update of the Excluded Adjuvant Field has been received from Sanofi, but the Gatekeeper shall not disclose to Novavax the identity of the Proposed Field, and Novavax will, no later than &#91;***&#93; thereafter, provide in writing an updated Excluded Adjuvant Fields list to the Gatekeeper, together with reasonable documentary evidence of Unavailability thereof. The Gatekeeper will compare the Proposed Field to the Excluded Adjuvant Fields and (i) if such Proposed Field is</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unavailable, then the Gatekeeper will notify Sanofi that such Proposed Field is an Excluded Adjuvant Field and (ii) if such Proposed Field is not Unavailable, then the Gatekeeper will notify both Parties that such Proposed Field is included within the Adjuvant Field, in each case (i) and (ii), no later than &#91;***&#93; after the Gatekeeper&#8217;s receipt of Sanofi&#8217;s notice with respect to the applicable Proposed Field. If such Proposed Field is not Unavailable, then, as of the date that the Sanofi receives written notice from the Gatekeeper, (A) such Proposed Field will be deemed to be included within the Adjuvant Field and (B) such Proposed Adjuvanted Product will be deemed a Licensed Adjuvanted Product.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93;.</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">In addition, during the Term, no later than &#91;***&#93; after a Field that was previously Unavailable is no longer Unavailable, Novavax will notify the Gatekeeper of the availability of such Field and provide an updated list of Excluded Adjuvant Fields to the Gatekeeper to reflect such change. If such newly available Field is a Field that Sanofi previously proposed to the Gatekeeper to include in the Adjuvant Field, but was Unavailable at the time of Sanofi&#8217;s proposal thereof, then the Gatekeeper will notify Sanofi (but not Novavax) of the removal of such previously Unavailable Field from the Excluded Adjuvant Field. Upon receipt of such notice from the Gatekeeper, such previously Unavailable Field shall be confirmed as included within the Adjuvant Field.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">For avoidance of doubt, (i) once a Field is confirmed to be included within the Adjuvant Field in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.3</a> (Procedures), Sanofi need not repeat the procedures set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4.3</a> (Procedures) with respect to such Field, and any Proposed Adjuvanted Product in such Field will automatically be deemed a Licensed Adjuvanted Product and (ii) a Proposed Adjuvanted Product with respect to which all Fields intended for such Proposed Adjuvanted Product are already included in the Adjuvant Field may still be a Distinct Licensed Adjuvanted Product for purposes of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4</a> (Licensed Adjuvanted Product Milestone Payments).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.37pt">The decision of the Gatekeeper as to whether a Field is or is not Unavailable will be final and unappealable, but the Parties retain the right to resolve disputes as to each Party&#8217;s compliance with the terms of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.4</a> (Procedures) (including whether a Party properly designated a Field as Unavailable) in accordance with the procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">No Adjuvant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:11.35pt">Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi will not, and will cause its Affiliates, Sublicensees, and Service Providers not to, modify, enhance, improve, or otherwise use the Adjuvant or any component thereof (including &#91;***&#93;) supplied by Novavax other than to conduct Research for selection of Adjuvant Fields or to Manufacture the Adjuvant as permitted hereunder and to incorporate and use the Adjuvant in Licensed Products in accordance to the terms and conditions of this Agreement.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.35pt">Assigned Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If Sanofi becomes aware that it or its Affiliates, Sublicensees, or Service Providers is using the Adjuvant or any component thereof (including &#91;***&#93;) supplied by Novavax in any manner not consistent with, or otherwise in violation of, Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.5.1</a> (Covenant) during the Term or any time thereafter, then, in any such case, Sanofi will (a) promptly notify Novavax of such unauthorized use and will disclose to Novavax any inventions or other Know-How developed or invented in connection with such unauthorized use (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unauthorized Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), and (b) assign, and hereby does assign (and will use reasonable efforts to cause its Affiliates, Sublicensees, and Service Providers to assign), all of its and their respective rights, title, and interests in and to any and all such Unauthorized Inventions. For the avoidance of doubt, any use by Sanofi, its Affiliates, or Service Providers of the Adjuvant to develop, invent, or create a different form, formulation, or composition of Matrix-M from the specifications for Matrix-M included in the DMF will be deemed an Unauthorized Invention.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Adjuvant In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party shall notify the other Party when such Party becomes aware of any Patents Controlled by a Third Party in a particular country or jurisdiction that may be &#91;***&#93; for the Development, Manufacture, Commercialization, or other Exploitation of the Adjuvant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Third Party Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Novavax shall have the first right, but not the obligation, to enter into an agreement for such Adjuvant Third Party Patents, and if Novavax exercises such right, then Novavax will use &#91;***&#93; efforts to obtain the right to sublicense such Adjuvant Third Party Patents to Sanofi and its Affiliates and its and their Sublicensees to Exploit Licensed Products. If Novavax does not enter into an agreement for Adjuvant Third Party Patents, or obtain the right under such agreement to sublicense such Adjuvant Third Party Patents to Sanofi and its Affiliates and its and their Sublicensees, in accordance with the terms of this Agreement, to Exploit Licensed Products, then to the extent such Adjuvant Third Party Patents are necessary (but not reasonably useful) for the Exploitation of Licensed Adjuvanted Products, Sanofi shall have the right, but not the obligation, to enter into an agreement for non-exclusive rights, or exclusive rights solely with respect to Licensed Adjuvanted Products, to such Adjuvant Third Party Patents for itself and its Affiliates and its and their Sublicensees to Exploit Licensed Product, and Sanofi will not enter any such agreement that would prevent Novavax from obtaining rights to the applicable Adjuvant Third Party Patents (other than for Licensed Adjuvanted Products).</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">No Implied Licenses&#59; Competing Products&#59; Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Except as expressly provided in this Agreement, no Party will be deemed by estoppel, implication, or otherwise to have granted the other Party any licenses or other rights with respect to any property owned or controlled by such Party. For clarity, no license or other right is granted hereunder by Sanofi or its Affiliates to Novavax or its Affiliates with respect to any property relating to any Sanofi adjuvant or any product that is proprietary to Sanofi (&#91;***&#93;) other than Sanofi Licensed COVID-19 Mono Assets. Neither Party will practice the Licensed Novavax Assets other than as expressly licensed and permitted under this Agreement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Except as expressly provided in this Agreement, each Party is free to engage in research, development, manufacturing, commercialization, and other activities relating to any products for which Marketing Authorization may be sought for any human pharmaceutical and diagnostic uses, including the prevention, prognosis, and diagnosis, and treatment of infection and other medical conditions and diseases caused by or mediated by SARS-CoV- 2, Influenza, or both SARS-CoV-2 and Influenza, whether alone or with other pathogens.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">Subject to the terms and conditions of this Agreement (including Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.1.8</a>), Novavax retains all rights, title, and interests under the Licensed Novavax Assets not granted under the Sanofi Licenses</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">Subject to the terms and conditions of this Agreement (including Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">2.1.7</a>), Sanofi retains all rights, title, and interests under the Sanofi Licensed COVID-19 Mono Assets not granted under the Novavax License.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 3&#58; RESEARCH AND DEVELOPMENT</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Owing to the threat of new Variants of SARS-CoV-2 and their changing prevalence, it is the expectation of the Parties that continuous Research and Development of Licensed COVID-19 Components is necessary to ensure that the Licensed COVID-19 Components are Directed To the most applicable Variants of SARS- CoV-2. Accordingly, with respect to the Licensed COVID-19 Component, during the Collaboration Term, the Parties agree to collaborate on Research and Development for the Licensed COVID-19 Component in accordance with the COVID-19 Research and Development Plan and COVID-19 Research and Development Budget as further set forth in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 3</a> (Research and Development).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Strain Selection Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Unless the Parties agree otherwise, until completion of the Strain Selection Technology Transfer as provided for in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 5</a> (Technology Transfer), as between the Parties, Novavax will perform the Strain Selection Activities and the costs related thereto will be allocated in accordance with Section</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs). For so long as Novavax is performing the Strain Selection Activities hereunder, the Parties shall collaborate through a working group established by the JRDC to facilitate the exchange of information regarding SARS-CoV-2 Strains of interest, and generally to provide a forum for scientific exchange. Following completion of the Strain Selection Technology Transfer, as between the Parties, Sanofi will perform the Strain Selection Activities. The Party that performs the Strain Selection Activities under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1</a> (General) shall, at least &#91;***&#93; provide a summary of the Data generated from such activities to the JRDC. The SARS-CoV-2 Variants that will be included in the Licensed COVID-19 Components after the Effective Date shall be determined in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). After the completion of the Strain Selection Technology Transfer and while Novavax is still Commercializing the Licensed COVID-19 Mono Product in at least one country, Sanofi will transfer the master virus seed for such Strain to Novavax and disclose any Know-How that is &#91;***&#93; to Manufacture the selected Strain for use in Novavax Products and the Licensed COVID-19 Mono Product, as contemplated by this Agreement.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Material Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For each SARS-CoV-2 Strain that is selected as part of the Strain Selection Activities in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1(a)</a> (Strain Selection Activities), Novavax will transfer to Sanofi all necessary quantities of the following Materials on a timely periodic basis, until the completion of the Strain Selection   Technology   Transfer&#58;   &#91;***&#93;</font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#91;***&#93;. Such deliveries of Materials will be coordinated through the working group established by the JRDC per Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">3.1.1(a)</a> (Strain Selection Activities).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">FDA working group on SARS-CoV-2 Variants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For so long as Novavax is performing the Strain Selection Activities hereunder, if permitted by the FDA, Sanofi shall have the right to attend meeting convened by the FDA of its strain selection technical working group on SARS-CoV-2 Variants together with Novavax. In the event that the FDA will not allow both Parties to participate in the FDA strain selection technical working group on SARS-CoV-2 Variants (or any successor working group thereto), Novavax&#8217;s personnel who participate in such working group shall coordinate with Sanofi with regard to such meetings, and Novavax shall keep Sanofi fully informed of the activities of the FDA strain selection technical working group on SARS-CoV-2 Variants (or any successor working group thereto). To the extent that Regulatory Authorities other than the FDA form working groups to monitor SARS-CoV-2 Variants, the provisions of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1(c)</a> shall apply to such other Regulatory Authorities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Further, in the event that industry working groups are convened in respect of SARS-CoV-2 Variants (with or without the participation of Regulatory Authorities), both Parties shall have the right to attend such industry working groups, and shall, with respect to Licensed COVID-19 Mono Products, coordinate their communications for such industry working groups. The costs related to such activities will be allocated in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs).</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Retired Strains</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The Parties agree that, for the purposes of this Agreement, neither Party shall have any obligation to conduct any Research activities with respect to Licensed COVID-19 Components for Strains selected by VRBPAC prior to the annual SARS-CoV-2&#47;COVID-19 strain selection meeting held in 2024.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">Activities Performed Outside of the COVID-19 Research and Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">for CIC Products and OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi may, in its discretion, and at its cost and expense, conduct Research activities outside of the COVID-19 Research and Development Plan with respect to Licensed COVID-19 Components in support of the Development and Commercialization of Licensed CIC Products and Licensed OC Products throughout the Territory. Novavax may, in its discretion, and at its cost and expense, conduct Research activities outside of the COVID-19 Research and Development Plan with respect to Licensed COVID-19 Components in support of the Commercialization of Novavax CIC Products and Novavax OC Products throughout the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such Research by Novavax outside of the COIVD-19 Research and Development Plan shall not include any Strain Selection Activities after Sanofi assumes responsibility for such activities. To the extent that either Sanofi or Novavax conduct Research activities with respect to Licensed COVID-19 Components outside of the COVID-19 Research and Development Plan as permitted under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1(e)</a> (Activities Performed Outside of the COVID-19 Research and Development Plan), each Party shall, through the JRDC co-chairs, unless prohibited by Applicable Laws, inform the other Party in advance of the intended public disclosure of any material scientific Data with respect to any SARS-CoV-2 Antigen within a Licensed COVID-19 Component with respect to which such Party is independently</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">performing any Research or Development, if such Data could &#91;***&#93; have a material impact to the other Party&#8217;s Exploitation of Licensed COVID-19 Components hereunder.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Mono Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In addition to the Licensed COVID-19 Component as described in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1</a> (Licensed COVID-19 Component), during the Collaboration Term, the Parties agree to collaborate on COVID-19 Research and Development for the Licensed COVID-19 Mono Product in accordance with the COVID-19 Research and Development Plan and COVID-19 Research and Development Budget as further set forth in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 3</a> (Research and Development), and neither Party shall independently outside of the COVID-19 Research and Development Plan and COVID-19 Research and Development Budget conduct any Research or Development of Licensed COVID-19 Mono Products. For clarity, Licensed COVID-19 Components that arise from the Research activities performed under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1</a> (Licensed COVID-19 Component) may be utilized by both Parties to Exploit Licensed COVID-19 Mono Products in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity). Allocation of costs related to such activities is set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">CIC Products and OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi shall have the right for Licensed CIC Products and Licensed OC Products (other than the Licensed COVID-19 Component incorporated therein), and Novavax shall have the right for Novavax CIC Products and Novavax OC Products (other than the Licensed COVID-19 Component incorporated therein), to conduct Research and Development for each such product that it is Exploiting in its sole discretion at it own cost and expense, but, in each case, within the scope of the CIC License and OC License, as applicable, and subject to other restrictions applicable to each Party as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 3</a> (Research and Development). For clarity, Sanofi may utilize in Licensed CIC Products and Licensed OC Products, and Novavax may utilize in Novavax CIC Products and Novavax OC Products, Licensed COVID-19 Components that arise from the Research and Development activities performed under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.1.1</a> (Licensed COVID-19 Components) as permitted under <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed Adjuvanted Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed Adjuvanted Products, Sanofi shall have the right to conduct Research and Development in its sole discretion at its own cost and expense, within the scope of the Adjuvant License and subject to other restrictions applicable to Sanofi as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 3</a> (Research and Development). As between the Parties, with respect to Novavax Adjuvant Products, Novavax shall have the right to conduct Research and Development in its sole discretion at its own cost and expense.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Collaborative Research and Development of Licensed COVID-19 Components and Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">COVID-19 Research and Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of the Effective Date, the Parties have agreed to an initial written plan for conducting (a) certain collaborative Research activities with respect to Licensed COVID-19 Components, and (b) Researching and Developing, and conducting certain Regulatory Activities and Medical Activities for, the Licensed COVID-19 Mono Products, which initial written plan is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">3.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (such plan, as it may be amended in accordance with the terms of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The COVID-19 Research and Development Plan will include the allocation of Research and Development activities as</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">between the Parties and target timelines for achieving Research and Development milestone events. Each Party may propose amendments to the COVID-19 Research and Development Plan through the JRDC at any time to reflect any material adjustments to the applicable Research and Development activities described therein, and each proposed update to the COVID-19 Research and Development Plan will be subject to review and determine whether to approve by the JRDC in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). At least &#91;***&#93;, the JRDC will review, discuss, and determine if changes are required to the then-current COVID-19 Research and Development Plan (for example, to update the COVID-19 Research and Development Plan with respect to the Variants of SARS-CoV-2 that have been selected in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) for inclusion in Licensed COVID-19 Mono Components or Licensed COVID-19 Mono Products for the current Season and any subsequent Season (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, the COVID-19 Research and Development Plan for the upcoming Seasons)) and the JRDC will prepare an update to the COVID-19 Research and Development Plan covering the period of the next &#91;***&#93;. Any amendments to the COVID-19 Research and Development Plan approved in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall become effective and supersede the applicable portion(s) of previous COVID-19 Research and Development Plan as of the date such approval is given.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">COVID-19 Research and Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of the Effective Date, the Parties have agreed to an initial rolling budget for the activities set forth in the COVID-19 Research and Development Plan for &#91;***&#93; and &#91;***&#93;, which budget is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">3.2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (COVID-19 Research and Development Budget) (such budget, as it may be updated in accordance with the terms of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Parties will collaboratively prepare the &#91;***&#93; update to the COVID-19 Research and Development Budget, and submit such initial draft of such update to the JRDC for the JRDC to review, discuss, and determine whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). The COVID-19 Research and Development Budget will be broken down by activity and costs, the break down of which, and any adjustments based on anticipated timing of events, will be determined by the JFC. For the initial COVID-19 Research and Development Budget attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">3.2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (COVID-19 Research and Development Budget), the period of such COVID-19 Research and Development Budget that includes &#91;***&#93; will be binding on the Parties in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs) and the remainder of the COVID-19 Research and Development Budget will serve as non-binding guidance for the Parties. Each update to the COVID-19 Research and Development Budget will include the budgets of the FTE Costs and Out-of-Pocket Costs anticipated to be incurred in the performance of activities to be conducted by or on behalf of Novavax under the COVID-19 Research and Development Plan for &#91;***&#93;. The COVID-19 Research and Development Budget may also include a high-level non-binding estimate for the COVID-19 Research and Development Budget for &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Budget Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). &#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Budget Updates and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party may propose amendments to the COVID- 19 Research and Development Budget through the JRDC to reflect proposed adjustments to the applicable COVID-19 Research and Development activities set forth in the COVID- 19 Research and Development Plan. No later than &#91;***&#93; of each Calendar Year, the JRDC will prepare (a) an updated COVID-19 Research and Development Budget covering the next &#91;***&#93; period (in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.2.2</a> (Contents)) and</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) an updated COVID-19 Research and Development Budget Forecast for Licensed COVID-19 Mono Products Directed To the then-current Variants of SARS-CoV-2. The Parties, through the JRDC, will use &#91;***&#93; to determine whether to grant their preliminary approval of such updates no later than &#91;***&#93; of each Calendar Year. &#91;***&#93; after the JRDC&#8217;s preliminary approval, such updates will be submitted to each Party for its internal budgeting process. After each Party performs its internal budgeting process, the JSC will review, discuss, and determine whether to grant its approval of such updates no later than &#91;***&#93; of each Calendar Year (or at a later time if agreed by the JSC) in accordance with, and subject to, <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance), including Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making). Any amendments to the COVID-19 Research and Development Budget approved in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall become effective and supersede the applicable amended portion(s) of the previous COVID-19 Research and Development Budget as of the date such approval is given.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Day-to-Day Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will be responsible for routine, non-strategic, operational- level decisions relating to the Research and Development activities for which it is assigned responsibility under the COVID-19 Research and Development Plan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such decisions will not conflict with the COVID-19 Research and Development Plan, or any decision of the JRDC or JSC with respect to such activity, or be a matter for which such Party does not have authority to take such decision per <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance), or is otherwise inconsistent with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.4</a> (Research and Development Diligence).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Research and Development Diligence. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement, each Party will use &#91;***&#93; to conduct all Research and Development activities allocated to it under the COVID-19 Research and Development Plan. Notwithstanding the generality of the foregoing, Sanofi will use &#91;***&#93; to Research and Develop at least (a) one (1) Licensed COVID-19 Mono Product in the U.S. and (b) one (1) Licensed CIC Product or Licensed OC Product in each Major Market country.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Research and Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Novavax Research and Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To the extent Novavax is conducting Research or Development, certain Regulatory Activities, or certain Medical Activities, in each case, under the COVID-19 Research and Development Plan, Novavax will provide the JRDC with &#91;***&#93; reports, within &#91;***&#93; after the end of each &#91;***&#93;, regarding its Research and Development activities (including associated Regulatory Activities), and such Medical Activities, with respect to each Licensed COVID- 19 Mono Product in the Territory, its progress compared to the COVID-19 Research and Development Plan, any anticipated or completed key Regulatory Filings, and a summary of all Novavax COVID-19 Know-How generated in the performance of such activities, in each case, during the applicable reporting period. Each &#91;***&#93; report of Research and Development activities delivered by Novavax in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">3.5.1</a> (Novavax Research and Development Reports) is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Research and Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.&#8221; Novavax Research and Development Reports are the Confidential Information of Novavax.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Sanofi Research and Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi will provide the JRDC with &#91;***&#93; reports, within &#91;***&#93; after the end of each &#91;***&#93;, regarding (a) its Research and Development activities under the COVID-19 Research and Development Plan (to the extent Sanofi conducts Research and Development activities under the COVID-19 Research and Development Plan) and (b) a high-level summary of Development of Licensed CIC Products, Licensed OC Products, and Licensed Adjuvanted Products, in each case, during the applicable reporting period. Each &#91;***&#93; report of Research and Development activities delivered by Sanofi in accordance with this Section</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">3.5.2</a> (Sanofi Research and Development Reports) is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sanofi Research and Development Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">.&#8221; Each Sanofi Research and Development Report will identify each Licensed Adjuvanted Product for which Sanofi filed an IND during the preceding &#91;***&#93;. Sanofi Research and Development Reports are the Confidential Information of Sanofi.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Transfer of Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party shall transfer to the other Party, in accordance with the COVID- 19 Research and Development Plan, Materials in its Control that are necessary to enable such other Party to carry out its activities under the COVID-19 Research and Development Plan.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 4&#58; REGULATORY</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to the Licensed COVID-19 Mono Products, during the Collaboration Term, the Parties agree to (a) conduct Regulatory Activities in accordance with the COVID-19 Research and Development Plan and this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 4</a> (Regulatory) and (b) transition to Sanofi the responsibility for all Regulatory Activities in accordance with the Regulatory Transfer Plan as further set forth in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 4</a> (Regulatory). Neither Party shall conduct Regulatory Activities other than as set forth in the COVID-19 Research and Development Plan, the Regulatory Transfer Plan, or this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 4</a> (Regulatory).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Regulatory Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of the Effective Date, the Parties have agreed to an initial plan, on a country-by-country basis, for the transition to Sanofi of all Regulatory Activities for the Licensed COVID-19 Mono Products to enable Sanofi to become the Regulatory Responsible Party for such Licensed COVID-19 Mono Products, which initial plan includes (a) the Transfer Date, on a country-by-country basis, when Sanofi will become the Regulatory Responsible Party, and assume responsibility, for all Regulatory Activities in such country and (b) the process for transferring the Regulatory Filings and Marketing Authorizations for Licensed COVID-19 Mono Products to Sanofi, which initial plan is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">4.1.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (Regulatory Transfer Plan) (such plan, as it may be amended in accordance with this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Each Party may propose amendments to the Regulatory Transfer Plan through the JSC at any time to reflect any material adjustments to the applicable Regulatory Activities described therein, which amendments will be subject to review, discussion, and determination whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Any amendments to the Regulatory Transfer Plan approved in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall become effective and supersede the applicable amended portion(s) of the previous Regulatory Transfer Plan as of the date such approval is given.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">CIC Products and OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to (a) Licensed CIC Products and Licensed OC Products, Sanofi shall have the exclusive right, and (b) Novavax CIC Products and Novavax OC Products, Novavax shall have the exclusive right, in each case (a) and (b), to conduct Regulatory Activities, be the Regulatory Responsible Party for, and file for and obtain Marketing Authorization for each such product that it is Exploiting in its sole discretion at its own cost and expense, but in each case within the scope of the CIC License and OC License, as applicable, and subject to other restrictions applicable to each Party as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 4</a> (Regulatory).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. With respect to Licensed Adjuvanted Products, Sanofi shall have the exclusive right to conduct Regulatory Activities, be the Regulatory Responsible Party for, and file for and obtain Marketing Authorization in its sole discretion at its own cost and expense, within the scope of the Adjuvant License and subject to other restrictions applicable to Sanofi as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 4</a> (Regulatory). Novavax shall have the exclusive right to conduct Regulatory Activities, be the Regulatory Responsible Party for, and file for and obtain Marketing Authorization in its sole discretion at its own cost and expense, for Novavax Adjuvant Products.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Regulatory Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">The Regulatory Responsible Party for Licensed COVID-19 Mono Products shall, in each country, jurisdiction, or region with respect to a Licensed COVID-19 Mono Product, be, unless the Parties agree otherwise in a separate agreement, responsible for all Regulatory Activities for the Licensed COVID-19 Mono Product in such country, jurisdiction, or region, making all Regulatory Filings, obtaining and maintaining Marketing Authorization, and interacting with Regulatory Authorities. Without limiting the foregoing, the Regulatory Responsible Party shall&#58; (i) be responsible to draft and file, in its own name or name of its designee, and shall own, the Regulatory Filings required to seek and maintain Marketing Authorization for such Licensed COVID-19 Mono Product in such country, jurisdiction, or region, and (ii) be responsible for, and the right to prepare and conduct, all communications with the applicable Regulatory Authorities in connection with (ii).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">On a country-by-country, jurisdiction-by-jurisdiction, and region-by-region basis, from the Effective Date until Sanofi becomes the Regulatory Responsible Party for Licensed COVID-19 Mono Products in a given country, jurisdiction, or region in the Collaboration COVID-19 Territory in accordance with the Regulatory Transfer Plan, Novavax shall be the Regulatory Responsible Party for all Licensed COVID-19 Mono Products in such country, jurisdiction, or region in the Collaboration COVID-19 Territory, and Sanofi shall have the right to participate (to the fullest extent permissible under Applicable Laws) in meetings between Novavax and Regulatory Authorities regarding the Licensed COVID- 19 Mono Products. The Parties shall undertake the transition process in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.5</a> (Transfer of Regulatory Filings) and the Regulatory Transfer Plan to transfer the Regulatory Filings and Marketing Authorization (where granted) for the Licensed COVID-19 Mono Products in such country, jurisdiction, or region as of the applicable Transfer Date.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">With respect to a Licensed COVID-19 Mono Product in a country, jurisdiction, or region, a Party that is not the Regulatory Responsible Party shall cooperate with, and provide reasonable assistance to, the Regulatory Responsible Party in order for the Regulatory Responsible Party to seek and maintain Marketing Authorization for such Licensed</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 Mono Product in such country, jurisdiction, or region. The Regulatory Responsible Party for the Licensed COVID-19 Mono Product in a country, jurisdiction, or region will consult with the other Party regarding, and keep the other Party informed of, the status of the preparation of all Regulatory Filings it intends to submit, any feedback from any Regulatory Authority regarding any such Regulatory Filings once submitted, and all Marketing Authorizations that it obtains with respect to such Licensed COVID-19 Mono Product in such country, jurisdiction, or region. Without limiting the generality of the foregoing, Sanofi will share, and will cause its Affiliates and Sublicensees to share, copies of their Marketing Authorizations reasonably requested by Novavax to fulfill its obligations under any Existing Strategic Partner Agreement. The Regulatory Responsible Party in a given country, jurisdiction, or region will reimburse the other Party for all FTE Costs and Out-of-Pocket Costs incurred in providing reasonable assistance to such Regulatory Responsible Party under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.2.3</a> in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.7</a> (Regulatory Costs).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">If a Party is the Regulatory Responsible Party for a Licensed COVID-19 Mono Product in a country, jurisdiction or region, and the other Party has been allocated Commercialization activities with respect to such Licensed COVID-19 Mono Products in accordance with this Agreement in such country, jurisdiction or region, then (a) the Regulatory Responsible Party must within &#91;***&#93; of receiving a written request from the other Party, deliver an executed all necessary letters of authorization or delegation of authority, in a form approved by the requesting Party, to enable the requesting Party to carry out its Commercialization activities in such country, jurisdiction or region and (b) the Parties will discuss in good faith expediting the timeline for Sanofi becoming the Regulatory Responsible Party in such country, jurisdiction, or region prior to Sanofi Commercializing in such country, jurisdiction, or region. &#91;***&#93;.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For so long as Novavax is the Regulatory Responsible Party for any Licensed COVID-19 Mono Product in any country, jurisdiction, or region, neither Party shall submit to any Regulatory Authority any proposed change to the process for Manufacturing such Licensed COVID-19 Mono Product (or any component thereof), without first discussing such proposed change with the other Party and considering, in good faith, any comments provided by the other Party (which comment shall be provided within a reasonable time based on the urgency of the proposed process change) prior to making the applicable submission to the applicable Regulatory Authority.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Regulatory Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, each Party will use &#91;***&#93; to conduct the Regulatory activities for Licensed COVID-19 Mono Products for which such Party is the Regulatory Responsible Party, whether itself, or by or through or with any Affiliate, Sublicensee, or Service Provider. Each Party that is the Marketing Authorization holder for the Licensed COVID-19 Mono Product in a country, jurisdiction, or region will use &#91;***&#93; to obtain and maintain approval from the applicable Regulatory Authority in such country, jurisdiction, or region to sell Licensed COVID-19 Mono Products that are Manufactured by (or on behalf of) Sanofi (as opposed to Novavax) under the Marketing Authorization for the Licensed COVID-19 Mono Product in such country, jurisdiction, or region.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Transfer of Regulatory Filings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Novavax will, in accordance with the Regulatory Transfer Plan, including the timelines set forth therein, initiate a process to transfer to Sanofi or its designated Affiliate, on a country-by-country, jurisdiction-by-jurisdiction, or region-by-region basis, no later than the applicable Transfer Date for such country, jurisdiction, or region, all Regulatory Filings for Licensed COVID-19 Mono Products held by Novavax or any of its Affiliates that are &#91;***&#93; for Sanofi to conduct the Regulatory Activities for which Sanofi is the Regulatory Responsible Party (such transferred Regulatory Filings, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transferred Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Parties will use &#91;***&#93; to complete such transfer in accordance with the timelines provided in the Regulatory Transfer Plan. Novavax and Sanofi shall cooperate to prepare and deliver any letters or other documents required by any Regulatory Authority to effectuate the transfer of such Transferred Regulatory Filings from Novavax to Sanofi. Notwithstanding any transfer of Regulatory Filings by Novavax or its Affiliate to Sanofi under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.5</a> (Transfer of Regulatory Filings), unless otherwise agreed by the Parties in a separate written agreement, for so long as Novavax continues to supply Sanofi with Licensed COVID-19 Mono Product or components thereof, (a) Novavax shall remain responsible for (i) preparing all CMC modules and other Manufacturing-related portions of Regulatory Filings for such Licensed COVID-19 Mono Product or components thereof and (ii) obtaining approvals required to conduct Manufacturing for such Licensed COVID-19 Mono Product or components thereof, and (b) Sanofi shall be responsible for all other portions of Regulatory Filings and Marketing Authorizations for such Licensed COVID-19 Mono Product or components thereof. The Parties shall cooperate to update the Regulatory Filings and approvals related to Manufacturing activities for any Licensed COVID-19 Mono Product or components thereof, as may be required to reflect Manufacturing improvements arising from activities conducted under this Agreement or an Ancillary Agreement with respect to any Licensed COVID-19 Mono Product or components thereof, or otherwise as required by Applicable Laws.</font></div><div style="margin-top:0.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Right of Reference&#59; BMF&#59; DMF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Novavax hereby grants to Sanofi and its Affiliates a right of reference to any INDs, Marketing Authorization Applications, BMFs, DMFs, and other Regulatory Filings and source documents Controlled by Novavax or any of its Affiliates for any Licensed COVID- 19 Mono Product, Licensed COVID-19 Component, or Adjuvant, for reference by Sanofi and its Affiliates, and its or their Sublicensees as &#91;***&#93; to support Sanofi&#8217;s Regulatory Activities with respect to the preparation, submission, and maintenance of any Regulatory Filings (including INDs, Marketing Authorization Applications, etc.) and in connection with obtaining and maintaining Marketing Authorization for any Licensed Products for which Sanofi and its Affiliates, and its or their Sublicensees is the Regulatory Responsible Party in accordance with this Agreement. Novavax will use &#91;***&#93; to deliver to the applicable Regulatory Authority, within &#91;***&#93; after a written request is received from Sanofi, a letter authorizing Sanofi and its Affiliates to exercise such right of reference. Novavax shall provide to Sanofi a draft of such letter prior to delivery to the applicable Regulatory Authority, and Sanofi may provide any comments thereto within &#91;***&#93; after receipt from Novavax. Novavax will consider any such timely comments provided by Sanofi in good faith prior to delivery of such letter to the applicable Regulatory Authority.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Without limiting the foregoing, upon Sanofi&#8217;s request, to the extent any applicable Novavax Know-How and Regulatory Filings have not been disclosed to Sanofi (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, before the COVID-19 Manufacturing Handover Date or before release of the Adjuvant Intermediate Technology Escrow), Novavax shall prepare appropriate BMFs or DMFs, as applicable, for the Adjuvant, Licensed COVID-19 Component, or Licensed COVID-19</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Mono Product, as applicable, and submit such BMFs or DMFs to the applicable Regulatory Authority in the Territory, and Novavax will be responsible for communicating with Regulatory Authorities in the Territory regarding such BMF or DMF, as applicable. Sanofi shall be entitled to reference such the BMF or DMF, as applicable for the Adjuvant, Licensed COVID-19 Component, or Licensed COVID-19 Mono Product, as applicable, in its Regulatory Filings for any Licensed Product in the Territory.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Until the Successful Completion of COVID-19 Manufacturing Technology Transfer and Adjuvant Manufacturing Technology Transfer, Novavax shall also provide to Sanofi at no cost, (a) the open part of the BMF or DMF, as applicable, for the Adjuvant, Licensed COVID-19 Component, or Licensed COVID-19 Mono Product, as applicable, such as the sections containing general information, control of drug substance, container closure system, and stability, (b) an electronic dossier containing data and information related to the Manufacture of Licensed Products in accordance with this Agreement, and (c) upon Sanofi&#8217;s written request, information in the closed part of the BMF or DMF, as applicable, for the Licensed COVID-19 Components, Licensed COVID-19 Mono Products, or the Adjuvant, as applicable, that Sanofi reasonably believes is necessary for preparing Regulatory Filings for any Licensed Product in the Territory for which Sanofi is the Regulatory Responsible Party, in each case (a)-(c), excluding any Adjuvant Intermediate Know-How. At the reasonable request of Sanofi, Novavax shall send representative(s) of Novavax to attend meetings with Regulatory Authorities in the Territory relating to the Regulatory Activities regarding the BMFs or DMFs for the Adjuvant, Licensed COVID- 19 Component, or Licensed COVID-19 Mono Products, as applicable.</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Communications with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Prompt Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will inform the other Party within &#91;***&#93;, or such shorter time as is necessary to comply with the reporting requirements of any applicable Regulatory Authority or under Applicable Law, after notification of any action by, or notification or other information that it receives (directly or indirectly) from, any Regulatory Authority in the Territory to the extent such information&#58; (a) raises any material concerns regarding the safety, efficacy, or quality of any Licensed COVID-19 Mono Product&#59; (b) indicates or suggests a potential material liability of either Party to any Third Party in connection with any Licensed COVID-19 Mono Product&#59; (c) is reasonably likely to lead to a clinical hold, recall, market withdrawal, or field alert with respect to any Licensed COVID-19 Mono Product&#59; or (d) relates to expedited and periodic reports of adverse events with respect to any Licensed COVID-19 Mono Product, or Licensed COVID-19 Mono Product complaints, and may have an adverse impact on the receipt or maintenance of Marketing Authorization or the continued Commercialization of a Licensed COVID-19 Mono Product. The Parties will reasonably cooperate with and assist each other in complying with regulatory obligations and communications, including by providing to the Regulatory Responsible Party, promptly after a request and within &#91;***&#93;  if such timing is required for the Regulatory Responsible Party for such product to comply with the reporting requirements of any applicable Regulatory Authority or under Applicable Law, such information and documentation that is in the other Party&#8217;s possession as may be &#91;***&#93; for the applicable Regulatory Responsible Party to prepare a response to an inquiry from a Regulatory Authority in the Regulatory Responsible Party&#8217;s purview with respect to a Licensed COVID-19 Mono Product. Each Party will also promptly provide the other Party with a copy of all correspondence received from a Regulatory Authority specifically regarding the matters</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">referred to in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">4.7.1</a> (Prompt Disclosures), including any matters regarding the safety, efficacy, or quality of any Licensed COVID-19 Mono Product.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Other Material Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To the extent not provided pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.7.1</a> (Prompt Disclosures), the Regulatory Responsible Party for the Licensed COVID-19 Mono Product will provide the other Party for its review and discussion a brief description of the principal issues raised in each material communication with Regulatory Authorities with respect to any Licensed COVID-19 Mono Product in the Territory &#91;***&#93; after receipt thereof, but in any event within &#91;***&#93; after receipt thereof. The Regulatory Responsible Party for the Licensed COVID-19 Mono Product will allow the other Party a reasonable opportunity to review and comment on such Regulatory Responsible Party&#8217;s proposed response to any material communications from any Regulatory Authority in the Territory with respect to any Licensed COVID-19 Mono Product in advance of the transmission of such response, and the Regulatory Responsible Party will reasonably consider all comments timely provided by the other Party in connection therewith.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:11.35pt;text-decoration:underline">Other Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">. In addition to its other obligations under this Agreement, each Party will disclose to the other Party the following regulatory information&#58;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Regulatory Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All material information Controlled or otherwise received by such Party pertaining to actions taken by Regulatory Authorities related to any Licensed COVID-19 Mono Product in the Territory, including any notice, audit notice, notice of initiation by Regulatory Authorities of investigations, inspections, detentions, seizures, or injunctions concerning any Licensed COVID-19 Mono Product in the Territory, notice of violation letter (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, an untitled letter), warning letter, service of process, or other inquiry&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that a Party will be entitled to redact those portions thereof to the extent not related to a Licensed COVID-19 Mono Product.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Regulatory Non-Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All information Controlled by such Party pertaining to notices from Regulatory Authorities in the Territory of non-compliance with Applicable Law in connection with any Licensed COVID-19 Mono Product, including receipt of a warning letter or other notice of alleged material non- compliance from any Regulatory Authority relating to any Licensed COVID-19 Mono Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that a Party will be entitled to redact those portions thereof to the extent not related to a Licensed COVID-19 Mono Product.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Compliance&#59; Audit of Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For any Licensed COVID-19 Mono Product for which (a) Sanofi is the Regulatory Responsible Party, and (b) Novavax, its Affiliates&#8217;, its Sublicensees&#8217;, and its and their Service Providers&#8217; perform any Research, Development, Manufacturing, or Regulatory Activities hereunder, Sanofi shall have the right, but not the obligation, to conduct an audit of Novavax&#8217;s and its Affiliates&#8217; records, maintained in connection with such activities on reasonable notice, during business hours, to confirm compliance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.8</a> (Compliance&#59; Audit of Records). Novavax will (i) use reasonable efforts to obtain a direct right for Sanofi to audit its Sublicensees and Service Providers, and (ii) if despite Novavax&#8217;s use of reasonable efforts, is unable to obtain a right for Sanofi to audit such Sublicensee or Service Provider, then Novavax will exercise its audit rights to the extent available under the applicable agreement with such Sublicensee or Service Provider to audit such Sublicensee or Service Provider in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.8</a> (Compliance&#59; Audit of Records). Such audit shall not take place more than once every &#91;***&#93; and shall not include the same records more than once, unless otherwise</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">required by Applicable Law or at the request of a Regulatory Authority. Each Party will cause its Affiliates, its Sublicensees, and its and their Service Providers to cooperate with the inspecting Party in connection with any such audit.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">The Parties will cooperate with regard to the reporting and handling of safety information involving the Licensed Products in accordance with Applicable Law. Within such time to ensure that all regulatory requirements and timelines are met, the Parties shall negotiate in good faith and execute a pharmacovigilance agreement setting forth the pharmacovigilance procedures for the Parties with respect to Licensed COVID-19 Mono Products that shall include safety data exchange procedures governing the exchange of information affecting each applicable Licensed COVID-19 Mono Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">., serious adverse events, emerging safety issues) to enable each Party to comply with all of its legal and regulatory obligations related to such Licensed COVID-19 Mono Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Each Party shall keep the other Party informed as to any matters related to patient safety and pharmacovigilance and any other material safety event (as defined in such Pharmacovigilance Agreement) in accordance with the timeline set forth therein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">As of the Effective Date, as between the Parties, Novavax will initially own and maintain the global safety database for all Licensed COVID-19 Mono Products in the Territory. The Parties will transfer the contents of the global safety database from Novavax to Sanofi by no later than &#91;***&#93;. As and from such date (or such other date as the Parties may agree in writing), Sanofi will own and maintain the global safety database for all Licensed COVID-19 Mono Products that are Exploited by the Parties after the Effective Date at Sanofi&#8217;s sole cost and expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that to the extent any information required to maintain such global safety database is in the possession or control of Novavax, its Affiliates, or its Strategic Partners, Novavax shall, within the timeline prescribed by Applicable Laws, provide such information to Sanofi. Each Party that is responsible under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.9.2</a> (Pharmacovigilance) to maintain the global safety database for Licensed COVID-19 Mono Products shall fully cooperate with the other Party (at such cooperating Party&#8217;s cost and expense) as reasonably requested by the maintaining Party. In the event that a Party is the Marketing Authorization holder for a Licensed COVID-19 Mono Product in a country, jurisdiction or region but is not the Party that is responsible to maintain the global safety database for the Licensed COVID-19 Mono Products in such country, jurisdiction or region, such Party shall, in accordance with Applicable Laws, remain responsible for local reporting obligations in such country, jurisdiction or region (and shall keep the other Party informed of such reporting). Each Party will bear and be responsible for costs and expenses incurred in the performance of its respective obligations under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.9.2</a> (Pharmacovigilance) in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.7</a> (Regulatory Costs).</font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 5&#58; TECHNOLOGY TRANSFER</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">General Technology Transfer and Technical Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Transfer Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Within &#91;***&#93; after the Effective Date, Novavax will establish a secure data room platform, through which Novavax will transfer to Sanofi all Novavax COVID-19 Know-How and Novavax Adjuvant Know-How required to be transferred in accordance with this Agreement (such secure platform, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Knowledge Portal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Transfer of Novavax Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Transfer of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will transfer to Sanofi, through the Knowledge Portal or such other means as the Parties may agree, all Novavax COVID-19 Know-How and Novavax Adjuvant Know-How (other than Novavax Manufacturing Know-How) that is &#91;***&#93; for Sanofi to Exploit the Licensed Products in accordance with the terms and conditions of this Agreement. All such Novavax COVID-19 Know-How and Novavax Adjuvant Know-How shall be in the format agreed to by the Parties through the applicable Committees and Novavax shall use &#91;***&#93; to provide such Know-How in accordance with the time frames set forth in the applicable plans, including the COVID-19 Research and Development Plan, the Regulatory Transfer Plan, and the Technology Transfer Plans, or as otherwise agreed to by the Parties through the applicable Committees.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will have the right to download and retain and make a copy(ies) of all such Know-How provided by the other Party, whether provided through the Knowledge Portal or otherwise (but, for clarity, such Know- How will remain subject to the confidentiality obligations set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure)) and shall only be used by the Receiving Party in accordance with the rights, licenses, and terms set forth in this Agreement.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Technical Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. During the Term, Novavax will make all of its relevant Representatives available (and, at the request of Sanofi, make the relevant Representatives of its or its Affiliates&#8217; or Sublicensees&#8217; and its and their Service Providers, as applicable) to Sanofi to answer Sanofi&#8217;s reasonable technical questions regarding the Licensed Novavax Assets, Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant (including components therein but excluding any Adjuvant Intermediate Technology, unless the Adjuvant Intermediate Escrow Trigger Event occurs) to enable Sanofi to practice the full scope of its rights under the Sanofi Licenses, including to Develop, Manufacture, and obtain and maintain Marketing Authorization for Licensed Products. Novavax will provide answers &#91;***&#93; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, within &#91;***&#93;) to any such reasonable requestions for Sanofi.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">COVID-19 Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 5</a> (Technology Transfer), for Licensed COVID-19 Components and Licensed COVID-19 Mono Products, Novavax and Sanofi shall, &#91;***&#93;, conduct a full technology transfer of all Novavax Manufacturing Know-How and Novavax Materials and all related CMC information Controlled by Novavax or its Affiliates (but excluding any CMC information that is not Know-How relating to the Manufacture of Adjuvant except if the COVID-19 Manufacturing Technology Transfer and the Adjuvant Manufacturing Technology Transfer occur concurrently), that is &#91;***&#93; to fully enable Sanofi, its Affiliates, or its or their Service Providers to Manufacture the Licensed COVID-19 Components and Licensed COVID-19 Mono Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;, and that portion of the COVID-19 Manufacturing Technology Transfer related to generating and selecting SARS-CoV-2 Strains for use in Licensed COVID-19 Components, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Strain Selection Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that for the purpose of the COVID-19 Manufacturing Technology Transfer, if the COVID-19 Manufacturing Technology Transfer occurs before the Adjuvant Manufacturing Technology Transfer, then the Adjuvant utilized to Manufacture Licensed COVID-19 Mono Products may be supplied by Novavax per Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.1.2</a> (Manufacture and Supply</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to Sanofi), rather than Manufactured by Sanofi. The initial written plan for COVID-19 Manufacturing Technology Transfer to effectuate such transfer for each of the Licensed COVID-19 Components and Licensed COVID-19 Mono Product are attached hereto as Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.2.1</a> (such plans collectively, as may be amended or replaced from time to time in accordance herewith, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Manufacturing Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Parties shall, no later than &#91;***&#93; after the Effective Date, provide the JMSC with an initial draft of the Technology Transfer Budget for the COVID-19 Manufacturing Technology Transfer Plan, which budget the JMSC will review, discuss, and determine whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Each Party may propose (a) that the JMSC prepare a new COVID-19 Manufacturing Technology Transfer Plan to replace the existing COVID-19 Manufacturing Technology Transfer Plan or (b) to amend the existing COVID-19 Manufacturing Technology Transfer Plan through the JMSC at any time to reflect any material adjustments to the applicable technology transfer activities described therein, and the new or amended COVID-19 Manufacturing Technology Transfer Plan will be subject to review, discussion, and approval by the JMSC in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Any new or amended COVID-19 Manufacturing Technology Transfer Plan approved in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall become effective as of the date such approval is given.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">COVID-19 Manufacturing Handover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All activities under the applicable COVID-19 Manufacturing Technology Transfer Plan shall, unless otherwise agreed by the Parties through the JMSC, be deemed to be complete when Sanofi, its Affiliates, or its or their Service Providers have completed process performance qualification (PPQ) for the Manufacture of Licensed COVID-19 Mono Product in accordance with the COVID-19 Manufacturing Technology Transfer Plan, including Manufacturing and release of each of the following per its specifications&#58; (a) Licensed COVID-19 Component and (b) Licensed COVID-19 Mono Products (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">COVID-19 Manufacturing Handover Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:8.55pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Adjuvant Technology Transfer. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subject to this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 5</a> (Technology Transfer), for the Adjuvant, Novavax and Sanofi shall conduct a full technology transfer of all Novavax Adjuvant Manufacturing Know-How and Novavax Materials and all related CMC information Controlled by Novavax or its Affiliates (that is not Novavax Adjuvant Know-How and excluding any CMC information relating to the Manufacture of Adjuvant Intermediates), that is &#91;***&#93; to fully enable Sanofi, its Affiliates, or its or their Service Providers to Manufacture the Adjuvant, starting from Adjuvant Intermediates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Parties will conduct the Adjuvant Manufacturing Technology Transfer in accordance with a written plan to be agreed by the Parties (such plan, as it may be amended or replaced from time to time in accordance with the terms of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Manufacturing Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). If the Parties are unable to agree to the terms of a proposed Adjuvant Manufacturing Technology Transfer Plan after good faith discussions, including at the JMSC, then the Parties shall appoint an independent technical expert acceptable to both Parties, with a minimum of &#91;***&#93; of experience in manufacturing operations and technology transfer in the pharmaceutical industry, to resolve any disagreements regarding the terms of a proposed Adjuvant Manufacturing Technology Transfer Plan. The decision of such technical expert shall be final and binding on both Parties and the Parties shall equally share the cost of engaging such an expert. The Parties shall provide the JMSC with draft of the Technology Transfer Budget for the Adjuvant Manufacturing Technology Transfer Plan, which budget the JMSC will review, discuss, and determine whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Each Party may propose (a) that the JMSC prepare a new Adjuvant Manufacturing Technology Transfer Plan to replace the existing Adjuvant Manufacturing Technology Transfer</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Plan or (b) to amend the existing Adjuvant Manufacturing Technology Transfer Plan through the JMSC at any time to reflect any material adjustments to the applicable technology transfer activities described therein, and the new or amended Adjuvant Manufacturing Technology Transfer Plan will be subject to review and discussion by the JMSC in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) and the Parties will approve such plan (subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making)). Any new or amended Adjuvant Manufacturing Technology Transfer Plan approved in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall become effective as of the date such approval is given. All activities under the applicable Adjuvant Manufacturing Technology Transfer Plan shall, unless otherwise agreed by the Parties through the JMSC, be deemed to be complete when Sanofi, its Affiliates, or its or their Service Providers have completed process performance qualification (PPQ) for the Manufacture of the Adjuvant in accordance with the Adjuvant Manufacturing Technology Transfer Plan (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Manufacturing Handover Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Technology Transfer Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Subject to the terms and conditions of this Agreement, each Party will use &#91;***&#93; to conduct the Technology Transfer activities allocated to it under each Technology Transfer Plan, including the timelines set forth in such Technology Transfer Plan(s) and otherwise pursuant to this Agreement, whether itself, or by or through or with any Affiliate or Sublicensee.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Updates to Technology Transfer Plan for Manufacturing Slots</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi may propose a reasonable acceleration to the timelines set forth in any Technology Transfer Plan, including for the purpose of meeting a Manufacturing slot deadline, which proposed amendment the JMSC will review, discuss, and determine whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 9</a> (Governance) (subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making)).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Adjuvant Intermediates Technology Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Establishment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties shall designate a neutral, independent Third Party agreed by the Parties to serve as an escrow agent to hold the Adjuvant Intermediate Technology Escrow. The Parties shall enter in a three (3)-way agreement with such escrow agent governing the confidentiality, maintenance, costs, release criteria, and technology transfer plan for escrow release, in each case, in accordance with this Agreement. Within &#91;***&#93; after entering into an escrow agreement with such escrow agent, Novavax shall deposit the Adjuvant Intermediate Technology into the Adjuvant Intermediate Technology Escrow.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Adjuvant Intermediate Technology Escrow will include (a) Adjuvant Intermediate Know-How that shall be stored electronically, with backups and disaster recovery protocols and other commercially reasonable safeguards, and (b) biological and chemical Material samples from the Manufacturing process for the Adjuvant Intermediate from raw material that shall be stored under appropriate conditions in compliance with GMP and Applicable Laws. Novavax shall be responsible for tracking and maintaining the viability and chemical purity of the stored Materials and shall replace any Materials that no longer meet the applicable specifications for such Materials for the intended applications.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. At least &#91;***&#93;, Novavax shall deposit in the Adjuvant Intermediate Technology Escrow any new Adjuvant Intermediate Technology that is not already in the then-current version of the Adjuvant Intermediate Technology Escrow.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Release from Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi, pursuant to a written notice, may instruct the escrow agent to release all Adjuvant Intermediate Technology from the Adjuvant Intermediate Technology Escrow, in accordance with the terms of the applicable escrow agreement, only upon the occurrence of the Adjuvant Intermediate Escrow Trigger Event.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Support Associated with Release from Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;***&#93; after the occurrence of the Adjuvant Intermediate Escrow Trigger Event, Novavax and Sanofi shall conduct a full technology transfer with respect to all Know-How and Materials held in the Adjuvant Intermediate Technology Escrow in accordance with the plan agreed by the Parties and set forth in the Adjuvant Intermediate Technology Escrow agreement to enable Sanofi to Manufacture the Adjuvant Intermediate. The Adjuvant Intermediate Technology Escrow agreement will provide that Novavax shall, after the Adjuvant Intermediate Escrow Trigger Event, transfer to Sanofi any CMC information Controlled by Novavax or its Affiliates related to the Adjuvant Intermediates, to the extent not already included in the Adjuvant Intermediate Technology Escrow. Each Party will reasonably cooperate with the other Party to effectuate such transfers.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***&#93;.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93;.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93;.</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Other Escrows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Establishment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties shall designate a neutral, independent Third Party agreed by the Parties to serve as an escrow agent to hold the Adjuvant Technology Escrow and COVID-19 Technology Escrow. The Parties shall</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">enter in a three (3)-way agreement with such escrow agent governing the confidentiality, maintenance, costs, release criteria, and technology transfer plan for escrow release, in each case, in accordance with this Agreement. Within &#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">after entering into an escrow agreement with such escrow agent, Novavax shall deposit (a) the Novavax Adjuvant Manufacturing Know-How and Novavax Adjuvant Materials that has not already been transferred to Sanofi as of such time into the Adjuvant Technology Escrow and (b) the Novavax COVID-19 Manufacturing Know-How and Novavax COVID-19 Materials that has not already been transferred to Sanofi as of such time into the COVID-19 Technology Escrow.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All Know-How in the Adjuvant Technology Escrow and COVID-19 Technology Escrow shall be stored electronically, with backups and disaster recovery protocols and other commercially reasonable safeguards. All biological and chemical Material samples in the Adjuvant Technology Escrow and COVID-19 Technology Escrow shall be stored under appropriate conditions in compliance with GMP and Applicable Laws. &#91;***&#93;.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. At least &#91;***&#93; prior to the Successful Completion of COVID-19 Manufacturing Technology Transfer or Adjuvant Manufacturing Technology Transfer, as applicable, Novavax shall deposit in each respective escrow any newly generated Novavax COVID-19 Manufacturing Know-How, Novavax Adjuvant Manufacturing Know-How, and Novavax Materials, in each case, that is not (a) already included in the Adjuvant Technology Escrow or COVID-19 Technology Escrow, as applicable and (b) has not been otherwise transferred to Sanofi pursuant to this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 5</a> (Technology Transfer).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Release from Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. At anytime before Successful Completion of COVID-19 Manufacturing Technology Transfer or Adjuvant Manufacturing Technology Transfer, as applicable, Sanofi may instruct the escrow agent to release the Adjuvant Technology Escrow or COVID-19 Technology Escrow in accordance with the terms of the applicable escrow agreement only upon the occurrence of an applicable Other Escrow Trigger Event.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Termination of Escrow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Adjuvant Technology Escrow and COVID-19 Technology Escrow shall automatically terminate upon the Successful Completion of COVID-19 Manufacturing Technology Transfer or Adjuvant Manufacturing Technology Transfer, as applicable. Novavax shall be responsible for coordinating with the escrow agent for the return or destruction of any Know-How and Materials.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Escrow Material License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax hereby grants to Sanofi, and confirms the grant to Sanofi of (notwithstanding any release of any of the foregoing technology from the escrow agent and not directly from Novavax), the licenses set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1</a> (Licenses) to use (a) the Adjuvant Intermediate Technology in the Adjuvant Intermediate Technology Escrow, (b) the Novavax Adjuvant Manufacturing Know-How and Novavax Adjuvant Materials in the Adjuvant Technology Escrow, and (c) the Novavax COVID-19 Manufacturing Know-How and Novavax COVID-19 Materials in the COVID-19 Technology Escrow, in each case ((a), (b), and (c)) solely to Exploit the Licensed Products as permitted under this Agreement. The foregoing license grant is effective as of the Effective Date, however, Sanofi covenants on behalf of itself and its Affiliates, successors, Service Providers, and Sublicensees, that it shall not exercise its rights under such</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">license until an Adjuvant Intermediate Escrow Trigger Event or an Other Escrow Trigger Event, as applicable, has occurred.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Ancillary Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. To the extent necessary to effectuate the Parties&#8217; obligations under this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 5</a> (Technology Transfer), the Parties will negotiate in good faith and execute any Ancillary Agreements that a Party may request be executed in order to comply with Applicable Law.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 6&#58; MANUFACTURING</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Novavax Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Supply for Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax shall be responsible for Manufacturing, whether itself or by or through any Affiliate or Service Provider, all supplies of the Licensed COVID-19 Mono Products and Licensed COVID-19 Component for Novavax&#8217;s and its Affiliates&#8217; Exploitation of Novavax Products in the Territory as provided in this Agreement. After the Successful Completion of COVID-19 Manufacturing Technology Transfer, Novavax may provide written notice to Sanofi that Novavax is interested in receiving supply of Licensed COVID-19 Mono Products from Sanofi solely to comply with its obligations under one (1) or more APAs or Existing Strategic Partner Agreements. Upon receiving such written notice, (a) the Parties will negotiate in good faith the terms under which the Parties may enter a supply agreement under which Sanofi will supply the Licensed COVID-19 Mono Product to Novavax, and (b) until the Parties enter such agreement, Sanofi may, but is not obligated to, supply Licensed COVID-19 Mono Products to Novavax in accordance with the terms of the COVID-19 Supply Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Manufacture and Supply to Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Licensed COVID-19 Mono Product and Licensed COVID Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax shall be responsible for the Manufacture of and supply to Sanofi, whether itself, or by any Affiliate, or through Service Providers, all non-GMP and GMP supplies of (i) Licensed COVID-19 Mono Product (in such forms or presentations as reasonably requested in writing by Sanofi) for any use (including use in Clinical Trials and for other Research or Development uses) or sale (or other Commercial use) of Licensed COVID-19 Mono Product in the Collaboration COVID-19 Territory and (ii) Licensed COVID-19 Component for use in Licensed CIC Product and Licensed OC Product in the Territory, in each case ((i) and (ii)), for the period starting from the Effective Date and ending on a country-by-country basis upon the later to occur of (A) the COVID-19 Manufacturing Handover Date, and (B) the date on which Sanofi sells a dose of Licensed COVID-19 Mono Products in such country that is Manufactured by or (or on behalf of) Sanofi (as opposed to Novavax).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Adjuvant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Unless otherwise agreed in writing, including in the Adjuvant Supply Agreement, Novavax shall be responsible for the Manufacture of and supply to Sanofi, whether itself, or by any Affiliate, or through any Service Provider, for any use (including use in Clinical Trials and for other Research or Development uses) or sale (or other Commercial use) permitted under this Agreement, (i) &#91;***&#93; and &#91;***&#93; until the Adjuvant Manufacturing Handover Date, and (ii) Adjuvant Intermediates, from and after the Adjuvant Manufacturing Handover Date, and until both (A) the Adjuvant Intermediate Escrow Trigger Event has occurred and Novavax has transferred to Sanofi the Adjuvant Intermediate</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Technology, and (B) Sanofi is able to obtain the Materials supplied by &#91;***&#93; to Novavax pursuant to the &#91;***&#93; that are used by Novavax to Manufacture the Adjuvant Intermediates.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Capacity Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For so long as Novavax is responsible for Manufacturing Licensed COVID-19 Mono Products, Licensed COVID-19 Components, ***&#93; and &#91;***&#93;, and &#91;***&#93; under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.1</a> (Novavax Manufacturing), Novavax and its Affiliates shall not allocate its and their Manufacturing capacity (including reactor space, labor and raw materials, and including capacity of its Service Providers available under Novavax&#8217;s agreements with such Service Providers) for any Licensed COVID-19 Mono Product, Licensed COVID-19 Component, &#91;***&#93; and &#91;***&#93;, and Adjuvant Intermediates, as it exists as of the Effective Date, in a manner less favorable to Sanofi (including the timing of forecasting, submission of orders, and billing) than for (i) any other customer to whom Novavax supplies the same Licensed COVID- 19 Mono Product, Licensed COVID-19 Component, &#91;***&#93; and &#91;***&#93;, or Adjuvant Intermediates, as applicable, or (ii) on and after the 2024&#47;2025 Season, Novavax&#8217;s own use other than to fulfil its commitments under the APAs, Existing Strategic Partner Agreements, and GAVI Arrangements.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Sanofi Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Sanofi General Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except for the Manufacturing and supply responsibilities that are allocated to Novavax under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.1</a> (Novavax Manufacturing), after the COVID-19 Manufacturing Handover Date, Sanofi shall be responsible to Manufacture, whether itself or by or through any Affiliate, Sublicensee, or Service Provider, all supplies of the Licensed Products for Sanofi&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; Exploitation of the Licensed Products in the Territory (or with respect to the Licensed COVID-19 Mono Product, the Collaboration COVID-19 Territory) as provided in this Agreement.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Supply Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Within &#91;***&#93; after the Effective Date, the Parties shall enter into one or more supply agreements governing the terms and conditions of Novavax&#8217;s supply to Sanofi of Licensed COVID-19 Mono Product (in such forms or presentations as reasonably requested in writing by Sanofi), including Licensed COVID-19 Component (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Select key terms that will be included in the applicable COVID-19 Supply Agreement are set forth in the term sheet attached hereto as Schedule</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3.1</a> (COVID-19 Supply Agreement Key Terms), which shall be binding on the Parties unless and until such time as the Parties have executed the applicable COVID-19 Supply Agreement. For clarity, within &#91;***&#93; after the Effective Date the Parties shall convene a meeting to discuss the contracting strategy (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, one (1) COVID-19 Supply Agreement for both Research and Development and Commercial supply or more than one</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(1) separate agreement), and within &#91;***&#93; after such meeting, Novavax will deliver the initial draft(s) of the COVID-19 Supply Agreement(s) to Sanofi, and Sanofi shall have &#91;***&#93; after the receipt of such initial draft of the COVID- 19 Supply Agreement(s) to provide its comments, and the Parties shall continue with the same cadence until the COVID-19 Supply Agreement(s) is executed per the first sentence of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">6.3.1.</a></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Within &#91;***&#93; after the Effective Date, the Parties shall enter into a supply agreement governing the terms and conditions of Novavax&#8217;s supply to Sanofi of (a) &#91;***&#93; and &#91;***&#93; and (b) Adjuvant Intermediates, as applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Select key terms that will be included the Adjuvant Supply Agreement are set forth in the term sheet attached hereto as Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3.2</a> (Adjuvant Supply Agreement Key Terms), which shall be binding on the Parties unless and until such time as the Parties have executed the Adjuvant Supply Agreement. For clarity, within &#91;***&#93; after the Effective Date the Parties shall convene a meeting to discuss the contracting strategy (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, one Adjuvant Supply Agreement for both Research and Development and Commercial supply or more than one (1) separate agreement), and within &#91;***&#93; after such meeting, Novavax will deliver the initial drafts of the Adjuvant Supply Agreement(s) to Sanofi, and Sanofi shall have &#91;***&#93; after the receipt of such initial draft of the Adjuvant Supply Agreement(s) to provide its comments, and the Parties shall continue with the same cadence until the Adjuvant Supply Agreement(s) is executed per the first sentence of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3.2.</a></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Quality Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Concurrent with the execution of the COVID-19 Supply Agreement(s) and the Adjuvant Supply Agreement(s), as applicable, the Parties will negotiate in good faith and execute one or more quality agreements with respect to the supply of any Licensed COVID-19 Mono Product, Licensed COVID-19 Component, &#91;***&#93; and &#91;***&#93;, Adjuvant Intermediates.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Manufacturing Site Change. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For so long as Novavax, by itself or by its Affiliates or Service Provider, Manufactures and supplies Licensed COVID-19 Mono Products (or any component thereof) to Sanofi hereunder (including under any Supply Agreement), Novavax will not change, and will not permit its Affiliate or Service Provider to change, the Manufacturing site from which Novavax supplies Sanofi the Licensed COVID-19 Products (or any component thereof), without the prior written consent of Sanofi.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 7&#58; COMMERCIALIZATION</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. With respect to Licensed COVID-19 Mono Products, during the Collaboration Term, the Parties agree to collaborate to conduct Commercialization activities for the Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory in accordance with the Licensed COVID-19 Mono Product Commercialization Framework as further described in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">7.2</a> (Licensed COVID-19 Mono Product Commercialization Framework). Except as expressly set forth in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 7</a> (Commercialization), neither Party shall conduct any Commercialization activities for any Licensed COVID-19 Mono Product in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:8.55pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">CIC Products and OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi shall have the right for Licensed CIC Products and Licensed OC Products, and Novavax shall have the right for Novavax CIC Products and Novavax OC Products, in each case, to conduct Commercialization activities for each such product that such Party is Exploiting in its sole discretion at its own cost and expense, but, in each case, within the scope of the CIC License and OC License, as applicable, and subject to other restrictions applicable to each Party as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 7</a> (Commercialization).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi shall have the right for Licensed Adjuvanted Products, and Novavax shall have the right for Novavax Adjuvant Products, to conduct Commercialization activities for each such product that such Party is Exploiting in its sole discretion at its own cost and expense, but, in each case, within the scope of the Adjuvant License and subject to other restrictions as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 7</a> (Commercialization).</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Licensed COVID-19 Mono Product Commercialization Framework</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties have agreed to an initial framework for the Commercialization of Licensed COVID-19 Mono Products pursuant to which they have allocated between them responsibility for Commercialization of Licensed COVID-19 Mono Products throughout the Collaboration COVID-19 Territory (such initial framework, and any updated or amended version thereof, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Licensed COVID-19 Mono Product Commercialization Framework</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The initial Licensed COVID-19 Mono Product Commercialization Framework is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">.</a> Beginning &#91;***&#93; (&#91;***&#93;), and thereafter in each Calendar Year for the Season commencing the following Calendar Year, no later than &#91;***&#93;, the JCC will review, discuss, and determine whether to approve updates to the Licensed COVID-19 Mono Product Commercialization Framework in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance), including which Party will be responsible for all Commercialization activities in the United States. Additionally, either Party may propose amendments to the Licensed COVID-19 Mono Product Commercialization Framework at any time, each of which updates the JCC will review, discuss, and determine whether to approve in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Each Licensed COVID-19 Mono Product Commercialization Framework will be developed in coordination with the Licensed COVID-19 Mono Product Medical Framework for the applicable Licensed COVID-19 Mono Product.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Existing APAs and Settlement Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi acknowledges that Novavax has certain rights and obligations under the APAs and Existing Settlement Arrangements in certain countries in the Collaboration COVID-19 Territory for the Manufacture and supply of Licensed COVID-19 Mono Products to such countries. Novavax shall have the right, in accordance with the Licensed COVID-19 Mono Product Commercialization Framework, to Commercialize Licensed COVID-19 Mono Products pursuant to each APA and the Gavi Arrangement for the remainder of the term of each such APA and the Gavi Arrangement. If, for a particular country in the Collaboration COVID- 19 Territory for which Novavax has entered an APA or for which the Gavi Arrangement applies, Novavax has the right to Commercialize Licensed COVID-19 Mono Products in such country, then Sanofi shall have the right, but not the obligation, to Commercialize Licensed COVID-19 Mono Products in such country in accordance with the Licensed COVID-19 Mono Product Commercialization Framework. The Parties will collaborate in good faith to effectuate a smooth transition as Novavax winds-down performance under each APA and Sanofi assumes the sole right to Commercialize in the applicable country. &#91;***&#93;. Upon the JCC&#8217;s approval, such proposed Settlement Arrangement will be deemed a Settlement Arrangement for purposes of this Agreement.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Commercialization Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will, whether itself or by or through or with any Affiliate, Sublicensees, or its or their Service Providers, use &#91;***&#93; to perform the Commercialization activities allocated to it in the Licensed COVID-19 Mono Product Commercialization Framework. Notwithstanding the generality of the foregoing, Sanofi will use &#91;***&#93; to (a) obtain Marketing Authorization for and Commercialize at least one (1) Milestone Eligible Licensed COVID-19 Mono Product in the United States and each other Major Market country and (b) obtain Marketing Authorization and Commercialize one</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(1) Licensed CIC Product or Licensed OC Product in each Major Market country, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">that on a Major Market-by-Major Market basis, once Sanofi is Commercializing a Licensed CIC Product or Licensed OC Product in a Major Market country, Sanofi&#8217;s obligations to Commercialize Licensed COVID-19 Mono Products in such Major Market under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">7.4</a> (Commercialization Diligence) will terminate.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%;padding-left:11.35pt;text-decoration:underline">Novavax Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">. To the extent Novavax is conducting Commercialization activities in the Collaboration COVID-19 Territory during an applicable &#91;***&#93; for Licensed COVID-19 Mono Products, within &#91;***&#93; after the end of each Calendar Quarter, Novavax will provide the JCC with a summary report of Novavax&#8217;s Commercialization performance, including a summary of financial and market information related thereto, and any Regulatory activities in connection therewith. Each &#91;***&#93; Commercialization report delivered by Novavax in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%;text-decoration:none">7.5.1</a> (Novavax Commercialization Reports) is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:119%">Novavax Commercialization Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">.&#8221; Novavax Commercialization Reports are the Confidential Information of Novavax.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%;padding-left:11.35pt;text-decoration:underline">Sanofi Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">. To the extent Sanofi is conducting Commercialization activities in the Collaboration COVID-19 Territory during an applicable &#91;***&#93; for Licensed Products, Sanofi will provide the JCC with a report summarizing Sanofi&#8217;s Commercialization activities for Licensed COVID-19 Mono Products, and with respect to other Licensed Products, Sanofi will provide information necessary for Novavax&#8217;s financial reporting requirements under Applicable Law. Each &#91;***&#93; Commercialization report delivered by Sanofi in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%;text-decoration:none">7.5.2</a> (Sanofi Commercialization Reports) is a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:119%">Sanofi Commercialization Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">.&#8221; Sanofi Commercialization Reports are the Confidential Information of Sanofi.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Advertising and Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Sanofi has the sole right with respect to the creation, preparation, production, reproduction, review (medical, legal, and regulatory), and filing with the applicable Regulatory Authorities of promotional materials relating to each Licensed Product that it is Commercializing. All rights, title, and interests, in and to any and all promotional materials for any Licensed Product created by or on behalf of Sanofi will be solely owned by Sanofi or its Affiliate. Sanofi will provide Novavax with the final draft of any major proposed promotional materials for the Licensed COVID-19 Mono Products and will consider in good faith comments provided by Novavax through the JCC that relate to such promotional materials for use in countries in which Novavax has obligations under an APA or has otherwise been allocated Commercialization activities in the Collaboration COVID-19 Territory under the Licensed COVID-19 Mono Product Commercialization Framework from time to time. Sanofi will supply Novavax an electronic copy of the promotional materials for the Licensed COVID-19 Mono Product under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.6.1</a> (Promotional Materials) for Novavax to service those countries in which Novavax has obligations under an APA or has otherwise been allocated Commercialization activities in the Collaboration COVID-19 Territory and Novavax may not, without the prior written consent of Sanofi, independently create or use promotional materials for Licensed COVID-19 Mono Products in any country in the Collaboration COVID-19 Territory.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Labelling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For so long as Novavax is the Regulatory Responsible Party with respect to a Licensed COVID-19 Mono Product in a country, jurisdiction, or region within the Collaboration COVID-19 Territory, Novavax will develop and approve packaging and labeling for such Licensed COVID-19 Mono Product, including the core data sheet for such Licensed COVID-19 Mono Product in such country, jurisdiction, or region, and Novavax will afford Sanofi an opportunity to provide comments on initial and material updates to the packaging and labeling for Licensed COVID-19 Mono Products through the JRDC. Sanofi shall provide its comments on any such proposed packaging and labeling to Novavax within &#91;***&#93; after Sanofi receives a copy of such proposed packaging or labeling, and Novavax will consider in good faith any such timely comments provided by Sanofi. Where Sanofi is the Regulatory Responsible Party with respect to a Licensed COVID-19 Mono Products in a country, jurisdiction, or region within the Collaboration COVID-19 Territory, Sanofi will develop and approve packaging and labeling for such Licensed COVID-19 Mono Products, including the core data sheet for such Licensed COVID-19 Mono Product in such country, jurisdiction, or region, and Sanofi will afford Novavax an opportunity to provide comments on &#91;***&#93; updates to the packaging and labeling for Licensed COVID-19 Mono Products through the JRDC. Novavax shall provide its comments on any such proposed packaging and labeling to Sanofi within &#91;***&#93; after Novavax receives a copy of such proposed packaging or labeling, and Sanofi will consider in good faith any such timely comments provided by Novavax.</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">CIC Products and Licensed OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed CIC Products and Licensed OC Products, as between the Parties, Sanofi shall have the sole right to develop and approve packaging and labeling for such products, including the core data sheet in the Territory. With respect to Novavax CIC Products and Novavax OC Products, as between the Parties, Novavax shall have the sole right to develop and approve packaging and labeling for such products, including the core data sheet in the Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed Adjuvanted Products, as between the Parties, Sanofi shall have the sole right to develop and approve packaging and labeling for such products, including the core data sheet in the Territory. With respect to Novavax Adjuvant Products, as between the Parties, Novavax shall have the sole right to develop and approve packaging and labeling for such products, including the core data sheet in the Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Sales and Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.3pt;text-decoration:underline">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. With respect to the Licensed COVID-19 Mono Products, during the Collaboration Term, each Party shall book sales for Licensed COVID-19 Mono Products sold by or on behalf of such Party in such country in the Collaboration COVID-19 Territory in accordance with the then- current Licensed COVID-19 Mono Product Commercialization Framework for the applicable Seasons.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">CIC Products and Licensed OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed CIC Products and Licensed OC Products, as between the Parties, Sanofi shall have the sole right to book sales of such Licensed Products sold by or on behalf of Sanofi, its Affiliates, or its or their Sublicensees or licenses in the Territory. With respect to Novavax CIC Products and Novavax OC Products, as between the Parties, Novavax shall have the sole right to book sales of such Novavax Products sold by or on behalf of Novavax, its Affiliates, or its or their Sublicensees or licenses in the Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. With respect to Licensed Adjuvanted Products in the Adjuvant Field, as between the Parties, Sanofi shall have the sole right to book sales of such Licensed Adjuvanted Products sold by or on behalf of Sanofi, its Affiliates, or its or their Sublicensees or licenses in the Territory. With respect to Novavax Adjuvant Products, as between the Parties, Novavax shall have the sole right to book sales of such Novavax Adjuvant Products sold by or on behalf of Novavax, its Affiliates, or its or their Sublicensees or licenses in the Territory.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Warehousing and Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party shall conduct all warehousing and distribution activities for Licensed COVID-19 Mono Products sold by or on behalf of such Party in such country in the Collaboration COVID-19 Territory in accordance with the Licensed COVID-19 Mono Product Commercialization Framework. For Licensed Products other than Licensed COVID-19 Mono Products, Sanofi shall, and for Novavax Products, Novavax shall, conduct all warehousing and distribution activities for such Licensed Products or Novavax Products, as applicable, sold by or on behalf of such Party, its Affiliates, its or their Sublicensees in the Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Training</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Unless otherwise agreed by the Parties in writing or set forth in the Licensed COVID- 19 Mono Product Commercialization Framework, as between the Parties, Sanofi has the sole right to create the contents of all training materials for all sales forces for the Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory. Sanofi will supply Novavax with final versions of training materials for the Licensed COVID-19 Mono Product under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">7.8</a> (Training) to service those countries in which Novavax has obligations under an APA or has otherwise been allocated Commercialization activities in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Recalls, Market Withdrawals, or Corrective Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. In the event that any Regulatory Authority issues or requests a Recall with respect to a Licensed Product in the Territory, the Regulatory Responsible Party for such Licensed Product, on a country-by-country basis, has the sole right to decide whether to conduct a Recall and the manner in which any such Recall will be conducted.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.3pt">Market Access Strategy&#59; Pricing Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.25pt;text-decoration:underline">Pricing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93; Season, except as specifically allocated to Sanofi in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Novavax shall have the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial pricing matters) for all Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93; Season, except as specifically allocated to Novavax in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Sanofi shall have the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial pricing matters) for all Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93; Season, the Party set forth in the Licensed COVID-19 Mono Product Commercialization Framework for the applicable Season as responsible for Commercialization in the United States shall have the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial pricing matters) for all Licensed COVID-19 Mono Products in the United States. For clarity, if Sanofi is the Party set forth in the Licensed COVID-19 Mono Product Commercialization Framework for the applicable Season, then Sanofi may offer to sell or sell Licensed COVID-19 Mono Products to customers in the United States together with other products (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, under the same contract)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that in such case Sanofi will not apply discounts to the Licensed COVID-19 Mono Products disproportionately as compared to such other products.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93; Seasons, except as specifically allocated to Novavax in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Sanofi has the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial pricing matters) for all Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory other than in the United States (other than pricing for Licensed Products sold under existing APAs and Settlement Arrangements, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that for Settlement Arrangements that are not Existing Settlement Arrangements, Novavax shall only have the right to submit confidential tenders, and any non-confidential tenders or other pricing by Novavax, in each case, will require Sanofi&#8217;s consent, not to be unreasonably withheld). For clarity, Sanofi may offer to sell or sell Licensed COVID-19 Mono Products to customers throughout the Collaboration COVID-19 Territory other than in the United States together with other products (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, under the same contract)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that in such case Sanofi will not apply discounts to the Licensed COVID-19 Mono Products disproportionately as compared to such other products.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Co-Commercialization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For clarity, in any Season in which both Parties have been allocated Commercialization activities under the Licensed COVID-19 Mono Product Commercialization Framework in the same country (other than pricing for Licensed Products sold under existing APAs and Settlement Arrangements, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that for Settlement Arrangements that are not Existing Settlement Arrangements, Novavax shall only have the right to submit confidential tenders, and any non-confidential tenders or other pricing by Novavax, in each case, will require Sanofi&#8217;s consent, not to be unreasonably withheld), Sanofi shall have the sole right to determine the market access strategy, including all matters relating to setting prices (including all discounts, rebates, and other similar commercial</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">pricing matters) for all Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">Cooperation&#59; Review by JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party that is the designated to have the right to determine prices of the Licensed COVID-19 Mono Products in a country for any specific Season under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.10.1</a> (Pricing) shall provide the other Party with an opportunity to review the &#91;***&#93; pricing policy created by such Party with respect to the applicable Licensed COVID-19 Mono Products in such country for such Season, &#91;***&#93; through the JCC, and the Party that creates such pricing policy shall consider in good faith the other Party&#8217;s reasonable comments with respect thereto that are delivered to such Party within &#91;***&#93; after such &#91;***&#93; pricing policy is distributed to the other Party for review by the JCC.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The Party that has been allocated responsibility to Commercialize Licensed COVID-19 Mono Products in a country for a given Season shall, unless the Parties agree otherwise in writing, be responsible for reporting its prices for such Licensed COVID-19 Mono Products to the applicable Governmental Authority in such country.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.25pt;text-decoration:underline">Pricing Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">&#91;***&#93; Season, except as specifically allocated to Sanofi in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Novavax shall have the sole right to apply for, and update, Pricing Approvals for all Licensed COVID-19 Mono Products in the United States and all countries within the Collaboration COVID-19 Territory in which Novavax has an APA or Settlement Arrangement.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93; Season, except as specifically allocated to Novavax in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Sanofi shall have the sole right to apply for, and update, Pricing Approvals for such Licensed COVID-19 Mono Products in all countries within the Collaboration COVID-19 Territory.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt">&#91;***&#93; Season, the Party set forth in the Licensed COVID-19 Mono Product Commercialization Framework for the applicable Season as responsible for Commercialization in the United States shall have the sole right to apply for, and update, Pricing Approvals for such Licensed COVID-19 Mono Products in the United States.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93; Season, except as specifically allocated to Novavax in the Licensed COVID-19 Mono Product Commercialization Framework or as otherwise agreed to in writing between the Parties, Sanofi shall have the sole right to apply for, and update, Pricing Approvals for such Licensed COVID-19 Mono Products in all countries within the Collaboration COVID-19 Territory other than the United States.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Pricing Approval if not Regulatory Responsible Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For clarity, in the event that a Party that is designated to have the right to apply for, and update, Pricing Approvals for such Licensed COVID-19 Mono Products in a country within the Collaboration COVID-19 Territory in accordance with paragraph (a)-(d) above is, at the relevant time, not the Regulatory Responsible Party, then the Regulatory Responsible Party shall act as the designated Party&#8217;s agent and shall fully cooperate and must apply for, and update, Pricing Approvals for such Licensed COVID-19 Mono Products in such country within the Collaboration COVID-19 Territory as directed by the other Party.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">CIC Products and Licensed OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed CIC Products and Licensed OC Products, as between the Parties, Sanofi shall have the sole right to apply for, and update, Pricing Approvals of such Licensed Products sold by or on behalf of Sanofi, its Affiliates, its or their Sublicensees or licenses in the Territory. With respect to Novavax CIC Products and Novavax OC Products, as between the Parties, Novavax shall have the sole right to apply for, and update, Pricing Approvals for such Novavax Products sold by or on behalf of Novavax, its Affiliates, or its or their Sublicensees or licenses in the Territory.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed Adjuvanted Products in the Adjuvant Field, as between the Parties, Sanofi shall have the sole right to apply for, and update, Pricing Approvals for such Licensed Adjuvanted Products sold by or on behalf of Sanofi, its Affiliates, or its or their Sublicensees or licenses in the Territory. With respect to Novavax Adjuvant Products, as between the Parties, Novavax shall have the sole right to apply for, and update, Pricing Approvals for such Novavax Adjuvant Products sold by or on behalf of Novavax, its Affiliates, or its or their Sublicensees or licenses in the Territory.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.3pt;text-decoration:underline">Housemarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Licensed COVID-19 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties, through the JCC, in consultation with regulatory experts, shall discuss whether it will be possible under Applicable Laws and regulatory guidance to include, in addition to Sanofi&#8217;s name, housemark, and logos, the name, housemark, and logos of Novavax on the packaging for the Licensed Products, and if so, how to implement such an arrangement on those particular packaging components. If it is permitted under Applicable Laws and regulatory guidance to include, in addition to Sanofi&#8217;s name, housemark, and logos, the name, housemark, and logos of Novavax on the packaging for a particular Licensed COVID-19 Product in a particular country, then Sanofi will, at Novavax&#8217;s request, include Novavax&#8217;s name, housemark and logo on the packaging for such Licensed COVID-19 Product in such country. If it is permitted under Applicable Laws and regulatory guidance to include, in addition to Sanofi&#8217;s name, housemark, and logos, the name, housemark, and logos of Novavax (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Matrix-M) on the packaging for a Licensed Adjuvanted Product, then Sanofi will use &#91;***&#93; to include at Novavax&#8217;s request, such name, housemark, or logo of Novavax on such packaging.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">CIC Products and Licensed OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed CIC Products and Licensed OC Products, Sanofi will have the right to include its name, housemark, and logos, on the packaging for such products. With respect to Novavax CIC Products and Novavax OC Products, Novavax will have the right to include its name, housemark, and logos on the packaging for such products.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:7.35pt;text-decoration:underline">Adjuvant Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. With respect to Licensed Adjuvanted Products in the Adjuvant Field, as between the Parties, Sanofi will have the right to include its name, housemark, and logos, shall appear on the packaging for such products. With respect to Novavax Adjuvant Products, Novavax will have the right to include its name, housemark, and logos on the packaging for such products.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 8&#58; MEDICAL</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Mono Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to Licensed COVID-19 Mono Products, during the Collaboration Term, the Parties agree to collaborate to conduct Medical Activities for the Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory in accordance with the Licensed COVID-19 Mono Product Medical Framework as further described in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">8.2</a> (Licensed COVID-19 Mono Product Medical Framework). Except as expressly set forth in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 8</a> (Medical), neither Party shall conduct any Medical Activities for any Licensed COVID-19 Mono Product in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Licensed CIC Products and Licensed OC Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi shall have the right for Licensed CIC Products and Licensed OC Products and Novavax shall have the right for Novavax CIC Products and Novavax OC Products, in each case, to conduct Medical Activities for each such product that such Party is Exploiting in its sole discretion at its own cost and expense, but, in each case, within the scope of the CIC License and OC License, as applicable, and subject to other restrictions applicable to each Party as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 8</a> (Medical).</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Licensed Adjuvanted Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. As between the Parties, Sanofi shall have the right for Licensed Adjuvanted Products and Novavax shall have the right for Novavax Adjuvant Products, to conduct Commercialization activities for each such product that such Party is Exploiting in its sole discretion at its own cost and expense, but, in each case, within the scope of the Adjuvant License and subject to other restrictions as set forth in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity) and in this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 8</a> (Medical).</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Licensed COVID-19 Mono Product Medical Framework</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties have agreed to an initial framework for Medical Activities to be conducted with respect to Licensed COVID-19 Mono Products and have allocated between them responsibility for performance of such Medical Activities for Licensed COVID-19 Mono Products throughout the Collaboration COVID-19 Territory (such initial framework, and any updated or amended version thereof, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Licensed COVID-19 Mono Product Medical Framework</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The initial Licensed COVID-19 Mono Product Medical Framework is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">8.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">.</a> The JMAC will review, discuss, and determine whether to approve any material amendments thereto in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance). Sanofi may make non-material amendments to the Licensed COVID-19 Mono Product Medical Framework from time to time in its reasonable discretion, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if Sanofi intends to make material amendments to Licensed COVID-19 Mono Product Medical Framework, then it will provide Novavax with a draft of such proposed amendments and Sanofi shall reasonably consider any comments from Novavax received within &#91;***&#93; of receipt thereof.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party will provide reasonable assistance, support, and information to the other Party as reasonably necessary in order to enable such other Party to conduct the Medical Activities related to Licensed COVID-19 Mono Products.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 9&#58; GOVERNANCE</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">The provisions of this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 9</a> (Governance) (other than those of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.8</a> (Joint Patent Committee)) shall apply solely to (a) the Licensed COVID-19 Mono Product and (b) the Licensed COVID-19 Component, to the extent expressly provided in (i) the COVID-19 Research and Development Plan or (ii) a Technology Transfer Plan.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Except as provided in the Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.1.1</a> (General), and notwithstanding any provision to the contrary set forth in this Agreement, the provisions of this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 9</a> (Governance) shall not apply to (a) any Licensed CIC Product, Licensed OC Product, or Licensed Adjuvanted Product or (b) any Novavax CIC Product, Novavax OC Product, or Novavax Adjuvant Product. For clarity, no Committee shall have any mandate hereunder with respect to any matter concerning any (a) Licensed CIC Product, Licensed OC Product, or Licensed Adjuvanted Product that is Exploited by Sanofi or (b) Novavax CIC Product, Novavax OC Product, or Novavax Adjuvant Product that is Exploited by Novavax.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">Except as provided in the Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.1.1</a> (General), all decisions with respect to (a) any Licensed CIC Product, Licensed OC Product, or Licensed Adjuvanted Product that is Exploited by Sanofi, its Affiliates, or its or their Sublicensees shall, as between the Parties, be made solely by, and in the discretion of, Sanofi, and (b) any Novavax CIC Product, Novavax OC Product, or Novavax Adjuvant Product that is Exploited by Novavax, its Affiliates, or its or their Sublicensees shall, as between the Parties, be made solely by, and in the discretion of, Novavax.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Formation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) to act within the JSC&#8217;s mandate. The JSC will be comprised of &#91;***&#93; Representatives from each Party.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">JSC Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, including Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.1</a> (General), the JSC will coordinate and oversee the collaborative activities of the Parties hereunder with respect to the Licensed COVID-19 Component and Licensed COVID-19 Mono Products and will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JSC Responsibilities). Any failure of the JSC to agree on matters within the purview of the JSC as set forth this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.2.2</a> (JSC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. From time to time, the JSC may establish and delegate duties, including any responsibilities of the JSC set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JSC Responsibilities), to Subcommittees on an &#8220;as-needed&#8221; basis to oversee particular activities, which delegations will be reflected in the minutes of the meetings of the JSC. Such Subcommittees may be established on an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">ad hoc </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">basis for purposes of a specific activity, or on such other basis as the JSC may determine and will be constituted and will operate as the JSC may determine&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">that each Subcommittee will have equal representation from each Party.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Research and Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint research and development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JRDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to coordinate and oversee the Parties&#8217; respective Research and Development activities under the COVID-19 Research and Development Plan and COVID-19 Research and Development Budget, and technology transfer activities pursuant to the COVID-19 Technology Transfer Plan, until such time as the JRDC is disbanded as provided herein. The JRDC will be comprised of &#91;***&#93; Representatives from each Party.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">JRDC Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, including Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.1</a> (General), the JRDC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.3.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JRDC Responsibilities). Any failure of the JRDC to agree on matters within the purview of the JRDC as set forth this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.3.2</a> (JRDC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Manufacturing and Supply Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint manufacturing and supply committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JMSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to act as a forum to coordinate and oversee the Parties&#8217; Manufacturing activities, including technology transfer activities pursuant to the COVID-19 Manufacturing Technology Transfer Plan and the Adjuvant Manufacturing Technology Transfer Plan, and for the delivery, quality, and supply of Licensed COVID-19 Components, Licensed COVID-19 Mono Products, &#91;***&#93; and &#91;***&#93;, and Adjuvant Intermediates that are Manufactured and supplied by Novavax to Sanofi pursuant to this Agreement (including under the COVID- 19 Supply Agreement and Adjuvant Supply Agreement entered into in furtherance of such Manufacturing activities) until such time as the JMSC is disbanded as provided herein. The JMSC will be comprised of &#91;***&#93; Representatives from each Party.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">JMSC Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Subject to the terms and conditions of this Agreement, the JMSC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.4.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JMSC Responsibilities). Any failure of the JMSC to agree on matters within the purview of the JMSC as set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.4.2</a> (JMSC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Commercialization Committe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint commercialization committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to act as a forum to coordinate and oversee the Parties&#8217; Commercialization activities for the Licensed COVID-19 Mono Product in the Collaboration COVID-19 Territory, until such time as the JCC is disbanded as provided herein. The JCC will be comprised of &#91;***&#93; Representatives from each Party.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">JCC Responsibilitie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s. Subject to the terms and conditions of this Agreement, the JCC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">9.5.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (JCC Responsibilities). Any failure of the JCC to agree on matters within the purview of the JCC as set forth this Section</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.5.2</a> (JCC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:9.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Medical Affairs Committe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formatio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint medical affairs committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JMAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to act as a forum to coordinate and oversee the Parties&#8217; Medical Activities for the Licensed COVID-19 Mono Product until such time as the JMAC is disbanded as provided herein. The JMAC will be comprised of an equal number of Representative from each Party, with &#91;***&#93; Representatives from each Party. If Novavax is not performing any Medical Activities hereunder for a period of &#91;***&#93; and is not allocated any Medical Activities for Licensed COVID-19 Mono Products for the upcoming Calendar Year in the then-current Licensed COVID-19 Mono Product Medical Framework, then the JMAC shall be automatically disbanded and any responsibilities allocated to it under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.6.2</a> (JMAC Responsibilities) shall automatically become responsibilities of the JSC.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">JMAC Responsibilitie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">s. Subject to the terms of this Agreement, the JMAC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.6.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JMAC Responsibilities). Any failure of the JMAC to agree on matters within the purview of the JMAC as set forth this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.6.2</a> (JMAC Responsibilities) will be resolved in accordance with the decision- making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Finance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formatio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint finance committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to act as a forum to coordinate and oversee financial matters hereunder, until such time as the JFC is disbanded as provided herein. The JFC will be comprised of an equal number of Representative from each Party, with &#91;***&#93; Representatives from each Party. If Novavax has not, for a period of &#91;***&#93;, performed any activities the costs of which are reimbursable by Sanofi hereunder, then the JFC shall be automatically disbanded and any responsibilities allocated to it under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">9.7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (JFC Responsibilities) shall automatically become responsibilities of the JSC.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">JFC Responsibilitie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s. Subject to the terms and conditions of this Agreement, the JFC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">9.7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (JFC Responsibilities). Any failure of the JFC to agree on matters within the purview of the JFC as set forth this Section</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.7.2</a> (JFC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Joint Patent Committe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">e.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Formation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the Effective Date, the Parties will establish a joint patent committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to coordinate between the Parties the oversight and handling of Patent matters (including Patent litigation) relating to Licensed COVID-19 Products until such time as the JPC is disbanded as provided herein. The JPC will be comprised of &#91;***&#93; from each Party that are each a patent counsel to such Party.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">External Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party may invite their respective external patent counsel to participate, as guests, in discussions and meetings of the JPC on an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">ad hoc </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">basis. Each Party that intends to invite its external counsel to a meeting of the JPC for the first time shall notify the other Party through its JPC co-chair at least &#91;***&#93; in advance of the applicable JPC meeting.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">JPC Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Subject to the terms of this Agreement, the JPC will be responsible for those matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">9.8.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (JPC Responsibilities). Any failure of the Parties to agree on matters within the purview of the JPC as set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.8.2</a> (JPC Responsibilities) will be resolved in accordance with the decision-making and escalation procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18</a> (Decision Making).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Committee Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party&#8217;s Representatives on a Committee will have experience appropriate to the matters under the purview of such Committee. Each Party will appoint its initial representatives for a Committee at the time such Committee is established and may appoint the same Person to more than one Committee as long as such appointment is in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.9</a> (Committee Members). Each Party may replace any of its Representatives on a Committee at any time by providing notice in writing to the other Party. Each Party will appoint one (1) of its Representatives on such Committee to act as a co-chairperson of such Committee (&#91;***&#93;). The co-chairpersons of each Committee will be responsible for setting the agenda for meetings of such Committee with input from the other members of such Committee, and for conducting the meetings of such Committee. Each member of a Committee will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. No Party will appoint a Representative to any Committee who&#58; (a) is not a director, officer, or employee of such Party without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned, or delayed&#59; (b) has not executed a written confidentiality agreement or other agreement that imposes obligations of confidentiality on such Representative that are at least as stringent as those contained in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure)&#59; or (c) does not have the authority to make decisions on behalf of such Party on matters within the scope of such Committee&#8217;s authority.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Party Non-Member Guests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party may invite those of its (or its Affiliates&#8217;) employees having expertise in a particular subject matter that is being reviewed or discussed at a meeting of any Committee and who has executed a written confidentiality agreement or other agreement that imposes obligations of confidentiality on such employee that are at least as stringent as those contained in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Party Non-Member Guest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to attend such meeting and participate as guests in such meeting&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that each Party shall notify the other Party through its co-chair (or designee) of the applicable Committee of the names of each of its Party Non-Member Guests who will attend a meeting at least &#91;***&#93; before the applicable meeting. If a Party desires to invite certain Party Non-Member Guests to multiple meetings of a given Committee, then such Party may request an advance waiver of such notice requirement with respect to the meetings that such Party expects that such Party Non-Member Guests will attend, and the co-chairs may agree in writing to so waive such notice obligation. Notwithstanding the foregoing, each Party&#8217;s Alliance Manager (or their designees) may attend any meeting of any Committee as a Party Non-Member Guest.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Non-Party Guests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.8.2</a> (External Counsel), no Third Party may attend a meeting of any Committee without the prior consent of both Parties (any such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Party Guest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Any Party that wishes to invite a Non-Party Guest to a Committee meeting must notify the other Party&#8217;s co-chair (or designee) of such Committee in writing at least &#91;***&#93; prior to any scheduled meeting. In the event a Party desires to invite certain Non- Party Guests to multiple meetings of a given Committee, then such Party may request an advance waiver of such notice requirement with respect to the meetings that such Party expects that Non- Party Guest will attend, and the co-chairs may agree in writing to so waive such notice obligation. No Non-Party Guest may attend any meeting of a Committee unless such Non-Party Guest has executed, prior to any meeting at which such Non-Party Guest would be present, a confidentiality agreement acceptable to both Parties. Any Non-Party Guest who attend any meeting of any</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Committee pursuant to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.11</a> (Non-Party Guests) may not vote on any matter put to a vote by, or requiring the approval of, such Committee, and shall not be counted for such purposes.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Meetings&#59; Quorum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as otherwise provided herein, each Committee will meet &#91;***&#93; after its formation on such dates and at such times and by such means (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, whether in person or through teleconference or video conference or otherwise) as agreed by the members of such Committee. Except with respect to the JPC, at least &#91;***&#93; prior to each such &#91;***&#93; Committee meeting, the applicable co-chairs will circulate to each Representative of such Committee a proposed agenda for such Committee meeting. In the event that the co-chairs of any Committee agree that there are no particular items within the purview of such Committee to be reviewed or discussed in any particular &#91;***&#93;, then such co- chairs may agree to not hold a meeting during such &#91;***&#93; upon reasonable advance notice to the members of such Committee. Upon &#91;***&#93; prior written notice, either Party may convene a special meeting of a Committee for the purpose of discussing any urgent matter within the purview of such Committee. Unless otherwise agreed by the Parties in writing, no meeting of any Committee formed hereunder may take place unless at least &#91;***&#93; Representative of each Party (&#91;***&#93;) appointed to such Committee is present for the entirety of the meeting and each Party will use reasonable efforts to cause its Representative(s) appointed to such Committee to participate in each Committee meeting of such Committee.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Committee Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party&#8217;s Representatives on each Committee will, collectively, have one vote (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Party Vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) on all matters brought before such Committee for a decision by consensus. Each Committee will make decisions as to matters within its jurisdiction by unanimous Party Vote of both Parties, which Party Vote will be reflected in the minutes of the committee meeting (except that the JPC may elect to reflect its decisions in a form other than the minutes to protect legal privilege). No vote of any Committee will be effective for purposes of this Agreement unless each Party has at least &#91;***&#93; representatives in attendance at the time the vote is taken (&#91;***&#93;). Should a decision be made by a Committee outside of a meeting, the unanimous Party Vote of both Parties on such decision may be made either by a written resolution unanimously agreed to in writing by each Representative on such Committee or by authorized signatories of each Party. For clarity, the phrase &#8220;determine,&#8221; &#8220;designate,&#8221; &#8220;confirm,&#8221; &#8220;approve,&#8221; or &#8220;determine whether to approve&#8221; by a Committee and similar phrases used in this Agreement will mean approval in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.13</a> (Committee Decisions).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The Parties recognize that for the Committees to function optimally, each Party should provide the other Party with timely information that is relevant to the mandate of such Committee. For avoidance of doubt, neither Party has any obligation to share any competitively sensitive information with the other Party including with respect to Licensed CIC Products, Licensed OC Products, Licensed Adjuvanted Products, Novavax CIC Products, Novavax OC Products, or Novavax Adjuvant Products.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Minutes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The responsibility for preparing the minutes for each Committee (other than the JPC) meeting will alternate between each Party on a meeting-by-meeting basis. The applicable Party&#8217;s designee responsible for the minutes will provide the other Party&#8217;s designee and the members of such Committee with draft written minutes for the Committee&#8217;s approval from each meeting within &#91;***&#93; days after each such meeting setting forth, among other things, a description, in reasonable detail, of the discussions at the meeting, each Party Vote, and a list of all decisions taken by such Committee, including any action assigned by such Committee. Such minutes will be effective only after being approved in writing by mutual consent of the co-chair of each Party for</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">such Committee. If the minutes of any meeting of the Committee are not approved by both co- chairs of the Committee within &#91;***&#93; days after the meeting, and the objecting Party, if any, has not appended a notice of objection with the specific details of the objection to the proposed minutes within such &#91;***&#93;-day period, then such minutes will be deemed to be approved by the Parties. Notwithstanding the foregoing, no Committee shall discuss any issue relating to any Patents (including with respect to any of their scope, patentability, validity, prosecution, or infringement), unless a JPC Representative for each Party is present. The Parties&#8217; JPC Representatives shall be solely responsible for documenting, at their discretion, any issues discussed by the JPC or any other Committee relating to any Patents, which documents and the content of such discussions, shall each be held in strict confidence by the Parties to protect their common interests and preserve the privileged status of any attorney-client communication, advice, or legal opinion reflected therein.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">s. Each Party will be responsible for its own expenses incurred to attend or participate in any Committee meeting, including the costs and expenses of such Party&#8217;s Third Party guests (including such Party&#8217;s external counsel with respect to the JPC).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Limitations of Committee Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Committee shall only have authority to determine, approve, or resolve matters that such Committee is expressly authorized to determine, approve, or resolve under this Agreement (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Committee Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). No Committee has the authority to&#58;</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a) modify or amend the terms and conditions of this Agreement&#59; (b) waive or determine either Party&#8217;s compliance with the terms and conditions of this Agreement&#59; (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement (d) breach or violation an agreement with a Third Party or Applicable Law&#59; (e) decide any issue for which this Agreement expressly requires the other Party&#8217;s approval or consent&#59; or (f) resolve any Dispute (other than a Committee Dispute) under this Agreement, including a Dispute as to whether a Committee Matter is a Sanofi Matter, a Novavax Matter, or a Status Quo Matter.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.3pt">Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Discussion and General Decision-Making Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties acknowledge that each Party shall, in good faith, discuss each Committee Matter with a view of reaching consensus of the Parties with respect to such Committee Matter, and if such consensus is not reached, then the provisions of the remainder of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making) shall apply.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Escalation to JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If a Subcommittee fails to reach consensus on a matter before it for decision within &#91;***&#93; from the date that the matter is first presented to such Subcommittee in writing (such matter, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subcommittee Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then the matter shall be referred in writing to the JSC. If a Subcommittee Dispute is escalated to the JSC by any Subcommittee, then each Party will provide an analysis to support its position with respect to the Subcommittee Dispute at the next meeting of the JSC (or a sooner </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ad hoc </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">meeting of the JSC for any matter that is urgent, would be prejudiced by delay to the next scheduled JSC meeting, or that the Parties otherwise agree for which an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ad hoc </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">meeting should be held).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Decisions of the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The JSC has the authority (a) to make decisions as to matters specifically delegated to it or expressly specified in this Agreement, and (b) to resolve Subcommittee Disputes. The JSC has no other authority under this Agreement. The JSC will use good faith efforts, in compliance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.3</a> (Decisions of the JSC), to promptly resolve any such matter for which it has authority, with a view of reaching</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">consensus of the Parties with respect to such matter. If, after the use of good faith efforts, the JSC fails to reach consensus regarding a Subcommittee Dispute or any other matter within the scope of the JSC&#8217;s authority as set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.3</a> (Decisions of the JSC) (in either case, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Committee Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then the matter shall be escalated in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives for Expedited Decision), other than a Subcommittee Dispute as to Item 2 of Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.5.2,</a> which Subcommittee Dispute shall be a Status Quo Matter in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(d)(i)(1)</a> (Status Quo Matters) without further escalation.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Escalation to Senior Executives for Expedited Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If the JSC fails to reach consensus regarding a Committee Dispute within &#91;***&#93; after being presented with such matter for decision-making, then, at the election of either Party, the JSC shall refer such dispute to the Senior Executives of the Parties, and the Senior Executives of the Parties will confer in good faith on the resolution of the issue within &#91;***&#93; following first receipt of such written notice. If the Senior Executives of the Parties reach consensus regarding such dispute, then the decision of the Senior Executives shall be binding upon the Parties as a decision of the JSC. If the Senior Executives do not reach consensus regarding a dispute that is escalated to them in accordance with this Section</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives for Expedited Decision) within such &#91;***&#93; period, then the matter will be decided as set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.5</a> (Final Decisions).</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.18.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.25pt;text-decoration:underline">Final Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Novavax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, after compliance with the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.1</a> (Discussion and General Decision-Making Process) and Section</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">9.18.2</a> (Escalation to JSC) or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;text-decoration:none">9.18.3</a> (Decisions of the JSC) (as applicable), Novavax will have the right to make the final decision with respect to&#58;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.76pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.54pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:15.32pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:15.76pt">&#91;***&#93;&#59; and</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.98pt">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(each such matter described in the foregoing clauses (i) through (v), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Novavax Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.88pt;text-decoration:underline">Sanofi Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As between the Parties, after compliance with the terms of Section</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.1</a> (Discussion and General Decision-Making Process) and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.2</a> (Escalation to JSC) or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.3</a> (Decisions of the JSC) (as applicable), Sanofi will have the right to make the final decision with respect to&#58;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.76pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.54pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.32pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.76pt">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.98pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9.15pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.76pt">&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;&#59;</font></div><div style="margin-top:8.55pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:13.54pt">&#91;***&#93;&#59; or</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.32pt">&#91;***&#93;&#59;</font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(each such matter described in the foregoing clauses (i) through (vii), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sanofi Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Change of Control Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If, after compliance with the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.1</a> (Discussion and General Decision-Making Process), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.3</a> (Decisions of the JSC), and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives), the Parties are not able to reach consensus with respect to any matter related to reasonably determining whether an Acquirer of Novavax (i) is unable or unwilling to cooperate with Sanofi to implement Sanofi&#8217;s Commercial strategy for Licensed COVID-19 Products or (ii) is not able or willing to perform Novavax&#8217;s obligations under this Agreement with substantially the same degree of skill that Novavax was using prior to such Change of Control as required under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1.2(b)</a> (Change of Control), then such matter will be resolved pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.98pt;text-decoration:underline">Status Quo Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.76pt;text-decoration:underline">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If, after compliance with the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.1</a> (Discussion and General Decision-Making Process), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.2</a> (Escalation to JSC) or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.3</a> (Decisions of the JSC) (as applicable), and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives), the Parties are not able to reach consensus with respect to any matters related to&#58;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:18.03pt">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.98pt">&#91;***&#93;&#59; or</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:18.03pt">&#91;***&#93;,</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(any such matter described in (1) through (7), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status Quo Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then neither Party will have unilateral final decision-making authority with respect to the final resolution of such Status Quo Matter, and unless and until consensus on such matter is reached, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">status quo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shall be maintained with respect to such Status Quo Matter and no further changes may be made or decisions may be taken unilaterally by either Party in relation to such Status Quo Matter, except with respect to the approval of any amendment or update to the COVID-19 Research and Development Budget or a Technology Transfer Budget (any such dispute, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Budget Status Quo Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), which matter will be resolved in accordance Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(d)(ii)</a> (Budget Status Quo).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.54pt;text-decoration:underline">Budget Status Quo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Notwithstanding Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(d)(i)</a> (In General), if, after compliance with the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.1</a> (Discussion and General Decision-Making Process), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.2</a> (Escalation to JSC), and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.4</a> (Escalation to Senior Executives), the Parties are unable to reach consensus with respect to any Budget Status Quo Matter, then the already-existing budget (if any) will remain in effect until the earlier of the date on which (a) the Parties agree on such budget for the applicable period, or (b) either Party refers such dispute for resolution by an independent arbitrator in accordance with the procedure set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (Baseball Arbitration Dispute Resolution) (such procedure, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Baseball Arbitration Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) (each such decision, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expert Budget Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) and such independent arbitrator renders an Expert Budget Decision&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that until the Parties agree to a budget or the arbitrator renders an Expert Budget Decision, such already existing budget will be &#91;***&#93;.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Disbandment of Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The JSC may, upon consensus, disband any Subcommittee at any time and either allocate the responsibilities of such Subcommittee to another Subcommittee or assume such responsibilities itself. All Committees, including the JSC, will, if not already disbanded, automatically disband upon the expiration or termination of the Collaboration Term.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.3pt">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.20.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:7.35pt;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Within &#91;***&#93; after the Effective Date, each Party will appoint a representative of such Party to act as its alliance manager under this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;). Each Party may replace its Alliance Manager at any time upon notice to the other Party.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Specific Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Alliance Managers (or their designees) will, unless the co- chairs of the JSC designate an alternate Person, attend all meetings of the JSC and will take and disseminate minutes of meetings of the JSC, including any decisions made at such meeting. The co-chairs for each Subcommittee will designate a Person to take and disseminate minutes of meetings of such Subcommittee, including any decisions made at</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">such meeting. The Alliance Managers (or their designees) will serve as the primary contact point between the Parties for the purpose of providing each Party with information regarding the other Party&#8217;s activities pursuant to this Agreement and will have the following responsibilities&#58; (a) schedule meetings of the JSC&#59; (b) draft and circulate draft agendas for meetings of the JSC&#59; (c) prepare the written minutes of any JSC meeting, and circulate drafts thereof, and ensure that approved minutes are archived and monitor and follow-up the execution of decisions and actions reflected in such minutes&#59; (d) generally facilitate communication, coordination, and collaboration between the Parties&#59; and (e) manage the dispute resolution process. Each Alliance Manager (and their designees) will conduct its responsibilities hereunder in good faith and with reasonable care and diligence.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 10&#58; FINANCIAL</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Up-Front Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. In partial consideration of the rights and licenses granted herein, Sanofi will pay Novavax a one-time, non-refundable upfront payment of Five Hundred Million Dollars ($500,000,000) within &#91;***&#93; days after the receipt of Novavax&#8217;s invoice, which invoice may be dated no earlier than the Effective Date.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Equity Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. In partial consideration for the grant of the rights and licenses herein, concurrent with the execution of this Agreement, the Parties or their designated Affiliates have executed the Securities Subscription Agreement.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Licensed COVID-19 Product Milestone Payments</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Development Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax shall notify Sanofi of the achievement of the Development milestone event described in rows A and D of Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.3.1</a> and Sanofi shall notify Novavax of the achievement of each Development milestone event described in rows B, C, E, and F of Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.3.1</a> (the events of rows A-F &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after the achievement thereof. Sanofi shall pay Novavax the COVID-19 Development milestone payment described in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.3.1</a> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after receipt of Novavax&#8217;s corresponding invoice dated after achievement of the COVID-19 Development Milestone Event&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.276%"><tr><td style="width:1.0%"></td><td style="width:7.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#b4c5e7;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.20pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.20pt;text-decoration:none">10.3.1</a> COVID-19 Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:8.20pt">Milestones</font></div></td></tr><tr><td colspan="6" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">COVID-19 Development Milestone Event</font></div></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.9pt;text-indent:-8.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:131%">COVID-19 Development Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">A.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Receipt of First Marketing Authorization by FDA of a Milestone Eligible Licensed COVID-19 Mono Product in the U.S.</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.4pt;text-indent:-0.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">One-Hundred and Seventy Five Million Dollars ($175,000,000)</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">B.</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Completion of the transfer to Sanofi of Marketing Authorization granted to Novavax in the U.S. for</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">the first Milestone Eligible Licensed COVID-19 Mono Product</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Twenty-Five Million Dollars ($25,000,000)</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">C.</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Completion of the transfer to Sanofi of Marketing Authorization granted to Novavax by the European Commission under the centralized procedure for the first Milestone Eligible Licensed COVID-19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Mono Product</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Twenty-Five Million Dollars ($25,000,000)</font></td></tr></table></div><div><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.276%"><tr><td style="width:1.0%"></td><td style="width:7.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">D.</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Database lock of the 12-month interim analysis of cohort 1 (6-11 year olds) of the Phase 2&#47;3 Clinical Trial with Novavax identifier 2019nCoV-503</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">(clinicaltrials.gov identifier NCT05468736)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fifty Million Dollars ($50,000,000)</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">E.</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Successful Completion of COVID-19 Manufacturing Technology Transfer</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Seventy-Five Million Dollars ($75,000,000)</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">F.</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Dosing of the fifth (5th) patient in the first Pivotal Clinical Trial of the first Licensed CIC Product conducted by or on behalf of Sanofi, its Affiliates, or their respective Sublicensees in the United</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">States or any EU country.</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">One Hundred and Twenty-Five Million Dollars ($125,000,000)</font></td></tr></table></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Each COVID-19 Development Milestone Payment in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.3.1</a> is payable one (1)-time only, upon the first occurrence of each COVID-19 Development Milestone Event by the applicable Licensed COVID-19 Product. The maximum COVID-19 Development Milestone Payment that Sanofi will pay to Novavax under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.3.1</a> (Milestones for Licensed COVID-19 Products) is Four Hundred Seventy-Five Million Dollars ($475,000,000).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Launch Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi shall notify Novavax of the achievement of the launch milestone event described in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.3.2</a> (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Launch Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after the achievement thereof by Sanofi, its Affiliates, or their respective Sublicensees. Sanofi shall pay Novavax each COVID-19 launch milestone payment described in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.3.2</a> (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Launch Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after receipt of Novavax&#8217;s corresponding invoice dated after achievement of the COVID-19 Launch Milestone Event&#58;</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.011%"><tr><td style="width:1.0%"></td><td style="width:55.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.15pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.15pt;text-decoration:none">10.3.2</a> COVID-19 Launch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:8.15pt">Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 Launch Milestone Event</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 Launch Milestone Payment</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">First Commercial Sale in the United States of the first Licensed CIC Product</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Two Hundred and Twenty-Five Million Dollars ($225,000,000)</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">The COVID-19 Launch Milestone Payment set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.3.2</a> is payable one (1)- time only, upon the First Commercial Sale of the first Licensed CIC Product in the U.S.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Licensed Adjuvanted Product Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Development Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi shall notify Novavax of the achievement of each Development milestone event described in the table below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) within &#91;***&#93; after the achievement thereof. Sanofi shall pay Novavax the Adjuvant Development Milestone payment described in the table below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Adjuvant Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) within &#91;***&#93; after receipt of Novavax&#8217;s corresponding invoice dated after achievement of the Adjuvant Development Milestone Event&#58;</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.613%"><tr><td style="width:1.0%"></td><td style="width:5.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#b4c5e7;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.25pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.25pt;text-decoration:none">10.4.1</a> Adjuvant Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:8.25pt">Milestones</font></div></td></tr><tr><td colspan="6" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjuvant Development Milestone Event</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjuvant Development Milestone Payment</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">A.</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">For a fifth (5th) and each subsequent Distinct Licensed Adjuvanted Product, the date on which either (i) the Gatekeeper provides written confirmation to Sanofi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">that the Proposed Field for such Distinct Licensed</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Million Dollars ($3,000,000)</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:5.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.613%"><tr><td style="width:1.0%"></td><td style="width:5.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Adjuvanted Product is not Unavailable or (ii) Sanofi provides written notice to Novavax identifying such Distinct Licensed Adjuvanted Product in accordance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:131%">with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:131%;text-decoration:none">3.5.2</a> (Sanofi Research and Development Reports).</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">B.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dosing of the fifth (5th) patient in the first Phase 1 Full Clinical Trial of the fifth (5th) and each subsequent Distinct Licensed Adjuvanted Product, conducted by or on behalf of Sanofi, its Affiliates, or their respective Sublicensees.</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Million Dollars ($3,000,000)</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:8.60pt">C.</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Dosing of the fifth (5th) patient in the first Pivotal Clinical Trial of the first Distinct Licensed Adjuvanted Product conducted by or on behalf of Sanofi, its</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:7.60pt">Affiliates, or their respective Sublicensees.</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Four Million Dollars ($4,000,000)</font></td></tr></table></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Each Adjuvant Development Milestone Payment in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4.1</a> is payable one (1)- time only for each Licensed Adjuvanted Product that is Distinct, upon the achievement of the Adjuvant Development Milestone Event by such Distinct Licensed Adjuvanted Product. The maximum Adjuvant Development Milestone Payment that Sanofi will pay to Novavax under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4.1</a> (Development Milestones) for each Distinct Licensed Adjuvanted Product is Ten Million Dollars ($10,000,000). For avoidance of doubt, Sanofi will provide written notice to Novavax for every Licensed Adjuvanted Product that achieves an Adjuvant Development Milestone Event, but (a) the first four (4) Distinct Licensed Adjuvanted Products Developed by or on behalf of Sanofi and (b) any non-Distinct Licensed Adjuvanted Product thereafter, in each case (a) and (b), do not trigger the Adjuvant Development Milestone Events set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4.1.</a></font></div><div style="margin-top:0.7pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Launch Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi shall notify Novavax of the achievement of each launch milestone event described in the table below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Launch Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after the achievement thereof. Sanofi shall pay Novavax the Adjuvant launch milestone payment described in the table below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Launch Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; after receipt of Novavax&#8217;s corresponding invoice dated after achievement of the Adjuvant Development Milestone Event&#58;</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.011%"><tr><td style="width:1.0%"></td><td style="width:55.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.20pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:8.20pt;text-decoration:none">10.4.2</a> Adjuvant Launch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:8.20pt">Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:117%">Adjuvant Launch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:117%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Event</font></div></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjuvant Launch Milestone Payment</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">First Commercial Sale in the United States of each Distinct Licensed Adjuvanted Product</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fifty Million Dollars ($50,000,000)</font></td></tr></table></div><div style="margin-top:1.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">The Adjuvant Launch Milestone Payment for the Licensed Adjuvanted Product is payable upon the First Commercial Sale of each Distinct Licensed Adjuvanted Product.</font></div><div style="margin-top:1.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi will notify Novavax in writing of the achievement of each sales- based milestone event set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4.3</a> (Adjuvant Sales Milestones) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) by Sanofi or its Affiliates or Sublicensees no later than &#91;***&#93; after the end of the Calendar Quarter in which such Sales Milestone Event is achieved. Sanofi will pay to Novavax the sales milestone payment corresponding to the applicable Sales Milestone Event set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.4.3</a> (Adjuvant Sales Milestones) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) no later than &#91;***&#93; after receipt of the applicable invoice from Novavax.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:5.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:63.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.011%"><tr><td style="width:1.0%"></td><td style="width:59.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.50pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.50pt;text-decoration:none">10.4.3</a> Adjuvant Sales Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales Milestone Event</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">First occurrence of Annual Net Sales of each Licensed Adjuvanted Product greater than $500,000,000</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fifty Million Dollars ($50,000,000)</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">First occurrence of Annual Net Sales of each Licensed</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Adjuvanted Product greater than $1,000,000,000</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">One Hundred Million Dollars</font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">($100,000,000)</font></div></td></tr></table></div><div style="margin-top:1.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For clarity, each Sales Milestone Payment will be paid only once for each Licensed Adjuvanted Product on the first achievement of the corresponding Sales Milestone Event by aggregate Net Sales of such Licensed Adjuvanted Product.</font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Licensed Adjuvanted Products for pre-Pandemic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. &#91;***&#93;.  </font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For purposes of calculating the royalties and royalty tiers in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5</a> (Royalties) for a given Licensed Product, only the applicable portion of Annual Net Sales for such Licensed Product, adjusted on the basis set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.174</a> (&#8220;Net Sales&#8221;) shall be included for purposes of such calculation. Notwithstanding any provision to the contrary set forth in this Agreement, with respect to any Licensed CIC Product or Licensed OC Product in a given country, in no event will the reductions permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4</a> (Royalty Adjustments) together with the Net Sales apportionment for Licensed CIC Products and Licensed OC Products as set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1.174</a> (&#8220;Net Sales&#8221;) result in an effective royalty rate for a Licensed CIC Product or Licensed OC Product in such country below &#91;***&#93; of the Annual Net Sales of such Licensed CIC Product or Licensed OC Product in such country.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Licensed COVID-19 Mono Product Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4</a> (Royalty Adjustments), during the COVID-19 Royalty Term, Sanofi will pay Novavax royalties on a tier-by-tier basis at the following royalty rates on Net Sales (including Cancellation Fees pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.3</a> (Cancellation Fees)) of the applicable Licensed COVID-19 Product sold by Sanofi, its Affiliates, and their respective Sublicensees in the Territory as set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.1</a> (Licensed COVID-19 Mono Product Royalty).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Licensed COVID-19 Mono Product Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. During the COVID-19 Royalty Term, Sanofi will pay Novavax royalties on Net Sales of Licensed COVID-19 Mono Products at the royalty rates set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.1(a)</a> (Royalty Rate).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:15.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.432%"><tr><td style="width:1.0%"></td><td style="width:82.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.55pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.55pt;text-decoration:none">10.5.1(a)</a> Licensed COVID-19 Mono Product Royalty Rate</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Portion of Aggregate Annual Net Sales for all Licensed COVID-19 Mono Products&#58;</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Licensed CIC Product and Licensed OC Product Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. On a Licensed CIC Product-by-Licensed CIC Product or Licensed OC Product-by-Licensed OC Product basis, as applicable, during the COVID-19 Royalty Term, Sanofi will pay Novavax royalties on Net Sales (including Cancellation Fees pursuant to Section</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.5.3</a> (Cancellation Fees)) of Licensed CIC Products and Licensed OC Products at the royalty rates set forth in Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.5.1(b)</a> (Royalty Rate).</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:15.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.432%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.55pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.55pt;text-decoration:none">10.5.1(b)</a> Licensed CIC Products and Licensed OC Products Royalty Rate</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Portion of Aggregate Territory-wide Annual Net Sales for each Licensed CIC Product or each Licensed OC Product&#58;</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Licensed Adjuvanted Product Royalty Rates.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi will pay Novavax royalties on Net Sales of all Licensed Adjuvanted Products in the Territory during the Adjuvant Royalty Term at a royalty rate of &#91;***&#93;.</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Sole Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For all Licensed Adjuvanted Products, the royalty rates set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.2</a>(a) (Rate) may be reduced only in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.2</a>(b) (Sole Reduction). On a Licensed Adjuvanted Product-by-Licensed Adjuvanted Product and country-by-country basis, Sanofi has the right to credit &#91;***&#93; of all consideration actually paid by Sanofi to a Third Party pursuant to an agreement between Sanofi and such Third Party entered into following the Effective Date to the extent in consideration for a license to Sanofi under Patents controlled by such Third Party that are necessary to Manufacture or Commercialize the Adjuvant (but not any Antigen or other component) in any Licensed Adjuvanted Product in such country against any royalties due in such Calendar Quarter to Novavax hereunder for the applicable Licensed Adjuvanted Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that in no event may Sanofi credit any amounts under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.2(b)</a> (Sole Reduction) that have already been, or that pursuant to the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">0</a> (Third Party Licenses) could be, credited against payments due to Novavax under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">0</a> (Third Party Licenses).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Cumulative Reductions Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In no event will the reductions set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.2</a>(b) (Sole Reduction) cause the royalties otherwise due to Novavax for any Licensed Adjuvanted Product in a given Calendar Quarter during the applicable Adjuvant Royalty Term for such Licensed Adjuvanted Product to be reduced by more than &#91;***&#93; of the amount that would otherwise be due in such Calendar Quarter for such Licensed Adjuvanted Product but for such reductions, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that any reductions not able to be made or taken in respect of royalties in a given Calendar Quarter as a result of this Section 10.5.3<a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">(c)</a> (Cumulative Reductions Floor) shall be carried forward for reduction in respect of royalties in future Calendar Quarters until fully exhausted.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Cancellation Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. On a Licensed Product-by-Licensed Product basis during the COVID- 19 Royalty Term or Adjuvant Product Royalty Term, as applicable, any Cancellation Fees</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">with respect to such Licensed Product shall be treated as Net Sales hereunder with respect to such Licensed Product.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Royalty Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. For all Licensed COVID-19 Products, the royalty rates set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.5.1</a> (Licensed COVID-19 Product Royalty Rates) may be reduced in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.5.4</a> (Royalty Adjustments).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Lack of Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.5</a> (Cumulative Reductions Floor) and the last sentence of the introductory paragraph of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5</a> (General), if, during the COVID-19 Royalty Term, on a country-by-country and Licensed COVID-19 Product-by-Licensed COVID-19 Product basis, for a given country and Licensed COVID-19 Product, (i) no Valid Claim of (A) a Novavax Patent or (B) a Joint Arising Patent Covers the composition of matter or a method of use (of an Indication that has received Marketing Authorization) of such Licensed COVID- 19 Product or the Manufacture or use thereof in such country and (ii) there is no Regulatory Exclusivity for such Licensed COVID-19 Product in such country, then the Net Sales in such country used for purposes of calculating worldwide Net Sales of such Licensed COVID-19 Product and royalty payments due to Novavax based on Net Sales of such Licensed COVID-19 Product in such country pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.1</a> (Licensed COVID-19 Product Royalty Rates) will be reduced by &#91;***&#93;.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Biosimilar Product Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.5</a> (Cumulative Reductions Floor) and the last sentence of the introductory paragraph of Section</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5</a> (General), if, during the COVID-19 Royalty Term, on a country-by-country Licensed COVID-19 Product-by-Licensed COVID-19 Product, and Calendar Quarter-by-Calendar Quarter basis, for a given country, Licensed COVID-19 Product and Calendar Quarter, (i) the MAA for a Biosimilar Product as to such Licensed COVID-19 Product has been approved and such Biosimilar Product is being sold in such country in such Calendar Quarter and (ii) the Net Sales of such Licensed COVID-19 Product in such country decline by the percentage described in a given row in the table below in a Calendar Quarter relative to the average Calendar Quarter Net Sales of such Licensed COVID-19 Product in such country achieved in the &#91;***&#93; consecutive Calendar Quarters immediately prior to the Calendar Quarter in which the initial sale of such Biosimilar Product after receipt of approval for the Marketing Authorization for such Biosimilar Product in such country occurred, then the Net Sales in such country used for purposes of calculating worldwide Net Sales of such Licensed COVID-19 Product will be reduced by the corresponding amount set forth in the table below on and after such Calendar Quarter&#58;</font></div><div style="padding-left:80.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.469%"><tr><td style="width:1.0%"></td><td style="width:46.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#b4c5e7;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.60pt">Table <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:7.60pt;text-decoration:none">10.5.4(b)</a> Biosimilar Reduction Percentage</font></div></td></tr><tr><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Decline in Net Sales in a Country</font></td><td colspan="3" style="background-color:#d9e1f3;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net Sales Reduction in such Country</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.5</a> (Cumulative Reductions Floor) and the last sentence of the introductory paragraph of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5</a> (General), on a</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensed COVID-19 Product-by-Licensed COVID-19 Product and country-by- country basis, Sanofi has the right to credit &#91;***&#93; of all consideration actually paid by Sanofi to a Third Party or any Acquirer pursuant to an agreement between Sanofi and such Third Party or Acquirer entered into following the Effective Date to the extent in consideration for a license to Sanofi under Patents controlled by such Third Party or Acquirer that (i) would be infringed by the sale of the Licensed COVID-19 Mono Product or (ii) Cover (A) the Licensed COVID-19 Component or (B) the Adjuvant, in each case, in such country against any royalties due to Novavax hereunder for the applicable Licensed Product in such country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Third Party License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding anything to the contrary in this Agreement, to the extent Sanofi is required to pay</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i) &#91;***&#93; or (ii) any royalty or other consideration under a Third Party License (including per any settlement of any Product Infringement Claim) that is attributable to Novavax&#8217;s breach of its representations and warranties hereunder, Sanofi shall have the right to deduct from the royalties owed to Novavax &#91;***&#93; of all such royalties and other consideration, and the cumulative reduction floor of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">10.5.5</a> (Cumulative Reductions Floor) shall not apply to that portion of reduction attributable to such payments.</font></div><div style="margin-top:8.55pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Compulsory Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. During the COVID-19 Royalty Term, if for a given country and a given Licensed COVID-19 Product (i) Sanofi is compelled by Applicable Law to grant a compulsory license permitting a Third Party the right to sell a Biosimilar Product as to such Licensed COVID-19 Product in such country at a royalty rate that is lower than the applicable royalty rate set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.1</a> (Licensed COVID-19 Product Royalty Rates) for the corresponding Licensed COVID-19 Product and (ii) such Third Party sells a Biosimilar Product as to such Licensed COVID-19 Product in such country pursuant to such compulsory license, then Net Sales in such country used for purposes of calculating worldwide Net Sales of such Licensed COVID-19 Product and royalty payments due to Novavax based on Net Sales of such Licensed COVID-19 Product in such country pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.1</a> (Licensed COVID-19 Product Royalty Rates) will be reduced by &#91;***&#93;.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Cumulative Reductions Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the last sentence of the introductory paragraph of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5</a> (General), in no event will the reductions set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4(a)</a> (Lack of Valid Claim), <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4(b)</a> (Biosimilar Product Competition), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">0</a> (Third Party Licenses), and <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4(d)</a> (Compulsory Licenses) cause the royalties otherwise due to Novavax for any Licensed COVID-19 Product in a given Calendar Quarter in a given country during the applicable COVID-19 Royalty Term for such Licensed COVID-19 Product to be reduced by more than &#91;***&#93; of the amount that would otherwise be due in such Calendar Quarter for such Licensed COVID-19 Product in such country but for such reductions, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if the Net Sales reduction under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.4(b)</a> (Biosimilar Product Competition) is &#91;***&#93;, then the royalties due for such Licensed COVID-19 Product in such Calendar Quarter may be reduced by more than &#91;***&#93; of the amounts otherwise due for such Licensed COVID-19 Product in such Calendar Quarter but for such reductions. Any reductions not able to be made or taken in respect of royalties in a given Calendar Quarter as a result of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.5.5</a> (Cumulative Reductions Floor) shall be carried forward for reduction in respect of royalties in future Calendar Quarters until fully exhausted.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Royalty Reports and Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Following the First Commercial Sale of a Licensed Product in the Territory and continuing until there are no Licensed Products being Commercialized in the Territory for which royalties are payable hereunder, Sanofi will deliver to Novavax within &#91;***&#93; a report summarizing on a Licensed Product-by-Licensed Product and country-by-country basis&#58; (a) total Net Sales and Cancellation Fees, in each case (i) and (ii), in the relevant &#91;***&#93;&#59; (b) to the extent such Net Sales and Cancellation Fees include sales or fees that are not denoted in Dollars, a summary of the amount of Net Sales and Cancellation Fees in local currency and any conversion per Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.14.2</a> (Exchange)&#59; and (c) royalties payable on such Net Sales and Cancellation Fees (each such report a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Royalty Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Within &#91;***&#93; following the receipt of each Royalty Report, Novavax will issue an invoice to Sanofi for the corresponding amount payable, and Sanofi shall pay such invoice (unless disputed) within &#91;***&#93; after receipt. In addition to the Royalty Reports, Sanofi shall provide Novavax with such other information requested by Novavax that is necessary for Novavax to comply with its royalty payment and financial reporting obligations under any Upstream License Agreement (including under Section 7.1 (Royalty Payments&#59; Reports) of the Upstream License Agreement)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided however </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that Sanofi shall have no obligation to provide to Novavax or any Third Party with whom Novavax has entered into a Upstream License Agreement any competitively sensitive information.</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Research and Development Plan Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Reimbursement&#59; In-Kind</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax will bear the COVID-19 Research and Development Plan Costs it incurs in the performance of activities allocated to it under the COVID-19 Research and Development Plan from the Effective Date until December 31, 2024. Commencing on January 1, 2025, Sanofi will reimburse Novavax, on a Calendar Quarter-by-Calendar Quarter basis, (a) for all COVID-19 Research and Development Plan Costs incurred by or on behalf of Novavax in the applicable Calendar Quarter in accordance with the COVID-19 Research and Development Budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowable Overruns and (b) for all other amounts required to be reimbursed by Sanofi in accordance with this Agreement. In the event that Novavax incurs any COVID-19 Research and Development Plan Costs above the COVID-19 Research and Development Budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowable Overruns, then Novavax shall bear such COVID-19 Research and Development Plan Costs itself. Sanofi will bear the COVID-19 Research and Development Plan Costs it incurs in the performance of activities allocated to it under the COVID-19 Research and Development Plan.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Reporting Research and Development Plan Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. COVID-19 Research and Development Plan Costs will initially be borne by the Party incurring the cost or expense, subject to reimbursement as provided in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6.1</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement&#59; In-Kind</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Within &#91;***&#93;, Novavax will provide Sanofi with a detailed, itemized invoice of the COVID-19 Research and Development Plan Costs incurred by or on behalf of it and its Affiliates during such &#91;***&#93; in the form agreed by the Parties through the JFC, as may be updated by the JFC from time to time (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Research and Development Plan Costs Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Within &#91;***&#93; following the receipt of each Research and Development Plan Costs Invoice, Sanofi will have the right to request reasonable additional information related to such COVID-19 Research and Development Plan Costs during such &#91;***&#93; in order to confirm that such reported COVID-19 Research and Development Plan Costs conform with the approved COVID-19 Research and Development Budget. Sanofi will pay the undisputed</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">amounts invoiced within &#91;***&#93; after receipt of such Research and Development Plan Costs Invoice.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">Sanofi will reimburse Novavax&#8217;s FTE Costs and Out-of-Pocket Costs that Novavax incurs in connection with transferring Novavax Materials pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">3.6</a> (Transfer of Materials).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Regulatory Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Reimbursement&#59; In-Kind.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Except as set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs), with respect to the specific Regulatory activities allocated to Novavax that are included in the COVID-19 Research and Development Plan and the corresponding COVID- 19 Research and Development Budget and this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.7</a> (Regulatory Costs), Novavax will bear the FTE Costs and Out-of-Pocket Costs incurred by Novavax in the performance of Regulatory activities by Novavax with respect to Licensed COVID-19 Mono Products in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Novavax will bear its own the Regulatory Costs incurred in the performance of the Regulatory activities allocated to it under the Regulatory Transfer Plan.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">In each country, jurisdiction, or region in which Sanofi is the Regulatory Responsible Party for a given Licensed COVID-19 Mono Product, Sanofi shall reimburse Novavax with respect to the FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Novavax to provide assistance to Sanofi under Section</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.6.2</a> (Right of Reference) and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.6.3</a> (Right of Reference).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">In each country, jurisdiction, or region in which Novavax (i) remains the Regulatory Responsible Party for a given Licensed COVID-19 Mono Product, and</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">is the sole Party that is Commercializing such Licensed COVID-19 Mono Product in such country, jurisdiction, or region, except for the specific Regulatory Costs referred to in paragraphs (a), (b), and (c) above, Novavax will bear all Regulatory Costs in connection with obtaining and maintaining Marketing Authorization for such Licensed COVID-19 Mono Product for such country, jurisdiction, or region.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">In each country, jurisdiction, or region in which Novavax (i) remains the Regulatory Responsible Party for a given Licensed COVID-19 Mono Product, and</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.24pt">both Parties are Commercializing such Licensed COVID-19 Mono Product, except for the specific Regulatory Costs referred to in paragraphs (a), (b), and (c) above, Sanofi will reimburse Novavax on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">pro rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">basis (based on doses of such Licensed COVID-19 Mono Product sold by each Party to final customers in such country, jurisdiction, or region) for all Regulatory Costs incurred by or on behalf of Novavax in connection with obtaining and maintaining Marketing Authorization for such Licensed COVID-19 Mono Product in such country, jurisdiction, or region.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.37pt">In each country, jurisdiction, or region in which Sanofi (i) is the Regulatory Responsible Party for a given Licensed COVID-19 Mono Product, and (ii) both Parties are Commercializing such Licensed COVID-19 Mono Product, except for</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the specific Regulatory Costs referred to in paragraphs (a), (b), and (c) above, Novavax will reimburse Sanofi on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">pro rata basi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s (based on doses of such Licensed COVID-19 Mono Product sold by each Party to final customers in such country, jurisdiction, or region) for all Regulatory Costs incurred by or on behalf of Sanofi in connection with obtaining and maintaining Marketing Authorization for such Licensed COVID-19 Mono Product in such country, jurisdiction, or region.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">In each country, jurisdiction, or region in which Sanofi is the Regulatory Responsible Party for a given Licensed COVID-19 Mono Product, and Sanofi the sole Party that is Commercializing such Licensed COVID-19 Mono Products in such country, jurisdiction, or region, except for the specific Regulatory Costs referred to in paragraphs (a), (b), and (c) above, Sanofi will bear all Regulatory Costs incurred in connection with obtaining and maintaining Marketing Authorization for such Licensed COVID-19 Mono Products in such country, jurisdiction, or region.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">Novavax will bear all FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Novavax in maintaining the global safety database in Calendar Year 2024. Commencing in Calendar Year 2025 and continuing until the transfer of the global safety database to Sanofi in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">4.9.2,</a> Sanofi will reimburse Novavax for fifty percent (50%) of the FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Novavax in maintaining the global safety database.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Reporting Regulatory Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All Regulatory Costs will initially be borne by the Party incurring the cost or expense, subject to reimbursement as provided in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.7.1</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement&#59; In-Kind</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Within &#91;***&#93;, Novavax will provide Sanofi with a detailed, itemized invoice of the costs incurred by or on behalf of it and its Affiliates during such &#91;***&#93; in the form agreed by the Parties through the JFC, as may be updated by the JFC from time to time (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Regulatory Costs Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Sanofi will pay the undisputed amounts in each Regulatory Costs Invoice within &#91;***&#93; after receipt of such Regulatory Costs Invoice.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Technology Transfer Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Reimbursement&#59; In-Kind</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi will reimburse Novavax, on a Calendar Quarter-by- Calendar Quarter basis for the Technology Transfer Costs incurred by or on behalf of Novavax in the applicable Calendar Quarter that are in accordance with Technology Transfer Budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowable Overruns. If Novavax incurs any Technology Transfer Costs under the applicable Technology Transfer Plan that are not in accordance with the applicable Technology Transfer Budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowable Overruns, then Novavax shall bear such Technology Transfer Costs itself. Sanofi will bear all FTE Costs and Out-of-Pocket Costs that it incurs in the performance of activities allocated to it under any Technology Transfer Plan. <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.1.3</a> (Technical Assistance). Each Party will bear its own FTE Costs and will each bear an equal (50%&#58;50%) share of all Out-of-Pocket Costs incurred in connection with maintaining the Adjuvant Intermediate Technology Escrow pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.6</a> (Adjuvant Intermediates Technology Escrow) and the Adjuvant Technology Escrow and COVID-19 Technology Escrow pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">5.7</a> (Other Escrows).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Technology Transfer Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Technology Transfer Costs will initially be borne by Novavax, subject to reimbursement as provided in Section 10.7.1 (Reimbursement&#59; In-Kind). Within &#91;***&#93;, Novavax will provide Sanofi with a detailed, itemized invoice of the Technology Transfer Costs reimbursable by Sanofi in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.8.1</a> (Reimbursement&#59; In-Kind) under the applicable Technology Transfer Budget that are incurred by or on behalf of it and its Affiliates during such &#91;***&#93; in the form agreed by the Parties through the JFC, as may be updated by the JFC from time to time (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Technology Transfer Costs Invoice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Within &#91;***&#93; following the receipt of each Technology Transfer Costs Invoice, Sanofi will have the right to request reasonable additional information related to such Technology Transfer Costs during such &#91;***&#93; in order to confirm that such reported Technology Transfer Costs are in accordance with the approved Technology Transfer Budget. Sanofi will pay the undisputed amounts invoiced within &#91;***&#93; after receipt of such Technology Transfer Costs Invoice.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will bear its own Manufacturing Costs incurred in connection with the Manufacturing for (a) the Exploitation of any Novavax CIC Products, Novavax OC Products, or Novavax Adjuvant Products and (b) the Exploitation of Licensed COVID-19 Mono Products in any country for which Novavax is performing Commercialization activities pursuant to Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7</a> (Commercialization) or the Licensed COVID-19 Mono Product Commercialization Framework. In addition, Novavax will reimburse Sanofi for all Licensed COVID-19 Mono Products that Sanofi may supply to Novavax in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.1.1</a> (Supply for Novavax). Sanofi shall bear its own Manufacturing Costs incurred in connection with the Manufacturing for (a) the Exploitation of Licensed CIC Products, Licensed OC Products, and Licensed Adjuvanted Products, and (b) the Exploitation of Licensed COVID-19 Mono Products in any country for which Sanofi is performing Commercialization activities pursuant to Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7</a> (Commercialization) or the Licensed COVID-19 Mono Product Commercialization Framework. In addition, Sanofi will reimburse Novavax for all Licensed COVID-19 Component, Licensed COVID-19 Mono Product, &#91;***&#93;, &#91;***&#93; or Adjuvant Intermediate, as applicable, that Novavax supplies to Sanofi under the COVID-19 Supply Agreement or Adjuvant Supply Agreement, as applicable, in accordance with such agreement, and in the event that the Parties have not executed a COVID-19 Supply Agreement or Adjuvant Supply Agreement, as applicable, in accordance with this Agreement.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Commercialization Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6</a> (Research and Development Plan Costs), with respect to the specific Medical Activities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, post-Marketing Authorization clinical trials) allocated to Novavax that are included in the COVID-19 Research and Development Plan, Novavax will bear its own costs and expenses incurred in connection with the (a) Commercialization of any Novavax CIC Product, Novavax OC Product, or Novavax Adjuvant Product and (b) the Commercialization of Licensed COVID-19 Mono Products for which Novavax is performing Commercialization activities pursuant to Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7</a> (Commercialization) or the Licensed COVID-19 Mono Product Commercialization Framework. Sanofi will bear its own costs and expenses incurred in connection with (a) the Commercialization of Licensed CIC Products, Licensed OC Products, and Licensed Adjuvanted Products, and (b) the Commercialization of Licensed COVID-19 Mono Products for which Sanofi is performing Commercialization activities pursuant to Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7</a> (Commercialization) or the Licensed COVID-19 Mono Product Commercialization Framework. For clarity, each Party shall bear its own FTE Costs and Out-of- Pocket Costs incurred in connection with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.10.1(g)</a> (Pricing Approvals).</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Revenues and Expenses&#59; Profits and Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as expressly provided pursuant to this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 10</a> (Financial), neither Party shall have any right to receive any payment from the other</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Party hereunder, including that neither Party shall have any right to receive all or any portion of any revenues or profits of the other Party, and neither Party will have any obligation to bear any losses or to pay or reimburse for any costs or expenses incurred by the other Party.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Medical Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to the Licensed COVID-19 Mono Product, the costs of Medical Activities that are set forth in the COVID-19 Research and Development Plan will be deemed COVID-19 Research and Development Costs and will be accounted for in the COVID-19 Research and Development Budget. Novavax shall report to Sanofi the costs incurred by Novavax in connection with conducting such Medical Activities in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.6.2</a> (Reporting Research and Development Plan Costs).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Patent Costs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Party Prosecuting and Maintaining a Patent will bear all FTE Costs and Out-of- Pocket Costs incurred by or on behalf of such Party in connection with such Prosecution and Maintenance.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.25pt">Other Payment Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:7.35pt;text-decoration:underline">Currency&#59; Payment Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All payments under this Agreement are expressed in Dollars and will be paid in Dollars, by wire transfer or automated clearing house payment to an account designated by the applicable Party, which account each Party may update from time to time in writing.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any calculations to be performed under this Agreement are denoted in a currency other than Dollars, then such amounts will be converted to their Dollar equivalent using the paying Party&#8217;s (or, as applicable, its Sublicensee&#8217;s) then-current standard procedures and methodology, including its then-current standard exchange rate methodology for the translation of foreign currency expenses into Dollars consistently applied.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Other Invoices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to any payment owed by one Party to the other Party under this Agreement for which no other invoicing and payment procedure is specified elsewhere herein, the payee Party shall issue an invoice for such payment which invoice shall refer to this Agreement and the specific provision under which the payment is owed, and the payor Party shall pay such invoice (unless disputed) within &#91;***&#93; after receipt.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Right to Reconcile Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If a court of competent jurisdiction has determined that Sanofi is entitled to any amount as damages for Novavax&#8217;s breach of this Agreement and Sanofi has not elected the alternative remedy set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)(ii)</a> (Termination for Material Breach), then Sanofi will have the right to offset any such amount owed by it to Novavax against amounts payable to Novavax under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that prior to exercising such offset right, Sanofi will notify Novavax of its intent to exercise such offset right. Such offsets will be in addition to any other rights or remedies available under this Agreement and Applicable Law.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">No Double Counting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To the extent any cost and expense of an activity conducted by a Party hereunder is reimbursable by the other Party under more than one (1) provision of this Agreement (e.g., the same activity is deemed an activity under the COVID-19 Research and Development Plan and a Technology Transfer Plan), such Party shall not seek reimbursement of such cost and expense under more than one (1) provision of this Agreement pursuant to which reimbursement may be sought, and the reimbursing Party</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">shall not be obligated to pay for any given reimbursable cost or expense for any activity more than once.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Withholding Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If any sum due to be paid to or by a Party hereunder is subject to any withholding, then the payor Party will pay such withholding to the appropriate Governmental Authority and deduct the amount paid from the amount then due to the payee Party. The payor Party will timely transmit to the payee Party an official tax certificate or other evidence of such withholding sufficient to enable the payee Party to claim such payment of taxes. The Parties will cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding in respect of royalties and other payments made by one Party to the other Party under this Agreement. The payee Party will provide the payor Party any tax forms that may be reasonably necessary in order for payor Party not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes, such recovery to be for the benefit of the Party bearing such withholding tax. In no event will the payor Party be obligated to make any adjustment or gross up payment to the payee Party as a result of any withholding or similar tax levied by any Governmental Authority in connection with any payments hereunder. If either Party is converted from a U.S. corporation to a legal entity that is not regarded for U.S. income tax purposes, and such conversion results in withholding tax that otherwise would not arise, then the converted Party will bear the cost of the resulting withholding tax. Novavax will provide Sanofi, from time to time, an executed US IRS W-9 form if requested by Sanofi to effectuate any payment hereunder, including with respect to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.1</a> (Up-Front Fee) and subsequently upon request by Sanofi.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Financial Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will keep and maintain accurate and complete records regarding its COVID-19 Research and Development Plan Costs, Manufacturing Costs for Materials supplied to Sanofi, Technology Transfer Costs, and any other costs and expenses that are reimbursable by Sanofi under this Agreement, and Sanofi will keep and maintain accurate and complete records regarding Net Sales and Cancellation Fees of Licensed Products required to prepare the reports, including the Royalty Report, or calculate payments required by Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">0</a> (Milestone Payments) or owed under any Upstream License Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Each Party shall retain Financial Records for a period of at least &#91;***&#93;. Upon &#91;***&#93; prior written notice, a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) will have the right to have an audit conducted of the other Party&#8217;s (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) Financial Records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such audit right may not be exercised more than &#91;***&#93; and shall be limited to the Financial Records of the Audited Party pertaining to any financial report or payment due in any Calendar Quarter ending not more than &#91;***&#93; prior to such Party&#8217;s request. The audit will be conducted by an independent certified public accounting firm of internationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Auditor shall examine the applicable Financial Records to determine the basis and accuracy of payments made or due under this Agreement during the period of time covered by the audit. The Auditor will be provided access to the Audited Party&#8217;s Financial Records at the Audited Party&#8217;s facility or facilities where such books and records are normally stored, and such examination will be conducted during the Audited Party&#8217;s normal business hours. The Audited Party has the right to require the Auditor to sign a customary non-disclosure agreement before providing the Auditor access to its Financial Records. Upon completion of the audit, the Auditor will provide both Parties a written report disclosing whether the Financial Records or the Royalty Reports, as applicable, covered by the audit, are correct or incorrect, and if incorrect, the specific details concerning any discrepancies. If the audit reveals an underpayment, then the Party that owes such payment will pay such underpayment to the other Party forthwith </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">interest in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.17</a> (Late Payment). If the audit reveals</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">an overpayment, then the Party that paid such overpayment may credit such amount against any future payments due to the other Party hereunder, and if none are expected within a Calendar Year, then such Party shall be paid by the other Party within &#91;***&#93; after receipt of an invoice for such amount that was overpaid. The costs and fees of any audit conducted by the Auditing Party under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits) will be borne by the Auditing Party, unless such audit reveals an underpayment of amounts owed to the Auditing Party exceeding the lesser of</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a) &#91;***&#93; and (b) &#91;***&#93; of the amount that was owed by the Audited Party with respect to the relevant period, in which case, the Audited Party will reimburse the Auditing Party for the reasonable expense incurred by the Auditing Party in connection with the audit.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Late Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Any undisputed payment under this Agreement that is not paid on or before the date such undisputed payment is due will bear interest, to the extent permitted by Applicable Law, at &#91;***&#93;.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 11&#58; CONFIDENTIALITY AND NON-DISCLOSURE</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Notwithstanding any provision to the contrary set forth herein&#58;</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">(a) the terms of this Agreement, Novavax COVID-19 Know-How, Novavax COVID-19 Materials, unpublished Novavax COVID-19 Patents, Joint Arising Patents, and Joint Arising Know-How&#59; (b) information in any plan (whether for Research, Development, Manufacturing, Commercialization, Medical Activities, Technology Transfer activities, or otherwise, and whether in draft or final form) created by either Party if such plan is reviewed by any Committee&#59; and (c) any budget (whether for Research, Development, Manufacturing, Commercialization, Medical Activities, Technology Transfer activities, or otherwise) created by either Party if such budget is reviewed by any Committee, in each case (a)-(c), will be treated as Confidential Information of both Parties with each Party treated as the Receiving Party with respect thereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that, to the extent any Confidential Information of a Disclosing Party is included in any report, notes, analyses, plan, budget, or other documents prepared or delivered by or on behalf of either Party hereunder, whether with respect to any Research, Development, Manufacturing, Commercialization, or other activity carried out hereunder, the Confidential Information of the Disclosing Party contained in any such report notes, analyses, plan, budget, or other documents shall remain the Confidential Information of the Disclosing Party&#59;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">the Novavax Adjuvant Know-How, Novavax Adjuvant Materials, Adjuvant Intermediate Technology, unpublished Novavax Adjuvant Patents and Novavax Commercialization Reports, will each be the Confidential Information of Novavax, with Sanofi deemed the Receiving Party with respect thereto&#59; and</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">the Sanofi Arising Know-How, Sanofi Arising Patents, Sanofi Commercialization Reports, and Sanofi Licensed COVID-19 Mono Assets will each be the Confidential Information of Sanofi, with Novavax deemed the Receiving Party with respect thereto.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) that receives or whose Affiliates receive any Confidential Information of the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) hereunder will&#58; (a) keep the</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disclosing Party&#8217;s Confidential Information confidential using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value (but in any event no less than reasonable efforts)&#59; (b) not publish, or allow to be published, and not otherwise disclose, or permit the disclosure of, the Disclosing Party&#8217;s Confidential Information&#59; and (c) not use, or permit to be used, the Disclosing Party&#8217;s Confidential Information for any purpose, other than to exercise the Receiving Party&#8217;s rights or perform the Receiving Party&#8217;s obligations under this Agreement, in each case, strictly in accordance with this Agreement, except, in each case ((a) &#8211; (c)), to the extent permitted under this Agreement or otherwise agreed in writing by the Disclosing Party. Without limiting the generality of the foregoing, to the extent either Party provides the other Party any Confidential Information owned by any Third Party, the Receiving Party will handle such Confidential Information in accordance with the terms of this Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11</a> (Confidentiality and Non-Disclosure) applicable to a Receiving Party. The Parties acknowledge and agree that any Confidential Information disclosed by the Disclosing Party to the Receiving Party prior to the Effective Date pursuant to the CDA will constitute the Confidential Information of the Disclosing Party hereunder.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%;padding-left:17.35pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">. Confidential Information will not include any information to the extent the Receiving Party can demonstrate by competent written evidence that such information&#58;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">was known to the Receiving Party or any of its Affiliates, without any obligation to the Disclosing Party or its Affiliates to keep it confidential, prior to disclosure to the Receiving Party or any of its Affiliates by the Disclosing Party&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">is subsequently disclosed to the Receiving Party or any of its Affiliates on a non- confidential basis by a Third Party that is not bound by a duty of confidentiality to the Disclosing Party or its Affiliate&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates in violation of this Agreement, generally known or available to the public, either before or after it is disclosed to the Receiving Party by the Disclosing Party&#59; or</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates, in each case, without the use of or reference to the Confidential Information of the Disclosing Party.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Notwithstanding Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">11.1</a> (Confidentiality), the Receiving Party may disclose the Disclosing Party&#8217;s Confidential Information to the extent such disclosure is reasonably necessary to&#58;</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:11.35pt">prosecute or defend litigation, including responding to a subpoena in a Third Party litigation&#59;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt">Prosecute and Maintain Patents in accordance with the terms of this Agreement&#59;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt">generate Regulatory Filings and file for and obtain Marketing Authorizations or Pricing Approvals, in each case, in accordance with the terms of this Agreement&#59;</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">satisfy Novavax&#8217;s obligations under the Upstream License Agreements or any Existing Strategic Partner Agreements or APAs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that, to the extent practicable, Sanofi shall have the right to review any proposed disclosure to an Upstream Licensor, Strategic</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Partner, or APA counterparty and request that Novavax redact, prior to any such disclosure, any commercially sensitive information that is not required to be shared with the Upstream Licensor, Strategic Partner, or APA counterparty in accordance with the Upstream License Agreement or any Existing Strategic Partner Agreements or APAs, as applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">further provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">that Sanofi provides such comments within &#91;***&#93; after Novavax provides such proposed disclosure to Sanofi&#59;</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">allow its Affiliates and actual or potential Sublicensees and actual or potential Service Providers, in each case, engaged in accordance with this Agreement to exercise the Receiving Party&#8217;s rights or perform the Receiving Party&#8217;s obligations under this Agreement strictly in accordance with this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that any such disclosure is covered by terms of confidentiality with such Affiliates, Sublicensees, and Service Providers that are consistent with the Receiving Party&#8217;s obligations under this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (but of shorter duration if customary, but, in any event, not less than &#91;***&#93; after the expiration or termination of the agreement with such Third Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that Confidential Information relating to manufacturing or CMC information, clinical data, or other information identified as, or customarily held in the pharmaceutical industry as, a trade secret, shall be held in confidence until such information is no longer deemed trade secret under Applicable Law). In any event, the Receiving Party will remain responsible for any violation of such confidentiality provisions by any Person who receives Confidential Information pursuant to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4.5</a> (Authorized Disclosure)&#59;</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">share with the Receiving Party&#8217;s advisors (including financial advisors, attorneys, and accountants), actual or potential acquisition or collaboration partners, financing sources, or investors, or underwriters on a need to know basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that any such disclosure is covered by terms of confidentiality with such advisors, partners, sources, investors, and underwriters that are consistent with the Receiving Party&#8217;s obligations under this Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11</a> (which may include professional ethical obligations) (but, in any event, not less than &#91;***&#93; after the expiration or termination of the agreement with such Third Party or as otherwise customary for the nature of the disclosure, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that Confidential Information held as a trade secret, including relating to manufacturing or CMC information, clinical data, or other information identified as, or customarily held in the pharmaceutical industry as, a trade secret, shall be held in confidence until such information is no longer deemed trade secret under Applicable Law). In any event, the Receiving Party will remain responsible for any violation of such confidentiality provisions by any Person who receives Confidential Information pursuant to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4.6</a> (Authorized Disclosure)&#59; or</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">to the extent required to comply with Applicable Law or a court or administrative order (excluding the United States Securities and Exchange Commission or a similar regulatory agency in a country other than the United States (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), which disclosures are subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures)), in each case, to the extent applicable to such Party at such time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that the Party who is required to make such disclosure under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4.7,</a> if permitted under Applicable Law or order, (a) provides the other Party with reasonable prior written notice, (b) coordinates with the other Party with respect to the wording and timing of any such disclosure and affords the other Party an opportunity to oppose or limit, or secure confidential treatment for, such required disclosure, (c) if unsuccessful in its efforts pursuant to clause (b), then takes all reasonable and lawful actions to obtain confidential treatment for such disclosure, and (d) discloses the minimum amount and scope of the Confidential Information necessary to comply with Applicable Law.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">If and whenever any Confidential Information is disclosed in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">11.4</a> (Authorized Disclosure), such disclosure will not cause any such information to cease to be Confidential Information for purposes of this Agreement, except to the extent that such disclosure results in a public disclosure of such information in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">11.3.2.</a></font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4.1</a> (Authorized Disclosure) or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4.7</a> (Authorized Disclosure), the Receiving Party will (a) except where impracticable or not legally permitted, notify the Disclosing Party of the Receiving Party&#8217;s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed and (b) use not less than the same efforts to secure confidential treatment of such information as it would to protect its own Confidential Information from disclosure (but no less than reasonable efforts), including, if requested by the Disclosing Party, reasonably cooperating with, and at the expense of, the Disclosing Party to secure such confidential treatment.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Required Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In addition to the disclosures permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4</a> (Authorized Disclosure), either Party may disclose the terms of this Agreement and other information relating to this Agreement or the transactions contemplated by this Agreement to the extent required to comply with the rules and regulations promulgated by a Stock Exchange, subject to the remainder of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures). Before a Party discloses this Agreement or any of its terms or other any other Confidential Information in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures), to the extent reasonably practicable and to the extent not prohibited by Applicable Law or judicial or administrative process, such Receiving Party will (a) notify the Disclosing Party of such required disclosure, (b) take all steps reasonably necessary to seek the continued confidential treatment of, or redact, such Confidential Information, and (c) only disclose that portion of Confidential Information that is legally required to be disclosed. Promptly before disclosing this Agreement or any of the terms hereof pursuant to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures), the Parties shall, to the extent not prohibited by Applicable Law or judicial or administrative process and to the extent reasonably practicable, coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules) with respect to filings required under Applicable Law, and the Parties shall use reasonable efforts to file redacted versions of this Agreement with the applicable governing bodies that are consistent with the coordinated redaction efforts between the Parties. In addition, the Parties hereby consent to the disclosure of a copy of this Agreement to any tax authority by the other Party (i) upon receipt of any legally enforceable information request by such tax authority,</font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii) in compliance with any legally enforceable filing requirement, or (iii) in connection with a submitted transfer pricing analysis. In the event of any such disclosure, the Party disclosing Confidential Information will make reasonable efforts to ensure that the information is maintained in confidence by the applicable tax authority, including marking any disclosed document as confidential.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. On or about the Effective Date, each of Sanofi and Novavax will issue separate press releases or other media statements announcing that this Agreement has been signed in substantially the forms attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (Initial Press Releases). Except as set forth in the preceding sentence or as expressly required or permitted under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.4</a> (Authorized Disclosure), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures), this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.6</a> (Public Announcements), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7</a> (Scientific COVID-19 Mono Publications), (a) no Party shall issue any press release or other similar public communication relating to this Agreement, its subject matter, or the transactions covered by it, or the activities of the Parties under or in connection with this Agreement, without the prior written approval of the other Party, and (b) if a Party wishes to issue any press release or other similar public communication relating to this Agreement, its subject</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">matter, or the transactions covered by it, or the activities of the Parties under or in connection with this Agreement other than a press release or public announcement required to comply with the rules and regulations promulgated by a Stock Exchange, the issuance of which will be subject to the terms of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.5</a> (Required Disclosures) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) and such Party has obtained the other Party&#8217;s prior written approval to the extent required pursuant to the forgoing clause (a), then such Party shall provide the other Party reasonable opportunity to review and comment on any such press release or public communication at least &#91;***&#93; in advance thereof (to the extent permitted under Applicable Law), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that the period of review and comment shall, notwithstanding the foregoing, be &#91;***&#93; during the months of August and December (to the extent permitted under Applicable Law). The issuing Party shall act in good faith to incorporate any comments provided by the other Party on such press release or public communication. In addition, the disclosing Party may make subsequent public disclosures reiterating the text of any Press Release previously issued in accordance with this Agreement without having to obtain the other Party&#8217;s prior consent and approval so long as the information in such Press Release remains true, correct, and the most current information with respect to the subject matter set forth therein. Similarly, after a Proposed Disclosure has been made available to the public, each Party may post such Proposed Disclosure or a link to it on its corporate web site (or any website managed by such Party in connection with a Clinical Trial for a Licensed Product, as appropriate) without the prior written consent of the other Party, so long as the information in such Proposed Disclosure remains true, correct, and the most current information with respect to the subject matter set forth therein.</font></div><div style="margin-top:0.6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Scientific COVID-19 Mono Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Publication Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The publication and presentation of (a) any Data relating to any Licensed COVID-19 Mono Product and (b) any other scientific publications relating to or supportive of the Licensed COVID-19 Mono Product, whether or not peer-reviewed such as abstracts, manuscripts, commentaries, letters to the editor, review-articles, book- chapters, or pre-prints ((a) and (b), collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Scientific COVID-19 Mono Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), in each case, shall be conducted in accordance with the terms of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7</a> (Scientific COVID-19 Mono Publications). The JRDC will develop, discuss, and determine whether to approve a strategy for such publications for each Licensed COVID-19 Mono Product, including the appropriate timing (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Publication Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), which Publication Strategy will align with the advice and strategies of the JPC and will include the registration and reporting of results of pharmaceutical company sponsored Clinical Trials in accordance with each Party&#8217;s internal policies.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Authorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Authorship of any publication will be determined in accordance with the guidelines published periodically by the International Committee of Medical Journal Editors. The publishing Party will properly acknowledge the contribution of each Party to the Data being published.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Prior Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Review Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except for a disclosure of the Disclosing Party&#8217;s Confidential Information that is permitted under Section 11.4 (Authorized Disclosure), Section</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.5 (Required Disclosures), or Section 11.6 (Public Announcements), prior to publishing or presenting any (i) Confidential Information of the other Party, or (ii) Scientific COVID-19 Mono Publication (each of (i) and (ii), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), a Party desiring to submit such Proposed Disclosure for publication (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Publishing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) shall provide the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reviewing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">with a copy of such Proposed Disclosure at least &#91;***&#93; (or at least &#91;***&#93; for any abstracts, posters, or presentations) prior to submission for publication (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) in order to allow the Reviewing Party an opportunity to review and comment on the Proposed Disclosure, and such comments will be reasonably taken into account by the Publishing Party. The Reviewing Party shall notify the Publishing Party in writing if the Reviewing Party has an objection to the Proposed Disclosure, whether due to such Proposed Disclosure not aligning with the Publication Strategy, the inclusion of any of its Confidential Information, or to allow time for the Reviewing Party to file for patent protection on any potentially patentable inventions that may be disclosed by the Proposed Disclosure. If the Reviewing Party reasonably determines that such Proposed Disclosure does not align with the Publication Strategy, then the JSC will review, discuss, and determine if such Proposed Disclosure aligns with the Publication Strategy and the Publishing Party may only submit the Proposed Disclosure for publication if the JSC determines that the Proposed Disclosure aligns with the Publication Strategy. If the Reviewing Party reasonably determines that its Confidential Information or a potentially patentable invention would likely be disclosed by such Proposed Disclosure, then it shall so advise the Publishing Party within the Review Period, whereupon the Publishing Party shall postpone publication of such Proposed Disclosure for a period of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Extended Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to afford the Reviewing Party the opportunity to further evaluate the patentability of any inventions that may be disclosed by the Proposed Disclosure&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that, if such Confidential Information of the Reviewing Party may be valuable as a trade secret, then the Reviewing Party shall notify the Publishing Party of such determination during the Extended Review Period, and the Publishing Party will remove such Confidential Information of the Reviewing Party from the Proposed Disclosure prior to submission for publication. If the Reviewing Party gives notice to the Publishing Party during the Extended Review Period that it intends to prepare and file a Patent application that contains any of its Confidential Information contained in such Proposed Disclosure, then the Publishing Party will postpone submission of the Proposed Disclosure for publication by an additional &#91;***&#93; to afford the Reviewing Party the opportunity to prepare and file such a Patent application. Notwithstanding any provision to the contrary set forth in this Agreement, the Publishing Party will not submit for publication any Proposed Disclosure that contains Confidential Information of the Reviewing Party without the written consent of the Reviewing Party.</font></div><div style="margin-top:0.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Disclosure of Clinical Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties acknowledge that each Party, respectively, adheres to certain industry group positions and has adopted certain policies, in each case, regarding the registration and reporting of results of pharmaceutical company sponsored clinical studies. Accordingly, either Party may, in accordance with each Party&#8217;s internal compliance policies, Regulatory Authority requirements, and Applicable Law, disclose aggregate clinical results or summaries thereof generated with respect to Licensed COVID-19 Mono Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such Party complies with the review process set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.7.3(a)</a> (Review Process).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 12&#58; PATENT AND KNOW-HOW MATTERS</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Novavax Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax shall solely own all rights, title, and interests in and to any and all Know-How that is first generated, conceived, discovered, created, invented, or otherwise made during the Term by or on behalf of Novavax or any of its Affiliates in the course of performing activities in accordance with this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Arising Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). As between the Parties, Novavax shall solely own all rights, title, and interests in and to any and all Patents that Cover any invention included in the Novavax Arising Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Arising Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Sanofi Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, except for Unauthorized Inventions, Sanofi shall solely own all rights, title, and interests in and to any and all Know-How that is first generated, conceived, discovered, created, invented, or otherwise made during the Term by or on behalf of Sanofi or any of its Affiliates in the course of performing activities in accordance with this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi Arising Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). As between the Parties, Sanofi shall solely own all rights, title, and interests in and to any and all Patents that Cover any invention included in the Sanofi Arising Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi Arising Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;, and together with the Novavax Arising Patents and the Joint Arising Patents, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Arising Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Joint Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, except for Unauthorized Inventions, the Parties will jointly own all rights, title, and interests in and to all Know-How that is first generated, conceived, discovered, created, invented, or otherwise made during the Term jointly by or on behalf of Novavax or its Affiliates or its or their Sublicensees, on the one hand, and Sanofi or its Affiliates or its or their Sublicensees, on the other hand, in the course of performing activities in accordance with this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Joint Arising Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). As between the Parties, the Parties will jointly own all rights, title, and interests in and to any and all Patents that Cover any invention included in the Joint Arising Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Joint Arising Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Except as expressly set forth in this Agreement, including <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity), each Party will not practice the Joint Arising Patents and Joint Arising Know-How without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned, or delayed.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Prosecution and Maintenance of Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Arising Patents</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:18.48pt">Sanofi shall have the sole right to Prosecute and Maintain the Sanofi Arising Patents.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Except for any Novavax Arising Patent that is a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:122%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> Right COVID-19 Patent, in which case Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.2.2</a> (Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:122%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> Right COVID-19 Patents) shall apply, Novavax shall have the sole right to Prosecute and Maintain Novavax Arising Patents.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt">Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patents.</font></div><div style="padding-left:72pt;padding-right:72pt"><img alt="image_11.jpg" src="image_11.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"></div><div style="margin-top:8.35pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Sanofi&#8217;s First Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Sanofi shall have the first right to be the Prosecuting Party for all (i) Novavax COVID-19 Patents Covering the Licensed COVID-19 Mono Products or Licensed COVID-19 Component and (ii) Joint Arising Patents, but </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any Novavax Adjuvant Patents and Novavax General Combo Patents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Right COVID-19 Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Sanofi shall,</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">through the JPC, keep Novavax reasonably informed of all Prosecution and Maintenance activities related thereto. Sanofi shall (i) provide to Novavax copies of all material communications from any Patent Authority regarding the Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patents, and drafts of any material filings to be made to such Patent Authorities &#91;***&#93;, or as soon as is practicable, before any final due date, (ii) afford Novavax a reasonable opportunity to review and comment on any drafts prior to their submission, and (iii) consider Novavax&#8217;s comments on such drafts in good faith.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Backup Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If Sanofi decides not to Prosecute and Maintain a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent in a given jurisdiction, and such decision (i) is not made for a strategic business reason intended to benefit the Licensed COVID-19 Products (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">where such reason is primarily for the purpose of (A) benefitting any product that is not a Licensed COVID-19 Product or (B) shortening or ending the COVID-19 Royalty Term for any Licensed COVID-19 Product) and (ii) will result in an irrevocable loss of rights in an invention disclosed or claimed in such Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent in such jurisdiction, then Sanofi shall provide reasonable prior written notice to Novavax of such decision (which notice shall, in any event, be given no later than &#91;***&#93; prior to the next deadline for any payment or filing that is necessary to avoid an irrevocable loss of rights). Novavax shall thereupon have the right, but not the obligation, to be the Prosecuting Party for such Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent at its expense in such country or other jurisdiction. Sanofi shall take all reasonable actions necessary to enable Novavax to become the Prosecuting Party in all respects, including executing all papers and instruments, or requiring its employees or contractors to execute such papers and instruments, so as to enable Novavax to Prosecute and Maintain the Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent in the applicable country or jurisdiction.</font></div><div style="margin-top:1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Novavax General Combo Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Novavax&#8217;s First Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax shall have the first right to be the Prosecuting Party for all Novavax General Combo Patents. Novavax shall, through the JPC, keep Sanofi reasonably informed of all Prosecution and Maintenance activities related thereto. Novavax shall (i) provide to Novavax copies of all material communications from any Patent Authority regarding the Novavax General Combo Patents, and drafts of any material filings to be made to such Patent Authorities &#91;***&#93;, or as soon as is practicable, before any final due date, (ii) afford Sanofi a reasonable opportunity to review and comment on any drafts prior to their submission, and (iii) consider Sanofi&#8217;s comments on such drafts in good faith.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Backup Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If Novavax decides not to Prosecute and Maintain a Novavax General Combo Patent in a given jurisdiction, and such decision (i) is not made for a strategic business reason intended to benefit a Novavax OC Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">abandoning any granted Patent where, in such jurisdiction, the presence or absence of a granted Patent is not reasonably anticipated to adversely impact pricing, approval, or Commercialization) and (ii) will result in an irrevocable loss of rights in an invention disclosed or claimed in such Novavax General Combo Patent in such jurisdiction, then Novavax shall provide reasonable prior written notice to Sanofi of such decision (which notice shall, in any event, be given no later than &#91;***&#93; prior to the next deadline for any payment or filing that is</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">necessary to avoid an irrevocable loss of rights). Sanofi shall thereupon have the right, but not the obligation, to be the Prosecuting Party for such Novavax General Combo Patents at its expense in such country or other jurisdiction. Novavax shall take all reasonable actions necessary to enable Sanofi to become the Prosecuting Party in all respects, including executing all papers and instruments, or requiring its employees or contractors to execute such papers and instruments, so as to enable Sanofi to Prosecute and Maintain the Novavax General Combo Patents in the applicable country or jurisdiction.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Novavax Adjuvant Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax will have the sole right (but not the obligation) to Prosecute and Maintain any Novavax Adjuvant Patent (including Joint Arising Patents that are Novavax Adjuvant Patents) at Novavax&#8217;s sole cost and expense.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Cooperation Regarding Novavax CIC Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upon Novavax&#8217;s written request, if any Novavax Patent being Prosecuted by Sanofi contains written description support for claims that would Cover a Novavax CIC Product or a Novavax Influenza Component but would not Cover a Licensed COVID-19 Product, then the Parties, through the JPC, will discuss (a) whether it is possible under Applicable Laws governing the Prosecution and Maintenance of Patent Rights, to file such claims in a separate Patent application, for example, by filing appropriate divisional(s), or continuations, that solely Cover the Novavax CIC Product or the Novavax Influenza Component and do not Cover a Licensed COVID-19 Product, (b) the potential for prejudice to the Prosecution and Maintenance, enforcement and defense of any claims of such Novavax Patent, and (c) a plan for coordination of the Prosecution and Maintenance of such separate Patent application and the Novavax Patent so as to minimize any such prejudice, which plan shall require at a minimum (i) that Novavax will diligently and timely provide Sanofi with all material communications with any Patent Authority in connection with such separate Patent application, including drafts of any proposed submissions to such Patent Authority, and shall consider in good faith Sanofi&#8217;s input on such communications, (ii) Novavax shall not take any action (including, for the avoidance of doubt, filing any terminal disclaimer) that would be reasonably likely to create a non-statutory double patenting issue between the separate Patent application and any other Novavax Patent Covering a Licensed COVID-19 Product, and (iii) Novavax will not make any remarks on the record that would disparage or call into question the scope, validity, enforceability, priority entitlement, or sufficiency of disclosure of a Novavax Patent Covering a Licensed COVID-19 Product. Following such JPC discussion, Sanofi shall consider in good faith whether to file such separate Patent application, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that the choice of whether or not to file such separate Patent application will be at Sanofi&#8217;s sole discretion.</font></div><div style="margin-top:0.7pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Unitary Patent System</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Capitalized terms used in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.3</a> (Unitary Patent System) and not otherwise defined in this Agreement will have the meanings given in the Rules of Procedure of the Unified Patent Court as adopted by decision of the Administrative Committee on 8 July 2022 and established by the Agreement on a Unified Patent Court of 19 February 2013 (OJ C 175, 20.6.2013, p. 1) (including any subsequent amendments).</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Unified Patent Court&#58; Opt-Out and Withdrawal of Opt-Out&#59; Request for Unitary Effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Prosecuting Party of any Patent under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.2</a> (Prosecution and Maintenance of Patents) shall have the sole right (but not the obligation) to (a) file an application to opt out any European Patent from the exclusive competence of the Unified Patent Court, (b) lodge</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">an application to withdraw an opt-out with respect to any European Patent from the exclusive competence of the Unified Patent Court, in accordance with Applicable Laws (including Article 83 of Unified Patent Court Agreement and Rule 5 of the Rules of Procedure of the Unified Patent Court), or (c) file a request for Unitary Effect for any European Patent. The Party that is not the Prosecuting Party of such Patent will cooperate with the Prosecuting Party in the preparation of any filing requested by the Prosecuting Party under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.3.2</a> (Unified Patent Court&#58; Opt-Out and Withdrawal of Opt- Out&#59; Request for Unitary Effect).</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Enforcement of Unitary Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If either Party receives notice in writing of any declaration of noninfringement in connection with the enforcement of any Unitary Patent under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement), then the Party receiving such notice shall notify the other Party as soon as is practicable and in any event within five (5) Business Days after the receipt of such notice. The Parties will cooperate to identify any available evidence of infringement or misappropriation of such Unitary Patent and to prepare and file a timely response to such declaration of noninfringement. For clarity, enforcement of any Unitary Patent shall be determined in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement).</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Patent Term Extension and Supplementary Protection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to any Licensed COVID-19 Products, Sanofi shall have the sole right to make decisions regarding which Patent to file for patent term extensions, including supplementary protection certificates and any other extensions that are now or become available in the future, wherever applicable, in any country or other jurisdiction in the Territory. Sanofi shall have the right to extend any Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent, but shall not file for an extension of any Novavax Patent that is not a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent without receiving Novavax&#8217;s prior written consent. Sanofi will, through the JPC, keep Novavax reasonably informed of its efforts to obtain such extension. Novavax shall provide prompt assistance, as requested by Sanofi, including by taking such action as Patent owner is required under any Applicable Law to obtain any such extension. Sanofi shall pay all expenses in regard to obtaining any such extension in any country or other jurisdiction in the Territory. For the avoidance of doubt, Novavax shall not have the right to extend the term of any Novavax Patent in connection with a Licensed Product of which the Marketing Authorization is in the name of Sanofi or its Affiliate or Sublicensees.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Patent Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Sanofi shall have the sole right to make all Patent listings and Patent-related submissions to Regulatory Authorities for Licensed Products in any country or other jurisdiction in the Territory, to the extent required or permitted by Applicable Law. Novavax shall provide prompt assistance to Sanofi to the extent necessary to effectuate the intent of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.5</a> by taking such action as Patent owner or as Regulatory Responsible Party as is required under any Applicable Law to enable such listing.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If a Party becomes aware of any infringement or other violation of a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent by a Third Party in any country the Territory, or becomes aware of any Invalidity Action asserted by a Third Party against a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then such Party shall promptly notify the other Party regarding such Infringement, which notice shall include a summary of all relevant evidence that such Party is aware of with respect thereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Infringement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Enforcement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><img alt="image_2.jpg" src="image_2.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patents. As between the Parties, Sanofi shall have the first right, but not the obligation, in its own name (or in the name of Novavax, to the extent required by Applicable Law), (i) to bring and control any Enforcement Action to enforce any Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent against any Infringement in the Territory (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Product Competitive Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), and (ii) to defend against any Invalidity Action brought against any Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID- 19 Patent in the Territory in response to a COVID-19 Product Competitive Infringement, in each case ((i) &#8211; (ii)), as it reasonably determines appropriate, using counsel of its own choice (any such Enforcement Action or defense against an Invalidity Action, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Enforcement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). If Sanofi does not institute a COVID-19 Enforcement Action other than for a strategic business reason intended to benefit a Licensed COVID-19 Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">where such reason is primarily for the purpose of benefitting any product that is not a Licensed COVID-19 Product) within &#91;***&#93; after a Party delivers an Infringement Notice to the other Party with respect to such Infringement or Invalidity Action or, if earlier, &#91;***&#93; prior to any final deadline for instituting a COVID-19 Enforcement Action before relinquishing any legal or equitable rights, defenses, or remedies with respect thereto that would otherwise be available, and Sanofi in its reasonable business judgment does not believe that a COVID-19 Enforcement Action would be detrimental to a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent or the commercial success of the Licensed COVID-19 Products as a whole, then Sanofi will promptly notify Novavax, and Novavax may, upon written notice to Sanofi, which shall be delivered within &#91;***&#93; after receiving Sanofi&#8217;s notice of non-enforcement, institute a COVID-19 Enforcement Action in its own name using counsel of its choice.</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Novavax General Combo Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax shall have the first right, but not the obligation, in its own name, (i) to bring and control any Enforcement Action to enforce any Novavax General Combo Patent against any Infringement in the Territory (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">General Combo Product Competitive Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), and (ii) to defend against any Invalidity Action brought against any Novavax General Combo Patent in the Territory in response to a General Combo Product Competitive Infringement, in each case ((i) &#8211; (ii)), as it reasonably determines appropriate, using counsel of its own choice (any such Enforcement Action or defense against an Invalidity Action, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">General Combo Product Enforcement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). If Novavax does not institute a General Combo Product Enforcement Action within &#91;***&#93; after a Party delivers an Infringement Notice to the other Party with respect to such Infringement or Invalidity Action or, if earlier, &#91;***&#93; prior to any final deadline for instituting a General Combo Product Enforcement Action before relinquishing any legal or equitable rights, defenses, or remedies with respect thereto that would otherwise be available, and Novavax in its reasonable business judgment does not believe that a General Combo Product Enforcement Action would be detrimental to a Novavax General Combo Product Patent or the commercial success of the Novavax OC Products as a whole, then Novavax will promptly notify Sanofi, and Sanofi may, upon written notice to Novavax, which shall be delivered within &#91;***&#93; after receiving Novavax&#8217;s notice of non-enforcement, institute a General Combo Product Enforcement Action in its own name using counsel of its choice.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">CIC and OC Product Enforcement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Notwithstanding Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.6.2</a>(a) (Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:122%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> Right COVID-19 Patents) and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.6.2</a>(b) (Novavax General Combo Patents), for any Infringement by a product that includes both an Antigen Directed To SARS-CoV-2 and an Antigen Directed To one or more other pathogens or organisms, then&#58;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.76pt">if Novavax has a Novavax Product being Commercialized, and Sanofi does not have a Licensed CIC Product or Licensed OC Product being Commercialized, in each case, directed to SARS-CoV-2 and to one of the same pathogens or organisms, then Novavax will have the first right, but not the obligation, in its own name, to bring and control any Enforcement Action&#59;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.54pt">if Novavax does not have a Novavax Product being Commercialized, and Sanofi does have a Licensed CIC Product or Licensed OC Product being Commercialized, in each case, directed to SARS-CoV-2 and to one of the same pathogens or organisms then Sanofi will have the first right, but not the obligation, in its own name, to bring and control any Enforcement Action&#59; and</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:15.32pt">if Novavax has a Novavax Product being Commercialized, and Sanofi has a Licensed CIC Product or Licensed OC Product being Commercialized, in each case, directed to SARS-CoV-2 and to one of the same pathogens or organisms, then the Party that is not bringing a COVID-19 Enforcement Action or General Combo Product Enforcement Action pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6.2</a>(a) (Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patents) and Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6.2</a>(b) (Novavax General Combo Patents) shall have the right to join the applicable Enforcement Action, and the Party controlling such Enforcement Action will reasonably cooperate to allow such other Party to join the Enforcement Action.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">The Parties will reasonably cooperate, including if necessary by executing common interest and other applicable agreements, to prosecute such Enforcement Action taking into account both Novavax Products and Licensed Products.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Priority of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. A Party&#8217;s right to initiate and control an Enforcement Action under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6.2</a> (Patent Enforcement) shall take precedence over a Party&#8217;s right as a Prosecuting Party under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.2</a> (Prosecution and Maintenance of Patents) to defend any validity or enforceability or other challenges against a Novavax Patent in any forum, including in an interference, derivation proceeding, pre- and post-grant opposition proceeding, post-grant patent proceedings (such as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">review and post grant review). By way of example, if a Party has the right to control a COVID-19 Enforcement Action in a district court with respect to a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6.2(a)</a> (Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patents), then that same Party shall concurrently have the right to control the defense against an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">review against such Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent at the Patent Trial and Appeal Board, even if the other Party is the Prosecuting Party for such Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Right COVID-19 Patent.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Novavax Sole Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will have the sole right, but not the obligation, to bring an appropriate suit or other action to abate any existing, alleged, or threatened</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">infringement involving any (i) Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:122%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> Right COVID-19 Patent against an infringement that is not a COVID-19 Product Competitive Infringement and (ii) Novavax Patent that is not a Sanofi 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:122%;position:relative;top:-2.8pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> Right COVID-19 Patent or Novavax General Combo Product Patent against any infringement, excluding, in each case, General Combo Product Competitive Infringement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Misappropriation of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. If a Party becomes aware that a Third Party has misappropriated any Novavax Know-How or Joint Arising Know-How (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;), then each Party will promptly notify the other Party regarding such Misappropriation which notice shall include a summary of all evidence such Party is aware of with respect thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Misappropriation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Enforcement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Novavax COVID-19 Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Sanofi shall have the first right, but not the obligation, in its own name (or in the name of Novavax to the extent required by Applicable Law), to bring and control any Enforcement Action against any Third Party in connection with any Misappropriation of any Novavax COVID-19 Know-How or Joint Arising Know-How that relates to the Licensed COVID-19 Mono Product or Licensed COVID-19 Component, as it reasonably determines appropriate, using counsel of its own choice. If Sanofi does not initiate an Enforcement Action to abate any such Misappropriation within &#91;***&#93; after a Party delivers a Misappropriation Notice to the other Party, and Sanofi in its reasonable business judgment does not believe that such Enforcement Action would be detrimental to the commercial success of a Licensed COVID-19 Products as a whole, then Sanofi will promptly notify Novavax, and Novavax may institute such Enforcement Action to abate such Misappropriation in its own name using counsel of its choice.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Adjuvant Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to any Misappropriation of (i) any Novavax Adjuvant Know-How that is not otherwise Novavax COVID-19 Know-How or (ii) any Joint Arising Know-How that relates to the Adjuvant, Novavax shall have the sole right, but not the obligation, in its own name (or to the extent required by Applicable Law or with Sanofi&#8217;s written consent, in the name of Sanofi), to bring and control action against any Third Party in connection with such Misappropriation.</font></div><div style="margin-top:9.2pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Joint Arising Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as set forth in Section 12.7<a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">(a)</a> (Novavax COVID- 19 Know-How) or Section 12.7<a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">(b)</a> (Adjuvant Know-How), for any other Joint Arising Know-How, unless the Parties agree otherwise, Sanofi shall have the first right to bring an action against such Misappropriation. If Sanofi does not initiate an Enforcement Action to abate any such Misappropriation within &#91;***&#93; after a Party delivers a Misappropriation Notice to the other Party, and Sanofi in its reasonable business judgment does not believe that such Enforcement Action would be detrimental to the commercial success of a Licensed Products, then Sanofi will promptly notify Novavax, and Novavax may institute such Enforcement Action to abate such Misappropriation in its own name using counsel of its choice.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">Novavax Sole Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Except as set forth in Section 12.7<a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">(a)</a> (Novavax COVID-19 Know-How), Section 12.7<a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">(b)</a> (Adjuvant Know-How), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.7.2(c)</a> (Joint Arising Know-How), Novavax will have the sole right, but not the obligation, to bring an appropriate suit or other action to abate any existing, alleged, or threatened Misappropriation involving any Novavax Know-How.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Defense of Product Infringement Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If a Party receives any demand or claim (not in connection with an Enforcement Action, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, not a counterclaim or crossclaim) alleging that the Exploitation of any Licensed COVID-19 Product in the Territory infringes, misappropriates, or otherwise violates any Patents, Know-How, or other property rights of any Third Party (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product Infringement Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then such Party will promptly notify the other Party and provide the other Party with a copy of such demand or claim, correspondence related thereto and summary of all evidence and other information that it is aware of relating to such demand or claim.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Right to Defend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi shall have the sole right, but not the obligation, using counsel of its choice, to develop the strategy for and otherwise institute a defense and settle any Product Infringement Claim with respect to any Licensed Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if such Product Infringement Claim escalates into a legal action and</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i) Novavax is a named co-defendant, (ii) Novavax joins as a co-defendant, or (iii) Novavax joins as a third party claimant, then Novavax shall reasonably cooperate with Sanofi in its defense using counsel that is reasonably acceptable to Sanofi, and Sanofi shall have the right to control the overall case strategy and lead both Parties&#8217; defenses against such Product Infringement Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, that Novavax shall not have the right to (A) join such legal action as a co-defendant or third-party claimant or (B) admit fault or infringement or settle any such dispute on its own, in each case (A) and (B), without Sanofi&#8217;s request or prior written consent. Novavax shall reasonably cooperate with Sanofi in the defense of all Product Infringement Claims, including by joining any action when requested by Sanofi and by making available to Sanofi all relevant Novavax personnel and records that Sanofi may request to serve as witnesses and otherwise satisfy its discovery burden.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">Novavax Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax shall have the sole right, but not the obligation, using counsel of its choice, to develop the strategy for and otherwise institute a defense and settle any Product Infringement Claim with respect to any (i) Novavax Product and (ii) on a country-by-country basis, any Licensed COVID-19 Mono Product Exploited, as between the Parties, solely by Novavax and not by Sanofi in a country.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Further Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. If a Third Party asserts a Product Infringement Claim against both Sanofi and Novavax alleging infringement by a Licensed COVID-19 Component common to Licensed COVID-19 Products Exploited by Sanofi and Novavax Products Exploited by Novavax, then the Parties shall confer in good faith to coordinate the defense and settlement of such claim and the allocation of expenses and costs or recoveries therefrom, in a manner that aligns with the rights</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">of each Party set forth in Sections <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.8.2(a)</a> (Licensed Products) through <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.8.2(b)</a> (Novavax Products).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The controlling Party in any action brought pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.7</a> (Misappropriation of Know-How), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.8</a> (Defense of Licensed Product Infringement Claims)&#58; (a) will discuss with the non-controlling Party the strategy for any such action and shall consider in good faith the non-controlling Party&#8217;s comments regarding such strategy&#59; and (b) will keep the non-controlling Party reasonably informed of the status and progress of such action including by providing copies of any pleadings filed relating to such actions promptly upon their being filed or received and will reasonably consult with the non-controlling Party, and will consider in good faith the non-controlling Party&#8217;s comments with respect thereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, that the controlling Party shall have the final decision with regards to the institution, operation, status and progress of any such action, including whether to institute, settle, or dismiss any such actions, subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.11</a> (Settlement). Notwithstanding any provision to the contrary set forth herein, Novavax shall notify and provide Sanofi with copies of any allegations of alleged patent invalidity, unenforceability, or non-infringement of any Novavax Patents, as soon as practicable following receipt thereof.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.25pt">Costs and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For any action brought by or against a Party pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.7</a> (Misappropriation of Know-How), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.8</a> (Defense of Licensed Product Infringement Claims), the controlling Party will be responsible for all of its own costs and expenses incurred in relation to such action, including attorneys&#8217; fees. The non-controlling Party will be responsible for all of its own costs if it participates in any such action, including attorneys&#8217; fees.</font></div><div style="margin-top:9.2pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">General Allocation of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any recoveries or amounts received as a result of any action brought by a Party pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.7</a> (Misappropriation of Know-How), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.8</a> (Defense Licensed Product Infringement Claims) shall be allocated as follows&#58; (a) first, to reimburse the controlling Party&#8217;s costs and expenses incurred in connection with such action, including reasonable attorneys&#8217; fees, (b) second, to reimburse the non-controlling Party&#8217;s costs and expenses incurred in connection with such action, if any, including reasonable attorneys&#8217; fees, and</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c) third, all remaining recoveries or amounts to the controlling Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">that, (i) to the extent that any award or settlement amount (whether by judgment or otherwise) is attributable to loss of sales or profits with respect to a Licensed Product and retained by Sanofi, such amounts shall be included as Net Sales hereunder with respect to such Licensed Product and (ii) in the event both Parties are parties to an Enforcement Action in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">12.6.2(c)</a> (CIC and OC Product Enforcement Actions), Novavax will retain all award or settlement amount attributable to a Novavax Product.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. A Party controlling any action or proceeding brought by or against a Party pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.6</a> (Patent Enforcement), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.7</a> (Misappropriation of Know-How), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.8</a> (Defense of Product Infringement Claims) may settle such action or proceeding in its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if such settlement is reasonably likely to materially adversely affect the other Party&#8217;s interests in the Licensed Novavax Assets in the Territory, including by way of admission of fault, infringement, misappropriation, invalidity, inequitable conduct or unenforceability that impacts the other Party, then such settlement may not be made without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Common Interest Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With regard to any privileged or Confidential Information or opinions disclosed pursuant to this Agreement by a Party to the other Party regarding Patents, Know-How, Materials, or other property owned by the Disclosing Party or a Third Party, the Parties agree that they have a common legal interest in determining whether, and to what extent, such Patents, Know-How, Materials, or other property may affect any Licensed Product, and a further common legal interest in defending against any actual or prospective Third-Party Claims based on allegations of misuse or infringement of Patents, Know-How, Materials, or other property relating to any Licensed Product. Accordingly, the Parties agree that all such information and materials obtained by Sanofi and Novavax from each other in which they have such a common legal interest</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable&#59; (b) by sharing such information, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials&#59; and (c) neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#8217;s written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against the other Party. The Parties may enter into a separate common interest agreement agreed by the Parties with respect to such information and materials, upon the request of either Party.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 13&#58; TRADEMARK MATTERS</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties and subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.11</a> (Housemarks), each Party has the sole right, but not the obligation, to develop (and thereafter modify and update) and register (in its own name or the name of its Affiliates or Sublicensees or their designees) trademarks it determines appropriate in its sole discretion for the Licensed COVID-19 Mono Products for which it is the Party responsible for Commercialization&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that on a Licensed COVID-19 Mono Product-by-Licensed COVID-19 Mono Product and country-by-country basis, if both Parties are Commercializing the same Licensed COVID-19 Mono Product in a country, then Sanofi shall have the sole right to develop and register trademarks for such Licensed COVID-19 Mono Product. As between the Parties, Sanofi has the sole right, but not the obligation, to develop (and thereafter modify and update), and register (in its own name or the name of its Affiliates or Sublicensees or their designees) trademarks it determines appropriate in its sole discretion for any Licensed CIC Product, Licensed OC Product, and Licensed Adjuvanted Product that it is Commercializing in the Territory. As between the Parties, Novavax has the sole right, but not the obligation, to develop (and thereafter modify and update) and register (in its own name or the name of its Affiliates or Sublicensees or their designees) trademarks it determines appropriate in its sole discretion for any Novavax Product.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Review of Licensed COVID-19 Mono Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will provide final versions (and any material updates thereto) of the proposed trademarks for each Licensed COVID-19 Mono Product to the JCC for the JCC to review and discuss, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that the Party responsible for Commercialization in each jurisdiction will have the sole right to choose the trademark for the Licensed COVID-19 Mono Product. Each Party will provide an update to the other Party through the JSC on an annual basis regarding the filing and prosecution of the trademarks used or intended for use with the Licensed COVID-19 Product.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Domain Names&#59; Websites</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, each Party has the sole right, but not the obligation, to select, register (in its own name or the name of its Affiliates or Sublicensees or their designees), and maintain all domain names and websites used in connection with the Licensed COVID-19 Mono Products for which it is the Party responsible for Commercialization in accordance with the Licensed COVID-19 Mono Product Commercialization Framework&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that on a Licensed COVID-19 Mono Product-by-Licensed COVID-19 Mono Product and country- by-country basis, if both Parties are Commercializing the same Licensed COVID-19 Mono Product in a country, then Sanofi shall have the sole right to select and register domain names for such Licensed COVID-19 Mono Product. As between the Parties, Sanofi has the sole right, but not the obligation, to select, register (in its own name or the name of its Affiliates or Sublicensees or their designees) and maintain all domain names and websites used in connection with any Licensed CIC Product, Licensed OC Product, and Licensed Adjuvanted Product that it is Commercializing in the Territory. As between the Parties, Novavax has the sole right, but not the obligation, to select, register (in its own name or the name of its Affiliates or Sublicensees or their designees) and maintain all domain names and websites used in connection with any Novavax Product that it is Commercializing in the Territory. To effectuate the foregoing, promptly after Sanofi is responsible for Commercialization in accordance with the Licensed COVID-19 Mono Product Commercialization Framework, Novavax will transfer to Sanofi or its designee those domain names and websites that should be under Sanofi&#8217;s control in accordance with the foregoing, but are Controlled by Novavax as of the Effective Date.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">License to Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Novavax hereby grants to Sanofi a non-exclusive, sublicensable (through multiple tiers), non-transferable (except in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.1</a> (Term&#59; Expiration)) license to use Novavax Trademarks to Commercialize Licensed Products. Sanofi agrees that all trademark goodwill that accrues based on all uses of the Novavax Trademarks, by operation of law or otherwise, shall inure to the sole and exclusive benefit of Novavax.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Trademark and Domain Name Infringement&#59; Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As between the Parties, Novavax has the sole right, but not the obligation, to enforce all Novavax Trademarks. Each Party has the right, in any infringement action arising from the use of the Novavax Trademarks brought against such Party, or its Affiliates or Sublicensees, to defend by itself, at its own expense, and the other Party shall provide reasonable assistance if requested by the defending Party.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax shall be solely responsible for costs associated with obtaining and maintaining the Novavax Trademarks. Novavax shall be solely responsible for costs incurred by or on its behalf in any action to enforce or defend its use of the Novavax Trademarks and shall have the right to retain recoveries associated therewith. Sanofi shall be solely responsible for costs incurred by or on its behalf in any action to defend its use of the Novavax Trademarks and shall have the right to retain recoveries associated therewith.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Falsified Medicines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will promptly notify the other Party in writing if it becomes aware of any Third Party that is Manufacturing or Commercializing a medical product purporting to be a Licensed Product that deliberately or fraudulently misrepresents its identity, composition, or source (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Falsified Medicine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). As between the Parties, Sanofi will have the first right, but not the obligation, to lead any detection program, investigation, or collaboration with any Governmental Authority and the first right, but not the obligation, to take action to enforce its rights against any Third Party that is Manufacturing or Commercializing such Falsified Medicines or contributing to any of these actions. If Sanofi declines to enforce its rights against such Third Party, then it will promptly notify Novavax, and Novavax will have the right, but not the obligation, to take such enforcement action. If requested by Sanofi, Novavax will reasonably cooperate with Sanofi with respect to any suspected Falsified Medicines to provide complementary information related to the applicable Licensed Product when necessary or requested by any Governmental Authority.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 14&#58; REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%;padding-left:17.35pt">Representations and Warranties of Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that&#58;</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Corporate Existence and Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Such Party is duly organized, validly existing, and in good standing under the Applicable Law of the jurisdiction of its formation and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the full right to grant the licenses and sublicenses granted by it hereunder.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Such Party has the requisite organizational power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by such Party and the consummation of the transactions contemplated hereby have been duly and validly authorized and no other organizational proceedings on the part of such Party or any of its Affiliates or any Parent Company are required therefor. Each Party has full shareholder and corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to&#58; (a) bankruptcy, insolvency, reorganization, moratorium, or other similar laws of general application affecting the rights and remedies of creditors&#59; or</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) laws governing specific performance, injunctive relief, and other equitable remedies.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The execution, delivery, and performance of this Agreement by such Party does not breach, violate, or conflict with any agreement or any provision thereof (including any confidentiality or non-competition obligation, any exclusivity obligation, or any provisions with respect to the ownership, prosecution, maintenance, and enforcement of intellectual property rights), or any instrument or understanding, oral or written, to which such Party (or any of its Affiliates) is a party or by which such Party (or any of its Affiliates) is bound, nor violate any Applicable Law of any Governmental Authority having jurisdiction over such Party (or any of its Affiliates).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Government Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. No other government authorization, consent, approval, license, exemption of, or filing or registration with, any court or governmental department, commission, board, bureau, agency, or instrumentality, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except as may be required to Exploit Licensed Products.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Third Party Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. It has obtained all necessary authorizations, consents, and approvals of any Third Party that are required to be obtained by it for, or in connection with, the execution and delivery of this Agreement and for the performance of its obligations hereunder (as contemplated as of the Effective Date), except as may be required to Exploit Licensed Products.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. (a) Neither it nor any of its Affiliates in the pharmaceutical industry, nor any of their officers, employees or agents, has been debarred or is subject to debarment pursuant to Section 306 of the FD&#38;C Act or analogous provisions of Applicable Law</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">outside the United States or is listed on any excluded list&#59; and (b) neither it nor any of its Affiliates has, to its knowledge, used in any capacity, in connection with the activities to be performed under this Agreement, any individual or entity that has been debarred pursuant to Section 306 of the FD&#38;C Act or analogous provisions of Applicable Law outside the United States, or that is the subject of a conviction described in such Section or analogous provisions of Applicable Law outside the United States, or listed on any excluded list.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Representations and Warranties of Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax hereby represents to Sanofi, as of the Effective Date that&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Novavax Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All Novavax Patents existing as of the Effective Date are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">14.2.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">.</a></font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">14.2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (Ownership), Novavax solely and exclusively owns or otherwise exclusively Controls each Existing Novavax Patent, all Novavax Know-How, and Novavax Materials. As of the Effective Date, all exclusively owned or otherwise exclusively Controlled Existing Novavax Patents, Novavax Know- How, and Novavax Materials and, to Novavax&#8217;s Knowledge, all in-licensed Novavax Patents, Novavax Know-How, and Novavax Materials are free and clear of all financial liens, encumbrances, and security interests. Neither Novavax nor any of its Affiliates owns or holds rights to any Patents, Know-How, or Materials that would otherwise qualify as a Licensed Novavax Asset but for the fact that Novavax or such Affiliate owns or holds rights to, but does not Control, such Patent, Know-How or Materials.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Validity and Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax has complied in all material respects with Applicable Law with respect to the Prosecution and Maintenance of the Existing Novavax Patents. Neither Novavax nor its Affiliates have received any written notice of any claim or threat of a claim or litigation by any Third Party against Novavax or its Affiliates that alleges that any Existing Novavax Patent is invalid or unenforceable, and there is no pending adverse action, suit, or Proceeding against Novavax in relation to any Existing Novavax Patent. All Novavax Patents are&#58; (a) subsisting, and, to the extent issued, to Novavax&#8217;s Knowledge, not invalid or unenforceable, in whole or in part&#59; (b) in the case of pending applications, being diligently prosecuted in the respective patent offices in accordance with Applicable Law, and Novavax has presented all relevant references, documents and information of which it and the inventors are aware to the relevant patent examiner at the relevant patent office&#59; and (c) being prosecuted and maintained in accordance with the policies and procedures of the applicable patent office, including that (i) every inventor of the claims thereof has been identified in accordance with the Applicable Laws of the relevant jurisdiction in which such Patent is issued or pending and (ii) all applicable fees required by such patent office have been paid by the due date for payment. To Novavax&#8217;s Knowledge, there is no reference or prior art that would preclude the issuance of any claim pending as of such date within any Novavax Patent.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Litigation and Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, or judicial, legal, administrative, or other Proceedings, or governmental investigations pending or, to Novavax&#8217;s Knowledge, threatened, against Novavax or its Affiliates that would reasonably be expected to adversely affect or restrict the ability of Novavax to consummate or perform the transactions and obligations contemplated under this Agreement, or that would adversely affect the Licensed Novavax</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Assets, Novavax&#8217;s Control thereof, or the Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant existing as of the Effective Date.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">No Misappropriation or Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To Novavax&#8217;s Knowledge, Novavax has not misappropriated, infringed, or otherwise violated any intellectual property right of a Third Party in connection with developing and Exploiting the Adjuvant or the Licensed COVID- 19 Mono Product. Neither Novavax nor its Affiliates have received any written notice of any Third Party Claim that any intellectual property right controlled by a Third Party would be infringed, misappropriated, or otherwise violated by the performance of the activities contemplated hereunder or by the Exploitation of the Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant as contemplated under this Agreement in accordance with this Agreement. To Novavax&#8217;s Knowledge, no Third Party is infringing, misappropriating, or otherwise violating the Licensed Novavax Asset existing as of the Effective Date.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">No Delinquency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To Novavax&#8217;s Knowledge, neither Novavax nor any of its Affiliates are in breach of any obligations to any Third Party, or engaged in any dispute with any Third Party, in connection with any Upstream License Agreement or any other agreement with a Third Party, in each case, that would materially limit Sanofi&#8217;s ability to Exploit the Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant in the Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">No Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. To Novavax&#8217;s Knowledge, neither Novavax nor any of its Affiliates are, or have ever received written notice of being, in material breach of any term or condition of any Upstream License Agreement or any other agreement with a Third Party, in each case, that would have a material adverse impact on Sanofi&#8217;s rights under this Agreement.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To Novavax&#8217;s Knowledge, valid and enforceable written assignments (by assignment agreement or employment agreement) exist and are recorded from all individuals who are identified as inventors on any Novavax Patent existing as of the Effective Date. To Novavax&#8217;s Knowledge, each Person who claims to be an inventor of an invention claimed in an Existing Novavax Patent is identified as an inventor of such invention in the filed patent documents for such Novavax Patent existing as of the Effective Date. No dispute regarding inventorship, authorship, or ownership has been alleged or threatened with respect to any Novavax Patent existing as of the Effective Date.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Protection of Know-How and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax and its Affiliates have taken commercially reasonable measures to protect the secrecy and confidentiality of all Novavax Know-How and the confidential and proprietary aspects of the Novavax Materials, in each case, existing as of the Effective Date, including by requiring relevant employees, consultants, and subcontractors to execute binding and enforceable agreements requiring all such employees, consultants, and subcontractors to maintain the confidentiality of all such Novavax Know-How and such confidential and proprietary aspects of such Novavax Materials. To Novavax&#8217;s Knowledge&#58; (a) the Novavax Know- How and the confidential aspects of Novavax Materials have not been disclosed to, or used or discovered by, any Third Party except pursuant to such confidentiality agreements&#59; and</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) there has not been a breach by any party of such confidentiality agreements.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Government Funding and Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To Novavax&#8217;s Knowledge, the inventions claimed in the Novavax Patents existing as of the Effective Date&#58; (a) were not conceived, discovered, developed, or otherwise made as a result of any research activities funded, in whole or in</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">part, by the federal government of the United States (or any agency thereof) or the government of any other country&#59; (b) are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. &#167;201(e)&#59; (c) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, codified at 35 U.S.C. &#167;&#167;200-212, or any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401&#59; (d) in the case of clauses (b) or (c), are not subject to similar obligations or restrictions under the Applicable Law of any other country&#59; and (e) are not the subject of any licenses, options or other rights of any Governmental Authority, within or outside the United States.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:7.35pt;text-decoration:underline">Compliance with Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax and its Affiliates have conducted, and their respective Representatives have conducted, prior to the Effective Date, all Research, Development, and Manufacturing of the Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant in accordance with all Applicable Laws in all material respects.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Diligence Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The information that Novavax has made available to Sanofi prior to the Effective Date in the electronic data room for Sanofi&#8217;s review prior to entering into this Agreement does not, to Novavax&#8217;s Knowledge, contain any untrue statement(s) of fact that Novavax would reasonably expect to be material to Sanofi&#8217;s decision to enter into this Agreement. To Novavax&#8217;s Knowledge, neither Novavax nor any of its Affiliates have knowingly withheld from Sanofi any correspondence received from any Regulatory Authority with respect to the Licensed COVID-19 Mono Product, Licensed COVID-19 Component, and Adjuvant that Novavax would reasonably expect to be material to Sanofi&#8217;s decision to enter into this Agreement.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Upstream License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax has provided Sanofi with a true, complete, and correct copy of each Upstream License Agreement. Each Upstream License Agreement is valid, binding, enforceable, and in full force and effect&#59; no notice of breach, default, or termination has been received or given under any Upstream License Agreement, and, to Novavax&#8217;s Knowledge, there is no act or omission by Novavax or any of its Affiliates that would provide a right to terminate any such agreement&#59; and to Novavax&#8217;s Knowledge, no circumstances or grounds exist that would reasonably be expected to give rise to a claim of material breach or a right of rescission, termination, revision, or amendment of any of the Upstream License Agreements, including the execution, delivery, and performance of this Agreement. Neither Novavax nor any of its Affiliates has waived any of their respective rights under any Upstream License Agreement in any manner that conflicts with or limits the scope of any of the rights or licenses granted to Sanofi hereunder, and, to Novavax&#8217;s Knowledge, no such rights have lapsed or otherwise expired or been terminated. Novavax has obtained all consents and provided all notices required to be provided under each Upstream License Agreement in connection with the execution and delivery of this Agreement and the performance by the Parties of their respective obligations hereunder, and the execution, delivery, and performance of this Agreement by the Parties does not and will not constitute a breach or default under any of the Upstream License Agreements.</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.3pt;text-decoration:underline">Novavax Trademarks and Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Existence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All Novavax Trademarks and Novavax Domain Names existing as of the Effective Date are listed on Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">14.2.14(a)</a> (Existence).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">14.2.14(b</a>) (Ownership)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Novavax solely and exclusively owns or otherwise exclusively Controls each Novavax</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Trademarks and Novavax Domain Names. As of the Effective Date, all exclusively owned or otherwise exclusively Controlled Novavax Trademarks and Novavax Domain Names are free and clear of all financial liens, encumbrances, and security interests.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Trademark Validity and Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax has complied in all material respects with Applicable Law with respect to the Prosecution and Maintenance of the Novavax Trademarks. Neither Novavax nor its Affiliates have received any written notice of any claim or written threat of a claim or litigation by any Third Party against Novavax or its Affiliates that alleges that any Novavax Trademark is invalid or unenforceable, and there is no pending adverse action, suit, or Proceeding against Novavax in relation to any Novavax Trademark. All Novavax Trademark are, to Novavax&#8217;s Knowledge, subsisting, and, to the extent issued, not invalid or unenforceable in whole or in part. To Novavax&#8217;s Knowledge, there is no reference or prior art that would preclude the issuance of any claim pending as of such date within any Novavax Trademark.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Litigation and Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, or judicial, legal, administrative, or other Proceedings, or governmental investigations pending or, to Novavax&#8217;s Knowledge, threatened, against Novavax or its Affiliates that would reasonably be expected to adversely affect the Novavax Trademarks existing as of the Effective Date.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Novavax Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. With respect to representations of Novavax hereunder that are qualified by Novavax&#8217;s Knowledge, the Chief Executive Officer, Chief Scientific Officer, President of Research and Development, Executive Vice President Chief Operating Officer, Senior Vice President of Global Manufacturing, and Senior Director of Legal Affairs Intellectual Property &#38; Transactions of Novavax have reasonably consulted with his or her direct reports as to such matters, and, with respect to Patent matters, have consulted with internal patent counsel(s) who attend to the Novavax Patent matters in the ordinary course.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Covenants of Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party hereby covenants to the other Party that during the Term&#58;</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Compliance with Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Such Party and its Affiliates will perform its and their activities and obligations pursuant to this Agreement in compliance with all Applicable Law in all material respects, including, to the extent applicable, the United States Foreign Corrupt Practices Act, GCP, GLP, and GMP, and with applicable industry ethical codes. Further, each Party hereby covenants to the other Party that during the Term its and its Affiliates&#8217; employees will not, and it will use reasonable efforts to cause its contractors to not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of any money, or give, promise or offer to give, or authorize the giving of, anything of value to a government official, government employee, political party official, candidate for political office, or any other Person for the purpose of improperly obtaining or retaining business for or with, or directing business to, any Person, including either Party (it being understood that such Party and its Affiliates, and to its knowledge, its and its Affiliates&#8217; Representatives, have not directly or indirectly promised, offered, or provided any bribe or any other corrupt payment, gratuity, emolument, kickback, gift or hospitality, or other</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">illegal or unethical benefit to a government official, government employee, political party official, candidate for political office or any other Person in connection with the performance of such Party&#8217;s obligations under this Agreement, and will not, directly or indirectly, engage in any of the foregoing).</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Such Party and its Affiliates will not, with respect to the performance of activities hereunder, knowingly employ, or otherwise use in any capacity, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. &#167; 335a, or any foreign equivalent thereof.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Such Party will not enter into any agreement, contract, commitment, or other arrangement, or otherwise take any action or fail to take any action, that would reasonably be expected to conflict with the rights granted to the other Party hereunder or otherwise prevent the other Party from exercising the rights granted to it hereunder.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">No Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Such Party will not knowingly misappropriate any trade secret of a Third Party in connection with the performance of its activities hereunder.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Government Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Such Party will obtain and maintain all permits, licenses, registrations, and other forms of authorizations and approvals from any Governmental Authority that are necessary or required to be obtained or maintained by such Party in order for such Party to perform its obligations hereunder in a manner that complies with all Applicable Law in all material respects.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Data Safeguards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party will comply with the terms, conditions, and obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%"> (Data Safeguards).</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Covenants of Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax hereby covenants to Sanofi that during the Term&#58;</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Upstream License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will not, without Sanofi&#8217;s prior written consent, which will be granted or withheld at Sanofi&#8217;s sole discretion, (a) amend, modify, or extend the Upstream License Agreements in any manner that would negatively affect Sanofi&#8217;s rights or obligations hereunder or (b) fail to comply with its obligations under the Upstream License Agreements in any manner that would negatively affect Sanofi&#8217;s rights or obligations hereunder.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">APAs, Existing Strategic Partner Agreements and Settlement Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will not, without Sanofi&#8217;s prior written consent, which will be granted or withheld at Sanofi&#8217;s sole discretion, amend, modify, extend, or otherwise make any change to any APA, Existing Strategic Partner Agreement, or any Settlement Arrangement, in each case, (i) to increase the scope of exclusivity, or (ii) in any other manner that would materially negatively affect Sanofi&#8217;s rights or obligations hereunder, including by increasing the quantity of products ordered or delivered, or increasing the price of products. Further, Novavax will not, in connection with any APA, Existing Strategic Partner Agreement, or Settlement Arrangement, order pre-filled syringes or unidose or single-dose vials of any Licensed COVID-19 Mono Product from a supplier that also supplies Licensed COVID- 19 Mono Products to Sanofi in any manner that would negatively affect Sanofi&#8217;s rights or obligations hereunder, without Sanofi&#8217;s prior written consent, such consent not to be unreasonably withheld.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Existing Supply Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Novavax will not, without Sanofi&#8217;s prior written consent, which will be granted or withheld at Sanofi&#8217;s sole discretion, amend, modify, extend, make any change to, or fail to comply with, any Existing Supply Agreements, in each case, (i) to increase the scope of exclusivity (but Novavax may extend the duration of any exclusivity in its sole discretion), or (ii) in any other manner that would materially negatively affect Sanofi&#8217;s rights or obligations hereunder. &#91;***&#93;.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">New Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except in connection with sales or tender offers for purposes of satisfying Novavax&#8217;s obligations under any Existing Settlement Arrangements, from and after the Effective Date, Novavax will not enter into any agreement or arrangement to Manufacture or Commercialize Licensed COVID-19 Mono Products, including any (i) APA without Sanofi&#8217;s prior written consent, which consent will be granted or withheld at Sanofi&#8217;s sole discretion or (ii) Settlement Arrangement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">unless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">approved by the JCC pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">7.3</a> (Existing APAs and Settlement Arrangements)&#59; except that Novavax may enter new agreements to Manufacture Licensed COVID-19 Mono Product that do not negatively affect Sanofi&#8217;s rights or obligations hereunder, and any such new agreement will be deemed an Existing Supply Agreement. &#91;***&#93;.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Assignment or Disposal of Licensed Novavax Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as permitted under Section</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment), Novavax will not sell, assign, or otherwise dispose of any Licensed Novavax Assets to any Third Party unless such Third Party agrees in writing to be bound by all relevant terms of this Agreement, including Novavax&#8217;s covenants in respect of the Licensed Novavax Assets under <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 2</a> (License Grants&#59; Exclusivity), <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 12</a> (Patent and Know-How Matters), and this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">14.4</a> (Covenants of Novavax).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Assignment Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. (a) All employees of each Party performing activities on behalf of such Party in connection with this Agreement are subject to a present obligation to assign to such Party all rights, title, and interests in and to any inventions developed by them in the conduct of such activities, whether or not patentable&#59; and (b) all Service Providers of either Party performing activities on behalf of such Party in connection with this Agreement are subject to subcontracts that provide that such Party will obtain ownership or a sublicensable license of any Know-How and Patents that are discovered, developed, invented, or created by such subcontractor in their performance of such activities to the extent such Know-How and Patents would otherwise fall within the definition of Licensed Novavax Assets.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Warranty Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY PATENTS, KNOW-HOW, MATERIALS, COMPOUND, PRODUCT, GOODS, SERVICES, RIGHTS, OR OTHER SUBJECT MATTER OF THIS AGREEMENT  AND  HEREBY  DISCLAIMS  ALL  IMPLIED  WARRANTIES  OF</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES AGREE THAT THE MILESTONE EVENTS AND NET SALES LEVELS SET FORTH IN THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS AND ROYALTY OBLIGATIONS IF SUCH MILESTONE EVENTS OR NET SALES LEVELS ARE ACHIEVED. NOVAVAX HEREBY ACKNOWLEDGES AND AGREES THAT NEITHER SANOFI NOR ITS AFFILIATES, OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OR ANY OTHER PERSON HAS MADE OR IS MAKING, AND NOVANVAX HAS NOT RELIED UPON AND IS NOT RELYING UPON, ANY REPRESENATAIONS OR WARRANTIES, PROJECTION, FORECAST, OR STATEMENT, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY ADVANCE ANY LICENSED PRODUCT OR DEVELOP, ACHIEVE MARKETING AUTHORIZATION FOR, MANUFACTURE, COMMERCIALIZE, OR OTHERWISE EXPLOIT ANY LICENSED PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH LICENSED PRODUCT WILL BE ACHIEVED.</font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 15&#58; INDEMNIFICATION&#59; INSURANCE&#59; LIMITATIONS</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:35.9pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi will indemnify, defend, and hold harmless Novavax, its Affiliates, and its and their respective employees, officers, directors, and agents and their respective successors, heirs, and assigns (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) from and against any liability, loss, damage, or expense (including reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) arising out of any Third Party suit, proceeding, investigation, claim, or demand (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) arising from or relating to&#58;</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">&#91;***&#93;&#59; or</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#91;***&#93;.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Indemnification by Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax will indemnify, defend, and hold harmless Sanofi, its Affiliates, and its and their respective employees, officers, directors, and agents and their respective successors, heirs, and assigns (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Sanofi Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;) from and against any Liability arising out of any Third Party Claim arising from or relating to&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:19.37pt;text-decoration:underline">&#91;***&#93;&#59; or</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt;text-decoration:underline">&#91;***&#93;&#59;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">&#91;***&#93;.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will notify the other Party in writing if it becomes aware of a claim for which such Party may seek indemnification hereunder. If any Proceeding (including</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any governmental investigation) is instituted against a Party with respect to which indemnity may be sought pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi) or <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.2</a> (Indemnification by Novavax), as applicable, such Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) will give prompt written notice of the claim to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) and provide the Indemnifying Party with a copy of any complaint, summons, or other written notice that the Indemnified Party receives in connection with any such claim. An Indemnified Party&#8217;s failure to deliver such written notice will relieve the Indemnifying Party of liability to the Indemnified Party under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi) or <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.2</a> (Indemnification by Novavax), as applicable, only to the extent such delay is prejudicial to the Indemnifying Party&#8217;s ability to defend such claim and allow the Indemnifying Party to assume the defense of the claim. Within thirty (30) days after delivery of such notice, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, elect to assume control of the defense of such claim with counsel reasonably satisfactory to the Indemnified Party. If a Party believes that a claim presented to it for indemnification is one as to which the Party seeking indemnification is not entitled to indemnification under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.1</a> (Indemnification by Sanofi) or <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1.2</a> (Indemnification by Novavax), as applicable, then it shall so notify the Party seeking indemnification. Provided that the Indemnifying Party is not contesting the indemnity obligation, the Indemnified Party, upon notice of such election, will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise (subject to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15.1</a> (Indemnification)). Following such election, the Indemnified Party may participate in the defense of such claim at its own expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if the Indemnified Party reasonably concludes, based on advice from counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such claim, then the Indemnifying Party shall be responsible for the reasonable fees and expenses of counsel to the Indemnified Party (but no more than one law firm acting as such) solely in connection therewith. The Indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim, will keep the Indemnified Party informed of the status and progress of the defense and any settlement discussions concerning such claim, and will not settle such claim or consent to any judgment in respect thereof, or otherwise resolve such claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld, conditioned, or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such consent will not be required with respect to any settlement or consent to judgment that (a) imposes no obligation or liability other than the payment of monetary awards for which the Indemnifying Party will be fully responsible, (b) does not include an admission of liability on the part of the Indemnified Party, and (c) includes a complete and unconditional release of the applicable Novavax Indemnified Parties or the applicable Sanofi Indemnified Parties, as the case may be, from all liability with respect to such claim. The Indemnified Party will cooperate with the Indemnifying Party in the Indemnifying Party&#8217;s defense of any claim for which indemnity is sought under this Agreement, at the Indemnifying Party&#8217;s cost and expense. The Indemnified Party shall not agree to any settlement of such claim or consent to any judgment in respect thereof without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, conditioned, or delayed.</font></div><div style="margin-top:1.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will, during the Term and for a period of &#91;***&#93; thereafter, at its own cost and expense, obtain and maintain &#91;***&#93; insurance coverage for its activities under this Agreement from insurance carriers licensed to do business under the laws of the country, state, commonwealth, province, or territory in which such Party&#8217;s obligations are provided, with insurers that carry a rating of at least &#91;***&#93;. Each</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Party will furnish to the other Party a certificate of insurance evidencing such insurance coverage upon request. Each Party will have the right to self-insure its activities under this Agreement.</font></div><div style="margin-top:9.1pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Limitation of Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">&#91;***&#93;.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt">&#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 16&#58; TERM&#59; TERMINATION</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Term&#59; Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The term of this Agreement shall commence on the Effective Date, and unless terminated earlier in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">16.2</a> (Termination of this Agreement), will expire when neither Party is Exploiting or is planning to Exploit a Licensed Product or Novavax Product (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">&#8221;).</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Termination of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Sanofi&#8217;s Termination for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi has the right to terminate this Agreement on a Region-by-Region or Sanofi License-by-Sanofi License basis, at will and in its sole discretion on &#91;***&#93; prior written notice to Novavax, except such notice period shall be &#91;***&#93; with respect to termination of the COVID-19 Mono License.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If either Party is in material breach of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) may deliver notice of such material breach to the Breaching Party referencing this</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach) with sufficient details regarding the specific actions or inactions of the Breaching Party giving rise to the material breach. Subject to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(b)</a> (Disagreement as to Material Breach), the Breaching Party shall have &#91;***&#93; from such notice to cure such material breach </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">unless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">such breach is a payment breach, for which the Breaching Party shall have &#91;***&#93; to cure such breach (such applicable period to cure, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). If the Breaching Party fails to cure such material breach within the Cure Period, then the Non-Breaching Party may terminate this Agreement in its entirety effective on written notice of termination to the Breaching Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that if the material breach solely relates to (a) a Licensed Product, then the Non- Breaching Party may not terminate this Agreement in its entirety and instead shall only have the right to terminate the Sanofi License grant under which such Breaching Party was Exploiting such Licensed Product (and all rights and obligations and Licensed Products under such license will also terminate), and (b) a Region, then the Non-Breaching Party may not terminate this Agreement in its entirety and instead shall only have the right to terminate this Agreement solely with respect to such Region.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Disagreement as to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Notwithstanding Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach), if the Parties, reasonably and in good faith, disagree as to whether there has been a material breach of this Agreement, then&#58; (i) the Party that disputes whether there has been a material breach may contest the allegation by referring such matter, prior to the expiration of the Cure Period, for resolution in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution)&#59; (ii) the relevant Cure Period with respect to such alleged material breach will be tolled in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution) from the date on which the Party that disputes whether there has been a material breach notifies the other Party of such Dispute and through the resolution of such Dispute in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution)&#59; and (iii) during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. If it is finally determined in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution) that such Breaching Party is in material breach, then from the date of such decision, the Cure Period will run and the Non- Breaching Party may terminate the Agreement if such breach is not cured in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach).</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Sanofi&#8217;s Alternative Remedy for Novavax&#8217;s Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If Sanofi has the right to terminate this Agreement for Novavax&#8217;s material breach pursuant to pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach), then Sanofi may, in lieu of terminating this Agreement elect (in its sole discretion) by written notice to Novavax, any or all of the following remedies solely with respect to the Licensed Products and Regions with respect to which Sanofi has the right to so terminate the Agreement pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach)&#58;</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:19.76pt">Where practicable, assume Novavax&#8217;s rights and obligations to conduct those activities for which Novavax&#8217;s failure to perform led to the material breach that gave rise to Sanofi&#8217;s termination right (such activities, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Step-In Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). If Sanofi elects to perform the Step-In Activities, then the Parties will coordinate to transfer the Step-In Activities to Sanofi. Any amounts incurred by Sanofi or its Affiliates to assume such Step-In Activities will be at its sole cost and expenses&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:17.54pt">all royalties or milestone payments that become due to Novavax hereunder after Sanofi&#8217;s election of this alternative remedy shall be reduced by &#91;***&#93; of what would otherwise be due to Novavax hereunder (i.e., such that Novavax would receive &#91;***&#93; of what would otherwise be due Novavax).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remedies set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Error! Reference source not found. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Sanofi&#8217;s Alternative Remedy for Novavax&#8217;s Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) shall be without limitation to any other rights or remedies that may be available to Sanofi under this Agreement or at law or equity, except that if elected, then the remedy set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)(ii)</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Sanofi&#8217;s Alternative Remedy for Novavax&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) shall be Sanofi&#8217;s sole and exclusive monetary remedy for such breach (including that Sanofi may not also exercise its right to receive a discount as a result of a supply delay under paragraph (a) of the Delivery Issues row of Schedule 6.3.1 &#47; Schedule 6.3.2), if Sanofi exercises its rights under this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)(ii)</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Sanofi&#8217;s Alternative Remedy for Novavax&#8217;s Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). In all cases, in the event that Sanofi has the right to terminate this Agreement pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(a)</a> (Material Breach), Sanofi will have the right to conduct the Step-In Activities pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)(i)</a> (Material Breach) whether or not Sanofi has elected the alternative remedy set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.2(c)(ii)</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Sanofi&#8217;s Alternative Remedy for Novavax&#8217;s Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) and whether or not Sanofi has exercised its offset right pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.14.4</a> (Right to Reconcile Payments).</font></div><div style="margin-top:0.8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi or any of its Affiliates files, assists a Third Party in filing or maintaining, or joins a Third Party in filing or maintaining, a Patent Dispute of any Novavax Patent, then Novavax may provide written notice of its intent to terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that a Patent Dispute under this Section 16.2.3 (Termination for Patent Challenge) shall not include&#58; (a) any reissue, reexamination, post-grant proceeding or any other administrative proceeding filed or requested to be filed by Sanofi or its Affiliates or Sublicensees after prior consultation and agreement with Novavax with respect to any Novavax Patent in a good faith effort to (i) reinforce the patentability, validity or enforceability of such Novavax Patent or (ii) expand the claim scope of such Novavax Patent with respect to Licensed Products&#59; (b) responses to compulsory discovery, subpoenas or other requests for information in a judicial or arbitration proceeding&#59; (c) compliance with any Applicable Law or court order&#59; (d) any Patent Dispute in which Sanofi submits all required documentation and otherwise uses best efforts to terminate or actually causes to be dismissed within &#91;***&#93; of receiving written notice from Novavax&#59;</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e) any challenge to the validity or Valid Claim status of a claim of a Novavax Patent in defense of an action first brought by Novavax or its Affiliates or licensors (or any of their respective licensees) with respect to such Novavax Patent&#59; (f) any Patent Dispute commenced by a Third Party that, after the Effective Date, becomes an Affiliate of Sanofi or its Sublicensee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such Patent Dispute (i) was commenced prior to the closing of the transaction by which the Third Party becomes an Affiliate of Sanofi or its Sublicensee and (ii) Sanofi or such Sublicensee causes such Third Party to file a motion to dismiss such Patent Dispute within &#91;***&#93; after such closing&#59; or (g) with respect to any Patent Dispute brought by a Sublicensee, if Sanofi acts to terminate the sublicense granted to such Sublicensee under the Novavax Patent within &#91;***&#93; of receiving written notice from Novavax. For clarity, a Patent Dispute hereunder shall not be deemed a material breach of Sanofi under this Agreement.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Termination for Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If, at any time during the Term, either Party makes an assignment for the benefit of creditors, appoints, or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy, or insolvency act, or has any such petition filed against it that is not discharged within &#91;***&#93; after the filing thereof, then the other Party may terminate this Agreement in its entirety by providing written notice of its intent to terminate this Agreement to such first Party, in which case, this Agreement will terminate on the date on which such first Party receives such written notice.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Consequences of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Upon the termination of this Agreement in whole or in part by either Party pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">16.2</a> (Termination of this Agreement), the following provisions shall apply on a Terminated Product-by-Terminated Product, and Terminated Territory-by- Terminated Territory basis&#58;</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Termination of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All rights and obligations of the Parties under this Agreement (including any licenses granted by a Party hereunder, except as necessary for the other Party to perform its surviving obligations hereunder) for the Terminated Products in the Terminated Territory shall cease except as otherwise set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">0</a> (Consequences of Termination) or elsewhere in this Agreement.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Inventory Sell-Off Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Within &#91;***&#93; after the effective date of termination (or if this Agreement is terminated pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.2.1</a> (Sanofi&#8217;s Termination for Convenience), then within &#91;***&#93; after the date of Sanofi&#8217;s termination notice), Sanofi will provide Novavax with a report of its currently on-hand and in-progress inventory with respect to the Terminated Products in the Territory. Sanofi may (with respect to the Terminated Products in the Terminated Territory) for a period of &#91;***&#93; after the date on which a notice of termination is effective (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sell-Off Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) to (i) complete Manufacture with respect to any in-progress inventory of Terminated Products subject to a purchase order dated prior to the effective date of termination, and</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii) continue to offer for sale and sell such on-hand and in-progress Terminated Products in such Terminated Territory (as applicable) to the extent related to such Terminated Product in Sanofi&#8217;s inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)). Sanofi will be responsible for, and comply with, all payment obligations under this Agreement in connection with such inventory sell-off, including the payment of any royalties with respect to Net Sales of such Terminated Products in the Terminated Territory and any milestone payments associated with a milestone event achieved in the course of such inventory sell-off. Sanofi will not sell or otherwise Exploit any Terminated Product in a Terminated Territory except as expressly set forth in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.3</a> (Consequences of Termination).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.25pt;text-decoration:underline">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Solely for Terminated Products that are Licensed COVID-19 Mono Products, and not any other Licensed Products, if as of the effective date of termination, Sanofi or its Affiliates or Sublicensees are conducting any Clinical Trials of such a Terminated Product, then, upon Novavax&#8217;s request and at Novavax&#8217;s election, Sanofi and its Affiliates and Sublicensees shall (a) wind down any such ongoing Clinical Trials pursuant to Applicable Law or any requirements from the applicable Regulatory Authorities in compliance with Novavax&#8217;s instructions and Applicable Law, or (b) to the extent permitted by Applicable Law and any requirements from the applicable Regulatory Authorities, transfer such Clinical Trials to Novavax at</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Novavax&#8217;s cost. If Novavax requests that any such Clinical Trials be transferred to Novavax as set forth in clause (b), then Novavax will assume any and all liabilities, including costs, for the conduct of such transferred Clinical Trials for Terminated Products that are Licensed COVID-19 Mono Products that arise after the effective date of such transfer.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.03pt">Sanofi and its Affiliates and Sublicensees have no obligation to, and will not, transfer to Novavax any Clinical Trials of a terminated Licensed CIC Product, Licensed OC Product, or Licensed Adjuvanted Product for any reason, and Sanofi shall wind down any ongoing Clinical Trials of such Licensed Products in accordance with Applicable Laws and reasonable medical practices.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Assignment and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Solely for Terminated Products that are Licensed COVID-19 Mono Products, and not any other Licensed Products, promptly following the effective date of termination&#58;</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:18.48pt;text-decoration:underline">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Sanofi (i) hereby assigns and transfers to Novavax or its designee(s) all of Sanofi&#8217;s rights, title, and interests in and to all Regulatory Filings, Marketing Authorizations, and Pricing Approvals relating to the Terminated Product with respect to the Terminated Territory, and (ii) will disclose to Novavax or its designee(s) all documents, records, and Materials that are owned or controlled by Sanofi for the Terminated Product(s) in the Terminated Territory.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Service Provider Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If at the time of such termination Sanofi or its Affiliates are party to an agreement with a Service Provider solely related to any Terminated Product in the Terminated Territory, then Sanofi will, and will cause its Affiliates to, upon Novavax&#8217;s election, use good faith efforts to assign to Novavax or its designee Sanofi&#8217;s or such Affiliate&#8217;s rights and obligations under such agreement and that solely relate to such Terminated Product in the Terminated Territory.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt;text-decoration:underline">Licensed Product Marks and Licensed Product Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Sanofi hereby assigns and transfers to Novavax or its designee(s), as of the effective date of termination, all of its rights, title, and interests in and to (i) any trademarks (to the extent such Licensed Product Marks do not contain Sanofi&#8217;s name, logo or housemark) and domain names, in each case, solely used in connection with the Terminated Product, (ii) any copyrights solely related to or used in the branding of Terminated Product, and (iii) any registrations or applications for registration for the foregoing ((i) &#8211; (iii), together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transferred Marks and Domains</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). Subject to the terms and conditions of this Agreement, commencing on the effective date of termination and continuing for &#91;***&#93; thereafter, Sanofi hereby grants to Novavax a non-exclusive, sublicensable (through multiple tiers), non-transferable (except in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment)) license solely to use Sanofi&#8217;s name, logo, or housemark to the extent included in any Licensed Product Mark to Commercialize the applicable Terminated Products.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, upon Novavax&#8217;s reasonable request, Sanofi will grant to Novavax a non-exclusive, worldwide, sublicensable, transferable, royalty-bearing license under the Sanofi Licensed COVID-19 Mono Assets to Exploit the Licensed COVID-19 Mono Products and Licensed COVID-19 Component (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;). The Parties shall negotiate in good faith fair and</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">reasonable market royalty rate(s) and other market terms and conditions of the Reversion License. If the Parties are unable to reach agreement on the economics terms of the Reversion License within &#91;***&#93; of such license becoming effective, then the Parties shall resolve the dispute through the Baseball Arbitration Procedures set forth in Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">9.18.5(d)(ii)</a> (Baseball Arbitration Dispute Resolution).</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.35pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Following the expiration or termination of this Agreement, if requested by the Disclosing Party, the Receiving Party will use diligent efforts to destroy, all files, records, and other materials containing or comprising the Disclosing Party&#8217;s Confidential Information, except to the extent such Confidential Information is &#91;***&#93; to conduct surviving obligations or exercise surviving rights. Notwithstanding the foregoing, (a) the Receiving Party will be permitted to retain access to such files, records, and other materials solely for archival and legal compliance purposes, and (b) the Receiving Party will not be required to destroy or segregate any electronic back- up tapes or other electronic back-up files that have been created solely by the Receiving Party&#8217;s automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with its standard archiving and back-up procedures. Each Party&#8217;s obligations under Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">11.1</a> (Confidentiality) will survive for &#91;***&#93; after the effective date of termination or expiration of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such obligations will survive for Confidential Information held as a trade secret for so long as such Confidential Information remains trade secret.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.35pt;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. All rights and licenses granted under or pursuant to this Agreement by a Party to the other are and will otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code. The Parties agree that the Non-Bankrupt Party will retain and may fully exercise all of their rights and elections under the Bankruptcy Code and any foreign equivalent thereto. The Parties further agree that if (a) a bankruptcy proceeding by or against a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) is commenced under the Bankruptcy Code&#59; (b) this Agreement is rejected as provided in the Bankruptcy Code&#59; and (c) the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, then, unless the Bankrupt Party continues to perform all of its obligations under this Agreement, the Non-Bankrupt Party will be entitled to a complete duplicate of, and complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments thereof. Upon such occurrence, such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party and the Non-Bankrupt Party will continue to pay all royalties and milestones hereunder to the fullest extent allowed under Section 365(n). The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the exercise by the Non-Bankrupt Party of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agrees to assist the Non-Bankrupt Party and its Affiliates in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Applicable Law. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; means Title 11, United States Code, as from time to time in effect.</font></div><div style="margin-top:0.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Surviving Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Accrued Rights&#59; Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. The expiration or termination of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of either Party prior to the date of such expiration or termination, and any and all damages or remedies</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">121</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(whether at law or in equity) arising from any breach hereunder, each of which will survive expiration or termination of this Agreement, unless otherwise expressly set forth herein. Such expiration or termination will not relieve any Party from obligations that are expressly indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set forth in this Agreement, the termination provisions of this <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 16</a> (Term&#59; Termination)are in addition to any other relief and remedies available to either Party under this Agreement, at law, or in equity.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Without limiting the provisions of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.5.1</a> (Accrued Rights&#59; Remedies), the rights and obligations of the Parties set forth in the following Sections and Articles of this Agreement will survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are expressly stated to survive termination or expiration of this Agreement&#58; Article <a href="#ic65efe10465541f1844e49bde32dfd4c_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">1</a> (Definitions) (to the extent the definitions are used in other surviving provisions), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1.5</a> (License to Novavax), Section 2.1.7 (Sanofi Covenants) (solely for so long as Sanofi is continuing to sell Terminated Products during the Sell-Off Period), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.5</a> (No Adjuvant Improvements), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.7</a> (No Implied Licenses&#59; Competing Products&#59; Retained Rights), Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10</a> (Financial) (solely with respect to any amounts that accrued prior to the effective date of expiration or termination of this Agreement or during the Sell-Off Period), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.16</a> (Financial Records&#59; Audits) (solely for thirty-six (36) months after the effective date of termination or expiration), <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">12.1</a> (Ownership), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">14.5</a> (Disclaimer), Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">15</a> (Indemnification&#59; Insurance&#59; Limitations), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.3</a> (Consequences of Expiration or Termination), this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">16.5</a> (Surviving Provisions), and Article <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17</a> (Miscellaneous).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ARTICLE 17&#58; MISCELLANEOUS</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:-27.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.3pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. This Agreement will not be assignable by either Party without the prior written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may, subject to the terms of this Agreement, assign this Agreement in its entirety, without the written consent of the other Party, to an Affiliate that is a tax resident in the United States only or to a Third Party that acquires all or substantially all of the business or assets of such Party to which this Agreement relates (whether by merger, reorganization, acquisition, sale of equity or assets, or otherwise)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that in the case of an assignment by Novavax to a Third Party, (a) Novavax only may so assign to a Third Party on or after the date that is &#91;***&#93; after the COVID-19 Manufacturing Handover Date, and (b) Novavax assigns to such Third Party its rights, title, and interests in the Licensed Novavax Assets. Notwithstanding any assignment of this Agreement by a Party to any Affiliate of such Party, such assigning Party shall remain fully liable for the performance of its obligations under this Agreement by such Affiliate. Novavax shall not, without the prior written consent of Sanofi (not to be unreasonably withheld), assign to any Third Party any of Novavax&#8217;s rights to receive payment from Sanofi under this Agreement, including the rights to receive royalty payments and milestones hereunder, except on or after the date that is &#91;***&#93; after the COVID-19 Manufacturing Handover Date to either (i) a single Third Party of Novavax&#8217;s entire interest in such royalty payments and milestones, and such Person may not further assign, in whole or in part, such royalty payments and milestones to any other Person or (ii) to more than one Third Party of Novavax&#8217;s entire interest in such royalty payments and milestones in a single transaction,</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that Novavax does not grant, and each Third Party expressly waives all, rights to bring any claim or cause of action directly against Sanofi, and such Persons may not further assign, in whole or in part, such royalty payments and milestones to any other Persons. Upon the effectiveness of Novavax&#8217;s assignment of royalty payments and milestones to any Third Party, Sanofi may disband the JSC and all Subcommittees, and as from the date on which such Committees are disbanded, Sanofi will have all decision-making authority allocated to the Committees. Notwithstanding Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">10.15</a> (Withholding Tax), the tax consequences of any assignment of this Agreement will, as between the Parties, be borne by the assigning Party (who will make the non-assigning Party whole with respect to all such tax consequences to the extent arising as a result of such assignment). The assigning Party will promptly notify the non-assigning Party in writing of any permitted assignment or transfer under the provisions of this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment). This Agreement will be binding upon the successors and permitted assigns of the Parties. Any assignment not in accordance with this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1</a> (Assignment) will be null, void, and of no legal effect.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:11.35pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Novavax will notify Sanofi within &#91;***&#93; following the date that there is a Change of Control of Novavax, in which case&#58;</font></div><div style="margin-top:8.95pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.48pt">Sanofi shall have the right, but not the obligation, to exercise those rights set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.1.2(b)</a> (Change of Control), by providing written notice to Novavax and the applicable Acquirer, if, the JSC reasonably determines that the Acquirer</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">(i) is unable or unwilling to cooperate with Sanofi to implement Sanofi&#8217;s Commercial strategy for Licensed COVID-19 Products or (ii) is not able or willing to perform Novavax&#8217;s obligations under this Agreement with substantially the same degree of skill that Novavax was using prior to such Change of Control.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:18.03pt">If the JSC determines including, if applicable, through the dispute resolution process set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18.5(c)</a> (Change of Control Matters) and <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution) that the criteria in clause (a) above are met then Sanofi may</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i) assume Novavax&#8217;s rights and obligations to perform any or all Novavax activities allocated to Novavax hereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Novavax&#8217;s obligation to supply Licensed COVID-19 Products, Adjuvant, or Adjuvant Intermediates, as applicable, to Sanofi in accordance with <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 6</a> (Manufacturing)&#59; and (ii) disband the JSC and all Subcommittees, and as from the date on which such Committees are disbanded, Sanofi shall have the sole right to make all decisions hereunder with respect to the Licensed COVID-19 Component and Licensed COVID-19 Products in the Collaboration COVID-19 Territory.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party will not be deemed to have defaulted under or breached any of its obligations under this Agreement, except for the payment of any amounts owed under this Agreement, to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides written notice of the Force Majeure to the other Party. Such excuse will continue for so long as the condition constituting a Force Majeure continues, on the condition that the nonperforming Party continues to use &#91;***&#93; to remove or mitigate the Force Majeure and resume performance of its obligations under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that after a period exceeding &#91;***&#93;, the Parties will promptly meet to discuss in good faith mitigation strategies to proceed in a manner that maintains and abides by the Agreement.</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Representation by Legal Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">hereof. In interpreting and applying the terms and provisions of this Agreement, no presumption will exist or be implied against the Party that drafted such terms and provisions.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All notices, requests, demands, waivers and other communications which are required or permitted hereunder will be in writing and sufficient if delivered personally or sent by nationally recognized overnight courier, addressed as follows&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If to Sanofi&#58;</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Sanofi Pasteur Inc. 1 Discovery Drive</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Swiftwater, Pennsylvania 18370 USA Attn&#58; &#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.20pt">&#91;***&#93;</font></div><div style="margin-top:1.85pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:18.70pt">with a copy (which does not constitute notice) to&#58; Sanofi Global Alliance Management</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7.60pt">Email&#58; &#91;***&#93;</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1271 Avenue of the Americas New York, NY 10020 Attention&#58; &#91;***&#93;</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:235%">Email&#58; &#91;***&#93; </font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:235%">If to Novavax&#58;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.15pt">Novavax, Inc.</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">700 Quince Orchard</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">Gaithersburg, Maryland 20878 USA Attn&#58; &#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.15pt">with copies (which will not constitute notice) to&#58;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Novavax Legal Department</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="margin-top:0.8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</font></div><div style="margin-top:0.8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:241%">Novavax&#8217;s Alliance Manager and</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ropes &#38; Gray LLP</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Boylston Street, Prudential Tower Boston, MA 02199</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:9.15pt">Attention&#58; &#91;***&#93;</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.2pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">or to such other address as the Party to whom written notice is to be given may have furnished to the other Party in writing in accordance herewith. In addition, each Party will deliver a courtesy copy to the other Party&#8217;s Alliance Manager concurrently with such notice. Any such notice will be deemed to have been given and received by the other Party&#58; (a) when delivered if personally delivered&#59; or (b) on receipt if sent by overnight courier.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. No amendment, modification, or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each of Sanofi and Novavax. For clarity, references in this Agreement to a &#8220;written acknowledgement&#8221; will not be deemed to be an amendment, modification, or supplement of this Agreement.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. No provision of this Agreement will be waived by any act, omission, or knowledge of a Party or its Representatives except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either Party of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.</font></div><div style="margin-top:8.75pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:17.35pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal, or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity, and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause or portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law.</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:123%;padding-left:17.35pt">Descriptive Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:123%">. The descriptive headings of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div><div style="margin-top:8.8pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:17.35pt">Export Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed upon or related to Novavax or Sanofi from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate Governmental Authority.</font></div><div style="margin-top:8.65pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. This Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of the &#91;***&#93;, excluding (a) the conflict of law principles thereof&#59; (b) the United Nations Conventions on Contracts for the International Sale of Goods&#59; (c) the 1974 Convention on the Limitation Period in the International Sale of Goods (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1974 Convention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;)&#59; and (d) the Protocol amending the 1974 Convention, done at Vienna April 11, 1980. Notwithstanding any provision to the contrary set forth in this Agreement, the interpretation and construction of any Patents shall be governed in accordance with the laws of the jurisdiction in which such Patents were filed or granted, as the case may be.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Jurisdiction&#59; Venue&#59; Service of Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except as otherwise provided in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12.4</a> (Equitable Relief), (a) each Party irrevocably submits to the exclusive jurisdiction of (i) the courts</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of the &#91;***&#93; located in &#91;***&#93;, or (ii) the United States District Court for the &#91;***&#93;, for the purposes of any actions, suits, and Proceedings (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;) arising out of this Agreement (except for government agency actions to adjudicate registered intellectual property rights, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, post-grant proceedings at the United States Patent and Trademark Office or other foreign equivalent Proceedings)&#59; (b) each Party agrees to commence any such Action either in the United States District Court for the &#91;***&#93; or if such Action may not be brought in such court for jurisdictional reasons, in the courts of &#91;***&#93;&#59; and (c) each Party irrevocably and unconditionally waives any objection to the laying of venue of any Action arising out of this Agreement in (i) the courts of &#91;***&#93;, or (ii) the United States District Court for the &#91;***&#93;, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum. Each of the Parties agrees that process may be served upon it in the manner specified in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.4</a> (Notices) and irrevocably waives and covenants not to assert or plead any objection that it might otherwise have to such jurisdiction, or to such manner of service of process.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith other than any dispute arising from a Novavax Matter, Sanofi Matter, or Status Quo Matter (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;), then (a) any dispute arising from a Novavax Matter, Sanofi Matter, or Status Quo Matter, will be resolved pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making), and (b) all other Disputes will be resolved pursuant to this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution).</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Informal Dispute Resolution&#59; Escalation to Senior Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In the event any Dispute is not a Novavax Matter, a Sanofi Matter, or a Status Quo Matter, and is not otherwise finally resolved pursuant to Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making), then the Parties will first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. If, after &#91;***&#93; from receipt of the written notice of such Dispute, such Dispute has not been resolved on an informal basis, either Party may refer any such Dispute to the Senior Executives of the Parties by delivering written notice to the other Party, and the Senior Executives of the Parties will confer in good faith on the resolution of the issue for a &#91;***&#93; period following receipt of such written notice. If any such Dispute is not resolved within such &#91;***&#93; period by the Senior Executives, then each Party may, at its sole discretion, seek resolution of such Dispute in accordance with Section</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.1pt">(Litigation).</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If the Parties cannot resolve a Dispute in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12.1</a> (Informal Dispute Resolution&#59; Escalation to Senior Executives), then either Party may commence litigation in accordance with Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.11</a> (Jurisdiction&#59; Venue&#59; Service of Process). The Parties agree to seek an early conference with the court and to advise the court of this Agreement.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. EXCEPT AS LIMITED BY APPLICABLE LAW, EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE, AND ENFORCEMENT HEREOF.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing in this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution), nothing contained in this Agreement will in any way limit or preclude a Party from, at any time, seeking equitable relief hereunder, whether preliminary or permanent, including a temporary or permanent restraining order, preliminary or permanent injunction, specific performance, or any other form of equitable relief, from any United States court of competent jurisdiction if necessary to protect the interests of such Party. Each Party agrees that its unauthorized release of the other Party&#8217;s Confidential Information or its breach of Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.1</a> (Licenses), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">2.5</a> (No Adjuvant Improvements), <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 5</a> (Technology Transfer), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.1.2</a> (Manufacture and Supply to Sanofi), Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">6.3</a> (Supply Agreements), <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">Article 11</a> (Confidentiality and Non-Disclosure), or Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">14.4</a> (Covenants of Novavax) of this Agreement may cause irreparable damage to the other Party for which recovery of damages may be inadequate, and that such other Party will be entitled to seek timely injunctive relief with respect to such breach and without the requirement of having to post bond or other security, as well as any further relief that may be granted by a court of competent jurisdiction.</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches), as well as all time periods in which a Party must exercise rights or perform obligations hereunder, will be tolled once the dispute resolution procedures set forth in Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">9.18</a> (Decision Making) or this Section <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">17.12</a> (Dispute Resolution) have been initiated and for so long as they are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a result. Further, with respect to any time periods that have run during the pendency of the Dispute, the applicable Party will have a reasonable period of time, or any specific timeframe established by the applicable tribunal&#8217;s decision, to exercise any rights or perform any obligations affected by the running of such time periods.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.35pt;text-decoration:underline">Certain Patent and other Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Notwithstanding any provision to the contrary set forth in this Agreement, any Patent Dispute shall be subject to adjudication in accordance with Applicable Law of the country or jurisdiction in which the relevant Patent is pending or has been issued. The Parties agree that the venue of any such adjudication involving a Patent pending in or issued by the United States shall be a U.S. federal district court (or appellate body, as necessary) sitting in &#91;***&#93;, and for a Patent pending in or issued by any other country, any competent court having jurisdiction over the subject of the Patent Dispute sitting in the capital of such country (or if there is not any such competent court in the capital, then in a location reasonably proximate to the capital), and each Party irrevocably submits to the jurisdiction of such court. Each Party agrees not to raise any objection at any time to the laying or maintaining of the venue of any action, suit, or proceeding for such purpose in any such court, irrevocably waives any claim that such action, suit, or other proceeding has been brought in an inconvenient forum, including any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">forum non conveniens </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">argument, and further irrevocably waives the right to object, with respect to such action, suit or other proceeding, that such court does not have any jurisdiction over such Party.</font></div><div style="margin-top:0.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. Each Party may use one (1) or more of its Affiliates to perform its obligations and duties under this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that such Party shall remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement and for the Affiliate&#8217;s compliance with the terms of this Agreement, including such Affiliate&#8217;s adherence to all waivers, disclaimers, and limitations in this Agreement in favor of the other Party hereunder.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. This Agreement (together with all schedules and exhibits attached hereto) constitutes and contains the complete, final, and exclusive understanding and agreement of the Parties and cancels and supersedes all prior negotiations (including as documented in any term sheet), correspondence, understandings, and agreements, whether oral or written, between the Parties respecting the subject matter hereof, including the CDA, which is hereby superseded and replaced in its entirety as of the Effective Date.</font></div><div style="margin-top:8.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Both Parties are independent contractors under this Agreement. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.35pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa)&#59; (b) the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221;&#59; (c) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall,&#8221; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">vice versa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#59; (d) any definition of or reference to any agreement, instrument, or other document herein will be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements, or modifications set forth herein)&#59; (e) any reference herein to any Person will be construed to include the Person&#8217;s successors and assigns&#59; (f) the words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder,&#8221; and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof&#59; (g) all references herein to Articles, Sections, or Schedules will be construed to refer to Articles, Sections, or Schedules of this Agreement, and references to this Agreement include all Schedules hereto&#59; (h) except as otherwise expressly set forth herein, provisions that require that a Party, the Parties, or any Committee hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; &#8220;approve,&#8221; or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding e-mail and instant messaging)&#59; (i) references to any specific law, rule, or regulation, or article, section, or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule, or regulation thereof&#59; (j) any action or occurrence deemed to be effective as of a particular date will be deemed to be effective as of 11&#58;59 PM ET on such date&#59; and (k) the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221; (and&#47;or). Unless otherwise specified, deadlines within which any payment is to be made or act is to be done within or following a specified time period after a date will be calculated by excluding the day, Business Day, month, or year of such date, as applicable, and including the day, Business Day, month, or year of the date on which the period ends. Whenever any payment to be made or action to be taken under this Agreement is required to be made or taken on a day other than a Business Day, such payment may be made, or such action may be taken on the next Business Day following such day. No prior draft of this Agreement may be used in the interpretation or construction of this Agreement.</font></div><div style="margin-top:0.65pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">No Third Party Rights or Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Except as expressly set forth in this Agreement (including in <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;text-decoration:none">Article 15</a> (Indemnification)), no provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement.</font></div><div style="margin-top:8.85pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;padding-left:13.35pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. This Agreement may be executed in two (2) counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:122%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, .pdf), each of which will be binding when received by the applicable Party.</font></div><div style="margin-top:9pt;padding-left:72pt;padding-right:72pt;text-indent:-27.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:13.25pt">Language&#59; Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">1.20.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%;padding-left:7.35pt;text-decoration:underline">English</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">. All meetings between the Parties shall be conducted in English. All documents exchanged by the Parties hereunder, including all reports, and all agendas and minutes of any Committee meetings, shall be written in English.</font></div><div style="margin-top:8.9pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.20.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.35pt;text-decoration:underline">Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In the event that a Party produces a document in a language other than English, such Party shall, upon written request of the other Party, provide a non-certified translation of such document to such Party within ten (10) Business Days. In the event that a Party wishes to receive a certified translation of any document provided by the other Party hereunder, such requesting Party shall retain a certified translator and the costs of such translation shall be borne by the Party requesting such certified transaction.</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.710%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</font></div></td></tr></table></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_16"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:122%">, the Parties have caused this Agreement to be executed by their representatives thereunto duly authorized as of the Effective Date.</font></div><div style="margin-top:0.5pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:11.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.420%"><tr><td style="width:1.0%"></td><td style="width:46.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:9.15pt">Sanofi Pasteur Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:9.15pt">Novavax, Inc.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.65pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58; &#91;***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#93;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.65pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John C. Jacobs&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.7pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name&#58; &#91;***&#93;</font></div><div style="margin-top:8.3pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Title&#58; &#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.7pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name&#58; John C. Jacobs</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div></td></tr></table></div><div style="height:133.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.300%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Collaboration and License Agreement&#93;</font></div></td></tr></table></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_19"></div><hr style="page-break-after:always"><div style="min-height:159.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">1.13</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjuvant Intermediate Technology</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.13 setting forth the Adjuvant Intermediate Technology has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:159.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 1.35</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">APAs</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.35 setting forth the APAs (as of the Effective Date) has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:159.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 1.106</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-indent:23.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Partner Exclusive Territory</font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.106 setting forth Existing Partner Exclusive Territory has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_22"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:6pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:4.95pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="height:120.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">1.107</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Partner Non-Exclusive Territory</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.107 setting forth the Existing Partner Non-Exclusive Territory has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:120.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_25"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">1.109</a></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Strategic Partner Agreements</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.109 setting forth the Existing Strategic Partner Agreements has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_28"></div><hr style="page-break-after:always"><div style="min-height:159.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 1.111</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Supply Agreements</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.111 setting forth the Existing Supply Agreements has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_31"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:17.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">1.193</a> Novavax Domain Names</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.193 setting forth the Novavax Domain Names has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_34"></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:34.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:122%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:122%;text-decoration:none">1.194</a> Novavax General Combo Patents</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:34.7pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:-1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.194 setting forth the Novavax General Combo Patents has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:34.7pt"><font><br></font></div><div style="margin-top:8.4pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_37"></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.15pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:6.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 1.206</font></div><div style="margin-top:6.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Novavax Trademarks</font></div><div style="margin-top:6.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.206 setting forth the Novavax Trademarks has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_40"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">1.270</a> Settlement Arrangements</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:19.3pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 1.270 setting forth the Settlement Agreements has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:19.3pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_43"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">3.2</a></font></div><div style="margin-bottom:0.2pt;margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Plan</font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 3.2 setting forth the COVID-19 Research and Development Plan has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">3.2.2</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Research and Development Budget</font></div><div style="margin-top:2.75pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:2.75pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 3.2.2 setting forth the COVID-19 Research and Development Budget has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:2.75pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:23.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">4.1</a> Regulatory Transfer Plan </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:0.55pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 4.1 setting forth the Existing Regulatory Transfer Plan has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">5.2.1</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Manufacturing Technology Transfer Plan</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 5.2.1 setting forth the COVID-19 Manufacturing Technology Transfer Plan has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 6.3.1 (COVID-19 Supply Agreement Key Terms)</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">and</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 6.3.2 (Adjuvant Supply Agreement Key Terms)</font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedules 6.3.1 and 6.3.2 setting forth the COVID-19 Supply Agreement Key Terms and Adjuvant Supply Agreement Key Terms have not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">7.2</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Licensed COVID-19 Mono Product Commercialization Framework</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 7.2 setting forth the Licensed COVID-19 Mono Product Commercialization Framework has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">8.2</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 Product Medical Framework</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(as of the Effective Date)</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 8.2 setting forth the COVID-19 Product Medical Framework has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:10.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">9.2.2</a> JSC Responsibilities</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:10.9pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.2.2 setting forth the JSC Responsibilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:14.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">9.3.2</a> JRDC Responsibilities</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.3.2 setting forth the JRDC Responsibilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_46"></div><hr style="page-break-after:always"><div style="min-height:159.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 9.4.2</font></div><div style="margin-top:0.25pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">JMSC Responsibilities</font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.4.2 setting forth the JMSC Responsibilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_49"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:11.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">9.7.2</a> JFC Responsibilities</font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.7.2 setting forth the JFC Responsibilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:8.25pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:11.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:122%;text-decoration:none">9.8.2</a> JPC Responsibilities</font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.8.2 setting forth the JPC Responsibilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule <a href="#ic65efe10465541f1844e49bde32dfd4c_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:none">9.18.5(d)(ii)</a></font></div><div style="margin-top:0.35pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Baseball Arbitration Dispute Resolution</font></div><div style="margin-top:0.85pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 9.18.5(d)(ii) setting forth the Baseball Arbitration Dispute Resolution has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_52"></div><hr style="page-break-after:always"><div style="min-height:113.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.35pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:5.7pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule 14.2.1</font></div><div style="margin-top:5.7pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Existing Novavax Patents</font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule 14.2.1 setting forth the Existing Novavax Patents has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:86.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic65efe10465541f1844e49bde32dfd4c_55"></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.05pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:19.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:117%">Exhibit A Initial Press Releases</font></div><div style="margin-top:0.3pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit A setting forth the Initial Press Releases has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:7.9pt;padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit B Data Safeguards</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:1.35pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit B setting forth the Data Safeguards has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="height:128.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>nvax-20240630xexhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4c8e6d58addd4f59a9ea506e14c72bb7_1"></div><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 10.5</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:9.05pt;padding-left:17.75pt;padding-right:17.75pt;text-align:center;text-indent:-0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="margin-top:9.05pt;padding-left:17.75pt;padding-right:17.75pt;text-align:center;text-indent:-0.25pt"><font><br></font></div><div style="margin-top:3.3pt;padding-left:157.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSULTING AGREEMENT</font></div><div style="margin-top:6.15pt;padding-left:5pt;padding-right:34.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">THIS CONSULTING AGREEMENT (this &#8220;Agreement&#8221;) is entered into as of May 29, 2024 by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Novavax, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(&#8220;Novavax&#8221;), a corporation having its principal office at 700 Quince Orchard Road, Gaithersburg, MD 20878 (&#8220;Novavax&#8221; or the &#8220;Company&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Filip Dubovsky </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(&#8220;Executive&#8221;).</font></div><div style="margin-top:11.75pt;padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">WHEREAS, Executive has resigned and intends to retire from his employment with the Company as its President, Research &#38; Development effective as of June 30, 2024 (the &#8220;Effective Date&#8221;)&#59;</font></div><div style="margin-top:12.1pt;padding-left:5pt;padding-right:34.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">WHEREAS, Executive has agreed to provide consulting services and act as advisor to the Company following his retirement and beginning on the Effective Date&#59; and</font></div><div style="margin-top:12.15pt;padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">WHEREAS, the Company and Executive desire to enter into this Agreement setting forth the terms of Executive&#8217;s consulting and advisory relationship with the company and certain other matters relating to the transition to a consultant.</font></div><div style="margin-top:12.1pt;padding-left:5pt;padding-right:35.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">NOW THEREFORE, in consideration of the premises and the mutual covenant and agreements herein contained, the parties hereto agree as follows&#58;</font></div><div style="margin-top:6.3pt;padding-left:5pt;padding-right:34.4pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">1.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:22.05pt">Consulting Services. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive agrees to serve as a senior advisor for matters relating to research and development and to provide related services as a consultant to the Company's Chief Executive Officer (&#8220;CEO&#8221;) and such other individuals, if any, as determined by Company's CEO from time to time, as well as to provide certain other consulting and advisory services relating to the Company's business as reasonably requested by the CEO from time to time (collectively, the &#34;Services&#34;). Executive agrees to devote between 40-50 hours&#47;month or an amount of time that is reasonably required to perform the Services. Nothing in this agreement will be construed to prevent or preclude Executive from working part-time or full-time for any other third party, provided Executive does not violate the terms of Section 5, herein below. The term of this Agreement will commence on the Effective Date and end on June 30, 2025, unless earlier terminated as provided herein (the &#34;Consulting Period&#34;). The Consulting Period may be extended by mutual written agreement of the parties.</font></div><div style="margin-top:3.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">2.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:22.05pt">Independent Contractor</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. Executive's relationship with the Company will be that of an independent contractor and not that of an employee. The CEO and Executive will jointly determine the method, details, and means of performing the Services. Executive will have no authority to enter into contracts that bind the Company or create obligations on the part of the Company without the prior written authorization of the Company. Executive acknowledges and agrees that he will not be eligible for any benefits available to employees of the Company other than as described in this Agreement. Services to be performed by Executive will be as agreed between Executive and the CEO, and Executive will be required to report only to the CEO or</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4c8e6d58addd4f59a9ea506e14c72bb7_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-right:34.75pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">such other individuals, if any, as determined by the CEO from time to time, concerning the Services performed under this Agreement. The nature and frequency of these reports will be left to the discretion of the CEO. Executive will have full responsibility for applicable withholding taxes for all compensation paid to Executive under this Agreement and will have full responsibility for compliance with all applicable labor and employment requirements with respect to Executive's self-employment. Executive agrees to indemnify, defend, and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements, including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Executive in his capacity as a non-employee of the Company.</font></div><div style="margin-top:3.2pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Compensation and Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:5.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Consulting Fee. </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">As compensation for the Services provided hereunder, during the Consulting Period, the Company will pay to Executive a consulting fee (the &#34;Consulting Fee&#34;) of $15,000.00 per month. The Consulting Fee will be paid to Executive on the first business day of each month during the Consulting Period, in arrears, and will be pro-rated for partial service.</font></div><div style="margin-top:2.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Regarding stock options previously granted (and not yet exercised) to Executive by the Company as of the Effective Date (the &#34;Stock Options&#34;) and all outstanding and unvested restricted stock unit awards previously granted to Executive by the Company as of the Effective Date (the &#34;RSUs&#34;, and together with the Stock Options the &#34;Equity Awards&#34;), the Equity Awards will remain outstanding and each of the Equity Awards that is unvested as of the Effective Date will continue to vest for so long as Executive continues to provide the Services during the Consulting Period, in each case, in accordance with the terms of the applicable equity plan and the equity award agreement between Executive and the Company and subject to the provisions of this Agreement. Executive's &#34;Service&#34; (as defined in the applicable equity award agreements) solely for purposes of the Equity Awards shall be deemed to terminate, upon the end of the Consulting Period or if either Executive or the Company exercise their rights, as set forth below, to terminate this Agreement before the end of the Consulting Period, Executive's &#34;Service&#34; shall be deemed to terminate on the date on which this Agreement terminates. With respect to any Stock Options that remain outstanding and unexercised as of the date on which this Agreement terminates, such Stock Options shall remain exercisable by Executive for a period of ninety (90) days thereafter.</font></div><div style="margin-top:3.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:35pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Reimbursable Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of the Services in</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5pt;padding-right:24.2pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">accordance with the applicable policies and procedures of the Company as in effect from time to time.</font></div><div style="margin-top:2.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.45pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. If Executive timely elects continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8217;), the Company shall pay Executive&#8217;s COBRA premiums to continue Executive&#8217;s coverage (including coverage for Executive&#8217;s eligible dependents, if applicable) (&#8220;COBRA Premiums&#8221;) for a period of up to 11 months beginning on July 1, 2024 or, if the Agreement is terminated before June 30, 2025, up to the termination of this Agreement (the &#8220;COBRA Premium Period&#8221;)&#59; provided, however, that the Company&#8217;s payment of such COBRA Premium benefits will immediately cease if, during the COBRA Premium Period Executive becomes eligible for health insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason. In the event Executive becomes covered under another employer&#8217;s health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event.</font></div><div style="margin-top:3.2pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Termination.</font></div><div style="margin-top:4.8pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(a)</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%;padding-left:17.75pt">The Company may terminate this Agreement immediately for Cause (as defined below) by providing written notice of such termination to Executive. This Agreement may be terminated by either party at any time without Cause (as defined below) by giving the other party thirty (30) days&#8217; advance written notice of such termination. In the event of a termination of this Agreement, the Company's only obligation will be to pay Executive any earned but unpaid Consulting Fee as of the termination date.</font></div><div style="margin-top:2.8pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(b)</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%;padding-left:17.07pt">For purposes of this Agreement, &#34;Cause&#34; shall be defined as (i) Executive&#8217;s willful refusal or failure to perform his material obligations hereunder that is not cured within fifteen (15) days of Executive&#8217;s receipt of written notice from the Company containing reasonable specificity of such refusal or failure and a statement of corrective action, or</font></div><div style="margin-top:0.15pt;padding-left:5pt;padding-right:35pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(ii) Executive&#8217;s unauthorized use or disclosure of confidential information (as defined in Section 5 of this Agreement).</font></div><div style="margin-top:13.65pt;padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%;padding-left:17.75pt">Upon termination of this Agreement for any reason, Executive shall promptly deliver to Novavax all Confidential Information and all copies thereof and immediately cease all use of Confidential Information. In addition, Executive shall promptly return any and all Novavax equipment used in the course of Executive&#8217;s performance of the Services. </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Written notice under this Section may be provided by (i) email if acknowledged in writing by the receiving party&#59; or (b) by delivery via first-class mail to the address listed for each party in the signature line at the end of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.75pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Restrictive Covenants and Other Obligations.</font></div><div style="margin-top:5.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(a)</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Continuing Obligations. </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive acknowledges and agrees that he remains bound by certain obligations under the Employment Agreement between the Company and Executive dated May 26, 2020, as amended (the &#34;Employment Agreement&#34;), which survive the termination of his employment by the terms thereof, which including without limitation his obligations under Sections 9-12 of the Employment Agreement (such obligations, together with any other covenant or obligations with respect to confidentiality, assignment of intellectual property, non-solicitation or noncompetition, the &#34;Continuing Obligations&#34;). The Company agrees to limit the extent of the Executives Non-Competition obligations to cover businesses and entities that compete directly with the Company.</font></div><div style="margin-top:3.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.45pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(b)</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Confidentiality</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive hereby reaffirms and agrees to comply with the policies and procedures of the Company and its affiliates for protecting confidential information (as described in Section 10 of the Employment Agreement) and will never disclose to any person (except as required by applicable law or for the proper performance of his duties and responsibilities to the Company and its affiliates), or use for his own benefit or gain, any confidential information obtained by Executive incident to his employment or other association with the Company or any of its affiliates. Executive understands that this restriction will continue to apply after the termination of this Agreement, regardless of the reason for such termination. For the avoidance of doubt, (i) nothing contained in this Agreement limits, restricts or in any other way affects </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">the Executive&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and (ii) Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret</font></div><div style="margin-top:0.5pt;padding-left:5pt;padding-right:35.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(y) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(z) in a complaint or other document filed under seal in a lawsuit or other proceeding&#59; provided, however, that notwithstanding this immunity from liability, Executive may be held liable if he unlawfully accesses trade secrets by unauthorized mean</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">s.</font></div><div style="margin-top:2.9pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Non-Compete and Non-Solicit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Without limiting the generality of subsection (a) above, nothing in this Agreement modifies or changes Executive&#8217;s obligations under Sections 11 or 12 of the Employment Agreement and Executive acknowledges and agrees that he continues to be bound by each of his undertakings under Sections 11 and 12 of the Employment Agreement.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6.75pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Remedies&#59; Enforceability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">If Executive commits a breach, or threatens to commit a breach, of any of the provisions of this Section 5, the Company shall have the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages may not provide an adequate </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">remedy to the Company. Executive therefore agrees that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Executive of any of the provisions of this Section 5, without having to post bond. If any of the covenants contained in this Section 5, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section 5, or any part thereof, is held to be unenforceable because of the duration or scope of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and&#47;or area of such provision and, in its reduced form, such provision shall then be enforceable. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other states within the geographical scope of such other covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-top:3.65pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(e)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Securities Trading&#59; Conflicts of Interest. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive further agrees that he will not buy, sell, or otherwise trade any securities of Novavax based on any material confidential information (as described in Section 10 of the Employment Agreement) learned as a consultant of Novavax, or tip others to do so. If Executive is ever unsure about Executive&#8217;s compliance with this Section 5(e), Executive shall contact the Company&#8217;s Executive Vice President, Chief Legal Officer, and Corporate Secretary. Executive further agrees that during the term of this Agreement he will continue to comply with all Company policies and processes related to insider trading and stock clearance and with the Company's Conflicts of interest and Outside Activities Policy.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:19.08pt">Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. All work produced hereunder, including, without limitation, all inventions, ideas, creations, designs, discoveries, developments, techniques, expressions, improvements, computer programs, specifications, operating instructions and all other documentation, data or other work product related to the Services provided by Executive under this Agreement (whether patentable or subject to copyright, or not), which are first</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5pt;padding-right:34.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">conceived, made or otherwise originated or acquired or first actually constructively reduced to practice during the term of this Agreement or within six (6) months following the expiration or termination of the Agreement, whether preliminary or final, and on whatever media rendered (collectively, the &#8220;Work Product&#8221;), shall be deemed work made for hire and made in the course of services rendered for Novavax and shall be the sole and exclusive property of Novavax. Novavax shall have the sole, absolute and unlimited right to protect by patent or copyright, and to make, have made, use, and sell the Work Product as it sees fit. To the extent that title to the Work Product may not be considered work for hire, Executive irrevocably agrees to transfer and assign to Novavax in perpetuity all worldwide right, title and interest in and to the patent rights, copyrights, trade secrets and other proprietary rights (including, without limitation, applications for registrations thereof) in, and ownership of, the Work Product that Executive may have, as and when such rights arise.</font></div><div style="margin-top:3.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">4.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:22.05pt">Section 409A of the Code. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">This Agreement is intended to comply with, or be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the &#34;Code&#34;), and shall be construed consistent with such intent. Notwithstanding the foregoing, in no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code. Executive's right to payment or reimbursement for expenses under this Agreement will be subject to the following additional rules&#58; (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made promptly, and in all events not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-top:3.25pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Miscellaneous.</font></div><div style="margin-top:2.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">No Severance. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Executive acknowledges and agrees that he is not eligible for any severance benefits in connection with or following his retirement, including, but not limited to, under the Company's Amended and Restated Change in Control Severance Benefit Plan. In addition, Executive acknowledges that he is not eligible to receive the second Retention Bonus Installment, as that term is defined in the Retention Bonus Agreement with an effective date of March 7, 2023.</font></div><div style="margin-top:3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Entire Agreement. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">This Agreement constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings with respect to the subject matter hereof&#59; it being understood that the Continuing Obligations and the plans and agreements</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5pt;padding-right:17.35pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">governing the Equity Awards will remain outstanding and will survive in accordance with their terms.</font></div><div style="margin-top:13.75pt;padding-left:5pt;padding-right:34.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(c)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Amendments and Waivers. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Any term of this Agreement may be amended or waived only with the written consent of the parties.</font></div><div style="margin-top:13.75pt;padding-left:5pt;padding-right:34.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(d)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Choice of Law. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">The validity, interpretation, construction, and performance of this Agreement will be governed by the laws of the State of Maryland, without giving effect to the principles of conflict of laws.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:34.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(e)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.75pt">Severability. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">If one or more provisions of this Agreement are held to be unenforceable under applicable law, such portion will be deemed to be modified or altered to the extent necessary to conform thereto or, if that is not possible, to be omitted from this Agreement. The invalidity of any such portion will not affect the force, effect, and validity of the remaining portion hereof.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:19.08pt">Counterparts. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(g)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">Successors. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">This Agreement is personal to Executive and, without the prior written consent of the Company, will not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement will inure to the benefit of and be enforceable by Executive's legal representatives. This Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, &#34;the Company&#34; will mean both the Company as defined above and any such successor assign to or of the Company. The Company shall require that any successor or assign agree to perform this Agreement in the same manner as the Company.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(h)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:17.07pt">No Publicity. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Neither the Company nor Executive shall directly or indirectly cause or permit any use of the other party's name or trademarks, without the other party's prior written consent, save and except as such disclosure is required by law or any securities exchange or governmental body to which either party is subject or submits, wherever situated, including (without limitation) the Securities and Exchange Commission, The NASDAQ OMX Group, or the Food and Drug Administration whether or not the requirement has the force of law.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:34.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">(i)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:19.74pt">Sunshine Act. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">Each of the Company and Executive acknowledge that certain state or federal laws now or in the future may require Novavax to disclose information regarding compensation, funding, gifts, payments, or other remuneration (&#34;Remuneration&#34;)</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5pt;padding-right:35pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">provided to physicians and other members of the health care community. Novavax may report information about Remuneration provided under this Agreement as required by applicable law. Once reported, such information will be publicly accessible.</font></div><div style="margin-top:2.85pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:22.05pt">Indemnification by Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">. The Company will indemnify, defend and hold Executive harmless from and against any and all third party claims, liability, suits, losses, damages and judgments and shall pay all reasonable costs and expenses as they are incurred in connection with the investigation of, preparation for or defense of any pending or threatened claim or any action or proceeding arising there from, that Consultant incurs as a result of having performed services on behalf of the Company. If any action or claim shall be brought or asserted against Executive, Executive shall promptly notify the Company in writing and the Company shall assume the defense of such action or claim. The Company&#8217;s obligation in this Section 8 shall survive termination of this Agreement, provided that the Executive&#8217;s acts that gave rise to such action or claim occurred during the term of the Agreement. Notwithstanding anything herein to the contrary, the Company will not be responsible for any indemnification caused by the gross negligence or willful misconduct of Executive.</font></div><div style="margin-top:3.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">4.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:137%;padding-left:22.05pt">Advice of Counsel. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">EACH PARTY ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:24.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:137%">IN WITNESS WHEREOF, the parties have caused this Consulting Agreement to be executed the day and year first above written.</font></div><div style="padding-left:5pt;padding-right:24.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:24.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"><tr><td style="width:1.0%"></td><td style="width:46.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.05pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOVAVAX, INC.</font></div></td></tr><tr style="height:84pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><img alt="image_0b.jpg" src="image_0b.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:227px"></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Ian Watkins</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; EVP, Chief Human Resources Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May 29, 2024</font></td></tr></table></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.688%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Novavax, Inc.</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consulting Agreement</font></div></td></tr></table></div></div><div style="padding-right:24.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"><tr><td style="width:1.0%"></td><td style="width:46.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.05pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FILIP DUBOVSKY </font></div></td></tr><tr style="height:84pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><img alt="image_1b.jpg" src="image_1b.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:227px"></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Filip Dubovsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mailing Address&#58; &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May 29, 2024</font></td></tr></table></div><div style="margin-top:2.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:185.05pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:185.05pt;padding-right:87.7pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:185.05pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.803%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>nvax-20240630xexhibit106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i999f133ef806447f9d3d27610e150438_1"></div><div style="min-height:133.2pt;width:100%"><div style="padding-right:24pt"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.6</font></div><div><font><br></font></div><div style="padding-left:3pt;padding-right:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">SUPPLY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">BETWEEN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">NOVAVAX INC</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">AND</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">SERUM LIFE SCIENCES LIMITED</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;) is made effective as of May 6, 2024 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;) by and between Novavax, Inc., a Delaware USA corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Novavax</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates, successors and permitted assigns), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Serum Life Sciences Limited</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, a company duly incorporated having its registered office situated in England and Wales, formerly known as Covicure Holdings Limited having its principal office at 15 Grosvenor Street, London, United Kingdom W1K 4QZ (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">SLS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221;). Novavax and SLS may each be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, SLS is in the business of supplying vaccines and other bio-pharmaceuticals (including vaccines and other bio-pharmaceuticals Manufactured (as defined below) through SLS&#8217;s authorized manufacturers)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">AND WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, Novavax has developed and is the exclusive owner of one or more Novavax antigens developed for use as a human vaccine against the COVID-19 coronavirus&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">AND WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, SLS wishes to supply to Novavax, and Novavax wishes to purchase from SLS, Product (as defined below), on the terms set forth in this Supply Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">AND</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, the Parties wish to record in writing the agreed technical and commercial terms for such supply by SLS of Product Manufactured by SLS or its Authorized Manufacturer (as defined below) to Novavax, as set forth in this Supply Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">AND WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, the Parties agree and accept that the Recitals stated above shall form an integral and enforceable part of the Supply Agreement, just like any other provision contained hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">NOW THEREFORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, the Parties covenant to each other as under  &#8211;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Definitions</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Adjuvant&#8221; means Matrix-M&#8482; (for clarity, combination of Matrix A and Matrix C).</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Affiliate&#8221; means (i) with respect to Novavax, any Person that controls, is controlled by, or is under common control with another Novavax, and (ii) with respect to SLS, any Person directly or indirectly controlled by the Cyrus Poonawalla Group (each a &#34;Cyrus Poonawalla Group Company&#34; or &#34;CPGC&#34;). &#34;Cyrus Poonawalla Group Company&#34; or &#34;CPGC&#34; means any entity controlled directly or indirectly by Dr. Cyrus Poonawalla, Mr. Adar Cyrus Poonawalla and their family members. For purposes of the preceding definition, &#34;control&#34; (including, with correlative meanings, the terms &#34;controlled by&#34; and &#34;under common control with &#34;) shall mean the possession, directly or indirectly, of more </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">than 50% of the outstanding voting securities of or comparable equity interest in any other type of a Person, or otherwise having the legal power to direct the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Applicable Law&#8221; means collectively all laws, rules, regulations, ordinances, decrees, judicial and administrative orders (and any license, franchise, permit, or similar right granted under any of the foregoing), and any policies and other requirements of any applicable Governmental Authority that govern or otherwise apply to a Party.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Background Intellectual Property&#8221; means any Intellectual Property Rights or Know-How (a) existing and Controlled by such Party as on the Effective Date or (b) was developed or obtained by or on behalf of such Party independent of this Supply Agreement, and without reliance upon the Confidential Information of the other Party.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Batch&#8221; means a specific quantity of Drug Substance or Drug Product that is intended to have uniform character and quality and that is produced in accordance with the Product Requirements applicable to such Drug Substance or Drug Product during the same cycle of Manufacturing.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Business Day&#8221; means any day other than a Saturday or Sunday, or bank or other public holiday in either Washington D.C., U.S.A, or London, UK or Pune, India </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;cGMPs&#8221; means current Good Manufacturing Practices regulations and standards enforced by the U.S. Food and Drug Administration, European Medicines Agency, Medicines &#38; Healthcare products Regulatory Agency (MHRA) in the United Kingdom or other applicable regulatory bod(ies) in other jurisdictions and which apply to the Manufacturing of the Product under this Supply Agreement. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Certificate of Analysis&#8221; or &#8220;CoA&#8221; means, with respect to a Batch, a certificate in the applicable format for the applicable Product manufactured under cGMP, from time to time during the term of Supply Agreement, issued by SLS, either itself, or through its Authorized Manufacturer, and executed by SLS&#8217;s (or, as applicable, its Authorized Manufacturer&#8217;s) responsible person certifying that a Batch meets the Product Requirements and such other criteria as identified in the Certificate of Analysis. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">&#8220;Certificate of Conformance&#8221; or &#8220;CoC&#8221; means, with respect to a Batch, a certificate in the applicable format for the applicable Product from time to time during the Term of the Supply Agreement, issued by SLS, either itself or through its Authorized Manufacturer&#8217;s, quality department and executed by SLS&#8217;s (or, as applicable, its Authorized Manufacturer&#8217;s) responsible person (a) listing the date of manufacture, unique Batch number, and quantity of Product in such Batch, (b) certifying that such Batch was Manufactured in compliance with the applicable Product Requirements, and </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(c) certifying that all investigative and corrective action reports are completed and approved.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Commercialize&#8221;, &#8220;Commercializing&#8221; or &#8220;Commercialization&#8221; or &#8220;Commercialized&#8221; for the purpose of this Supply Agreement, means any and all activities undertaken by Novavax in and limited to Novavax Exclusive Territory or Non-Exclusive Territory which are directed to the marketing, promotion, distribution, pricing, reimbursement, offering for sale, and sale of the Product and interacting with Governmental Authority in the applicable country or region for the Product, but excluding activities directed to Manufacturing, Medical Affairs, or Development.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Commercially Reasonable Efforts&#8221; means, &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Control&#8221; or Controlled&#8221; means the possession by a Party (whether by ownership, license, or otherwise other than pursuant to this Supply Agreement) of, (a) with respect to any tangible Know-How, the legal authority or right to physical possession of such tangible Know-How, with the right to provide such tangible Know-How to the other Party on the terms set forth herein, (b) with respect to Patent Rights, Regulatory Approvals, regulatory submissions, intangible Know&#173; How, or other intellectual property rights, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Approvals, regulatory submissions, intangible Know-How, or other intellectual property rights on the terms set forth herein, in each case ((a) and (b)), without (i) breaching or otherwise violating the terms of any arrangement or agreement with a third party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use, licenses, or sublicense, or (ii) incurring any additional payment obligations to a third party as a result of such access, right to use, license, or sublicense, and (c) with respect to any product or materials, the legal authority or right to grant a license or sublicense under Patent Rights that cover such product or materials or Know-How that relates to such product or materials on the terms set forth herein.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Develop&#8221;, &#8220;Developing&#8221; or &#8220;Development&#8221; means all internal and external research, development, and regulatory activities related to pharmaceutical, biologic, or vaccine products, including (a) research, non-clinical testing, toxicology, testing and studies, non-clinical and preclinical activities, and clinical trials, and (b) preparation, submission, review, and development of data or information for the purpose of submission to a regulatory authority to obtain authorization to conduct clinical trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical, biologic, or vaccine product, but excluding activities directed to Manufacturing, Medical Affairs, or Commercialization. Development will include development and regulatory activities for additional forms, formulations, or indications for a pharmaceutical, biologic, or vaccine product after receipt of Regulatory Approval of such product (including label expansion), including clinical trials initiated following receipt of Regulatory Approval or </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">any clinical trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable regulatory authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing studies, observational studies, pediatric studies, implementation and management of registries and analysis thereof, in each case, if required by any regulatory authority in any region worldwide to support or maintain Regulatory Approval for a pharmaceutical, biologic, or vaccine product in such region).&#34;Develop,&#34; &#34;Developing,&#34; and &#34;Developed&#34; will be construed accordingly.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Drug Product&#8221; means any coronavirus vaccine product derived from Novavax&#8217;s Intellectual Property Rights and Know-How and comprised of Adjuvant and one or more strain specific Drug Substance(s) and that is to be Manufactured and supplied to Novavax as contemplated under this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Drug Substance&#8221; means any active drug ingredient in human vaccine against COVID-19 coronavirus that contains one or more proprietary Novavax COVID antigens, including any prototypes, mutants and variants thereof, and that is to be Manufactured as contemplated under this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;End Customer&#8221; means, as applicable, a US End Customer or an Ex-US End Customer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Ex-US End Customer&#8221; means an end customer to whom Drug Product or, as applicable, Novavax Drug Product is distributed in any country in the Novavax Territory other than the United States, such as a pharmacy, group purchasing organization, clinic or hospital.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Facility&#8221; means any facility set forth in which Product is Manufactured, either by SLS or through its Authorized Manufacturer, subject to the terms of Exhibit A attached hereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Governmental Authority&#8221; means any legislative, executive, or judicial unit of any governmental authority or instrumentality (international, national, federal, state, provincial, or municipal, in any country or other jurisdiction), or any tribunal, department, agency, board, bureau, commission, official, or other regulatory, administrative, or judicial authority thereof, including any administrative or regulatory agency or commission, and any court, in each instance having legal jurisdiction over the subject matter before it.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Intellectual Property Rights&#8221; means Patent Rights as well as rights in all other intellectual property including trademarks, trade names, service marks, domain names, copyrights, trade secrets, rights in and to databases (including rights to prevent the extraction or reutilisation of information from a database), design rights, topography </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">rights and all rights or forms of protection of a similar nature whether registered or applications for registration thereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.21</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Know-How&#8221; means any proprietary information and materials, including records, discoveries, improvements, modifications, processes, techniques, methods, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data, and analytical and quality control data), dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever, know-how, and trade secrets (in each case, patentable, copyrightable, or otherwise).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Latent Defect&#8221; means &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.23</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means activities which include, without limitation, the formulation, processing, packaging, labeling, filling, finishing, assembly, shipping, storage, or freight of any pharmaceutical, biologic, or vaccine product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including quality assurance and stability testing, characterization testing, quality control release testing of drug substance and drug product, quality assurance batch record review and release of product, process development, qualification, and validation, scale-up, preclinical, clinical, and commercial manufacture and analytic development, and product characterization, but excluding activities directed to Development, Medical Affairs, or Commercialization. &#34;Manufacturing&#34; and &#34;Manufactured&#34; will be construed accordingly.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Manufacturing Defect&#8221; means &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.25</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Manufacturing Process&#8221; means the process, or applicable portion(s) thereof for the Manufacture, analysis, documentation, quality evaluation, storage, and shipping of components, intermediates, and Product. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.26</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Medical Affairs&#8221; means any and all activities conducted by or on behalf of a Party's or any of its Affiliates' medical affairs departments, including communications with key opinion leaders, medical education, symposia, advisory boards (to the extent related to medical affairs or clinical guidance), activities performed in connection with patient registries, and other medical programs and communications, including educational grants, research grants (including conducting investigator initiated studies), and charitable donations to the extent related to medical affairs and not to activities that involve the promotion, marketing, sale, or other Commercialization of the Product and are not conducted by or on behalf of a Party's or any of its Affiliates' medical affairs departments. Medical Affairs excludes any activities directed to Manufacturing, Development, or Commercialization.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Non-Exclusive Territory&#8221; means those countries designated as low or middle income countries (including any sub-designations of low or middle income countries (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, a &#34;high middle income country&#34;) according to the then most recent published Word Bank classification of countries as of May 5, 2023, excluding any such countries with respect to which Novavax reclaims exclusive Commercialization rights at any time during the Term.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Novavax Drug Product&#8221; means any coronavirus vaccine product derived from Novavax&#8217;s Intellectual Property Rights and Know-How and comprised of Adjuvant and one or more strain specific Drug Substance(s), which Drug Substance(s) are Manufactured and supplied to Novavax under this Supply Agreement in Drug Substance form and subsequently incorporated by Novavax or its Affiliates, (sub)licensee or other designee into such vaccine product. For clarity, &#8220;Novavax Drug Product&#8221; excludes Drug Product that is Manufactured and supplied to Novavax under this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Novavax Exclusive Territory&#8221; means the countries of &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Patent Rights&#8221; means all rights, title and interests in and to (a) all national, regional, and international patents and patent applications filed in any country of the world including provisional patent applications and all supplementary protection certificates, (b) all patent applications filed either from such patents, patent applications, or provisional applications or from an application claiming priority from any of these, including any continuation, continuation-in part, divisional, provisional, converted provisional, or continued prosecution application, or any substitute applications, (c) any patent issued with respect to or in the future issued from any such patent applications, including utility models, petty patents and design patents and certificates of invention, and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations, and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Person&#8221; means any individual, corporation, partnership, limited liability company, firm, association, joint venture, joint stock company, trust, unincorporated organization, or other entity, or any Governmental Authority.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.32</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Product&#8221; means, as applicable, (i) Drug Substance for use in the formulation and Manufacture of any coronavirus vaccine product derived from Novavax&#8217;s Intellectual Property Rights and Know-How and comprised of Adjuvant and one or more strain specific Drug Substance(s), or (ii) Drug Product, in each case, (i) or (ii), for use by Novavax or its Affiliate, (sub)licensee, subcontractor or other designee in connection with the Development or Commercialization of coronavirus vaccine products derived from Novavax&#8217;s Intellectual Property Rights and Know-How and </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">comprised of Adjuvant and one or more strain specific Drug Substance(s),  in the Novavax Territory and&#47;or the Non-Exclusive Territory.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.33</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Product Delivery&#8221; has the meaning given in Section 2.4.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.34</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt"> &#8220;Product Requirements&#8221; means the applicable Certificate of Analysis, and Certificate of Conformance, cGMP, any applicable Regulatory Approval, the requirements of all applicable Regulatory Authorities, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">the Quality Agreement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">and the Applicable Law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.35</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Provisional Purchase Order&#8221; has the meaning given in Schedule 2.2.3 (Provisional Purchase Orders&#59; Provisional Batches).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.36</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Purchase Order&#8221; means a Firm Purchase Order or a Provisional Purchase Order, as applicable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.37</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Regulatory Approval&#8221; shall mean (i) with respect to Novavax, all necessary approvals, authorizations, licenses or permissions under the Applicable Law or by the applicable Government &#47; Regulatory &#47; other concerned Authority, towards import into, and sale and commercialization of the Product in, each country in the Novavax Exclusive Territory and&#47;or the Non-Exclusive Territory, and (ii) with respect to SLS and its Authorized Manufacturer, all necessary approvals, authorizations, licenses or permissions under the Applicable Law or by the applicable Government &#47; Regulatory &#47; other concerned Authority towards Manufacture of the Products.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.38</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Regulatory Authority&#8221; means any governmental agency or authority, responsible for granting Regulatory Approvals for the Product in a country within the Novavax Exclusive Territory or the Non-Exclusive Territory, and including, without limitation, the FDA in the United States, the EMA in the European Union and the MHRA in the United Kingdom.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.39</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Seasonal Year&#8221; means each 12-month period running from July 1st of the previous calendar year through June 30th of the current calendar year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.40</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt"> &#8220;Statement of Work&#8221; or &#8220;SOW&#8221; means a mutually agreed upon document setting forth the pricing, INCOTERMS, delivery details and payments and other pertinent information, in order to prepare for, initiate and conduct the activities contemplated under this Supply Agreement, for the Development and Manufacture and supply of the Product.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.41</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;Supply Price&#8221; means the DS Supply Price, the Risk Share Price or the Full Supply Price (as such terms are defined on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto) to be paid by Novavax to SLS for Manufacture and supply </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">of Drug Substance or Drug Product hereunder, as applicable and as set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.42</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">&#8220;US End Customer&#8221; means an end customer to whom Drug Product or, as applicable, Novavax Drug Product is distributed in the United States, such as a pharmacy (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, CVS), superstore (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">, Walmart), group purchasing organization, clinic or hospital.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Delivery, Inspection and Recall for Product to be supplied by SLS to Novavax</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Statement of Work.</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax will provide SLS a Statement of Work in the form and format mutually agreed between the Parties setting out, among other details, the quantity of the Product to be supplied, the destination of delivery of the Product (which will be as set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto, except as the Parties may otherwise agree in writing), the &#91;***&#93; agreed for the delivery (which &#91;***&#93; will be as set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto, except as the Parties may otherwise agree in writing). Such a SOW shall be provided by Novavax at least &#91;***&#93; before issuing a Proposed Purchase Order (as defined hereunder). For the sake of clarity, the SOW is not binding on SLS until the same is executed by the Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Firm Purchase Orders. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Subsequent to SLS accepting the SOW, Novavax will issue a proposed written purchase order to SLS (each a &#8220;Proposed Purchase Order&#8221;) specifying the quantity of Product being ordered &#91;***&#93;, the price per dose &#91;***&#93;,  the requested delivery date (&#8220;Product Delivery Date&#8221;), Novavax Purchase Order number, place of delivery (which place of delivery shall be as set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto, except as the Parties may otherwise agree in writing) (&#8220;Product Delivery Destination&#8221;), and any other information necessary for the &#91;***&#93; delivery of such Product.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Acceptance of Firm Purchase Orders. </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS will review each Proposed Purchase Order and will, no later than &#91;***&#93; after SLS&#8217;s receipt of each such Proposed Purchase Order, notify Novavax in writing of SLS&#8217;s acceptance, rejection or proposed modification of such Proposed Purchase Order&#59; provided that neither SLS nor its Authorized Manufacturer may reject any Proposed Purchase Order that sets forth the same quantities and deliver dates set forth in the applicable SOW, unless Novavax is unable to provide the necessary quantities of Adjuvant required for such volumes (each a &#8220;Firm Purchase Order&#8221;).  </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">No Other Terms. </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">No terms, provisions, or conditions of any Firm Purchase Order that conflict with the terms of this Supply Agreement or terms, provisions or conditions of any other business form or written authorization used by Novavax or SLS will have any effect on the rights, duties, or obligations of the Parties under or otherwise modify this Supply Agreement, any other Proposed Purchase Order or any other Firm Purchase Order, regardless of any failure of Novavax or SLS to object to such terms, provisions, or conditions.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Provisional Purchase Orders&#59; Provisional Batches. The provisions set forth on Schedule 2.2.3 (Provisional Purchase Orders&#59; Provisional Batches) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Subcontracting.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">The Parties agree that SLS can subcontract its obligations under this Supply Agreement provided that the subcontractor has been approved by Novavax in writing, &#91;***&#93;, and appointed in accordance with the Quality Agreement (such approved subcontractor, an &#8220;Authorized Manufacturer&#8221;).</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">&#91;***&#93;. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">&#91;***&#93;.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1.33pt">Product Delivery. </font></div><div style="padding-left:32.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS or its Authorized Manufacturer will deliver Products to &#91;***&#93; (except as the Parties may otherwise agree in writing) and in accordance with the &#91;***&#93; set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto (except as the Parties may otherwise agree) (&#8220;Product Delivery&#8221;). Risks of loss to the Product &#91;***&#93;, and title to the Product &#91;***&#93; (except as the Parties may otherwise agree) in accordance with the &#91;***&#93; set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto (except as the Parties may otherwise agree in writing). SLS will Manufacture or have Manufactured, either itself or through an</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Authorized Manufacturer, and SLS will supply Product specified in an accepted Firm Purchase Order for delivery on the applicable Product Delivery Date, or such other extended delivery date mutually agreed by the Parties in writing. &#91;***&#93;. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Delivery Responsibilities. </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS or its Authorized Manufacturer will notify Novavax when a Batch of the Product is ready to be shipped (&#8220;Shipment Readiness Notification&#8221;). SLS or its Authorized Manufacturer under this Supply Agreement, will be responsible for appropriate packaging, labelling, and issuance of carrier&#8217;s declaration for all Products shipped under this Supply Agreement. SLS and Novavax will ensure that each of their respective employees and the employees of their respective Affiliates and, in the case of Novavax, subcontractors or, in the case of SLS, </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Authorized Manufacturer involved in activities related to shipments (and in the case of Novavax, receipt of shipments) of Product have received &#91;***&#93; training to properly handle such Product. </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Storage. </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax or its designee shall &#91;***&#93; take delivery of Batches of the Product at &#91;***&#93; (or such other location as the Parties may otherwise agree in writing) &#91;***&#93;. If Novavax fails to make arrangements to take delivery of any Products on the applicable Product Delivery Date, &#91;***&#93;. </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Failure to Satisfy Product Delivery Date.  </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If SLS or its Authorized Manufacturer fails to deliver the full quantity of the Product ordered in a Firm Purchase Order on the delivery date set forth in such Purchase Order (&#8220;Supply Failure&#8221;), then SLS shall not be held liable for any Supply Failure to the extent due to &#91;***&#93;.   </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Product Labelling.</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Since the Product shall be Manufactured by SLS&#8217;s Authorized Manufacturer on behalf of SLS and supplied to Novavax by SLS for sale and Commercialisation by Novavax in the Novavax Exclusive Territory and Non-Exclusive Territory, the Parties shall mutually agree &#91;***&#93; on the Product packaging and labelling requirements on a country-to-country basis. Accordingly, the Firm Purchase Order, as may be applicable, shall specify and include all packaging and labeling requirements for the Product to be supplied by SLS, or its Authorized Manufacturer, under such Firm Purchase Order. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Product Inspection&#59; Non-Conforming Batches of the Product&#59; Product Shortfalls. </font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Product Inspection&#59; Acceptance&#47;Rejection&#59; Manufacturing Defects. </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">For a period of &#91;***&#93; following delivery of any Product hereunder (the &#8220;Delivered Product Inspection Period&#8221;), Novavax will have the right to inspect such Product to determine whether such Product conforms to the applicable Product Requirements as per this Supply Agreement and&#47;or the Quality Agreement.</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Notwithstanding the foregoing, if Novavax discovers a Manufacturing Defect following the Delivered Product Inspection Period, then Novavax will have the right to notify SLS in writing of Novavax&#8217;s rejection of such Product as non-conforming within &#91;***&#93; following Novavax&#8217;s discovery of such non-conformance and, in any event, no later than &#91;***&#93; after the date the applicable Product was delivered to Novavax. In case of SLS&#8217;s agreement as to the existence of, or (as applicable) a Laboratory&#8217;s finding (pursuant to Section 2.6.2 below) of, a non-conformance of a particular quantity of Product as per this Supply Agreement and&#47;or the Quality Agreement, SLS will, at Novavax&#8217;s option, (a)&#160;&#91;***&#93; or (b)&#160;&#91;***&#93;. For clarity, any change in the Product specifications or Product requirements by Novavax or any regulatory agencies after Product manufactured as per Novavax given specifications or requirements by SLS or SLS authorized manufacrurer will not be considered under Manufacturing defect or Non-conforming batches.</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Product Non-Conformance Disputes. </font></div><div style="padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In the event of a disagreement between the Parties concerning whether or not a Batch meets the applicable Product Requirements, Novavax and SLS will appoint &#91;***&#93; to undertake analysis of the Batch to determine whether or not it meets the applicable Product Requirements. Each Party will &#91;***&#93; cooperate with and provide &#91;***&#93; information, documentation, and materials &#91;***&#93; relevant to the disagreement to the &#91;***&#93;. &#91;***&#93;. All costs and expenses incurred by the &#91;***&#93; (Non-Conformance Disputes) shall be borne by &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Product Shortfalls.</font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">During the Delivered Product Inspection Period, Novavax will have the right to inspect the applicable delivered Product to determine whether the quantity of such delivered Product conforms to the quantity of Product as per the Purchase Order, and to notify SLS in writing of any Product shortfall based upon such determination. In the event of any such shortfall, SLS will, at Novavax&#8217;s option, (a)&#160;deliver to Novavax, &#91;***&#93;, the short quantity of Product in conformance with the Product Requirements (which quantity of Product, for clarity, may include conforming Product from Provisional Batch(es) at Novavax&#8217;s instruction, subject to the applicable provisions of this Supply Agreement) by a date mutually agreed by the Parties or (b) &#91;***&#93;.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Latent Defects, Pharmacovigilance, Adverse Events and Recalls.  </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">All Parties confirm that since &#8211;</font></div><div style="padding-left:68.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:25.36pt">SLS or its Authorized Manufacturer(s) are performing this Supply Agreement solely for Novavax&#59; </font></div><div style="padding-left:68.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:22.7pt">Novavax owns and controls Adjuvant and shall supply Adjuvant to SLS&#8217;s Authorized Manufacturer as set forth in this Supply Agreement, subject to the applicable terms and conditions hereof&#59; and </font></div><div style="padding-left:68.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:20.04pt">Novavax shall have the right to inspect and determine whether each Batch conforms to the applicable Product Requirements</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">hence, Novavax will have &#91;***&#93;, over handling any and all claims related to (a) any Latent Defects in the Products, (b) all pharmacovigilance activities, (b) any adverse events notifications and complaints, and (c) whether and under what circumstances to require a Recall of the Product in a country in the Novavax Exclusive Territory and Non-Exclusive Territory. &#91;***&#93;.   </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Conditions for Manufacture, Supply and Delivery of Product by SLS.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.8.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">SLS shall commence Manufacturing operations, either itself or through its Authorized Manufacturer, and shall supply and deliver the Product only after it or its Authorized Manufacturer receives all Regulatory Approvals and &#91;***&#93; approvals, authorizations, permissions, licenses or any other requirements, </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">conditions or approvals of the Regulatory Authority &#47; Government Authority in &#91;***&#93;.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.8.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Novavax confirms that the Manufacture, supply and Product Delivery obligations of SLS in relation to the Product under each and every Firm Purchase Order are entirely subject to receipt by SLS or its Authorized Manufacturer of all Regulatory Approvals and any &#91;***&#93; authorisations from the Regulatory Authority &#47; Government Authority, including any export permissions and &#47; or any other requirements, conditions or approvals in &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">Notwithstanding anything to the contrary in this Supply Agreement or any SOW, if, for any reason other than Novavax&#8217;s failure to supply the Adjuvant required to Manufacture Drug Product or a defect in the Adjuvant supplied by Novavax hereunder, SLS is unable to deliver at least &#91;***&#93; of the quantity of Product ordered under a given Purchase Order within &#91;***&#93; after the applicable required delivery date under such Purchase Order (&#8220;Late Delivery&#8221;), then, as a non-exclusive remedy for such Late Delivery, Novavax shall have the right, at its sole discretion, to cancel such Purchase Order and Novavax shall not be required to pay any amount in connection with (including any payment for the Product affected by) such Late Delivery.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Adjuvant Supplied by Novavax. The provisions set forth on Schedule 2.9 (Adjuvant Supplied by Novavax) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Inventory of Drug Substance&#59; Drug Substance Safety Stock. The provisions set forth on Schedule 2.10 (Inventory of Drug Substance&#59; Drug Substance Safety Stock) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Regulatory matters for the Supply Agreement</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Regulatory Approvals. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Specific and restricted to the context of this Supply Agreement, SLS, either itself or through its Authorized Manufacturer, will be &#91;***&#93; for obtaining and maintaining any permits or other Regulatory Approvals required under Applicable Law to Manufacture or have Manufactured the Product. &#91;***&#93;. All such documents shall be available in English. If Novavax requires such documentation to be translated into a non-English language, then SLS will (or will cause its Authorized Manufacturer to) provide a certified translation in the language requested by Novavax &#91;***&#93;.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Documentation for Product Master File. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;, Novavax will maintain and keep updated drug master files for the Product. SLS shall (or shall cause its Authorized Manufacturer to) provide all &#91;***&#93; documentation and information to Novavax &#91;***&#93;. At Novavax &#91;***&#93; request, SLS will (or will cause its Authorized Manufacturer to) provide other reasonable assistance and take other &#91;***&#93; </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">action as may be requested by Novavax or any Regulatory Authorities to maintain and give Novavax the benefit of such master files or to otherwise assist with regulatory filings related to the Product. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Records and Accounting by SLS. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS will keep and shall ensure that its Authorized Manufacturer keeps records of the Manufacture (including production data), testing, and shipping of each Batch and retain samples of all Batches in accordance with the applicable quality agreement executed by all Parties and any Authorized Manufacturer of SLS for the Product being supplied under this Supply Agreement (the &#8220;Quality Agreement&#8221;).</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Audits and Regulatory Inspections. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Audits and regulatory inspection of SLS&#8217;s manufacturing facility &#47; those of any Authorized Manufacturer&#8217;s facilities approved for use under this Supply Agreement, as the case may be, shall be conducted in accordance with the Quality Agreement. Novavax agrees to execute &#91;***&#93; confidentiality agreement required by SLS&#8217;s Authorized Manufacturer in connection with such visit, audit or inspection of the facilities of such Authorized Manufacturer, and will comply with such Authorized Manufacturer&#8217;s reasonable rules and regulations. In the event Novavax foresees the existence of an operational issue in the Manufacture of any component of the Product that Novavax &#91;***&#93; believes &#91;***&#93; may result in a cGMP or other regulatory deficiency or failure of SLS to meet its obligations under this Supply Agreement or the Quality Agreement (such as failure of a Product to meet the Product Requirements), then Parties shall agree &#91;***&#93; to conduct joint inspections.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Notification of Regulatory Inspections. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If any Governmental Authority provides SLS or its Authorized Manufacturer notice of its intent to conduct an inspection or investigation, or to take any other type of regulatory action with respect to any facility where the Product is manufactured under this Supply Agreement, then SLS will give Novavax notice &#91;***&#93; of its receipt of such notice. SLS will provide to Novavax information and findings pertaining thereto &#91;***&#93; after receipt. &#91;***&#93;, then Novavax shall be entitled to be present during any such inspection or investigation.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Reports. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS will supply &#91;***&#93; data &#91;***&#93; relating to the Products, &#91;***&#93;, that Novavax requires or otherwise requests &#91;***&#93;. Further, SLS will (and will cause its Authorized Manufacturer to) (a) provide Novavax with written reports in the format &#91;***&#93; required by Novavax and (b) hold meetings with Novavax&#8217; representatives &#91;***&#93; on the progress of their performances under this Supply Agreement &#91;***&#93;.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Complaints.  </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In connection with any Product complaints or customer communications &#91;***&#93; relating to the Product that are received by SLS or its Authorized Manufacturer, SLS will &#91;***&#93; </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">report such to Novavax. In addition to what is agreed between the Parties under the Quality Agreement, for the sake of clarity, it is reiterated that Novavax shall be &#91;***&#93; to conduct investigation of any such complaints and otherwise handle all claims or complaints towards any Latent Defects in the Products, or any adverse events notifications, or any Product recalls.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Payments&#59; Invoicing&#59; Taxes&#59; Financial Reports</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Invoice and Payment. </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">The provisions set forth on Schedule&#160;4.1.1 (Supply Price and Invoicing) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">All invoices issued and payments to be made between the Parties under this Supply Agreement shall be made in U.S. dollars and shall be paid by wire transfer in immediately available funds to a bank account designated by SLS. </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">If, due to restrictions or prohibitions imposed by national or international authority, a given payment cannot be made as provided in this Section 4.1, then the Parties will consult with a view to finding a &#91;***&#93; acceptable solution. Upon agreement of the Parties in a Firm Purchase Order, Novavax may deliver such payment in the relevant country and in the local currency of the relevant country.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">The provisions set forth on Schedule 4.1.4 (Delivery Postponements Requested by Novavax) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Taxes</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Responsibility. </font></div><div style="padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Except as expressly set forth in Section 4.2.2 (Withholding Taxes) and stated below, each Party will pay any and all taxes levied by Applicable Law on account of all payments received by such Party from the other Party or any third party as a result of this Agreement, including all taxes based on any net income of such Party. </font></div><div style="padding-left:63pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Withholding Taxes. </font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS will provide such information and documentation to Novavax as are &#91;***&#93; requested by Novavax to determine if any withholding taxes apply to any payments to be made by Novavax to SLS under this Agreement. If any taxes are required to be withheld with respect to any such payments to be made by Novavax to SLS under this Agreement, Novavax will&#58; (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, (c) send evidence of the obligation together with proof of tax payment to SLS &#91;***&#93;, and (d) &#91;***&#93;. &#91;***&#93;. &#91;***&#93;.</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">No other Taxes.</font></div><div style="padding-left:64.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">No other taxes would be levied&#47;withheld by either Party other than the taxes mentioned specifically above.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;. &#91;***&#93;.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Incentive Payments. The provisions set forth on Schedule 4.3 (Incentive Payments) attached hereto shall apply to this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Intellectual Property</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Background Intellectual Property. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Each Party retains its respective ownership in its Background Intellectual Property.  </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Ownership of Improvements. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Novavax shall own all right in and title to improvements made to &#91;***&#93;. &#91;***&#93;. In the event SLS, either itself or through its Authorized Manufacturer, conceives, develops or reduces to practice during the Term of this Supply Agreement any improvements to &#91;***&#93;, then SLS shall, and shall cause its Authorized Manufacturer to, &#91;***&#93; disclose in writing to Novavax any such improvements and the same shall form part and parcel of &#91;***&#93;.</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">For the sake of clarity all Intellectual Property Rights in relation to the Adjuvant, Drug Substance and the Drug Product, shall be the exclusive proprietary concern of Novavax.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Covenant Not to Sue.</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Each Party acknowledges and agrees that the covenants not to sue agreed to by the Parties and&#47;or their Affiliates under any other agreement applies to the performance under, and activities contemplated by, this Supply Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> </font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Confidentiality</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Definition.</font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8220;Confidential Information&#8221; means the terms and provisions of this Supply Agreement and other Know-How, trade secrets, inventions, materials, and other proprietary information and data of a financial, commercial, or technical nature (in whatever form) that a Party (&#8220;Disclosing Party&#8221;) or any of its Affiliates has supplied or otherwise made available to the other Party (&#8220;Receiving Party&#8221;) or its Affiliates, which are disclosed in writing or orally and whether or not specifically marked or designated by the Disclosing Party as confidential. For clarity, Novavax Confidential Information includes Adjuvant </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">and all other data, information and Know-How associated therewith. For clarity, SLS&#8217;s Confidential Information includes (i) all data, information and Know-How owned or controlled by SLS in relation to any Development or Manufacturing activities conducted hereunder this Supply Agreement, (ii) all Records, reports  books of accounts maintained by SLS in the performance of this Supply Agreement, and (iii) any non-public information or data that may be disclosed to or shared with, or to which Novavax or any of its Affiliates or any other Third Party acting on its behalf (including any auditors appointed by Novavax) may be exposed to during any site visits or inspection visits or regulatory visits at any of SLS&#8217;s and &#47; or its Authorized Manufacturer&#8217;s facilities (as the case may be). </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Obligations on Receiving Party. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The Receiving Party will (a) protect all Confidential Information of the Disclosing Party against unauthorized disclosure to Third Parties and (b) not use or disclose the Confidential Information of the Disclosing Party, except as permitted by or in furtherance of exercising rights or carrying out obligations hereunder. The Receiving Party will treat all Confidential Information provided by the Disclosing Party with the same degree of care as the Receiving Party uses for its own similar information, but in no event less than a reasonable degree of care. The Receiving Party may disclose the terms and conditions of this Supply Agreement and the Confidential Information to its Affiliates, and their respective directors, officers, employees, subcontractors (or in the case of SLS, its Authorized Manufacturer), sublicensees, consultants, attorneys, accountants, banks, financial advisors, funders and investors (collectively, &#8220;Representatives&#8221;) who have an absolute need-to-know such information to carry out the activities and transactions or to exercise its rights contemplated by this Supply Agreement , provided that the such Representatives are bound by written obligations of confidentiality at least as restrictive as those set forth in this Supply Agreement. Each Party will promptly notify the other Party of any misuse or unauthorized disclosure of the other Party&#8217;s Confidential Information. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Exceptions to Confidentiality. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The obligations under this Article 6 (Confidentiality) will not apply to any information to the extent the Receiving Party &#91;***&#93;&#58;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Supply Agreement by the Receiving Party or any Representatives to whom it disclosed such information&#59;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">was known to, or was otherwise in the possession of, the Receiving Party prior to the time of disclosure by the Disclosing Party&#59;</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">is disclosed to the Receiving Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party&#59; or </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">is independently developed by or on behalf of the Receiving Party or any of its Affiliates, as evidenced by its written records, without use or access to the Confidential Information.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Permitted Disclosures. </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">6.4.1 Compliance with Law. </font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The Receiving Party may disclose Confidential Information of the Disclosing Party that the Receiving Party is required to disclose under Applicable Laws or a court order or other governmental order, &#91;***&#93;.</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:35.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">6.4.2 SEC Filings and Other Disclosures. </font></div><div style="padding-left:71.5pt;text-align:justify;text-indent:0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax may disclose such &#91;***&#93; redacted terms of this Supply Agreement ***&#93; only to the extent &#91;***&#93; required to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission or similar security regulatory authorities in other countries. &#91;***&#93;.</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:35.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">6.4.3 Other Permitted Disclosure. </font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Notwithstanding the restrictions set forth in this Article 6 (Confidentiality), Novavax may disclose the terms and provisions of this Supply Agreement to any Third Party in connection with any actual or bona fide prospective acquisition, merger, financing, transfer or sale of all or substantially all of the assets of the business of Novavax to which this Supply Agreement relates as permitted under Section 11.3 (Assignment)&#59; provided that such Third Party is bound by written obligations of confidentiality at least as restrictive as those set forth in this Supply Agreement. Novavax agrees that in the event it is requested to disclose any portion of SLS&#8217;s Confidential Information to such Third Party for the context laid out above, then, it must secure &#91;***&#93; consent from SLS, &#91;***&#93;.</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:35.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">6.4.4 Continuing Confidentiality Obligations. </font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If and whenever any Confidential Information is disclosed in accordance with this Section 6.4 (Permitted Disclosures), such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Supply Agreement). </font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Ongoing Obligation for Confidentiality. </font></div><div style="padding-left:32.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Upon expiration or termination of this Supply Agreement, the Receiving Party will, and will &#91;***&#93; its Representatives to, destroy, delete, or return &#91;***&#93; any Confidential Information of the Disclosing Party, &#91;***&#93;. &#91;***&#93;.</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Representations, Warranties and Covenants</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:2.73pt">Representations, Warranties and Covenants of Each Party. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Each Party represents, warrants and covenants that&#58; </font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">it has full corporate power and authority to execute, deliver, and perform under this Supply Agreement, and has taken all corporate action required by Applicable Laws and its organizational documents to authorize the execution and delivery of this Supply Agreement and the consummation of the transactions contemplated by this Supply Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">this Supply Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">all consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required to be obtained in connection with this Supply Agreement have been obtained&#59; and </font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">the execution and delivery of this Supply Agreement and all other instruments and documents required to be executed pursuant to this Supply Agreement, and the consummation of the transactions contemplated hereby do not and will not&#58; (a) conflict with or result in a breach of any provision of its organizational documents&#59; (b) result in a breach of any agreement to which it is a party that would impair the performance of its obligations hereunder&#59; or (c) violate any Applicable Laws.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:2.73pt">Representations, Warranties and Covenants of SLS. </font></div><div style="padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS represents, warrants and covenants that&#58;</font></div><div style="padding-left:31.5pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">neither it nor any person or entity acting for or on behalf of SLS will, in connection with the performance of this Supply Agreement, (i) use any funds for contributions, gifts, entertainment, or other payments related to political activity or (ii) make any payment to any government official, in each case in violation of any Applicable Law&#59;</font></div><div style="padding-left:100.4pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">(i) neither it nor any Authorized Manufacturer has been debarred under the provisions of  the Applicable Law, or by any Regulatory Authority, (ii) neither it nor any Authorized Manufacturer will use in any capacity, in connection with the performance of this Agreement, any person  or entity who has been debarred pursuant to the foregoing, and (iii) if at any time during the term of this Supply </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Agreement, it or any person  or entity engaged by SLS to perform this Supply Agreement (a) becomes debarred, or (b) receives notice of action or threat of action with respect to its debarment, SLS shall notify Novavax immediately, and Novavax shall have the right to terminate this Supply Agreement immediately.</font></div><div style="padding-left:31.5pt;text-align:justify"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:2.73pt">Batch Warranties. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS warrants that all Batches Manufactured, either by itself or through its Authorized Manufacturer, under this Supply Agreement will&#58;</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">for Batches delivered for Commercial use, be Delivered with full title and with the applicable Certificate of Analysis, Certificate of Conformance, Master Batch Record, applicable master safety data sheet, and additional Batch-related documentation identified in the Quality Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">be Manufactured in accordance with cGMP or otherwise in accordance with all Applicable Law and the terms of the applicable Quality Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:11.57pt">at the time of the Product Delivery, conform to the applicable Product Specifications in all respects.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:2.73pt">Representations, Warranties and Covenants of Novavax. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax represents, warrants and covenants that&#58;</font></div><div style="padding-left:64.4pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">All Novavax Background Intellectual Property, Adjuvant and any Novavax Know-How provided to SLS under this Supply Agreement or under any Firm Purchase Order have been Manufactured by Novavax (or procured from a Third Party manufacturing them, as the case may be), strictly in accordance with all Applicable Laws and cGMP&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">Novavax controls or has all such right title and interest in the Novavax Background Intellectual Property, Adjuvant, and any Novavax Know-How, as may necessary for supply to and use by SLS, either itself or through its Authorized Manufacturer, thereof, for the performance of SLS&#8217;s obligations under this Supply Agreement&#59; and</font></div><div style="padding-left:72pt;text-indent:-40.5pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">Supply to and use by SLS, either itself or through its Authorized Manufacturer, of any Novavax Background Intellectual Property, Adjuvant and any Novavax Know-How for the Development or Manufacture of the Product under this Supply Agreement or any Firm Purchase Order (i) is free of any Third Party lien, (ii) does not infringe any valid Third Party Intellectual Property Rights, (iii) is not in violation of any agreement or other contractual arrangement by which Novavax may be bound and (iv) is compliant with all Applicable Laws which may apply to the Supply Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">Novavax assures and warrants that it shall supply the Adjuvant to SLS&#8217;s Authorized Manufacturer for the purposes set forth on Schedule&#160;2.9 (Adjuvant Supplied by Novavax) at the price set forth on Schedule&#160;2.9 (Adjuvant Supplied by Novavax).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.4.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:16.07pt">Novavax assures and takes responsibility of providing required biological material for Product Manufacturing and providing technology transfer documents for Drug Substance, Drug Product and know-how with analytical methods for Product testing along with Product specifications to SLS and or SLS&#8217;s Authorized Manufacturer, in each case, solely to the extent (i) specified to be provided by Novavax as set forth in the applicable SOW, and (ii) necessary for the Manufacture of Product by SLS&#8217;s Authorized Manufacturer for Novavax under this Agreement&#59; provided that SLS shall (and shall cause its Authorized Manufacturer to) use such material, documents, know-how, methods and specifications solely for the purposes of Manufacturing Product for Novavax under this Supply Agreement and for no other purposes.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:7.23pt">DISCLAIMER OF WARRANTIES. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:121%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:7.23pt">&#91;***&#93;. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">EXCEPT FOR DAMAGES RESULTING FROM &#91;***&#93;, IN NO EVENT WILL EITHER PARTY HAVE ANY CLAIMS AGAINST OR LIABILITY TO THE OTHER PARTY WITH RESPECT TO ANY &#91;***&#93;.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Indemnification and Insurance</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Indemnification by SLS. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS will indemnify, defend, and hold harmless Novavax and its Affiliates and their respective officers, directors, employees, successors, and permitted assigns, (each a &#8220;Novavax Indemnified Party&#8221;) from and against any and all losses, liabilities, damages, costs, fees, and expenses (including reasonable attorneys&#8217; fees) (collectively, &#8220;Losses&#8221;) suffered by any Novavax Indemnified Party in connection with any suits or claims brought by any Third Party (&#8220;Claims&#8221;) arising out of or resulting from (in each case, &#91;***&#93;&#58; </font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;&#59;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;&#59;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;&#59; </font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Indemnification by Novavax. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax will indemnify, defend, and hold harmless SLS and its Affiliates and their respective officers, subcontractors, directors, employees, successors, and permitted assigns (each, a &#8220;SLS Indemnified Party&#8221;) from and against Losses suffered by any SLS Indemnified Party in connection with any Claims arising out of or resulting from &#91;***&#93;&#58;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;&#59;</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">&#91;***&#93;.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Indemnification Procedure. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In connection with any Claim for which an Indemnified Party seeks indemnification from the other Party pursuant to this Supply Agreement, the Indemnified Party will&#58; (a) give the other Party &#91;***&#93; written notice of the Claim&#59; provided, &#91;***&#93;&#59; (b) cooperate with the other Party, at the other Party&#8217;s expense, in connection with the defense and settlement of the Claim&#59; and (c) permit the other Party to control the defense and settlement of the Claim&#59; provided, however, that the other Party may not settle the Claim without the Indemnified Party&#8217;s prior written consent &#91;***&#93;. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by counsel of its selection and at its own expense.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Insurance. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS and Novavax, each at their own expense, shall obtain and thereafter maintain during the term of the Supply Agreement &#91;***&#93; all &#91;***&#93; insurance covering each Party&#8217;s performance under this Supply Agreement, as may be applicable to each Party under </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">the respective Applicable Law. Each Party shall provide the other a certificate of insurance upon the written request of the other Party.   </font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:32.81pt">Term and Termination</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Term. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Supply Agreement will commence upon the Effective Date of the Supply Agreement and, if not otherwise terminated earlier pursuant to this Article 9, will continue in full force and effect until 30 June 2028 or until two (2) years after the date of expiration or termination of the last Firm Purchase Order, whichever is later (&#8220;Term&#8221;).   </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Termination for Cause.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">9.2.1&#160;&#160;&#160;&#160;Either Party (&#8220;Non-Breaching Party&#8221;) will have the right, without prejudice to any other remedies available to it at law or in equity, to terminate this Agreement in the event the other Party breaches (&#8220;Breaching Party&#8221;) any of its material obligations hereunder and fails to cure such breach within &#91;***&#93; after receiving notice thereof&#59; provided, however, that (a) if the breach by its nature is not curable, then the Non-Breaching Party will be entitled to seek such relief within &#91;***&#93; of providing written notice to the Breaching Party, and (b) &#91;***&#93; (&#8220;Cure Period&#8221;), in each case (a) and (b), at the end of which such termination shall become effective, unless, such allegedly breaching Party disputes such breach in accordance with Section 9.2.2 below. Any termination by a Party under this Section 9.2 (Termination for Cause) will be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from the other Party.</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">9.2.2 If the Parties &#91;***&#93; disagree as to whether there has been a material breach, including whether such breach was material or curable, the Party that disputes whether there has been a material &#47; curable breach may contest the allegation in accordance with Section 11.2 (Dispute Resolution). Notwithstanding anything to the contrary in Section 9.2.1, if a Party contests the allegation in accordance with Section 11.2, the Cure Period for any dispute will extend from the date that written notice was first provided to the Breaching Party by the Non-Breaching Party until the end of the escalation period stipulated under Section 11..2, and it is understood and acknowledged that, during such period, all of the terms and conditions of this Agreement will remain in effect, and the Parties will continue to perform all of their respective obligations under this Agreement.</font></div><div style="padding-left:32.2pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Termination and Bankruptcy. </font></div><div style="padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Supply Agreement may be terminated by a Party &#91;***&#93; upon written notice to the other Party if the other Party files a petition in bankruptcy or of insolvency, or is adjudicated insolvent, or takes advantage of the insolvency law in any state or </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">country, or makes an assignment for the benefit of creditors, or a receiver, trustee or other court officer is applied for or appointed for its property.</font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Termination for Change of Control of Novavax. </font></div><div style="padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">SLS shall have the right, in their sole discretion to terminate this Supply Agreement by a written notice of &#91;***&#93; to Novavax, in the event Novavax undergoes a change of control event as stipulated under Section 11.3.2 and the party acquiring or merging with or in any other manner controlling Novavax (i) refuses to be bound by the terms and conditions of this Supply Agreement, or (ii) does not perform the obligations of Novavax under this Supply Agreement.</font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div style="padding-left:32.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:1.33pt">Termination by Mutual Consent. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In the event the applicable Regulatory Authority in the Novavax Exclusive Territory or the Non-Exclusive Territory does not approve any of the Products (or any other product containing or comprised of any of the Products) for marketing or distribution or withdraws marketing or distribution approval, or SLS fails to maintain the consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required to Manufacture the Products then all Parties may mutually agree in good faith to decide the path forward, including modifications of the commercial terms and&#47;or termination.  </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:26.14pt">Effects of Expiry &#47; Termination</font></div><div style="padding-left:37.45pt;text-align:justify"><font><br></font></div><div style="padding-left:37.45pt;text-align:justify;text-indent:-23.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:6.58pt">Accrued Rights.</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Expiration or termination of this Supply Agreement will not relieve the Parties of any liability that accrued hereunder prior to the effective date of such expiration or termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Supply Agreement, and any such expiration or termination will be without prejudice to the rights of either Party against the other. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:37.45pt;text-align:justify;text-indent:-23.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:6.58pt">Return of Confidential Information. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Upon the expiration or termination of this Supply Agreement, the Receiving Party will &#91;***&#93; to the Disclosing Party &#91;***&#93; all Confidential Information of the Disclosing Party that is in the Receiving Party&#8217;s possession or under its control (other than any Confidential Information required to continue to exercise a Party&#8217;s rights that survive termination of this Supply Agreement). Notwithstanding the foregoing, the Receiving Party shall not be required to return or destroy Confidential Information contained in any computer system back-up records made in the ordinary course of business and  shall be entitled to retain &#91;***&#93; Confidential Information, &#91;***&#93; to comply with Applicable Law and to monitor its continuing obligations under the Supply Agreement, &#91;***&#93;.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:37.45pt;text-align:justify;text-indent:-23.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:6.58pt">Survival. </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The following provisions, as well as any other provisions which by their nature are intended to survive termination or expiration, will survive termination or expiration of this Supply Agreement&#58; Section 2.7 (Latent Defects, Pharmacovigilance, Adverse Events and Recalls)&#59; Article 5 (Intellectual Property Rights)&#59; Article 6 (Confidential Information)&#59; Article 7 (Representations and Warranties)&#59; Article 8 (Indemnification and Insurance)&#59; Article 10 (Effects of Expiry &#47; Termination) and Article 11 (Miscellaneous).  </font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">Article 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;padding-left:26.14pt">Miscellaneous</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">No Third Party Obligation on SLS</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Novavax expressly agrees that SLS is performing its obligations under this Supply Agreement, either itself or through its Authorized Manufacturer, solely in the capacity of supplier of the Product in mutually agreed quantities between the Parties under any and all Firm Purchase Orders issued hereunder. SLS shall not be bound by or obligated to any Third Party to fulfill any Product supply commitments or assurances or covenants as a result of this Supply Agreement, whether as of the Effective Date of this Supply Agreement, or at any time during the Term, which are given by Novavax to any Third Party, including without limitation to any Government Authority &#47; Regulatory Authority in any country within the Novavax Exclusive Territory or the Non-Exclusive Territory, or any international for-profit organization  or any international non-profit organization or any statutory or governmental entity or any other private or public corporation (other than an Affiliate of Novavax), and Novavax shall be solely obligated to fulfill any and all of its covenants to any such Third Party without any recourse to SLS.</font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">For the sake of clarity, by executing this Supply Agreement, SLS shall not, either directly, or by any implication, be responsible for or become to a party to, any obligations, commitments, promises or other assurances by Novavax to any Third Party in relation to the supply of the Product, &#91;***&#93;.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Dispute Resolution and Escalation. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The Parties recognize that a dispute may arise relating to this Supply Agreement. In the event of such a dispute, the authorized officers from each Party will negotiate &#91;***&#93; to settle any such dispute within &#91;***&#93;.  If such officers are unable to resolve the dispute, then either Party may commence legal proceedings in accordance with Section 11.5 below. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> </font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Assignment. </font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Assigning to Affiliates.</font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">No Party hereto may assign any right or obligation hereunder to a Third Party without the &#91;***&#93; consent of the other Party hereto. Notwithstanding the </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">foregoing, either Party may assign this Agreement, or all of its rights or obligations hereunder to any Affiliate of such Party &#91;***&#93;. </font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Change of Control. </font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Subject to &#91;***&#93;, Novavax may assign this Supply Agreement, or all of its rights or obligations hereunder and thereunder to any Affiliate of Novavax, or to any Person that acquires all or substantially all of the stock or assets of the business to which this Supply Agreement relates (by merger, stock or asset purchase, operation of law, or otherwise), provided that such Third Party acquiring Novavax shall be bound by the terms and conditions of this Supply Agreement and accordingly be obligated to perform all the obligations and responsibilities of Novavax under this Supply Agreement, and provided further that, in the event of any failure of any such party acquiring or merging with Novavax to comply with the provisions of this Section 11.3.2, SLS reserves its right to &#91;***&#93;. </font></div><div style="padding-left:71.5pt;text-align:justify"><font><br></font></div><div style="padding-left:64.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:9.33pt">Successors and Assigns. </font></div><div style="padding-left:71.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Supply Agreement will be binding on and insure to the benefit of the Parties, their executors, administrators, successors and permitted assigns.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Severability. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Should one or more of the provisions of this Supply Agreement become void or unenforceable as a matter of law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Supply Agreement, and the Parties agree to substitute a valid and enforceable provision therefor which, as nearly as possible, achieves the desired economic effect and mutual understanding of the Parties under this Supply Agreement.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Governing Law and Legal Proceedings. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Supply Agreement, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of &#91;***&#93; without regard to conflict of law principles thereof. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to any Purchase Order made pursuant to this Supply Agreement.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Waivers and Amendments. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Supply Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver will be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Supply Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Relationship of the Parties. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Nothing contained in this Supply Agreement will be deemed to constitute a partnership, joint venture, or legal entity of any type between SLS and Novavax, or to constitute one as the agent of the other. Moreover, as between SLS on the one hand, and Novavax on the other, this Supply Agreement, or any of the transactions contemplated hereby are not to be construed, as a partnership for any tax purposes and each Party will act solely as an independent contractor, and nothing in this Supply Agreement will be construed to give one the power or authority to act for, bind, or commit the other.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">Notices.</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">All notices, consents, waivers, and other communications under this Supply Agreement must be in writing and will be deemed to have been duly given when&#58; (a) delivered by hand (with written confirmation of receipt)&#59; (b) sent by fax (with written confirmation of receipt), provided that a copy is sent by an internationally recognized overnight delivery service (receipt requested)&#59; or (c) sent by email to the addressee, and marked as &#8220;Notice&#8221; under this Section 11.8, provided sender receives electronic confirmation of receipt by such recipient, or (d) when received by the addressee, if sent by an internationally recognized overnight delivery service, receipt requested, in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by written notice)&#58;</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If to Novavax&#58;</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax, Inc.</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">700 Quince Orchard Road</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;Gaithersburg, MD 20878</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;Attn&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;E&#58; &#91;***&#93;  </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If to SLS&#58;</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Serum Life Sciences Ltd.</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">15 Grosvenor Street </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">London, United Kingdom W1K 4QZ</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Attention&#58; &#91;***&#93;</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">E&#58; &#91;***&#93;  </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.33pt">&#160;&#160;&#160;&#160;Further Assurances.</font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Novavax and SLS hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge, and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to carry out the intent and purposes of this Supply Agreement.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">No Third Party Beneficiary Rights. </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Except as expressly provided in this Supply Agreement, this Supply Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Entire Agreement. This Supply Agreement, the Exhibit(s), Firm Purchase Orders, and the Quality Agreement, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a material provision of this Supply Agreement and any Firm Purchase Order, the order of precedence shall be as follows&#58; Supply Agreement, the Exhibit(s) and the Firm Purchase Order, unless any such conflict is specifically and expressly identified in the applicable a Firm Purchase Order, in which case, such conflicting provision in the Firm Purchase Order shall control. Notwithstanding the foregoing, the Quality Agreement shall control with respect to all quality matters. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Force Majeure. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Neither Party will be liable or deemed in default for failure to perform any duty or obligation that such Party may have under this Supply Agreement where such failure has been occasioned by any act of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest, other factors that affect the supply or procurement of Raw Materials, or intervention of any Governmental Authority (&#8220;Force Majeure&#8221;), and which is beyond its reasonable control&#59; &#91;***&#93;. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Cumulative Remedies. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Except as otherwise set forth in this Supply Agreement, no remedy referred to in this Supply Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Supply Agreement or otherwise available under Applicable Law.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.3pt;text-align:justify;text-indent:-20.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.26pt">Waiver of Rule of Construction. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Supply Agreement. Accordingly, any rule of construction that any ambiguity in this Supply Agreement will be construed against the drafting Party will not apply. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Construction&#59; Rules of Construction. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Interpretation of this Supply Agreement will be governed by the following rules of construction&#58; (a) words in the singular will be held to include the plural and vice versa, and words of one gender will be held to include the other gender as the context requires&#59; (b) references to the terms &#8220;Section,&#8221;  or &#8220;clause&#8221; are to a Section of this Supply Agreement unless otherwise specified&#59; (c) the terms &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;hereto,&#8221; and derivative or clause or similar words refer to this entire Supply </font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Agreement&#59; (d) the word &#8220;including&#8221; and words of similar import when used in this Supply Agreement will mean &#8220;including without limitation,&#8221; unless otherwise specified&#59; (e) the word &#8220;or&#8221; will not be exclusive&#59; (f) references to &#8220;written&#8221; or &#8220;in writing&#8221; include in electronic form&#59; (g) the titles and headings contained in this Supply Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Supply Agreement&#59; (h) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59; (i) references to &#8220;days&#8221; will mean calendar days, unless otherwise specified&#59; and (j) a reference to any Person includes such Person&#8217;s successors and permitted assigns.</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:35.2pt;text-align:justify;text-indent:-21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">1.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:34.46pt">Counterparts. </font></div><div style="padding-left:35.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Supply Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Supply Agreement may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures will be deemed to bind each Party as if they were original signatures. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:17.6pt;padding-right:17.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">-------------&#91;Signature page follows on the next page&#93;--------------</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:133.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30</font></div><div><font><br></font></div></div></div><div id="i999f133ef806447f9d3d27610e150438_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In Witness Whereof, the Parties have caused this Supply Agreement to be executed by their respective duly authorized officers as of the Effective Date.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">NOVAVAX, INC.<br><br><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#47;s &#47;Mark J. Casey&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;(Signature)<br><br>Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">Mark J. Casey&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">EVP, CLO&#160;&#160;&#160;&#160;</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">SERUM LIFE SCIENCES LIMITED</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#47;s&#47; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#93;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;(Signature)<br><br>Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline"> &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#93;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"><br><br>Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;text-decoration:underline">&#93;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%"><br><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">FACILITIES</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit A setting forth the Facilities has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedules to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;. </font></div><div style="padding-left:35.2pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;text-decoration:underline">SCHEDULE 2.2.3</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROVISIONAL PURCHASE ORDERS&#59; PROVISIONAL BATCHES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Without limiting and in addition to Section 2.2.1 of this Supply Agreement regarding Firm Purchase Orders, in order to mitigate against shortages, delays or other impairment or disruption in supply of Drug Product, Novavax may submit to SLS provisional purchase order(s), without specifying a Product Delivery Date or Product Delivery Destination, for one or more Batch(es) of unlabeled (i.e., bright stock) Drug Product (each, a &#8220;Provisional Purchase Order&#8221;). SLS shall Manufacture, either itself or through its Authorized Manufacturer, the quantities of Drug Product set forth in each Provisional Purchase Order (&#8220;Provisional Batch(es)&#8221;) for the sole benefit of Novavax and shall store the Provisional Batch(es) at a secure facility in compliance with GMP pending written instructions from Novavax to deliver all or some of the Provisional Batch(es). Upon receipt of such written instructions, SLS or its Authorized Manufacturer will deliver such Provisional Batch(es) to Novavax or its designee in accordance with such instructions and Section 2.4 of this Supply Agreement. Any Provisional Batch(es) that are delivered to Novavax or its designee shall be counted towards Novavax&#8217;s binding commitment for the forecasting period that includes the date of delivery. Following such delivery of Provisional Batch(es), SLS shall issue an invoice at the time of shipment initiation of such delivery, and Novavax shall pay to SLS, the applicable Supply Price for such Provisional Batch(es) in accordance with Schedule 4.1.1 (Supply Price and Invoicing) attached to this Supply Agreement, unless such Provisional Batch(es) are delivered as replacement for non-conforming or short Product in accordance with Section 2.6 of this Supply Agreement (in which case such Provisional Batch(es) will be delivered at no cost to Novavax). If any Provisional Batch(es) are not requested by Novavax to be delivered to Novavax or its designee prior to &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#93; before the expiration of the shelf-life expiry or written notice from Novavax to destroy such Provisional Batch(es), then  upon receipt of written notice from Novavax that such Provisional Batch is to be destroyed or on the date that is &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#93; prior to the expiration of the shelf-life, whichever is earlier, SLS shall invoice Novavax for such un-delivered Provisional Batch(es) at the Risk Share Price (as defined in Schedule 4.1.1 (Supply Price and Invoicing) attached to this Supply Agreement), and Novavax will pay to SLS all undisputed amounts set forth in such invoice within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#93; after receipt of invoice. For clarity, SLS or its Authorized Manufacturer shall be responsible for destroying, and all costs of destruction of, un-delivered Provisional Batch(es).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;text-decoration:underline">SCHEDULE 2.9</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADJUVANT SUPPLIED BY NOVAVAX</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) Notwithstanding any other applicable agreement between the Parties and&#47;or their Affiliates, Novavax will supply Adjuvant to SLS&#8217;s Authorized Manufacturer solely for the Manufacture of Drug Product under this Supply Agreement, on a &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; basis to the Authorized Manufacturer with &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; at the Authorized Manufacturer&#8217;s manufacturing Facility. Title and risk of loss to Adjuvant transfers to SLS upon &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. SLS&#8217;s Authorized Manufacturer, being the importer on record for Adjuvant, shall be responsible for &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. Novavax will use its &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; to deliver Adjuvant required for usage in Product engineering, development, PPQs, clinical batches and for various Product presentations and COVID-19 variants as mutually discussed and agreed between NVAX and SLS teams and Manufacture of Drug Product under each Purchase Order at least &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; before the scheduled fill date of the corresponding Drug Product as mutually agreed between the Parties for the performance of such Purchase Order(s). For the avoidance of doubt, Novavax&#8217;s supply of Adjuvant for any reason other than for SLS&#8217;s Authorized Manufacturer to Manufacture Product to be supplied to Novavax under this Supply Agreement shall be governed by the terms and conditions of the applicable agreement in connection with which such Adjuvant is supplied by Novavax, including without limitation the Adjuvant price and related payment terms. SLS shall ensure that its Authorized Manufacturer (i) segregates the Adjuvant supplied hereunder from any other materials held by such Authorized Manufacturer, including without limitation any Adjuvant purchased from Novavax under any other agreements pursuant to which Novavax supplies Adjuvant to the Authorized Manufacturer or its Affiliates, and (ii)  upon Novavax&#8217;s written request, promptly returns all or part of such Adjuvant to Novavax or its designated carrier without delay at SLS&#8217;s cost and expense.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other agreements, terms or documents between or among the Parties to the contrary, SLS shall, and shall ensure that its Authorized Manufacturer shall, use the Adjuvant supplied hereunder solely for the purpose of Manufacturing the Drug Product to be supplied to Novavax in accordance with this Supply Agreement and for no other purpose, including for the manufacture, development or commercialization of any products containing Adjuvant that are the subject of separate agreements. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Starting April 15, 2024, SLS shall (or shall cause its Authorized Manufacturer to) provide Novavax with a &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; report containing (i) &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;, and&#59; (ii) &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. On a &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; basis, upon Novavax&#8217;s written request, SLS shall (and shall cause its Authorized Manufacturer to) permit Novavax to access SLS&#8217;s and its Authorized Manufacturer&#8217;s inventory records and shall provide reasonable assistance to Novavax for its confirmation of the accuracy of such breakdown of the Adjuvant consumption and inventory reconciliation, including the observation of an &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; inventory count or other frequency as required by Novavax&#8217; financial reporting requirements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%;text-decoration:underline">SCHEDULE 2.10</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVENTORY OF DRUG SUBSTANCE&#59; DRUG SUBSTANCE SAFETY STOCK</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) SLS shall (or shall cause its Authorized Manufacturer to) provide Novavax with a &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; report containing (i) &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;, and (ii) &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Prior to the beginning of each Seasonal Year during the Term, the Parties shall negotiate in good faith and agree upon a mutually acceptable, written Drug Substance safety stock plan for the upcoming Seasonal Year (each such plan, a &#8220;Safety Stock Plan&#8221; and the quantities of Drug Substance to be kept in safety stock at any given time pursuant to such Safety Stock Plan, the &#8220;Safety Stock&#8221;). SLS (either itself or through its Authorized Manufacturer) will maintain the Safety Stock for the sole benefit of Novavax and will use Safety Stock solely to Manufacture and supply Product to Novavax under this Supply Agreement. The Safety Stock shall be stored at a secure facility in compliance with GMP. SLS (either itself or through its Authorized Manufacturer) will at all times maintain the level of Safety Stock required under the then-current Safety Stock Plan by promptly replenishing the Drug Substance held as Safety Stock. SLS shall (or shall cause its Authorized Manufacturer to) keep Novavax routinely informed of the level of Safety Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE 4.1.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUPPLY PRICE AND INVOICING</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">The price to be paid by Novavax to SLS for the Manufacture and supply of Drug Substance that is delivered in accordance with Section 2.4 of this Supply Agreement is set forth in this Schedule 4.1.1 and shall be &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; (&#8220;DS Supply Price&#8221;), subject to adjustment from time to time as set forth in clause (e) below of this Schedule 4.1.1. At the time of initiation of the shipment of Drug Substance (or at such other time as may be agreed by the Parties in writing and evidenced in a Purchase Order), SLS shall issue an invoice to Novavax at the DS Supply Price for the quantities of Drug Substance being shipped, and Novavax will pay SLS &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the invoice amount before the shipment of such Drug Substance and balance &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; of the invoice amount within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; from the delivery of the shipment of the Drug Substance. For the avoidance of doubt, the DS Supply Price only applies to Drug Substance delivered to Novavax or its designee in accordance with Section 2.4 of this Supply Agreement pursuant to Purchase Orders placed by Novavax, and does not apply with respect to (and Novavax shall not pay for any cost of Manufacturing) any Drug Substance that is utilized in the Manufacture of Drug Product by or on behalf of SLS under this Supply Agreement.  SLS or its Authorized Manufacturer shall ship Drug Substance with &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. The Authorized Manufacturer of SLS shall be responsible for the exportation clearance and process and act as Exporter of Record.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">The prices to be paid by Novavax to SLS for the Manufacture and supply of Drug Product delivered in accordance with Section 2.4 of this Supply Agreement shall be as set forth below in this clause (b), subject to adjustment from time to time as set forth in clause (e) below of this Schedule 4.1.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.36pt">The following supply prices (the &#8220;Risk Share Price&#8221;) shall be applicable to all Drug Product delivered in accordance with Section 2.4 of this Supply Agreement&#58; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt">The following supply prices (the &#8220;Full Supply Price&#8221;) shall be applicable only to Drug Product that is distributed to an End Customer&#58; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. Notwithstanding the foregoing, if Drug Product is Manufactured by or on behalf of SLS or its Authorized Manufacturer utilizing Drug Substance manufactured and supplied by Novavax or its Affiliate or subcontractor, the Full Supply Price for each presentation of such Drug Product shall be&#58; &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.04pt">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; for Drug Product Delivery to Novavax&#58; SLS or its Authorized Manufacturer shall ship Drug Product with &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;. The Authorized Manufacturer of SLS shall be responsible for the exportation clearance and process and act as Exporter of Record.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1.36pt">At the time of initiation of Product Shipment of Drug Product (or at such other time as may be agreed by the Parties in writing and evidenced in a Purchase Order), SLS shall issue an invoice to Novavax which shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">specify (A) the Full Supply Price for the quantities of Drug Product to be shipped, (B) &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; of the partial payment&#47;Risk Share Price for the quantities of Drug Product shipped which will be due within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; from the date of invoice at the Risk Share Price, and (C) the remainder that will be due or credited in accordance with clause (c) below of this Schedule&#160;4.1.1. Within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; after receipt of such invoice, Novavax will pay SLS all undisputed amounts set forth in such invoice being the partial payment at the applicable Risk Share Price.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">Within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; after the end of each &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; during the Term, Novavax will provide a written report to SLS reflecting&#58; (i) the number of doses of Drug Product distributed to End Customers in the Novavax Territory during the immediately preceding calendar quarter, broken down by presentation (i.e., 5DV, UDV and PFS)&#59; (ii) the remainder payable to SLS with respect to such number of doses, which shall be equal to the difference between the Full Supply Price for such number of doses and the Risk Share Price paid for such number of doses (for example, with respect to the PFS presentation, &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#93; (the &#8220;Remainder Amount&#8221;)&#59; (iii) the number of doses of Drug Product, broken down by presentation (i.e., 5DV, UDV and PFS), that were delivered in accordance with Section 2.4 of this Supply Agreement (for which Novavax was invoiced and made partial payment at the Risk Share Price in accordance with clause (b)(i) of this Schedule&#160;4.1.1) but that were destroyed in the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; or otherwise determined by Novavax to be no longer distributable to End Customers (due to expiry or otherwise) (&#8220;Unsaleable Doses&#8221;)&#59; and (iv) if applicable, the number of doses of Drug Product for which Novavax was invoiced in &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; but for which neither a Remainder Amount has been paid (and for which a Remainder Amount is owing) nor a credit memo has been issued (and which are Unsaleable) as of the end of the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; (until all doses of Drug Product for which Novavax has been invoiced have been accounted for as either distributed to End Customers or Unsaleable Doses). Novavax will remit to SLS the Remainder Amount owed as set forth in such report within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; of SLS&#8217;s receipt of such written report.  In addition, upon receipt of each such report, SLS will issue a credit memo to Novavax for the Unsaleable Doses in an amount equal to the difference between the Full Supply Price invoiced by SLS for the Unsaleable Doses and the Risk Share Price paid by Novavax for such Unsaleable Doses. Upon SLS&#8217;s written request, no more than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; during the Term, Novavax shall (A) permit an independent, reputable professional accountant appointed by SLS (at SLS&#8217;s cost) and reasonably acceptable to Novavax, during normal business hours on no less than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; prior written notice to Novavax and at a time and date to be agreed upon by the Parties (such agreement not to be unreasonably withheld), to have access to and review (but not copy) Novavax&#8217;s applicable sales records at Novavax&#8217;s applicable premises, solely to the extent necessary to enable such accountant to verify the accuracy of the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; reports provided by Novavax pursuant this clause (c) of this Schedule&#160;4.1.1 during the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; period preceding such review (each, a &#8220;Records Review&#8221;), and (B) provide reasonable assistance to such accountant for its confirmation of the accuracy of such reports during such Records Review. Prior to receiving such access and performing such Records </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Review, such accountant shall execute a confidentiality agreement on terms acceptable to Novavax and no less stringent than the confidentiality and non-use terms set forth in this Supply Agreement. Any records reviewed by such accountant during such Records Review shall constitute the Confidential Information of Novavax, and such accountant shall be permitted to disclose information furnished to such accountant during such Records Review solely to the extent necessary to convey to SLS its findings as to the accuracy of the applicable reports provided by Novavax under this Schedule&#160;4.1.1 (a copy of which findings will be shared with Novavax at the time such findings are shared by the accountant with SLS).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">For clarity, unless and until Drug Product is distributed to an End Customer, the only Supply Price payable by Novavax for Drug Product Manufactured and supplied pursuant to this Agreement shall be the Risk Share Price. For further clarity, the Remainder Amount will be payable based on the number of doses of Drug Product distributed to End Customers, regardless of whether the End Customers sell or return such doses.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">SLS shall have the right, not more than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; during the Term, to increase each Supply Price by no more than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;, solely for (i) inflation, by a percentage that is equal to the percentage increase in the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; for the immediately preceding &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; period (the &#8220;PPI Inflation Rate&#8221;), and (ii) increases in Raw Materials costs or Manufacturing process costs&#59; provided that, for clarity, regardless of SLS&#8217;s or its Authorized Manufacturer&#8217;s increased costs to Manufacture and supply Drug Substance or Drug Product, whether due to inflation or increased Raw Materials or processing costs, any such annual increase in a Supply Price shall not exceed &#91;***&#93; (each such annual increase, an &#8220;Annual Price Increase&#8221;). SLS shall provide Novavax at least &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; prior written notice of any such Annual Price Increase. Further, in the event of a material change in SLS&#8217;s cost structure (defined as raw material costs, consumables costs and processing costs increasing by greater than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; above the annual PPI Inflation Rate) due to volume fluctuations and &#47; or other force majeure events including the prevalent geopolitical scenarios, the Parties will discuss and negotiate in good faith to modify the pricing beyond the latest Annual Price Increase to reflect the material change in SLS&#8217;s cost structure. For the avoidance of doubt, any increased Supply Price shall not apply to any Product ordered under any Purchase Orders submitted prior to the effective date of such increase.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE 4.1.4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DELIVERY POSTPONEMENTS REQUESTED BY NOVAVAX</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that Novavax requests SLS to delay the delivery of a Batch after SLS (or its Authorized Manufacturer) has provided the Shipment Readiness Notification for such Batch as set forth in Section 2.4.1 of this Supply Agreement, the Parties will discuss in good faith and agree upon a revised Product Delivery Date&#59; provided, however, that such revised Product Delivery Date shall be earlier than &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; prior the expiration of the shelf-life of such Batch. If the Parties fail to agree on a revised Product Delivery Date before &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; from the expiration of the shelf-life of such Batch, the Parties hereby agree with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) For the Batches which are shipped&#47;delivered as per the Revised Product Delivery Date, SLS will issue an invoice to Novavax for the amount payable for such Batch in accordance with Section 4.1.1 of this Supply Agreement and set forth in the applicable Firm Purchase Order. For the Batches which are not requested by Novavax to be shipped before &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; prior to the expiration of the shelf-life of such Batch, SLS will issue an invoice to Novavax, &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; before the expiration of the shelf-life of such Batch. Novavax will pay SLS all undisputed amounts within &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; of receipt of such invoice&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) At Novavax&#8217; sole discretion and with written instruction to SLS (or its Authorized Manufacturer), SLS will (or will cause its Authorized Manufacturer to), (i) destroy expired or non-salable Batch(es) at its Facility at its sole cost and expense in accordance with the Quality Agreement and Applicable Laws, and upon destruction, provide a certificate of destruction to Novavax in a timely manner&#59; or (ii)&#160;deliver the &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; shelf-life Batch(es) or non-salable Batch(es) to Novavax with &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE 4.3</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCENTIVE PAYMENTS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">For purposes of this Schedule&#160;4.3, the following capitalized terms shall have the meanings ascribed to them below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Commercial Market&#8221; means any private sector market, specifically excluding (a) any governmental health ministry, department, or other agency of any government, (b) any non-profit entity or non-governmental organization, (c) any organization or fund sponsored, funded, or supported by the World Bank or the United Nations, including United Nations procurement agencies, and (d) any government or other governmental, international, or bilateral agency or entity. For clarity, the Commercial Market excludes, without limitation, UNICEF, GAVI, CEPI, and USAID.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Developed Countries&#8221; means Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Australia, Canada, Iceland, Japan, Liechtenstein, New Zealand, Norway, Switzerland, United Kingdom, and United States.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;List Price&#8221; means, with respect to each presentation of (i) with respect to the DP Incentive Payment calculation, Drug Product (five-dose vial presentation of Drug Product (&#8220;5DV&#8221;), unit-dose vial presentation of Drug Product (&#8220;UDV&#8221;), or pre-filled syringe presentation of Drug Product (&#8220;PFS&#8221;)) or (ii) with respect to the DS Incentive Payment calculation, Novavax Drug Product, the published wholesale or list price for such presentation, which is (a)&#160;in the United States, the Wholesale Acquisition Cost (&#8220;WAC&#8221;), and (b)&#160;in Developed Countries other than the United States, the published price comparable to the WAC.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Net Doses&#8221; means the total number of doses of (i) with respect to the DP Incentive Payment calculation, Drug Product or (ii) with respect to the DS Incentive Payment calculation, Novavax Drug Product, in each case ((i)-(ii)), that are distributed to End Customers, regardless of whether the End Customers sell or return such doses.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Net Sales&#8221; means the gross amount recognized in the GAAP revenue accounts of Novavax with respect to sales of (i) with respect to the DP Incentive Payment calculation, the applicable Drug Product, or (ii) with respect to the DS Incentive Payment calculation, the applicable Novavax Drug Product, in each case ((i)-(ii)), by Novavax to third parties (whether an end-customer, a distributor or otherwise) less the following deductions to the extent allowed, applied or taken by such third parties, or otherwise recorded as a reduction to GAAP gross sales, and not otherwise recovered by or reimbursed to Novavax, including estimated amounts periodically reconciled to actual charges&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;&#59; </font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:4.02pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:6.69pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:3.35pt">&#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Novavax or its Affiliate receives non-cash consideration for a Drug Product or, as applicable, a Novavax Drug Product sold to a third party during the Term, then the Net Sales for such Drug Product or, as applicable, such Novavax Drug Product will be calculated based on the average arms-length cash selling price for the Drug Product or, as applicable, the Novavax Drug Product over the immediately prior &#91;***&#93; on a country-by-country basis in the Novavax Territory. No deduction will be made for any cost incurred by Novavax in Developing, Manufacturing, or Commercializing the Drug Product or, as applicable, the Novavax Drug Product, except as permitted pursuant to clauses (a) to (h) above&#59; provided that Drug Product or, as applicable, Novavax Drug Product transferred to third parties in reasonable quantities for clinical trials, compassionate use or expanded access programs, indigent programs, promotional sampling, in each case, will be included in Net Sales only to the extent that Novavax or its Affiliate invoices or receives payment at greater than cost for such Drug Product or, as applicable, such Novavax Drug Product. If a single item falls into more than one of the categories set forth in clauses (a) to (h) above, then such item may not be deducted more than once.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transfers or sales between Novavax and its Affiliates will be disregarded for purposes of calculating Net Sales, except if such purchaser is an end user. Net Sales also exclude any sale of the Drug Product or, as applicable, the Novavax Drug Product to any Government Authorities.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Net Selling Price&#8221; or &#8220;NSP&#8221; means the Net Sales divided by the corresponding Net Doses.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;SKU&#8221; means the unique stock keeping unit associated with (a) a specific presentation of (i) with respect to the DP Incentive Payment calculation, Drug Product (e.g., 5DV, UDV, or PFS) or (ii) with respect to the DS Incentive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment calculation, Novavax Drug Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (b) the List Price for such presentation of Drug Product or, as applicable, Novavax Drug Product.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.35pt">Drug Product Incentive Payments. With respect to Drug Product Manufactured and supplied under this Agreement (excluding, for clarity, Drug Substance that is Manufactured and supplied to Novavax under this Agreement in Drug Substance form) and delivered to Commercial Markets in the Developed Countries, Novavax shall, on a per SKU basis solely to the extent that the List Price for such SKU exceeds $&#91;***&#93;, make a semi-annual incentive payment to SLS (as defined in the tables below, &#8220;DP Incentive Payment&#8221;) under the following circumstances&#59; provided that in no event shall any DP Incentive per dose per SKU of Drug Product (as calculated in the left-hand column of the tables below) exceed $&#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent the Net Selling Price of Drug Product delivered under this Agreement and distributed to the Commercial Market in any of the Developed Countries, on a per SKU basis, is greater than &#91;***&#93; of the List Price but equal to or less than &#91;***&#93; of the List Price, on a per SKU basis, Novavax will make the following DP Incentive Payment&#58;</font></div><div style="margin-bottom:8pt;padding-left:66.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.393%"><tr><td style="width:1.0%"></td><td style="width:51.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify;text-indent:22.85pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:63.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent the Net Selling Price of Drug Product delivered under this Agreement and distributed to the Commercial Market in any of the Developed Countries, on a per SKU basis, is greater than &#91;***&#93; of the List Price, on a per SKU basis, Novavax will make the following DP Incentive Payment&#58;</font></div><div style="margin-bottom:8pt;padding-left:66.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.393%"><tr><td style="width:1.0%"></td><td style="width:50.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:63.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The DP Incentive Payment shall be made based on the incremental Net Selling Price above the applicable percentage of the List Price.  For example, </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, (A) no DP Incentive Payments shall be due or owing under this Agreement with respect to any Drug Product, on a per SKU basis, that has a List Price equal to or less than $&#91;***&#93; and (B) no DP Incentive per dose per SKU of Drug Product (for purposes of calculating the DP Incentive Payment) shall exceed $&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">Drug Substance Incentive Payments. With respect to Drug Substance that is Manufactured and supplied to Novavax under this Agreement in Drug Substance form and subsequently incorporated by Novavax or its Affiliates, (sub)licensee or other designee into Novavax Drug Product (excluding, for clarity, Drug Product that is Manufactured and supplied to Novavax under this Supply Agreement) that is delivered to Commercial Markets in the Developed Countries, Novavax shall, on a per SKU basis solely to the extent that the List Price for such SKU exceeds $&#91;***&#93;, make a &#91;***&#93; incentive payment to SLS (as defined in the tables below, &#8220;DS Incentive Payment&#8221; and any DS Incentive Payment or DP Incentive Payment, an &#8220;Incentive Payment&#8221;) under the following circumstances&#58;</font></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent the Net Selling Price of applicable Novavax Drug Product incorporating Drug Substance delivered under this Agreement and distributed to the Commercial Market in any of the Developed Countries, on a per SKU basis, is greater than &#91;***&#93; of the List Price, on a per SKU basis, Novavax will make the following DS Incentive Payment&#58;</font></div><div style="margin-bottom:8pt;padding-left:66.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.393%"><tr><td style="width:1.0%"></td><td style="width:51.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:121%">&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, no DS Incentive Payments shall be due or owing under this Agreement with respect to any Novavax Drug Product, on a per SKU basis, that has a List Price equal to or less than $&#91;***&#93; per dose.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.57pt">Incentive Payment Calculation and Remittance. Any Incentive Payment payable under this Agreement shall be calculated &#91;***&#93; (each, an &#34;Incentive Calculation Date&#34;) for the preceding &#91;***&#93; of the applicable Seasonal Year (each such &#91;***&#93; period, an &#8220;Incentive Period&#8221;). Within &#91;***&#93; following the Incentive Calculation Date for an Incentive Period in which an Incentive Payment is due, Novavax shall remit the Incentive Payment to SLS together with the delivery of a written sales report to SLS showing the applicable Net Sales and Net Selling Price(s) recognized during such Incentive Period (including gross sales, number of doses in each presentation, price per dose, Net Selling Price(s), and reasonable details relating to the reductions from gross sales in calculating Net Sales).</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>nvax-20240630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7185e8c0c6f5438e81dd931e22c93be7_1"></div><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.35pt;padding-right:5.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">I, John C. Jacobs, certify that&#58;</font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:21.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Novavax, Inc.&#59;</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:21.55pt;padding-right:6.4pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:21.55pt;padding-right:6.05pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:11.85pt;padding-left:21.55pt;padding-right:6.1pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.75pt;padding-right:5.95pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%;padding-left:24.25pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:11.8pt;padding-left:37.75pt;padding-right:5.9pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:23.66pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:37.75pt;padding-right:6.35pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:24.25pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.75pt;padding-right:6.1pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:125%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:125%;padding-left:23.66pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7185e8c0c6f5438e81dd931e22c93be7_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.2pt;padding-left:21.6pt;padding-right:6.1pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">5) The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.2pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.05pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.4pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5.25pt"><img alt="image_02.jpg" src="image_02.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:549px"></div><div style="margin-top:4.4pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Date&#58; August 8, 2024&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John C. Jacobs&#160;&#160;&#160;&#160;</font></div><div style="margin-top:1.9pt;padding-left:83.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">John C. Jacobs</font></div><div style="margin-top:1.45pt;padding-left:83.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>nvax-20240630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic6a949975a5549eaa21d1cf3bb0b27ef_1"></div><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.35pt;padding-right:5.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:0.2pt;padding-right:0.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">I, James P. Kelly, certify that&#58;</font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:21.1pt;text-indent:-15.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:6.96pt">I have reviewed this Quarterly Report on Form 10-Q of Novavax, Inc.&#59;</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:21.6pt;padding-right:6.4pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:21.6pt;padding-right:6.05pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%;padding-left:7.46pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:11.85pt;padding-left:21.6pt;padding-right:6.1pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:5.95pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:126%;padding-left:8.05pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:11.8pt;padding-left:37.8pt;padding-right:5.9pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.35pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.05pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.1pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:125%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:125%;padding-left:7.46pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic6a949975a5549eaa21d1cf3bb0b27ef_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.2pt;padding-left:21.6pt;padding-right:6.15pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.2pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.05pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.45pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:7.46pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:0.9pt"><font><br></font></div><div style="padding-left:91.8pt;padding-right:323.55pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%">Date&#58; August 8, 2024&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%;text-decoration:underline"> &#47;s&#47; James P. Kel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%">ly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%;text-decoration:underline"> -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%"> James P. Kelly</font></div><div style="padding-left:91.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:10.90pt">Executive Vice President, Chief</font></div><div style="margin-top:0.75pt;padding-left:91.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Financial Officer and Treasurer</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>nvax-20240630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia31d0a8dd5e0487da19b0ab790823504_1"></div><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.35pt;padding-right:5.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:123.12pt;padding-right:123.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:123%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 UNITED STATES CODE &#167;1350</font></div><div style="margin-top:0.75pt;padding-left:123.12pt;padding-right:123.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:5.9pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">In connection with the Quarterly Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the fiscal period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John C. Jacobs, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58;</font></div><div style="margin-top:0.8pt;padding-left:37.8pt;padding-right:6.05pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.33pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:37.8pt;padding-right:6.05pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.33pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report.</font></div><div style="margin-top:5.5pt"><font><br></font></div><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Date&#58; August 8, 2024&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John C. Jacobs</font></div><div style="margin-top:1.95pt;padding-left:24.3pt;padding-right:386.55pt;text-indent:59.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:130%">John C. Jacobs President and Chief Executive Officer</font></div><div style="margin-top:10.8pt;padding-left:5.35pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>nvax-20240630xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9f9c033b418e4f8eae25154b6d55aabf_1"></div><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.2pt;padding-right:5.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:142.3pt;text-indent:-119.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:123%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 UNITED STATES CODE &#167;1350 (SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="margin-top:0.75pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.4pt;padding-right:5.9pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">In connection with the Quarterly Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the fiscal period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James P. Kelly, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.8pt;padding-right:6.05pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:130%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:130%;padding-left:8.33pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:11.45pt;padding-left:37.8pt;padding-right:6.05pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%;padding-left:8.33pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report.</font></div><div style="margin-top:5.5pt"><font><br></font></div><div style="padding-left:70.2pt;padding-right:342.75pt;text-indent:-64.8pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:2px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%">Date&#58; August 8, 2024&#160;&#160;&#160;&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%;text-decoration:underline">y&#58; &#47;s&#47; James P. Ke</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:134%">lly James P. Kelly</font></div><div style="padding-left:70.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:10.90pt">Executive Vice President, Chief Financial Officer,</font></div><div style="margin-top:1.45pt;padding-left:70.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">and Treasurer</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nvax-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.novavax.com/role/OrganizationandBusiness">
        <link:definition>9952158 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952159 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.novavax.com/role/MarketableSecurities">
        <link:definition>9952160 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.novavax.com/role/FairValueMeasurements">
        <link:definition>9952161 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.novavax.com/role/Revenue">
        <link:definition>9952162 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreements" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements">
        <link:definition>9952163 - Disclosure - Collaboration, License, and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShare" roleURI="http://www.novavax.com/role/EarningsLossperShare">
        <link:definition>9952164 - Disclosure - Earnings (Loss) per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>9952165 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.novavax.com/role/Inventory">
        <link:definition>9952166 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.novavax.com/role/Goodwill">
        <link:definition>9952167 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.novavax.com/role/LongTermDebt">
        <link:definition>9952168 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.novavax.com/role/StockholdersDeficit">
        <link:definition>9952169 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.novavax.com/role/StockBasedCompensation">
        <link:definition>9952170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.novavax.com/role/IncomeTaxes">
        <link:definition>9952171 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.novavax.com/role/CommitmentsandContingencies">
        <link:definition>9952172 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.novavax.com/role/Restructuring">
        <link:definition>9952173 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.novavax.com/role/SubsequentEvents">
        <link:definition>9952174 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.novavax.com/role/MarketableSecuritiesTables">
        <link:definition>9954472 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.novavax.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.novavax.com/role/RevenueTables">
        <link:definition>9954474 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareTables" roleURI="http://www.novavax.com/role/EarningsLossperShareTables">
        <link:definition>9954475 - Disclosure - Earnings (Loss) per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>9954476 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.novavax.com/role/InventoryTables">
        <link:definition>9954477 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.novavax.com/role/GoodwillTables">
        <link:definition>9954478 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.novavax.com/role/LongTermDebtTables">
        <link:definition>9954479 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.novavax.com/role/StockBasedCompensationTables">
        <link:definition>9954480 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.novavax.com/role/RestructuringTables">
        <link:definition>9954481 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.novavax.com/role/MarketableSecuritiesDetails">
        <link:definition>9954483 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails">
        <link:definition>9954484 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails">
        <link:definition>9954486 - Disclosure - Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofProductRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails">
        <link:definition>9954487 - Disclosure - Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails">
        <link:definition>9954488 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreementsDetails" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails">
        <link:definition>9954489 - Disclosure - Collaboration, License, and Supply Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareDetails" roleURI="http://www.novavax.com/role/EarningsLossperShareDetails">
        <link:definition>9954490 - Disclosure - Earnings (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9954491 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.novavax.com/role/InventoryDetails">
        <link:definition>9954492 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillScheduleofGoodwillDetails" roleURI="http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails">
        <link:definition>9954493 - Disclosure - Goodwill - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofConvertibleNotesPayableDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails">
        <link:definition>9954494 - Disclosure - Long-Term Debt -Schedule of Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.novavax.com/role/LongTermDebtNarrativeDetails">
        <link:definition>9954495 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofInterestExpenseDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails">
        <link:definition>9954496 - Disclosure - Long-Term Debt -Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitDetails" roleURI="http://www.novavax.com/role/StockholdersDeficitDetails">
        <link:definition>9954497 - Disclosure - Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails">
        <link:definition>9954499 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails">
        <link:definition>9954500 - Disclosure - Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails">
        <link:definition>9954501 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails">
        <link:definition>9954502 - Disclosure - Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesDetails">
        <link:definition>9954503 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails">
        <link:definition>9954504 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringandRelatedCostsDetails" roleURI="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails">
        <link:definition>9954505 - Disclosure - Restructuring -Schedule of Restructuring and Related Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails">
        <link:definition>9954506 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nvax_LicensingRoyaltiesAndOtherMember" abstract="true" name="LicensingRoyaltiesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" abstract="false" name="ShareBasedCompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_CompensationStockIssuedUnderIncentiveProgram" abstract="false" name="CompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ProvisionForExcessAndObsoleteInventory" abstract="false" name="ProvisionForExcessAndObsoleteInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_NetProceedsFromTheExerciseOfStockBasedAwards" abstract="false" name="NetProceedsFromTheExerciseOfStockBasedAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" abstract="false" name="NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GrantsUSGovernmentContractAndJointVentureAbstract" abstract="true" name="GrantsUSGovernmentContractAndJointVentureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_LiquidityAndGoingConcernPolicyTextBlock" abstract="false" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" abstract="false" name="ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" abstract="false" name="InterestExpenseRelatedToConvertibleNotesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_SanofiPasteurInc.APAMember" abstract="true" name="SanofiPasteurInc.APAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ProceedsFromCollaborationAndLicenseAgreement" abstract="false" name="ProceedsFromCollaborationAndLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GovernmentBackedSecuritiesMember" abstract="true" name="GovernmentBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_FivePointZeroConvertibleNotesDue2027Member" abstract="true" name="FivePointZeroConvertibleNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" abstract="true" name="GaviAdvancePurchaseAgreementCOVAXFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_SettlementAgreementMember" abstract="true" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_AustralianAPAMember" abstract="true" name="AustralianAPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CanadaAdvancePurchaseAgreementMember" abstract="true" name="CanadaAdvancePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_NewZealandTerminationOfTheAgreementMember" abstract="true" name="NewZealandTerminationOfTheAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_MatrixMAdjuvantSalesMember" abstract="true" name="MatrixMAdjuvantSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_USGovernmentPartnershipMember" abstract="true" name="USGovernmentPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_TransitionServicesMember" abstract="true" name="TransitionServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AustraliaRevenueAgencyMemberMember" abstract="true" name="AustraliaRevenueAgencyMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NewZealandRevenueAgencyMember" abstract="true" name="NewZealandRevenueAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RemainingPerformanceObligationAmount" abstract="false" name="RemainingPerformanceObligationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CollaborationAgreementUpfrontPaymentAmount" abstract="false" name="CollaborationAgreementUpfrontPaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_SettlementPayment" abstract="false" name="SettlementPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" abstract="true" name="AccountsReceivableBeforeAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredRevenueIncreaseDecreaseAbstract" abstract="true" name="DeferredRevenueIncreaseDecreaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" abstract="true" name="JointCommitteeOnVaccinationAndImmunizationJCVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" abstract="true" name="WholesaleDistributorFeesDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ProductReturnsMember" abstract="true" name="ProductReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_AmountsChargedAgainstProductSales" abstract="false" name="AmountsChargedAgainstProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_TakedaArrangementMember" abstract="true" name="TakedaArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" abstract="true" name="BillMelindaGatesMedicalResearchInstituteArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" abstract="true" name="LicensedCOVID19ProductsAndRoyaltyPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" abstract="true" name="ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" abstract="true" name="TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" abstract="true" name="TransferOfEMAApprovalOfTheCOVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" abstract="true" name="DatabaseLockOfAnExistingPhase23ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" abstract="true" name="CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" abstract="true" name="CICProductRelatedDevelopmentAndLaunchMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_FirstFourAdjuvantProductsMember" abstract="true" name="FirstFourAdjuvantProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AdjuvantProductsThereafterMember" abstract="true" name="AdjuvantProductsThereafterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TransferOfTechnologyMember" abstract="true" name="TransferOfTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ClinicalMilestoneMember" abstract="true" name="ClinicalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_CostReimbursementMember" abstract="true" name="CostReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RoyaltyPeriod" abstract="false" name="RoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_NumberOfDosesToBeDistributed" abstract="false" name="NumberOfDosesToBeDistributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_CollaborationAgreementUpfrontPaymentReceived" abstract="false" name="CollaborationAgreementUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" abstract="false" name="ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CollaborationAgreementInitialTransactionPrice" abstract="false" name="CollaborationAgreementInitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CollaborationAgreementVariableConsideration" abstract="false" name="CollaborationAgreementVariableConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_NumberOfQuarterlyInstallmentPayments" abstract="false" name="NumberOfQuarterlyInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_InventoryFirmPurchaseCommitmentRecoveries" abstract="false" name="InventoryFirmPurchaseCommitmentRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" abstract="true" name="ThreePointSeventyFiveConvertibleNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_August2023SalesAgreementMember" abstract="true" name="August2023SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_June2021SalesAgreementMember" abstract="true" name="June2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SecuritiesSubscriptionArrangementMember" abstract="true" name="SecuritiesSubscriptionArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SaleOfStockAmountOfRemainingUnissuedShares" abstract="false" name="SaleOfStockAmountOfRemainingUnissuedShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_TwoThousandTwentyThreeStockInducementPlanMember" abstract="true" name="TwoThousandTwentyThreeStockInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_TwoThousandFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_TwoThousandFiveStockIncentivePlanMember" abstract="true" name="TwoThousandFiveStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_LossContingencyPeriodToAnswer" abstract="false" name="LossContingencyPeriodToAnswer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_LossContingencyExtensionPeriod" abstract="false" name="LossContingencyExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" abstract="false" name="PaymentsForSeveranceAndEmployeeBenefitCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_JohnC.JacobsMember" abstract="true" name="JohnC.JacobsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_JohnTrizzinoMember" abstract="true" name="JohnTrizzinoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_FilipDubovskyMember" abstract="true" name="FilipDubovskyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>nvax-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb523242-2c4f-4e50-be8c-749566f69980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77e27df1-e771-438a-8e2b-3d42abd65f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb523242-2c4f-4e50-be8c-749566f69980" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_77e27df1-e771-438a-8e2b-3d42abd65f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d7ce0822-6658-42bf-8e6d-5d7a3a6c7292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eb523242-2c4f-4e50-be8c-749566f69980" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d7ce0822-6658-42bf-8e6d-5d7a3a6c7292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b0639b45-435c-4405-9170-ce3a0fd49b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bfb96a18-5bb1-41fb-880b-0405e4a2a4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b0639b45-435c-4405-9170-ce3a0fd49b7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bfb96a18-5bb1-41fb-880b-0405e4a2a4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_d962247d-38ce-4c71-a6af-801dad527276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b0639b45-435c-4405-9170-ce3a0fd49b7d" xlink:to="loc_us-gaap_CostOfRevenue_d962247d-38ce-4c71-a6af-801dad527276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d9aa8792-0f55-48a2-9d3d-77d096fa8255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b0639b45-435c-4405-9170-ce3a0fd49b7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d9aa8792-0f55-48a2-9d3d-77d096fa8255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab00c12a-d4f6-4163-b784-1e88b78c3d88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7bf7905b-60b2-45fa-806b-d7493f8d02fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ab00c12a-d4f6-4163-b784-1e88b78c3d88" xlink:to="loc_us-gaap_Revenues_7bf7905b-60b2-45fa-806b-d7493f8d02fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2fc58f09-6a4e-4f6a-9075-124b8e316d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ab00c12a-d4f6-4163-b784-1e88b78c3d88" xlink:to="loc_us-gaap_CostsAndExpenses_2fc58f09-6a4e-4f6a-9075-124b8e316d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5670e1c-ae4d-420b-8b35-8219efc29ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbd0cb12-2faa-4e21-beb3-48c19abfb509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5670e1c-ae4d-420b-8b35-8219efc29ba0" xlink:to="loc_us-gaap_OperatingIncomeLoss_fbd0cb12-2faa-4e21-beb3-48c19abfb509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_d4d3ff4c-7239-400a-bc1b-8aeeee57dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5670e1c-ae4d-420b-8b35-8219efc29ba0" xlink:to="loc_us-gaap_InterestExpenseNonoperating_d4d3ff4c-7239-400a-bc1b-8aeeee57dd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0f226c89-e2b6-4917-9420-14986d4055cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e5670e1c-ae4d-420b-8b35-8219efc29ba0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0f226c89-e2b6-4917-9420-14986d4055cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee1504be-3078-44be-9fc2-96b81b7e1e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ef8f612d-3f60-4973-a538-b75ac650b335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee1504be-3078-44be-9fc2-96b81b7e1e5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ef8f612d-3f60-4973-a538-b75ac650b335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ebeab65d-0afd-4f90-8a6e-eb558a1bcc67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee1504be-3078-44be-9fc2-96b81b7e1e5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ebeab65d-0afd-4f90-8a6e-eb558a1bcc67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_41d98f0c-975f-424b-8359-73ab671e82c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c506eb4-cf2c-4d6e-bd36-560cfb97b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_41d98f0c-975f-424b-8359-73ab671e82c6" xlink:to="loc_us-gaap_NetIncomeLoss_5c506eb4-cf2c-4d6e-bd36-560cfb97b9c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0cb83fd9-d79a-43ae-9b86-6397d8afdba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_41d98f0c-975f-424b-8359-73ab671e82c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0cb83fd9-d79a-43ae-9b86-6397d8afdba8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fb827795-5b43-4c61-be51-79da66b833be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fb827795-5b43-4c61-be51-79da66b833be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_30f18637-ac95-4be4-bb11-7a55215ecf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_30f18637-ac95-4be4-bb11-7a55215ecf9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_951ed0fc-219b-411e-9fdf-1ab39ca3c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:to="loc_us-gaap_CommonStockValue_951ed0fc-219b-411e-9fdf-1ab39ca3c4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_473ed195-f178-4d0b-ba61-8a48cbc00175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_473ed195-f178-4d0b-ba61-8a48cbc00175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_cfaec200-df06-4a18-805a-ece78ee9679a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a8c10685-9ded-42ae-905f-25a50133a9b3" xlink:to="loc_us-gaap_TreasuryStockCommonValue_cfaec200-df06-4a18-805a-ece78ee9679a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1aace33d-5a5d-4241-af23-d449265ee841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1aace33d-5a5d-4241-af23-d449265ee841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0a42cd32-c626-4294-abcf-1d04da1a5881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0a42cd32-c626-4294-abcf-1d04da1a5881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b22516b7-ee41-472d-bd9e-e83450700c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b22516b7-ee41-472d-bd9e-e83450700c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bd905b82-9644-4289-914c-75fffbbcf9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bd905b82-9644-4289-914c-75fffbbcf9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ecf16d3e-6623-4cf6-a25a-bab2366e4504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d720f6e2-2502-4a70-933d-3b7e86540e96" xlink:to="loc_us-gaap_AccountsPayableCurrent_ecf16d3e-6623-4cf6-a25a-bab2366e4504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cc7f6f5e-397a-49d8-8288-8ba9b90a013c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:to="loc_us-gaap_AssetsCurrent_cc7f6f5e-397a-49d8-8288-8ba9b90a013c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b7e7c85a-df9d-400c-a1c3-114b0c22010b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b7e7c85a-df9d-400c-a1c3-114b0c22010b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5ddbac20-6331-4839-924a-835c57e32d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5ddbac20-6331-4839-924a-835c57e32d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_4069d190-8c7f-4a8f-b906-78e2cdc30f0c" xlink:href="nvax-20240630.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:to="loc_nvax_LeaseRightOfUseAsset_4069d190-8c7f-4a8f-b906-78e2cdc30f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_00df0bc3-77e0-4f1c-b63f-a5f1d8856665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3b92d1f4-da45-42b5-a7d8-cfb9582f80bf" xlink:to="loc_us-gaap_Goodwill_00df0bc3-77e0-4f1c-b63f-a5f1d8856665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a2f8a6a4-c229-4538-843f-fc2399e6ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_AccountsReceivableNet_a2f8a6a4-c229-4538-843f-fc2399e6ce62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2fe3bc4d-9dfc-4dec-8182-1b279ea1a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2fe3bc4d-9dfc-4dec-8182-1b279ea1a5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9a347a7-bd60-49f9-ad16-4894449e8311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9a347a7-bd60-49f9-ad16-4894449e8311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7a8eb43-4310-4174-9876-c7d3ee6bd55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7a8eb43-4310-4174-9876-c7d3ee6bd55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_23303b6b-7b73-4371-b037-f34a7fcb3a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_InventoryNet_23303b6b-7b73-4371-b037-f34a7fcb3a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_126bb290-a68e-4443-ae9d-a89e07c26c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c5d6d5fd-8e89-4a67-b6ac-e385a2bc7a83" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_126bb290-a68e-4443-ae9d-a89e07c26c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b1784a98-7ffc-4fce-9b9a-9715783ad157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b1784a98-7ffc-4fce-9b9a-9715783ad157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_e65d0ee0-c435-4470-a3bf-9fc29e2e94b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_e65d0ee0-c435-4470-a3bf-9fc29e2e94b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a782de53-b63f-4d02-aa90-3e4421c27ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a782de53-b63f-4d02-aa90-3e4421c27ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_98c04964-0f68-4827-bc94-324acf5ef5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:to="loc_us-gaap_LiabilitiesCurrent_98c04964-0f68-4827-bc94-324acf5ef5e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f21b384f-7b68-4ff5-a948-198556a374c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e1ebffdd-81b0-44dc-8c16-43b77628d453" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f21b384f-7b68-4ff5-a948-198556a374c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c38125cd-3fc5-415a-975e-ceb59444abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1c6fd20f-6316-4cea-bfc4-3acf2ce32f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c38125cd-3fc5-415a-975e-ceb59444abc8" xlink:to="loc_us-gaap_Liabilities_1c6fd20f-6316-4cea-bfc4-3acf2ce32f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fe194eb3-64bb-41d6-92c9-daad03a36d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c38125cd-3fc5-415a-975e-ceb59444abc8" xlink:to="loc_us-gaap_StockholdersEquity_fe194eb3-64bb-41d6-92c9-daad03a36d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f307b6cf-0629-4e1e-b74f-2075a76a24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c38125cd-3fc5-415a-975e-ceb59444abc8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f307b6cf-0629-4e1e-b74f-2075a76a24b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3e6423d2-8708-4509-8c8f-1691b2b16f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c38125cd-3fc5-415a-975e-ceb59444abc8" xlink:to="loc_us-gaap_PreferredStockValue_3e6423d2-8708-4509-8c8f-1691b2b16f74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7610d3fc-0c73-44b9-bdd8-6bf8dad1dda2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7610d3fc-0c73-44b9-bdd8-6bf8dad1dda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_517eef77-5c97-498a-b6fa-9f4f90cf4684" xlink:href="nvax-20240630.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_517eef77-5c97-498a-b6fa-9f4f90cf4684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1ef53d01-5218-4e39-a5a7-d3d93b575fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1ef53d01-5218-4e39-a5a7-d3d93b575fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_4ba9eed0-9996-4677-ba42-453940dc4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_4ba9eed0-9996-4677-ba42-453940dc4d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_49df717c-b134-45a1-b92e-d833f66b6a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51670921-94bc-4b88-a201-51278b21c011" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_49df717c-b134-45a1-b92e-d833f66b6a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8f8105fd-088e-4f77-808b-547ef6aab739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_40566632-aaae-4754-8118-c13eea393d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8f8105fd-088e-4f77-808b-547ef6aab739" xlink:to="loc_us-gaap_PaymentsForSoftware_40566632-aaae-4754-8118-c13eea393d54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_946acf23-bdb5-4175-992c-14b7186fcb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8f8105fd-088e-4f77-808b-547ef6aab739" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_946acf23-bdb5-4175-992c-14b7186fcb9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_14a004ba-a219-42d6-a484-a923bdc36929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8f8105fd-088e-4f77-808b-547ef6aab739" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_14a004ba-a219-42d6-a484-a923bdc36929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8987cecd-eb2f-4863-8ce6-c25dbf0ecece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c3d83c-3abc-4103-bace-225325f8af43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8987cecd-eb2f-4863-8ce6-c25dbf0ecece" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3c3d83c-3abc-4103-bace-225325f8af43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97709380-d346-4fc6-8623-ee9b5f14ff49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8987cecd-eb2f-4863-8ce6-c25dbf0ecece" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97709380-d346-4fc6-8623-ee9b5f14ff49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b981f94-57ce-4470-b021-545503a53cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8987cecd-eb2f-4863-8ce6-c25dbf0ecece" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b981f94-57ce-4470-b021-545503a53cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268a44bf-6b43-4d9e-bf2e-a9549386118a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8987cecd-eb2f-4863-8ce6-c25dbf0ecece" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268a44bf-6b43-4d9e-bf2e-a9549386118a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b1967368-7e1d-41f4-9334-0ccce4b7eb34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_NetIncomeLoss_b1967368-7e1d-41f4-9334-0ccce4b7eb34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_d2af2d92-c498-4d79-a7c4-71829474e337" xlink:href="nvax-20240630.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_d2af2d92-c498-4d79-a7c4-71829474e337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7af145eb-4f8f-4d1a-8950-c7c002df6023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7af145eb-4f8f-4d1a-8950-c7c002df6023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f78d8386-cb3b-4b62-9ded-0387cc8f8bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f78d8386-cb3b-4b62-9ded-0387cc8f8bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e0d18fd8-6430-43f6-8d92-0e865401a6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e0d18fd8-6430-43f6-8d92-0e865401a6d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8260becb-d817-484b-9c0e-7ff00946336e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8260becb-d817-484b-9c0e-7ff00946336e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7215c038-c3f1-47ce-bfd3-7ca77843d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_ShareBasedCompensation_7215c038-c3f1-47ce-bfd3-7ca77843d7d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dc1ad4d9-b960-4bba-bf78-91cecd8c550d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dc1ad4d9-b960-4bba-bf78-91cecd8c550d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_58e7cb41-c5af-4597-a6c3-806586a5abea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_DepreciationAndAmortization_58e7cb41-c5af-4597-a6c3-806586a5abea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5dcdaec4-cda1-43d3-9dac-839712c673d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7618f01-84b5-4dbe-a800-872733c29a62" xlink:to="loc_us-gaap_AssetImpairmentCharges_5dcdaec4-cda1-43d3-9dac-839712c673d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f65cc2bd-c342-4f93-99a0-8cb1b46379f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8596948-fc25-4d09-b3bb-efd806989877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f65cc2bd-c342-4f93-99a0-8cb1b46379f4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8596948-fc25-4d09-b3bb-efd806989877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cff7d216-9bf7-4726-8c57-f1a87ec9df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f65cc2bd-c342-4f93-99a0-8cb1b46379f4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cff7d216-9bf7-4726-8c57-f1a87ec9df8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_040ad108-2a05-4dd1-93e9-d9eee53caa89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_f65cc2bd-c342-4f93-99a0-8cb1b46379f4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_040ad108-2a05-4dd1-93e9-d9eee53caa89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EarningsLossperShareDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#EarningsLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/EarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2944db9b-7c8b-4253-83be-700574f431f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e35e42f8-b75f-48ea-b7a4-737da1888d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2944db9b-7c8b-4253-83be-700574f431f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e35e42f8-b75f-48ea-b7a4-737da1888d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_18c6e58f-3d7b-4d64-88b4-3e2d85fa08cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2944db9b-7c8b-4253-83be-700574f431f1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_18c6e58f-3d7b-4d64-88b4-3e2d85fa08cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_25ec19ec-8897-4dc6-8702-3bcc46ec8abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_a3f8d002-d2c5-412b-a2ec-a38e98eff10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_25ec19ec-8897-4dc6-8702-3bcc46ec8abb" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_a3f8d002-d2c5-412b-a2ec-a38e98eff10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b78f37e-0b8a-4274-bb79-e139b20cbaed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_25ec19ec-8897-4dc6-8702-3bcc46ec8abb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b78f37e-0b8a-4274-bb79-e139b20cbaed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9882ee0b-495b-4305-b542-531dc19b54b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c042eefe-fb05-4b75-b56f-32d1ce7f555b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9882ee0b-495b-4305-b542-531dc19b54b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c042eefe-fb05-4b75-b56f-32d1ce7f555b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcccc014-3db8-4ac8-a6c7-980ec27ac796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9882ee0b-495b-4305-b542-531dc19b54b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcccc014-3db8-4ac8-a6c7-980ec27ac796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_355b4b58-c062-47a7-8233-37ae948a38f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9882ee0b-495b-4305-b542-531dc19b54b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_355b4b58-c062-47a7-8233-37ae948a38f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6a31aa31-b953-41a4-b646-485d53a77711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_a18d4f5c-fda0-4cc9-91b7-6c4810e3dcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6a31aa31-b953-41a4-b646-485d53a77711" xlink:to="loc_us-gaap_InventoryRawMaterials_a18d4f5c-fda0-4cc9-91b7-6c4810e3dcb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_cfdc3eef-d2c2-452c-a1bc-518adeec8c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6a31aa31-b953-41a4-b646-485d53a77711" xlink:to="loc_us-gaap_InventoryWorkInProcess_cfdc3eef-d2c2-452c-a1bc-518adeec8c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e130855d-8946-485f-ac39-3220a11fe071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6a31aa31-b953-41a4-b646-485d53a77711" xlink:to="loc_us-gaap_InventoryFinishedGoods_e130855d-8946-485f-ac39-3220a11fe071" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtScheduleofConvertibleNotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8cc70435-e321-4b2f-a406-0a25a3fca8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66364ca8-d181-4667-9742-4e99c75fd19d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_8cc70435-e321-4b2f-a406-0a25a3fca8f0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_66364ca8-d181-4667-9742-4e99c75fd19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_804383a0-7984-4744-9864-67fdd49c3235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_8cc70435-e321-4b2f-a406-0a25a3fca8f0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_804383a0-7984-4744-9864-67fdd49c3235" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8394b76a-692a-458b-b142-ff464bc037e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ea866d11-3a56-464c-bf7a-790ddb008125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_8394b76a-692a-458b-b142-ff464bc037e7" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ea866d11-3a56-464c-bf7a-790ddb008125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97c1d72e-76d2-4c4c-ac52-1afd26b7a0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_8394b76a-692a-458b-b142-ff464bc037e7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97c1d72e-76d2-4c4c-ac52-1afd26b7a0e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringScheduleofRestructuringandRelatedCostsDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_97aa2218-efd6-41df-a44c-a2a7f6dbb49b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_de49aa3e-f870-49fb-9b8a-b7f6bf51d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_97aa2218-efd6-41df-a44c-a2a7f6dbb49b" xlink:to="loc_us-gaap_SeveranceCosts1_de49aa3e-f870-49fb-9b8a-b7f6bf51d59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_96381960-6587-4fe1-b9bb-938f1a20043e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_97aa2218-efd6-41df-a44c-a2a7f6dbb49b" xlink:to="loc_us-gaap_AssetImpairmentCharges_96381960-6587-4fe1-b9bb-938f1a20043e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>nvax-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:to="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:to="loc_srt_ProductsAndServicesDomain_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:to="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ab93c21-da40-4c6d-929f-25c92d1676ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_us-gaap_ProductMember_6ab93c21-da40-4c6d-929f-25c92d1676ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensingRoyaltiesAndOtherMember_fe79414e-1012-428f-acbe-dcaeb3741d39" xlink:href="nvax-20240630.xsd#nvax_LicensingRoyaltiesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_nvax_LicensingRoyaltiesAndOtherMember_fe79414e-1012-428f-acbe-dcaeb3741d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_576f95ec-f995-4fc6-aeec-f4c5488d9083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_us-gaap_GrantMember_576f95ec-f995-4fc6-aeec-f4c5488d9083" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_044a9382-4657-44d9-9ba2-1976c4ff3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:to="loc_us-gaap_Revenues_044a9382-4657-44d9-9ba2-1976c4ff3c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_5c9f8fc3-28a6-45f3-8a6b-ae81f52a30f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_CostOfRevenue_5c9f8fc3-28a6-45f3-8a6b-ae81f52a30f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a2560fb-b3f4-4bb2-ab65-8f06bf2449c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a2560fb-b3f4-4bb2-ab65-8f06bf2449c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_79b92119-ca1f-481b-8361-f61bc9ea8efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_79b92119-ca1f-481b-8361-f61bc9ea8efa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_89ea2aff-454a-4733-9d72-acb0f2d4c349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_CostsAndExpenses_89ea2aff-454a-4733-9d72-acb0f2d4c349" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_31f8b6f9-e204-4b68-ae42-291e825d9294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_OperatingIncomeLoss_31f8b6f9-e204-4b68-ae42-291e825d9294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_345cbb6f-5fec-4d1c-86ce-d78530c900c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:to="loc_us-gaap_InterestExpenseNonoperating_345cbb6f-5fec-4d1c-86ce-d78530c900c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c136ab3-6cd1-4f24-9c49-94d3de7ad106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c136ab3-6cd1-4f24-9c49-94d3de7ad106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c1c7429-e44a-4c53-bcdb-27d95076e619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c1c7429-e44a-4c53-bcdb-27d95076e619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_abdf1a4d-d13c-4981-8d72-96755d14f019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_abdf1a4d-d13c-4981-8d72-96755d14f019" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11e95ca0-0845-47b9-a518-54d2fa24854f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_NetIncomeLoss_11e95ca0-0845-47b9-a518-54d2fa24854f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_04b82829-08a2-4d17-9569-1351fba85b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:to="loc_us-gaap_EarningsPerShareBasic_04b82829-08a2-4d17-9569-1351fba85b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_503823f4-951a-499c-825d-e34015ec3e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_503823f4-951a-499c-825d-e34015ec3e5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a543aef-ca1f-46fe-9308-fa3e374bd1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a543aef-ca1f-46fe-9308-fa3e374bd1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e8eff58-55a1-4b48-bf65-e3ef50cdf642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e8eff58-55a1-4b48-bf65-e3ef50cdf642" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:to="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32097ef0-e47e-4e0f-a5a2-4578246ee79c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:to="loc_us-gaap_EquityComponentDomain_32097ef0-e47e-4e0f-a5a2-4578246ee79c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:to="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76199508-7760-4e8c-ade3-a0e7000c89a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_CommonStockMember_76199508-7760-4e8c-ade3-a0e7000c89a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c98b62e1-16eb-46e4-bd46-12a563af728a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c98b62e1-16eb-46e4-bd46-12a563af728a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c63ad4e1-60c1-4b45-a1d2-0b93fce26fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_RetainedEarningsMember_c63ad4e1-60c1-4b45-a1d2-0b93fce26fbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_a55db702-bb23-4941-8fc7-a2333109250a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_TreasuryStockCommonMember_a55db702-bb23-4941-8fc7-a2333109250a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0415c20e-a3d1-4bf0-936c-7ca6b0c7e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0415c20e-a3d1-4bf0-936c-7ca6b0c7e06c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f39c26b7-26d6-4a1b-b03d-28f4e14f1399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f39c26b7-26d6-4a1b-b03d-28f4e14f1399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3968f859-a315-4ad7-a5b8-33e34886d1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockholdersEquity_3968f859-a315-4ad7-a5b8-33e34886d1cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a7ead54-00db-4b1f-9d6c-ea9a68365a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a7ead54-00db-4b1f-9d6c-ea9a68365a9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_868ba0ae-b1a8-4945-987c-a5f65646af69" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_868ba0ae-b1a8-4945-987c-a5f65646af69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_0d3ea0d6-6466-4142-87f8-d75accc68d94" xlink:href="nvax-20240630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_0d3ea0d6-6466-4142-87f8-d75accc68d94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e85afc95-b675-4834-9019-14e273876b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e85afc95-b675-4834-9019-14e273876b1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ccba6dc8-d9d4-44c0-ab79-7e9b88241892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ccba6dc8-d9d4-44c0-ab79-7e9b88241892" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27160717-1a8c-4130-a602-71c407e8c440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27160717-1a8c-4130-a602-71c407e8c440" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_885e5087-a5ac-4573-a6b3-f506a7b48823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_885e5087-a5ac-4573-a6b3-f506a7b48823" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf480186-e8b7-42eb-8f46-a4bf0e2452a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_NetIncomeLoss_bf480186-e8b7-42eb-8f46-a4bf0e2452a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6795ffaa-eceb-459c-b506-f614053cbda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da6c6012-1483-4842-bc27-d135557b0012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81890c60-7f21-4677-b6aa-b02fd2e7ff69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81890c60-7f21-4677-b6aa-b02fd2e7ff69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_0afbdb69-1396-4792-9872-312f12cee7cb" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_0afbdb69-1396-4792-9872-312f12cee7cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_ca3da89e-ff6a-420c-810e-1d689b44c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_ca3da89e-ff6a-420c-810e-1d689b44c059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6cb45a52-dd8d-4494-876d-ac33aa375277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6cb45a52-dd8d-4494-876d-ac33aa375277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement_885c1ecd-bf10-4009-afcb-60e481668f98" xlink:href="nvax-20240630.xsd#nvax_ProceedsFromCollaborationAndLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement_885c1ecd-bf10-4009-afcb-60e481668f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de384a0c-9317-4df9-875e-9d8846d8c230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de384a0c-9317-4df9-875e-9d8846d8c230" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1b0a210a-d59b-4a64-8255-5364231121de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1b0a210a-d59b-4a64-8255-5364231121de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WorkingCapital_e8708219-5a74-4ae3-953e-9373a373c619" xlink:href="nvax-20240630.xsd#nvax_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_nvax_WorkingCapital_e8708219-5a74-4ae3-953e-9373a373c619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c20311f3-1f28-4fa3-b0bc-4d61064a28fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NetIncomeLoss_c20311f3-1f28-4fa3-b0bc-4d61064a28fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4b45cb2-2ed8-4d53-a16c-a28215189186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4b45cb2-2ed8-4d53-a16c-a28215189186" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7d96b735-be50-4876-9e70-0d2565543942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7d96b735-be50-4876-9e70-0d2565543942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_32aab3ea-ccbc-4d17-9dc9-de30d83f782a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_32aab3ea-ccbc-4d17-9dc9-de30d83f782a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6da99715-e092-449b-aee9-e96ccd2f9d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6da99715-e092-449b-aee9-e96ccd2f9d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8fb3ee7-c020-4663-b149-af4b64e184c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8fb3ee7-c020-4663-b149-af4b64e184c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3520a29b-9a32-4a50-b214-ae3bc1a20cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3520a29b-9a32-4a50-b214-ae3bc1a20cb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_486247b2-f1d2-47ea-9421-43a37f1d16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_486247b2-f1d2-47ea-9421-43a37f1d16a9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_434ae07d-4e5b-40c0-a6ca-93044de1c54b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_434ae07d-4e5b-40c0-a6ca-93044de1c54b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e533c374-7a5e-4c44-939b-b6748596ccaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e533c374-7a5e-4c44-939b-b6748596ccaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fe0e7f2f-351e-49a6-96ca-760eb37e6441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fe0e7f2f-351e-49a6-96ca-760eb37e6441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9ca7e3f9-9871-462f-b3f8-83ed018b2414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9ca7e3f9-9871-462f-b3f8-83ed018b2414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0f78e9f-880c-4535-8415-4de706a74d73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f0f78e9f-880c-4535-8415-4de706a74d73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33675ba2-9f76-443e-964b-5b8fcdb7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33675ba2-9f76-443e-964b-5b8fcdb7e344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember_e3900f97-3aab-425d-ab3d-15f04d129ba1" xlink:href="nvax-20240630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_nvax_GovernmentBackedSecuritiesMember_e3900f97-3aab-425d-ab3d-15f04d129ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_22d76cfe-b3ea-4a08-b25e-da5e82b34471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_22d76cfe-b3ea-4a08-b25e-da5e82b34471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5b4581cc-0417-4816-9ec9-c440c36fe306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5b4581cc-0417-4816-9ec9-c440c36fe306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2533512c-ee4c-4013-a481-97b01dbeb6ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2533512c-ee4c-4013-a481-97b01dbeb6ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_aabf982c-590b-43a5-b2b2-d1b89e82445e" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_aabf982c-590b-43a5-b2b2-d1b89e82445e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1ee7a717-bb45-48db-a575-bdc3ed73b74a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1ee7a717-bb45-48db-a575-bdc3ed73b74a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_877b4b6d-802a-4dbd-83e4-0f3f346eae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_877b4b6d-802a-4dbd-83e4-0f3f346eae6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MarketableSecuritiesMember_79e2d914-701e-4c67-96e5-3b70b25d36a4" xlink:href="nvax-20240630.xsd#nvax_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:to="loc_nvax_MarketableSecuritiesMember_79e2d914-701e-4c67-96e5-3b70b25d36a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_50b67b8d-b18a-467b-9814-c39f774ea3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_50b67b8d-b18a-467b-9814-c39f774ea3a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d85892b2-cb62-46ba-9c6c-f45d52d33b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d85892b2-cb62-46ba-9c6c-f45d52d33b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ccfb76b5-6d75-4d0a-901f-03d18744950a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ccfb76b5-6d75-4d0a-901f-03d18744950a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91600b43-020f-4f0a-afbd-baa90c51058f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91600b43-020f-4f0a-afbd-baa90c51058f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ad77f211-c0d1-48c1-a3b0-32637ece7ad8" xlink:href="nvax-20240630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ad77f211-c0d1-48c1-a3b0-32637ece7ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_ee92c0e0-01a6-4b59-b192-581e7628e333" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_SettlementAgreementMember_ee92c0e0-01a6-4b59-b192-581e7628e333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember_370a3875-9a06-41cb-8b73-8d893d29a326" xlink:href="nvax-20240630.xsd#nvax_AustralianAPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_AustralianAPAMember_370a3875-9a06-41cb-8b73-8d893d29a326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_3468a774-324f-487e-9d8d-e6f4c4ebe0ed" xlink:href="nvax-20240630.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_3468a774-324f-487e-9d8d-e6f4c4ebe0ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandTerminationOfTheAgreementMember_ef18bc48-dca7-459d-820c-52d08da1c626" xlink:href="nvax-20240630.xsd#nvax_NewZealandTerminationOfTheAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_NewZealandTerminationOfTheAgreementMember_ef18bc48-dca7-459d-820c-52d08da1c626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_6a15b8fc-670e-4a39-9fe8-70e6e734dae0" xlink:href="nvax-20240630.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_6a15b8fc-670e-4a39-9fe8-70e6e734dae0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_8806398d-b043-4d29-a8e7-1f25f0f78c5e" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_8806398d-b043-4d29-a8e7-1f25f0f78c5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_8e1730e5-33da-463e-a74e-84e426842a36" xlink:href="nvax-20240630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_USGovernmentPartnershipMember_8e1730e5-33da-463e-a74e-84e426842a36" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a02ec7d-6093-4e8b-a765-7f8b1d76a551_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:to="loc_srt_ProductsAndServicesDomain_0a02ec7d-6093-4e8b-a765-7f8b1d76a551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:to="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_44903c7d-1d95-43e9-98ea-88e8c5c67a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_us-gaap_ProductMember_44903c7d-1d95-43e9-98ea-88e8c5c67a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicenseFeesMember_48a37465-73cf-4ceb-a703-094cc8197f3d" xlink:href="nvax-20240630.xsd#nvax_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_nvax_LicenseFeesMember_48a37465-73cf-4ceb-a703-094cc8197f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransitionServicesMember_90b77f61-21e6-47a1-9349-199282e9f9ac" xlink:href="nvax-20240630.xsd#nvax_TransitionServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_nvax_TransitionServicesMember_90b77f61-21e6-47a1-9349-199282e9f9ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ea6006d-27a9-4331-ac86-58cd224d90c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ea6006d-27a9-4331-ac86-58cd224d90c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_dcf58c23-91d4-41d5-9bb8-116b3297a106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_dcf58c23-91d4-41d5-9bb8-116b3297a106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b791d538-0362-4de3-9158-fdaa3f10f6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:to="loc_us-gaap_AccountsReceivableMember_b791d538-0362-4de3-9158-fdaa3f10f6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e9235b69-efcd-4dd6-959d-6622c78af2ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e9235b69-efcd-4dd6-959d-6622c78af2ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustraliaRevenueAgencyMemberMember_82085f1c-0613-41ff-93e1-815a18f6791e" xlink:href="nvax-20240630.xsd#nvax_AustraliaRevenueAgencyMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_nvax_AustraliaRevenueAgencyMemberMember_82085f1c-0613-41ff-93e1-815a18f6791e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_11ceebaa-ed35-4f6d-baf1-7ee593337927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_11ceebaa-ed35-4f6d-baf1-7ee593337927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandRevenueAgencyMember_8021ace3-0681-4d90-a272-71c4be6ea457" xlink:href="nvax-20240630.xsd#nvax_NewZealandRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_nvax_NewZealandRevenueAgencyMember_8021ace3-0681-4d90-a272-71c4be6ea457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:to="loc_srt_SegmentGeographicalDomain_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:to="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_9235eec1-21a8-4825-aa02-01841d17b9f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:to="loc_srt_NorthAmericaMember_9235eec1-21a8-4825-aa02-01841d17b9f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_d9aa0690-8047-4844-8886-1b717ed04eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_d9aa0690-8047-4844-8886-1b717ed04eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8a705e0b-81e4-422a-baea-7e9fdd57eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8a705e0b-81e4-422a-baea-7e9fdd57eea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_42a8431a-0fbe-4769-92db-b9e0a1ef8c02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_42a8431a-0fbe-4769-92db-b9e0a1ef8c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_d63e7bdb-49a7-4df2-ae84-dae078407a57" xlink:href="nvax-20240630.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_d63e7bdb-49a7-4df2-ae84-dae078407a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_267b6a9a-9129-4740-a7ca-2ec5bfff6b11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:to="loc_srt_ScenarioForecastMember_267b6a9a-9129-4740-a7ca-2ec5bfff6b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_9eaf82a1-b22a-471c-ad9a-7355fc2f3440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_BilledContractReceivables_9eaf82a1-b22a-471c-ad9a-7355fc2f3440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_b5b0ddb5-ecd5-402f-99aa-1e4adaf313bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_UnbilledContractsReceivable_b5b0ddb5-ecd5-402f-99aa-1e4adaf313bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RemainingPerformanceObligationAmount_3e6e1fde-b3c8-4e70-8453-66d8a8e1657d" xlink:href="nvax-20240630.xsd#nvax_RemainingPerformanceObligationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_RemainingPerformanceObligationAmount_3e6e1fde-b3c8-4e70-8453-66d8a8e1657d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4ca48979-4dcf-4618-8fe9-00fd76e6f750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4ca48979-4dcf-4618-8fe9-00fd76e6f750" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_38904078-8f5b-447c-b728-e311d060684e" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_38904078-8f5b-447c-b728-e311d060684e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2d908898-9024-4684-b676-29adcfb03fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2d908898-9024-4684-b676-29adcfb03fe8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6831d807-935f-48b5-a642-1e9f52822ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_LitigationSettlementExpense_6831d807-935f-48b5-a642-1e9f52822ed0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_c5f60c4d-29c8-433a-81fd-dc7892cb9b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_GrantsReceivable_c5f60c4d-29c8-433a-81fd-dc7892cb9b53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d866e5b-4f03-4c80-8f64-66f998407ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d866e5b-4f03-4c80-8f64-66f998407ddd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_72951173-404c-40a5-8e1a-a54f29dd179a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_72951173-404c-40a5-8e1a-a54f29dd179a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3546fee7-d885-44bf-8942-09040d88c277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3546fee7-d885-44bf-8942-09040d88c277" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fa5ad262-5aa6-4bb8-9bb8-702de0a5ef61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_Revenues_fa5ad262-5aa6-4bb8-9bb8-702de0a5ef61" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_d8659b1d-83e8-408d-82d8-4a109c48d53e" xlink:href="nvax-20240630.xsd#nvax_SettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_SettlementPayment_d8659b1d-83e8-408d-82d8-4a109c48d53e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_43c6a233-676b-4b2b-a56a-654ecde4d912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_43c6a233-676b-4b2b-a56a-654ecde4d912" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0eea1489-adba-4e9a-a660-008bccc374aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0eea1489-adba-4e9a-a660-008bccc374aa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_8cabc76f-c580-4225-81ff-7977b5f65929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_8cabc76f-c580-4225-81ff-7977b5f65929" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75beae06-5373-4f4c-9658-3abee6562072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75beae06-5373-4f4c-9658-3abee6562072" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6180ecce-e7e4-41e8-916f-dadd2777d101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6180ecce-e7e4-41e8-916f-dadd2777d101" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27c66105-1914-442a-9d40-7e8ae99f482c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27c66105-1914-442a-9d40-7e8ae99f482c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_9a45cb04-3e00-4bf5-b313-d1bbfc25022b" xlink:href="nvax-20240630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_9a45cb04-3e00-4bf5-b313-d1bbfc25022b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_fe09716b-6c28-4d37-97a7-355776341fe4" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_fe09716b-6c28-4d37-97a7-355776341fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions_90d1246f-1dfa-403f-a8f0-92860e858fe0" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_ContractWithCustomerLiabilityDeductions_90d1246f-1dfa-403f-a8f0-92860e858fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions_71379911-4c25-4612-b9d7-0af3b4715f84" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_ContractWithCustomerLiabilityAdditions_71379911-4c25-4612-b9d7-0af3b4715f84" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:to="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c36c261e-62df-4be2-858d-850495f20b91_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:to="loc_srt_ProductsAndServicesDomain_c36c261e-62df-4be2-858d-850495f20b91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:to="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_535fb93d-cd73-40a5-9352-b2c8b89ed05c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:to="loc_us-gaap_ProductMember_535fb93d-cd73-40a5-9352-b2c8b89ed05c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:to="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5ed10216-3cd7-4c56-8122-e85bd6f4238c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:to="loc_srt_SegmentGeographicalDomain_5ed10216-3cd7-4c56-8122-e85bd6f4238c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:to="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_ef830f10-9f86-4468-b914-201360d1136f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_srt_NorthAmericaMember_ef830f10-9f86-4468-b914-201360d1136f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b79bdef8-3c7c-42b3-bd12-42b1441c8120" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_srt_EuropeMember_b79bdef8-3c7c-42b3-bd12-42b1441c8120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_16befb50-4d5e-4b53-b932-6f8e3d98c424" xlink:href="nvax-20240630.xsd#nvax_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_nvax_RestOfTheWorldMember_16befb50-4d5e-4b53-b932-6f8e3d98c424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6baec6f6-cddd-4071-8ef7-718d5f4cdd09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:to="loc_us-gaap_Revenues_6baec6f6-cddd-4071-8ef7-718d5f4cdd09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d389ab85-7bc7-4264-9342-15a44e48f962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d389ab85-7bc7-4264-9342-15a44e48f962" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:to="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0629092-8026-4d3b-9863-beed01a2ddf2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:to="loc_srt_ProductsAndServicesDomain_f0629092-8026-4d3b-9863-beed01a2ddf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:to="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_69549828-c859-4d0a-8957-b0dd56b0e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:to="loc_us-gaap_ProductMember_69549828-c859-4d0a-8957-b0dd56b0e38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_7d47ae36-1022-4bcf-b550-43e27a70e117_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_7d47ae36-1022-4bcf-b550-43e27a70e117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_3ce75472-bcff-480c-a210-f0d5905563be" xlink:href="nvax-20240630.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:to="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_3ce75472-bcff-480c-a210-f0d5905563be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember_4b325b01-fc53-4102-8312-52c7c15c46a6" xlink:href="nvax-20240630.xsd#nvax_ProductReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:to="loc_nvax_ProductReturnsMember_4b325b01-fc53-4102-8312-52c7c15c46a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:to="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fff01468-ea33-48df-b8a1-4200fdbb4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fff01468-ea33-48df-b8a1-4200fdbb4cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_7a2b5d4e-26ec-4146-92e2-0aa8ce1fd6c5" xlink:href="nvax-20240630.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_7a2b5d4e-26ec-4146-92e2-0aa8ce1fd6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b7a7e180-c34f-4520-aea4-28afb926cf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b7a7e180-c34f-4520-aea4-28afb926cf5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5f906ec1-685d-4ddc-8cd6-d75b10a224ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fd2f68e-874f-4421-8948-e21cc75d4414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0fd2f68e-874f-4421-8948-e21cc75d4414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_1ea53289-21a5-4ae4-8531-ec1d256dfb9b" xlink:href="nvax-20240630.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_TakedaArrangementMember_1ea53289-21a5-4ae4-8531-ec1d256dfb9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_b24d421e-08ea-4b31-97df-f311ca6eb568" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_b24d421e-08ea-4b31-97df-f311ca6eb568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_40d5c503-d4ad-4da5-a4e8-447b42728203" xlink:href="nvax-20240630.xsd#nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_40d5c503-d4ad-4da5-a4e8-447b42728203" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_bb2ca7e5-a3c7-409b-a5b4-9a5fc5071c67" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_SettlementAgreementMember_bb2ca7e5-a3c7-409b-a5b4-9a5fc5071c67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_698138a3-57d0-486e-b937-41001aa2ef52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_698138a3-57d0-486e-b937-41001aa2ef52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_cdfe228b-919a-4ed8-8021-e8dced24b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_cdfe228b-919a-4ed8-8021-e8dced24b6a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_973ab6d0-a15c-4f55-a99c-a98a5b29064a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:to="loc_srt_ProductsAndServicesDomain_973ab6d0-a15c-4f55-a99c-a98a5b29064a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:to="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_80f157fb-0275-4e48-990e-2d5c5bc4a6a0" xlink:href="nvax-20240630.xsd#nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_80f157fb-0275-4e48-990e-2d5c5bc4a6a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_41847c4e-9a33-4d4d-ae54-378334aec012" xlink:href="nvax-20240630.xsd#nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_41847c4e-9a33-4d4d-ae54-378334aec012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_5132c0b6-a981-496b-8364-37e63e88a62d" xlink:href="nvax-20240630.xsd#nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_5132c0b6-a981-496b-8364-37e63e88a62d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_7bbcb391-59b3-449c-a3f6-7adc68a81919" xlink:href="nvax-20240630.xsd#nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_7bbcb391-59b3-449c-a3f6-7adc68a81919" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_2be2a547-0e72-47ab-b40f-5bf532d58414" xlink:href="nvax-20240630.xsd#nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_2be2a547-0e72-47ab-b40f-5bf532d58414" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_6e6a215d-7bd7-4436-b040-c7affe9f6034" xlink:href="nvax-20240630.xsd#nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_6e6a215d-7bd7-4436-b040-c7affe9f6034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_ea61d874-9469-4727-a52f-94c11cd43c5a" xlink:href="nvax-20240630.xsd#nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_ea61d874-9469-4727-a52f-94c11cd43c5a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstFourAdjuvantProductsMember_f7fcef9b-3d37-4698-bc16-e3a0dc035eda" xlink:href="nvax-20240630.xsd#nvax_FirstFourAdjuvantProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_FirstFourAdjuvantProductsMember_f7fcef9b-3d37-4698-bc16-e3a0dc035eda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AdjuvantProductsThereafterMember_f0720925-207c-479d-996d-854dfa41e9fa" xlink:href="nvax-20240630.xsd#nvax_AdjuvantProductsThereafterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_AdjuvantProductsThereafterMember_f0720925-207c-479d-996d-854dfa41e9fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicenseFeesMember_95c1810c-9e1a-44cf-a3ab-56c48e49f54c" xlink:href="nvax-20240630.xsd#nvax_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_LicenseFeesMember_95c1810c-9e1a-44cf-a3ab-56c48e49f54c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d93ef9a2-efb4-46e1-bcf9-cf7fe6edd699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_us-gaap_LicenseMember_d93ef9a2-efb4-46e1-bcf9-cf7fe6edd699" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransitionServicesMember_ebb56795-1883-46cf-8c8f-e1f8c95acd42" xlink:href="nvax-20240630.xsd#nvax_TransitionServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransitionServicesMember_ebb56795-1883-46cf-8c8f-e1f8c95acd42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfTechnologyMember_b055e474-e919-45f1-866f-ccf3a3792f96" xlink:href="nvax-20240630.xsd#nvax_TransferOfTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfTechnologyMember_b055e474-e919-45f1-866f-ccf3a3792f96" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ClinicalMilestoneMember_535792b8-64ac-4f57-96a2-1f7151c39bba" xlink:href="nvax-20240630.xsd#nvax_ClinicalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_ClinicalMilestoneMember_535792b8-64ac-4f57-96a2-1f7151c39bba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CostReimbursementMember_c78e0f55-bc60-4a30-b92c-b8154f0a5aca" xlink:href="nvax-20240630.xsd#nvax_CostReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CostReimbursementMember_c78e0f55-bc60-4a30-b92c-b8154f0a5aca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2b98fce3-1fbf-4c44-8289-d37e2acd5c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2b98fce3-1fbf-4c44-8289-d37e2acd5c47" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_a22215e8-3d81-4725-93f0-7dda42bece85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_a22215e8-3d81-4725-93f0-7dda42bece85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_d45930bd-5239-400e-b722-620c31d10627" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:to="loc_nvax_SettlementAgreementMember_d45930bd-5239-400e-b722-620c31d10627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_fc3b0539-31fd-4c51-a384-8418d8258d99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_fc3b0539-31fd-4c51-a384-8418d8258d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6946d99b-2e82-4616-aed0-73097138d388_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6946d99b-2e82-4616-aed0-73097138d388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a5eaaa2d-49d4-4530-a834-4a90d58a0fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:to="loc_us-gaap_PrivatePlacementMember_a5eaaa2d-49d4-4530-a834-4a90d58a0fc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e9c1a9ba-c067-48f1-9186-7164dc33d83f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e9c1a9ba-c067-48f1-9186-7164dc33d83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c8418e7c-ab05-4ffb-b60e-5d20fa05145a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c8418e7c-ab05-4ffb-b60e-5d20fa05145a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod_c95e27e5-7dfb-4675-9c98-f51a56dd7936" xlink:href="nvax-20240630.xsd#nvax_RoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_RoyaltyPeriod_c95e27e5-7dfb-4675-9c98-f51a56dd7936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_ed1e001a-41a6-4741-bb6a-45e1bc8edaee" xlink:href="nvax-20240630.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_ed1e001a-41a6-4741-bb6a-45e1bc8edaee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentReceived_3f1eb4d0-1602-4189-a844-13ff8b9b4508" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentReceived_3f1eb4d0-1602-4189-a844-13ff8b9b4508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_08986c1b-ab3e-43d0-91ac-a63d764238e4" xlink:href="nvax-20240630.xsd#nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_08986c1b-ab3e-43d0-91ac-a63d764238e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementInitialTransactionPrice_c2273752-1f76-4e49-8878-78f5b0f2d38c" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementInitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementInitialTransactionPrice_c2273752-1f76-4e49-8878-78f5b0f2d38c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_307432fa-6256-42f9-b9a6-db8b9736205b" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_307432fa-6256-42f9-b9a6-db8b9736205b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementVariableConsideration_69a1d6fe-0506-4d7b-adad-60f76dc7422d" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementVariableConsideration_69a1d6fe-0506-4d7b-adad-60f76dc7422d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d9f97345-feb0-4b18-9fa4-57ecbb586d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_Revenues_d9f97345-feb0-4b18-9fa4-57ecbb586d1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d57bb05a-5bbf-4a00-8056-9e4f8c8580f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d57bb05a-5bbf-4a00-8056-9e4f8c8580f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_b29abfca-2ed6-49af-9a21-c3805b48f863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_DeferredRevenue_b29abfca-2ed6-49af-9a21-c3805b48f863" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e728a6a-da1d-40df-b551-aeca1458df20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e728a6a-da1d-40df-b551-aeca1458df20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a383a4a-28d3-402e-8e2d-db20634bb6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a383a4a-28d3-402e-8e2d-db20634bb6bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_88a924db-19be-4e80-bca2-5f4a27bd7e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_88a924db-19be-4e80-bca2-5f4a27bd7e8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_670470b6-cb89-4bf1-9c0f-1aa0fa06acdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_670470b6-cb89-4bf1-9c0f-1aa0fa06acdc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2840d8b-b1d6-4749-8397-d7d5c1d05582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2840d8b-b1d6-4749-8397-d7d5c1d05582" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_769ab372-6035-4371-8a10-a9c7fa3bc386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_769ab372-6035-4371-8a10-a9c7fa3bc386" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3194ec4d-8a70-453d-a824-437ceb34fdff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3194ec4d-8a70-453d-a824-437ceb34fdff" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementTerm_177efb82-df8a-4b69-a02d-f817d916de2f" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborativeArrangementTerm_177efb82-df8a-4b69-a02d-f817d916de2f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_19eb793a-3d39-4f13-a382-b216e62c3750" xlink:href="nvax-20240630.xsd#nvax_SettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_SettlementPayment_19eb793a-3d39-4f13-a382-b216e62c3750" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_6219425a-6da2-4a24-aee4-c7bf998fb2f0" xlink:href="nvax-20240630.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_6219425a-6da2-4a24-aee4-c7bf998fb2f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6c753870-d70f-4061-a7fa-803439fc91a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6c753870-d70f-4061-a7fa-803439fc91a2" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtScheduleofConvertibleNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa4263ab-7f0d-4548-b7aa-c9c435c304d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa4263ab-7f0d-4548-b7aa-c9c435c304d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_f8142233-92e2-4de9-a944-fe8eca0c715e" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_f8142233-92e2-4de9-a944-fe8eca0c715e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a92fd23-bdf0-42f9-94a0-c5c0a9804804_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a92fd23-bdf0-42f9-94a0-c5c0a9804804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_58526547-f654-49a6-af78-25545dcb4147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:to="loc_us-gaap_UnsecuredDebtMember_58526547-f654-49a6-af78-25545dcb4147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3e616c33-ee19-4a27-8b43-1013cf222044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3e616c33-ee19-4a27-8b43-1013cf222044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8af95b6d-552b-4bba-8f03-f100ba388f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8af95b6d-552b-4bba-8f03-f100ba388f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_e55d9376-8146-4143-85ca-7f56c59952aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_e55d9376-8146-4143-85ca-7f56c59952aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b9e46cf8-0cbb-4a1b-981f-51e72978a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b9e46cf8-0cbb-4a1b-981f-51e72978a9d0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:to="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_68e89c00-da1a-4347-b42f-dce736bbfb7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_68e89c00-da1a-4347-b42f-dce736bbfb7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_faecaeed-d479-4276-b148-b2ec8d884c5f" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_faecaeed-d479-4276-b148-b2ec8d884c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_994bca9f-1fa0-4b12-8310-0f85ace92f88" xlink:href="nvax-20240630.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_994bca9f-1fa0-4b12-8310-0f85ace92f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f254aa9-86d2-453c-b580-0149bf44f14e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f254aa9-86d2-453c-b580-0149bf44f14e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9749e6ba-9874-43bf-a947-7d414283eaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:to="loc_us-gaap_UnsecuredDebtMember_9749e6ba-9874-43bf-a947-7d414283eaa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_eb808aae-73ea-42bc-aa42-37eb8e3eeb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_eb808aae-73ea-42bc-aa42-37eb8e3eeb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_12533cb6-6a32-4c93-a009-6b084f2cf86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_RepaymentsOfDebt_12533cb6-6a32-4c93-a009-6b084f2cf86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_aa6aebeb-a8ae-48ea-a985-4e367af4f627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_aa6aebeb-a8ae-48ea-a985-4e367af4f627" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockholdersDeficitDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fedd54c2-dadc-4bb4-bc30-c6dd337d4923_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:to="loc_us-gaap_ClassOfStockDomain_fedd54c2-dadc-4bb4-bc30-c6dd337d4923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:to="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ac35d89-f448-4229-9c9a-956d992ce479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:to="loc_us-gaap_CommonStockMember_8ac35d89-f448-4229-9c9a-956d992ce479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember_042f2ac4-95f5-4de8-9014-8b800e8708f4" xlink:href="nvax-20240630.xsd#nvax_August2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_nvax_August2023SalesAgreementMember_042f2ac4-95f5-4de8-9014-8b800e8708f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_161af252-7afa-4228-b183-7849ec2f6831" xlink:href="nvax-20240630.xsd#nvax_June2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_nvax_June2021SalesAgreementMember_161af252-7afa-4228-b183-7849ec2f6831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9786529d-93e6-47bb-839a-563bc4818c37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_us-gaap_PrivatePlacementMember_9786529d-93e6-47bb-839a-563bc4818c37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24ee1c71-3d05-4a96-9670-b1e12268ed8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24ee1c71-3d05-4a96-9670-b1e12268ed8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_c87fa328-130a-46c1-9316-b8b14e1fbcec" xlink:href="nvax-20240630.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_c87fa328-130a-46c1-9316-b8b14e1fbcec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_e6f446d2-459a-4c45-b753-a7433c370641" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_e6f446d2-459a-4c45-b753-a7433c370641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3b28118-2fe0-46d7-8e5a-49b89a865e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3b28118-2fe0-46d7-8e5a-49b89a865e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ad6edccd-6912-4604-9255-3300668abd70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ad6edccd-6912-4604-9255-3300668abd70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_71979ec2-23db-4bce-be94-d46d93930319" xlink:href="nvax-20240630.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_71979ec2-23db-4bce-be94-d46d93930319" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c3f26e9-b125-4cde-972d-0047536bf3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c3f26e9-b125-4cde-972d-0047536bf3ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d20ddaf1-b17b-4109-8d7c-7d1bdc88bb21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d20ddaf1-b17b-4109-8d7c-7d1bdc88bb21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d20cc338-6af4-4abc-9c42-42f0b36ce83b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d20cc338-6af4-4abc-9c42-42f0b36ce83b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_8c443a05-0052-485c-8e30-8be324b1114e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_StockIssued1_8c443a05-0052-485c-8e30-8be324b1114e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_031c0df2-77ee-49d7-a9f2-f89ac6259ff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:to="loc_us-gaap_PlanNameDomain_031c0df2-77ee-49d7-a9f2-f89ac6259ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:to="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_b5f8fc32-a0ca-4f52-ae04-49c1bf1d3b60" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_b5f8fc32-a0ca-4f52-ae04-49c1bf1d3b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_32a6b21e-eced-423e-907e-13ef9aeedb1e" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_32a6b21e-eced-423e-907e-13ef9aeedb1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:to="loc_srt_RangeMember_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:to="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ea1cb78-f7c1-44c3-9f33-9cb8f02e29bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:to="loc_srt_MinimumMember_6ea1cb78-f7c1-44c3-9f33-9cb8f02e29bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df3e3570-e99a-42a1-b4ee-a258720f188f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:to="loc_srt_MaximumMember_df3e3570-e99a-42a1-b4ee-a258720f188f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a02116fb-7965-4b52-abbf-16821baefa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:to="loc_us-gaap_EmployeeStockMember_a02116fb-7965-4b52-abbf-16821baefa8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3089a897-7e0f-4b74-a0bc-1f923dc87285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3089a897-7e0f-4b74-a0bc-1f923dc87285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_00dc53db-cc64-4d3e-b646-38146d78f779" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_00dc53db-cc64-4d3e-b646-38146d78f779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3d3e3e3c-fe85-4c81-84d6-1a213a1558dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3d3e3e3c-fe85-4c81-84d6-1a213a1558dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fcb90e2a-cf28-467d-a528-c60dd37f0e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fcb90e2a-cf28-467d-a528-c60dd37f0e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_0e18835b-0c1f-4417-941b-8e8d616b0c6f" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_0e18835b-0c1f-4417-941b-8e8d616b0c6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_755ecb63-af06-4187-bc74-67af8b16fabd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_755ecb63-af06-4187-bc74-67af8b16fabd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_74f7d50b-3298-4532-944e-304e81eee372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_74f7d50b-3298-4532-944e-304e81eee372" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96ed4365-62fb-40e7-bd12-73811ddddb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96ed4365-62fb-40e7-bd12-73811ddddb4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_081ea42e-6557-4642-884c-edf5ca9813a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_081ea42e-6557-4642-884c-edf5ca9813a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49bac609-c79f-40dc-96d8-8d95cf8d9a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49bac609-c79f-40dc-96d8-8d95cf8d9a4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8e0298ee-c95b-4981-8dd1-7c9ba27d8ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8e0298ee-c95b-4981-8dd1-7c9ba27d8ed6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf3889b2-a71d-4edc-861f-cf9b512601c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf3889b2-a71d-4edc-861f-cf9b512601c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f82608b8-b79c-4688-ae56-9e195fa99d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f82608b8-b79c-4688-ae56-9e195fa99d0e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_a8868337-82f4-4fff-b590-60d101b76dab" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_a8868337-82f4-4fff-b590-60d101b76dab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cd7879ed-4650-409a-a2c1-407db6d0d448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cd7879ed-4650-409a-a2c1-407db6d0d448" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3e5b1145-644b-456d-aaaf-40241ca054c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3e5b1145-644b-456d-aaaf-40241ca054c1" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6755db87-1f99-492f-bb4f-6ded2ec0dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_CostOfSalesMember_6755db87-1f99-492f-bb4f-6ded2ec0dca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0ffbf1d-a3e2-4854-84bb-727bf54e3e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0ffbf1d-a3e2-4854-84bb-727bf54e3e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_47b415b7-ac28-4104-a51a-cb206ef1ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_47b415b7-ac28-4104-a51a-cb206ef1ceb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acc1d972-e0d7-4d06-9cd6-259737115d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acc1d972-e0d7-4d06-9cd6-259737115d91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:to="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_87e52ca1-60ac-4274-9eb1-2829a689c3ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:to="loc_us-gaap_PlanNameDomain_87e52ca1-60ac-4274-9eb1-2829a689c3ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:to="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_dd99e253-a8b9-42d8-935f-9b0850b629c7" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_dd99e253-a8b9-42d8-935f-9b0850b629c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_5ffc48a2-1982-4b5c-b219-35062d0f46ff" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_5ffc48a2-1982-4b5c-b219-35062d0f46ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_045389e3-56fd-482d-8845-985c3a7a7b6f" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_045389e3-56fd-482d-8845-985c3a7a7b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_927ad2b8-30e4-40e6-b638-5f0f5c862b59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_927ad2b8-30e4-40e6-b638-5f0f5c862b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01b01d43-09a1-4b31-8796-4cd8ece7d244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01b01d43-09a1-4b31-8796-4cd8ece7d244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84653322-ea45-4f04-bb1e-afde8b06765c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84653322-ea45-4f04-bb1e-afde8b06765c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6d4d2a-9ac4-4667-9a64-46fa5028d7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6d4d2a-9ac4-4667-9a64-46fa5028d7b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4703691-1efe-4f96-8a28-666c2fd66b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b704ea8-c251-4da4-9714-9aac7a27a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b704ea8-c251-4da4-9714-9aac7a27a7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69a89ad6-6ee4-4005-b6fc-8ef3845b83a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69a89ad6-6ee4-4005-b6fc-8ef3845b83a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59f00ee0-de2b-47fd-9638-de14587db46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59f00ee0-de2b-47fd-9638-de14587db46f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b06dcc8-3e15-42a0-abaa-b75138414f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b06dcc8-3e15-42a0-abaa-b75138414f84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a62ce65a-934e-4938-b155-094e59017582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a62ce65a-934e-4938-b155-094e59017582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cbf5e76-0983-4cb2-849a-78b135a2d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24d8e805-e7b6-4fcd-9e80-881aefe7e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24d8e805-e7b6-4fcd-9e80-881aefe7e7e7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:to="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a8f6a36-363c-4ea6-912a-ccaac83b5aee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a8f6a36-363c-4ea6-912a-ccaac83b5aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59432380-aa44-4fd5-9fb9-abaf3abfaa42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59432380-aa44-4fd5-9fb9-abaf3abfaa42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:to="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e18f919-46ff-43d3-a22b-c13ca2d989ce_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:to="loc_srt_RangeMember_9e18f919-46ff-43d3-a22b-c13ca2d989ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:to="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c28839f8-1799-4d89-b62f-a7ec6bb2ecf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:to="loc_srt_MinimumMember_c28839f8-1799-4d89-b62f-a7ec6bb2ecf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2eb03ced-6495-4cb4-9bf7-894d02e407e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:to="loc_srt_MaximumMember_2eb03ced-6495-4cb4-9bf7-894d02e407e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5613904f-cd79-40c9-af6b-942a5680f103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5613904f-cd79-40c9-af6b-942a5680f103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7223b64-81d7-4a86-a04b-7779b49e5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7223b64-81d7-4a86-a04b-7779b49e5ed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9ad828b7-baa9-4c40-9794-f506ff590380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9ad828b7-baa9-4c40-9794-f506ff590380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e0e71e2b-f315-437d-8fe7-3ef5fa58ec02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e0e71e2b-f315-437d-8fe7-3ef5fa58ec02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_722a745e-2c66-44e8-9c0e-e29bfe91def0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_722a745e-2c66-44e8-9c0e-e29bfe91def0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b3787fa-648c-4d4a-9f2b-8dd0cbc4faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b3787fa-648c-4d4a-9f2b-8dd0cbc4faf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3ba130f2-f011-4078-8f3d-9214a1281873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3ba130f2-f011-4078-8f3d-9214a1281873" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e08b61d0-23e3-4673-977a-f9283fe277be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e08b61d0-23e3-4673-977a-f9283fe277be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dacb198c-1232-42d8-99e1-f39e410dc54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dacb198c-1232-42d8-99e1-f39e410dc54d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:to="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f2178ace-6b0b-4119-9124-82226be466b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f2178ace-6b0b-4119-9124-82226be466b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29876373-fdf4-4619-80ad-4a0a668e9b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29876373-fdf4-4619-80ad-4a0a668e9b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:to="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d36df2d-8011-4978-b961-0a00ebd3491b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:to="loc_us-gaap_PlanNameDomain_6d36df2d-8011-4978-b961-0a00ebd3491b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:to="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_a5fa9bb4-4292-400d-92ae-196b08fee774" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_a5fa9bb4-4292-400d-92ae-196b08fee774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_40f6a279-9ad1-43f5-b751-be536124cc95" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_40f6a279-9ad1-43f5-b751-be536124cc95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b07aba8a-2140-4b32-85ba-40f3c190c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b07aba8a-2140-4b32-85ba-40f3c190c059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29a55cb7-22c6-448e-a973-f9407ca066f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29a55cb7-22c6-448e-a973-f9407ca066f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4cd8c793-619a-4b1a-acd0-32f7301efdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4cd8c793-619a-4b1a-acd0-32f7301efdeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ce45fba-a27e-4d87-a86b-4ce084ece384" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ce45fba-a27e-4d87-a86b-4ce084ece384" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074c8742-ed29-4774-8074-00e38d313ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_866c8a52-4ca7-4330-93f2-8e2115371a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_866c8a52-4ca7-4330-93f2-8e2115371a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60b3b5be-0397-4751-9368-e4373ccdbdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60b3b5be-0397-4751-9368-e4373ccdbdaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff597ec5-956b-44d5-9595-395a6b949d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff597ec5-956b-44d5-9595-395a6b949d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f63c5a1-74ba-4c27-906c-aa8952151c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f63c5a1-74ba-4c27-906c-aa8952151c56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d823ebc-6c09-450f-9ca5-4a92a054cc60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_cdf0fa01-0b55-43f3-b129-a685ea25add9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:to="loc_us-gaap_DomesticCountryMember_cdf0fa01-0b55-43f3-b129-a685ea25add9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1c7df603-463c-4ca4-8929-3f5b202ac295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1c7df603-463c-4ca4-8929-3f5b202ac295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_12f059da-fcf3-4fa1-b804-5df0a8c8ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_12f059da-fcf3-4fa1-b804-5df0a8c8ac7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cd77239d-e7ee-462c-b1ed-e2943f4e911f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cd77239d-e7ee-462c-b1ed-e2943f4e911f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_eea742c8-943e-48fa-a321-9d85773c0c0d" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:to="loc_nvax_SettlementAgreementMember_eea742c8-943e-48fa-a321-9d85773c0c0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_67279a75-b57a-416f-b4bf-01ed0ade71d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_67279a75-b57a-416f-b4bf-01ed0ade71d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_89cddfa1-35b8-4603-a162-ceef166dcfcc" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:to="loc_nvax_SettlementAgreementMember_89cddfa1-35b8-4603-a162-ceef166dcfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_295552e8-4bf8-4b4b-9b4b-4cc1ee770547_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_295552e8-4bf8-4b4b-9b4b-4cc1ee770547_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e836307-f7e1-4595-811d-708534365ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:to="loc_us-gaap_SubsequentEventMember_6e836307-f7e1-4595-811d-708534365ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_df011c10-b950-49fa-8356-a9fd4367edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_df011c10-b950-49fa-8356-a9fd4367edbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_58fcb467-a059-40ea-8f81-e14c66af34c9" xlink:href="nvax-20240630.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_58fcb467-a059-40ea-8f81-e14c66af34c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fd458b48-868a-4d22-ba9d-92e7b30bac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fd458b48-868a-4d22-ba9d-92e7b30bac3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_99d0e629-3723-4279-ad64-84678c6ebf15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_99d0e629-3723-4279-ad64-84678c6ebf15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c2b174a0-5c46-43b3-b181-0f4befd78a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c2b174a0-5c46-43b3-b181-0f4befd78a11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyExtensionPeriod_21fb8f78-9942-4bd3-9a92-7724bbdb289a" xlink:href="nvax-20240630.xsd#nvax_LossContingencyExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_nvax_LossContingencyExtensionPeriod_21fb8f78-9942-4bd3-9a92-7724bbdb289a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringScheduleofRestructuringandRelatedCostsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c9473898-8063-4490-920a-0304e32ae34a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c9473898-8063-4490-920a-0304e32ae34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b59f21a6-bc50-42ac-a07a-89ce0f6e3d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b59f21a6-bc50-42ac-a07a-89ce0f6e3d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1cd82c7-37d9-4f0c-b909-506a6cc81fac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1cd82c7-37d9-4f0c-b909-506a6cc81fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d10b6aac-b8c3-4d26-8532-957f1e72bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_CostOfSalesMember_d10b6aac-b8c3-4d26-8532-957f1e72bae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_681dc3f7-59fc-4de2-b014-7e1b9033fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_SeveranceCosts1_681dc3f7-59fc-4de2-b014-7e1b9033fc9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_dfa84d0b-0683-4043-8f0e-5dadc939188d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_AssetImpairmentCharges_dfa84d0b-0683-4043-8f0e-5dadc939188d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_22d0550d-433c-4bb2-afd1-258e5c975fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_RestructuringCharges_22d0550d-433c-4bb2-afd1-258e5c975fd1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_37893335-51b5-4508-9cef-736370a6471f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_37893335-51b5-4508-9cef-736370a6471f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_db86ec29-6a65-4776-8891-abb968fcdfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_db86ec29-6a65-4776-8891-abb968fcdfb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_77600d9f-c9b2-4e62-af11-f623614243dd" xlink:href="nvax-20240630.xsd#nvax_PaymentsForSeveranceAndEmployeeBenefitCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_77600d9f-c9b2-4e62-af11-f623614243dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f379df48-77a5-4e31-b71f-5afd43a4f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_SeveranceCosts1_f379df48-77a5-4e31-b71f-5afd43a4f2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a97680e1-8106-4e40-a420-23c58533637e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_AssetImpairmentCharges_a97680e1-8106-4e40-a420-23c58533637e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ea120d47-cb1e-421e-874e-04f93d3c2a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ea120d47-cb1e-421e-874e-04f93d3c2a7c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnC.JacobsMember_f75cafe3-ebb7-4114-9218-0fe95148b28f" xlink:href="nvax-20240630.xsd#nvax_JohnC.JacobsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_JohnC.JacobsMember_f75cafe3-ebb7-4114-9218-0fe95148b28f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnTrizzinoMember_7ef7a5c3-11b6-4a8b-9b1a-99118bd88177" xlink:href="nvax-20240630.xsd#nvax_JohnTrizzinoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_JohnTrizzinoMember_7ef7a5c3-11b6-4a8b-9b1a-99118bd88177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMember_f1a80e19-f241-4be1-9c56-128e9157e841" xlink:href="nvax-20240630.xsd#nvax_FilipDubovskyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_FilipDubovskyMember_f1a80e19-f241-4be1-9c56-128e9157e841" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>nvax-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_04d6b183-ea83-4700-98b7-c64099b9278d_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:href="nvax-20240630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MarketableSecuritiesMember_e2634dbc-c2f0-4b55-b1c7-e2c921c339f2_terseLabel_en-US" xlink:label="lab_nvax_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_nvax_MarketableSecuritiesMember_label_en-US" xlink:label="lab_nvax_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_nvax_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_nvax_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MarketableSecuritiesMember" xlink:href="nvax-20240630.xsd#nvax_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MarketableSecuritiesMember" xlink:to="lab_nvax_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d59444b8-5f4a-4b43-9f28-8bb46278a62b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription rate cap</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_83f182ab-ac72-430b-a1b8-be6ae6c5ecfe_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer refund liability, current</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9b6ea71f-cb2e-49bd-86d6-7d2cd61512ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_612a286d-fa4b-414f-b3e3-9cba248804f7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_e06b990e-35f4-4eae-8257-88baf228a6f8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Semi-finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d87ce812-503f-4f0a-8ff0-2dc8a13ced15_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_0ee4c972-0c84-465d-826f-070c9317ef73_terseLabel_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from the exercise of stock-based awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_label_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_documentation_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:href="nvax-20240630.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:to="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_713c258b-579c-4044-9dd2-ee9688c1bfd2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10168608-cfcb-48b8-b81d-790ef1272468_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_175be37f-df43-470f-be27-61383c003103_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c78c8584-0621-4331-b363-ac9dc73b3c66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_312c876d-7e4c-4d11-8b98-371fdee2afed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a624d7ef-2f64-4994-a65a-ef9f0862ff38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5321c268-8932-4110-ab9e-4c201b96aede_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_ae41139a-ca14-433d-ad57-068b28129c3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JohnTrizzinoMember_label_en-US" xlink:label="lab_nvax_JohnTrizzinoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">John Trizzino [Member]</link:label>
    <link:label id="lab_nvax_JohnTrizzinoMember_documentation_en-US" xlink:label="lab_nvax_JohnTrizzinoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">John Trizzino</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnTrizzinoMember" xlink:href="nvax-20240630.xsd#nvax_JohnTrizzinoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JohnTrizzinoMember" xlink:to="lab_nvax_JohnTrizzinoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_2dba3dd2-eff6-45b0-9031-59ee04171dc6_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_fbd45f1b-71b7-45fe-a97d-55cac2b3aa93_terseLabel_en-US" xlink:label="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for severance and employee benefit costs</link:label>
    <link:label id="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_label_en-US" xlink:label="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Severance And Employee Benefit Costs</link:label>
    <link:label id="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_documentation_en-US" xlink:label="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Severance And Employee Benefit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:href="nvax-20240630.xsd#nvax_PaymentsForSeveranceAndEmployeeBenefitCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:to="lab_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_232c6769-2067-4c2c-b185-aec31fd9d1e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0343239c-0954-4a9d-adfc-3a13d4361bf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TransitionServicesMember_962df772-2d67-46c1-9402-1c292764159e_terseLabel_en-US" xlink:label="lab_nvax_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Services</link:label>
    <link:label id="lab_nvax_TransitionServicesMember_label_en-US" xlink:label="lab_nvax_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Services [Member]</link:label>
    <link:label id="lab_nvax_TransitionServicesMember_documentation_en-US" xlink:label="lab_nvax_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransitionServicesMember" xlink:href="nvax-20240630.xsd#nvax_TransitionServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TransitionServicesMember" xlink:to="lab_nvax_TransitionServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ae7ec545-9a8b-4b91-bf5d-5dcaada36149_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ddecd6b9-ad16-4a41-a8ef-1bf931b90601_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72e0679a-5cfd-4527-ba47-9983d540f701_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance ending (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_36757f97-1216-4743-99ce-5d531e9a7842_terseLabel_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Subscription Arrangement</link:label>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_label_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Subscription Arrangement [Member]</link:label>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_documentation_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Subscription Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember" xlink:href="nvax-20240630.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SecuritiesSubscriptionArrangementMember" xlink:to="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementVariableConsideration_253dabe1-e10c-466b-92af-d8057fac1801_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">collaboration agreement variable consideration</link:label>
    <link:label id="lab_nvax_CollaborationAgreementVariableConsideration_label_en-US" xlink:label="lab_nvax_CollaborationAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Variable Consideration</link:label>
    <link:label id="lab_nvax_CollaborationAgreementVariableConsideration_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementVariableConsideration" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementVariableConsideration" xlink:to="lab_nvax_CollaborationAgreementVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e915253c-b125-433b-ab0f-a27bdb62ac19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_fc6dc730-6576-46b3-ad76-8babec4ed1a6_terseLabel_en-US" xlink:label="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill &amp; Melinda Gates Medical Research Institute Arrangement</link:label>
    <link:label id="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_label_en-US" xlink:label="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill &amp; Melinda Gates Medical Research Institute Arrangement [Member]</link:label>
    <link:label id="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_documentation_en-US" xlink:label="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill &amp; Melinda Gates Medical Research Institute Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:href="nvax-20240630.xsd#nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:to="lab_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_647b5643-bce9-4004-9ff1-d6ebafeaef02_terseLabel_en-US" xlink:label="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CIC Product-Related Development and Launch Milestones</link:label>
    <link:label id="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_label_en-US" xlink:label="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIC Product-Related Development and Launch Milestones [Member]</link:label>
    <link:label id="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_documentation_en-US" xlink:label="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CIC Product-Related Development and Launch Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:href="nvax-20240630.xsd#nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:to="lab_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_9968b8e7-add3-4fb7-8a36-4f6ed2866ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service, Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7ab4dda-bf5a-45db-aa6e-fc8f3e146409_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0594bedd-6f84-4336-8f2e-c677a6702748_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_74abde9e-bb2e-4e0b-9312-f1d7cb5f13f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e835c1fe-8907-40d3-97f4-5df99d027673_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7ea78e9e-5e75-4b5d-9c28-653cd2d8fd1e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bf6b7a33-c1e4-4574-983c-0161b7f3bd66_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5e67053b-2f1e-40c4-9f36-361fc59a55ed_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3572b53d-b4c0-4f4d-895c-808fe44b6e6b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9c4e4a15-0edc-44ab-b290-b19ecccb8979_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_39b5fb62-83c6-4501-9a13-8ec30b70dba1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_4bb3504e-3928-4a77-98b6-5022303b2840_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on convertible notes</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9a0d22-ad36-42a2-97a9-c12062eab37b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c6cec21-0b86-4530-acb1-dad315445979_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2e3e15f6-7407-4a6d-9f10-82aa81c6c19d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3a935a70-1c52-45c8-a939-9e57fbc959f4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_c1fc7d83-2b04-4a5b-8879-1a6be98026ed_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_45681490-d861-444c-98ae-d525035f84a0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AustraliaRevenueAgencyMemberMember_08b0829b-b73a-474d-aa2c-4312579d556b_terseLabel_en-US" xlink:label="lab_nvax_AustraliaRevenueAgencyMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia Revenue Agency Member</link:label>
    <link:label id="lab_nvax_AustraliaRevenueAgencyMemberMember_label_en-US" xlink:label="lab_nvax_AustraliaRevenueAgencyMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia Revenue Agency Member [Member]</link:label>
    <link:label id="lab_nvax_AustraliaRevenueAgencyMemberMember_documentation_en-US" xlink:label="lab_nvax_AustraliaRevenueAgencyMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Australia Revenue Agency Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustraliaRevenueAgencyMemberMember" xlink:href="nvax-20240630.xsd#nvax_AustraliaRevenueAgencyMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AustraliaRevenueAgencyMemberMember" xlink:to="lab_nvax_AustraliaRevenueAgencyMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e2d103f8-2846-47e8-9b77-2c5df3be1fd5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45fd5f49-0cee-4537-9302-ed2c041a2bc6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f0e9aae-f216-4d3f-9212-3d69fd0659a1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense:</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RemainingPerformanceObligationAmount_e02647f1-cb41-4943-add4-ace43a98ca08_terseLabel_en-US" xlink:label="lab_nvax_RemainingPerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of transaction price not yet satisfied</link:label>
    <link:label id="lab_nvax_RemainingPerformanceObligationAmount_label_en-US" xlink:label="lab_nvax_RemainingPerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Performance Obligation, Amount</link:label>
    <link:label id="lab_nvax_RemainingPerformanceObligationAmount_documentation_en-US" xlink:label="lab_nvax_RemainingPerformanceObligationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RemainingPerformanceObligationAmount" xlink:href="nvax-20240630.xsd#nvax_RemainingPerformanceObligationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RemainingPerformanceObligationAmount" xlink:to="lab_nvax_RemainingPerformanceObligationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0aaa6821-f4a4-4511-9c71-db9e3f80edf8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d6e0cf48-33f4-4e7d-9fff-05e3e9d3997a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_dafdc0f7-349b-45ed-af2e-bcc7e5a8b806_terseLabel_en-US" xlink:label="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</link:label>
    <link:label id="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_label_en-US" xlink:label="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA [Member]</link:label>
    <link:label id="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_documentation_en-US" xlink:label="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:href="nvax-20240630.xsd#nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:to="lab_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2d77f2f1-efb2-44f1-8b3a-ec6990043a2e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_370e45d6-9a12-4eb6-a8ba-cf41c6db2f49_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase of shares each anniversary</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f276a9ec-3a05-4ee0-a346-5f44d44a0c00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding (less than)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_604de697-c7bb-4a8d-a236-85261c3a21f2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_25a695ce-7bbd-433a-bf4a-48aedbeb2131_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_25d64c40-cd2f-411f-955c-8dcd85af50ba_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_88474dd8-3b66-4772-abef-9a828965c72a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_f4415bad-8ce5-48b0-91af-ca710e77c14b_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2005&#160;Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Five Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_ee3d92c6-e1d2-4d42-8df2-d04251c0e8c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8d47b92c-985c-4d99-b568-493755b7a0dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e71116fe-92ae-4a53-8d44-cd226eb60869_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_60b7b7ab-c49b-4400-8c1e-4716da2f6ae9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_65a086d9-9417-4714-8b0e-0e0d547525e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_21f49335-ca30-43f8-be7a-57f7b4816c2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_688dacac-d485-4f0f-899d-8e5090e5d0ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from calculations of diluted net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_6ce84676-a3c7-4bce-8617-d7d7353ae27c_terseLabel_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture [Abstract]</link:label>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_label_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture [Abstract]</link:label>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_documentation_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:to="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc1f6527-ccd1-494a-bb33-e5e5cef37ec9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1418a138-beba-459b-bcbc-168b49d8382c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eaeb8ee8-8918-4606-846e-453ad0a1a45e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_7519b6d1-8c1f-42a8-8b05-24ca346ae5ad_terseLabel_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under incentive programs</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation stock issued under incentive program</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued issued under incentive programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20240630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f0cfd8ab-18b5-4f49-937e-05fa7bc3f43a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LicenseFeesMember_6ca50ede-9e76-4636-874c-edb76c11861e_terseLabel_en-US" xlink:label="lab_nvax_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fees</link:label>
    <link:label id="lab_nvax_LicenseFeesMember_label_en-US" xlink:label="lab_nvax_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_nvax_LicenseFeesMember_documentation_en-US" xlink:label="lab_nvax_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicenseFeesMember" xlink:href="nvax-20240630.xsd#nvax_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LicenseFeesMember" xlink:to="lab_nvax_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aa6cb841-3c81-42b5-a34f-b7bcd27fc497_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6e1a0cee-38a8-41b8-8f7d-e50ef26a2795_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_fdb1a2da-727e-4522-8f96-7f74b08a60ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_0c8efc41-baee-47af-ac33-215e6c6d6711_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_4faedb3c-bcd8-46e9-8039-3cb2029b4842_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit losses, beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_059051a1-7e7f-4b76-af00-1815146dc920_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit losses, end balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_c2b70353-98ce-48a9-9c61-de46e415a9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_3973cc3a-c3d7-4d4f-b62e-dc8b37364aac_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_81fcdcc8-9ff5-4749-9759-9ca22ecdf8be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_5a7b85de-0f9c-4344-a221-88269e327e8a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_d2b21611-9569-4c3e-a8ac-aa6bea1b4730_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9a5b5982-14ef-44f1-b112-d803ae49b175_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2682985b-9192-4fde-a73b-5b857ce2a072_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8c8fa9ad-4c43-4112-ade7-a2f21d71df69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33c7a538-bed5-4bbd-9d37-b32129b3abb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_5ce50d73-bdea-4c48-a30e-066a25f99132_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b3c42094-53da-43e1-aa67-f8ec7a5e7f58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_f318cdfa-a9c8-4828-a16b-1674029e7496_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_266c323e-7b38-48b9-9363-5cc2a11bfca2_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f752ca0d-8a0d-4742-830c-3771b5f80035_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_650cbc7a-06ba-45b2-91ee-ff4e6858d3e6_terseLabel_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of quarterly installment payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_label_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_documentation_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:href="nvax-20240630.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:to="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_02876e25-4171-4cd8-9298-bdc7976d4406_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_34bad8f1-f80d-45f4-a7fc-ad853f8c63f6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fffd1148-ef7a-483f-9c27-0b2520a32486_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_abb9798f-cacf-4243-b593-512fd7a2fbe0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_00bd0d61-0340-404b-ae14-0e53d755d4c8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_aedcc334-98b1-4393-97b7-93d2d5bf95ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_e5594659-a3e7-4e6c-a477-4cdfcf2c8b7e_terseLabel_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada Revenue Agency</link:label>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_label_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49b36e7d-7f77-42ad-a9e0-addf4f8bc503_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d046bfc-ded5-43c5-aae3-a8bfc08728d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1a3157bc-d3a8-4741-86c4-7d7f64cef36e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_fdbfa8b7-a903-4016-aaa7-a36b95ea5442_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_062f2f09-aceb-47c5-b74c-dd82e1c6b4a6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_fc888438-dd8b-4918-aa10-8fd39b6ffc6f_terseLabel_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada APA</link:label>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_label_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada Advance Purchase Agreement [Member]</link:label>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Canada Advance Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember" xlink:href="nvax-20240630.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CanadaAdvancePurchaseAgreementMember" xlink:to="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5fd06eb-a90a-4684-a9ac-77a16e47c465_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fdefcc15-b28b-464e-9653-0d39e12c0191_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_531af791-04f1-4865-8231-9ba87654ea5c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting unit</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e3f6079f-7e35-4bab-8893-b196100bb0c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bebdce93-d843-4afe-a7ef-ad7dc442f86d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of investments classified as available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8dd08421-a69b-4c95-aa0a-0c6e707a3174_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7af50433-f5b4-418f-9b9f-9878ec6157e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_233fa569-a5e3-4471-b3c6-82e47c8403c2_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0603aa83-ea6a-422c-bf65-ff91e9bbd91d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_98d65198-b5e5-4efc-9d70-4b7fd44fc04c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_86a1cff9-d6bb-490f-8cf8-67398784c4cd_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:to="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborativeArrangementTerm_784ff89a-90e0-4f41-9794-cee1dea5b383_terseLabel_en-US" xlink:label="lab_nvax_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_nvax_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_nvax_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementTerm" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborativeArrangementTerm" xlink:to="lab_nvax_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_eaee2fcf-dcbc-4a63-b65e-98a42431f716_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_5907630b-6070-4181-bde1-7fcb932acec4_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Government Partnership</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_label_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Partnership [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Government Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember" xlink:href="nvax-20240630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentPartnershipMember" xlink:to="lab_nvax_USGovernmentPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_7304f9f5-dd4e-47cd-af11-16b3ef6f140e_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6c57079b-81be-40ac-a9a9-20513d4a9738_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SanofiPasteurInc.APAMember_625d88bf-e9bd-4e5b-b5cd-64fff8ddec43_terseLabel_en-US" xlink:label="lab_nvax_SanofiPasteurInc.APAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Pasteur Inc. APA</link:label>
    <link:label id="lab_nvax_SanofiPasteurInc.APAMember_label_en-US" xlink:label="lab_nvax_SanofiPasteurInc.APAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Pasteur Inc. APA [Member]</link:label>
    <link:label id="lab_nvax_SanofiPasteurInc.APAMember_documentation_en-US" xlink:label="lab_nvax_SanofiPasteurInc.APAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi Pasteur Inc. APA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SanofiPasteurInc.APAMember" xlink:to="lab_nvax_SanofiPasteurInc.APAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_63d81338-dd02-44c8-9df5-ddeb0ba77d71_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_47a9f9d1-2a74-43e1-a1d0-4b844c3a0dd3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2161a17-9c3c-4af9-8b0a-e7dd7fd55585_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_43343546-0a1d-48f2-9546-a1a1a01e5bef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_78a92e9c-0004-4e06-9da7-56f8f5fc20e7_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_a46271c2-2494-4658-901f-f0b08df8690c_terseLabel_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets from new lease agreements</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:href="nvax-20240630.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:to="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b009bc1d-dc50-4e8d-a617-c8384cecf9b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2b1fab3c-d474-4501-bb45-5329f27ba5a8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_80fe9c50-2940-485c-9c87-c54a95411712_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized loss on available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_878b3c1a-403b-44c2-a092-aa96c6a399ff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2b86c8f1-706f-4df1-813a-70dd8da7d911_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">&#8203;Weighted average number of common shares outstanding, dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_76f219b3-3571-457c-ab33-7abb73dd2a62_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_67a0d822-9393-4458-a654-ec68ec5caca6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_15c9f96f-f86f-41ae-868e-a05d3b2cb2b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:to="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_579ebbff-b9f9-46ad-935a-0281df351b24_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ee739ef9-e290-4a6a-b448-ee96de080047_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f9983f50-c47e-4ddc-9567-fada0878b521_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_89c2f8c0-ae19-47c0-bd1b-60de2c3d2580_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f8eace16-7103-4735-8be0-40ed371057e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_91187346-45fc-4872-bca0-6740aef636cb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a80b9819-4d75-450a-9061-b5f468749ed8_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration, License, and Supply Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_50a672a5-65dd-4ed6-bb28-e4879bfd55a1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_dba1803a-2f56-4a29-b0cb-77b9f5412288_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_eed20c32-2e41-4e07-8108-878f156bd4da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_585d403c-c25a-4923-981d-0e89ab8f647d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_5003426a-4ceb-437c-b5f5-200c6d2430f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of 2023 Convertible notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_d8fef8ca-e166-4b86-81e9-86cf988af8ed_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under incentive programs (in shares)</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Stock Issued Under Incentive Program</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued in incentive program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_f2412c07-5dae-4b4f-8edc-52416889b3e4_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed contracts receivable</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_565959ca-4db4-4215-b1e2-4cd8b2783b75_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_e4b42f10-f8e3-40d7-b21a-0eb3d4d8d262_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ef24366-b27c-4cee-86fc-66ca0e64b2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_8b11df80-6561-4907-9b09-5e49845c46a7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_bcafe06e-f34d-4b74-8b7d-0837d69aa663_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_71d2d60b-dad8-48ec-aa80-cd35139259c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_1d3d40f6-666c-4b9d-a4dc-3f305c977123_terseLabel_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_label_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_documentation_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer" xlink:href="nvax-20240630.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LossContingencyPeriodToAnswer" xlink:to="lab_nvax_LossContingencyPeriodToAnswer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4b8bae40-2dc9-44ba-a53d-80c21282e450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e9bfb5c7-dc78-4fa2-87ca-ae4e7f91bd87_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9b62a05a-e42b-4f6c-970a-3dccafd621f5_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_497c8a99-cd17-4f99-8597-be5cacdf9b09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5d5794b7-cb51-4470-8263-ba97c516ee06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a11d8ac5-99a8-4581-a26a-fc437be03a56_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6796b56c-6a4a-45d1-afe6-fe47014979b0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6fad08f9-bfbc-4471-a63b-905fc2a5ea52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1137785e-5d11-4ab5-80d9-aab454488153_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_96c48ca3-0252-4161-92fd-fff4513a3c02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3f71fd13-03e9-48f6-976d-84959ce2bdfd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3f4a640e-9bcc-48f5-b165-71bfc72953da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Abstract]</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborativeArrangementAbstract" xlink:to="lab_nvax_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_7de3aca0-c4e3-44bb-8753-59ccc0235763_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3971df8d-5331-4dbc-84ac-960fff697cd8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8c00d119-463c-4be4-8ccd-72045ae387ec_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CostReimbursementMember_d8672533-c14f-40ae-82d9-8baf3481197b_terseLabel_en-US" xlink:label="lab_nvax_CostReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost reimbursement</link:label>
    <link:label id="lab_nvax_CostReimbursementMember_label_en-US" xlink:label="lab_nvax_CostReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost reimbursement [Member]</link:label>
    <link:label id="lab_nvax_CostReimbursementMember_documentation_en-US" xlink:label="lab_nvax_CostReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CostReimbursementMember" xlink:href="nvax-20240630.xsd#nvax_CostReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CostReimbursementMember" xlink:to="lab_nvax_CostReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_428b53e3-1341-4e9d-8953-0af7a1d77d8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_062206e3-a4b0-4717-a17f-d346deb089c7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_537453dc-02b3-4d97-9e30-4f1bfb47b0ad_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_606e9828-e23b-4d21-8b3e-14da34baa354_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ec8a1031-9785-47ff-b7b5-dad3538607f5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NewZealandTerminationOfTheAgreementMember_db641a02-d0cd-4772-8075-c43e569e8282_terseLabel_en-US" xlink:label="lab_nvax_NewZealandTerminationOfTheAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Zealand, termination of the agreement</link:label>
    <link:label id="lab_nvax_NewZealandTerminationOfTheAgreementMember_label_en-US" xlink:label="lab_nvax_NewZealandTerminationOfTheAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Zealand, termination of the agreement [Member]</link:label>
    <link:label id="lab_nvax_NewZealandTerminationOfTheAgreementMember_documentation_en-US" xlink:label="lab_nvax_NewZealandTerminationOfTheAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Zealand, termination of the agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandTerminationOfTheAgreementMember" xlink:href="nvax-20240630.xsd#nvax_NewZealandTerminationOfTheAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NewZealandTerminationOfTheAgreementMember" xlink:to="lab_nvax_NewZealandTerminationOfTheAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_94a30303-306d-42c7-b9d8-058a42eacf55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_25d6ee47-74d7-42ed-94d6-7db278c0b16d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f20c80cb-ac74-41be-baaa-6ecfb54f1bba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6500e6cd-446a-4fee-a632-5d350f09f028_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used in Estimation of Fair Value of Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a6f1fa45-3cea-4e1d-8119-38c1856a14a8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_7b0779ac-ca6e-4600-96e6-131102476696_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5ebb44ac-5f64-4269-9765-11d78b789da6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b8331ae6-fc7b-41c9-a327-bb806e063d39_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6446cd6f-a398-44cf-8ccc-c3c4d8096c9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9d31e820-e69d-4941-8c88-574f33f4b781_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_22ed8375-df97-49aa-8727-c5dab77ca8de_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7169f59d-c6da-4b3b-b6db-aeb7113d5a7c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_5e55e680-6f77-4413-ae8d-1177b2cfa5f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_bfe3374e-6729-4123-9ceb-173b9638b650_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9927258d-369d-4c0b-98de-7b05b8fce73d_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7692c3b3-14ad-4171-9b54-e0b2b1883c97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_47d68586-5e61-4461-bd43-8572f505e2d3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e099f43f-11a4-483d-89b8-73ce213ff941_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_7728dfbc-4e4d-4fff-9c51-6c921f6fcad0_negatedTerseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_31857d2b-4118-4333-867f-187932a89084_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:to="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bb0cd81a-3468-4876-907b-8459e9ad05c9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_de06413a-42f2-47b6-8007-adb9472c3f67_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0d62bdd4-f349-4e5e-93d6-614a658fb1db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in product sales</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_45ddba08-64ab-47f0-ae4e-37b151c81b1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credits/deductions</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_16f3fc62-3ebb-4b1c-90b5-ea224e3e191a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_75cfe33c-6eff-44d3-8b66-3aa46db85068_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6e32fa47-e7cf-4280-abfc-990cefd8d4f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8bdbbd21-ac37-492a-9b38-a8c680a13474_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_1dff85ce-3a5c-4064-9f78-95a0f4a6a928_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward" xlink:to="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_904e91a2-8e98-4a73-9165-82a875675197_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AdjuvantProductsThereafterMember_aef75d09-2acf-405f-84e7-ea4b086a78b2_terseLabel_en-US" xlink:label="lab_nvax_AdjuvantProductsThereafterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjuvant Products Thereafter</link:label>
    <link:label id="lab_nvax_AdjuvantProductsThereafterMember_label_en-US" xlink:label="lab_nvax_AdjuvantProductsThereafterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjuvant Products Thereafter [Member]</link:label>
    <link:label id="lab_nvax_AdjuvantProductsThereafterMember_documentation_en-US" xlink:label="lab_nvax_AdjuvantProductsThereafterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjuvant Products Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AdjuvantProductsThereafterMember" xlink:href="nvax-20240630.xsd#nvax_AdjuvantProductsThereafterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AdjuvantProductsThereafterMember" xlink:to="lab_nvax_AdjuvantProductsThereafterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0c4bc209-cd7f-4434-8abc-cf5504d61533_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9da3b57f-b6a0-4712-a89f-43b3a274a871_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_a7a9bbe4-b07c-4460-b402-b007a001c4f3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cf90387-f5c3-422e-8cd3-ce1d4cdfc55c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6c715848-9598-4034-94c0-9e5ed6b741d4_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_461b7375-d18c-4b2f-b704-d61a24f54bc0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3787750b-cd53-4cec-923c-b2898c6f5e15_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7cba05af-dbb5-4b75-87c2-9e5bd0708c1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_8bb63e53-4568-484a-a9cf-d1c9089ab1e1_terseLabel_en-US" xlink:label="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Database lock of an Existing Phase 2/3 clinical trial</link:label>
    <link:label id="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_label_en-US" xlink:label="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Database lock of an Existing Phase 2/3 clinical trial [Member]</link:label>
    <link:label id="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_documentation_en-US" xlink:label="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Database lock of an Existing Phase 2/3 clinical trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:href="nvax-20240630.xsd#nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:to="lab_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84ed1237-d9e6-44ec-9dc8-30462ade042f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition services revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_b484c93c-deff-4c86-a937-57d9d026875b_terseLabel_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-backed securities</link:label>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_label_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Backed Securities [Member]</link:label>
    <link:label id="lab_nvax_GovernmentBackedSecuritiesMember_documentation_en-US" xlink:label="lab_nvax_GovernmentBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to government backed securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember" xlink:href="nvax-20240630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentBackedSecuritiesMember" xlink:to="lab_nvax_GovernmentBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_4eec5a60-6e46-4027-bce1-ee3a350535fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc55cc4e-655b-4e44-a7b7-6c1766d6bc98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_cd8cf045-75b6-4e2d-a99d-f616d7357877_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_c5912a38-a09c-45ed-ab05-623f9c67c905_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fcfb955-631b-4c77-bfab-9e0e88d1886f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_97e34b03-928e-4e92-9ecd-ae1a67a165d1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_6f43216c-0c8f-4e62-96fd-6b910b853c67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a8a1682a-aedb-40ba-93fa-9349e27d9db6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f9febd7b-b1da-440b-92b9-facb358a5a34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cc040b8a-54eb-4c5f-8487-087be10f01af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ea78d382-5445-4b2d-b608-114ffca2efce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, prepaid expenses, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a56c6963-65c7-47a1-a6d3-39a3fc282f8e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1cf186d1-9dd5-425d-9a50-3bb82caf3839_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Restructuring charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b5f3076d-717e-4a8f-97cd-9da19f6b73c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_388f64ab-0be2-467d-84b5-af31df4a4834_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal, state and local, income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_66181be1-f848-49e1-88cf-9b64daa21c53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of costs related to issuance of 2027 Convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7468d861-702c-4a0b-a23a-401e7b9426f5_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0ef14707-493c-4f6e-a4f0-dc91a8775133_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0e103d43-8495-42c3-a1dc-e7acba5b5ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3b0eaa21-d6cf-4fb3-844d-3a78d80d3271_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0fc50784-ffaa-40e5-bfdb-98f506a37024_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c8132d5e-ba4e-49ba-93e8-a9fa7795dc50_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_560e4040-68db-47df-b900-4fe080bf1ba4_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_796ebd7b-b128-4a59-b517-9d638698ae2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5df5031b-ca2f-435c-8882-05d85c93c305_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ff7ef573-55c0-4fbe-a382-d4dcb33dfe94_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_88d2bdd5-3eaa-4d0e-9577-9d27a43cd974_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_a8740c67-6161-41c5-b278-dedab05dfbe7_terseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.00% Convertible notes due 2027</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_label_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027 [Member]</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_documentation_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:to="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_96ab7c53-436c-4fec-8e84-3c99f8537d3f_terseLabel_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matrix-M Adjuvant Sales</link:label>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_label_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Matrix-M Adjuvant Sales [Member]</link:label>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_documentation_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Matrix-M Adjuvant Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember" xlink:href="nvax-20240630.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MatrixMAdjuvantSalesMember" xlink:to="lab_nvax_MatrixMAdjuvantSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e87453cf-1033-41b1-b36d-243f7783494b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Unvested, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3e419d84-a25e-42a4-8221-dee232f78729_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Unvested, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a63496a-adcb-4319-9199-5e7e8ef05400_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementMember_8446f6d1-f846-4413-a74a-d32d60db4579_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement Agreement</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_label_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Agreement [Member]</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementMember" xlink:to="lab_nvax_SettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_5629483a-31ca-43c3-b0b1-54ac0b66df29_terseLabel_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset" xlink:href="nvax-20240630.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseRightOfUseAsset" xlink:to="lab_nvax_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_8a97517b-6dc9-4eb3-8857-cc3bf13b8908_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lawsuits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_03406bbb-828a-4697-a3c3-b39acc9def1b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_5fff8734-0619-46a3-b37f-b91912a29700_terseLabel_en-US" xlink:label="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensed COVID-19 Products and Royalty Payments</link:label>
    <link:label id="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_label_en-US" xlink:label="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensed COVID-19 Products And Royalty Payments [Member]</link:label>
    <link:label id="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_documentation_en-US" xlink:label="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensed COVID-19 Products And Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:href="nvax-20240630.xsd#nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:to="lab_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cf7bcca2-f2df-411a-b4cd-6c8faeb5aad8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LicensingRoyaltiesAndOtherMember_a8f98314-cdf3-4e26-b33d-fe6eac2f2568_terseLabel_en-US" xlink:label="lab_nvax_LicensingRoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing, royalties, and other</link:label>
    <link:label id="lab_nvax_LicensingRoyaltiesAndOtherMember_label_en-US" xlink:label="lab_nvax_LicensingRoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing, Royalties, and Other [Member]</link:label>
    <link:label id="lab_nvax_LicensingRoyaltiesAndOtherMember_documentation_en-US" xlink:label="lab_nvax_LicensingRoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing, Royalties, and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensingRoyaltiesAndOtherMember" xlink:href="nvax-20240630.xsd#nvax_LicensingRoyaltiesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LicensingRoyaltiesAndOtherMember" xlink:to="lab_nvax_LicensingRoyaltiesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_ed02410b-73a4-41a1-85df-1651e50637f3_terseLabel_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts charged against product sales</link:label>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_label_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts Charged Against Product Sales</link:label>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_documentation_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amounts Charged Against Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales" xlink:href="nvax-20240630.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AmountsChargedAgainstProductSales" xlink:to="lab_nvax_AmountsChargedAgainstProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c081f85e-e75d-4740-a044-7739f607c139_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2a75eba-496c-41db-87f4-e878a9b0849a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_aefd9bac-a16e-4b87-b2fd-90acb23aa3d3_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_388b80c3-f3b4-43b9-a385-a7de61ea607d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58df31bc-7c3b-444d-abfd-613f03aa5458_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bb656c23-e36d-4aed-92bb-3dc45bb780a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4e61d3df-e606-47a8-a86e-5c4fad87ec4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0f4ad019-072f-4f8d-87f7-8c431985aac0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TakedaArrangementMember_6d7f1639-8bf9-4aea-915e-ca9933c43cb1_terseLabel_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_label_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Arrangement [Member]</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_documentation_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember" xlink:href="nvax-20240630.xsd#nvax_TakedaArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TakedaArrangementMember" xlink:to="lab_nvax_TakedaArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_ee3ecceb-ede0-4d24-a48d-a00a09663cee_verboseLabel_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, firm purchase commitment, recoveries</link:label>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_label_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Recoveries</link:label>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_documentation_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:href="nvax-20240630.xsd#nvax_InventoryFirmPurchaseCommitmentRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:to="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_f135e90b-9fb1-4284-bc57-ca7d89cff37f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.00% Convertible notes due 2027</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_acd54f3f-79c4-4996-be3f-e901883fd332_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_37a971e1-3a05-4667-a6fb-f7d46aadcc4f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c63dc50d-cf5a-4f29-a119-213c7db45c6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_c9465f93-6f80-470a-a00d-ed76601cea36_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_dbc2a588-a69b-42c8-b80c-c2bcde3a565a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_c2d794c7-a4a2-4b13-a357-dff1e33597ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_da8bae7b-a25b-44cd-9433-8c3fdb4b73d4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_df4a5aff-5806-4f76-ba5c-dc30e0de7774_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d0861e3d-818b-4a6b-832b-7cc759e49dfe_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66827479-f232-49f7-92e0-40c83675331a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement_7d540bb5-77af-4e15-8dfc-7a59967ff042_terseLabel_en-US" xlink:label="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaboration and license agreement</link:label>
    <link:label id="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement_label_en-US" xlink:label="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration And License Agreement</link:label>
    <link:label id="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement_documentation_en-US" xlink:label="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:href="nvax-20240630.xsd#nvax_ProceedsFromCollaborationAndLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:to="lab_nvax_ProceedsFromCollaborationAndLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_f3a1736d-8890-44c6-bd15-432d934cb69d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_845abfa3-7f20-4a21-8a40-0b8f8cd0daa9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_7f170034-2bcd-428a-8bd8-c786e2ee091c_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction gain (loss)</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_4bc79a7c-3c53-4e49-a1af-97ec3d83b0c5_verboseLabel_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_label_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense Related to Convertible Notes [Table Text Block]</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of interest expense related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:href="nvax-20240630.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:to="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_43c40ea3-3ac4-4024-9d2c-c46f60b16139_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WorkingCapital_3844f0ab-5a9f-4389-97cd-3c26117dfe51_terseLabel_en-US" xlink:label="lab_nvax_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_nvax_WorkingCapital_label_en-US" xlink:label="lab_nvax_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_nvax_WorkingCapital_documentation_en-US" xlink:label="lab_nvax_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WorkingCapital" xlink:href="nvax-20240630.xsd#nvax_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WorkingCapital" xlink:to="lab_nvax_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6a2bf046-f958-4b46-b370-64bb8488ed3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c2c7e353-b1da-4488-93fd-9aa9380a93b4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_b7442822-f69c-4a04-b5cd-dcba20d1d21f_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, cost basis, 1,376,106 shares at June&#160;30, 2024 and 1,000,323 shares at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LossContingencyExtensionPeriod_17180550-1be8-4ebe-82b7-8fcbd15641a5_terseLabel_en-US" xlink:label="lab_nvax_LossContingencyExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency extension period</link:label>
    <link:label id="lab_nvax_LossContingencyExtensionPeriod_label_en-US" xlink:label="lab_nvax_LossContingencyExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Extension Period</link:label>
    <link:label id="lab_nvax_LossContingencyExtensionPeriod_documentation_en-US" xlink:label="lab_nvax_LossContingencyExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyExtensionPeriod" xlink:href="nvax-20240630.xsd#nvax_LossContingencyExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LossContingencyExtensionPeriod" xlink:to="lab_nvax_LossContingencyExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b38874e2-71f8-4815-a981-c2907473dccd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_946efafd-68ad-427f-a527-dd62abaf6971_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under the Sales Agreement not settled at quarter-end</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e1ca5335-467a-498b-8688-64706127daa5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_b7d2ba8d-f3f0-4fb2-8ec8-42f84e3a5268_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_f1696e57-7f1a-4c3e-bc5f-ec3f5f442857_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6e786fe0-b8ea-43a4-93b2-64e2df024306_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_0dfca7c2-7779-4541-90df-c326f282633a_terseLabel_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks</link:label>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks [Member]</link:label>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:href="nvax-20240630.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:to="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_79db381f-33e9-4a59-9e81-ee6951bb218b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bf700b53-c937-448c-b167-013750a30752_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_0c0bf31c-b3c3-4256-a7ad-0db647c6485c_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015&#160;Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_40cd862b-6ee2-48c2-aa01-99a5f78b66f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8db8ba76-7453-456e-ba5f-e2f0f4bc44e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Value&#8203;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_244d3dbc-21cc-4ea7-ad34-85d954a12e9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4445a130-7788-49e4-a3cf-8d12b6668465_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_871d5a93-d3b9-4051-883b-385db7dd9246_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Firm purchase commitment loss</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5a70ef47-93f1-4102-95ef-a6beae7ac4c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_babcf11b-0749-4662-9ef0-0435fbea3720_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementInitialTransactionPrice_6313f00d-89f4-4959-b708-9aa984adaf32_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial transaction price at inception</link:label>
    <link:label id="lab_nvax_CollaborationAgreementInitialTransactionPrice_label_en-US" xlink:label="lab_nvax_CollaborationAgreementInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Initial Transaction Price</link:label>
    <link:label id="lab_nvax_CollaborationAgreementInitialTransactionPrice_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Initial Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementInitialTransactionPrice" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementInitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementInitialTransactionPrice" xlink:to="lab_nvax_CollaborationAgreementInitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b207aca6-7654-40bb-80be-eac59d37f317_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ClinicalMilestoneMember_155a880d-2adf-43db-a54a-9514e980074c_terseLabel_en-US" xlink:label="lab_nvax_ClinicalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Milestone</link:label>
    <link:label id="lab_nvax_ClinicalMilestoneMember_label_en-US" xlink:label="lab_nvax_ClinicalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Milestone [Member]</link:label>
    <link:label id="lab_nvax_ClinicalMilestoneMember_documentation_en-US" xlink:label="lab_nvax_ClinicalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ClinicalMilestoneMember" xlink:href="nvax-20240630.xsd#nvax_ClinicalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ClinicalMilestoneMember" xlink:to="lab_nvax_ClinicalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_76a64e29-b4e3-4555-81f3-1fbf6d4d425b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ea34b2cf-1c62-48f1-96f0-24c6aa26298e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d5afeec-316b-4784-91e3-bf135d8b9fb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_4594b74b-7d12-43b1-bcce-4d1e96c86734_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, number of positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6d5ed4c9-89dc-48d1-98ac-dc5c476face9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProductReturnsMember_a8900fd7-715a-4f4d-8000-e85c4810179e_terseLabel_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Returns</link:label>
    <link:label id="lab_nvax_ProductReturnsMember_label_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Returns [Member]</link:label>
    <link:label id="lab_nvax_ProductReturnsMember_documentation_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember" xlink:href="nvax-20240630.xsd#nvax_ProductReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProductReturnsMember" xlink:to="lab_nvax_ProductReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_d295e52f-6ddb-4cd6-818d-28e93522208f_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of doses to be distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_label_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed" xlink:href="nvax-20240630.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesToBeDistributed" xlink:to="lab_nvax_NumberOfDosesToBeDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_5227d1d3-b96a-4353-99cd-290e8c8c693b_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:to="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AustralianAPAMember_17dfd440-1dc0-4a43-a99c-7ef748b77923_terseLabel_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australian APA</link:label>
    <link:label id="lab_nvax_AustralianAPAMember_label_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australian APA [Member]</link:label>
    <link:label id="lab_nvax_AustralianAPAMember_documentation_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Australian APA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember" xlink:href="nvax-20240630.xsd#nvax_AustralianAPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AustralianAPAMember" xlink:to="lab_nvax_AustralianAPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9818ae7d-e280-4fbb-b20b-d6cedc168720_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c15c19f7-c249-4b38-87e6-3864945b6d03_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_June2021SalesAgreementMember_8e224265-2a54-4701-a809-66ddb2138d23_terseLabel_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_label_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember" xlink:href="nvax-20240630.xsd#nvax_June2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_June2021SalesAgreementMember" xlink:to="lab_nvax_June2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5f946f2e-a866-479b-ae85-b55acdb060d6_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_607db45f-1603-4696-92eb-83346ebe7e1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Domain]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:to="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_edcb1c05-5a4f-47d5-b1d4-0e96b5a8dbf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_August2023SalesAgreementMember_d4d0c74c-0b95-4770-82ed-ba6c98cd6354_terseLabel_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:label id="lab_nvax_August2023SalesAgreementMember_label_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2023 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_August2023SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember" xlink:href="nvax-20240630.xsd#nvax_August2023SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_August2023SalesAgreementMember" xlink:to="lab_nvax_August2023SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c9ec056a-696a-477b-a4fb-70d26ed65802_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_f5045c54-358e-4b9f-a53e-fe2850c12541_terseLabel_en-US" xlink:label="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completion of the Technology Transfer of the Company&#8217;s Manufacturing Process for the COVID-19 Vaccine</link:label>
    <link:label id="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_label_en-US" xlink:label="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Completion of the Technology Transfer of the Company&#8217;s Manufacturing Process for the COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_documentation_en-US" xlink:label="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Completion of the Technology Transfer of the Company&#8217;s Manufacturing Process for the COVID-19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:href="nvax-20240630.xsd#nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:to="lab_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_675b66bc-7180-4a8a-b38c-1050e7878469_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_958dcadd-36b6-49b0-9cea-48e68ff55a76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3492650d-a00d-43ae-b39b-bba0d0bbf808_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_93516bca-1503-4a63-b7bf-46f7129c7a22_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_857fb8d1-6006-4990-845b-ea2ae7669e60_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb98fe61-bffb-4911-af5f-e06c137a71ee_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c1d07b87-5579-4f8f-9b2e-31e307608c9b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3909cba2-5221-470f-ac9c-bae3f8d710c0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_ddfb1b66-59d3-4515-bef2-736793e03738_terseLabel_en-US" xlink:label="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</link:label>
    <link:label id="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_label_en-US" xlink:label="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA [Member]</link:label>
    <link:label id="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_documentation_en-US" xlink:label="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:href="nvax-20240630.xsd#nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:to="lab_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_389bd4cf-b66c-4fdf-952e-8aa6dee542f3_terseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:href="nvax-20240630.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:to="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_2c100b4f-4349-4a0f-a07c-c213b94e70e2_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2a86f2e1-bb71-459c-99b1-4f37de145b82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d03fe993-a2c0-4d0f-8073-2a1bf3379d97_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1699c76e-793e-4ed1-91d5-df2d83de245e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e89b49a8-3c3d-47f2-a4ab-3ddb25d4a22b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_5a1cc170-6241-45e8-bfd4-e58f2f792eb5_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_68e103f1-571b-4627-945c-1ca5b11f1d19_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash interest payments, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_ded5173b-50fc-4ee4-88e1-513a6c0e6e3d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Licensing and Transition Services</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_d75c2539-d658-4bcc-ad98-f0ab5d84f7ca_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement upfront payment amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_label_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:to="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_67d1a187-bf3c-4ec9-80e7-c21a4943570a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4c8e58b3-1a08-49cd-ad3d-5a74958e5670_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5cf8fcaa-d733-410a-84e1-0644d62e2128_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_a1f39492-8e61-412d-9e9c-9806b227e429_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_89f13ecf-767a-48b2-92b5-79f949f0aac5_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9ce53fa5-de3f-4a1b-8e0a-c9aed6d9fc58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_828383e4-4184-4b93-a261-8f03c5910927_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_00efa01b-5399-4dde-ab1a-1847309c4608_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d47003d-bf96-4ec2-9c30-f317e0318b0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per&#160;Share Weighted- Average Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96658f1e-9ddf-492f-8c04-8963ee35abe0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7e5369ca-c521-4f58-af3d-66364b20e634_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_bf98d829-3c97-4e8f-a9d1-c84590f47a0f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_831ab0c6-6681-449e-b980-99aa21e53f37_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2a02931c-226f-481f-9a3b-f8a9a2664345_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a324ef7d-5759-4e60-a4bf-2c9a0ab91063_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3b3b8ecb-3153-43ac-9e5e-41f2e05c94e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bd3d7b12-3be4-4f92-9de9-26a71319febc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fdc6a48c-c453-42b1-9e3c-a5b2d78fd0c8_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ec8e12c-9cce-4003-b676-643b93d173ee_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b81db3cd-119e-4a6b-ae4e-385c0af99e6e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c3c51db5-6d54-43b9-856b-17bb4b4356f4_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JohnC.JacobsMember_label_en-US" xlink:label="lab_nvax_JohnC.JacobsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">John C. Jacobs [Member]</link:label>
    <link:label id="lab_nvax_JohnC.JacobsMember_documentation_en-US" xlink:label="lab_nvax_JohnC.JacobsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">John C. Jacobs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnC.JacobsMember" xlink:href="nvax-20240630.xsd#nvax_JohnC.JacobsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JohnC.JacobsMember" xlink:to="lab_nvax_JohnC.JacobsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_bc4419b7-fdca-4d3e-9f75-d3159033a815_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue Gross to Net Deductions Balances</link:label>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue Gross To Net Deductions Balances [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue Gross To Net Deductions Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:to="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b61a6d19-f242-4a4b-813d-d2e32140e8f4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3998d82b-41c4-4a14-9874-ee7bdd5021f0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f9e6d6e7-5f63-4c4b-ba61-1ae1cf38ba17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8b02a259-26d1-4b82-8d41-501b735b1319_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d3a1c461-7258-4ee4-af9d-aaeee9ed9733_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59b2fb39-f342-4c53-bce2-615de163041a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_504f2357-4b68-4f23-b60e-81ca73316c4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6be91f6e-e226-40f3-a7f6-860d2b6f1da0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e7787fd-d24c-4248-9f8c-3d815ae1ceee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_52e8bd01-ff26-472c-a324-ad82d6425a0c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized contract cost, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8e9951c8-f411-41d2-831f-3aecf664f830_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ca612cc6-6b51-4b6b-a64a-3467e538ac3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDiluted_e120e5e2-6bdc-4c97-8731-c0c5c55bdbd5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss), dilutive</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_d07a765c-a598-4dbe-9375-6ea4d1a001b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares sold, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_f6178119-e324-45d2-a847-4201ed690c14_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_82bc5cf2-5a4b-4d78-915b-75172693a0e8_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_db9232e5-3a38-4dbf-b64a-77a92b6d94ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_589f798d-da3c-4085-a489-872b9ccc1acc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a24b8ef4-d5a4-406b-bca2-011730d6e921_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b29d1bbb-e131-4d9d-a446-0eaf6e86b1e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97f7dc8a-06da-49d8-b8e3-a91823979ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FirstFourAdjuvantProductsMember_c76d5ff8-ad89-4106-b537-55c4583345fd_terseLabel_en-US" xlink:label="lab_nvax_FirstFourAdjuvantProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Four Adjuvant Products</link:label>
    <link:label id="lab_nvax_FirstFourAdjuvantProductsMember_label_en-US" xlink:label="lab_nvax_FirstFourAdjuvantProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Four Adjuvant Products [Member]</link:label>
    <link:label id="lab_nvax_FirstFourAdjuvantProductsMember_documentation_en-US" xlink:label="lab_nvax_FirstFourAdjuvantProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Four Adjuvant Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstFourAdjuvantProductsMember" xlink:href="nvax-20240630.xsd#nvax_FirstFourAdjuvantProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FirstFourAdjuvantProductsMember" xlink:to="lab_nvax_FirstFourAdjuvantProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3e7a9ebb-be62-4e74-ae9a-9e8e84736309_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_8e929dc2-12cf-4a6a-97fd-e3f81c29ac6f_terseLabel_en-US" xlink:label="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development, tech transfer, launch, and sales milestone payments</link:label>
    <link:label id="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_label_en-US" xlink:label="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payments</link:label>
    <link:label id="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_documentation_en-US" xlink:label="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:href="nvax-20240630.xsd#nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:to="lab_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a9f6c948-cbff-44df-881f-c763b384bd88_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value, 600,000,000 shares authorized at June&#160;30, 2024 and December&#160;31, 2023; 161,267,120 shares issued and 159,891,014 shares outstanding at June&#160;30, 2024 and 140,506,093 shares issued and 139,505,770 shares outstanding at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NewZealandRevenueAgencyMember_7fefde56-5164-4c46-8c89-e2f0329215ec_terseLabel_en-US" xlink:label="lab_nvax_NewZealandRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New zealand Revenue Agency</link:label>
    <link:label id="lab_nvax_NewZealandRevenueAgencyMember_label_en-US" xlink:label="lab_nvax_NewZealandRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New zealand Revenue Agency [Member]</link:label>
    <link:label id="lab_nvax_NewZealandRevenueAgencyMember_documentation_en-US" xlink:label="lab_nvax_NewZealandRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New zealand Revenue Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandRevenueAgencyMember" xlink:href="nvax-20240630.xsd#nvax_NewZealandRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NewZealandRevenueAgencyMember" xlink:to="lab_nvax_NewZealandRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454f2f6f-14f1-477d-90ab-734c3e72aae1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_aa9a6a95-eef4-43f7-8c0a-9e07a5f4c1b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a35c6617-26ef-41f4-90d4-16ff43222100_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b364a431-fb07-42df-8322-73fa29e01ca4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4eb454e3-711e-4c65-bc96-c8d84982760c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_2053e336-3f42-4eed-8d25-045604a73774_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_5a47da62-719e-429a-b0c3-ee35ef12ad8f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_a19af44f-3225-41b1-9443-fe62ceb98495_negatedLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_433cd704-56cc-4f00-a319-ce087a7b0764_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09fe8f31-fe0d-48e8-a2c1-d77be91a6851_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6cbb2f11-0f46-431b-8179-1a3dbb024152_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value, 2,000,000 shares authorized at June&#160;30, 2024 and December&#160;31, 2023; no shares issued and outstanding at June&#160;30, 2024 and December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9728f02b-c3d3-4f29-9048-fdeabbb0faab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_61878c5d-68f1-4c3a-ad35-5f1d17387fa0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_5bc4ace9-78a0-4627-b266-de0c72c67546_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_c164281c-3af8-4348-a60d-8712660506ff_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_dcfc5ee6-3110-440e-90dd-bb7adc04e818_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_ee63773a-56bf-48f5-8926-fb6ca2877835_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_883aafad-5c0f-4414-a8fd-8a4e7acb9de7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5a596790-d5e0-45c7-a3c9-ee3388660506_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sales of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_5a8f15a2-f982-43bb-bb33-76d59feadc7f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TransferOfTechnologyMember_ed0cca83-4213-479d-83f6-98fc51b54b2b_terseLabel_en-US" xlink:label="lab_nvax_TransferOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of Technology</link:label>
    <link:label id="lab_nvax_TransferOfTechnologyMember_label_en-US" xlink:label="lab_nvax_TransferOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer of Technology [Member]</link:label>
    <link:label id="lab_nvax_TransferOfTechnologyMember_documentation_en-US" xlink:label="lab_nvax_TransferOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer of Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfTechnologyMember" xlink:href="nvax-20240630.xsd#nvax_TransferOfTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TransferOfTechnologyMember" xlink:to="lab_nvax_TransferOfTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bf1190e2-845b-4d4e-8ff1-32d1f94d55f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_a0842fb7-0a02-4be6-bf34-a90cc505f53f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b5fc0cca-dfc1-4cc1-9dc1-b9ce26840e7d_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4faea1b-af08-422a-ac89-fd2aa25ff427_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss), basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RoyaltyPeriod_71c3bee9-c773-4f50-a49e-a73b5e5164e3_terseLabel_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_nvax_RoyaltyPeriod_label_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Period</link:label>
    <link:label id="lab_nvax_RoyaltyPeriod_documentation_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod" xlink:href="nvax-20240630.xsd#nvax_RoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RoyaltyPeriod" xlink:to="lab_nvax_RoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_60e5dd29-2ca8-413a-975d-a8e8c9e6c49c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5368610f-1356-4253-a376-868fa3fd1274_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e27c2e0-6583-444a-87cc-a72959a9bd3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8ccfeca8-567a-46bc-96b9-7547850cbe98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8038707e-fe60-428c-89fa-0f0207bba5a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 15)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_818cfc3e-c2a1-421a-8873-99eb7b9b8e2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_6a4e9152-891f-4a82-a44e-4d290cdfcfb0_terseLabel_en-US" xlink:label="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of EMA Approval of the COVID-19 Vaccine</link:label>
    <link:label id="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_label_en-US" xlink:label="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer of EMA Approval of the COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_documentation_en-US" xlink:label="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer of EMA Approval of the COVID-19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:href="nvax-20240630.xsd#nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:to="lab_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bcc215c6-e76a-49a5-81ed-c18c563b6a82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b143c196-f1bf-4774-b0a1-5d03f4b180da_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_198d0780-bc36-491e-abf2-897e33851c55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value:</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_afe7304e-5a84-4868-be9e-0bd8b0d928f4_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_769fc6ef-416c-46ba-b482-1a1d45b32afd_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_3cd5b996-8ff2-499c-99cc-565bfe72a5ed_terseLabel_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining unissued capital</link:label>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_label_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Amount Of Remaining Unissued Shares</link:label>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_documentation_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Amount Of Remaining Unissued Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:href="nvax-20240630.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:to="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ad683dac-fda0-481c-8b8c-04ab5db96c6a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RestOfTheWorldMember_901636e5-e4cb-4009-ba6f-c3b37c12cc17_terseLabel_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_label_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of the World [Member]</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of the World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember" xlink:href="nvax-20240630.xsd#nvax_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RestOfTheWorldMember" xlink:to="lab_nvax_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_12267a38-f68a-4d33-bc46-41ddf7f4f53e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_74813f18-0124-4957-9f1a-b3af17b4e407_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9c6ff0ac-d59d-4e04-b898-ef0ba42f7a11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6535dcf5-b666-404d-ac34-1b094b515b66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Option and Appreciation Rights Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_46d05d90-9971-4ecf-9d5f-1cf903d226ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, stock options and vesting RSA's</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_96b95fb4-ed2f-439f-ae3b-0ce3d3c30d1f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4968639d-c8a0-4298-9351-e2000d299b3d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0be13ef7-3f03-4774-bc36-7c8047628093_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_872a8875-3672-4904-81c8-e8ee16633652_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ef276fa2-6c77-4f5e-9ab8-805caca62367_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_cfa90b76-c557-4004-aad4-4d3f5e1dad17_terseLabel_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_label_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI) [Member]</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_documentation_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:href="nvax-20240630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:to="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9486572d-fcfc-414d-a2a8-945208b32d17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b5b6e966-6290-4679-90a5-1ac67020a844_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_df643c19-7b28-41cd-bae0-cd8eab532a37_negatedNetLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b18649d2-e6fe-4760-9273-af502a93a416_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_15ee4aeb-4b0e-4bf1-b760-5b83c502407f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b6ad8f69-5fc2-4d44-b6e4-41424d5ef1ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f5a9f0b2-38e1-4352-b111-02290b3dbf30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_680cedcd-2fb1-4796-a19f-71e07d008596_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ba6c28f0-f159-445f-8f58-82df7da22f3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb28e37c-acb8-4f2f-aff9-7baf0ea798d4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_ab28aaa8-c6f6-424b-8418-174ababa5264_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance and employee benefit costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_94463b15-6190-4081-9ae7-251295b6aab4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">&#8203;Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bfd06dd3-f2c2-4f0d-bb9b-5c51ee29a024_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5e160d2a-0e3f-4815-9a88-4d72598a1af8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_42740b8a-5606-45e4-a05e-e42ac726e6b9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_07a3b6a7-a11c-4922-a084-3040ae60943b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_60187868-c0b6-4158-b98a-34fb2fa92e5c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_6d6762ac-447a-4fd8-a118-1d0cc186de18_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c8f572f4-dfb1-4f41-9ff4-b3062eee828a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementPayment_00110ada-4aa2-4074-ab2b-8e59ecb7a81b_terseLabel_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_label_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_documentation_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment" xlink:href="nvax-20240630.xsd#nvax_SettlementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementPayment" xlink:to="lab_nvax_SettlementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_649f2615-5bf7-4638-bc7b-b7bf31b34d3b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_53265d9b-e44b-43d3-8b81-7b6c67c9a44c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding and Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_84501ba7-6711-4807-95dc-3deeee084b47_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_d7777eea-755b-496d-bd7f-c728a1991aab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_bc67731a-a5de-492f-bc7d-fb934c785faa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_dc53e28a-39d7-4215-884a-4e3d9f045343_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum grant price, percent of common stock fair value</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_a9a064e6-a670-41ec-880f-b84ddce8f8ae_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost&#8203;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_e09dc9e6-1488-4623-9d99-8947c7696196_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2a1c67e4-f5c5-4a4f-9fe9-7d25977de2ac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef015a5d-e36c-4a29-8879-3628be13b6aa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ba97a96e-2bbe-4f66-a110-325af4550397_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_83c08ab4-47a5-46f1-a2e3-4f883c609676_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c018badf-f15e-4efd-9b24-fff999eb1f8e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f8c02de3-ea59-4650-8842-3e49ac55a5ba_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_adc67e93-ad4a-4f96-9449-ce10283e9b75_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_393af8a9-58fc-4705-91b9-c8f898a89fa0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdcf3abd-66ea-4665-b4ac-67dee17e3331_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_66d91fb7-3d43-41e0-92b1-4b283db46738_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bd6446a2-1ace-48b4-bb19-de9e0e1b44d7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_a9cdcbe2-4d46-413b-87e4-5e7de5368e4f_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Inducement&#160;Plan</link:label>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Three Stock Inducement Plan [Member]</link:label>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_documentation_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Three Stock Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:to="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_4c30c1de-b7cd-4f3c-8e71-57bd5d1fa697_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_19281057-edda-485d-a935-9e7db51a9b43_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentReceived_e27b607b-9c8f-4f85-9e26-23ebd148a9ce_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentReceived_label_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Upfront Payment Received</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:to="lab_nvax_CollaborationAgreementUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_383d5f33-bae8-4024-961e-ebdf7509b294_terseLabel_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="nvax-20240630.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ec94c3c7-8afb-4c9d-b63c-fe46b706020d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_300318e0-557a-46af-bd0e-b36a0404e08a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">&#8203;Weighted average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_fb24b310-33d4-4126-adb8-d318a4240876_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_8c7eb60f-8c3f-441d-a16d-2d620443a496_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8493c974-a0e3-4782-9469-128976e2d902_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2552e78b-2027-4cde-8352-2391300b0eaa_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_8077c3e2-4a4b-46de-beb5-784f284743c4_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c352397f-2591-4158-9460-c4471b31c64c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FilipDubovskyMember_label_en-US" xlink:label="lab_nvax_FilipDubovskyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Filip Dubovsky [Member]</link:label>
    <link:label id="lab_nvax_FilipDubovskyMember_documentation_en-US" xlink:label="lab_nvax_FilipDubovskyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Filip Dubovsky</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMember" xlink:href="nvax-20240630.xsd#nvax_FilipDubovskyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FilipDubovskyMember" xlink:to="lab_nvax_FilipDubovskyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_8215d0f4-b61f-42e4-b82a-99912078d89c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_8173a47d-548b-45f1-b4fd-2c7e4863223c_terseLabel_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_label_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_documentation_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:href="nvax-20240630.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:to="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40ca3835-f3cc-4857-bbbb-6926fa010bcb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_78ea9139-ea45-4331-9b15-3e89187307d3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_fbb02f1b-428f-4028-a723-7e2b63589c72_terseLabel_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes due 2023</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_label_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023 [Member]</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_documentation_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:href="nvax-20240630.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:to="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_57422a64-76d5-41fd-9df9-7b93e183ce01_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_d9f8391b-132a-4f6f-a958-0f8c6f52e7b7_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share Based Compensation Restricted Stock Awards Activity</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:to="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3cb1732c-8245-47d7-a062-3cbeab472ced_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4dc1b855-d73c-47ed-ba32-8fcde884b8d1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_6b3a25ed-1af2-4287-b8dd-2da3b69f4d2d_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>nvax-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e53c2f49-92e9-4848-9c1d-01ad87fefe0b,g:fd91fba9-c480-4a9f-be44-c83fc7e5ba24-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20240630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_51134204-3352-4204-bc82-b99dc2e95b2e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentType_51134204-3352-4204-bc82-b99dc2e95b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0376cd7c-dd86-4446-b92f-3edea99a8835" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentQuarterlyReport_0376cd7c-dd86-4446-b92f-3edea99a8835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_82e7d00a-cd19-436e-8038-1106314b3a9e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentPeriodEndDate_82e7d00a-cd19-436e-8038-1106314b3a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a2d8a5cf-7304-489e-8ea9-4eb80eb58b9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentTransitionReport_a2d8a5cf-7304-489e-8ea9-4eb80eb58b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1fe2f15a-7f43-4228-937c-e295c2de2df1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityFileNumber_1fe2f15a-7f43-4228-937c-e295c2de2df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_51af0898-9708-4d1e-b988-1b4cc6b232a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityRegistrantName_51af0898-9708-4d1e-b988-1b4cc6b232a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8dd41bf6-b20e-46f7-93a6-df8c17d73f1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8dd41bf6-b20e-46f7-93a6-df8c17d73f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d0d7b9d0-f753-4672-815a-553bfeb5a239" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityTaxIdentificationNumber_d0d7b9d0-f753-4672-815a-553bfeb5a239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d2c099c6-86e0-415c-bcea-5c81463fc6c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityAddressAddressLine1_d2c099c6-86e0-415c-bcea-5c81463fc6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7a4e0b07-b195-41ba-801a-ec959e5efc2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityAddressCityOrTown_7a4e0b07-b195-41ba-801a-ec959e5efc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_ce9dd816-0c0b-4594-a19a-90d18f131a6f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityAddressCountry_ce9dd816-0c0b-4594-a19a-90d18f131a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2be4f848-b711-41e1-bfe5-f8dbf6706ffe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityAddressPostalZipCode_2be4f848-b711-41e1-bfe5-f8dbf6706ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_76d4c8a1-0c13-47da-838a-e93c038a39c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_CityAreaCode_76d4c8a1-0c13-47da-838a-e93c038a39c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_23cad48b-6990-44cd-afdd-e80fda36f6ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_LocalPhoneNumber_23cad48b-6990-44cd-afdd-e80fda36f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ce498ff6-c0e3-461d-8d21-fdb2547e7c25" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_Security12bTitle_ce498ff6-c0e3-461d-8d21-fdb2547e7c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3c4f97ff-67ab-4f23-84b4-666a5fa4bb1a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_TradingSymbol_3c4f97ff-67ab-4f23-84b4-666a5fa4bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_28ce0c92-1d1c-43cb-8537-5319f08d1601" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_SecurityExchangeName_28ce0c92-1d1c-43cb-8537-5319f08d1601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2a849eef-9058-48fb-9eaa-88bcafeb7579" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityCurrentReportingStatus_2a849eef-9058-48fb-9eaa-88bcafeb7579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9e34973d-39ed-45e5-aecd-6ef401d4598b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityInteractiveDataCurrent_9e34973d-39ed-45e5-aecd-6ef401d4598b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_668ba1d3-c0d1-47c1-a375-c2b0d51ed788" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityFilerCategory_668ba1d3-c0d1-47c1-a375-c2b0d51ed788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f495c635-2b99-49ed-b837-77094cc2a93d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntitySmallBusiness_f495c635-2b99-49ed-b837-77094cc2a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_036be29b-a910-412d-ae3e-c3c38075fe17" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityEmergingGrowthCompany_036be29b-a910-412d-ae3e-c3c38075fe17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1a5a3ad6-3224-4a77-96bb-9a5c8e4fc9ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityShellCompany_1a5a3ad6-3224-4a77-96bb-9a5c8e4fc9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bbe31dac-b30c-4b08-a707-64c2781084a8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bbe31dac-b30c-4b08-a707-64c2781084a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_de707b2b-fe9d-48d9-82bb-ec7d9f58716f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_AmendmentFlag_de707b2b-fe9d-48d9-82bb-ec7d9f58716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a027bb00-5ffb-419b-92a2-1aaefb436f34" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentFiscalYearFocus_a027bb00-5ffb-419b-92a2-1aaefb436f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9d2e074d-fd0c-4efe-a17d-e4d41b5fc263" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9d2e074d-fd0c-4efe-a17d-e4d41b5fc263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_00cff970-78d1-40da-af51-a86da227bb49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_EntityCentralIndexKey_00cff970-78d1-40da-af51-a86da227bb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d85376ce-d416-4760-9311-0d27534e5354" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ad5f27f-065e-4e50-bcd7-586f4793e1e7" xlink:to="loc_dei_CurrentFiscalYearEndDate_d85376ce-d416-4760-9311-0d27534e5354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d26ee29d-fbb9-4639-b3b0-a92ebee6ab14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d26ee29d-fbb9-4639-b3b0-a92ebee6ab14" xlink:to="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:to="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c96e0e1e-df41-4387-bdcc-f2bdda9d2ff3" xlink:to="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ab93c21-da40-4c6d-929f-25c92d1676ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_us-gaap_ProductMember_6ab93c21-da40-4c6d-929f-25c92d1676ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensingRoyaltiesAndOtherMember_fe79414e-1012-428f-acbe-dcaeb3741d39" xlink:href="nvax-20240630.xsd#nvax_LicensingRoyaltiesAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_nvax_LicensingRoyaltiesAndOtherMember_fe79414e-1012-428f-acbe-dcaeb3741d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_576f95ec-f995-4fc6-aeec-f4c5488d9083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62be0393-381d-48b8-8b09-29d2ac57ea9e" xlink:to="loc_us-gaap_GrantMember_576f95ec-f995-4fc6-aeec-f4c5488d9083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d225da54-92cc-433d-81b5-fc25a9fe89d2" xlink:to="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_044a9382-4657-44d9-9ba2-1976c4ff3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_63aa2929-4f25-4c62-bf20-6c7596880874" xlink:to="loc_us-gaap_Revenues_044a9382-4657-44d9-9ba2-1976c4ff3c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_5c9f8fc3-28a6-45f3-8a6b-ae81f52a30f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_CostOfRevenue_5c9f8fc3-28a6-45f3-8a6b-ae81f52a30f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a2560fb-b3f4-4bb2-ab65-8f06bf2449c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a2560fb-b3f4-4bb2-ab65-8f06bf2449c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_79b92119-ca1f-481b-8361-f61bc9ea8efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_79b92119-ca1f-481b-8361-f61bc9ea8efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_89ea2aff-454a-4733-9d72-acb0f2d4c349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_383cc3b6-290d-4b4a-b101-a10dde631ed8" xlink:to="loc_us-gaap_CostsAndExpenses_89ea2aff-454a-4733-9d72-acb0f2d4c349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_31f8b6f9-e204-4b68-ae42-291e825d9294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_OperatingIncomeLoss_31f8b6f9-e204-4b68-ae42-291e825d9294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_345cbb6f-5fec-4d1c-86ce-d78530c900c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:to="loc_us-gaap_InterestExpenseNonoperating_345cbb6f-5fec-4d1c-86ce-d78530c900c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c136ab3-6cd1-4f24-9c49-94d3de7ad106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_b70ebbfe-910e-47a0-8568-ad359556aeed" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c136ab3-6cd1-4f24-9c49-94d3de7ad106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c1c7429-e44a-4c53-bcdb-27d95076e619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c1c7429-e44a-4c53-bcdb-27d95076e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_abdf1a4d-d13c-4981-8d72-96755d14f019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_abdf1a4d-d13c-4981-8d72-96755d14f019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11e95ca0-0845-47b9-a518-54d2fa24854f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_NetIncomeLoss_11e95ca0-0845-47b9-a518-54d2fa24854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_04b82829-08a2-4d17-9569-1351fba85b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:to="loc_us-gaap_EarningsPerShareBasic_04b82829-08a2-4d17-9569-1351fba85b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_503823f4-951a-499c-825d-e34015ec3e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f43c935d-4c47-4d9e-b946-6b8b01600ab8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_503823f4-951a-499c-825d-e34015ec3e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c3a427b-adea-4cd1-9cb5-641badfff114" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a543aef-ca1f-46fe-9308-fa3e374bd1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a543aef-ca1f-46fe-9308-fa3e374bd1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e8eff58-55a1-4b48-bf65-e3ef50cdf642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_6c004081-c20c-4f8b-a741-c8364f5f9d2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e8eff58-55a1-4b48-bf65-e3ef50cdf642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_699c8b3a-e75a-4c74-af03-a292e8436d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05ea8610-9e4b-4f0b-9af5-b3ec6804bec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_699c8b3a-e75a-4c74-af03-a292e8436d03" xlink:to="loc_us-gaap_NetIncomeLoss_05ea8610-9e4b-4f0b-9af5-b3ec6804bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_64c5da15-1be5-47b0-8a46-8674f511b0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_699c8b3a-e75a-4c74-af03-a292e8436d03" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_64c5da15-1be5-47b0-8a46-8674f511b0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b07015b2-39e1-4e60-90e2-943bd81f8be8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_64c5da15-1be5-47b0-8a46-8674f511b0fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b07015b2-39e1-4e60-90e2-943bd81f8be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_794b18ee-3628-4367-aa53-1ef96783c5db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_64c5da15-1be5-47b0-8a46-8674f511b0fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_794b18ee-3628-4367-aa53-1ef96783c5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2238aff2-8205-4a54-8107-22b992dcd1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_64c5da15-1be5-47b0-8a46-8674f511b0fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2238aff2-8205-4a54-8107-22b992dcd1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7da64e09-5746-40e5-83eb-0e309b9b3c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_699c8b3a-e75a-4c74-af03-a292e8436d03" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7da64e09-5746-40e5-83eb-0e309b9b3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e537b2d7-1371-4e7b-aa45-cdebd82d0fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e537b2d7-1371-4e7b-aa45-cdebd82d0fb6" xlink:to="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f18606f-a5a6-4b3c-b7d4-01dab2e941de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f18606f-a5a6-4b3c-b7d4-01dab2e941de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ac6f4ba5-be44-4e0f-b2bf-f6cc2dc7f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ac6f4ba5-be44-4e0f-b2bf-f6cc2dc7f49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_da600885-bef2-41b6-8d2f-4d484408ba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_da600885-bef2-41b6-8d2f-4d484408ba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d6b06fc3-cefc-48ca-8c7e-f2b21828847d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_AccountsReceivableNet_d6b06fc3-cefc-48ca-8c7e-f2b21828847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_230f74b9-7328-40a8-9ecb-194f269dcee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_InventoryNet_230f74b9-7328-40a8-9ecb-194f269dcee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d9bdb9b-eb80-47b9-83cc-b70432c42b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d9bdb9b-eb80-47b9-83cc-b70432c42b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_30402b76-36cd-4261-96a3-5c50e418efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ad35ee97-5279-41c7-9015-2d8a395a386a" xlink:to="loc_us-gaap_AssetsCurrent_30402b76-36cd-4261-96a3-5c50e418efb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_316556cb-570c-4237-9192-4416786c89bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_316556cb-570c-4237-9192-4416786c89bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_bb470297-5a24-45f9-b57d-66f890ee401e" xlink:href="nvax-20240630.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_nvax_LeaseRightOfUseAsset_bb470297-5a24-45f9-b57d-66f890ee401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f7fa3687-c5fa-4a8c-8955-8a3715e4dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_us-gaap_Goodwill_f7fa3687-c5fa-4a8c-8955-8a3715e4dc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9958a833-5456-46be-bc29-4e5ea48366f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9958a833-5456-46be-bc29-4e5ea48366f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d975b74e-1309-489f-a4f8-97111b52375e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fad04d2-4c2e-45bc-8396-2c1faea0e359" xlink:to="loc_us-gaap_Assets_d975b74e-1309-489f-a4f8-97111b52375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e537b2d7-1371-4e7b-aa45-cdebd82d0fb6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b11305a5-92c8-49cf-b35e-3ebae05fa9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_AccountsPayableCurrent_b11305a5-92c8-49cf-b35e-3ebae05fa9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ddfdc722-48cf-4d04-8082-f9a98237ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ddfdc722-48cf-4d04-8082-f9a98237ce36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0678670c-dd0c-4472-98f4-447f04aceab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0678670c-dd0c-4472-98f4-447f04aceab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7ade5352-dc7f-4a25-9144-eb43f6bffaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7ade5352-dc7f-4a25-9144-eb43f6bffaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6180ffbb-9be5-435f-9c9b-03bb87be24af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6180ffbb-9be5-435f-9c9b-03bb87be24af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_96b97a70-e4b1-42f3-95bf-0973e8310275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_017bc15c-3536-4475-9752-a6d59f0434a3" xlink:to="loc_us-gaap_LiabilitiesCurrent_96b97a70-e4b1-42f3-95bf-0973e8310275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2856e8df-4a6e-484d-9abd-31d76e1bd0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2856e8df-4a6e-484d-9abd-31d76e1bd0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_c6ef8bbb-c059-4e40-8ee7-ce6524209101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_c6ef8bbb-c059-4e40-8ee7-ce6524209101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_61b03817-1f2c-4618-ac6d-4e6c0f280c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_61b03817-1f2c-4618-ac6d-4e6c0f280c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2a4369a9-9a8e-4104-8c0e-a94babc5b0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2a4369a9-9a8e-4104-8c0e-a94babc5b0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b932ae2d-aadd-44c9-be32-c8d6a40316f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_Liabilities_b932ae2d-aadd-44c9-be32-c8d6a40316f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c9b39e0f-893e-49a3-9989-b1414a2c25f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c9b39e0f-893e-49a3-9989-b1414a2c25f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3e643c8c-aa31-46ea-9c80-aefadfa63897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_PreferredStockValue_3e643c8c-aa31-46ea-9c80-aefadfa63897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_256705df-3ced-4730-be5f-9b2fdec7e4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_CommonStockValue_256705df-3ced-4730-be5f-9b2fdec7e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8c31d02b-7edb-42b8-beed-cdc87074a353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8c31d02b-7edb-42b8-beed-cdc87074a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bce5bffb-d57a-4270-a770-743128541400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bce5bffb-d57a-4270-a770-743128541400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_48d7540a-aa47-43d9-b69f-436b1e493296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_TreasuryStockCommonValue_48d7540a-aa47-43d9-b69f-436b1e493296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_82989aa3-c2c5-4b73-b9f5-4a6430bd7112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_82989aa3-c2c5-4b73-b9f5-4a6430bd7112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c9e4516f-af25-40c3-abd1-2d75dc65dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cde1e006-ff45-4026-8319-84b98598b783" xlink:to="loc_us-gaap_StockholdersEquity_c9e4516f-af25-40c3-abd1-2d75dc65dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_acb815e9-bd42-43ed-8c24-411c71a0e608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc5bb31-fad2-473e-8969-ea504970f527" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_acb815e9-bd42-43ed-8c24-411c71a0e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9d9587ea-1542-4ff9-91e3-18b7df1d2fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9d9587ea-1542-4ff9-91e3-18b7df1d2fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cf96cad0-2a3c-4bb9-bf4e-4c66af905ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cf96cad0-2a3c-4bb9-bf4e-4c66af905ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_980c258e-0ed8-47f8-8c3e-7c1a3c8600c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_980c258e-0ed8-47f8-8c3e-7c1a3c8600c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_94f0feb5-ab46-4528-96d2-5a7f5340a27d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_94f0feb5-ab46-4528-96d2-5a7f5340a27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14c479ba-b180-406d-ac86-ab44e056c38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14c479ba-b180-406d-ac86-ab44e056c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_92f3ec3e-f13e-442a-a717-7e7564128cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_92f3ec3e-f13e-442a-a717-7e7564128cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_05e812b0-71f6-4db5-94a7-82a3d713482f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_CommonStockSharesIssued_05e812b0-71f6-4db5-94a7-82a3d713482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4d850856-7630-4d37-a818-2a8f8cea267e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4d850856-7630-4d37-a818-2a8f8cea267e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_00bfc22a-47aa-4637-9d6d-51edb9e67e85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ae9c986b-65ec-4f75-aae0-84bd23aed87d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_00bfc22a-47aa-4637-9d6d-51edb9e67e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_930219c1-2a4a-4bca-a010-28a40deda6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_930219c1-2a4a-4bca-a010-28a40deda6f1" xlink:to="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32097ef0-e47e-4e0f-a5a2-4578246ee79c" xlink:to="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76199508-7760-4e8c-ade3-a0e7000c89a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_CommonStockMember_76199508-7760-4e8c-ade3-a0e7000c89a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c98b62e1-16eb-46e4-bd46-12a563af728a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c98b62e1-16eb-46e4-bd46-12a563af728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c63ad4e1-60c1-4b45-a1d2-0b93fce26fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_RetainedEarningsMember_c63ad4e1-60c1-4b45-a1d2-0b93fce26fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_a55db702-bb23-4941-8fc7-a2333109250a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_TreasuryStockCommonMember_a55db702-bb23-4941-8fc7-a2333109250a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0415c20e-a3d1-4bf0-936c-7ca6b0c7e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695e93cd-90fb-4ff7-b910-b4139a82e907" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0415c20e-a3d1-4bf0-936c-7ca6b0c7e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2c63eff-46f9-4526-a676-d3029d2699a5" xlink:to="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcc8dbc4-262e-4113-8dbd-0f8442353ad2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f39c26b7-26d6-4a1b-b03d-28f4e14f1399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f39c26b7-26d6-4a1b-b03d-28f4e14f1399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3968f859-a315-4ad7-a5b8-33e34886d1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockholdersEquity_3968f859-a315-4ad7-a5b8-33e34886d1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a7ead54-00db-4b1f-9d6c-ea9a68365a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a7ead54-00db-4b1f-9d6c-ea9a68365a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_868ba0ae-b1a8-4945-987c-a5f65646af69" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_868ba0ae-b1a8-4945-987c-a5f65646af69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_0d3ea0d6-6466-4142-87f8-d75accc68d94" xlink:href="nvax-20240630.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_0d3ea0d6-6466-4142-87f8-d75accc68d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e85afc95-b675-4834-9019-14e273876b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e85afc95-b675-4834-9019-14e273876b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ccba6dc8-d9d4-44c0-ab79-7e9b88241892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ccba6dc8-d9d4-44c0-ab79-7e9b88241892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27160717-1a8c-4130-a602-71c407e8c440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27160717-1a8c-4130-a602-71c407e8c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_885e5087-a5ac-4573-a6b3-f506a7b48823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_885e5087-a5ac-4573-a6b3-f506a7b48823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf480186-e8b7-42eb-8f46-a4bf0e2452a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_NetIncomeLoss_bf480186-e8b7-42eb-8f46-a4bf0e2452a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6795ffaa-eceb-459c-b506-f614053cbda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6795ffaa-eceb-459c-b506-f614053cbda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da6c6012-1483-4842-bc27-d135557b0012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_412cffb3-3b40-4336-a939-253c58403c4a" xlink:to="loc_us-gaap_StockholdersEquity_da6c6012-1483-4842-bc27-d135557b0012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4a14781b-ee06-40bf-aa42-7d40a3d8114a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_08487f53-d1e8-42d3-b519-46cf28ddd191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4a14781b-ee06-40bf-aa42-7d40a3d8114a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_08487f53-d1e8-42d3-b519-46cf28ddd191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20240630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b707fea9-3c6f-4c4c-bfe9-ae8dcd1ec1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b707fea9-3c6f-4c4c-bfe9-ae8dcd1ec1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4751592-258c-48bb-9200-12f6e10cffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b707fea9-3c6f-4c4c-bfe9-ae8dcd1ec1ab" xlink:to="loc_us-gaap_NetIncomeLoss_a4751592-258c-48bb-9200-12f6e10cffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b707fea9-3c6f-4c4c-bfe9-ae8dcd1ec1ab" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1033d9f2-d3bb-45c4-a134-bb5d9f2fb893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_us-gaap_DepreciationAndAmortization_1033d9f2-d3bb-45c4-a134-bb5d9f2fb893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_338dbdf4-f063-4606-8682-68e1ada63bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_us-gaap_ShareBasedCompensation_338dbdf4-f063-4606-8682-68e1ada63bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_b609e74c-0a6b-4fde-a68a-ca50c1bb0fb8" xlink:href="nvax-20240630.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_b609e74c-0a6b-4fde-a68a-ca50c1bb0fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ad7e8dd3-0fa5-49ee-8dbc-b38abc5ae367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_us-gaap_AssetImpairmentCharges_ad7e8dd3-0fa5-49ee-8dbc-b38abc5ae367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6a18b6e5-3ed5-4fda-80dd-59f5a8ad2fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6a18b6e5-3ed5-4fda-80dd-59f5a8ad2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b031a23-30ac-4b87-a704-5a7c7e6ad609" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f7bb3f0f-7232-4643-9599-b731ee65be9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f7bb3f0f-7232-4643-9599-b731ee65be9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbc03e2f-8fbb-485f-8d0f-a31acc1925fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbc03e2f-8fbb-485f-8d0f-a31acc1925fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_86bcd7d9-16d1-4e35-8309-1f9612e41bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_86bcd7d9-16d1-4e35-8309-1f9612e41bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6406e5fd-297e-4c6e-adee-fe6bac0a36e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9498ea64-745f-40af-8bfd-f67b823a6a46" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6406e5fd-297e-4c6e-adee-fe6bac0a36e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fee8cfba-9db4-4853-aeee-72a79a810b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b707fea9-3c6f-4c4c-bfe9-ae8dcd1ec1ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fee8cfba-9db4-4853-aeee-72a79a810b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_fa790feb-8089-41ad-8cc4-38a3424bad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_fa790feb-8089-41ad-8cc4-38a3424bad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_617bb121-81aa-4536-bf6a-a17bda9417d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_617bb121-81aa-4536-bf6a-a17bda9417d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_1d50387a-2f09-47a0-9be2-22db2a6536d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:to="loc_us-gaap_PaymentsForSoftware_1d50387a-2f09-47a0-9be2-22db2a6536d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2c8266a0-f600-4487-bbe3-ff35e721af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_81208aae-b066-4ec2-b0ac-ba3818881260" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2c8266a0-f600-4487-bbe3-ff35e721af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecba1b22-a0b1-4be2-9ccb-978dfbf5c749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecba1b22-a0b1-4be2-9ccb-978dfbf5c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_90768033-9891-449e-bf12-8f6a929d3ad6" xlink:href="nvax-20240630.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_90768033-9891-449e-bf12-8f6a929d3ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_041f4802-7436-4f61-9a85-0ee4a66bc96d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_041f4802-7436-4f61-9a85-0ee4a66bc96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_c0236c66-bce0-4feb-b113-ecf4833bab76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_c0236c66-bce0-4feb-b113-ecf4833bab76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_d462eb92-33c7-4a0d-ba22-af9e8d698047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_d462eb92-33c7-4a0d-ba22-af9e8d698047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_269d5cde-4b73-4bb4-8b64-e88413ae6cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48297dbf-1c49-4e5b-a64b-c79243554906" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_269d5cde-4b73-4bb4-8b64-e88413ae6cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc8e95d0-c62d-40c5-b95e-36f6385a068d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc8e95d0-c62d-40c5-b95e-36f6385a068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d00f396b-fb34-4d45-bf0c-9d1d929d163c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d00f396b-fb34-4d45-bf0c-9d1d929d163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0735ddc9-8ee3-4f76-9972-b2d5af00b25e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0735ddc9-8ee3-4f76-9972-b2d5af00b25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25e0b53c-2e0e-40b2-8ee1-caecaf2344d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25e0b53c-2e0e-40b2-8ee1-caecaf2344d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6d7e376c-2b08-4793-b780-ce21e0c5e8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6d7e376c-2b08-4793-b780-ce21e0c5e8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_0bd34e81-b9cc-43e5-8be6-dcc34fc4b062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6d7e376c-2b08-4793-b780-ce21e0c5e8bf" xlink:to="loc_us-gaap_StockIssued1_0bd34e81-b9cc-43e5-8be6-dcc34fc4b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_47af7161-5150-4c77-8340-ac6e6747b4eb" xlink:href="nvax-20240630.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6d7e376c-2b08-4793-b780-ce21e0c5e8bf" xlink:to="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_47af7161-5150-4c77-8340-ac6e6747b4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_369abd1c-f788-443a-9f1b-5222d699218f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6d7e376c-2b08-4793-b780-ce21e0c5e8bf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_369abd1c-f788-443a-9f1b-5222d699218f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_74ba7d23-98d8-4739-9931-c4d7565fe478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a18146a6-b47f-4cff-8b62-09d312ab0dfa" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_74ba7d23-98d8-4739-9931-c4d7565fe478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_732035b2-37a8-4b62-b7a0-29f23c5e190c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_74ba7d23-98d8-4739-9931-c4d7565fe478" xlink:to="loc_us-gaap_InterestPaidNet_732035b2-37a8-4b62-b7a0-29f23c5e190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_55181d4a-2c05-4637-b959-ed2b3385e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_74ba7d23-98d8-4739-9931-c4d7565fe478" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_55181d4a-2c05-4637-b959-ed2b3385e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="nvax-20240630.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdff9004-0f83-446d-9906-451c39fb56d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_9fb4968f-6ade-4602-a701-65bdf3c51c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdff9004-0f83-446d-9906-451c39fb56d8" xlink:to="loc_us-gaap_NatureOfOperations_9fb4968f-6ade-4602-a701-65bdf3c51c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nvax-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_423b45e5-bc58-4a63-bb7c-05b7ed47f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_4b1d2c05-ba2f-4c86-a77a-5a6bd38422c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_423b45e5-bc58-4a63-bb7c-05b7ed47f93e" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_4b1d2c05-ba2f-4c86-a77a-5a6bd38422c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/MarketableSecurities" xlink:type="simple" xlink:href="nvax-20240630.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1657ce86-94e9-418c-8ca8-b6d66fc88a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_865c6c98-10ce-4276-b41a-65d7a0d58425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1657ce86-94e9-418c-8ca8-b6d66fc88a21" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_865c6c98-10ce-4276-b41a-65d7a0d58425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nvax-20240630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_134eb2fc-079d-4256-aa67-22e25973396e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_36986985-42f2-48e9-84df-4dfc01c82f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_134eb2fc-079d-4256-aa67-22e25973396e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_36986985-42f2-48e9-84df-4dfc01c82f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Revenue" xlink:type="simple" xlink:href="nvax-20240630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_3f4f843c-950b-4f8f-bc75-1104f3e2f829" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e79e78b2-946d-4965-9f87-ef21eae2114f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_3f4f843c-950b-4f8f-bc75-1104f3e2f829" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e79e78b2-946d-4965-9f87-ef21eae2114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="simple" xlink:href="nvax-20240630.xsd#CollaborationLicenseandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_b6e90256-27ea-4f68-b5c8-b05905c05cc9" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fd37a780-4193-42dd-8dd0-77a959c3467b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_b6e90256-27ea-4f68-b5c8-b05905c05cc9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fd37a780-4193-42dd-8dd0-77a959c3467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EarningsLossperShare" xlink:type="simple" xlink:href="nvax-20240630.xsd#EarningsLossperShare"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EarningsLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_276aef53-b2ca-4756-88ed-930d4bc74b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3bb09a18-0e62-4fb2-934f-966775cb4219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_276aef53-b2ca-4756-88ed-930d4bc74b83" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3bb09a18-0e62-4fb2-934f-966775cb4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nvax-20240630.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5fb34848-197c-49e8-afb5-99e5bfaa502a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_71f44338-ce8e-4e90-8c98-ccc84b07958e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5fb34848-197c-49e8-afb5-99e5bfaa502a" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_71f44338-ce8e-4e90-8c98-ccc84b07958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Inventory" xlink:type="simple" xlink:href="nvax-20240630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_46244bd6-a5e0-4e33-9203-e991c50a6a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_691302b2-0391-47ea-9144-b0d236b82beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46244bd6-a5e0-4e33-9203-e991c50a6a3f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_691302b2-0391-47ea-9144-b0d236b82beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Goodwill" xlink:type="simple" xlink:href="nvax-20240630.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5f223a-73cf-48df-8e44-f69fa19c7832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_deaf3649-6b8a-4df3-a6b0-2897c505e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5f223a-73cf-48df-8e44-f69fa19c7832" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_deaf3649-6b8a-4df3-a6b0-2897c505e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebt" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e2bc208b-9864-423a-b4b2-566690d679cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2091d64c-aae5-4689-8bbc-e711f8fd6491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e2bc208b-9864-423a-b4b2-566690d679cb" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2091d64c-aae5-4689-8bbc-e711f8fd6491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5e5b3562-fb91-4062-ab13-f2f18d193bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb98bcce-913f-4546-b74f-0815498bef19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5e5b3562-fb91-4062-ab13-f2f18d193bae" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb98bcce-913f-4546-b74f-0815498bef19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487f9151-a36b-4088-b2db-25f3416d1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dea133a-b2de-4090-b561-2edf2c28f91b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487f9151-a36b-4088-b2db-25f3416d1b17" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7dea133a-b2de-4090-b561-2edf2c28f91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nvax-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_edfc5080-c879-481f-883a-2bbe101c022c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5c7b86ea-a1eb-4041-8ba3-159337240616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_edfc5080-c879-481f-883a-2bbe101c022c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5c7b86ea-a1eb-4041-8ba3-159337240616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nvax-20240630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8712a928-80ef-43f8-bb13-bc537653cfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6d419262-09cb-47ef-8cf5-56315e89dea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8712a928-80ef-43f8-bb13-bc537653cfe0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6d419262-09cb-47ef-8cf5-56315e89dea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Restructuring" xlink:type="simple" xlink:href="nvax-20240630.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_de9661a2-f3db-4b43-9cc3-09cd55c22846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f1e752a6-efe0-4d59-8262-a50e022bf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_de9661a2-f3db-4b43-9cc3-09cd55c22846" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f1e752a6-efe0-4d59-8262-a50e022bf23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nvax-20240630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b1f0cfd6-246d-4ada-88cc-ac2d7ff9b0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_aa3bff1e-b9ab-4483-8a10-74d240d07fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b1f0cfd6-246d-4ada-88cc-ac2d7ff9b0d6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_aa3bff1e-b9ab-4483-8a10-74d240d07fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nvax-20240630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6a0c5f5c-6d02-4b40-94d7-e3142aa9ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6a0c5f5c-6d02-4b40-94d7-e3142aa9ebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_fb4339f9-fbea-4f97-a785-865263b6203c" xlink:href="nvax-20240630.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_fb4339f9-fbea-4f97-a785-865263b6203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_f80b8c65-cbe9-4a77-9854-0428dc810845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_f80b8c65-cbe9-4a77-9854-0428dc810845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9cba7741-ceb2-4710-9388-a4164b74bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_us-gaap_UseOfEstimates_9cba7741-ceb2-4710-9388-a4164b74bc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_a0b99c19-66b1-4943-a9f5-979688403054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_a0b99c19-66b1-4943-a9f5-979688403054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06b7e3ae-dc0f-4d87-b69e-12323bf4ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0ac9e5-3374-454c-8626-92e8d77cfa3d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06b7e3ae-dc0f-4d87-b69e-12323bf4ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c778a89-141e-4500-b5e6-163850759f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aa4573b7-ae6a-479d-86a8-d45aa22d85de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c778a89-141e-4500-b5e6-163850759f14" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aa4573b7-ae6a-479d-86a8-d45aa22d85de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06065255-a574-4391-b602-03cef4ef8980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_c6ed14d4-d1b1-4ac3-89e1-df987875992c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06065255-a574-4391-b602-03cef4ef8980" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_c6ed14d4-d1b1-4ac3-89e1-df987875992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_caf20825-1311-4f7b-8874-b950be9691a1" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_ee29f3c3-9eb6-41ec-b3f4-b281312b66f1" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_caf20825-1311-4f7b-8874-b950be9691a1" xlink:to="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_ee29f3c3-9eb6-41ec-b3f4-b281312b66f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4b652953-ba71-4570-b8f4-0aa6d6da0fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_caf20825-1311-4f7b-8874-b950be9691a1" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4b652953-ba71-4570-b8f4-0aa6d6da0fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_2fe28988-060e-4012-8bef-726d88569f61" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_caf20825-1311-4f7b-8874-b950be9691a1" xlink:to="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_2fe28988-060e-4012-8bef-726d88569f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EarningsLossperShareTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#EarningsLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EarningsLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_974ccd82-2200-4f81-8543-ee09ba8106a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fc0fa838-0a6e-485d-b153-04e8cde20f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_974ccd82-2200-4f81-8543-ee09ba8106a2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fc0fa838-0a6e-485d-b153-04e8cde20f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_185b4f61-ea1a-479b-953c-55e49c61fbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6feb1227-d740-4c2c-a8f2-272b8c28f770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_185b4f61-ea1a-479b-953c-55e49c61fbcf" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6feb1227-d740-4c2c-a8f2-272b8c28f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_149079bd-e958-420a-bb7f-58b4cff63cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37a338a7-5d10-4fa3-bb01-6ac5661458a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_149079bd-e958-420a-bb7f-58b4cff63cb8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37a338a7-5d10-4fa3-bb01-6ac5661458a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8afda01-a5af-4eac-9d8f-089de8f6b5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_9c3e3513-3331-4872-876a-a80fae2cc246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8afda01-a5af-4eac-9d8f-089de8f6b5b0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_9c3e3513-3331-4872-876a-a80fae2cc246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2836bd15-1a9f-4779-ab96-83bebec08cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_804f3f8c-bf92-450c-8fff-d17713a47418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2836bd15-1a9f-4779-ab96-83bebec08cf4" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_804f3f8c-bf92-450c-8fff-d17713a47418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_4e6d96bb-44d8-4506-b802-c94ba44f47d7" xlink:href="nvax-20240630.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2836bd15-1a9f-4779-ab96-83bebec08cf4" xlink:to="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_4e6d96bb-44d8-4506-b802-c94ba44f47d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afdd4e9b-a16c-4665-90be-e9f840e92f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_27cf8b59-81c1-47ca-b063-66c5d8840131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afdd4e9b-a16c-4665-90be-e9f840e92f66" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_27cf8b59-81c1-47ca-b063-66c5d8840131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d119e092-b893-4d95-a681-a5e795bf07b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afdd4e9b-a16c-4665-90be-e9f840e92f66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d119e092-b893-4d95-a681-a5e795bf07b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5bb19588-9662-40bc-8327-104739dd40ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afdd4e9b-a16c-4665-90be-e9f840e92f66" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5bb19588-9662-40bc-8327-104739dd40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_9176e9a5-6a9c-4319-80f4-03708d44bdcd" xlink:href="nvax-20240630.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afdd4e9b-a16c-4665-90be-e9f840e92f66" xlink:to="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_9176e9a5-6a9c-4319-80f4-03708d44bdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringTables" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_473dfefc-f960-4b68-a251-d0eed468db72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_33959bad-cc1a-4cd6-9489-22c1d4cebce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_473dfefc-f960-4b68-a251-d0eed468db72" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_33959bad-cc1a-4cd6-9489-22c1d4cebce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a0edd4ed-8f16-4149-b07d-064d08415392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0edd4ed-8f16-4149-b07d-064d08415392" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81890c60-7f21-4677-b6aa-b02fd2e7ff69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_0afbdb69-1396-4792-9872-312f12cee7cb" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be311706-d982-440e-b900-9e56e5baa8a1" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_0afbdb69-1396-4792-9872-312f12cee7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8451696-121b-44d4-a861-cb64dd918348" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_ca3da89e-ff6a-420c-810e-1d689b44c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_ca3da89e-ff6a-420c-810e-1d689b44c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6cb45a52-dd8d-4494-876d-ac33aa375277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6cb45a52-dd8d-4494-876d-ac33aa375277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement_885c1ecd-bf10-4009-afcb-60e481668f98" xlink:href="nvax-20240630.xsd#nvax_ProceedsFromCollaborationAndLicenseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_nvax_ProceedsFromCollaborationAndLicenseAgreement_885c1ecd-bf10-4009-afcb-60e481668f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de384a0c-9317-4df9-875e-9d8846d8c230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_de384a0c-9317-4df9-875e-9d8846d8c230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1b0a210a-d59b-4a64-8255-5364231121de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1b0a210a-d59b-4a64-8255-5364231121de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WorkingCapital_e8708219-5a74-4ae3-953e-9373a373c619" xlink:href="nvax-20240630.xsd#nvax_WorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_nvax_WorkingCapital_e8708219-5a74-4ae3-953e-9373a373c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c20311f3-1f28-4fa3-b0bc-4d61064a28fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NetIncomeLoss_c20311f3-1f28-4fa3-b0bc-4d61064a28fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4b45cb2-2ed8-4d53-a16c-a28215189186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f164aad-fb1d-4183-b010-a94f02fb3350" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4b45cb2-2ed8-4d53-a16c-a28215189186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0be4b594-9cb0-4633-8385-aca6dbf9bdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0be4b594-9cb0-4633-8385-aca6dbf9bdf7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_61fe1a26-9a40-4a02-8890-3cf3bee1a0c7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7d96b735-be50-4876-9e70-0d2565543942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca925453-7316-4da8-9b1b-ebc9fc2057d3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7d96b735-be50-4876-9e70-0d2565543942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0418865f-1457-4f5f-9e9f-87c502553f92" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_32aab3ea-ccbc-4d17-9dc9-de30d83f782a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_32aab3ea-ccbc-4d17-9dc9-de30d83f782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6da99715-e092-449b-aee9-e96ccd2f9d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6da99715-e092-449b-aee9-e96ccd2f9d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8fb3ee7-c020-4663-b149-af4b64e184c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8fb3ee7-c020-4663-b149-af4b64e184c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3520a29b-9a32-4a50-b214-ae3bc1a20cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3520a29b-9a32-4a50-b214-ae3bc1a20cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_486247b2-f1d2-47ea-9421-43a37f1d16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1fda45f8-fdc3-4908-b3bf-f4a0c7d4e9db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_486247b2-f1d2-47ea-9421-43a37f1d16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93a7f7e3-21eb-4808-8513-40d1c2706f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93a7f7e3-21eb-4808-8513-40d1c2706f43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_434ae07d-4e5b-40c0-a6ca-93044de1c54b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e533c374-7a5e-4c44-939b-b6748596ccaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e533c374-7a5e-4c44-939b-b6748596ccaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fe0e7f2f-351e-49a6-96ca-760eb37e6441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fe0e7f2f-351e-49a6-96ca-760eb37e6441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9ca7e3f9-9871-462f-b3f8-83ed018b2414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd25bdb2-93d6-4d08-8e6c-d43e4af89e48" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9ca7e3f9-9871-462f-b3f8-83ed018b2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f0f78e9f-880c-4535-8415-4de706a74d73" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33675ba2-9f76-443e-964b-5b8fcdb7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33675ba2-9f76-443e-964b-5b8fcdb7e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentBackedSecuritiesMember_e3900f97-3aab-425d-ab3d-15f04d129ba1" xlink:href="nvax-20240630.xsd#nvax_GovernmentBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_nvax_GovernmentBackedSecuritiesMember_e3900f97-3aab-425d-ab3d-15f04d129ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_22d76cfe-b3ea-4a08-b25e-da5e82b34471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_22d76cfe-b3ea-4a08-b25e-da5e82b34471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5b4581cc-0417-4816-9ec9-c440c36fe306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d91b1b6-23ba-4e40-b743-78604073e196" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5b4581cc-0417-4816-9ec9-c440c36fe306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2533512c-ee4c-4013-a481-97b01dbeb6ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_aabf982c-590b-43a5-b2b2-d1b89e82445e" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c766c0c0-03d1-454d-91df-aa8ac28cb158" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_aabf982c-590b-43a5-b2b2-d1b89e82445e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1ee7a717-bb45-48db-a575-bdc3ed73b74a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_877b4b6d-802a-4dbd-83e4-0f3f346eae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_877b4b6d-802a-4dbd-83e4-0f3f346eae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MarketableSecuritiesMember_79e2d914-701e-4c67-96e5-3b70b25d36a4" xlink:href="nvax-20240630.xsd#nvax_MarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a65886f0-f64f-4473-a9c7-84292e36ab5e" xlink:to="loc_nvax_MarketableSecuritiesMember_79e2d914-701e-4c67-96e5-3b70b25d36a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4243aa8-979f-40d5-b682-abc0f83c5e25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_50b67b8d-b18a-467b-9814-c39f774ea3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d81f19b8-3baf-4daa-bdfb-cd9286fe94aa" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_50b67b8d-b18a-467b-9814-c39f774ea3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d85892b2-cb62-46ba-9c6c-f45d52d33b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1ac3f5b1-8717-4f10-961b-aaaf8ca5217a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_d85892b2-cb62-46ba-9c6c-f45d52d33b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ccfb76b5-6d75-4d0a-901f-03d18744950a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916262e4-5bb1-4fa0-bfa9-3035e81f9594" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ccfb76b5-6d75-4d0a-901f-03d18744950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_472a6023-16a8-4a6c-a5e8-3e79f38a3feb" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_472a6023-16a8-4a6c-a5e8-3e79f38a3feb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91600b43-020f-4f0a-afbd-baa90c51058f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ad77f211-c0d1-48c1-a3b0-32637ece7ad8" xlink:href="nvax-20240630.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_ad77f211-c0d1-48c1-a3b0-32637ece7ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_ee92c0e0-01a6-4b59-b192-581e7628e333" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_SettlementAgreementMember_ee92c0e0-01a6-4b59-b192-581e7628e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember_370a3875-9a06-41cb-8b73-8d893d29a326" xlink:href="nvax-20240630.xsd#nvax_AustralianAPAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_AustralianAPAMember_370a3875-9a06-41cb-8b73-8d893d29a326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_3468a774-324f-487e-9d8d-e6f4c4ebe0ed" xlink:href="nvax-20240630.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_3468a774-324f-487e-9d8d-e6f4c4ebe0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandTerminationOfTheAgreementMember_ef18bc48-dca7-459d-820c-52d08da1c626" xlink:href="nvax-20240630.xsd#nvax_NewZealandTerminationOfTheAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_NewZealandTerminationOfTheAgreementMember_ef18bc48-dca7-459d-820c-52d08da1c626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_6a15b8fc-670e-4a39-9fe8-70e6e734dae0" xlink:href="nvax-20240630.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_6a15b8fc-670e-4a39-9fe8-70e6e734dae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_8806398d-b043-4d29-a8e7-1f25f0f78c5e" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_8806398d-b043-4d29-a8e7-1f25f0f78c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_8e1730e5-33da-463e-a74e-84e426842a36" xlink:href="nvax-20240630.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b298ce0-70c5-46fa-87ea-3134c32fd2d7" xlink:to="loc_nvax_USGovernmentPartnershipMember_8e1730e5-33da-463e-a74e-84e426842a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a02ec7d-6093-4e8b-a765-7f8b1d76a551" xlink:to="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_44903c7d-1d95-43e9-98ea-88e8c5c67a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_us-gaap_ProductMember_44903c7d-1d95-43e9-98ea-88e8c5c67a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicenseFeesMember_48a37465-73cf-4ceb-a703-094cc8197f3d" xlink:href="nvax-20240630.xsd#nvax_LicenseFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_nvax_LicenseFeesMember_48a37465-73cf-4ceb-a703-094cc8197f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransitionServicesMember_90b77f61-21e6-47a1-9349-199282e9f9ac" xlink:href="nvax-20240630.xsd#nvax_TransitionServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f4eb3234-9b7b-4076-922f-47637b85f424" xlink:to="loc_nvax_TransitionServicesMember_90b77f61-21e6-47a1-9349-199282e9f9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ea6006d-27a9-4331-ac86-58cd224d90c5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_dcf58c23-91d4-41d5-9bb8-116b3297a106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_dcf58c23-91d4-41d5-9bb8-116b3297a106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b791d538-0362-4de3-9158-fdaa3f10f6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_84947014-644b-4066-ab5d-ef4acb831eee" xlink:to="loc_us-gaap_AccountsReceivableMember_b791d538-0362-4de3-9158-fdaa3f10f6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e9235b69-efcd-4dd6-959d-6622c78af2ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustraliaRevenueAgencyMemberMember_82085f1c-0613-41ff-93e1-815a18f6791e" xlink:href="nvax-20240630.xsd#nvax_AustraliaRevenueAgencyMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_nvax_AustraliaRevenueAgencyMemberMember_82085f1c-0613-41ff-93e1-815a18f6791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_11ceebaa-ed35-4f6d-baf1-7ee593337927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_11ceebaa-ed35-4f6d-baf1-7ee593337927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NewZealandRevenueAgencyMember_8021ace3-0681-4d90-a272-71c4be6ea457" xlink:href="nvax-20240630.xsd#nvax_NewZealandRevenueAgencyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1eca8468-9a92-46f8-b4e7-9d46a209e3c0" xlink:to="loc_nvax_NewZealandRevenueAgencyMember_8021ace3-0681-4d90-a272-71c4be6ea457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6d30a05d-af8f-4d51-bf6a-2002ce5ddedc" xlink:to="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_9235eec1-21a8-4825-aa02-01841d17b9f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_66a9ed22-2892-461a-939e-af0b60889eb0" xlink:to="loc_srt_NorthAmericaMember_9235eec1-21a8-4825-aa02-01841d17b9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_d9aa0690-8047-4844-8886-1b717ed04eab" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8a705e0b-81e4-422a-baea-7e9fdd57eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_fece5981-416a-4214-9f03-75e70053e545" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8a705e0b-81e4-422a-baea-7e9fdd57eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_42a8431a-0fbe-4769-92db-b9e0a1ef8c02" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_d63e7bdb-49a7-4df2-ae84-dae078407a57" xlink:href="nvax-20240630.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_53d22150-f064-4d95-8bf6-d24d85326b64" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_d63e7bdb-49a7-4df2-ae84-dae078407a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_63b92fb2-a13d-4ef3-acf0-7b8cad9bcd09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_267b6a9a-9129-4740-a7ca-2ec5bfff6b11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cb20db43-2e6a-4458-9b7b-468602cbbd5c" xlink:to="loc_srt_ScenarioForecastMember_267b6a9a-9129-4740-a7ca-2ec5bfff6b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_193c652c-03d7-41dc-a693-329738bdc6f9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_9eaf82a1-b22a-471c-ad9a-7355fc2f3440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_BilledContractReceivables_9eaf82a1-b22a-471c-ad9a-7355fc2f3440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_b5b0ddb5-ecd5-402f-99aa-1e4adaf313bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_UnbilledContractsReceivable_b5b0ddb5-ecd5-402f-99aa-1e4adaf313bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RemainingPerformanceObligationAmount_3e6e1fde-b3c8-4e70-8453-66d8a8e1657d" xlink:href="nvax-20240630.xsd#nvax_RemainingPerformanceObligationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_RemainingPerformanceObligationAmount_3e6e1fde-b3c8-4e70-8453-66d8a8e1657d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4ca48979-4dcf-4618-8fe9-00fd76e6f750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4ca48979-4dcf-4618-8fe9-00fd76e6f750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_38904078-8f5b-447c-b728-e311d060684e" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_38904078-8f5b-447c-b728-e311d060684e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2d908898-9024-4684-b676-29adcfb03fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2d908898-9024-4684-b676-29adcfb03fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6831d807-935f-48b5-a642-1e9f52822ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_LitigationSettlementExpense_6831d807-935f-48b5-a642-1e9f52822ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_c5f60c4d-29c8-433a-81fd-dc7892cb9b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_GrantsReceivable_c5f60c4d-29c8-433a-81fd-dc7892cb9b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d866e5b-4f03-4c80-8f64-66f998407ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d866e5b-4f03-4c80-8f64-66f998407ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_72951173-404c-40a5-8e1a-a54f29dd179a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_72951173-404c-40a5-8e1a-a54f29dd179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3546fee7-d885-44bf-8942-09040d88c277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3546fee7-d885-44bf-8942-09040d88c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fa5ad262-5aa6-4bb8-9bb8-702de0a5ef61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_Revenues_fa5ad262-5aa6-4bb8-9bb8-702de0a5ef61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_d8659b1d-83e8-408d-82d8-4a109c48d53e" xlink:href="nvax-20240630.xsd#nvax_SettlementPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_nvax_SettlementPayment_d8659b1d-83e8-408d-82d8-4a109c48d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_43c6a233-676b-4b2b-a56a-654ecde4d912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_43c6a233-676b-4b2b-a56a-654ecde4d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0eea1489-adba-4e9a-a660-008bccc374aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0eea1489-adba-4e9a-a660-008bccc374aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_8cabc76f-c580-4225-81ff-7977b5f65929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_8cabc76f-c580-4225-81ff-7977b5f65929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75beae06-5373-4f4c-9658-3abee6562072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75beae06-5373-4f4c-9658-3abee6562072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6180ecce-e7e4-41e8-916f-dadd2777d101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_82e2766a-aa40-4276-a65d-d54eb1de0537" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6180ecce-e7e4-41e8-916f-dadd2777d101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_68874294-02ed-434c-87a0-901a2e463b29" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_68874294-02ed-434c-87a0-901a2e463b29" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_7b33d1c6-24eb-4070-99b9-7827aaf4c82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:to="loc_us-gaap_AccountsReceivableGross_7b33d1c6-24eb-4070-99b9-7827aaf4c82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_b5081126-f6b1-4400-b828-0b89cc33a591" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_b5081126-f6b1-4400-b828-0b89cc33a591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_9b58933e-0d13-47a8-b62b-0f598ebf7caa" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_9b58933e-0d13-47a8-b62b-0f598ebf7caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_a248fcb0-1074-4b45-b81a-fb1966e7d2de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_f259a7b3-cab3-445c-b72b-effa1fdb66e0" xlink:to="loc_us-gaap_AccountsReceivableGross_a248fcb0-1074-4b45-b81a-fb1966e7d2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_68874294-02ed-434c-87a0-901a2e463b29" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_33d31c51-cc2b-412f-9b47-5efc4af02fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_33d31c51-cc2b-412f-9b47-5efc4af02fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_86115e50-86db-4a98-8828-6ce6841740b3" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_86115e50-86db-4a98-8828-6ce6841740b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_c274606a-2d08-43ea-8924-d2a80256bcaf" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_c274606a-2d08-43ea-8924-d2a80256bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_438ecc2e-b08b-4be5-bedb-4d8081ca846f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_65e1becd-9431-4194-8449-34c93a985d4c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_438ecc2e-b08b-4be5-bedb-4d8081ca846f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:href="nvax-20240630.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_68874294-02ed-434c-87a0-901a2e463b29" xlink:to="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_663105ed-0962-4596-9388-ce403d73ac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_663105ed-0962-4596-9388-ce403d73ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions_ff32c347-8686-45f4-a85a-846f6f5c825e" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:to="loc_nvax_ContractWithCustomerLiabilityAdditions_ff32c347-8686-45f4-a85a-846f6f5c825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions_944c49e5-ace4-4864-a840-3c9050ed58ad" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:to="loc_nvax_ContractWithCustomerLiabilityDeductions_944c49e5-ace4-4864-a840-3c9050ed58ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c267bb0d-b204-43c9-af92-a7fadf9c82d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_68983cdf-65cb-4a8c-8cef-6b841123e23d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c267bb0d-b204-43c9-af92-a7fadf9c82d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_68874294-02ed-434c-87a0-901a2e463b29" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27c66105-1914-442a-9d40-7e8ae99f482c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_9a45cb04-3e00-4bf5-b313-d1bbfc25022b" xlink:href="nvax-20240630.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8c6d2dc-336c-4f09-a7c1-51a119be953f" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_9a45cb04-3e00-4bf5-b313-d1bbfc25022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e569ee1f-4c56-478a-99a6-be6a4a801b5d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_fe09716b-6c28-4d37-97a7-355776341fe4" xlink:href="nvax-20240630.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_fe09716b-6c28-4d37-97a7-355776341fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions_90d1246f-1dfa-403f-a8f0-92860e858fe0" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_ContractWithCustomerLiabilityDeductions_90d1246f-1dfa-403f-a8f0-92860e858fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions_71379911-4c25-4612-b9d7-0af3b4715f84" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ebb30c4-69c9-47c9-a138-2e2fd38d5798" xlink:to="loc_nvax_ContractWithCustomerLiabilityAdditions_71379911-4c25-4612-b9d7-0af3b4715f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_bfe7485b-b72e-4849-8998-68f0eea06268" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_bfe7485b-b72e-4849-8998-68f0eea06268" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:to="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c36c261e-62df-4be2-858d-850495f20b91" xlink:to="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_535fb93d-cd73-40a5-9352-b2c8b89ed05c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73c702f8-83a2-4970-b1bd-7c5fd5170ba1" xlink:to="loc_us-gaap_ProductMember_535fb93d-cd73-40a5-9352-b2c8b89ed05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:to="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5ed10216-3cd7-4c56-8122-e85bd6f4238c" xlink:to="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_ef830f10-9f86-4468-b914-201360d1136f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_srt_NorthAmericaMember_ef830f10-9f86-4468-b914-201360d1136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b79bdef8-3c7c-42b3-bd12-42b1441c8120" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_srt_EuropeMember_b79bdef8-3c7c-42b3-bd12-42b1441c8120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_16befb50-4d5e-4b53-b932-6f8e3d98c424" xlink:href="nvax-20240630.xsd#nvax_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0c96080-5a39-45f5-aa27-cb814492cc75" xlink:to="loc_nvax_RestOfTheWorldMember_16befb50-4d5e-4b53-b932-6f8e3d98c424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fdde89c-046c-4c5d-bb97-c2816c7a07c6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6baec6f6-cddd-4071-8ef7-718d5f4cdd09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:to="loc_us-gaap_Revenues_6baec6f6-cddd-4071-8ef7-718d5f4cdd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d389ab85-7bc7-4264-9342-15a44e48f962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8557d75d-4a6b-4a69-8d1e-a98f9b73470c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d389ab85-7bc7-4264-9342-15a44e48f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_c534bc4a-1c35-48ad-ab65-0748136272fe" xlink:href="nvax-20240630.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_c534bc4a-1c35-48ad-ab65-0748136272fe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:to="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f0629092-8026-4d3b-9863-beed01a2ddf2" xlink:to="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_69549828-c859-4d0a-8957-b0dd56b0e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e59de30-0c49-4df9-9134-c3a813deec63" xlink:to="loc_us-gaap_ProductMember_69549828-c859-4d0a-8957-b0dd56b0e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_7d47ae36-1022-4bcf-b550-43e27a70e117" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_3ce75472-bcff-480c-a210-f0d5905563be" xlink:href="nvax-20240630.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:to="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_3ce75472-bcff-480c-a210-f0d5905563be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember_4b325b01-fc53-4102-8312-52c7c15c46a6" xlink:href="nvax-20240630.xsd#nvax_ProductReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_07b5038f-df86-460a-a888-a8076ce10cca" xlink:to="loc_nvax_ProductReturnsMember_4b325b01-fc53-4102-8312-52c7c15c46a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1a3147cf-6693-4d16-a5c9-c4b43fe21f40" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:href="nvax-20240630.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a29b0a3-2644-4fb3-b741-ca2d16aaba69" xlink:to="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fff01468-ea33-48df-b8a1-4200fdbb4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fff01468-ea33-48df-b8a1-4200fdbb4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_7a2b5d4e-26ec-4146-92e2-0aa8ce1fd6c5" xlink:href="nvax-20240630.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_7a2b5d4e-26ec-4146-92e2-0aa8ce1fd6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b7a7e180-c34f-4520-aea4-28afb926cf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b7a7e180-c34f-4520-aea4-28afb926cf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5f906ec1-685d-4ddc-8cd6-d75b10a224ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_0f808a54-e283-453a-b778-f0e5b84a02f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5f906ec1-685d-4ddc-8cd6-d75b10a224ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_10af1c31-b66c-4aeb-b802-0fcd1b29b413" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_10af1c31-b66c-4aeb-b802-0fcd1b29b413" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0fd2f68e-874f-4421-8948-e21cc75d4414" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_1ea53289-21a5-4ae4-8531-ec1d256dfb9b" xlink:href="nvax-20240630.xsd#nvax_TakedaArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_TakedaArrangementMember_1ea53289-21a5-4ae4-8531-ec1d256dfb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SanofiPasteurInc.APAMember_b24d421e-08ea-4b31-97df-f311ca6eb568" xlink:href="nvax-20240630.xsd#nvax_SanofiPasteurInc.APAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_SanofiPasteurInc.APAMember_b24d421e-08ea-4b31-97df-f311ca6eb568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_40d5c503-d4ad-4da5-a4e8-447b42728203" xlink:href="nvax-20240630.xsd#nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember_40d5c503-d4ad-4da5-a4e8-447b42728203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_bb2ca7e5-a3c7-409b-a5b4-9a5fc5071c67" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15addba7-8c94-4e67-ac46-e9da1984b02c" xlink:to="loc_nvax_SettlementAgreementMember_bb2ca7e5-a3c7-409b-a5b4-9a5fc5071c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_698138a3-57d0-486e-b937-41001aa2ef52" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_cdfe228b-919a-4ed8-8021-e8dced24b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_dd3519fa-f2bb-4db0-95de-29537eeabe6e" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_cdfe228b-919a-4ed8-8021-e8dced24b6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_973ab6d0-a15c-4f55-a99c-a98a5b29064a" xlink:to="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_80f157fb-0275-4e48-990e-2d5c5bc4a6a0" xlink:href="nvax-20240630.xsd#nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember_80f157fb-0275-4e48-990e-2d5c5bc4a6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_41847c4e-9a33-4d4d-ae54-378334aec012" xlink:href="nvax-20240630.xsd#nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_41847c4e-9a33-4d4d-ae54-378334aec012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_5132c0b6-a981-496b-8364-37e63e88a62d" xlink:href="nvax-20240630.xsd#nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember_5132c0b6-a981-496b-8364-37e63e88a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_7bbcb391-59b3-449c-a3f6-7adc68a81919" xlink:href="nvax-20240630.xsd#nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember_7bbcb391-59b3-449c-a3f6-7adc68a81919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_2be2a547-0e72-47ab-b40f-5bf532d58414" xlink:href="nvax-20240630.xsd#nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember_2be2a547-0e72-47ab-b40f-5bf532d58414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_6e6a215d-7bd7-4436-b040-c7affe9f6034" xlink:href="nvax-20240630.xsd#nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember_6e6a215d-7bd7-4436-b040-c7affe9f6034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_ea61d874-9469-4727-a52f-94c11cd43c5a" xlink:href="nvax-20240630.xsd#nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember_ea61d874-9469-4727-a52f-94c11cd43c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstFourAdjuvantProductsMember_f7fcef9b-3d37-4698-bc16-e3a0dc035eda" xlink:href="nvax-20240630.xsd#nvax_FirstFourAdjuvantProductsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_FirstFourAdjuvantProductsMember_f7fcef9b-3d37-4698-bc16-e3a0dc035eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AdjuvantProductsThereafterMember_f0720925-207c-479d-996d-854dfa41e9fa" xlink:href="nvax-20240630.xsd#nvax_AdjuvantProductsThereafterMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_AdjuvantProductsThereafterMember_f0720925-207c-479d-996d-854dfa41e9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LicenseFeesMember_95c1810c-9e1a-44cf-a3ab-56c48e49f54c" xlink:href="nvax-20240630.xsd#nvax_LicenseFeesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_LicenseFeesMember_95c1810c-9e1a-44cf-a3ab-56c48e49f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d93ef9a2-efb4-46e1-bcf9-cf7fe6edd699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_us-gaap_LicenseMember_d93ef9a2-efb4-46e1-bcf9-cf7fe6edd699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransitionServicesMember_ebb56795-1883-46cf-8c8f-e1f8c95acd42" xlink:href="nvax-20240630.xsd#nvax_TransitionServicesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransitionServicesMember_ebb56795-1883-46cf-8c8f-e1f8c95acd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TransferOfTechnologyMember_b055e474-e919-45f1-866f-ccf3a3792f96" xlink:href="nvax-20240630.xsd#nvax_TransferOfTechnologyMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_TransferOfTechnologyMember_b055e474-e919-45f1-866f-ccf3a3792f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ClinicalMilestoneMember_535792b8-64ac-4f57-96a2-1f7151c39bba" xlink:href="nvax-20240630.xsd#nvax_ClinicalMilestoneMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_ClinicalMilestoneMember_535792b8-64ac-4f57-96a2-1f7151c39bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CostReimbursementMember_c78e0f55-bc60-4a30-b92c-b8154f0a5aca" xlink:href="nvax-20240630.xsd#nvax_CostReimbursementMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_nvax_CostReimbursementMember_c78e0f55-bc60-4a30-b92c-b8154f0a5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2b98fce3-1fbf-4c44-8289-d37e2acd5c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6c11ea9-001f-4ee1-a807-cd4a4d795054" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2b98fce3-1fbf-4c44-8289-d37e2acd5c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a22215e8-3d81-4725-93f0-7dda42bece85" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_d45930bd-5239-400e-b722-620c31d10627" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:to="loc_nvax_SettlementAgreementMember_d45930bd-5239-400e-b722-620c31d10627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_fc3b0539-31fd-4c51-a384-8418d8258d99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_0e7f09ac-e6ae-4e85-923c-e15347b5c198" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_fc3b0539-31fd-4c51-a384-8418d8258d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6946d99b-2e82-4616-aed0-73097138d388" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_a5eaaa2d-49d4-4530-a834-4a90d58a0fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ca0ae7-4b18-4ff6-b1a6-14dbc48129fb" xlink:to="loc_us-gaap_PrivatePlacementMember_a5eaaa2d-49d4-4530-a834-4a90d58a0fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9c1a9ba-c067-48f1-9186-7164dc33d83f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c8418e7c-ab05-4ffb-b60e-5d20fa05145a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cee3c2de-9cfc-418a-b224-2569a3377d28" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c8418e7c-ab05-4ffb-b60e-5d20fa05145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc29d8ef-fdd3-44be-8828-6a025e82d854" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod_c95e27e5-7dfb-4675-9c98-f51a56dd7936" xlink:href="nvax-20240630.xsd#nvax_RoyaltyPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_RoyaltyPeriod_c95e27e5-7dfb-4675-9c98-f51a56dd7936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_ed1e001a-41a6-4741-bb6a-45e1bc8edaee" xlink:href="nvax-20240630.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_ed1e001a-41a6-4741-bb6a-45e1bc8edaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentReceived_3f1eb4d0-1602-4189-a844-13ff8b9b4508" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentReceived_3f1eb4d0-1602-4189-a844-13ff8b9b4508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_08986c1b-ab3e-43d0-91ac-a63d764238e4" xlink:href="nvax-20240630.xsd#nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments_08986c1b-ab3e-43d0-91ac-a63d764238e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementInitialTransactionPrice_c2273752-1f76-4e49-8878-78f5b0f2d38c" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementInitialTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementInitialTransactionPrice_c2273752-1f76-4e49-8878-78f5b0f2d38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_307432fa-6256-42f9-b9a6-db8b9736205b" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_307432fa-6256-42f9-b9a6-db8b9736205b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementVariableConsideration_69a1d6fe-0506-4d7b-adad-60f76dc7422d" xlink:href="nvax-20240630.xsd#nvax_CollaborationAgreementVariableConsideration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborationAgreementVariableConsideration_69a1d6fe-0506-4d7b-adad-60f76dc7422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d9f97345-feb0-4b18-9fa4-57ecbb586d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_Revenues_d9f97345-feb0-4b18-9fa4-57ecbb586d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d57bb05a-5bbf-4a00-8056-9e4f8c8580f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d57bb05a-5bbf-4a00-8056-9e4f8c8580f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_b29abfca-2ed6-49af-9a21-c3805b48f863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_DeferredRevenue_b29abfca-2ed6-49af-9a21-c3805b48f863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e728a6a-da1d-40df-b551-aeca1458df20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e728a6a-da1d-40df-b551-aeca1458df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a383a4a-28d3-402e-8e2d-db20634bb6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a383a4a-28d3-402e-8e2d-db20634bb6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_88a924db-19be-4e80-bca2-5f4a27bd7e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_88a924db-19be-4e80-bca2-5f4a27bd7e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_670470b6-cb89-4bf1-9c0f-1aa0fa06acdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_670470b6-cb89-4bf1-9c0f-1aa0fa06acdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2840d8b-b1d6-4749-8397-d7d5c1d05582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2840d8b-b1d6-4749-8397-d7d5c1d05582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_769ab372-6035-4371-8a10-a9c7fa3bc386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_769ab372-6035-4371-8a10-a9c7fa3bc386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3194ec4d-8a70-453d-a824-437ceb34fdff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3194ec4d-8a70-453d-a824-437ceb34fdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementTerm_177efb82-df8a-4b69-a02d-f817d916de2f" xlink:href="nvax-20240630.xsd#nvax_CollaborativeArrangementTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_CollaborativeArrangementTerm_177efb82-df8a-4b69-a02d-f817d916de2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_19eb793a-3d39-4f13-a382-b216e62c3750" xlink:href="nvax-20240630.xsd#nvax_SettlementPayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_SettlementPayment_19eb793a-3d39-4f13-a382-b216e62c3750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_6219425a-6da2-4a24-aee4-c7bf998fb2f0" xlink:href="nvax-20240630.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_6219425a-6da2-4a24-aee4-c7bf998fb2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6c753870-d70f-4061-a7fa-803439fc91a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08f4af44-2f2e-4510-9869-8f2c9b21ca0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6c753870-d70f-4061-a7fa-803439fc91a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EarningsLossperShareDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#EarningsLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_652dbc75-3fb5-43f4-8d34-f4c8e0ed7651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_730f29e6-98e8-497f-97cf-740720bdca3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_652dbc75-3fb5-43f4-8d34-f4c8e0ed7651" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_730f29e6-98e8-497f-97cf-740720bdca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_68888265-5081-4b66-a84e-94adb10474fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_730f29e6-98e8-497f-97cf-740720bdca3c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_68888265-5081-4b66-a84e-94adb10474fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_23a82f2b-32d0-418c-a5fd-f19b965761fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_730f29e6-98e8-497f-97cf-740720bdca3c" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_23a82f2b-32d0-418c-a5fd-f19b965761fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_64db43eb-3c49-4970-9a2d-aebdad69d345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_730f29e6-98e8-497f-97cf-740720bdca3c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_64db43eb-3c49-4970-9a2d-aebdad69d345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a3a0bd03-6c2f-48f8-9670-4ff0ffbe4017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_652dbc75-3fb5-43f4-8d34-f4c8e0ed7651" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a3a0bd03-6c2f-48f8-9670-4ff0ffbe4017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c7c506f-7005-4e9b-9769-83a2f387d5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a3a0bd03-6c2f-48f8-9670-4ff0ffbe4017" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c7c506f-7005-4e9b-9769-83a2f387d5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bd845124-6aa6-4308-966f-0e6ac9b89d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a3a0bd03-6c2f-48f8-9670-4ff0ffbe4017" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bd845124-6aa6-4308-966f-0e6ac9b89d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f568e4fc-f4e9-41a1-abdb-ce028e07895f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a3a0bd03-6c2f-48f8-9670-4ff0ffbe4017" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f568e4fc-f4e9-41a1-abdb-ce028e07895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_498cd841-628a-44ee-bab0-5114eff20c98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_652dbc75-3fb5-43f4-8d34-f4c8e0ed7651" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_498cd841-628a-44ee-bab0-5114eff20c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2f840d3e-e022-4d8b-87ad-dfd038a4cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_498cd841-628a-44ee-bab0-5114eff20c98" xlink:to="loc_us-gaap_EarningsPerShareBasic_2f840d3e-e022-4d8b-87ad-dfd038a4cf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0b2abe5b-70ed-4b39-93f7-1a7ee66ff798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_498cd841-628a-44ee-bab0-5114eff20c98" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0b2abe5b-70ed-4b39-93f7-1a7ee66ff798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8abd8e4-ecfa-42d5-a5a2-b1ca8605c69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_652dbc75-3fb5-43f4-8d34-f4c8e0ed7651" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8abd8e4-ecfa-42d5-a5a2-b1ca8605c69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_20fc580d-5972-4559-92fa-93d13ba8568b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fb46c47-6951-4431-8676-e6e4ee4a42b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_20fc580d-5972-4559-92fa-93d13ba8568b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fb46c47-6951-4431-8676-e6e4ee4a42b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_73fd371c-ba68-4024-9a8a-3d05abf016aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_20fc580d-5972-4559-92fa-93d13ba8568b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_73fd371c-ba68-4024-9a8a-3d05abf016aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_928afb8b-d45c-49b6-835b-bd44e8ee3aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_20fc580d-5972-4559-92fa-93d13ba8568b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_928afb8b-d45c-49b6-835b-bd44e8ee3aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1ad80bf-a0be-4a12-a2af-6f265fd3dd09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_20fc580d-5972-4559-92fa-93d13ba8568b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1ad80bf-a0be-4a12-a2af-6f265fd3dd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8cdfbf74-6a0f-47d1-85fd-331fe1be2afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryRawMaterials_8cdfbf74-6a0f-47d1-85fd-331fe1be2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_497f2547-767f-44c3-926d-3db332b83c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryWorkInProcess_497f2547-767f-44c3-926d-3db332b83c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_4a79d6db-0cc3-4189-aed1-dc2b32452d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryFinishedGoods_4a79d6db-0cc3-4189-aed1-dc2b32452d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4f286cc7-cbf1-4299-b3b4-ea794147fbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryNet_4f286cc7-cbf1-4299-b3b4-ea794147fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_35dcfb80-67e6-410e-a6bf-b9caad795d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryWriteDown_35dcfb80-67e6-410e-a6bf-b9caad795d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f8ef28c1-a8b3-43a3-9c78-1ab74006f607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f8ef28c1-a8b3-43a3-9c78-1ab74006f607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_344b538d-d784-4836-8c15-8e904cdc3a7c" xlink:href="nvax-20240630.xsd#nvax_InventoryFirmPurchaseCommitmentRecoveries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e77c79f3-835a-400b-98fd-dfbf6df5b800" xlink:to="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_344b538d-d784-4836-8c15-8e904cdc3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#GoodwillScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6ade207-16db-4134-8b90-2438bb5927b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_3002a485-ccb5-476e-8be9-a580bee7a107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6ade207-16db-4134-8b90-2438bb5927b1" xlink:to="loc_us-gaap_NumberOfReportingUnits_3002a485-ccb5-476e-8be9-a580bee7a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_40c36ef5-92ad-4e6d-929e-6bc8beaf5302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6ade207-16db-4134-8b90-2438bb5927b1" xlink:to="loc_us-gaap_GoodwillRollForward_40c36ef5-92ad-4e6d-929e-6bc8beaf5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_23295cd8-9e21-4eb3-a7ea-f98522f084a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40c36ef5-92ad-4e6d-929e-6bc8beaf5302" xlink:to="loc_us-gaap_Goodwill_23295cd8-9e21-4eb3-a7ea-f98522f084a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e0b9e360-2570-4049-83dc-6b76fcb86c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40c36ef5-92ad-4e6d-929e-6bc8beaf5302" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e0b9e360-2570-4049-83dc-6b76fcb86c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2b95fa2-493d-4b3e-8277-49f3b755728a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_40c36ef5-92ad-4e6d-929e-6bc8beaf5302" xlink:to="loc_us-gaap_Goodwill_b2b95fa2-493d-4b3e-8277-49f3b755728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtScheduleofConvertibleNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9137079a-1660-429a-8bef-1e14ce49bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9137079a-1660-429a-8bef-1e14ce49bf17" xlink:to="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fa4263ab-7f0d-4548-b7aa-c9c435c304d0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_f8142233-92e2-4de9-a944-fe8eca0c715e" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f9f8e145-fc48-4122-b139-bb0e37ac231c" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_f8142233-92e2-4de9-a944-fe8eca0c715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2a92fd23-bdf0-42f9-94a0-c5c0a9804804" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_58526547-f654-49a6-af78-25545dcb4147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e453d8e9-83ad-4ace-a4bd-0f81da95f37c" xlink:to="loc_us-gaap_UnsecuredDebtMember_58526547-f654-49a6-af78-25545dcb4147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87539ac0-5349-4b7f-8781-7d9bc14151bb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3e616c33-ee19-4a27-8b43-1013cf222044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3e616c33-ee19-4a27-8b43-1013cf222044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8af95b6d-552b-4bba-8f03-f100ba388f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8af95b6d-552b-4bba-8f03-f100ba388f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_e55d9376-8146-4143-85ca-7f56c59952aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_e55d9376-8146-4143-85ca-7f56c59952aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b9e46cf8-0cbb-4a1b-981f-51e72978a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c366af2f-af43-48e2-9c1d-8f6d598a118c" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_b9e46cf8-0cbb-4a1b-981f-51e72978a9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_663e006e-32d1-4eb4-b20d-4e8014965248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_663e006e-32d1-4eb4-b20d-4e8014965248" xlink:to="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:to="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_68e89c00-da1a-4347-b42f-dce736bbfb7b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_faecaeed-d479-4276-b148-b2ec8d884c5f" xlink:href="nvax-20240630.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_faecaeed-d479-4276-b148-b2ec8d884c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_994bca9f-1fa0-4b12-8310-0f85ace92f88" xlink:href="nvax-20240630.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0de9766d-5516-4cb6-9950-0d8965414a11" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_994bca9f-1fa0-4b12-8310-0f85ace92f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f254aa9-86d2-453c-b580-0149bf44f14e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9749e6ba-9874-43bf-a947-7d414283eaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3b32ba17-2a22-4045-8c27-ae779660fda5" xlink:to="loc_us-gaap_UnsecuredDebtMember_9749e6ba-9874-43bf-a947-7d414283eaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e59f608-6b9e-4c33-8f9a-827fa195611d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_eb808aae-73ea-42bc-aa42-37eb8e3eeb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_eb808aae-73ea-42bc-aa42-37eb8e3eeb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_12533cb6-6a32-4c93-a009-6b084f2cf86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_RepaymentsOfDebt_12533cb6-6a32-4c93-a009-6b084f2cf86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_aa6aebeb-a8ae-48ea-a985-4e367af4f627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba6f8f88-e9d3-4495-bf39-a17c8932c58d" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_aa6aebeb-a8ae-48ea-a985-4e367af4f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1a1c3da6-ea8f-4836-a136-7a628f673b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_08dfd743-d119-4829-b3e0-6bd4958c75ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1a1c3da6-ea8f-4836-a136-7a628f673b30" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_08dfd743-d119-4829-b3e0-6bd4958c75ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ef045aea-931e-4727-897a-7a185967a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1a1c3da6-ea8f-4836-a136-7a628f673b30" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ef045aea-931e-4727-897a-7a185967a29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_79f4a59f-dd52-48db-b483-d831be37cc94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1a1c3da6-ea8f-4836-a136-7a628f673b30" xlink:to="loc_us-gaap_InterestExpenseDebt_79f4a59f-dd52-48db-b483-d831be37cc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockholdersDeficitDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_779b6520-7090-43a0-ac00-32f463f242c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_779b6520-7090-43a0-ac00-32f463f242c2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fedd54c2-dadc-4bb4-bc30-c6dd337d4923" xlink:to="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ac35d89-f448-4229-9c9a-956d992ce479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73007de2-ba03-479d-a907-be5abcc7868f" xlink:to="loc_us-gaap_CommonStockMember_8ac35d89-f448-4229-9c9a-956d992ce479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ecc0892c-e71f-4eaa-9ef4-0e617ac4b725" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember_042f2ac4-95f5-4de8-9014-8b800e8708f4" xlink:href="nvax-20240630.xsd#nvax_August2023SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_nvax_August2023SalesAgreementMember_042f2ac4-95f5-4de8-9014-8b800e8708f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_161af252-7afa-4228-b183-7849ec2f6831" xlink:href="nvax-20240630.xsd#nvax_June2021SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_nvax_June2021SalesAgreementMember_161af252-7afa-4228-b183-7849ec2f6831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9786529d-93e6-47bb-839a-563bc4818c37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c22e7e-46de-42d7-bcff-1dd863fd7894" xlink:to="loc_us-gaap_PrivatePlacementMember_9786529d-93e6-47bb-839a-563bc4818c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24ee1c71-3d05-4a96-9670-b1e12268ed8f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_c87fa328-130a-46c1-9316-b8b14e1fbcec" xlink:href="nvax-20240630.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11eefc81-ddbe-40bb-9b73-63b873dea26c" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_c87fa328-130a-46c1-9316-b8b14e1fbcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_1ab2bceb-90be-467d-b113-2243ce624598" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_e6f446d2-459a-4c45-b753-a7433c370641" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_e6f446d2-459a-4c45-b753-a7433c370641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3b28118-2fe0-46d7-8e5a-49b89a865e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3b28118-2fe0-46d7-8e5a-49b89a865e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ad6edccd-6912-4604-9255-3300668abd70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ad6edccd-6912-4604-9255-3300668abd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_71979ec2-23db-4bce-be94-d46d93930319" xlink:href="nvax-20240630.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_71979ec2-23db-4bce-be94-d46d93930319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c3f26e9-b125-4cde-972d-0047536bf3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c3f26e9-b125-4cde-972d-0047536bf3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d20ddaf1-b17b-4109-8d7c-7d1bdc88bb21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d20ddaf1-b17b-4109-8d7c-7d1bdc88bb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d20cc338-6af4-4abc-9c42-42f0b36ce83b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d20cc338-6af4-4abc-9c42-42f0b36ce83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_8c443a05-0052-485c-8e30-8be324b1114e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7fe0d342-4160-4c26-ace9-b9625a636904" xlink:to="loc_us-gaap_StockIssued1_8c443a05-0052-485c-8e30-8be324b1114e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4107aa0d-c538-4251-8297-00004ecd0377" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4107aa0d-c538-4251-8297-00004ecd0377" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_031c0df2-77ee-49d7-a9f2-f89ac6259ff4" xlink:to="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_b5f8fc32-a0ca-4f52-ae04-49c1bf1d3b60" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_b5f8fc32-a0ca-4f52-ae04-49c1bf1d3b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_32a6b21e-eced-423e-907e-13ef9aeedb1e" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bdf02661-824a-4e79-9a06-96bc1dd28495" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_32a6b21e-eced-423e-907e-13ef9aeedb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7a61c1fa-e39e-4bbd-91cf-ba8a63bf6c55" xlink:to="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ea1cb78-f7c1-44c3-9f33-9cb8f02e29bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:to="loc_srt_MinimumMember_6ea1cb78-f7c1-44c3-9f33-9cb8f02e29bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df3e3570-e99a-42a1-b4ee-a258720f188f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c18d490a-ca5b-4fd5-8b2d-05de58924f75" xlink:to="loc_srt_MaximumMember_df3e3570-e99a-42a1-b4ee-a258720f188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a9136afa-b0d1-4a26-8f2d-ef76a2fa832c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a02116fb-7965-4b52-abbf-16821baefa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31792496-86a8-465c-b5f8-25e3c985fd49" xlink:to="loc_us-gaap_EmployeeStockMember_a02116fb-7965-4b52-abbf-16821baefa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2aa1d968-a5d0-4993-988e-8b93b7360f28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3089a897-7e0f-4b74-a0bc-1f923dc87285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3089a897-7e0f-4b74-a0bc-1f923dc87285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_00dc53db-cc64-4d3e-b646-38146d78f779" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_00dc53db-cc64-4d3e-b646-38146d78f779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3d3e3e3c-fe85-4c81-84d6-1a213a1558dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3d3e3e3c-fe85-4c81-84d6-1a213a1558dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fcb90e2a-cf28-467d-a528-c60dd37f0e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fcb90e2a-cf28-467d-a528-c60dd37f0e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_0e18835b-0c1f-4417-941b-8e8d616b0c6f" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_0e18835b-0c1f-4417-941b-8e8d616b0c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_755ecb63-af06-4187-bc74-67af8b16fabd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_755ecb63-af06-4187-bc74-67af8b16fabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_74f7d50b-3298-4532-944e-304e81eee372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_74f7d50b-3298-4532-944e-304e81eee372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96ed4365-62fb-40e7-bd12-73811ddddb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96ed4365-62fb-40e7-bd12-73811ddddb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_081ea42e-6557-4642-884c-edf5ca9813a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_081ea42e-6557-4642-884c-edf5ca9813a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49bac609-c79f-40dc-96d8-8d95cf8d9a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49bac609-c79f-40dc-96d8-8d95cf8d9a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8e0298ee-c95b-4981-8dd1-7c9ba27d8ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8e0298ee-c95b-4981-8dd1-7c9ba27d8ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf3889b2-a71d-4edc-861f-cf9b512601c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf3889b2-a71d-4edc-861f-cf9b512601c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f82608b8-b79c-4688-ae56-9e195fa99d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f82608b8-b79c-4688-ae56-9e195fa99d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_a8868337-82f4-4fff-b590-60d101b76dab" xlink:href="nvax-20240630.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_a8868337-82f4-4fff-b590-60d101b76dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cd7879ed-4650-409a-a2c1-407db6d0d448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cd7879ed-4650-409a-a2c1-407db6d0d448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3e5b1145-644b-456d-aaaf-40241ca054c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8861ce99-a62b-41ce-ac4b-aa4485b442b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3e5b1145-644b-456d-aaaf-40241ca054c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a7aaa72-55f1-4849-a6b2-6a048b179a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a7aaa72-55f1-4849-a6b2-6a048b179a78" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b1e9f2d-1b8a-4fee-9295-d17d1b4483d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6755db87-1f99-492f-bb4f-6ded2ec0dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_CostOfSalesMember_6755db87-1f99-492f-bb4f-6ded2ec0dca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0ffbf1d-a3e2-4854-84bb-727bf54e3e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0ffbf1d-a3e2-4854-84bb-727bf54e3e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_47b415b7-ac28-4104-a51a-cb206ef1ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5b9fc163-81fa-45eb-b885-a9128bcfbbc8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_47b415b7-ac28-4104-a51a-cb206ef1ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b56ab4-271a-4a4d-94c9-33a5cc3cb983" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acc1d972-e0d7-4d06-9cd6-259737115d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6e17c4e1-5014-4a42-887b-6986df9d9d42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acc1d972-e0d7-4d06-9cd6-259737115d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409146bf-4194-4e8b-ba61-284e39f3e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_409146bf-4194-4e8b-ba61-284e39f3e7e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:to="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_87e52ca1-60ac-4274-9eb1-2829a689c3ba" xlink:to="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_dd99e253-a8b9-42d8-935f-9b0850b629c7" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_dd99e253-a8b9-42d8-935f-9b0850b629c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_5ffc48a2-1982-4b5c-b219-35062d0f46ff" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_5ffc48a2-1982-4b5c-b219-35062d0f46ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_045389e3-56fd-482d-8845-985c3a7a7b6f" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3490089c-0a0c-4abe-836a-51f927dd670a" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_045389e3-56fd-482d-8845-985c3a7a7b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4666a721-c409-4451-a114-45e5ecab7af8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_927ad2b8-30e4-40e6-b638-5f0f5c862b59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_927ad2b8-30e4-40e6-b638-5f0f5c862b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01b01d43-09a1-4b31-8796-4cd8ece7d244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01b01d43-09a1-4b31-8796-4cd8ece7d244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84653322-ea45-4f04-bb1e-afde8b06765c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84653322-ea45-4f04-bb1e-afde8b06765c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6d4d2a-9ac4-4667-9a64-46fa5028d7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6d4d2a-9ac4-4667-9a64-46fa5028d7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4703691-1efe-4f96-8a28-666c2fd66b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_205f783e-b801-4bbd-bcee-9c18e055d9c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4703691-1efe-4f96-8a28-666c2fd66b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b704ea8-c251-4da4-9714-9aac7a27a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b704ea8-c251-4da4-9714-9aac7a27a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69a89ad6-6ee4-4005-b6fc-8ef3845b83a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69a89ad6-6ee4-4005-b6fc-8ef3845b83a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59f00ee0-de2b-47fd-9638-de14587db46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_59f00ee0-de2b-47fd-9638-de14587db46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b06dcc8-3e15-42a0-abaa-b75138414f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b06dcc8-3e15-42a0-abaa-b75138414f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a62ce65a-934e-4938-b155-094e59017582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a62ce65a-934e-4938-b155-094e59017582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cbf5e76-0983-4cb2-849a-78b135a2d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c0a23aa5-06ee-400d-8c9b-5967ee6edadd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cbf5e76-0983-4cb2-849a-78b135a2d39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24d8e805-e7b6-4fcd-9e80-881aefe7e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49ad9f2c-4681-4de5-bc06-61fd09c4f192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_24d8e805-e7b6-4fcd-9e80-881aefe7e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b0437a1-f73d-4a5d-a35d-de1ae14b8d70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b0437a1-f73d-4a5d-a35d-de1ae14b8d70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:to="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7a8f6a36-363c-4ea6-912a-ccaac83b5aee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59432380-aa44-4fd5-9fb9-abaf3abfaa42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9db43058-fba1-4447-a375-a55dfcd9e86e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59432380-aa44-4fd5-9fb9-abaf3abfaa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:to="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9e18f919-46ff-43d3-a22b-c13ca2d989ce" xlink:to="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c28839f8-1799-4d89-b62f-a7ec6bb2ecf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:to="loc_srt_MinimumMember_c28839f8-1799-4d89-b62f-a7ec6bb2ecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2eb03ced-6495-4cb4-9bf7-894d02e407e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_315c3586-c9a7-46f4-a4e7-d113d6276a8c" xlink:to="loc_srt_MaximumMember_2eb03ced-6495-4cb4-9bf7-894d02e407e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c688b095-1147-40ac-aa06-deb7f70d750d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cc1d0ef-49fb-4321-8141-f8b5e6d4d58a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5613904f-cd79-40c9-af6b-942a5680f103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5613904f-cd79-40c9-af6b-942a5680f103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7223b64-81d7-4a86-a04b-7779b49e5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7223b64-81d7-4a86-a04b-7779b49e5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9ad828b7-baa9-4c40-9794-f506ff590380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9ad828b7-baa9-4c40-9794-f506ff590380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e0e71e2b-f315-437d-8fe7-3ef5fa58ec02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e0e71e2b-f315-437d-8fe7-3ef5fa58ec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_722a745e-2c66-44e8-9c0e-e29bfe91def0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_722a745e-2c66-44e8-9c0e-e29bfe91def0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b3787fa-648c-4d4a-9f2b-8dd0cbc4faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4b3787fa-648c-4d4a-9f2b-8dd0cbc4faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3ba130f2-f011-4078-8f3d-9214a1281873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3ba130f2-f011-4078-8f3d-9214a1281873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e08b61d0-23e3-4673-977a-f9283fe277be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e08b61d0-23e3-4673-977a-f9283fe277be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dacb198c-1232-42d8-99e1-f39e410dc54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a18782e3-d0c0-43de-aa88-9a4576793bea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dacb198c-1232-42d8-99e1-f39e410dc54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60d836a5-8ec5-4ce1-a998-cfff25385782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60d836a5-8ec5-4ce1-a998-cfff25385782" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:to="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c6dfbc72-6cf6-40a2-bfb6-8b17d1a92993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f2178ace-6b0b-4119-9124-82226be466b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f2178ace-6b0b-4119-9124-82226be466b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29876373-fdf4-4619-80ad-4a0a668e9b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c14de1ed-9a29-4ce5-a709-1c30103cd409" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29876373-fdf4-4619-80ad-4a0a668e9b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:to="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6d36df2d-8011-4978-b961-0a00ebd3491b" xlink:to="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_a5fa9bb4-4292-400d-92ae-196b08fee774" xlink:href="nvax-20240630.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_a5fa9bb4-4292-400d-92ae-196b08fee774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_40f6a279-9ad1-43f5-b751-be536124cc95" xlink:href="nvax-20240630.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_033a3115-88f5-47ee-91f5-78911914882b" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_40f6a279-9ad1-43f5-b751-be536124cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70574866-c0db-47a7-9c83-f7d62925f630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b07aba8a-2140-4b32-85ba-40f3c190c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b07aba8a-2140-4b32-85ba-40f3c190c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29a55cb7-22c6-448e-a973-f9407ca066f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29a55cb7-22c6-448e-a973-f9407ca066f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4cd8c793-619a-4b1a-acd0-32f7301efdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4cd8c793-619a-4b1a-acd0-32f7301efdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ce45fba-a27e-4d87-a86b-4ce084ece384" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ce45fba-a27e-4d87-a86b-4ce084ece384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074c8742-ed29-4774-8074-00e38d313ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d128d94e-60a2-4c90-a626-3639f0f0bde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_074c8742-ed29-4774-8074-00e38d313ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3d5273e-ea2f-4548-81d9-228f5dc69ca4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_866c8a52-4ca7-4330-93f2-8e2115371a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_866c8a52-4ca7-4330-93f2-8e2115371a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60b3b5be-0397-4751-9368-e4373ccdbdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60b3b5be-0397-4751-9368-e4373ccdbdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff597ec5-956b-44d5-9595-395a6b949d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff597ec5-956b-44d5-9595-395a6b949d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f63c5a1-74ba-4c27-906c-aa8952151c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f63c5a1-74ba-4c27-906c-aa8952151c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d823ebc-6c09-450f-9ca5-4a92a054cc60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e854a09f-5ad1-4f95-9e3a-f779ce661429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d823ebc-6c09-450f-9ca5-4a92a054cc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5b7bc5c9-da58-4733-ba72-e6a3b2767c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b7bc5c9-da58-4733-ba72-e6a3b2767c44" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ea5ec1d2-9a43-4f84-9127-b2be20ecd29e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_cdf0fa01-0b55-43f3-b129-a685ea25add9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_35ce7f84-8799-4135-8d8a-9c45c72ba1b4" xlink:to="loc_us-gaap_DomesticCountryMember_cdf0fa01-0b55-43f3-b129-a685ea25add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a2ae7693-23b0-4cab-aa49-f6df3cada67a" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1c7df603-463c-4ca4-8929-3f5b202ac295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1c7df603-463c-4ca4-8929-3f5b202ac295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_12f059da-fcf3-4fa1-b804-5df0a8c8ac7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_29ce9bd4-4adc-4388-a7fc-43b7c82573ba" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_12f059da-fcf3-4fa1-b804-5df0a8c8ac7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce146d7f-36ff-43b4-a416-0467d1a9bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce146d7f-36ff-43b4-a416-0467d1a9bd76" xlink:to="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cd77239d-e7ee-462c-b1ed-e2943f4e911f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_eea742c8-943e-48fa-a321-9d85773c0c0d" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c96dbae0-ce77-4070-a2a0-a5a446ba5576" xlink:to="loc_nvax_SettlementAgreementMember_eea742c8-943e-48fa-a321-9d85773c0c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_67279a75-b57a-416f-b4bf-01ed0ade71d8" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_89cddfa1-35b8-4603-a162-ceef166dcfcc" xlink:href="nvax-20240630.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_48d03b53-23cb-4271-86d2-c2020f5ac43e" xlink:to="loc_nvax_SettlementAgreementMember_89cddfa1-35b8-4603-a162-ceef166dcfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_295552e8-4bf8-4b4b-9b4b-4cc1ee770547" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e836307-f7e1-4595-811d-708534365ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0fe1e6ba-f9db-4dd9-a77b-64644fafb462" xlink:to="loc_us-gaap_SubsequentEventMember_6e836307-f7e1-4595-811d-708534365ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ac985d0d-49b9-438b-bdce-cf49ba9ee372" xlink:to="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_df011c10-b950-49fa-8356-a9fd4367edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_df011c10-b950-49fa-8356-a9fd4367edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_58fcb467-a059-40ea-8f81-e14c66af34c9" xlink:href="nvax-20240630.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_58fcb467-a059-40ea-8f81-e14c66af34c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fd458b48-868a-4d22-ba9d-92e7b30bac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fd458b48-868a-4d22-ba9d-92e7b30bac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_99d0e629-3723-4279-ad64-84678c6ebf15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_99d0e629-3723-4279-ad64-84678c6ebf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c2b174a0-5c46-43b3-b181-0f4befd78a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c2b174a0-5c46-43b3-b181-0f4befd78a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyExtensionPeriod_21fb8f78-9942-4bd3-9a92-7724bbdb289a" xlink:href="nvax-20240630.xsd#nvax_LossContingencyExtensionPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8cf24376-0e9c-4377-b939-86a0e69c2664" xlink:to="loc_nvax_LossContingencyExtensionPeriod_21fb8f78-9942-4bd3-9a92-7724bbdb289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringScheduleofRestructuringandRelatedCostsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_40973f75-c274-4d3a-a130-827fcbaeb5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_40973f75-c274-4d3a-a130-827fcbaeb5f6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c9473898-8063-4490-920a-0304e32ae34a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b59f21a6-bc50-42ac-a07a-89ce0f6e3d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b59f21a6-bc50-42ac-a07a-89ce0f6e3d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1cd82c7-37d9-4f0c-b909-506a6cc81fac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d1cd82c7-37d9-4f0c-b909-506a6cc81fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d10b6aac-b8c3-4d26-8532-957f1e72bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9062a2b5-7216-4c6c-9313-1dab8a0398dc" xlink:to="loc_us-gaap_CostOfSalesMember_d10b6aac-b8c3-4d26-8532-957f1e72bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0fab94f6-007c-4e96-9d9c-3c8b98022fe5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_681dc3f7-59fc-4de2-b014-7e1b9033fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_SeveranceCosts1_681dc3f7-59fc-4de2-b014-7e1b9033fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_dfa84d0b-0683-4043-8f0e-5dadc939188d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_AssetImpairmentCharges_dfa84d0b-0683-4043-8f0e-5dadc939188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_22d0550d-433c-4bb2-afd1-258e5c975fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_7b93c668-ffc0-4c95-b85a-59b7115b8baf" xlink:to="loc_us-gaap_RestructuringCharges_22d0550d-433c-4bb2-afd1-258e5c975fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="nvax-20240630.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0253e5aa-ba86-4981-aee8-e3db04fe9901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0253e5aa-ba86-4981-aee8-e3db04fe9901" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_37893335-51b5-4508-9cef-736370a6471f" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_db86ec29-6a65-4776-8891-abb968fcdfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_38207fae-ab21-4ed8-8910-9290ce865c3a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_db86ec29-6a65-4776-8891-abb968fcdfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8584168d-934f-42c1-a839-450b2191bcdf" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_77600d9f-c9b2-4e62-af11-f623614243dd" xlink:href="nvax-20240630.xsd#nvax_PaymentsForSeveranceAndEmployeeBenefitCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts_77600d9f-c9b2-4e62-af11-f623614243dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f379df48-77a5-4e31-b71f-5afd43a4f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_SeveranceCosts1_f379df48-77a5-4e31-b71f-5afd43a4f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a97680e1-8106-4e40-a420-23c58533637e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_AssetImpairmentCharges_a97680e1-8106-4e40-a420-23c58533637e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ea120d47-cb1e-421e-874e-04f93d3c2a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70b0e23c-c340-44a8-b263-efadfde531e2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ea120d47-cb1e-421e-874e-04f93d3c2a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnC.JacobsMember" xlink:href="nvax-20240630.xsd#nvax_JohnC.JacobsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_JohnC.JacobsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JohnTrizzinoMember" xlink:href="nvax-20240630.xsd#nvax_JohnTrizzinoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_JohnTrizzinoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMember" xlink:href="nvax-20240630.xsd#nvax_FilipDubovskyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_FilipDubovskyMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@    P    %" 8   !Q>@TO    "7!(67,  $SE
M  !,Y0%USO"5    $TE$051XVF-@8&#X3R(>C!I( @ O0B_1WIFO,     !)
'14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@    ,   !%" 8   "/*5S.    "7!(67,  $SE
M  !,Y0%USO"5    &TE$051XVF-@0 8QNA/_CW)&.:,<:G.P"H   "A#C(RL
/EX7.     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_02.jpg
<TEXT>
begin 644 image_02.jpg
MB5!.1PT*&@H    -24A$4@  #+(    +" 8   #15442    !F)+1T0 _P#_
M /^@O:>3    "7!(67,   [$   .Q &5*PX;    RDE$051XG.W; 0W , P$
ML;0:\#!?4?0C;3:"(W"KN]\"              " R_9T
M /]@9 $              "#"R (              $"$D04
M ( ((PL                11A8                BC"P
M  !$&%D               "(,+(                0\535FHX
<      #@^PY]'P*8AN13%P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
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M O@(T+9Z-O]DZYGOC9% XGQP"_KWD-B P#>>6W5>^T\ WPSCN-GH?Q.EMU\
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M.E.@MAQF1$1$1'0>.*^"%_7J9YX2$"\$V<PJH3VN;7YRH?O3'^\9D<)HL#8
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M;J3+(2(B(B(B(B(*U=@/7BP6B][+4H+#C(B(B(B(B(AH3!OSP8OJ=F?HOB'
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M_9KFT;QSI!3ZGR/EIBMO<ATN/%QS],A1.P"+:E3C# F&:P#\#\2W[E(  "
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MYY&=K9U]9@Y6% 5&B]&UKW#?T"YS1$1$1$1$-  ,7B@@*:42:8E,C+9$9P"
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M=0'XG912//_'YU,:FAK^8_?^W5=;.ZUS&AH:H,D^HW,$@'@IY756JQ56JQ4
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M+??6JZH8/VY\]S>_]LW<[!G9#>'NCXB(B(B(AE9(O0KH_%6"$E@]5LVN>>_
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M<N1(I#G=?$5=:]T*A]N!*=.GX/*EET- 0$+"X7"8=N_?/3ZLDS*,HJ.C90\
MWF I,2H1"](7!&RW?LMZN7/'3G=34Q/<;K>GJJ*J-CXR?OOL>;.K(BP1D)H4
M<&&<A%P5I 0W>@;0N-UNNS3($V>^69-;$R&%O*S@9,&*AM8&& P&+34UM7'Y
MXN7KOO[MKS^=DY/SFZ5+EO:=0T8"PN._HTU71Q>ZV[T=7 P& ]+&]ULENA\%
MRND5A0# H!J<Z>/33V3%9>WM<V@IU4\__73BF^^\N>JO;_WUH<-'#S_SV=;/
M?O3/C?]<6)A?F-[8V)AJL]ONJRZKO@( +!:+$J%&Q)A4T_B>$5=P.IRVUJ;6
M$T*(T\N83QD_!>/'C8=1-:+G7&GE9>4U*Y>NW*%7[\<??VSI;.R\J+FA^6+5
MH")]<KISP<(%-D51X-$\<+@=<2D34Z[% .?=NONVN]LNR+Q@8W)<<H')8(+#
MX5"+"XLS-G^T^>Z__>QO(8=M1$1$1$0T]!B\4& .0+B]-[BJJB(A.0'9UV:'
MU+2\O-P<$Q^S6#-H][6VMTJCT8C)DR<WK;YQ]1]>_?NK?\QMR-W9T=XQL]7:
M&MG;1DH)A]V!EFK]57S2LM,P+GT<+)'>:5F$(F"P&!"=I#]UR:9MFQ+*R\MO
M+*DJ,45%1KDOO?S2AE77K6J'\ XW:F]OESMW[71+]!]*,BK: :U3 WIN\56#
MBJ3D)%QXZ84!F\6UQ)GLK?:4IJ8F**JB&2U&:W=[=VZT%KTI8V*&!" \\,06
M5A<ND5+JGJQUZ]89;EQYXP2CT6A0% 5""FONSMP/SMSFC4UO))PH.G'3B?P3
M$4((1$9&VB[.OGC3S[_S\\>^^]7O;GCS[V]V-U4W]2E6>B1LK?Z'CCFZ'' [
MW1!"P&@R(CDC.>AI4J&>_G]%46".,G=,RIS4)_3XW>]^9_[EKW]Y\7OOO/?(
M@=P#/]^>N_V'QPN/7U)04 "GR^GM-2.E['9TVQK*&ZR][5QFE]34+\9&=71T
M6#>\M>$]G/Y6@/&1XQ%KBH6JJ*=KB(F,P;)ERW3K?>655Z+W[MI[<5U=78S!
M8'#-FSVO=,8%,XZ9S3T]MPQJA-OHGHL!!B^+%BWJ+BXLWCQ[^NR_I:6E=4 "
MK<VML<>/'K]M3\&>NS[9^PG#%R(B(B*B4<+@A0+R='NDN],M(;V]$5(FI.#:
M*ZX-J>T_/_YG='YQ_N4-UH8Y (2JJ/;DQ.2]]SQ^SSM""$]U?G6LV^9>KDKU
M],VFQ^5!0TT#MGZXU>]^74X7>H>!*$)!7%0<IJ7VGQXC)R?'<'C[X8D[/]XY
MJZNC2T19HJQ9J5EO>ZR>]WNW,1J,IEE39TWI*N\:$Q.1MK>WH[VK'2ZW=ZH0
M15$0'1F-Q'$ZJ^KTD%***Y9>,2Y[8?;U#KL#D9&18OFRY<:;I]WL3I^<7CHI
M8U*%P6! =W>WN;JJ>L[F39L7ZNVGH[8C;LZL.==%1T5'&@U&+3T]O7W1_$6G
MESC.R<DQ?)+[2=JF[9MF6UNMPF P("DEJ77Q18O?2EF94K\Q=V/$A&D3YN:?
MS%?/W*_;XT9#G?[B.NOSUJ.BJ0)MW6T O+V=3 93T!#, \_IH486BP69,S,[
MTJ:E[>@Y'\K??O^W<6]M>NORS=LV/_G9ML\>.;COX )KA]42%1/E29V4VI$0
MG^!4% 7QT?%=<S+G?)::D>I= CH=B$Z,ACG"?/I8FJ9Y2DI*VH00I\<V.52'
M$!:A"L5;JM%@Q.2,R;CKKKOZU;YERQ:#$&):=77UU:UMK8B,B;3.2Y_WEK/=
MN2\J*@H X'*[4-%0X:F25:'/+.WCU7M>[;QAS0T?9"[,_-?XU/%=0@BEM;5U
MRK[\?8^\M^&]K[;M;6/X0D1$1$0T"AB\4$!M;6UH[6@]'72$NN"0E%(YNO_H
MA%T[=EU><;+".Z<*/.W5#=5;$I#0L45N,3B=SG&Y>W)C;+8O>D-X- _:.MKD
ML9)C'G_[5E450GCO;X40,*MFQ%MT5C5J1ZRJJ-<W-#1D2DAW9'3DR?GCYO_Y
MI9=?6F<VF2&$0$QTC''1XD538$1JZ&=E^.15Y:&VH19VNW?:&U55$9L8"S\C
MKTYKL#=$=GHZ9P" $,*9DI)R"G.AU;36G#3$&-9'146Y72Z7H::Z9L:[&]_]
M^@>O?C!=RKZ]?(Z4'HDX67-RII32J$&S"9,X=N\C]YY.3!P-CAB+QW)M2WW+
M;(_' TN$!3,R9]@7KEY8# "5QRICS2;S2JG(F#/W*S6)+D>7_N?-ST-%104Z
MVSM/;RMM,NB2RMH9L_6JJNJ:.G%JW0-W/F!?MVZ=^I>__&7*KL.[[BLK*/NO
MO;OVWG3L^#&85;.<-&E2V^)+%^]=<<.*?=%1T9U1D5'N"^9=4'S[RMO?6+MV
MK1L TI&.!%,"HHQ19QY. .@3)FGMFJNKOJO:WFUW H!0!:(2HW#__??WJW77
MKET)BJ+<;.VPSE(-JBLF.:9PQMP9&S(S,A$5X3V.V^UV=+9U5MAA#WLYZ=-%
M7B7<U3.K3TQ;/.V7BY8L>F?:C&E6I\N)@L*"R7NV[/F/YU][_JX7GWMQS RK
M(R(B(B(Z7S!XH8 :VAK0T=D!*24414%L="QF3YD=M-W?__[WZ+CXN!4=K1V7
M>SP>&(U&.67J%,<E-US2*(30$NH2S*F34R\01C&KMW='#V$P& RW7WN[[G2L
MV6G9F)PZ&3&1/??V M ,6K\!&G*+-$0G14^OM];?WFIM-0JCZ# D&C[]S;'?
M%,2EQXF$<0E0A(+(J$A[^J3TXU%I42<'>(J&E-UN%QZ/1_3VYM"D!IO'AC/#
M*3VYNW/=KO:?A@  ( !)1$%4>8?SG(JBP"B,UII3->\!\&3\6T:+Q61YUVPR
ME[O=;M34U<3NW+WS]D,G#GT7'3C= V)+SA9#757=A(.Y!U.[NKH0&QUK3QV7
MFC]_^OQZ -@BMQBB,Z*GVZRV-=96JTD((555[9@X?N+!I6E+.Z64XL3!$U&Y
M.W/'VSIMI_]=D9#P2 \ZNSKU"\\#.MH[X'0[(:5$5UM79VMYZ^%@YTF!<CH$
MM#OM7?N.[MO=W-%<NW?3WO1-'VSZYK[<?4\TU3:MZFCNT"R1EK8I4Z<<O.RR
MRU[^MSO^[5<I22EY4*!.2)E0NN3:):]^Z_%O]9D05U54*(:>CR"\P[W,4>8^
MQZ_KK&O;_NGVCYJ;FD^OX.3R]%_0Z,"! T8CC)G-]<VWM;:W(CHJNFOFI)F[
MYUTRKSYE4HJEMV>-YM$Z3 [3]IEBIM]5D4*Q]JJU[B\_\>7"KW[CJT]?N>S*
MUY*2DDI<3I=R[,BQ]/>WOO_(X:+#M_L&;D1$1$1$-+P8O%!00GXQG&+BA(E!
MAQI)*<7QDN.)5555U]77URL 8#0:N^;-F+?C@6\_<!@ -KRQP7CTT-&4[L[N
MN#/;*HJ"<8GCXJY:<=75>OO.SLY&UN0LQ,?V]'"1@'1*N.U]YN?%UHZM\4Z7
M\_JRRK)9PB!DRH24YHLOOOC#6^;?(F;-GV6(38B%A(3+Z7+7E-74"2&L.H<;
M<1,L$V2$.<*#G@68'0X'"O(*Y*>??NKVU^;#X@]-B>F)DZMKJDTFHTE.2I_4
MO7#:PG(AA/SVHF^[:@MJ3Z3$IVR,BHSR.!P.G"@Z$;]M[[;5K[_S^G3 ^WUM
M[-@8W]G5>8.MRS9?415M^HSIUD<??+2F]QCND^XH&2V75[=4SP8 @]$@QZ6,
M*Q<)XOF(Q(CJXN)BT]294Z=V.[OG=G6=T;M%]@RCJ:W0K7W]^O4H*BA"2W,+
M-$V3#<T-K;_ZW:\VA7J^A")@-!F=3ND\=?N-M\=MV[?MF_OW[G_@R+$C<1)2
M2YN2UI T)>D?2Y8M6?N/?_SC)WNW[]U15U57/?>"N=LR9F:\\-"_/_2RHB@=
M?7:J KWS]JJJBKAQ<9BU:%:?3>ZXXP[GAL\VG+*[O#U>I)1GS #SA=+2TGBK
MS7I327G)#$UJ<M+D26TW++_A@-ELMFL&K<9FM]D!P&PV6^9?/'\F?'K6#,15
MXBKW73??=6+>['D_N_3R2]],2TES==N[E;R3>9-RC^;>]]C3CPUHV6HB(B(B
M(AH8!B\44'U]/5J:6]"[RHY!,2 R,C)@F[SU>49GC7-*06[!#+O-+HPF(Y+3
MDIO2,]+_?/FLRPL!H#JO.KJFHF;!J<I3L)@L,!J\J\/T+"D<$QT??;&__:LF
M5>M=T4;3--@<-M2VUIY^7TII.-5\:D9A2>&:AIH&-3(BTGE!Y@4E/_C*#RHO
M77,I%LY?*)(G)$-*B?:V=O70X4-QFJ9%^3O>2!H_?;S=97<5=MN[&R%ZEAHN
M*3)^=N0SOY.\-.UIBDN<D'BM"ZY8">E4S6KI55^ZZO3LQ%][X&O6^=GSW\F:
MDU5F,IO0;>O&[KV[H]<^N_;JY__K^1F;-FU*J6VMO;FXHOBNII8F@R72TA&;
M%/O^-8NN^0CP#AL[\=F)I.*\XBNKZZJ-0@C$QL0ZEUZQ],1+OWYIOQ!"V[-G
MCZ&AOF&B)K49$(#9:(:B>/]Y<;E<J*RHU*T]/S\?=15U6E>;-ZR14LJ*^@JG
M[L8]LK*R,'7"5!$3$0,! 8-B4!.B$B95UE=^K;RJ_/LU#34)%K-%FSUO=L/U
M-U__CVOONO;I5U]X=:,0HCL]/;T]9D;,ZRMN7O&C-2^M^<O$B1.[??>O>M33
MJS"IBHK$_Y^]^PZ/HSS7!G[/%DFKWF5+EBWW)A=< ^Y@FNDU! @].(08XA#R
M 4F.31)"#N?00PHAL0F00TQO!F.P#+CC7F7)5K&M9G5IU;;-]\>SP\ZN5]*N
MM"NW^W==NF#7L[.S,^_.SOO,\SYO8C(FYIY0W%B!Y%DI .!RNE!768>77W[Y
MNP54556^V?Q-RH[].ZXJ/5IJ-)O,'=E9V;MO''_CU]5CJYM6?KQR=7UM?3T
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MC]L ; +P"8 UD*",LYOW3 'P2P 7N!^7 7@(O& \4T0 F 9@F>ZY-@"? 7@
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M%_$G(B(*"P9>J*]%P'NJ3Q?D0KPWJ@$\"T]QQ*X*YL8". ]R00;W>W_;Q?*
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M=MX:!RF^G O9=_ICH9T?M=_//0 V0MK]V1X((R*B,&+@A?J:'=(1UL0".!?
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M^Y@(&8ISO?NQ5A.A$M(A,$(NVH?"NXAP*H![(<-G]#,]^8J$9"H\ N^BENT
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M[6J&9(=UMF\T9GAF+]($\]WV=RS-".Y8]H86=+D!?1]T 60_OX,3@RYZ-DC
M=;G/\R;X;X?:4#5-$R3 WM6Q;(><P]Z$G&]W0MK.F3IU/1$1G63,> '@4I!H
M4$_V5IQU&B&S%-@@,Q!,@N?.N9X)4A1RL/NQ W*W;">D(Y8/N<-9B-!EPL3!
M>_A.&^0"+9"Q_\V0NZN70PK]]50-9"A%=YT *TX< F" _V*89DA6D190<D("
M7T\AL("' W*']<^0F9L N8"_#)(=$4BF2#/".YPH$#9(^PGWD*-62"I]*F2H
M1P6\BW]VQ0EI \7P=$:#Z9QI095/ MA&WZ$5C9#A;=W5VK%",G.TX18*)!C@
MR[?=N="S=O<29&8C0-K=Y0B\W9T*VN#='BK=CP/1V_8 2)O6SKE=:<&)YY3.
MCFUO^-9YZ:HFBS9#D<:WD&YGZ]2FE?97.R8*4I=+XSMTJ3,*3OQN5R&X8UF+
MWAW+GM('71Z%IQY*7P5=  E2O8K VJ'O\5#@_[=-@7?AW4A(<.P;='U^L +X
M"!*H.02YCN@NXXF(B*A'&'@!8%"]+NBH[S1"[FCM!O!]R$7H4'0]>Y ^$',-
MI"/_*>0B?#4"3[OO2CR\9S>H ? &NK]0U"__&GH>>-$7V^R. X$'"6+AN6,,
M2.=A X*[T&YQOZ8"4DC8 LD.2H;W-.'^V"$7M>$JGAN,SH8<S8>TJV7H78>^
M'7+WO C2IK,A=[N#">C8(1TZK7/664#-'VTH47>!#0=./&[^.M[^N. I'@I(
MQWR@G^5\[T9K;2C8=K<1/6MWIX)VR/'H37MPP+L]^'8VNQ*N<TIO^-9YT>I)
M^3NFOC,4M<!_,6S?=9H@ 8TA.+&HNS8T3N,[=*DSVG>[V+U>K<WW]KL=Z+'L
MC9,==+%#O@,% 2P;3#OL ' 0GHS%1 "W0?;Q#LA,>>U^7F>#9'A]&^#[$!$1
M]1@#+P  =9!<P]))T 'I4&V'I&Z?![D8SG#_9:+K(45Q\!3??!DRC&5?+[;'
M".G8Z8<$M,!_W8K.M$,N O6%(X/1"LGB"330XX^_[[8%WNGQ6L9",%3(S#C?
M0F;C *3#,!S==X!;T;MC$TKZ(4=CX*F1DPJ9LG@C>K^M-DA'-Y#.+N#)*DB
M# F;A)[?!6^#M*&>Z$#/9N2*A*<SI^=;:+JS3G-7M':W!<!5[N>B('>U3X?
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M6Z<),BM>?\B^U^J[V"#'(9C"L@D(S;'LR\RE.@ O0X(N@*<8[2L _MO]7!*
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MZ' I)$LDF*$#$9!T]!_#,RTF(!=@*T*\G7&0SM\O 9SGWDXCY((Z"G+QM@#
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MOP6>B3K9//0@,\=?!=>91 .+-S4VRXY3E>7 QTC6Q>NG-4=.,U@.G$OR.>]
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MB-+8@E9*[J;UT?>;G:=*97TG*NOU3/]N+>U*!QHT[H.V/$Z7WUUH^^&L\NM
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M<P*5>6B5DH[YDH=>U+9">I 8UDI&4'LU=R,S_7\84ZT?TX1N1J.H;A2Q .E
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MD=]NE/=ZR;8'-;']I8\9\M^)E6%(^8&5^]]CGI.?QPPU[Q_\+9.%.<*W0OT
M&Y]<P\OWL1@K;;*&R<BNZ)YL^]@/,./+2QGU2BGB*<S#[';L8('ESA',*/AV
MS+OR#"R630C[L;[SCP:?:?,4G#:6L+']KS'ORC]"1A<A"I'A14R*;'#[%N8*
M^TJ&RFP,3V/*\=]@*\--3\[V8RNFW\4"@[X,<U5_/L.\'L96-+\)/(3MY_\.
MHZ?M]#%E0!234M:W8R?<_!^YYZBLIXL^=B+%[V G';T!6X'_$<QC).^I=!BK
MVV]CL6'NPE;4Z\;ZJ,NQP$LFE/8!ANWB<NQXXQ=@^^SS[>+AP6_V '^.E=NT
MG\2Q%ULA/<>YUL0VHXR#F&?-U127W](@W>]C\O</V%:N.S"OHU=B99E-8C/C
MRU\%YN$ =A3Z]QG*^Q+6+NY.>:D(UC YV17=LQ^; '\#VRI]+B:WSV4HO]GQ
MR(]B_<97@0\QG9YQJ61&ZRNQ&#=9G)L?9=08=01KX]_%RF,GIL-5G:JX4CF,
MZ>W[L?+Z)RP>T#:J/:6$6/'(\"(FR1',S?H=F!O]1BS@X7,'GV<RW)J0D4TP
MOH=U^%_'+.Q?)FQE8A^FE#P\^/XXU<K&H<'S'\3<S4_#E.Y,@=X/W,\PFOX^
M+#9)?K_L86Q@;RI/>1YC-'ACV?V^M/;4^%U,GD+N3RWK_"DE967=%@>QE?NM
MN6O_F/BLI[!5]NS^HK)SR_B?L,EC%4<&S\O?^ZW O/G>,_3>IX%/8P%C7X:M
M0+Z$X7'),#SEZJN8,A=C<''++29O51S$9&YK0\_+$Y+'PUBY/ B<B97?2QBV
MB^SX[K]C&+^@2U)EZBG,N)%?C0[=9O2XD]YW!]=\Y,OOY0SE+RN_(]@D8L_@
M=[L8E;V'L"T86>R,)XB+Q["(>2$\DDOS:6S!H.W MKXVVQ1-R=DA3'ZWMO#L
M:><0X_7S2,UG'L9TJUW8]I\S,-TJVR*WB+7/G5BYQTZ8G\;ZVGP;KYOG/ <9
MEX='$YZSA,G11[#8+B_%/"[S6P6SXZ*_CK7SMHT'BYAQ=VO+Z3R!?YM1W?0/
M8D;DO5AY[:%=#Q=?W_"=%M,3HE5ZD\Y %;,7;+F!GF<?<I_-BW=>=T/W.1(M
ML@HSM+QX\/DAQ@.H[L<ZX6]@@^6>#O,7PZF8X2*;5.[&/& F>13NT<IZ3 E4
M60LAII$9S.#S.89;?A[&XLQ\?E*96N&\ /@O#..4/(@"M@LAA&@1>;R(:2+;
M\_\P[;M?EW$LMAIZ(K;*\CTLP.=BX/VSF!M[?B7_"+;B*49IHJQ_!)6U$&)Z
M>2;FU9D970YCAN&V3S,20@@AQ)0@PXL0X\P!%V-[@G=B[KI_@\59".%9C)XX
M<A#; M"V2_ERQ"WKW5A9WQ5XO\I:"#'-]+"MLV_(77L<.\EJTK&+A!!""-$1
M,KP(,<XBYC7QDX//0<SH\B#5^XRS(Y!=);O)8)%'$[ZROAN+4Y%:UI]N/)="
M")'&<=C)?5D X24L-L9_GUB.A!!""-$Y,KP(,<Y^1@.L'0N\ G@+9D#Y!RQP
MV<'!WV> $[!(^6=A)V=D>\6/8/%H[FD[T\N4_9B1)>-8+/C=6[&)25%9K\6.
MC[Z<T;+>PV2WJ0DA5B8SV E",Y@GRPP62/<UV,E]&4]B<5V.IA-DA!!""%&!
M#"]"C',0.U7EK[%]^6![\Z\&7H6=JO,=AF[B65#@'P<V,-S'#W;RS">P;31B
MG**R_@_8$:Y%97TZ%A31+>N/H[(60G3/*BS0]P785L=56.RIG\8,]V#&X8>P
M4U:$$$((L8*0X44(/X\ -P*_C4WRP0(D7C3XA+ 7,[I\K/'<'5T\2OVR?@([
M5EQE+828!#/8T?:WE/SF<60<%D(((58D,Y/.@!!3RGYL>]!O 7].7!#$ \"7
M@#\ -J- KU4T5=8WH+(60DR&JM/4,N/P1[O)CA!"""&F"7F\"%',DYC'RB[@
MYX SL-,I?AC;[I)Q!/@NMM7E4>Q4G6W8R3R'.LSO<B8KZX> 2U%9"R&6%T>
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M5/%);'4T1K:^A$V,?5X*95R"K>Y?1+U^PC>.YMF.M;O0<;5JDG\OEN]L3+P
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%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
MB5!.1PT*&@H    -24A$4@   S4    #" 8   "J)R'!    "7!(67,  $SE
M  !,Y0%USO"5    +TE$051XVNW7P0D ,!##,.^_])6.$9!!"^27J@,  %CT
CRQ   ,#TJ3E)DB1)&NX!R#XQVHH?A4H     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_1b.jpg
<TEXT>
begin 644 image_1b.jpg
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M"C5Z^WWN@W^!&8.5X8?!"A$1$1%=-)3!K@!1'Y@&X&.X&M2A@UR72U4H@*T
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MA&1O%2(B(B(B(B(:6,,J6%'T^CO@>8GE2J?3MFV@ZT-$1$1$1$1$E[9A%:Q
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MEI96]O.'?_X8@.,#58>+@912>>*))\9F9V0_7%U5?8W18&PK*BH:GSPI^4D
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MXJ"&QH;+A"(@(! >%FZ?%#NI7 A1Z^NUW7WWW8;\VOR9EF++K3)F(<D  "
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M(:THK?%G/_O9&T[5^>7JY:MM*U>N+!9"M*W_[7I(*=4E"Y>,WE:[;8[%XEK
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M3$93VY577KDU<4/B<_]^X]_'A!!M/97;TM*B*:I2KPCEN+3+@]&AT2=[$ZH
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MM#HG(R?*VF:%7J>/F#Q]\G(IY6>^/F]$1$1$1,,->ZR0_S*!YN9FK;&YT0D
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M(B'1$1AXH%C:+3%6BW5Y2[-KE62]3H^H$5&MIP^>]MIS0A.:H\W25F-WV!T
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MV2E?(_FDOMH>C#'HM7I[;EKNQI:Q+6\PQGP L&39$C9SP4Q!I^^;@(>Y/*Z
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MKG3=HFTEVU9OWK3YYQ^\]<$-[_[IW<23XUN]>K6<F)C8-"IQU#]##"%= 2D
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MV^W&QH\WHG^MG \^^$!765$YM[BT^&I!$H3TK'2+R^?Z^&C%T>MKZVN5@B#
MH#>XTI+3-EU^]>7K&6,> )AX^<1NQ1;%5Z-'C;YJ1\<.G2S)O?M@NTMWQRD5
MRA_X_#Y9I50AX KH=V[:N7#75[M"?KWZU^5:M[:^5EW;OOBFQ5B4L8@#"/36
MKKGNNNL<[TOO?];1W#')TFE99+5:38(@R-$QT;:4T2D565E9KSVZ^M%O$C6)
M1X%@C[';;KO-N&WGMI1N9S=$080"BN[#6P]_.9S)2$(((8000LX5)5;(D"47
M)#OJC]67JC2J0I_'QV1)#BG=65J "YQ86;5J5>"AAQYJ;C0W[J]OJ)\LR1+:
M;>W&S=LW+\Q(R;C]@[4?O .@]OK[KG?LVKJKN+&]L:K5TIKA=#E9:7EIG%_T
M/ZC1: H[.SMGU=76Q;@\+D1&1?KS\_(/A:A#_O3 E0\TK%FS1M==T_U17%Q<
M45UM':2 )-IM]E$5NRL>UW7JA.5+E^]_^2\OFSS.X!?K"J4"T<G13!^MOZB&
M,##&I%G7S:IQB:Y_A9I"IW1:._5<Y@&?TV<%('/.Q1=>>&%$V;ZRZZJ/5HL,
M#"'&$-^$@@D'%UVUZ./'[WO\K/?5W=+=Z92=[T7'1%_1VMB:QCG7='5V3=NR
M=4M>^>'R4+_?C]C86/>$&1/VA@@A?=/I,L8DOHG7.'.=OVRP-%0UM33I/&X/
ME*+2$Q$:<?#6']VZ8\-;&^QMYK;4Q(3$B99VBT:GT>V+#HM^^A=)OWB_:%=1
M< ::SW@KY_R/C+$8QEC-V<:=-24K8&NWV<IVE<'O][.FQJ98?\#_H-5AS0T+
M#<L_4G9DC-EJAE:O]2>F)U9,GSO]N7L>N.?->Q^\]Y1M+IVQM/M@Y,%=]>7U
MLQM;&X5C-<<4D('0D%!?;D%NQ<+"A>\SQOQG?7('(4E2!/.QN[?NV+HXX _@
M</WA3N[A(VOJ:R8Y'4X68@R1\O+SJB>,G?#B["FS^Y(T<\;.<:SYXYHO)N9/
M_/Q8Y;%%%HM%VSME..<</K\/  2?WX?*FLJ0K@^Z;M!K]0LS,S+K.EH[2CUJ
M3Y758L7^B/W<ZK:V*Y7*4KU>CY_<]A/_\Z\]7]_=TOW+FHZ:)K?=/1D<]I&9
M(W?/N';&[IL7W/S1\[]]OO\AB(73"I/,-O."ZLIJ*%0*I*6G8?GRY5)/0I<0
M0@@AA)!+ B56R)"%989U-;<V?Y8R(N6'E>65:JO-*F[9O27BE4]>B;ISR9V6
M,[<P-(PQ>='$1?6R6WXS(BPBS]9ET_J\/I@;S-$I<2GW..$L!5";'Y?OO'_E
M_9^$Q(2$AX2%W.?H<(QT.5RL>&=QK"B*18%  *(@\LB(2->D*9,J+E]Z^:LK
M[EC1P!C#CW_\8V^WN_L(<[$*F]669>NRP=GM5-95UF6.C!NY;$'^ D=.?LZ,
M+YJ_  #X_#Y/MZ>[JG>JVHO)EG5;'$N6+/G*F&'<4=U0/5TA*0YU-W;_DS$6
M6/OY6E-S:_-EI0=+Q_@\/BA52D0E1'5.FCSIW7')X\ZZMPH K%NWSG?S-3<?
M#DL,>]_O\*^P=%CT]?7UBN/'CX=RSA$9$2E/&#^A9=Y-\[[XU1._&K MF\,"
M (X"6,4Y9XPQ>'P>,,;X],+I6+MVK6B,-'XINL6_[SZT.T)KU'Y0?J#\W?XW
MX#W_=@(XZZ0* (S-'FMK:VC[J+.I<WQ+4XL8\ =82V-+C+G%?*,@" @$ @@Q
MA/B3TY,/I^6E/;]ZY>I_GNEYOO766VV/W?W8^LS4S.O,'>:1/I\/:HU:3DI*
M:IMTV:3UF3F9M><2XV TLB8@.:3VNN-U;I?#I3U6?2Q4%,1K , 48I)R"W(;
MKKCZBC<?N>^1?;]YX3<#M@V+#VN-]D0_E34ZBTNR-+/=TM[7M8HQ)BC52JU*
MJ=*XG"XT-C0*C+&(NKJZ"# 4FB),W./RH%G?+#N]3DM "FSC$N>MMM:V8RW'
MGKSMH=O*-Y5M6JF7]85<XET3\R<>&#114@K6V=*I<3E<D0 @BB*/C([T+URZ
M,/#HSQ_]KJ>'$$(((820[PTE5LB0K;IM5> E_E(C<[/RYKKF<7[)KXV*CQK'
MO&PT@ N66 & 28LG.1IK&K^,28SY>N_NO;'MG>T(,81(^5GYE:$C0OL*;?YI
M]9]LA86%_XB/C$? &+B_R]V5WM[6#K_?#X5"P6.B8RQIB6F?7GGEE9_]Z/8?
MO=>OGHB<E9%5Y;0Z?S_RZ,@[2_:7:$2%B)"($(L X7U;NTTV&HQ]4] Z'(ZN
M3S=\^BF>@_U"'O=0S9LWS]S:V?K'V*I82WUY_<=_>.T/[TY>,IE]N>7+U)JC
M-=>;F\T:QAB,1J,O,ROST.QELS\:2J^!!Q8]T/GA@0__X?:X$U0:U>6=G9UZ
MI\L)C48C9Z1GM%RY],KW9J?.+CE=&[W[[3^,JJBH2.(K>?7Z@O6_Z-)UZ:;]
M:UKK^>K5\.)O7NS^TXM_^D"OT4_[\O,OL[J[NI.=#B<"@0"8P& RF@)YV7D5
M$_,G/O>[/__N'V?3TX0Q)JUY>DVM$\ZWFCN:'ZJMK]7$Q\6WCAHUZNUK;[WV
MG?,1NUVR=]0TUOPU(3EA1%=[UU2SV0Q)EKA6HW6-2!]QX(JKK_CDX9\\_'^#
M#:LI*BKRK5FS9M^D<9.>='@=5_=/K"A4"F526E**R60:75-1HPX)"4GS2WY=
MMZ,;'H<'YB8SS$UF',9A 4",( C+5%J5V\_\G]18:R0@V"L&P);3Q;_BI178
MMV>?W-C<* $0)%D*6+NM#3'I,335,B&$$$((N:108H4,&6,L\.JKKQ[+&9WS
M1GU=?7)K6ZLQQ!!R7&%57-#BM0"P>O5JN:2DI+ZNKNXWOVG\C:FCJP,)T0F!
M_[WQ?X]'3HBL[K]N:6EIU_WWW_\&#W!?G;GNLLV?;X;?[X=&JPF,FS"N*BLJ
MZR]WW7%7XUUWW-7_V#B SI4_7OEV3EI.]=Z#>PU*M1))HY)LKZ][??<3/WMB
M>GMKNX2>F;5D298:&AIL9U/H=3@\_/##[DJY\JN0[I CT2'138PQONKI59%'
MJX\N+MM?EM_MZ(9:K>9I26GME\VX;%U.3(YY*/L9OV*\?^7*E673)D_[=8(E
MP5*RLR2NQE4#I5+ICXV.+;_QYAO_RA@+#*5MMIK) &P ;%^^]>50FAB\7<:D
MRLK*HZF9J?_;:FZ=47VT>F;-L6"G%U$0$14;Y9HS?\Z67ZSZQ3_/9?A.X<.%
M76'KP][KZNB*ZFCO""W(*CB2M3AK3;*0W'H^XBXJ*O*]_-N7]T>:(O^RHW1'
MZ]=??AV<E<A@;,\>D[W^D9\\LN=T!6=7K%CA!W"@YZ?/QL\V*CKDCH3BXN)L
M[N+&O(*\61U='=&'J@[!?,P,E]<UH!VE4HGXA'C;])G3WUPT=M&WBOF>BE/M
MU*JCU&,LARP"8PP*A<(G*L6:.&/<R=.#$T(((8000KX+<=ZO5XGS?\V_]3/O
MUZN&.S82G-[UU5=?3;WO9_?][L8[;OS@^MNOOZ)L;9EJN.,:#.=<L?/@SIBQ
M:6-C ,3$QL9&;:O89CS7=M:L6:-<?LWR!9F9F5X G#'&U6IU4TQDS WG/^KS
M9^7*E0+G7 $ :]:L,3WR^"/WC"D84PV "X+ P\/"[<NO6OY:>WM[XG?=%^=<
MJ*RL#+EAZ0TQ &(,!D/4S0MNUG_7=B^TE2M7*FZX(1@S@!B]7A\S[^IY$;WG
M[5QQSH62-26F_(S\J$TO;#*<WVB#[;>UM1G>W/!F;[S1.3DY8>>S?<ZY:>?!
MG3%+[UL:$QT=W7=NT.\<_>#'/XCDG&O.I>W_?NB_DZZ]Z=I/M3JMS!CCL;&Q
MCL=__O@%K<]$""&$$$+(?R1*K%S\..="97-EU*Z#NPJ'.Y;O0V%AH3(F(F:.
M3JOS N *A8+'Q<<U+5RR\ ?#'=NIS)HU2W';#VX;N7KUZNL^>_NSC!4K5BRX
M?.GE=2&F$,X8XZ&AH8$9,V;L77'SBKSACI7\^^.<"RMN7S$F9TS.;J52R1EC
M/#(JTOS4,T\],-RQ$4(((800<JZ$,Z]"R.DQQN3,^$S+Y-S)I<,=R_?AAAMN
M4!5,+4CV!7P"$*P%HM:KI?CT^(MR&!  (!J:9F?SC)+2DF<^V/C!SP[L/W#W
M-YN_2;%WVV'0&Z0Q.6-JEUZS],V__.,O- R#7'#-S<V:"=,F9(,CT>_W!Z=:
M9HJN0SL/?3K<L1%"""&$$'*N*+%"R#F*2HX*'5<P[@JM5BL"@"S+?H_3TQP>
M&EY]IFV'2VI4J@' U&^V?I.T<=/&.ZNJJZZV.^S0Z_52=E9VW9SY<]8\\L C
M:X9:_X20<U%IKE2Y_>X,K5$;!P!JC1ICQXR5E]^TW#O<L1%"""&$$'*NJ'@M
M(>>HNZ%;Y;%[$@0(#  $)OBXQ(\:GC3LPR^'.[K!189%JMW=[E1)DGAU7343
M(" R/%+*&)U1.V_ZO)>>_/F3+PF"<%'.:$3^_;SQ^AM"X]%&L;XA.($7 _.%
MAH36+;AJ 256""&$$$+()8=ZK!!RCLJKRGEU;;7?[_>#,0:]08]9TV;QU6RU
M/-RQG9('[0I9\6)B:N(642D>T&EU!Z853MMUY=57OG3/;^YY\72SQQ!R/G'.
M6:PN-DSVRA,Z+!U@C,$O^;O+#Y=_I6?Z]N&.CQ!"""&$D'-%/58(.4>;=VV&
MS^/C/K\/# QZC9[EC\IG:[%VN$,[I6>>><;YX(,/?CI2/;+I>,/Q^'!=.&Z]
MZE;G-7=?4\P8<PYW?.0_"K/9;&%^V3\K( 6@4"H0DQ@C%2PIL)W+=-:$$$((
M(81<+"BQ0L@YJCM2QWRRCW&)0V "%$H%CXJ-&NZPSNC99Y]U R@& $>7 ]?>
M<RUPSS '1?[C//?<<\KFMN:8LL-E(@ (@B!'A$<XK[_A>MN;S[TYW.$10@@A
MA!!RSF@H$"'GH*RL3/7 G0\DQ8;%1H$#G'.XO"ZW0^TH&^[8"+D4A"G#3&G)
M:4M\'I\& +C, XX.1VU64M:.X8Z-$$(((820H:#$"B'G0.O1:O,*\@I34U(S
M@&!BI:.]P_;7O_SUX^&.C9!+@;7;JN$!GJY2JA0 H%:IY5'IHSHSDS(;ASLV
M0@@AA!!"AH(2*X2<@P9[ VOH:%"[_6XE +#@?U)U1;5KN&,CY%+@@4?V^7P^
M60[6>M;H-)@P>P*]%Q%"""&$D$L6?9@EY!RLW[P>>P[OX1U='0  011@"C.Q
M[.QL<9A#(^22PQB#J! 1'A,^W*$00@@AA! R9)18(>0<;%Z_&0=V'8"MW08
M$!4B(F(C4+BX<)@C(^32Q#B#Z*.\)"&$$$((N731K$"$G(.Z W5P*]P(R $
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M7PZA+0G!V1N>Z;=, 2 10-90 R3_]J(!W(/@C%2$$-*?'\&D_7T WC_I=U$
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MGI-X!-^;XOO]SH_@>Y,%P7-Y,4\SW/\XDC#P=3F X.M0[_NM&0.+ZA-"""$
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M%J#=T1L)W['K1Q/DCZ3*NAWMPC5Z3-J,%H%'$L>Q\5V"+J<^BSTW>7V3]]D
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MM-(DSL?YP#\>_=Z%K CF!IP[A":AC0I.FP?G$N1;($U#S_U$:L\2U(],J\]
MF3 N1HN0/(+-$')_<Y02S+)PKCZ5A(MADNG/0<^X7/!CQRC)Q5<'<J%+D]X=
M=FTH;[O[(]6U.Z/^K$<[]Z'MN9ODXJT#62KN6.=Z-8KQLJBKE<U(P @=8[.>
MR^Z,S;PU UF-^.?]C'SCV<9462[ <=IB=135_T;OLUE(2"U'V@VHE]+!T =(
MNB#-!MX>E;$SI2W.!I&5Z*7H^N]!]SR4>H@JCAXD!+DQ?BJ*F[6HS#E9XM.3
M2"0U#,,P:L2$%0"*E=+H&HUC "V8/@2<BR8L_X6L0_Y!Y8G;##1)N11%Z*\U
M!68KFNS[+AQ;R(X;48I^-&D+V8W/HA=9X80*.5ED6:.E4X0ZBX,\%)%Y]9^\
MSZ:0S)90BEXT$6T&?)<@/TO5?)1^=,\ZE#&(Q+%?$9O,EZ. A!/G\O)BPBU4
MTO2A-E0- U27':*39-!(1SJ0\Q:J;W?^>5/(3MMJ-)X>)(Z%,H "H_J+W&:.
M4S)9V8P$U5!"GHO+)+3$^ZP'O;?S,%BBK*QWQT841-91*:5PEB5&6C3R2=^G
M#A1@^3]01K23D<BR5YDRJV$*$N]]4:4/B4AY1!7(3D_MW(%*D78#VH*LR<P-
MR# ,HP[D= 4J+H?"5F?=42SRZD*ATC'%6\:E,MLN VB"\%>T"-T#+9KVB?Z=
MCW;1EI#M,C07"2O;(_>.$&N/+%P<"Y\A\EE9%-'$S7?CR,,PU?EM.]K)G@RF
MA94I:#)9H?6/819)2X%.E/&E$K5>5[W)<@EJ0Z+*NY%%5"-2^K8@0; 3F;I/
MB?Z=@Q8P"U'[/Y XJ&Q>TM8NXW5N%E-1]@Q'+>UNGO=[!V'M;CSI1:)CM6E+
M^TF*ELW(*+)8R7N-+FVQ&U\[*+^[WDRTHO;7[ R0/R!P'V.?RQ+O[UDNB ,H
M*UY>>E!@VM>7*,O1CS965I$,K%W*'2BO)<:FZ'O>X'U_&Q)Y=B=V.?XC<OFY
M#\TI'D-Q5:IQ/^Q"8OGQ)*^Y'\6TRB.J.)QXY 2E<NY ;5&YOOBT 5F>&89A
M&'4@;XR5Y;!UN<WL>-RR5Q>*S XX='G#*V,X7&"VNU JUNG(_6=/M"!;0FQ"
M["^T9@"O09.F:A?%;6B!Z\@KJOCGK:WB/*A^TNIH1POT-&G+@3G4%@_"T8:"
MOU:BUNMJ!%E9@IRI]E^H7PR/5B3Z[8$"O,Y'[75Q].\2M'BIU^[H".H'U3!*
M;=92:::0;'>UQB%QE!(0)Y*-*+[%UKQ8J6;Q#AH3_2Q.[8QU.6E62@D S<8P
M^471(6(7.]"U5G*K'26?"XQCD&2LFE)E%9$(?PW*'@0:EX]'<:O28W*6&U"Y
M@*Q#:'[QC>C[T\)1.K9;+XH-MAQ972Y';JT;"6<N\#[&MJ,9Z+K^B^K$REN)
MX]'X[D#IV"]348P;-V8.(ZO-?^8LTS ,PRA!+F&E6"S\ME#@I ;594(HC!;/
MH)*YBHXLE5G#:"S.^L,76N8A5XDC@$. @XFM6&:A&!G7HPE87M*[X+W8Q*,2
MD]FDW[D$78Y2@3I__P7( NJOU.:^U(($K!>BG<(7$Z>=-6JCD^PL1$9CJ=:B
M*2U2MS-Y+%9<IC5'GMA6XTDUHFA:6&FE<;&+1@D/5KP9Q:ERPDJIE,)9;D ;
M40R4<G2C0-$@MY]]*9W);RH*WOMR9'5S [*\^05R;PK!%^=&T=S"64GN@83F
M3Y'/A=BEI[X995B"TMF!TG%J>H!?4YU 9AB&8620*\9*>WO%%]6D8M&QRXXL
M% I'AAR[M5W[)&8$68+<A-+!GH<BX_N3D7G(XJ#6 *3&ML$@2DGLQT#Q78*J
M=0%H02+=:2AX[;E4%E6&D%7/K<CO_O'RAQN&T6 *:&'MB\>UQ# RPNA'X[+O
MUCN=L3%$TFY PTA4J!0#J(@$PLM0S)-OHGA8E>*C34>6L1<"'R1_7+<!9$WS
MWUXYLU  _A>5.JD,W22SOSEW(#\ ;QNRCDQG RJ79<DP#,/(22Z+E557+]VX
MZ)AO_XQ"X=6-JM!X4BP6+RR$6*L4BS];=?7)>4P^C?'!I7S\+-JQ<J; TY#+
MT%S&9CRI1-J%HH/)D[DB+RYS3*UMNX_FCPM1B6X4+/%XXHE[VB4H+[. MP&?
MR/C;$/+AWX#NW[KHWPW WU! W6$D'FYM[6\SVBFM1[MK]K3$1DS:93 K(U4S
MTL98-[U^JHN)T8R,YW-I02)5*!N _T/"!\0IFOT8(G/0..W(:XG1C[+K_!%9
MP!V,7-YW1<_=_:29";P%W;]S"!O/7+#^BY%H-(<XWLP\E(KZ'^C=$$H_>F>L
M1!8Q4]$[[)G$@=F=BY!C$+5?L\8U#,.H(WECK%"D<'4!)KVP$L56.3+DV"*%
MJQM<G6V%.<"KO-\W [=0FTEU$9F77T72Q]IEJLD[01PD::Z>#O@:2@&),LV$
M,_EV"_6G4=!66YRJ':U"0L8WB ,:^BY!3V2?FDD["ES\+N^S813\<#EZ#LNC
MWS>A2?%&DCNE6:F+)R/6[K8NLH*9AI".\=2,,9>RF,I82[->DME8FH4V%,,H
MCV@Y!7BV]WO(<RE$Y^5-09T.6#Q$^7>T2RG\ 60IDHXAXF*AO-P[)VW!$<H0
M$AON14+Z0O3N?PZRB%F QF0_B]%TX!5(E*]4IB^J_ KUHR\C$6=W=#]?A-X9
MGR(\MM<H<F>]!MTG4-R6EQ(+*VDWH&[@:LP-R# ,HZ[D3K>\YKJE5T%Q9?VK
M,GYL?_2R)871XK*PHXLK=<U&'5B(8EDLBWX^C_R::Z4/[?*D _!5DS%D&&6\
M\,F;$<*9CC?;PMAEY7!,P6)4^ P@RYNKO,^J=0F:C8+A.H%F&/GB7X*$FO<!
M5P+7(;>?QQAK?IZ5H6HRDFYWG<2Q;(S)1Q=:;';F.*<0G>>/R</((J&9*2!+
M C]%[2@2!T,M5@IH$1UZ;"TNK!WDBW?EGHO_KAHA^5Q&&"O45/M^=6W',4#Y
M^YB54MAW!YI&TA*C7@%9G3O1+X%+T?A_-AJ_KR4Y5J<M9DJQ 8GVOXI^=P%T
M_],[9C9P$LH(EX<>X/?>[RZM\A2RW8"V(,'*, S#J".YA16 8K'PR7I79#QI
M:RO^M% HA&0" @I?:FQMMBGZ209ZFPH\MX[?_8#W>Q$)+GD90HM<WXIF*OFR
M8;6C7;1J4^4VB@&2)L8S@,/)/Y&? 1R-,@SLQN1(0QK*!K1;>9OWF7,).C['
M]Z2ML[J![P)?(RS+5 N:9.]5Z<!)P"#U;7>'L_6UN\E&WH#5;DQ<XGWF!/%F
MIA.-_8=[GVU!\3M"+2WS9#]J(SNC6RB=Q)EL0LAZ+OW$E@Z@=^(CC'TGYEW\
MMZ$,0+X%:#IP;A;=)&.!.'<@M^%134#65G2?]T8BS<%ECBU&W_MW%.SV;&1I
MZY@*'%2A/%![OROUV6849/?/WF?S@=/)E_',95)T\6@Z@&>A9YOE!G0?X4%W
M#<,PC$"J$E8FL]7*HF._O0P*@8ODXLK5UR[]8F-KM$W10W(",1.9J]:Z0,JR
M$!E$.U=Y*:()Y&^]S^8 )Q"^$)R),A8U&UM(NE\X<^$\5BNMR&S\B\!%P/G
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M2PM:Y+\/"2OSRQZ=31=P%' P\$+@J\!O@9'Z5-$PZDX7<$#T_T.!8>!^X!O
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M5%G&.N!S:#)8CK0 \1#5]9VG4?:H2GUG:Q)67'L+7<QG_6P&ODGY]I9>-*U
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M#HU<LQU80ZON_B_P<WHC8)F+A&7_$LG#;^FMH&,WX"S@^<WC6WN<7A*CP,N
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MOXKV,FB@1>B'T/<IBQ%4EZ)]V0ZT"?;)0-[V0\Y-KT3]9)Z\#<>D];N<:6T
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M7<0B[$*[5_.'T&(FZ^Z%$XH4%:Q$'8^F,4$U.W^]RI-?U@^CB7>>LKX4$ZQ
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M9 SX.2W!RBYHX7 QW2V60EH+V]&B/2\--.&_#CD,!$VL3T ^#+(L"G>AY2/
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MGTOK@Q6D51:[(&VR-Z1=F(,_(2?5600K9:3OS'^_B\QB+1*0,2LQP8K1#]P
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M::C\#J#5+EQXZSOI3VC0HG5J,Q)>1'>3LYH!K??2>[!Y+D2T_)Y*J_ZY\IM
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ML9PKTG:V[&=-S<<)/?H3GD.4H:Z86 $     3.TD?:R'DQO2,-C_6WUN> (
M
M
=      # *?L/4=G]6# 5#Q\     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
MB5!.1PT*&@H    -24A$4@   S8    #" 8   !!$)K"    "7!(67,  $SE
M  !,Y0%USO"5    +DE$051XVNW7P0D ,!##,.^_= NW14 &+9!?JAX  ,"P
BRQ   ,#\L9$D29*DZ3[;VV/Q]O%]#@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nvax-20240630_g1.jpg
<TEXT>
begin 644 nvax-20240630_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $ !) # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**^!?^
M"IGQ&\2_#>X^&D_AK6;G2)+]=22Y,!&)!&;4ID$$<>8_3UYZ"MZ-&5>HJ<=V
M1.2A'F9]]45^"?\ PTU\4?\ H<]0_P#'/_B:/^&FOBC_ -#GJ'_CG_Q->G_9
M-?NOQ_R.;ZU#LS][**_!/_AIKXH_]#GJ'_CG_P 31_PTU\4?^ASU#_QS_P")
MH_LFOW7X_P"0?6H=F?O917X)_P##37Q1_P"ASU#_ ,<_^)H_X::^*/\ T.>H
M?^.?_$T?V37[K\?\@^M0[,_>RBOP3_X::^*/_0YZA_XY_P#$T?\ #37Q1_Z'
M/4/_ !S_ .)H_LFOW7X_Y!]:AV9^]E%?@G_PTU\4?^ASU#_QS_XFC_AIKXH_
M]#GJ'_CG_P 31_9-?NOQ_P @^M0[,_>RBOP3_P"&FOBC_P!#GJ'_ (Y_\31_
MPTU\4?\ H<]0_P#'/_B:/[)K]U^/^0?6H=F?O917X)_\--?%'_H<]0_\<_\
MB:/^&FOBC_T.>H?^.?\ Q-']DU^Z_'_(/K4.S/WLHK\$_P#AIKXH_P#0YZA_
MXY_\31_PTU\4?^ASU#_QS_XFC^R:_=?C_D'UJ'9G[V45^"?_  TU\4?^ASU#
M_P <_P#B:/\ AIKXH_\ 0YZA_P".?_$T?V37[K\?\@^M0[,_>RBOP3_X::^*
M/_0YZA_XY_\ $T?\--?%'_H<]0_\<_\ B:/[)K]U^/\ D'UJ'9G[V45^"?\
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MFOW7X_Y!]:AV9^]E%?@G_P --?%'_H<]0_\ '/\ XFC_ (::^*/_ $.>H?\
MCG_Q-']DU^Z_'_(/K4.S/WLHK\$_^&FOBC_T.>H?^.?_ !-'_#37Q1_Z'/4/
M_'/_ (FC^R:_=?C_ )!]:AV9^]E%?@G_ ,--?%'_ *'/4/\ QS_XFC_AIKXH
M_P#0YZA_XY_\31_9-?NOQ_R#ZU#LS][**_!/_AIKXH_]#GJ'_CG_ ,31_P -
M-?%'_H<]0_\ '/\ XFC^R:_=?C_D'UJ'9G[V45^"?_#37Q1_Z'/4/_'/_B:/
M^&FOBC_T.>H?^.?_ !-']DU^Z_'_ "#ZU#LS][**_!/_ (::^*/_ $.>H?\
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M/[)K]U^/^0?6H=F?O917X)_\--?%'_H<]0_\<_\ B:/^&FOBC_T.>H?^.?\
MQ-']DU^Z_'_(/K4.S/WLHK\$_P#AIKXH_P#0YZA_XY_\31_PTU\4?^ASU#_Q
MS_XFC^R:_=?C_D'UJ'9G[V45^"?_  TU\4?^ASU#_P <_P#B:/\ AIKXH_\
M0YZA_P".?_$T?V37[K\?\@^M0[,_>RBOP3_X::^*/_0YZA_XY_\ $T?\--?%
M'_H<]0_\<_\ B:/[)K]U^/\ D'UJ'9G[V45^"?\ PTU\4?\ H<]0_P#'/_B:
M/^&FOBC_ -#GJ'_CG_Q-']DU^Z_'_(/K4.S/WLHK\$_^&FOBC_T.>H?^.?\
MQ-'_  TU\4?^ASU#_P <_P#B:/[)K]U^/^0?6H=F?O917X)_\--?%'_H<]0_
M\<_^)H_X::^*/_0YZA_XY_\ $T?V37[K\?\ (/K4.S/WLHK\$_\ AIKXH_\
M0YZA_P".?_$T?\--?%'_ *'/4/\ QS_XFC^R:_=?C_D'UJ'9G[V45^"?_#37
MQ1_Z'/4/_'/_ (FC_AIKXH_]#GJ'_CG_ ,31_9-?NOQ_R#ZU#LS][**_!/\
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M\--?%'_H<]0_\<_^)H_LFOW7X_Y!]:AV9^]E%?@G_P --?%'_H<]0_\ '/\
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M4.S/WMHHHKQ3L"BBB@ K\X?^"PG_ #23_N+_ /ME7Z/5^</_  6$_P":2?\
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M'?%<=X;_ &VIK/QMX_N?$/@R#Q-X(\9QQ0WOA>\U6X?R4BSY7EW,A=P068G
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M'>G>+]0\5?\ "/V.L7+VVDQVFBW&I&?:[1F64Q[?L\996P[\8&3C(KPGQ?\
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M;:-J_AFXU$MYJ0H5219Q$,-\S\;.C'G.&''[/$T^91=_N\M?GKY&W-3E:_\
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MK6=;U"^=;HQMO\A+&)!NR-B[L,I&2?FR!7SU^TE^T(GQXUG2GL-$N_#FC:9
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M:?\ MEUVO_=V_P"&^8OW5G_P3N?V</V'?#FA_$3X<S?$'QIH-SX@U>S.K_\
M"O;JR,KW%J\,A7,A?!9<;BNS&8VP3MS7Q/\ $"S@T_Q[XDM+:)8+:#4[F***
M,85%65@% ]  *^K_  3_ ,%"-&T6X\(>(/$OPBL?$WQ \-:<-)MO$R:NUJ[6
MX1E'[OR7 ?#-D\_??&T-BOD/Q-K/_"1>)-5U;R?L_P!ONY;KR=V[9O<MMS@9
MQG&<"M\/&M[24JOZ=WM;]=2*CARI1,VBBBN\P"BBB@ HHHH ^P_^">OPK\,_
M$B'XG3:_X0TOQC=Z78VLNGV>K71MHO,9I0P,H!V A1\VTXQTJ]\0/V1?!GQ
M_:*\>V'@CQ-I?A#X<^%]-@U#6M5:0WMOITKH=T,?S@ORK'!8;<,.H"UX%\)/
MCE_PJWP!\3/#/]B?VG_PFFF1Z=]J^U^3]CV%SOV[&\S._IE>G6M#]G#]H@?
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M ,BT?\.F?A%_T,?C;_P.L_\ Y%K[6HH^NXC^=A[&GV/BG_ATS\(O^AC\;?\
M@=9__(M'_#IGX1?]#'XV_P# ZS_^1:^UJ*/KN(_G8>QI]CXI_P"'3/PB_P"A
MC\;?^!UG_P#(M'_#IGX1?]#'XV_\#K/_ .1:^UJ*/KN(_G8>QI]CXI_X=,_"
M+_H8_&W_ ('6?_R+1_PZ9^$7_0Q^-O\ P.L__D6OM:BCZ[B/YV'L:?8^*?\
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M6W_]UU^CU%']HXK^?\%_D'U>GV/SA_X<]_\ 56__ "V__NNC_ASW_P!5;_\
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M^+S*2O'5?]NG7'+G)7C&Z]?^"<S_ ,.>_P#JK?\ Y;?_ -UT?\.>_P#JK?\
MY;?_ -UUTW_#U _]$O\ _+@_^Y:/^'J!_P"B7_\ EP?_ '+56S3^N4K^S)?R
M?C_P3F?^'/?_ %5O_P MO_[KH_X<]_\ 56__ "V__NNNF_X>H'_HE_\ Y<'_
M -RT?\/4#_T2_P#\N#_[EHMFG]<H?V9+^3\?^"6_"_\ P2/^']II2Q^(O&GB
M75=2WL3<:6MO90E>P$3QS'([G?SZ"M?_ (=,_"+_ *&/QM_X'6?_ ,BUSO\
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M ##^SI_R?D=%_P .F?A%_P!#'XV_\#K/_P"1:/\ ATS\(O\ H8_&W_@=9_\
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MS)?R?C_P3F?^'/?_ %5O_P MO_[KH_X<]_\ 56__ "V__NNNF_X>H'_HE_\
MY<'_ -RT?\/4#_T2_P#\N#_[EHMFG]<H?V9+^3\?^"<S_P .>_\ JK?_ );?
M_P!UT?\ #GO_ *JW_P"6W_\ ===-_P /4#_T2_\ \N#_ .Y:/^'J!_Z)?_Y<
M'_W+1;-/ZY0_LR7\GX_\$YG_ (<]_P#56_\ RV__ +KH_P"'/?\ U5O_ ,MO
M_P"ZZZ;_ (>H'_HE_P#Y<'_W+1_P]0/_ $2__P N#_[EHMFG]<H?V9+^3\?^
M"<S_ ,.>_P#JK?\ Y;?_ -UT?\.>_P#JK?\ Y;?_ -UUTW_#U _]$O\ _+@_
M^Y:/^'J!_P"B7_\ EP?_ '+1;-/ZY0_LR7\GX_\ !.9_X<]_]5;_ /+;_P#N
MNC_ASW_U5O\ \MO_ .ZZZ;_AZ@?^B7_^7!_]RT?\/4#_ -$O_P#+@_\ N6BV
M:?URA_9DOY/Q_P""<S_PY[_ZJW_Y;?\ ]UT?\.>_^JM_^6W_ /===-_P]0/_
M $2__P N#_[EH_X>H'_HE_\ Y<'_ -RT6S3^N4/[,E_)^/\ P3F?^'/?_56_
M_+;_ /NNC_ASW_U5O_RV_P#[KKIO^'J!_P"B7_\ EP?_ '+1_P /4#_T2_\
M\N#_ .Y:+9I_7*']F2_D_'_@G,_\.>_^JM_^6W_]UT?\.>_^JM_^6W_]UUTW
M_#U _P#1+_\ RX/_ +EH_P"'J!_Z)?\ ^7!_]RT6S3^N4/[,E_)^/_!.9_X<
M]_\ 56__ "V__NNC_ASW_P!5;_\ +;_^ZZZ;_AZ@?^B7_P#EP?\ W+1_P]0/
M_1+_ /RX/_N6BV:?URA_9DOY/Q_X)S/_  Y[_P"JM_\ EM__ '71_P .>_\
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M.3AMY_\ !/&_^'/?_56__+;_ /NNC_ASW_U5O_RV_P#[KK]'J*\[^T<5_/\
M@O\ (Y?J]/L?G#_PY[_ZJW_Y;?\ ]UT?\.>_^JM_^6W_ /==?H]11_:.*_G_
M  7^0?5Z?8_.'_ASW_U5O_RV_P#[KH_X<]_]5;_\MO\ ^ZZ_1ZBC^T<5_/\
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M1;K$CR2%P^ $/;YJAX=JWO+>Q7M/(].^,^CV.M?"?Q?;ZA:0WD(TF[<)/&'
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M_/R/WK_,/;TOYU]Z/!MHHVBO>?\ AAWXV?\ 0E?^56Q_^/4?\,._&S_H2O\
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M?0U\,>&=(T9)3.FG6<-HLK#!<1H$#$=LXS6I10 4444 %%%% !1110 4444
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M  '3_"C_ (1O2?\ H%V7_@.G^% %O[9!_P ]X_\ OL4?;(/^>\?_ 'V*J?\
M"-Z3_P! NR_\!T_PH_X1O2?^@79?^ Z?X4 6_MD'_/>/_OL5A^-+J%O#=R!-
M&3OB/WA_SU6M'_A&])_Z!=E_X#I_A6/XNT'3(-!G>/3K2-P\6&6!01^\7OB@
M#H_MD'_/>/\ [[%'VR#_ )[Q_P#?8JI_PC>D_P#0+LO_  '3_"C_ (1O2?\
MH%V7_@.G^% %O[9!_P ]X_\ OL4?;(/^>\?_ 'V*J?\ "-Z3_P! NR_\!T_P
MH_X1O2?^@79?^ Z?X4 6_MD'_/>/_OL4?;(/^>\?_?8JI_PC>D_] NR_\!T_
MPH_X1O2?^@79?^ Z?X4 6_MD'_/>/_OL4?;(/^>\?_?8JI_PC>D_] NR_P#
M=/\ "C_A&])_Z!=E_P" Z?X4 6_MD'_/>/\ [[%'VR#_ )[Q_P#?8JI_PC>D
M_P#0+LO_  '3_"C_ (1O2?\ H%V7_@.G^% %O[9!_P ]X_\ OL4?;(/^>\?_
M 'V*J?\ "-Z3_P! NR_\!T_PH_X1O2?^@79?^ Z?X4 6_MD'_/>/_OL4?;(/
M^>\?_?8JI_PC>D_] NR_\!T_PH_X1O2?^@79?^ Z?X4 6_MD'_/>/_OL4?;(
M/^>\?_?8JI_PC>D_] NR_P# =/\ "C_A&])_Z!=E_P" Z?X4 6_MD'_/>/\
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M#_GO'_WV*/MD'_/>/_OL54_X1O2?^@79?^ Z?X4?\(WI/_0+LO\ P'3_  H
MM_;(/^>\?_?8H^V0?\]X_P#OL54_X1O2?^@79?\ @.G^%'_"-Z3_ - NR_\
M =/\* +?VR#_ )[Q_P#?8H^V0?\ />/_ +[%5/\ A&])_P"@79?^ Z?X4?\
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M#_GO'_WV*/MD'_/>/_OL54_X1O2?^@79?^ Z?X4?\(WI/_0+LO\ P'3_  H
MM_;(/^>\?_?8H^V0?\]X_P#OL54_X1O2?^@79?\ @.G^%'_"-Z3_ - NR_\
M =/\* +?VR#_ )[Q_P#?8H^V0?\ />/_ +[%5/\ A&])_P"@79?^ Z?X4?\
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M_P#)"Y_^-T?\--_#3_H9/_)"Y_\ C=?!M%?7?ZG8#^>?WQ_^1/S+_B*&<_\
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M_P --_#3_H9/_)"Y_P#C='_#3?PT_P"AD_\ )"Y_^-U\&T4?ZG8#^>?WQ_\
MD0_XBAG/_/JE_P" S_\ DS[R_P"&F_AI_P!#)_Y(7/\ \;H_X:;^&G_0R?\
MDA<__&Z^#:*/]3L!_//[X_\ R(?\10SG_GU2_P# 9_\ R9]Y?\--_#3_ *&3
M_P D+G_XW1_PTW\-/^AD_P#)"Y_^-U\&T4?ZG8#^>?WQ_P#D0_XBAG/_ #ZI
M?^ S_P#DS[R_X:;^&G_0R?\ DA<__&Z/^&F_AI_T,G_DA<__ !NO@VBC_4[
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M:?\ 0R?^2%S_ /&Z^#:*/]3L!_//[X__ "(?\10SG_GU2_\  9__ "9]Y?\
M#3?PT_Z&3_R0N?\ XW1_PTW\-/\ H9/_ "0N?_C=?!M%'^IV _GG]\?_ )$/
M^(H9S_SZI?\ @,__ ),^\O\ AIOX:?\ 0R?^2%S_ /&Z/^&F_AI_T,G_ )(7
M/_QNO@VBC_4[ ?SS^^/_ ,B'_$4,Y_Y]4O\ P&?_ ,F?>7_#3?PT_P"AD_\
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M;HM]XS2%F8'W&0O_  &L:^\>:)H.H?%WP_?6TVHZGK%_+'9V,-NTAD<H54Y
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M(K&<&2Q<:J]M%<\IR_AZ+G26W/\ %&WNRTWDVFY-C+7_ (]HO]P?RK)\9?\
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M+MQ_OQ?^C5I/[0U__H"VO_@P/_QNLCQ9?:V^@SB32+6--\>6^W$_\M%QQY=
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MMJE<MMR <\<'M5KP/X1M? GA/3="LB7@LXMGF$8,C$DNY'8EB3CWI?[0U_\
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M 6U_\&!_^-T?VAK_ /T!;7_P8'_XW0!N45A_VAK_ /T!;7_P8'_XW1_:&O\
M_0%M?_!@?_C= &Y16'_:&O\ _0%M?_!@?_C=']H:_P#] 6U_\&!_^-T ;E(>
M>*Q/[0U__H"VO_@P/_QNC^T-?_Z MK_X,#_\;H XKXH_!O3?'BF6>!6N%&%E
M PZ_0]?PZ5YS8ZY\2?@[((A(WB[0H^/LE\Q^T1KZ)+UZ#OD#LM>]_P!H:_\
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MLQK%E&%BT&S4#TO_ /[75K^T-?\ ^@+:_P#@P/\ \;KMAQ3C82Y^2+?FI?\
MR1Y53P\RNI#V:J5(Q[)P7_MA\4_\,Q_$K_H6_P#R?MO_ (Y1_P ,R?$O_H6_
M_)^V_P#CE?:W]H:__P! 6U_\&!_^-T?VAK__ $!;7_P8'_XW75_KEC_Y(?=+
M_P"2//\ ^(79-_S]J_\ @4/_ ) ^*?\ AF3XE_\ 0M_^3]M_\<H_X9D^)?\
MT+?_ )/VW_QROM;^T-?_ .@+:_\ @P/_ ,;H_M#7_P#H"VO_ (,#_P#&Z/\
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M_!@?_C='^N6/_DA]TO\ Y(/^(79-_P _:O\ X%#_ .0/BG_AF3XE_P#0M_\
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M_H"VO_@P/_QNC_7+'_R0^Z7_ ,D'_$+LF_Y^U?\ P*'_ ,@?%/\ PS)\2_\
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M8'_XW0!N45A_VAK_ /T!;7_P8'_XW1_:&O\ _0%M?_!@?_C= &Y16'_:&O\
M_0%M?_!@?_C=']H:_P#] 6U_\&!_^-T ;E%8?]H:_P#] 6U_\&!_^-T?VAK_
M /T!;7_P8'_XW0!N45A_VAK_ /T!;7_P8'_XW1_:&O\ _0%M?_!@?_C= &Y1
M6'_:&O\ _0%M?_!@?_C=']H:_P#] 6U_\&!_^-T ;E%8?]H:_P#] 6U_\&!_
M^-T?VAK_ /T!;7_P8'_XW0!N45A_VAK_ /T!;7_P8'_XW1_:&O\ _0%M?_!@
M?_C= &Y16'_:&O\ _0%M?_!@?_C=']H:_P#] 6U_\&!_^-T ;E%8?]H:_P#]
M 6U_\&!_^-T?VAK_ /T!;7_P8'_XW0!N45A_VAK_ /T!;7_P8'_XW1_:&O\
M_0%M?_!@?_C= &Y16'_:&O\ _0%M?_!@?_C=']H:_P#] 6U_\&!_^-T ;E%8
M?]H:_P#] 6U_\&!_^-T?VAK_ /T!;7_P8'_XW0!N45A_VAK_ /T!;7_P8'_X
MW1_:&O\ _0%M?_!@?_C= &Y16'_:&O\ _0%M?_!@?_C=']H:_P#] 6U_\&!_
M^-T ;E%8?]H:_P#] 6U_\&!_^-T?VAK_ /T!;7_P8'_XW0!N45A_VAK_ /T!
M;7_P8'_XW1_:&O\ _0%M?_!@?_C= &Y16'_:&O\ _0%M?_!@?_C=']H:_P#]
M 6U_\&!_^-T ;E%8?]H:_P#] 6U_\&!_^-T?VAK_ /T!;7_P8'_XW0!N45A_
MVAK_ /T!;7_P8'_XW1_:&O\ _0%M?_!@?_C= &Y16'_:&O\ _0%M?_!@?_C=
M*NH:]N&[1K4#/)%^3_[3H$;=%%% !1110 4444 %%%% !1110 4444 %%%%
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M"G_05_\ )>7_ .(KYUHH_P!>LR_Y]P^Z7_R0?ZL8/^>7WK_Y$^BO^%L>%/\
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MQ_OQ?^C5K;K$\9?\B[<?[\7_ *-6@"K\1M,EU?P7J=O"N^4()%4=3M8,1]<
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M$0P_96FVJ-P)W%B>#M'8UZ=16/\ J]@&TW%MI<N_37\=7_2-/[6Q232>[O\
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MI7YN5+R459+=WZMOS.7$8EUXQBU:U_FV[OT] HHHKTCC"BBB@ HHHH ****
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M_P"@5_Y,2_\ Q='^HN9?\_(??+_Y$/\ 6?!_R2^Y?_)'SK17T5_PJ?PI_P!
MK_R8E_\ BZ/^%3^%/^@5_P"3$O\ \71_J+F7_/R'WR_^1#_6?!_R2^Y?_)'S
MK17T5_PJ?PI_T"O_ "8E_P#BZ/\ A4_A3_H%?^3$O_Q='^HN9?\ /R'WR_\
MD0_UGP?\DON7_P D?.M%?17_  J?PI_T"O\ R8E_^+H_X5/X4_Z!7_DQ+_\
M%T?ZBYE_S\A]\O\ Y$/]9\'_ "2^Y?\ R1\ZT5]%?\*G\*?] K_R8E_^+H_X
M5/X4_P"@5_Y,2_\ Q='^HN9?\_(??+_Y$/\ 6?!_R2^Y?_)'SK17T5_PJ?PI
M_P! K_R8E_\ BZ/^%3^%/^@5_P"3$O\ \71_J+F7_/R'WR_^1#_6?!_R2^Y?
M_)'SK17T5_PJ?PI_T"O_ "8E_P#BZ/\ A4_A3_H%?^3$O_Q='^HN9?\ /R'W
MR_\ D0_UGP?\DON7_P D?.M%?17_  J?PI_T"O\ R8E_^+H_X5/X4_Z!7_DQ
M+_\ %T?ZBYE_S\A]\O\ Y$/]9\'_ "2^Y?\ R1\ZT5]%?\*G\*?] K_R8E_^
M+H_X5/X4_P"@5_Y,2_\ Q='^HN9?\_(??+_Y$/\ 6?!_R2^Y?_)'SK17T5_P
MJ?PI_P! K_R8E_\ BZ/^%3^%/^@5_P"3$O\ \71_J+F7_/R'WR_^1#_6?!_R
M2^Y?_)'SK17T5_PJ?PI_T"O_ "8E_P#BZ/\ A4_A3_H%?^3$O_Q='^HN9?\
M/R'WR_\ D0_UGP?\DON7_P D?.M%?17_  J?PI_T"O\ R8E_^+H_X5/X4_Z!
M7_DQ+_\ %T?ZBYE_S\A]\O\ Y$/]9\'_ "2^Y?\ R1\ZT5]%?\*G\*?] K_R
M8E_^+H_X5/X4_P"@5_Y,2_\ Q='^HN9?\_(??+_Y$/\ 6?!_R2^Y?_)'SK17
MT5_PJ?PI_P! K_R8E_\ BZ/^%3^%/^@5_P"3$O\ \71_J+F7_/R'WR_^1#_6
M?!_R2^Y?_)'SK17T5_PJ?PI_T"O_ "8E_P#BZ/\ A4_A3_H%?^3$O_Q='^HN
M9?\ /R'WR_\ D0_UGP?\DON7_P D?.M%?17_  J?PI_T"O\ R8E_^+H_X5/X
M4_Z!7_DQ+_\ %T?ZBYE_S\A]\O\ Y$/]9\'_ "2^Y?\ R1\ZT5]%?\*G\*?]
M K_R8E_^+H_X5/X4_P"@5_Y,2_\ Q='^HN9?\_(??+_Y$/\ 6?!_R2^Y?_)'
MSK17T5_PJ?PI_P! K_R8E_\ BZ/^%3^%/^@5_P"3$O\ \71_J+F7_/R'WR_^
M1#_6?!_R2^Y?_)'SK7UQ7(_\*G\*?] K_P F)?\ XNNNK[KAC(L3DOMOK$HO
MGY;<K?3FWNEW/F,ZS2CF7L_8IKEOO;K;LWV"BBBON3Y@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_
M4M"L]6D1[E92R# ,4\D?'OM89_&M"B@##_X0S2_[MU_X'3__ !='_"&:7_=N
MO_ Z?_XNMRB@9A_\(9I?]VZ_\#I__BZ/^$,TO^[=?^!T_P#\76Y10!A_\(9I
M?]VZ_P# Z?\ ^+H_X0S2_P"[=?\ @=/_ /%UN44 8?\ PAFE_P!VZ_\  Z?_
M .+H_P"$,TO^[=?^!T__ ,76Y10!A_\ "&:7_=NO_ Z?_P"+H_X0S2_[MU_X
M'3__ !=;E% &'_PAFE_W;K_P.G_^+H_X0S2_[MU_X'3_ /Q=;E% &'_PAFE_
MW;K_ ,#I_P#XNC_A#-+_ +MU_P"!T_\ \76Y10!A_P#"&:7_ ';K_P #I_\
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M_P"!T_\ \71_PAFE_P!VZ_\  Z?_ .+K<HH P_\ A#-+_NW7_@=/_P#%T?\
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M (0S2_[MU_X'3_\ Q='_  AFE_W;K_P.G_\ BZ_)S_AO+X[_ /0]?^4BP_\
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M !BC^P<3_-'\?\@^N0[,_6/_ (0S2_[MU_X'3_\ Q='_  AFE_W;K_P.G_\
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MAZ_\I%A_\8H_L'$_S1_'_(/KD.S/UC_X0S2_[MU_X'3_ /Q='_"&:7_=NO\
MP.G_ /BZ_)S_ (;R^.__ $/7_E(L/_C%'_#>7QW_ .AZ_P#*18?_ !BC^P<3
M_-'\?\@^N0[,_6/_ (0S2_[MU_X'3_\ Q='_  AFE_W;K_P.G_\ BZ_)S_AO
M+X[_ /0]?^4BP_\ C%'_  WE\=_^AZ_\I%A_\8H_L'$_S1_'_(/KD.S/UC_X
M0S2_[MU_X'3_ /Q='_"&:7_=NO\ P.G_ /BZ_)S_ (;R^.__ $/7_E(L/_C%
M'_#>7QW_ .AZ_P#*18?_ !BC^P<3_-'\?\@^N0[,_6/_ (0S2_[MU_X'3_\
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M (0S2_[MU_X'3_\ Q='_  AFE_W;K_P.G_\ BZ_)S_AO+X[_ /0]?^4BP_\
MC%'_  WE\=_^AZ_\I%A_\8H_L'$_S1_'_(/KD.S/UC_X0S2_[MU_X'3_ /Q=
M'_"&:7_=NO\ P.G_ /BZ_)S_ (;R^.__ $/7_E(L/_C%'_#>7QW_ .AZ_P#*
M18?_ !BC^P<3_-'\?\@^N0[,_6/_ (0S2_[MU_X'3_\ Q='_  AFE_W;K_P.
MG_\ BZ_)S_AO+X[_ /0]?^4BP_\ C%'_  WE\=_^AZ_\I%A_\8H_L'$_S1_'
M_(/KD.S/UC_X0S2_[MU_X'3_ /Q='_"&:7_=NO\ P.G_ /BZ_)S_ (;R^.__
M $/7_E(L/_C%=A\&_P!M3XT^*OB]X'T75?&?VK2]2UVQL[N#^R[)/,ADN$1U
MW+"&&58C(((SP:F61XF,7)N.GK_D"Q<&[:GZ9_\ "&:7_=NO_ Z?_P"+H_X0
MS2_[MU_X'3__ !=;E%?/':8?_"&:7_=NO_ Z?_XNC_A#-+_NW7_@=/\ _%UN
M44 8?_"&:7_=NO\ P.G_ /BZ/^$,TO\ NW7_ ('3_P#Q=;E% &'_ ,(9I?\
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MK,]O\1UL8M16YVF>%GC5'P0<;<ET P%+=*F&7NZYY6U_._RZ ?H-XP\9:)X
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MXK(LGPM\8HZAT;1KP%6&01Y#\&OPVUQT7QAKUM%&L44-_<1I&@ 55$C   =
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M_E6OO_C]'^L.$_EE]R_S#ZG4[H_)#;1MK];_ /AA7X'?]"1_Y5K[_P"/T?\
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M_P#C]'^L.$_EE]R_S#ZG4[H_)#;1MK];_P#AA7X'?]"1_P"5:^_^/T?\,*_
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M+W_HF_C7_P  [;_Y(KT>B@#SC_A<%[_T3?QK_P" =M_\D4?\+@O?^B;^-?\
MP#MO_DBO1Z* /./^%P7O_1-_&O\ X!VW_P D4?\ "X+W_HF_C7_P#MO_ )(K
MT>B@#SC_ (7!>_\ 1-_&O_@';?\ R11_PN"]_P"B;^-?_ .V_P#DBO1Z* /.
M/^%P7O\ T3?QK_X!VW_R11_PN"]_Z)OXU_\  .V_^2*]'HH \X_X7!>_]$W\
M:_\ @';?_)%'_"X+W_HF_C7_ , [;_Y(KT>B@#SC_A<%[_T3?QK_ . =M_\
M)%'_  N"]_Z)OXU_\ [;_P"2*]'HH \X_P"%P7O_ $3?QK_X!VW_ ,D4?\+@
MO?\ HF_C7_P#MO\ Y(KT>B@#SC_A<%[_ -$W\:_^ =M_\D4?\+@O?^B;^-?_
M  #MO_DBO1Z* /./^%P7O_1-_&O_ (!VW_R11_PN"]_Z)OXU_P# .V_^2*]'
MHH \X_X7!>_]$W\:_P#@';?_ "11_P +@O?^B;^-?_ .V_\ DBO1Z* /./\
MA<%[_P!$W\:_^ =M_P#)%'_"X+W_ *)OXU_\ [;_ .2*]'HH \X;XOWC<'X;
M^-#_ -N=M_\ )%9.K>._[6C99OAEXR.?^G*U_P#DBO7:* /D3Q7X-MM4OC=P
M?#+Q=%,3DG[';@'W($^"?K6CX4T<Z6RO<?#GQC*1Z6=M_P#'Z^J<9HK6=:I4
M2C.3:6UWMZ'-2PU"A*4Z--1<G=V25WW=MWZGDVE_$ Z7&J0_#+QFN/2SM?\
MY(K3'Q@O%Z?#?QH/^W.V_P#DBO1Z*R.D\X_X7!>_]$W\:_\ @';?_)%'_"X+
MW_HF_C7_ , [;_Y(KT>B@#SC_A<%[_T3?QK_ . =M_\ )%'_  N"]_Z)OXU_
M\ [;_P"2*]'HH \X_P"%P7O_ $3?QK_X!VW_ ,D4?\+@O?\ HF_C7_P#MO\
MY(KT>B@#SC_A<%[_ -$W\:_^ =M_\D4?\+@O?^B;^-?_  #MO_DBO1Z* /./
M^%P7O_1-_&O_ (!VW_R11_PN"]_Z)OXU_P# .V_^2*]'HH \X_X7!>_]$W\:
M_P#@';?_ "11_P +@O?^B;^-?_ .V_\ DBO1Z* /./\ A<%[_P!$W\:_^ =M
M_P#)%'_"X+W_ *)OXU_\ [;_ .2*]'HH \X_X7!>_P#1-_&O_@';?_)%'_"X
M+W_HF_C7_P  [;_Y(KT>B@#SC_A<%[_T3?QK_P" =M_\D4?\+@O?^B;^-?\
MP#MO_DBO1Z* /./^%P7O_1-_&O\ X!VW_P D4?\ "X+W_HF_C7_P#MO_ )(K
MT>B@#SC_ (7!>_\ 1-_&O_@';?\ R11_PN"]_P"B;^-?_ .V_P#DBO1Z* /.
M/^%P7O\ T3?QK_X!VW_R11_PN"]_Z)OXU_\  .V_^2*]'HH \X_X7!>_]$W\
M:_\ @';?_)%'_"X+W_HF_C7_ , [;_Y(KT>B@#SC_A<%[_T3?QK_ . =M_\
M)%'_  N"]_Z)OXU_\ [;_P"2*]'HH \X_P"%P7O_ $3?QK_X!VW_ ,D4?\+@
MO?\ HF_C7_P#MO\ Y(KT>B@#SC_A<%[_ -$W\:_^ =M_\D4?\+@O?^B;^-?_
M  #MO_DBO1Z* /./^%P7O_1-_&O_ (!VW_R11_PN"]_Z)OXU_P# .V_^2*]'
MHH \X_X7!>_]$W\:_P#@';?_ "11_P +@O?^B;^-?_ .V_\ DBO1Z* /./\
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M%[_T3?QK_P" =M_\D4?\+@O?^B;^-?\ P#MO_DBO1Z* /./^%P7O_1-_&O\
MX!VW_P D4?\ "X+W_HF_C7_P#MO_ )(KT>B@#SC_ (7!>_\ 1-_&O_@';?\
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M *)OXU_\ [;_ .2*]'HH \X_X7!>_P#1-_&O_@';?_)%'_"X+W_HF_C7_P
M[;_Y(KT>B@#SC_A<%[_T3?QK_P" =M_\D4^'XN7LTR1_\*Z\9)N8+N>TM@HR
3>I/VCI7HE% !1110(**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428792944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Quince Orchard Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,093,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428813824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 415,484<span></span>
</td>
<td class="nump">$ 424,426<span></span>
</td>
<td class="nump">$ 509,339<span></span>
</td>
<td class="nump">$ 505,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">46,242<span></span>
</td>
<td class="nump">55,777<span></span>
</td>
<td class="nump">105,451<span></span>
</td>
<td class="nump">89,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">106,946<span></span>
</td>
<td class="nump">219,475<span></span>
</td>
<td class="nump">199,625<span></span>
</td>
<td class="nump">466,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">101,298<span></span>
</td>
<td class="nump">93,717<span></span>
</td>
<td class="nump">188,096<span></span>
</td>
<td class="nump">206,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">254,486<span></span>
</td>
<td class="nump">368,969<span></span>
</td>
<td class="nump">493,172<span></span>
</td>
<td class="nump">762,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">160,998<span></span>
</td>
<td class="nump">55,457<span></span>
</td>
<td class="nump">16,167<span></span>
</td>
<td class="num">(257,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(4,143)<span></span>
</td>
<td class="num">(3,124)<span></span>
</td>
<td class="num">(8,254)<span></span>
</td>
<td class="num">(7,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">7,731<span></span>
</td>
<td class="nump">5,532<span></span>
</td>
<td class="nump">11,385<span></span>
</td>
<td class="nump">29,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax expense (benefit)</a></td>
<td class="nump">164,586<span></span>
</td>
<td class="nump">57,865<span></span>
</td>
<td class="nump">19,298<span></span>
</td>
<td class="num">(234,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">2,205<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 162,381<span></span>
</td>
<td class="nump">$ 58,008<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>&#8203;Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">148,379<span></span>
</td>
<td class="nump">89,362<span></span>
</td>
<td class="nump">144,147<span></span>
</td>
<td class="nump">87,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">165,855<span></span>
</td>
<td class="nump">104,065<span></span>
</td>
<td class="nump">145,121<span></span>
</td>
<td class="nump">87,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 19,904<span></span>
</td>
<td class="nump">$ 285,163<span></span>
</td>
<td class="nump">$ 102,228<span></span>
</td>
<td class="nump">$ 277,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_LicensingRoyaltiesAndOtherMember', window );">Licensing, royalties, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">395,580<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">407,111<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 137,079<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 224,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_LicensingRoyaltiesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_LicensingRoyaltiesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196425930608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 162,381<span></span>
</td>
<td class="nump">$ 58,008<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale marketable securities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">467<span></span>
</td>
<td class="num">(5,011)<span></span>
</td>
<td class="num">(13,080)<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">317<span></span>
</td>
<td class="num">(5,011)<span></span>
</td>
<td class="num">(13,230)<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 162,698<span></span>
</td>
<td class="nump">$ 52,997<span></span>
</td>
<td class="nump">$ 1,601<span></span>
</td>
<td class="num">$ (237,697)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428688512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 680,162<span></span>
</td>
<td class="nump">$ 568,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">369,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">10,486<span></span>
</td>
<td class="nump">10,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">32,105<span></span>
</td>
<td class="nump">297,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">9,172<span></span>
</td>
<td class="nump">41,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">102,013<span></span>
</td>
<td class="nump">226,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,203,370<span></span>
</td>
<td class="nump">1,143,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">288,559<span></span>
</td>
<td class="nump">305,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">169,507<span></span>
</td>
<td class="nump">185,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">123,377<span></span>
</td>
<td class="nump">127,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">33,833<span></span>
</td>
<td class="nump">35,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,818,646<span></span>
</td>
<td class="nump">1,797,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">79,962<span></span>
</td>
<td class="nump">132,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">159,221<span></span>
</td>
<td class="nump">394,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">666,390<span></span>
</td>
<td class="nump">241,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">9,427<span></span>
</td>
<td class="nump">5,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">242,811<span></span>
</td>
<td class="nump">861,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,157,811<span></span>
</td>
<td class="nump">1,635,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">533,431<span></span>
</td>
<td class="nump">622,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">168,848<span></span>
</td>
<td class="nump">168,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liabilities</a></td>
<td class="nump">54,970<span></span>
</td>
<td class="nump">55,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">335,292<span></span>
</td>
<td class="nump">33,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,250,352<span></span>
</td>
<td class="nump">2,514,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized at June&#160;30, 2024 and December&#160;31, 2023; no shares issued and outstanding at June&#160;30, 2024 and December&#160;31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 600,000,000 shares authorized at June&#160;30, 2024 and December&#160;31, 2023; 161,267,120 shares issued and 159,891,014 shares outstanding at June&#160;30, 2024 and 140,506,093 shares issued and 139,505,770 shares outstanding at December&#160;31, 2023</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,477,748<span></span>
</td>
<td class="nump">4,192,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,806,120)<span></span>
</td>
<td class="num">(4,820,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, cost basis, 1,376,106 shares at June&#160;30, 2024 and 1,000,323 shares at December&#160;31, 2023</a></td>
<td class="num">(94,439)<span></span>
</td>
<td class="num">(92,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(10,508)<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(431,706)<span></span>
</td>
<td class="num">(716,927)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 1,818,646<span></span>
</td>
<td class="nump">$ 1,797,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196430312160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">161,267,120<span></span>
</td>
<td class="nump">140,506,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">159,891,014<span></span>
</td>
<td class="nump">139,505,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,376,106<span></span>
</td>
<td class="nump">1,000,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196431450784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,806,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2022</a></td>
<td class="num">$ (634,078)<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 3,737,979<span></span>
</td>
<td class="num">$ (4,275,889)<span></span>
</td>
<td class="num">$ (90,659)<span></span>
</td>
<td class="num">$ (6,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">48,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,947,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="nump">67,972<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">67,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(235,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,183,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2023</a></td>
<td class="num">(754,519)<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">3,855,916<span></span>
</td>
<td class="num">(4,511,786)<span></span>
</td>
<td class="num">(91,424)<span></span>
</td>
<td class="num">(8,177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,139,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2023</a></td>
<td class="num">(895,582)<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">3,767,733<span></span>
</td>
<td class="num">(4,569,794)<span></span>
</td>
<td class="num">(91,226)<span></span>
</td>
<td class="num">(3,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,947,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="nump">67,972<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">67,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(5,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">58,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,183,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2023</a></td>
<td class="num">$ (754,519)<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">3,855,916<span></span>
</td>
<td class="num">(4,511,786)<span></span>
</td>
<td class="num">(91,424)<span></span>
</td>
<td class="num">(8,177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2023</a></td>
<td class="nump">139,505,770<span></span>
</td>
<td class="nump">140,506,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2023</a></td>
<td class="num">$ (716,927)<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">4,192,164<span></span>
</td>
<td class="num">(4,820,951)<span></span>
</td>
<td class="num">(92,267)<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,093,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="nump">256,409<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">256,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(13,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2024</a></td>
<td class="nump">159,891,014<span></span>
</td>
<td class="nump">161,267,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2024</a></td>
<td class="num">$ (431,706)<span></span>
</td>
<td class="nump">$ 1,613<span></span>
</td>
<td class="nump">4,477,748<span></span>
</td>
<td class="num">(4,806,120)<span></span>
</td>
<td class="num">(94,439)<span></span>
</td>
<td class="num">(10,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,700,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2024</a></td>
<td class="num">(867,084)<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="nump">4,204,775<span></span>
</td>
<td class="num">(4,968,501)<span></span>
</td>
<td class="num">(93,950)<span></span>
</td>
<td class="num">(10,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,093,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold, net</a></td>
<td class="nump">256,409<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">256,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 162,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2024</a></td>
<td class="nump">159,891,014<span></span>
</td>
<td class="nump">161,267,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2024</a></td>
<td class="num">$ (431,706)<span></span>
</td>
<td class="nump">$ 1,613<span></span>
</td>
<td class="nump">$ 4,477,748<span></span>
</td>
<td class="num">$ (4,806,120)<span></span>
</td>
<td class="num">$ (94,439)<span></span>
</td>
<td class="num">$ (10,508)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued issued under incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in incentive program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196432812576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="nump">$ 3,830<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">$ 3,830<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196429312176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">23,279<span></span>
</td>
<td class="nump">19,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">25,655<span></span>
</td>
<td class="nump">48,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProvisionForExcessAndObsoleteInventory', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">18,472<span></span>
</td>
<td class="nump">31,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">10,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(2,687)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">14,176<span></span>
</td>
<td class="num">(19,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Accounts receivable, prepaid expenses, and other assets</a></td>
<td class="nump">390,766<span></span>
</td>
<td class="num">(266,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other liabilities</a></td>
<td class="num">(366,484)<span></span>
</td>
<td class="num">(443,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">111,037<span></span>
</td>
<td class="nump">357,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">230,714<span></span>
</td>
<td class="num">(497,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
<td class="num">(9,753)<span></span>
</td>
<td class="num">(26,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale marketable securities</a></td>
<td class="num">(369,582)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Internal-use software</a></td>
<td class="num">(622)<span></span>
</td>
<td class="num">(4,563)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(379,957)<span></span>
</td>
<td class="num">(31,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">263,272<span></span>
</td>
<td class="nump">61,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards', window );">Net proceeds from the exercise of stock-based awards</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease payments</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(26,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2023 Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(325,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of costs related to issuance of 2027 Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,591)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">264,102<span></span>
</td>
<td class="num">(293,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(3,111)<span></span>
</td>
<td class="num">(8,992)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">111,748<span></span>
</td>
<td class="num">(830,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">583,810<span></span>
</td>
<td class="nump">1,348,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">695,558<span></span>
</td>
<td class="nump">517,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Sale of common stock under the Sales Agreement not settled at quarter-end</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset', window );">Right-of-use assets from new lease agreements</a></td>
<td class="num">(8,289)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">2,137<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest payments, net of amounts capitalized</a></td>
<td class="nump">7,180<span></span>
</td>
<td class="nump">11,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds</a></td>
<td class="num">$ (649)<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From The Exercise Of Stock-Based Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NetProceedsFromTheExerciseOfStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProvisionForExcessAndObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Excess And Obsolete Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProvisionForExcessAndObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196531373248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a global company that is advancing protein-based vaccines with its Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> adjuvant. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology, and patented Matrix-M&#8482; adjuvant to enhance the immune response. In May 2024, Novavax entered into a collaboration and licensing agreement (the &#8220;Collaboration and License Agreement&#8221; or &#8220; Sanofi CLA&#8221;) with Sanofi Pasteur Inc. (&#8220;Sanofi&#8221;) to co-commercialize Novavax&#8217;s current standalone COVID-19 vaccines (&#8220;COVID-19 Vaccine&#8221;), including Novavax&#8217;s Nuvaxovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, prototype COVID-19 vaccine (&#8220;NVX-CoV2373,&#8221; or &#8220;prototype vaccine&#8221;) and XBB COVID-19 vaccine  (&#8220;NVX-CoV2601&#8221;), and the Company&#8217;s updated vaccine for the 2024-2025 vaccination season (&#8220;NVX-CoV2705,&#8221; or &#8220;updated vaccine&#8221; and, collectively with NVX-CoV2373 and NVX-CoV2601, the Company&#8217;s &#8220;COVID-19 Vaccine&#8221; or &#8220;COVID-19 Program&#8221;). This agreement is discussed in greater detail in Note 6 of Novavax&#8217;s consolidated financial statements. The partnership with Sanofi allows Novavax to broaden access to its vaccine and adjuvant and refocus on clinical-stage research and development and pipeline expansion beginning in 2025.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through the end of the 2024-2025 vaccination season, Novavax will continue commercialization of its COVID-19 Vaccine.  Local regulatory authorities have also specified nomenclature for the labeling of NVX-CoV2373 and NVX-CoV2601 within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221;, &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula),&#8221; respectively, for the U.S., and &#8220;Nuvaxovid&#8482;&#8221; for ex-US territories) collectively referred to as the Company&#8217;s &#8220;COVID-19 Program,&#8221; or &#8220;COVID-19 Vaccine&#8221;). </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, the Company has submitted an amendment to the previously granted October 2023 Emergency Use Authorization (&#8220;EUA&#8221;) to the U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;), filed for a type II variation of the existing Marketing Authorization (&#8220;MA&#8221;) with the European Medicines Agency (&#8220;EMA&#8221;) and the United Kingdom's (&#8220;U.K.&#8221;) Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), and filed for authorization with Health Canada for the Company&#8217;s updated vaccine. Currently, the Company significantly depends on its supply agreement with Serum Institute of India Pvt. Ltd. (&#8220;SII&#8221;) and its subsidiary, Serum Life Sciences Limited (&#8220;SLS&#8221; and together with SII, &#8220;Serum&#8221;), for co-formulation, filling, and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID-19-Influenza Combination (&#8220;CIC&#8221;) and stand-alone influenza vaccine candidates. In addition, Novavax&#8217;s adjuvant is included in the University of Oxford and SII&#8217;s R21/Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">malaria vaccine which has received authorizations in a number of countries with doses administered in 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax&#8217;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#8217;s proprietary Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434622992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive income (loss), changes in stockholders&#8217; deficit, and cash flows for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were a $1.6&#160;million loss and a $6.7&#160;million loss, and a $0.2&#160;million loss and $16.1&#160;million gain for the three and six months ended June&#160;30, 2024 and 2023, respectively, which are reflected in Other income (expense).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2023. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span id="id646a6b9d9154d26bde005a7bb4415f3_15397"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA and a securities subscription agreement (the &#8220;Subscription Agreement&#8221;) with Sanofi as a result of which, the Company received a total of $568.8 million during the second quarter of 2024 (See Note 6).  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had $680.2 million in cash and cash equivalents, $369.4 million in marketable securities, and working capital of $45.6 million. During the six months ended June&#160;30, 2024, the Company recognized net income of $14.8 million, and had net cash flows provided by operating activities of $230.7 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Based on the Company&#8217;s current cash and cash equivalents and marketable securities balances and its current cash flow forecast for the one-year going concern look forward period, the Company has concluded that it will have sufficient capital available to fund its operations for the one-year period from the date that these financial statements are issued. As of December 31, 2023, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to significant uncertainty related to its ability to successfully develop, manufacture, distribute, and market its updated vaccine and execute on certain cost-reduction initiatives as described in Note 16. The Sanofi CLA has alleviated the substantial doubt.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Licensing and Transition Services</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s third-party licensing agreements may contain multiple performance obligations, including licenses and transition services. The Company evaluates licensing agreements under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;) to determine the distinct performance obligations. Prior to recognizing revenue, the Company estimates the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple performance obligation arrangements, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, the Company considers discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, the Company applies judgment in determining the forecasted revenue, expected margins, and the discount rate. These estimates are subjective and require the Company to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset. For performance obligations recognized over time, the Company recognizes revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, the Company considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, and indirect administrative costs. Estimating the total cost at completion of the Company&#8217;s performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on the Company&#8217;s contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. The Company has not experienced any material adjustments as a result of changes in estimates arising from this process.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities, and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 for additional information on the severance and employee benefit costs for terminated employees and impairment of assets in connection with the Company&#8217;s Restructuring Plan as defined in Note 16.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434619328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities <div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities were classified as available-for-sale as of June&#160;30, 2024 and comprised of (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369,582&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(150)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369,432&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div>As of June&#160;30, 2024, investments in marketable securities, comprising corporate debt securities, were due to mature within one year. Based on the Company&#8217;s policy under the expected credit loss model, including an assessment of unrealized losses on the portfolio as of June 30, 2024, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more-likely-than-not to hold these investments for a period of time sufficient for a recovery of the Company&#8217;s cost basis. As of June&#160;30, 2024, the Company held no securities that were in an unrealized loss position for more than 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196427358208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,587</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as cash and cash equivalents as of June 30, 2024 and December 31, 2023, respectively, on the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes $232.0 million classified as Cash and cash equivalents and $369.4&#160;million classified as marketable securities as of June&#160;30, 2024, on the consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics. Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six&#160;months ended June&#160;30, 2024 and 2023, the Company did not have any transfers between levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196532353888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $29.8 million and $286.4 million related to amounts that were billed to customers and $2.3 million and $10.8 million related to amounts which had not yet been billed to customers as of June&#160;30, 2024 and December&#160;31, 2023, respectively. During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#8217;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;There was no allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $6.2 million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $2.2&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $225.0&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties and constrained variable consideration, was approximately $2 billion, of which $1.2&#160;billion was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront and other payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on the timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request the Company&#8217;s updated vaccine under certain of the Company&#8217;s APAs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an APA with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;), entered into in May 2021 (the &#8220;Gavi APA&#8221;), the Company received upfront payments of $700&#160;million from Gavi (the &#8220;Advance Payment Amount&#8221;) to be applied against purchases of the Company&#8217;s prototype vaccine by certain countries participating in the COVAX Facility. As of December&#160;31, 2023, the remaining Gavi Advance Payment Amount was $696.4&#160;million. In February 2024, the Company entered into a Termination and Settlement Agreement with Gavi (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under, or otherwise in connection with the Gavi APA. On February 22, 2024, the claims and counterclaims were dismissed with prejudice. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid in February 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of the Company&#8217;s vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In total, the Gavi settlement agreement is comprised of $700 million of potential consideration, consisting of the $75&#160;million initial settlement payment, deferred payments of up to $400&#160;million that may be reduced through annual vaccine credits, and the additional credit of up to $225&#160;million that may be applied for certain qualifying sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $3.6&#160;million difference between the refund liability recorded as of December&#160;31, 2023 of $696.4&#160;million and the $700 million of total consideration under the arrangement as a reduction to revenue during the six months ended June&#160;30, 2024. As of June&#160;30, 2024, the remaining amounts included on the Company&#8217;s consolidated balance sheet were  $225&#160;million in non-current Deferred revenue for the additional credit that may be applied against future qualifying sales, $90&#160;million in Other current liabilities, and $305&#160;million in Other non-current liabilities. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SII under the SII R21 Agreement (see Note 6), which will continue for the deferred payment term of the Gavi Settlement Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:34.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,586</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,785</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,397</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,921</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). Product sales in the U.S. are recorded net of gross-to-net deductions. During the six months ended June&#160;30, 2024, product sales in North America includes $4.8&#160;million of gross-to-net deductions in excess of the WAC, primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales, partially offset by updates to estimated product returns. During the six months ended June&#160;30, 2024, product sales for the rest of the world includes a $3.6&#160;million reduction to revenue recognized pursuant to the Gavi Settlement Agreement as discussed above. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits/deductions </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of June&#160;30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,587&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $4.0&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 no gross-to-net deductions were included in Accounts receivable. As of December&#160;31, 2023, $2.6 million of gross-to-net deductions were included in Accounts receivable. As of June&#160;30, 2024 and December&#160;31, 2023, $55.5 million and $103.1 million of gross-to-net deductions were included in Accrued expenses, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the Commonwealth of Australia (&#8220;Australia&#8221;) for the purchase of doses of COVID-19 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine (the &#8220;Australia APA&#8221;). In March 2024, the Company and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $54.0 million, including $6.0 million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until the Company receives authorization from Therapeutic Goods Administration (&#8220;TGA&#8221;). The Company does not expect approval in time for product delivery in 2024 which could result in a loss or deferral of approximately $240 million of contract value. The Company plans to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $119.1 million was classified as current Deferred revenue and $14.7 million was classified as non-current Deferred revenue with respect to the Australia APA in the Company&#8217;s consolidated balance sheet.  If the Company is unable to satisfy its obligations under the Australia APA, $92.5 million of deferred revenue may become refundable and approximately $225 million of remaining funds under the contract may no longer be available.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not anticipate achieving regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, the Company plans to seek an amendment to the Canada APA to address possible alternatives, which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $452.1&#160;million was classified as current Deferred revenue and $136.1&#160;million was classified as non-current Deferred revenue with respect to the Canadian APA in the Company&#8217;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Pharmaceutical Management Agency (&#8220;Pharmac&#8221;), a New Zealand Crown entity, provided notice of its termination of its APA (the &#8220;New Zealand APA&#8221;). As of June&#160;30, 2024, $31.3&#160;million was classified as current Deferred revenue with respect to such agreement in the Company&#8217;s consolidated balance sheet. New Zealand has requested a refund of certain advanced payments and the Company is in discussion with Pharmac on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both, whether its termination of the New Zealand APA was appropriate under the New Zealand APA, and whether a refund of the advanced payments is appropriate under the New Zealand APA. Ap</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proximately $125&#160;million of the contract value related to future deliverables may no longer be available if the APA is terminated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing, Royalties, and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, royalties, and other includes Licensing payments, Transition Services revenue, and Technology Transfer revenue from the Company&#8217;s Collaboration and License Agreement with Sanofi (&#8220;Sanofi CLA&#8221;); royalty milestone payments; sales-based royalties; and Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024, respectively, the Company recognized $386.3&#160;million and $390.3&#160;million in revenue related to license fees and $2.7&#160;million and $10.2&#160;million in revenue related to Matrix-M&#8482; adjuvant sales, respectively. During the three and six months ended June&#160;30, 2024, the Company recognized $6.6&#160;million of Transition Services revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June&#160;30, 2023, the Company recognized $2.2&#160;million and $3.2&#160;million in revenue related to Matrix-M&#8482; adjuvant sales. During the three and six months ended June&#160;30, 2023, the Company did not recognize revenue related to license fees or milestone payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants </span></div>The Company&#8217;s U.S. government agreement consisted of a Project Agreement (the &#8220;Project Agreement&#8221;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#8220;USG Agreement&#8221;). As of December&#160;31, 2023, the Company recognized the full $1.8&#160;billion funding in revenue.Collaboration, License, and Supply Agreements <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the Company&#8217;s material collaborations, license and supply agreements were as follows: </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously granted SII exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, NVX-CoV2601, its updated vaccine, and its CIC vaccine candidate. SII agreed to purchase the Company's Matrix-M&#8482; adjuvant and the Company granted SII a non-exclusive license to manufacture the antigen drug substance component of the Company&#8217;s COVID-19 Vaccine in SII&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SII equally split the revenue from SII&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. In May 2024, the Company and SLS entered into a supply agreement (the &#8220;SLS Supply Agreement&#8221;) under which SLS will supply the Company with antigen drug substance and finished COVID-19 Vaccine doses. The SLS Supply Agreement includes the general terms and conditions of supply orders between the Company and SLS. The Company and SLS intend to execute statements of work and firm purchase orders to included specific quantities to be delivered under the SLS Supply Agreement. The Company will supply SLS with all Matrix-M&#8482; adjuvant needed to manufacture  finished COVID-19 Vaccine doses. In March 2020, the Company entered into an agreement with SII that granted SII a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant (&#8220;SII R21 Agreement&#8221;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). In December 2023, R21/Matrix-M&#8482; received prequalification by the World Health Organization (&#8220;WHO&#8221;). Under the SII R21 Agreement, SII purchases the Company's Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA under which the Company granted and Sanofi received the following: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i)&#160;&#160;&#160;&#160;A co-exclusive license to commercialize the Company&#8217;s current stand-alone COVID-19 Vaccine, including the Company&#8217;s prototype vaccine and updated vaccines, that address seasonal variants throughout the world (the &#8220;COVID-19 Vaccine Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)&#160;&#160;&#160;&#160;A sole license to develop and commercialize combination products containing a potential combination of the Company&#8217;s COVID-19 Vaccine and Sanofi&#8217;s seasonal influenza vaccine (&#8220;COVID-19 and influenza Combination Products&#8221; or &#8220;CIC Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize combination products containing both the Company&#8217;s COVID-19 Vaccine and one or more non-influenza vaccines (&#8220;Other Combination Products&#8221; and together with the COVID-19 Vaccine Products, CIC Products, and Other Combination Products, &#8220;Licensed COVID-19 Products&#8221;); and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize other vaccine products selected by Sanofi that include the Company&#8217;s Matrix-M&#8482; adjuvant (as described below, the &#8220;Adjuvant Products&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also responsible for performing services related to the technology transfer of its manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; components to Sanofi. Until the successful completion of such transfer, the Company will supply Sanofi with both COVID-19 Vaccine Products and Matrix-M&#8482; intermediary components for Sanofi&#8217;s use and is eligible for reimbursement of such costs from Sanofi. In addition, the Company is responsible for certain research and development and medical affairs services related to the COVID-19 Vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sanofi CLA, the Company will continue to commercialize its updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, Sanofi and the Company will commercialize the COVID-19 Vaccine Products worldwide in accordance with a commercialization plan agreed by the Company and Sanofi, under which the Company will continue to supply its existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, the Company and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sanofi CLA, the Company received a non-refundable upfront payment of $500&#160;million in the second quarter of 2024. In addition, the Company will also be eligible to receive development, technology transfer, launch, and sales milestone payments totaling up to $700 million in the aggregate with respect to the COVID-19 Vaccine Products and royalty payments on Sanofi&#8217;s sales of such licensed products. Milestone payments are comprised of a payment of $175&#160;million upon the approval of the marketing authorization for a COVID-19 Vaccine Product in a pre-filled syringe from the FDA, $25&#160;million upon the transfer of such approval to Sanofi, $25&#160;million upon the transfer of EMA approval of a COVID-19 Vaccine Product in a pre-filled syringe to Sanofi, $50&#160;million upon database lock of an existing Phase 2/3 clinical trial (identifier 2019nCoV-503), $75&#160;million upon the completion of the technology transfer of the Company&#8217;s manufacturing process for the COVID-19 Vaccine Products to Sanofi, and up to $350&#160;million in CIC Product-related development and launch milestones.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive development, launch, and sales milestone payments of up to $200 million for each of the first four Adjuvant Products and $210 million for each Adjuvant Product thereafter, and royalty payments on Sanofi&#8217;s sales of all such licensed products. In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, a portion of the technology transfer costs and research and development costs incurred by the Company will be reimbursed by Sanofi in accordance with agreed upon plans and budgets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed whether the Sanofi CLA fell within the scope of ASC 808,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) based on whether the arrangement involved joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. The Company determined that the Sanofi CLA did not fall within the scope of ASC 808, as the Company does not share in the significant financial risks of Sanofi's development or commercialization activities. The Company then analyzed the arrangement pursuant to the provisions of ASC 606 and determined that the arrangement represents a contract with a customer and is therefore within the scope of ASC 606.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations in the Sanofi CLA and determined that they were within the scope of ASC 606: delivery of (i) the licenses described above (the COVID-19 Vaccine license, CIC Products license, Other Combination Product license, and Adjuvant Products license) (collectively the &#8220;Sanofi CLA Licenses&#8217;), (ii) research and development transition services that support further regulatory approval and development of the COVID-19 Vaccine, referred to as the Sanofi Transition Services, and (iii) technology transfer of the existing manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; adjuvant, referred to as the &#8220;Sanofi Technology Transfer&#8221;. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Sanofi and therefore are not considered separate performance obligations within the Sanofi CLA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sanofi CLA Licenses performance obligations are considered functional intellectual property and distinct from other promises under the contract as Sanofi can benefit from the licenses on their own or together with other readily available resources. Also, the Sanofi Transition Services provide a distinct benefit to Sanofi within the context of the contract, separate from the licenses, as the services could be provided by Sanofi or another third party without the Company&#8217;s assistance. The Sanofi Technology Transfer obligation is distinct as Sanofi can benefit from the Sanofi CLA Licenses transferred by the Company at the inception of the agreement with other readily available resources. Therefore, each represents a separate performance obligation within the contract with a customer under the scope of ASC 606 at contract inception.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price at inception of the Sanofi CLA to be $620.2&#160;million, consisting of (i) fixed consideration (the $500 million upfront nonrefundable fee), (ii) and $120.2&#160;million of variable consideration attributed to a $50.0&#160;million clinical milestone and $70.2&#160;million of estimated cost reimbursement related to Sanofi Transition Services and Sanofi Technology Transfer. Since the clinical milestone allocated to Sanofi Transition Services is entirely within the Company&#8217;s control, and the cost reimbursement variable consideration allocated to Sanofi Transition Services and Sanofi Technology Transfer would be recognized as revenue only as the costs are incurred, the Company determined it is not probable that a significant reversal of cumulative revenue would occur. The Company utilized the expected value method to determine the amount of these payments. The Company excluded certain regulatory and technology transfer milestones from the transaction price that were determined to be inherently uncertain of achievement and are highly susceptible to factors outside of the Company&#8217;s control. Sales-based royalties and launch milestones are related to the license of the intellectual property rights and the Company will recognize revenue for these in the period when subsequent sales are made or sale-based milestones are achieved pursuant to the sales-based royalty exception under ASC 606. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the fixed consideration (i.e., the $500 million nonrefundable upfront fee) to the performance obligations in the Sanofi CLA based on each performance obligation&#8217;s relative standalone selling price, or SSP, as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$386.3&#160;million for the upfront transfer of the licenses; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$110.2&#160;million for Transition Services; and</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$3.5&#160;million for Technology Transfer. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SSP for the licenses were determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. In developing such estimates, the Company applied judgment in determining the forecasted revenues, expected margins, and the discount rate. The SSP for the ongoing Transition Services and Technology Transfer were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue related to the licenses at a point in time upon transfer of the rights and control of the license to Sanofi during the second quarter 2024. The Sanofi Transition Services and Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Technology Transfer for the three and six month period ended June&#160;30, 2024 was $6.6&#160;million. The Company&#8217;s consolidated balance sheet as of June&#160;30, 2024 includes a deferred revenue balance of $109.2&#160;million ($50.9&#160;million included in Deferred revenue, current portion and $58.3&#160;million included in Deferred revenue, non-current portion) related to Transition Services and Technology Transfer.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an asset for $35.0&#160;million of direct costs incurred to obtain the Sanofi CLA. These costs are amortized to expense over the expected period of the benefit in a manner that is consistent with the transfer of the related goods and services in the Sanofi CLA. The Company recognized $27.1&#160;million of amortization expense related to the asset in Selling, general, and administrative expense in the second quarter of 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, 6,880,481 shares of the Company&#8217;s common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to the Company of $68.8 million. The opening price of the Company&#8217;s common stock on the date of the sale approximated $10.00 per share and therefore all gross proceeds were allocated to stockholders&#8217; deficit. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Medical Research Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into a three-year agreement with the Bill &amp; Melinda Gates Medical Research </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute to provide the Company&#8217;s Matrix-M&#8482; adjuvant for use in preclinical vaccine research. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;) and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;) to resolve disputes regarding amounts that Fujifilm claimed were due under a prior Confidential Settlement Agreement and Release effective September 30, 2022 (the &#8220;CSAR&#8221;) by and between the Company and Fujifilm.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CSAR, the Company agreed to pay up to $185.0 million to Fujifilm in connection with the cancellation of manufacturing activity at FDBT. The final two quarterly installments due to Fujifilm in 2023 under the CSAR, totaling $68.6 million, were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT. In October 2023, the Company sent Fujifilm a notice of breach and refused to pay the final two installments based on its contention that Fujifilm had not used commercially reasonable efforts to mitigate losses and should have offset some portion of the final two payments. In October 2023, Fujifilm filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the full amount (the &#8220;Fujifilm Arbitration&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement, in March 2024, the Company paid $42.0 million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the CSAR, and Fujifilm agreed to dismiss the Fujifilm Arbitration. This payment is less than amounts previously accrued for and reflected in Research and development expense, and accordingly, the Company recorded a benefit of $26.6 million as Research and development expense during the six months ended June&#160;30, 2024 upon the execution of the Settlement Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Program, and in doing so, recognizes that significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants, U.S. Government Contract and Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434621232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Supply Agreements</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable included $29.8 million and $286.4 million related to amounts that were billed to customers and $2.3 million and $10.8 million related to amounts which had not yet been billed to customers as of June&#160;30, 2024 and December&#160;31, 2023, respectively. During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#8217;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;There was no allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $6.2 million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $2.2&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $225.0&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties and constrained variable consideration, was approximately $2 billion, of which $1.2&#160;billion was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront and other payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on the timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request the Company&#8217;s updated vaccine under certain of the Company&#8217;s APAs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an APA with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221;), entered into in May 2021 (the &#8220;Gavi APA&#8221;), the Company received upfront payments of $700&#160;million from Gavi (the &#8220;Advance Payment Amount&#8221;) to be applied against purchases of the Company&#8217;s prototype vaccine by certain countries participating in the COVAX Facility. As of December&#160;31, 2023, the remaining Gavi Advance Payment Amount was $696.4&#160;million. In February 2024, the Company entered into a Termination and Settlement Agreement with Gavi (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under, or otherwise in connection with the Gavi APA. On February 22, 2024, the claims and counterclaims were dismissed with prejudice. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid in February 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of the Company&#8217;s vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In total, the Gavi settlement agreement is comprised of $700 million of potential consideration, consisting of the $75&#160;million initial settlement payment, deferred payments of up to $400&#160;million that may be reduced through annual vaccine credits, and the additional credit of up to $225&#160;million that may be applied for certain qualifying sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $3.6&#160;million difference between the refund liability recorded as of December&#160;31, 2023 of $696.4&#160;million and the $700 million of total consideration under the arrangement as a reduction to revenue during the six months ended June&#160;30, 2024. As of June&#160;30, 2024, the remaining amounts included on the Company&#8217;s consolidated balance sheet were  $225&#160;million in non-current Deferred revenue for the additional credit that may be applied against future qualifying sales, $90&#160;million in Other current liabilities, and $305&#160;million in Other non-current liabilities. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SII under the SII R21 Agreement (see Note 6), which will continue for the deferred payment term of the Gavi Settlement Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:34.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,586</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,785</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,397</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,921</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). Product sales in the U.S. are recorded net of gross-to-net deductions. During the six months ended June&#160;30, 2024, product sales in North America includes $4.8&#160;million of gross-to-net deductions in excess of the WAC, primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales, partially offset by updates to estimated product returns. During the six months ended June&#160;30, 2024, product sales for the rest of the world includes a $3.6&#160;million reduction to revenue recognized pursuant to the Gavi Settlement Agreement as discussed above. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits/deductions </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of June&#160;30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,587&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $4.0&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 no gross-to-net deductions were included in Accounts receivable. As of December&#160;31, 2023, $2.6 million of gross-to-net deductions were included in Accounts receivable. As of June&#160;30, 2024 and December&#160;31, 2023, $55.5 million and $103.1 million of gross-to-net deductions were included in Accrued expenses, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the Commonwealth of Australia (&#8220;Australia&#8221;) for the purchase of doses of COVID-19 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine (the &#8220;Australia APA&#8221;). In March 2024, the Company and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $54.0 million, including $6.0 million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until the Company receives authorization from Therapeutic Goods Administration (&#8220;TGA&#8221;). The Company does not expect approval in time for product delivery in 2024 which could result in a loss or deferral of approximately $240 million of contract value. The Company plans to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $119.1 million was classified as current Deferred revenue and $14.7 million was classified as non-current Deferred revenue with respect to the Australia APA in the Company&#8217;s consolidated balance sheet.  If the Company is unable to satisfy its obligations under the Australia APA, $92.5 million of deferred revenue may become refundable and approximately $225 million of remaining funds under the contract may no longer be available.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not anticipate achieving regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC on or before </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, the Company plans to seek an amendment to the Canada APA to address possible alternatives, which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $452.1&#160;million was classified as current Deferred revenue and $136.1&#160;million was classified as non-current Deferred revenue with respect to the Canadian APA in the Company&#8217;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Pharmaceutical Management Agency (&#8220;Pharmac&#8221;), a New Zealand Crown entity, provided notice of its termination of its APA (the &#8220;New Zealand APA&#8221;). As of June&#160;30, 2024, $31.3&#160;million was classified as current Deferred revenue with respect to such agreement in the Company&#8217;s consolidated balance sheet. New Zealand has requested a refund of certain advanced payments and the Company is in discussion with Pharmac on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both, whether its termination of the New Zealand APA was appropriate under the New Zealand APA, and whether a refund of the advanced payments is appropriate under the New Zealand APA. Ap</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proximately $125&#160;million of the contract value related to future deliverables may no longer be available if the APA is terminated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing, Royalties, and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing, royalties, and other includes Licensing payments, Transition Services revenue, and Technology Transfer revenue from the Company&#8217;s Collaboration and License Agreement with Sanofi (&#8220;Sanofi CLA&#8221;); royalty milestone payments; sales-based royalties; and Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024, respectively, the Company recognized $386.3&#160;million and $390.3&#160;million in revenue related to license fees and $2.7&#160;million and $10.2&#160;million in revenue related to Matrix-M&#8482; adjuvant sales, respectively. During the three and six months ended June&#160;30, 2024, the Company recognized $6.6&#160;million of Transition Services revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three and six months ended June&#160;30, 2023, the Company recognized $2.2&#160;million and $3.2&#160;million in revenue related to Matrix-M&#8482; adjuvant sales. During the three and six months ended June&#160;30, 2023, the Company did not recognize revenue related to license fees or milestone payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants </span></div>The Company&#8217;s U.S. government agreement consisted of a Project Agreement (the &#8220;Project Agreement&#8221;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#8220;USG Agreement&#8221;). As of December&#160;31, 2023, the Company recognized the full $1.8&#160;billion funding in revenue.Collaboration, License, and Supply Agreements <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the Company&#8217;s material collaborations, license and supply agreements were as follows: </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serum</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously granted SII exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, NVX-CoV2601, its updated vaccine, and its CIC vaccine candidate. SII agreed to purchase the Company's Matrix-M&#8482; adjuvant and the Company granted SII a non-exclusive license to manufacture the antigen drug substance component of the Company&#8217;s COVID-19 Vaccine in SII&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SII equally split the revenue from SII&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. In May 2024, the Company and SLS entered into a supply agreement (the &#8220;SLS Supply Agreement&#8221;) under which SLS will supply the Company with antigen drug substance and finished COVID-19 Vaccine doses. The SLS Supply Agreement includes the general terms and conditions of supply orders between the Company and SLS. The Company and SLS intend to execute statements of work and firm purchase orders to included specific quantities to be delivered under the SLS Supply Agreement. The Company will supply SLS with all Matrix-M&#8482; adjuvant needed to manufacture  finished COVID-19 Vaccine doses. In March 2020, the Company entered into an agreement with SII that granted SII a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant (&#8220;SII R21 Agreement&#8221;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). In December 2023, R21/Matrix-M&#8482; received prequalification by the World Health Organization (&#8220;WHO&#8221;). Under the SII R21 Agreement, SII purchases the Company's Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA under which the Company granted and Sanofi received the following: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i)&#160;&#160;&#160;&#160;A co-exclusive license to commercialize the Company&#8217;s current stand-alone COVID-19 Vaccine, including the Company&#8217;s prototype vaccine and updated vaccines, that address seasonal variants throughout the world (the &#8220;COVID-19 Vaccine Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)&#160;&#160;&#160;&#160;A sole license to develop and commercialize combination products containing a potential combination of the Company&#8217;s COVID-19 Vaccine and Sanofi&#8217;s seasonal influenza vaccine (&#8220;COVID-19 and influenza Combination Products&#8221; or &#8220;CIC Products&#8221;);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize combination products containing both the Company&#8217;s COVID-19 Vaccine and one or more non-influenza vaccines (&#8220;Other Combination Products&#8221; and together with the COVID-19 Vaccine Products, CIC Products, and Other Combination Products, &#8220;Licensed COVID-19 Products&#8221;); and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize other vaccine products selected by Sanofi that include the Company&#8217;s Matrix-M&#8482; adjuvant (as described below, the &#8220;Adjuvant Products&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also responsible for performing services related to the technology transfer of its manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; components to Sanofi. Until the successful completion of such transfer, the Company will supply Sanofi with both COVID-19 Vaccine Products and Matrix-M&#8482; intermediary components for Sanofi&#8217;s use and is eligible for reimbursement of such costs from Sanofi. In addition, the Company is responsible for certain research and development and medical affairs services related to the COVID-19 Vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sanofi CLA, the Company will continue to commercialize its updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, Sanofi and the Company will commercialize the COVID-19 Vaccine Products worldwide in accordance with a commercialization plan agreed by the Company and Sanofi, under which the Company will continue to supply its existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, the Company and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sanofi CLA, the Company received a non-refundable upfront payment of $500&#160;million in the second quarter of 2024. In addition, the Company will also be eligible to receive development, technology transfer, launch, and sales milestone payments totaling up to $700 million in the aggregate with respect to the COVID-19 Vaccine Products and royalty payments on Sanofi&#8217;s sales of such licensed products. Milestone payments are comprised of a payment of $175&#160;million upon the approval of the marketing authorization for a COVID-19 Vaccine Product in a pre-filled syringe from the FDA, $25&#160;million upon the transfer of such approval to Sanofi, $25&#160;million upon the transfer of EMA approval of a COVID-19 Vaccine Product in a pre-filled syringe to Sanofi, $50&#160;million upon database lock of an existing Phase 2/3 clinical trial (identifier 2019nCoV-503), $75&#160;million upon the completion of the technology transfer of the Company&#8217;s manufacturing process for the COVID-19 Vaccine Products to Sanofi, and up to $350&#160;million in CIC Product-related development and launch milestones.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive development, launch, and sales milestone payments of up to $200 million for each of the first four Adjuvant Products and $210 million for each Adjuvant Product thereafter, and royalty payments on Sanofi&#8217;s sales of all such licensed products. In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, a portion of the technology transfer costs and research and development costs incurred by the Company will be reimbursed by Sanofi in accordance with agreed upon plans and budgets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed whether the Sanofi CLA fell within the scope of ASC 808,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) based on whether the arrangement involved joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. The Company determined that the Sanofi CLA did not fall within the scope of ASC 808, as the Company does not share in the significant financial risks of Sanofi's development or commercialization activities. The Company then analyzed the arrangement pursuant to the provisions of ASC 606 and determined that the arrangement represents a contract with a customer and is therefore within the scope of ASC 606.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations in the Sanofi CLA and determined that they were within the scope of ASC 606: delivery of (i) the licenses described above (the COVID-19 Vaccine license, CIC Products license, Other Combination Product license, and Adjuvant Products license) (collectively the &#8220;Sanofi CLA Licenses&#8217;), (ii) research and development transition services that support further regulatory approval and development of the COVID-19 Vaccine, referred to as the Sanofi Transition Services, and (iii) technology transfer of the existing manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#8482; adjuvant, referred to as the &#8220;Sanofi Technology Transfer&#8221;. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Sanofi and therefore are not considered separate performance obligations within the Sanofi CLA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sanofi CLA Licenses performance obligations are considered functional intellectual property and distinct from other promises under the contract as Sanofi can benefit from the licenses on their own or together with other readily available resources. Also, the Sanofi Transition Services provide a distinct benefit to Sanofi within the context of the contract, separate from the licenses, as the services could be provided by Sanofi or another third party without the Company&#8217;s assistance. The Sanofi Technology Transfer obligation is distinct as Sanofi can benefit from the Sanofi CLA Licenses transferred by the Company at the inception of the agreement with other readily available resources. Therefore, each represents a separate performance obligation within the contract with a customer under the scope of ASC 606 at contract inception.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price at inception of the Sanofi CLA to be $620.2&#160;million, consisting of (i) fixed consideration (the $500 million upfront nonrefundable fee), (ii) and $120.2&#160;million of variable consideration attributed to a $50.0&#160;million clinical milestone and $70.2&#160;million of estimated cost reimbursement related to Sanofi Transition Services and Sanofi Technology Transfer. Since the clinical milestone allocated to Sanofi Transition Services is entirely within the Company&#8217;s control, and the cost reimbursement variable consideration allocated to Sanofi Transition Services and Sanofi Technology Transfer would be recognized as revenue only as the costs are incurred, the Company determined it is not probable that a significant reversal of cumulative revenue would occur. The Company utilized the expected value method to determine the amount of these payments. The Company excluded certain regulatory and technology transfer milestones from the transaction price that were determined to be inherently uncertain of achievement and are highly susceptible to factors outside of the Company&#8217;s control. Sales-based royalties and launch milestones are related to the license of the intellectual property rights and the Company will recognize revenue for these in the period when subsequent sales are made or sale-based milestones are achieved pursuant to the sales-based royalty exception under ASC 606. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the fixed consideration (i.e., the $500 million nonrefundable upfront fee) to the performance obligations in the Sanofi CLA based on each performance obligation&#8217;s relative standalone selling price, or SSP, as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$386.3&#160;million for the upfront transfer of the licenses; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$110.2&#160;million for Transition Services; and</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">$3.5&#160;million for Technology Transfer. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SSP for the licenses were determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. In developing such estimates, the Company applied judgment in determining the forecasted revenues, expected margins, and the discount rate. The SSP for the ongoing Transition Services and Technology Transfer were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue related to the licenses at a point in time upon transfer of the rights and control of the license to Sanofi during the second quarter 2024. The Sanofi Transition Services and Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Technology Transfer for the three and six month period ended June&#160;30, 2024 was $6.6&#160;million. The Company&#8217;s consolidated balance sheet as of June&#160;30, 2024 includes a deferred revenue balance of $109.2&#160;million ($50.9&#160;million included in Deferred revenue, current portion and $58.3&#160;million included in Deferred revenue, non-current portion) related to Transition Services and Technology Transfer.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an asset for $35.0&#160;million of direct costs incurred to obtain the Sanofi CLA. These costs are amortized to expense over the expected period of the benefit in a manner that is consistent with the transfer of the related goods and services in the Sanofi CLA. The Company recognized $27.1&#160;million of amortization expense related to the asset in Selling, general, and administrative expense in the second quarter of 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, 6,880,481 shares of the Company&#8217;s common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to the Company of $68.8 million. The opening price of the Company&#8217;s common stock on the date of the sale approximated $10.00 per share and therefore all gross proceeds were allocated to stockholders&#8217; deficit. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Medical Research Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into a three-year agreement with the Bill &amp; Melinda Gates Medical Research </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute to provide the Company&#8217;s Matrix-M&#8482; adjuvant for use in preclinical vaccine research. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;) and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Settlement Agreement&#8221;) to resolve disputes regarding amounts that Fujifilm claimed were due under a prior Confidential Settlement Agreement and Release effective September 30, 2022 (the &#8220;CSAR&#8221;) by and between the Company and Fujifilm.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CSAR, the Company agreed to pay up to $185.0 million to Fujifilm in connection with the cancellation of manufacturing activity at FDBT. The final two quarterly installments due to Fujifilm in 2023 under the CSAR, totaling $68.6 million, were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT. In October 2023, the Company sent Fujifilm a notice of breach and refused to pay the final two installments based on its contention that Fujifilm had not used commercially reasonable efforts to mitigate losses and should have offset some portion of the final two payments. In October 2023, Fujifilm filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the full amount (the &#8220;Fujifilm Arbitration&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement, in March 2024, the Company paid $42.0 million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the CSAR, and Fujifilm agreed to dismiss the Fujifilm Arbitration. This payment is less than amounts previously accrued for and reflected in Research and development expense, and accordingly, the Company recorded a benefit of $26.6 million as Research and development expense during the six months ended June&#160;30, 2024 upon the execution of the Settlement Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Program, and in doing so, recognizes that significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434502464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) per Share</span><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share data):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,897)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities excluded from calculations of diluted net income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196433945648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted Cash<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2024 and December&#160;31, 2023, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196530982640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:60.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments, offset by recoveries of such commitments, are recorded as a component of cost of sales in the Company&#8217;s consolidated statements of operations. For the three and six months ended June&#160;30, 2024, inventory write-downs were $9.7&#160;million and $18.5&#160;million, respectively, and losses on firm purchase commitments were $1.7&#160;million. For the three and six months ended June&#160;30, 2023, inventory write-downs were $19.1&#160;million and $31.5&#160;million, respectively, and losses on firm purchase commitments were $0.7&#160;million and $8.5&#160;million. In addition, for the three and six months ended June&#160;30, 2023 the Company recorded recoveries on firm purchase commitments of $17.9&#160;million and $18.8&#160;million, respectively, related primarily to negotiated reductions to previously recognized firm purchase commitments<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434566304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reporting unit, which has a negative carrying amount as of June&#160;30, 2024 and December&#160;31, 2023. The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2024 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,077)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434037872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate of the 2027 Convertible notes is 6.2%. During the six months ended June&#160;30, 2023, the Company repaid the outstanding principal amount of $325.0&#160;million on its 3.75% Convertible notes due in 2023, together with accrued </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but unpaid interest on the maturity date. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the convertible notes payable&#160;consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434540384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">Stockholders&#8217; Deficit<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an At Market Issuance Sales Agreement (the &#8220;August 2023 Sales Agreement&#8221;), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the three and six months ended June&#160;30, 2024, the Company sold $12&#160;million shares of its common stock resulting in net proceeds of approximately $188&#160;million, under the August 2023 Sales Agreement. As of June&#160;30, 2024, the remaining balance available under the August 2023 Sales Agreement was approximately $51&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2023, the Company sold </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million shares of its common stock under its June 2021 Sales Agreement resulting in net proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$68&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which $6&#160;million was included in prepaid expenses and other current assets as of June&#160;30, 2023 and received in cash in July 2023.</span></div>In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, 6,880,481 shares of the Company&#8217;s common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to the Company of $68.8&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434541696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company established the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved 1.0&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of June&#160;30, 2024, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under the 2023 Inducement Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to 27.5&#160;million shares of common stock under equity awards granted under the 2015 Plan. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on April&#160;18, 2034. As of June&#160;30, 2024, there were 9.4&#160;million shares available for issuance under the 2015 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Inducement Plan and the 2015 Plan permit, and the 2005 Plan permitted, the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock units (&#8220;RSUs&#8221;). In addition, under the 2023 Inducement Plan and the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of share-based awards are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:f-743">one</span> to four years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024 and 2023, there was no stock-based compensation expense capitalized into inventory. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, there was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$73&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately one year and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2024. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2024 and 2023 was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $2 million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan, and 2005 Plan for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,787,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">703,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(329,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(518,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(57,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,642,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.06&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,076,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.67&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.67&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.13</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.86</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%-3.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%-4.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4%-131.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.3%-121.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.4%-140.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9-6.4</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $12.3&#160;million and 7.0 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $3.7&#160;million and 6.0 years, respectively. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,714,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,441,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(921,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(605,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,629,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June 2013. The ESPP currently authorizes an aggregate of 2.2 million shares of common stock to be purchased, and the aggregate number of shares will continue to increase 5% on January 1 of each year up to a maximum of 3.5 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). As of June&#160;30, 2024, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434094400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. Significant pieces of objective evidence evaluated by the Company were the cumulative loss incurred over the three-year period ended June&#160;30, 2024 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2024, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#8220;NOLs&#8221;) have been used to reduce taxable income. As of June&#160;30, 2024, the Company has $2.3&#160;billion of U.S. Federal NOLs carryforward, and all are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), which limits allowable NOL deductions to 80% of federal taxable income. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023, the Company recognized $2.2&#160;million and $(0.1)&#160;million of federal, state, and foreign income tax expense (benefit), respectively. During the six months ended June&#160;30, 2024 and 2023, the Company recognized $4.5&#160;million and $1.0&#160;million of federal, state, and foreign income tax expense, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434067504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contingencies</span><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $47&#160;million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024. Ahead of the May 23 settlement hearing, on April 11, 2024, Plaintiffs filed a motion seeking the Maryland Court&#8217;s final approval of the settlement. At the May 23 settlement hearing, the Maryland Court granted final approval of the settlement. The Maryland Court closed the Sinnathurai Action on May 24, 2024. Upon the Maryland Court&#8217;s final approval, the Company relieved the $47&#160;million estimated settlement liability within Accrued expenses and the $47&#160;million estimated insurance recovery within Prepaid expenses and other current assets on the consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Needleman Action was also filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order, and, on April 15, 2024, the court entered a further order extending the stay until June 6, 2024. On June 7, 2024, the court entered another order extending the stay until August 5, 2024. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint. On August 5, 2024, the parties agreed to a further 90-day extension to November 4, 2024, which remains subject to court approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, following the ruling on the motion to dismiss the Sinnathurai Action, the Delaware Court entered an order granting the Mesa Action parties&#8217; request to set a briefing schedule in connection with a motion to stay by defendants. On February 28, 2023, the court granted the defendants&#8217; motion and stayed the Mesa Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On August 31, 2023, the Mesa plaintiffs filed a motion to lift the stay in the Mesa Action. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. On May 3, 2024, the plaintiffs filed a consolidated complaint. On May 14, 2024, the parties filed a stipulation staying the action until June 6, 2024. On July 12, 2024, the court entered an order staying the action until August 5, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the above derivative claims is not reasonably estimable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434589376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring </span><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a global restructuring and cost reduction plan (the &#8220;2023 Restructuring Plan&#8221;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#8217;s global workforce, as well as the consolidation of facilities and infrastructure. In January 2024, the Company announced further reductions to its global workforce which supplemented the 2023 Restructuring Plan and both are jointly referred to as the &#8220;Restructuring Plan.&#8221; </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following restructuring charge related to the Restructuring Plan in the consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:41.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Restructuring charges of $0.5&#160;million, $0.3&#160;million and $0.3&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $1.9&#160;million and $4.8&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the six months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $2.7&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and employee benefit costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the reporting period and had no requirements for future service. The Company paid a total of $5.5&#160;million for the severance and employee benefit costs during the six months ended June&#160;30, 2024 and had no remaining liability as of June&#160;30, 2024 or December&#160;31, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The Company performed an impairment evaluation for the applicable long-lived assets, which is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the six months ended June&#160;30, 2024, the Company recorded an impairment charge of $1.7&#160;million related to the impairment of capitalized internal-use software. During the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded an impairment charge of $10.1&#160;million related to the impairment of </span></div>long-lived assets, including $5.9&#160;million related to ROU assets for facility leases. The Company did not recognize any impairment of assets related restructuring charges during the three months ended June&#160;30, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434611280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, Pharmac provided notice of its termination of the New Zealand APA (see Note 5).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196433998560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 162,381<span></span>
</td>
<td class="nump">$ 58,008<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196429610256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nvax_JohnC.JacobsMember', window );">John C. Jacobs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John C. Jacobs, President and Chief Executive Officer</span></div>On May 28, 2024, John C. Jacobs, our President and Chief Executive Officer and a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Jacobs, acting through a broker, may sell up to an aggregate of 47,526 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 27, 2024 to April 30, 2025. The plan is scheduled to terminate on April 30, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Jacobs or the broker, or as otherwise provided in the plan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">John C. Jacobs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Executive Officer and a member of our board of directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On May 28, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 30, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">246 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">47,526<span></span>
</td>
<td class="nump">47,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nvax_JohnTrizzinoMember', window );">John Trizzino [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Trizzino, President and Chief Operating Officer</span></div>On June 17, 2024, John Trizzino, our President and Chief Operating Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Trizzino, acting through a broker, may sell up to an aggregate of 218,669 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from September 16, 2024 to May 7, 2025. The plan is scheduled to terminate on May 7, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Trizzino or the broker, or as otherwise provided in the plan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">John Trizzino<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Operating Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On June 17, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 7, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">218,669<span></span>
</td>
<td class="nump">218,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nvax_FilipDubovskyMember', window );">Filip Dubovsky [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filip Dubovsky, MD, Former President, Research &amp; Development</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2024 , Filip Dubovsky, MD, our former President, Research &amp; Development, terminated a Rule 10b5-1 trading plan that he had originally adopted on December 12, 2023. The plan was for the sale of up to 13,365 shares of our common stock. Sales under the plan were scheduled to occur from March 15, 2024 to June 14, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Filip Dubovsky<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">MD, our former President<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">May 10, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">233 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">13,365<span></span>
</td>
<td class="nump">13,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nvax_JohnC.JacobsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nvax_JohnC.JacobsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nvax_JohnTrizzinoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nvax_JohnTrizzinoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nvax_FilipDubovskyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nvax_FilipDubovskyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196433982192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive income (loss), changes in stockholders&#8217; deficit, and cash flows for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were a $1.6&#160;million loss and a $6.7&#160;million loss, and a $0.2&#160;million loss and $16.1&#160;million gain for the three and six months ended June&#160;30, 2024 and 2023, respectively, which are reflected in Other income (expense).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2023. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span id="id646a6b9d9154d26bde005a7bb4415f3_15397"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company entered into the Sanofi CLA and a securities subscription agreement (the &#8220;Subscription Agreement&#8221;) with Sanofi as a result of which, the Company received a total of $568.8 million during the second quarter of 2024 (See Note 6).  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had $680.2 million in cash and cash equivalents, $369.4 million in marketable securities, and working capital of $45.6 million. During the six months ended June&#160;30, 2024, the Company recognized net income of $14.8 million, and had net cash flows provided by operating activities of $230.7 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Based on the Company&#8217;s current cash and cash equivalents and marketable securities balances and its current cash flow forecast for the one-year going concern look forward period, the Company has concluded that it will have sufficient capital available to fund its operations for the one-year period from the date that these financial statements are issued. As of December 31, 2023, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to significant uncertainty related to its ability to successfully develop, manufacture, distribute, and market its updated vaccine and execute on certain cost-reduction initiatives as described in Note 16. The Sanofi CLA has alleviated the substantial doubt.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Licensing and Transition Services</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Licensing and Transition Services</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s third-party licensing agreements may contain multiple performance obligations, including licenses and transition services. The Company evaluates licensing agreements under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;) to determine the distinct performance obligations. Prior to recognizing revenue, the Company estimates the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple performance obligation arrangements, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, the Company considers discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, the Company applies judgment in determining the forecasted revenue, expected margins, and the discount rate. These estimates are subjective and require the Company to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset. For performance obligations recognized over time, the Company recognizes revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, the Company considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, and indirect administrative costs. Estimating the total cost at completion of the Company&#8217;s performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on the Company&#8217;s contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. The Company has not experienced any material adjustments as a result of changes in estimates arising from this process.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring</a></td>
<td class="text"><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div>The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities, and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196529852768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investments classified as available-for-sale</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities were classified as available-for-sale as of June&#160;30, 2024 and comprised of (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369,582&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(150)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369,432&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196548151200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,587</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as cash and cash equivalents as of June 30, 2024 and December 31, 2023, respectively, on the consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span>Includes $232.0 million classified as Cash and cash equivalents and $369.4&#160;million classified as marketable securities as of June&#160;30, 2024, on the consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196530104544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock', window );">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</a></td>
<td class="text">During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#8217;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,849)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;There was no allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $6.2 million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div>(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $2.2&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $225.0&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:34.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,586</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,785</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,397</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,921</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock', window );">Schedule of Revenue Gross to Net Deductions Balances</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits/deductions </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of June&#160;30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,587&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $4.0&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants, U.S. Government Contract and Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue Gross To Net Deductions Balances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434607920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share data):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss), dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,897)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, dilutive</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities excluded from calculations of diluted net income (loss) per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196531867456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Classified as Other non-current assets as of June&#160;30, 2024 and December&#160;31, 2023, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196515530352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:60.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196515690304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2024 was as follows (in thousands):<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,077)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196434610784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Notes Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense incurred in connection with the convertible notes payable&#160;consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon interest </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196432765152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option and Appreciation Rights Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan, and 2005 Plan for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2005&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,787,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">703,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(329,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(518,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(57,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,642,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.06&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,076,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.67&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.67&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Estimation of Fair Value of Stock</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.13</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.86</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%-3.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%-4.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4%-131.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.3%-121.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.4%-140.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9-6.4</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock', window );">Schedule of Share Based Compensation Restricted Stock Awards Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Inducement&#160;Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015&#160;Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per&#160;Share<br/>Weighted-<br/>Average<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,714,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,441,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(921,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(605,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,629,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Restricted Stock Awards Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196427387584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following restructuring charge related to the Restructuring Plan in the consolidated statements of operations (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:41.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Restructuring charges of $0.5&#160;million, $0.3&#160;million and $0.3&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $1.9&#160;million and $4.8&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the six months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $2.7&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three and six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2023</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196429590032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax', window );">Foreign currency transaction gain (loss)</a></td>
<td class="num">$ (1,600)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="num">$ (6,700)<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">680,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">369,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_WorkingCapital', window );">Working capital</a></td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">162,381<span></span>
</td>
<td class="nump">$ 58,008<span></span>
</td>
<td class="nump">14,831<span></span>
</td>
<td class="num">(235,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,714<span></span>
</td>
<td class="num">$ (497,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsFromCollaborationAndLicenseAgreement', window );">Proceeds from collaboration and license agreement</a></td>
<td class="nump">$ 568,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProceedsFromCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration And License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProceedsFromCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196429320320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost&#8203;</a></td>
<td class="nump">$ 369,582<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair&#160;Value&#8203;</a></td>
<td class="nump">$ 369,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, number of positions | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost&#8203;</a></td>
<td class="nump">$ 369,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair&#160;Value&#8203;</a></td>
<td class="nump">$ 369,432<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428983840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nvax_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 369,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 188,086<span></span>
</td>
<td class="nump">$ 171,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">5.00% Convertible notes due 2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">188,086<span></span>
</td>
<td class="nump">171,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">826,466<span></span>
</td>
<td class="nump">245,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">5.00% Convertible notes due 2027</a></td>
<td class="nump">217,587<span></span>
</td>
<td class="nump">100,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">601,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">5.00% Convertible notes due 2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nvax_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nvax_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nvax_GovernmentBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nvax_GovernmentBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196422615024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RemainingPerformanceObligationAmount', window );">Amount of transaction price not yet satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,821,000<span></span>
</td>
<td class="nump">$ 907,410,000<span></span>
</td>
<td class="nump">1,199,821,000<span></span>
</td>
<td class="nump">$ 907,410,000<span></span>
</td>
<td class="nump">863,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,484,000<span></span>
</td>
<td class="nump">424,426,000<span></span>
</td>
<td class="nump">509,339,000<span></span>
</td>
<td class="nump">505,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=nvax_MatrixMAdjuvantSalesMember', window );">Matrix-M Adjuvant Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,952,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,904,000<span></span>
</td>
<td class="nump">285,163,000<span></span>
</td>
<td class="nump">102,228,000<span></span>
</td>
<td class="nump">277,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,755,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_LicenseFeesMember', window );">License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_TransitionServicesMember', window );">Transition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, expense</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember', window );">Australian APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember', window );">Australian APA | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember', window );">Australian APA | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember', window );">Australian APA | Australia Revenue Agency Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer refund liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember', window );">Canada APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember', window );">Canada APA | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer refund liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_NewZealandTerminationOfTheAgreementMember', window );">New Zealand, termination of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_NewZealandTerminationOfTheAgreementMember', window );">New Zealand, termination of the agreement | New zealand Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer refund liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Transition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Transition services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">US Government Partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RemainingPerformanceObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Performance Obligation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RemainingPerformanceObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=nvax_MatrixMAdjuvantSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=nvax_MatrixMAdjuvantSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_TransitionServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_TransitionServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nvax_AustraliaRevenueAgencyMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nvax_AustraliaRevenueAgencyMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_NewZealandTerminationOfTheAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_NewZealandTerminationOfTheAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nvax_NewZealandRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nvax_NewZealandRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428747360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,916,000<span></span>
</td>
<td class="nump">$ 96,210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,326,000<span></span>
</td>
<td class="nump">793,039,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(937,462,000)<span></span>
</td>
<td class="num">(486,684,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, ending balance</a></td>
<td class="nump">$ 39,780,000<span></span>
</td>
<td class="nump">$ 402,565,000<span></span>
</td>
<td class="nump">39,780,000<span></span>
</td>
<td class="nump">402,565,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for doubtful accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,675,000)<span></span>
</td>
<td class="num">(13,835,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses, end balance</a></td>
<td class="num">(7,675,000)<span></span>
</td>
<td class="num">(7,675,000)<span></span>
</td>
<td class="num">(7,675,000)<span></span>
</td>
<td class="num">(7,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,520,000<span></span>
</td>
<td class="nump">549,551,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,150,000<span></span>
</td>
<td class="nump">414,816,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,849,000)<span></span>
</td>
<td class="num">(56,957,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">1,199,821,000<span></span>
</td>
<td class="nump">907,410,000<span></span>
</td>
<td class="nump">1,199,821,000<span></span>
</td>
<td class="nump">907,410,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Contract with customer, liability, deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,849,000<span></span>
</td>
<td class="nump">56,957,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,150,000<span></span>
</td>
<td class="nump">$ 414,816,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember', window );">Joint Committee on Vaccination and Immunization (JCVI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Contract with customer, liability, deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196427642400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 415,484<span></span>
</td>
<td class="nump">$ 424,426<span></span>
</td>
<td class="nump">$ 509,339<span></span>
</td>
<td class="nump">$ 505,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Reduction in product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">19,904<span></span>
</td>
<td class="nump">285,163<span></span>
</td>
<td class="nump">102,228<span></span>
</td>
<td class="nump">277,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Reduction in product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,755)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">90,586<span></span>
</td>
<td class="nump">58,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 18,128<span></span>
</td>
<td class="nump">$ 283,645<span></span>
</td>
<td class="nump">$ 16,397<span></span>
</td>
<td class="nump">$ 218,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428795872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Credits/deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">1,199,821<span></span>
</td>
<td class="nump">1,199,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Credits/deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Wholesale Distributor Fees, Discounts, and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Credits/deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Product Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Credits/deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">$ 54,587<span></span>
</td>
<td class="nump">$ 54,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AmountsChargedAgainstProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Charged Against Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AmountsChargedAgainstProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_ProductReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_ProductReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196425673248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements (Details)<br> $ / shares in Units, $ in Thousands, dose in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 10, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,484<span></span>
</td>
<td class="nump">$ 424,426<span></span>
</td>
<td class="nump">$ 509,339<span></span>
</td>
<td class="nump">$ 505,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customer, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,272<span></span>
</td>
<td class="nump">61,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,946<span></span>
</td>
<td class="nump">$ 219,475<span></span>
</td>
<td class="nump">199,625<span></span>
</td>
<td class="nump">$ 466,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_LicenseFeesMember', window );">License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_TransitionServicesMember', window );">Transition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_TransferOfTechnologyMember', window );">Transfer of Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember', window );">Takeda Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementInitialTransactionPrice', window );">Initial transaction price at inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementVariableConsideration', window );">collaboration agreement variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">6,880,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">$ 68,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Licensed COVID-19 Products and Royalty Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Transfer of EMA Approval of the COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Database lock of an Existing Phase 2/3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Completion of the Technology Transfer of the Company&#8217;s Manufacturing Process for the COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | CIC Product-Related Development and Launch Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | First Four Adjuvant Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Adjuvant Products Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments', window );">Development, tech transfer, launch, and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Transition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Transition services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customer, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Clinical Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Cost reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember', window );">Sanofi Pasteur Inc. APA | Product and Service, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember', window );">Bill &amp; Melinda Gates Medical Research Institute Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfQuarterlyInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementInitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Initial Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementInitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfQuarterlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Quarterly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfQuarterlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_TransitionServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_TransitionServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_TransferOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_TransferOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SanofiPasteurInc.APAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_FirstFourAdjuvantProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_FirstFourAdjuvantProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_AdjuvantProductsThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_AdjuvantProductsThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_ClinicalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_ClinicalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_CostReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_CostReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196422570000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss), basic</a></td>
<td class="nump">$ 162,381<span></span>
</td>
<td class="nump">$ 58,008<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Interest on convertible notes</a></td>
<td class="nump">2,608<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDiluted', window );">Net income (loss), dilutive</a></td>
<td class="nump">$ 164,989<span></span>
</td>
<td class="nump">$ 60,590<span></span>
</td>
<td class="nump">$ 14,831<span></span>
</td>
<td class="num">$ (235,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">&#8203;Weighted average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">148,379<span></span>
</td>
<td class="nump">89,362<span></span>
</td>
<td class="nump">144,147<span></span>
</td>
<td class="nump">87,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">17,476<span></span>
</td>
<td class="nump">14,703<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">&#8203;Weighted average number of common shares outstanding, dilutive (in shares)</a></td>
<td class="nump">165,855<span></span>
</td>
<td class="nump">104,065<span></span>
</td>
<td class="nump">145,121<span></span>
</td>
<td class="nump">87,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculations of diluted net income (loss) per share (in shares)</a></td>
<td class="nump">4,544<span></span>
</td>
<td class="nump">6,791<span></span>
</td>
<td class="nump">21,654<span></span>
</td>
<td class="nump">23,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428018368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 680,162<span></span>
</td>
<td class="nump">$ 568,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current</a></td>
<td class="nump">10,486<span></span>
</td>
<td class="nump">10,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">4,910<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 695,558<span></span>
</td>
<td class="nump">$ 583,810<span></span>
</td>
<td class="nump">$ 517,941<span></span>
</td>
<td class="nump">$ 1,348,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428009440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Semi-finished goods</a></td>
<td class="nump">7,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">9,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Firm purchase commitment loss</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryFirmPurchaseCommitmentRecoveries', window );">Inventory, firm purchase commitment, recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryFirmPurchaseCommitmentRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Firm Purchase Commitment, Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryFirmPurchaseCommitmentRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428739696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting unit | reporting_unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 127,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(4,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 123,377<span></span>
</td>
<td class="nump">$ 127,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196427715040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt -Schedule of Convertible Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">$ (6,402)<span></span>
</td>
<td class="num">$ (7,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Total convertible notes payable</a></td>
<td class="nump">$ 168,848<span></span>
</td>
<td class="nump">168,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 175,250<span></span>
</td>
<td class="nump">$ 175,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196430058128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">Convertible notes due 2023 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196427683392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt -Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest</a></td>
<td class="nump">$ 2,192<span></span>
</td>
<td class="nump">$ 2,191<span></span>
</td>
<td class="nump">$ 4,384<span></span>
</td>
<td class="nump">$ 5,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense on convertible notes payable</a></td>
<td class="nump">$ 2,608<span></span>
</td>
<td class="nump">$ 2,582<span></span>
</td>
<td class="nump">$ 5,216<span></span>
</td>
<td class="nump">$ 6,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196431365680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,272<span></span>
</td>
<td class="nump">$ 61,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Sale of common stock under the Sales Agreement not settled at quarter-end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Subscription Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">6,880,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share, price per share (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">$ 68,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | August 2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SaleOfStockAmountOfRemainingUnissuedShares', window );">Remaining unissued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | June 2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 188,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SaleOfStockAmountOfRemainingUnissuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Amount Of Remaining Unissued Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SaleOfStockAmountOfRemainingUnissuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_August2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_August2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196422581472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock options and vesting RSA's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining term, outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease', window );">Percentage increase of shares each anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Subscription rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Maximum discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember', window );">2023 Inducement&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Remaining term, exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196426353696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,099<span></span>
</td>
<td class="nump">$ 20,292<span></span>
</td>
<td class="nump">$ 25,655<span></span>
</td>
<td class="nump">$ 48,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,177<span></span>
</td>
<td class="nump">9,946<span></span>
</td>
<td class="nump">11,682<span></span>
</td>
<td class="nump">23,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,818<span></span>
</td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 12,275<span></span>
</td>
<td class="nump">$ 23,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196422538784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember', window );">2023 Inducement&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">422,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">422,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares) | shares</a></td>
<td class="nump">124,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">10.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 11.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">4,787,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">703,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(329,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(518,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">4,642,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares) | shares</a></td>
<td class="nump">3,076,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 38.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">7.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">8.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">46.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">34.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 43.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember', window );">2005&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">58,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(57,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares) | shares</a></td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 119.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">119.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">108.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 108.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196419238560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)</a></td>
<td class="nump">$ 14.13<span></span>
</td>
<td class="nump">$ 6.79<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 7.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">121.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.40%<span></span>
</td>
<td class="nump">114.30%<span></span>
</td>
<td class="nump">120.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.30%<span></span>
</td>
<td class="nump">121.80%<span></span>
</td>
<td class="nump">140.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196425504272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">2023 Inducement&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">363,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(102,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, ending balance (in shares) | shares</a></td>
<td class="nump">261,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per&#160;Share Weighted- Average Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">10.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">2015&#160;Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">3,714,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">4,441,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(921,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="num">(605,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested, ending balance (in shares) | shares</a></td>
<td class="nump">6,629,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per&#160;Share Weighted- Average Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 19.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">5.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">24.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">18.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested, ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 9.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196428803488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Federal, state and local, income tax expense (benefit)</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196422545168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LossContingencyPeriodToAnswer', window );">Period to answer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of lawsuits filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LossContingencyExtensionPeriod', window );">Loss contingency extension period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LossContingencyExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LossContingencyExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LossContingencyPeriodToAnswer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Period To Answer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LossContingencyPeriodToAnswer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196429023280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring -Schedule of Restructuring and Related Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="nump">$ 1,119<span></span>
</td>
<td class="nump">$ 4,643<span></span>
</td>
<td class="nump">$ 5,520<span></span>
</td>
<td class="nump">$ 4,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">10,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">14,724<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">14,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140196431949120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts', window );">Payments for severance and employee benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="nump">$ 1,119,000<span></span>
</td>
<td class="nump">$ 4,643,000<span></span>
</td>
<td class="nump">5,520,000<span></span>
</td>
<td class="nump">$ 4,643,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,081,000<span></span>
</td>
<td class="nump">1,669,000<span></span>
</td>
<td class="nump">$ 10,081,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PaymentsForSeveranceAndEmployeeBenefitCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Severance And Employee Benefit Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PaymentsForSeveranceAndEmployeeBenefitCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#+R,&VG)!R0I[=(A%+#7-_*BP4UY:<E+Z_!.?!_4DZ/] ?D(SY'/L3FON.3
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M()V2G/HJ"=&%X<%B'50QL:OB_3%J\]K4J#A@$=.% 813B[DQ+T$XRC#1QRB
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M(:58MS]7/%OPJ@&H_Y="R.U!<X'=RWJS?P%02P,$%     @ H#P(6<XX7FO
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M2Q.'(P/!HS:P&@.K:S!\Q<!N#.RWKC!L#(9O7<%I#"KI>JV]"EP .?2GE!P
ME6C!)E^JZ%?6(EX9EOLDXE3\FPD[[L]7RVCU<1'</H4!B)[$XSY</D5@]1[,
M5_</C^&'<!DM/H=@L13C$%Q]7$71-1B 3U$ KMY=@W<@P^ I)26#.&%3G0NG
M)+4>-P[<U0Y8KSA@@WN"><I B!.4*.R#\_;N&7M=!*.-B/42D3OK+.%O);X!
MMO$+L QKJ/!G_G9S6R7G_ZT>_N?53X)AM]O#KOCL5_@B#CD298$#L@%S4HA:
ME,HBL4=@@6-2(/#'[9IQ*K[W/U6YK]F':G99 R=L!V,TTP0Q0W2/-/_GGTS7
M^%45^$N2!9<D"R]$=I*B89NBX3EV?RD.DZS.Q55.&+M6Y:&F<"L*>73L?=.U
M;,^<ZOOC"/=ACF<8WBDJ4) -/;O#%?91 \MVO/&HQ9W(=5JYSMD=N>(IHB ^
MV8HG\B<J_<XE]^$ER8)+DH47(CM)C-LFQOWA/BRQZ%7R[!^4 )D+(#N!/<QR
MN,[10#0U P9S)(XO^HRXG ,,Q27->(:4)T>]H'.\A4S'Z.S9/JB#"-Y"$YZC
M.8G'J(W'Z&P\1!\CNA0L#G%*$8Z_ E$E,<MAW1\E?XFS7196E>Y1SY>A.^K(
M[F,&CF%V/L) @3)MP^N*5\'$AZ\.@-<&P#L;@!]^J2KI7L\3V^Q*[V-4TA4H
MT[;LKG05[%7IXU;Z^*ST^;\3/5959W?<J;OS/LRQQN-.= (5F=$MSGV0*,XC
MMU><]:/.LD!T6[7T3"2UQ+SN(MK9]M9P6S7+G?D[<S(W%?.!N&74EX+O]/45
MY1[2;889R-%&+&7<C$2.:-WVUP-.=E5?NR9<=,G5:RIN2HA*@/A_0PA_&<@%
MVKN7_PU02P,$%     @ H#P(6>B;-A D!P  #!X  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RM66UOVS80_BN$5VP=X-1\D2BI30RD2;=UV-JBR;;/
MBLS$0F71):FDV:_?47(L6:28!.N'-I)U/#UW/-[SD#J^D^J+7@MAT+=-5>N3
MV=J8[>O%0A=KL<GU*[D5-3RYEFJ3&[A5-PN]52)?M8,VU8)BS!>;O*QGR^/V
MMT]J>2P;4Y6U^*20;C:;7-V_%96\.YF1V<,/G\N;M;$_+);'V_Q&7 CSU_:3
M@KO%WLNJW(A:E[)&2ER?S$[)ZS/&[8#6XN]2W.G!-;*A7$GYQ=Z\7YW,L$4D
M*E$8ZR*'/[?B3%25]00XONZ<SO;OM .'UP_>?VF#AV"N<BW.9/5/N3+KDUDZ
M0RMQG3>5^2SO?A.[@&+KKY"5;O]'=SM;/$-%HXW<[ 8#@DU9=W_S;[M$# :0
M:&( W0V@3QW =@-8&VB'K WK/#?Y\EC).Z2L-7BS%VUNVM$035G;:;PP"IZ6
M,,XLSSY^N/CXQ_OST\MWY^CMZ1^G'\[>H8O?WKV[O$!'Z*^+<_3RQ<_H!2IK
M=+F6C<[KE3Y>&'BS';\H=F]YV[V%3KSE]Z9^A1B>(XIIY!E^%AY^+@H83MKA
M['#X N+=!TWW0=/6'YL*NE%*U ;E6@NC7_OBZ1Q$?@=V;;W6V[P0)S-8/%JH
M6S%;_O@#X?B-+[KOY.P@5K:/E86\+\]RO48P:ZBP%^)K4][F%03OG<7.%6]=
MV09PN^0I)IP>+VZ'\;AF,4]C'._-#I!&>Z11$.F?N?HB3'Y5":1%T:C2E,*+
MLG,3#U[/>!:Q,4K7#/L!QGN <1#@9Z&-*@LCNF3ZH,7..PF.4CY"YK6R"\.'
MCN_1\2"ZTZ*0#<PK--="P"1#'GT(N9L\2@93UR%TK6B6T&@B@<D>8A*$^+Z^
MA<J3ZMX'+'%>F9%D/*>N441XQOVPTCVL- CKDQ+;O%PA\0W(40O=+A=IUD)!
M!QYV"A_LU#.7%!,V NZ:4<K;;N9#GNV19T'DE]+DU1- 9BY(BAE+\ BEQXY$
M+$U3/TR">Y;!CZ08A(<R]VUJ;1/:@A0P<U0+XV43[*8K3>,X&^'UV#$<)PF9
MP#M@11)>ZI;]D;Q&C19=7J>Q$C=I/(MQ,L;JL4MC2J9RVY,9"?+'\E<I5W=E
M57G!4<_,P\0[X'QV211/]"32LP\)T\_'=AG5LCYZO$IWK@YFDZ5LO)1\9C$9
MU,8AU)Y^2)A_NL44@.<2"DE)RJ-Q>_<9)ED291/MD_0$1.(G"9>JS*_*JB5(
MKWHA02)[KGSY7MX.@^YYC3R1V+;Y_12K$9>PDBQSA(O'C##*R=3$],1&PLP&
M&%4C>@KQ8G3)"ZJ64C(&Z=JQ+.)\JE'T-$?"/'<NK@74SPH4 O!PXT^D2U2<
M<Y:-F<)C1R/")C/9,QH)4]I#B6^E:O=YT(.ORSJO"X$J ?NU8>U[ W Y+(NH
MT^]<JYA$U ^>]C1'PS3W\4 T/(*4>D@NHBD9UX/'+N4DPA/U0'N2HV&2.U0/
MCZ'UT!>)$P]<'Q]"@V93> >[MC#1/:5^J4MD,6,1<U"Z=IS"6IRH7]H3'GUD
MOR5!Y$+IVFU,+8T(MBWJ4AGA:1JE8[1>.]B93:#M.8^&.>_#@)B?M<RHRW%Q
ME#F"TF<&/6]"]M*>"&EX*^;*BL?PNGLNQF*:C1G":T?85%GT)$;#)-:MM<=
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M*^$Z0,W/&)//'5T6E66P_Q=02P,$%     @ H#P(6==M,45?"P  -V,  !@
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M8';H!^T5/92*5FV&;$K5B G_V, [UV8?N\=!AI,TC2:\,R!TZ(?HVT84.^B
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M<X&=S! !SI<:VV!S0PKBM[&+_P%02P,$%     @ H#P(635G.%BK#P  1"P
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M_&O?SHN+TUEQ?GI^^0EY%\/F+UC>Q0%Y>W99_/-ZX8.#L_QKWX9%WN5^>11
MW_I.E?KE$2+$:[?11Z_^^(>SJ]/O/J'MY:#MY:>D_S^/ZC\ENWBMO/$T\"UM
ML0V*H^MNK1%AI6TZU6YI?-^JOC)!5T5I6X_)E:(?2].JMC2J+CQF:H1W\,5:
M;72QT+HM8+9..8PS+8MS%49KQ$18%RO=:J?J>DMO=$?2U*A?YPSD=C4TQ-P
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MY>CYRRD^3P_\IN2=#OZ.\"3+//^*_WB3_/ADB #)5*Y*7$' _V[EE4Q37 C
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MV?)*"YT)$+\LVBKXJ% K."@=3G[;@T!*DE" .\MW:@6'RXPD\\9B8P2]KF9
MH.T.9ZCHU!K>13C@<,B)@198%_FNQ:_11F:R@&/?AX#CA@:%%KWV^1R1 _"2
M?XA_Y\M4;01O@:H>(6>#>Z?*+?[;P!<)H/I.EH_0PC&H20>_,U@"C4O(-:M4
M:(TG%Q[:=94E9.>J/1P<C/Y>W*,_H$,V<4N"BFUA!O#P'ED5#@"?PPJI$F",
M "/(.8\X@W ZN7:$\6PP_,Y#,"U[H4/06\=ID%?+LDPE+49T^EG<*K0ZB=)
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M\GCX A^A/T<O4 =DI2Q(WM!^9]$U\"2HJ%%TBHL$K^ >_K607=E PQHMRP/
MGYP/O=(GKJ'%PM4ODUL"\(/1]9>DC.Q>B+ZE1&62(H^)#6 %,+FO"HA3D# ]
M& +&*//R?B\=8I?W#JL4!Q2HT$@WKM1>$(?8D.?];Y?_ 6VS(H):%=X1;+'?
M@+DA?)O1U'D:4FXG\XL@S!Q$;[+HM5P6E2CN [/@/*Z0,B+Z) O@>;:5R'$W
MWIY=@AUI6K86^;J>]SBVBQN;9@D>L]FT'XMBJ4I6\8C?E91H/8Q;!F(KA<9'
MEZ">&+%,'C ]$1A0M0.5 JX:/H*<$#.KDWXEA7:G-(;I:$LRX^?2@4*(!M'[
M$&OCT*#:/<A&58@^\PE913#T.T6&GA8%K^@+&+\5F)4/5:$K 8@QKD(OONH$
M4IJ";31\: '7N=/(N! M H<_54]10A5ZEJ!E C?$/DQ2,K-L8?5TN-->*+*(
M#6[!@YXJ6-_%UE[9P].@<]"B91G]SUAXW&SA)1)>(/,M!9H&,/E@&XOH7@HT
M6T5>;="A;2Y/[(+.#E*R*14+5O<MD,@;QF &('-> T!8P&+DF6JPOZEY%#5J
MCO;X9!JHC\#IZ@1I$-V@M];>&@WM4CK+:$]F-2&K8> ]Y-7,8LRJ#1/KH)V^
M100Y-JDRHHO)8^#+NGM[0B[BU-+6P&-U&JR'I%+K>SP>.5X,RGV?<C.PL0U#
M!R<E*VW5&_BQ9^!)@?4A5,(_(5K:J23A-!A^[C3@($R=1:!26:EALI>\37)
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MD(9]4%AK/E.7H/3+!,FHEU@,4NN\X,J103+7244',V%1IH]?B$W"$D)'Q?]
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M+6U&T52C*0M:VK;?6M.X?_;8N,D3T(<L]N J6Z>5S/[T7M!I\Z 48[K'K@(
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M"9,#0TSP7M)L6+L;0YH"9^ DC6[#Z0&QH@.3>EQ*+[)!6%-+8W?HPSA*!3C
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M3ZX$B7QQ!" WES%/&@D6^=S?:(E0\M*PEVN5?%U]46N5[MSF#;I?Y=F:2U:
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M#>UW%MT"3X**&D7GN$CP"N[A7PO9E0TTK-&R/ #\V>70*WWB&EHL7/TZ.1"
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M _= 939/X7H*#!509+%=@0J0E'CN0"^NUD"G;W"#V!;5GC?NC2<YZV!7#X_
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MS'?TYU8*$")\ +Y'K-I_X ;NE]!_^']02P,$%     @ H#P(62[**_"# P
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MA4;#R3@ U8V@;F-D[=M^+8T=(GY9V:F-RCG8\XV49K]Q ?K_@>PW4$L#!!0
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M43L#^KY1)*=?N ##3X7E/U!+ P04    " "@/ A9MTQ ,7X#  "Z"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R=5FUOXD80_BLC7W1M)8J-(80F
M@$22JYI*5T47M?U0]<-B#_8JZUW?[CJ0?]^9-3CD"HCV"^S+S#//,[NSX^G:
MV&=7(GK85$J[651Z7U_'L<M*K(3KFQHU[:R,K82GJ2UB5UL4>7"J5)PFR3BN
MA-31?!K6'NU\:AJOI,9'"ZZI*F%?;U&9]2P:1+N%+[(H/2_$\VDM"GQ"_WO]
M:&D6=RBYK% [:3187,VBQ>#Z=L3VP> /B6NW-P96LC3FF2</^2Q*F! JS#PC
M"/I[P3M4BH&(QM<M9M2%9,?]\0[]YZ"=M"R%PSNC_I2Y+V?1)((<5Z)1_HM9
M_X);/9>,EQGEPB^L6]OA5019X[RIML[$H)*Z_1>;;1[V'";)$8=TZY &WFV@
MP/)>>#&?6K,&R]:$QH,@-7@3.:GY4)Z\I5U)?G[^Y$WV7!J5HW7?P3VN9";]
M-/8$S09QMH6Y;6'2(S!C^&RT+QU\TCGF[_UCHM3Q2G>\;M.3@+\VN@_#I =I
MDHY.X T[G<. -SQ+YZ>OC?2O\)OQ"'\MELY;NAU_'Y+=HHX.HW+%7+M:9#B+
MJ"0<VA>,YA\_#,;)S0G.HX[SZ!3Z^6=S/LS'#Y-T<'6S X,'#8NFH&O&>1[V
MP)<(=Z:JA7X%U!XMYB"U-R#(T,-G89_IH7APKA$Z0W@2"ATL"HM(A>KA>_;G
M&&ERLX?[K5VP&-S\T(-U*;,2A**WP0'QH4B2P)'BY4"UJZ"I>?'B,DGH^BO%
ME2PU%-8X![4U&6+NP*S E8).@$?2.\A,59&E8^F] $9:J'R$9T%D0$3UC[B1
MSDM=')<F.FEOV0"ZF\BZ!N_TOJT>4=N'^\9R-';R)>VV*N4&JK9XD(NGA=]=
M_?='XN@4X6*0=JDXKII>3$<O$\<CRIJD[6=+U#3;2'K54+T2XF2R@^Q!0RQL
M"'OB"/NP"$ 'R%KD9L"!ET*%7(H7(958*CP/&];"?<OP<K C^'_2.#R0QJO^
M3^>DL67,RT</^#^E>KR7:=IM"^!BW%%A[5)GJLG;RT;O2BUD#KBA/NSX2I)8
M0VHLM0=K.;QP#HF?^->!#(.QQ0RI\P6T3+BRO<+$A2WZA]ZI>*^?5&B+T#4Y
M+XWV;6OI5KO&O&C[T9MYV]6IK JI'2A<D6O2O[J,P+:=LIUX4X?NM#2>>ET8
MEO1Q@98-:']EZ)'>3CA ][DR_P=02P,$%     @ H#P(63,)4_Z%"P  1R
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M.#Q]2ZJ3$"FBYH8*J"A!G3ULQ3[,7Z+&]7N=]$= TBLF0>9?^S=]>(^DOE#
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MRM("O%\8X],70M#\_.O]/P%02P,$%     @ H#P(69#4^F<@!@  &Q$  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULU5C;;MLX$/T5P@V*%E!ERW8N
MS0W(I;N; D6#I-M]6.P#+5$V4XI422J.]^OW#"7+4NIDL\"^]"46)<[,F3/#
MF6&.E\9^<PLA/'LHE'8G@X7WY>%PZ-*%*+B+32DTON3&%MQC:>=#5UK!LR!4
MJ.%X--H;%ESJP>EQ>'=M3X]-Y974XMHR5Q4%MZMSH<SR9) ,UB]NY'SAZ<7P
M]+CD<W$K_._EM<5JV&K)9"&TDT8S*_*3P5ER>#ZE_6'#5RF6KO/,R).9,=]H
M<96=#$8$2"B1>M+ \7,O+H12I @POC<Z!ZU)$NP^K[7_$GR'+S/NQ(51?\C,
M+TX&!P.6B9Q7RM^8Y6^B\6>7]*5&N?"7+>N]4VQ.*^=-T0@#02%U_<L?&AXZ
M @>C)P3&C< XX*X-!927W//38VN6S-)N:*.'X&J0!CBI*2BWWN*KA)P_O1'.
MVRKUE95Z?CST4$D?AFDC?EZ+CY\0WV.?C/8+QS[H3&1]^2&@M'C&:SSGXV<5
M?JQTS":CB(U'X^DS^B:M?Y.@;_(2_QC7&;L1BGN1L3/*!^FE<.S/LQEV(4'^
MVL9 ;6"ZW0 =FD-7\E2<#' JG+#W8G#Z^E6R-SIZ!OZTA3]]3ON_A^=9\>W@
M^I1<:?:)KXCN2<3\0K +4Y1<K\"5-I5.P11G<V5F7.$0/B8S-<[C=5;59ZQ4
M7+,WI.7UJX/Q>'1$:EG?X#7VA*_)T=N(+1<R73"I4U5EB 1GA;&"Y0:I#\M2
MWT,6-<#CD4GOV,7GKU>7[Y+W["M/4W@;=:Q[$[:4LA1$!'.H7!E,UGZE2%2I
M*VBUG+9S)?\.#\SD0:[@NLKY&J86GNI)!$@]"QV*R(MD_\BMZ:']*),I0'''
MEJ@T]-O8=D;)K+4'.U+5R4<T2IU;OB9)Q!24CT"#*AG.P5.!R2N+#W8#T*TY
M>(RHX=E59:D$\0EITOE$? *HF?$+QA&-.R.U5RNJP<):DC1KQYHP_Z@A;D+,
MOG206Y$:FS6F<Z/0$6A_/ZW2!;=S@9?U,6THWX(1&='G%KN=QP_YYXAEM*XZ
MUHZ]";M-Y>"9>WL(6%:(7O%BM_*A_X*HKQG:/-V*>^@$^X$B493*K*!H)K3(
MI0_GP;$=ED0)<G2'3:.]Z02_N]'N>-2NKT"'M"&M@9([)R 4LFE\Q))1-#I(
MH&%O[_UZ\<5X1/-F&T]ODK<=>\DTV@?4';8?)0>=%[1KFWB@:6<4[Z*W* 6F
M(EI-UJO@9/\%\J$YK92V"*T+3CBNA(O(AN 6F4:"&;A2I@Q^TOH6)R(<QSG8
MLEQ%X2W/T-8DU5_JSTP\X-0ZTH6T*$5HVFH5K:-]T8WV;2_:GS?11LZ'W3Y$
MN:B#*D)0T6!$VV#B%Y.2Q._[I$SC@Y^4%(<\_S\H&<?[?4J29//])^.D3A2R
M\BP[$Q:_K )\:%ZCO.<YL$'/;!4L;9H)@-:UN8(=^U25(QX!7'I5%T/44$'N
MNQ9&R5>U:Z$A"^LY42 LV*K[30/-Q=N+,>_H(A5;1.L^3X K-#4B3;0.+A<&
MO0XHM?$REU (BN&,M#U-6>U334%IK*<5 B%-%JPN> 8-^/:]DK:)%1G**VJ)
MC&87F8J^"ZBB!-^'ZD@)NMM)P#;=7Q*O#KKGCT<?*]UZ2$Y)/J-^OJ*^""!]
M$0"Y1-2*&:(\2>I$BK<W 31^]#/=7%F6$AUX>U[T1P)QSU45,IV:OS)Z_DXA
M2;*U6N)";NS5YS*<[B9=E. T;RD^,S@:QJZ"GR;/P3D+$R2I36L3FOW*)0T>
M;E99G-)/F%, *7L4'&'ISD@@=-=X@[4;(HZI1*9\IL2/V-L1T6%ZF=V!&3H%
M=U4V;\L%S6SU=(JK&,UQ*W9/HU-N31'T@SV)"UQ3*[")7(<;I?%TM"#;9!G/
M[JIZW@R3%"\P:.%Q?51B=OG2/.G'9W/6>E0T+9PR-^D4TT>CC^PE2LI+Z6EV
M#9' "<,@^P[#,G,F]TM.TV,'Y(OKVG_&.XJ3EP'>=@L:=BZLA8!.NI8[I#[H
MKN^N[=OVYG]67W@WV^M_&R#YYA*57(D<HJ-X?W? ;'T5KQ?>E.'ZBW$6E^GP
MN! <%9<VX'MND 7-@@RT_P\Y_0=02P,$%     @ H#P(6;2D=^@U @  ^P0
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M@C)8""3KLB3B80H%WTX<S]DYKNDZ5\:!XZ@B:UB"NJD60ENX8\EH"4Q2SI"
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M'AA8Q\K!B K 0%IXXW%H&/;HY/1L>I; O>QL\&A%BH(L"+ ?2\Z)L0SDCZ\
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MW602/M&Y O4JF1/'?$V:(8\O!YA:<XNVK8C%?>Q*[D=0E/=;ZPN GKZI<D#
M9+=@K>CB??N8$8+Z'GS^B+ !) FI(M"1XX0V*8BF52.]^K8Q-PO:P-0"!XJ]
MF,% TY0=,DMM ?98RE-X,M"UX$R\9ZC'[I@#6(]6O3M!D.<6).5(:ZH^S^(
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M5FW("+X7C..Q'X9A=^_H87A ?U)N!G>G<$Y]1V-_$L?==255)14U@.]38@[
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M:(TA(J@;$U'C*C[WJH+<A+E>0E[BLR@((<C\-"8/VREZP)UL4"JKO4AMIP8
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MFZIKN-/E!C:JH?=-920DV)WJ#&$9!OA0X=Z>F=94I-=3^++3B$_*!%;BX:G
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M:KNLZ&=$[1(H7BIEMX;;H/]KLW]02P,$%     @ H#P(66N)9M*< @  JP4
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MK2PUMU_6-$U1.P<Z+Y6R.\,E&.9S]A=02P,$%     @ H#P(6<U]?E U P
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M;UVYET/7-PZ9Q2.#I5I[)D;*6(@G,_@ZZ5N.800<0FT@*/XM8 B<&R3D\;L
MM<H]C>/Z\PK].A./8L94P5#P7VRBYWVK8Y$)3&G*]9U8?H%"4,O@A8*K[)<L
M"UO'(F&JM(@*9V00L3C_I\]%(-8<?'>'@U<X>%L.GK?#P2\<LLC9.;-,UHAJ
M&O2D6!)IK!'-/&2QR;Q1#8O-,=YKB:L,_73P@\HGT'3,@=Q#F$JF&2AR,L(Y
MQM4I.2(L)C_G(E4TGJB>K7%/XVF'!?X@Q_=VX']+XW/B.PWB.5Z3/-R/R,G1
M*5'Y5B\5>,-ZO!&$B.=F>/X*;Q/&QA"4<?#*.'@9KK]/'*KDYC#-:AB3=)<J
MH2'T+<PJ!7(!5G#\R6T[GZNT'@AL0[%?*O;KT(.K2$C-_L"$#(72QY\ZGN-7
MD1SD,.T,QE2%1>"WNZV.U[,7ZUK>FCFEQ0;!9DFP64OP1@JER$.,U8EG/&^P
M*E6>28[3JMPZ)U=GL4&N59)K[4?N.XZKWYC6F[W/W-8VP;=&.PBV2X+M6H+7
ME,G\77FD/(6:\VU7G6_3WS[?]D<97I0,+VH9CF"L5Y4 DZU!Z )KCDG!,VQ/
M9XIR:)!0Q)K%*=8?DKX&FYO@)T(QTPH:Q/5(A'9S183$M7@&LD'B-!J#)&):
M&BKRMZ[R#"[>?8UJ!?UGOG;*<'5JPS44,A&2:L NM1&X*BFU4/M6J0.!;:CN
MEJJ[AZG+W4,J/A#8AF+7>6W)SF$J<X'S;FDN[#Z0N^[:O<$]4'4N@.KRJM9D
MD^!K0W=KN^<^%;I >J=$5UCM(OG:@]WZ)OSQ*NU6MN&W9;K";INEO79=-'=U
MS+$9GAWA,$4?Y_P")<K\^IL/M$BR&^18:+R/9H]S_&0 :0QP?2J$7@W,I;3\
M" G^ 5!+ P04    " "@/ A9A!Y$ . &   <.P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6RUFVUSVC@0Q[^*ANO=M#-ML"7+0(\PTY+V'J:9R31I
M[[4!)7AB;&H+TL[<AS_9N*P5S()]ZS<)#])?^J-%_+1KCY^2]#%;*J79]U44
M9Y>]I=;KM_U^-E^J59!=)&L5FW?NDW05:/,T?>AGZU0%BZ+3*NISQ_'[JR",
M>Y-Q\=I-.ADG&QV%L;I)6;99K8+TQWL5)4^7/;?W\X7/X<-2YR_T)^-U\*!N
ME?ZRODG-L_Y>91&N5)R%2<Q2=7_9>^>^G?I>WJ%H\3543UGE,<NMS)+D,7_R
MU^*RY^0S4I&:ZUPB,/^V:JJB*%<R\_A6BO;V8^8=JX]_JG\LS!LSLR!3TR3Z
M)USHY65OV&,+=1]L(OTY>?I3E89DKC=/HJSXRYYV;>6HQ^:;3">KLK.9P2J,
M=_^#[^4'4>G@>D<Z\+(#/[>#*#N(PNAN9H6MJT 'DW&:/+$T;VW4\@?%9U/T
M-F[".%_&6YV:=T/33T\^!F'*O@;11K%K%62;5)DUTAE[>:5T$$;9*_:&?;F]
M8B]?O&(O6!BSNV6RR8)XD8W[VHR?J_3GY5CO=V/Q(V/]O8DOF'!>,^YPKZ;[
M%.]^I>:FNUMT%W;WOG&]M\[WUGFAYQW1FP;9DADGK'CPX=LFW 91;K[.&2J5
M?]?>9NM@KBY[YLN4J72K>I/??G%]Y_<ZGT1BEFNQ=RT*=7'$];LL4_46!:5%
M(C'+HK>WZ*$+>Y?H(&+S?%45K&JQU&:K>C2!/8L4R]1\DX8Z5+4?QFX$OQ@A
MWPJW$R[,UNB,^]NJ370B+6W*O4V)VKP&+[>H%U2FZ<(2B5F._;UCOV7L^I06
MB<0LBX.]Q4'GL3LXB%WAC[R#V$4GTM+F<&]SB-J4%X[S*YLF\5:E.LPMQ8E6
M&5N8WR&SO0_J;*&*3=>82,PR/]J;'Z%A_"D,9F%T=/E&E#Z)Q"R?K@-PX:#+
M?*5FVD!#IM--CA6OS6.MS$":I8%6KUFFS;\%6ZMT;MXVV%@+%;LQAI5X=BX<
M^2R:\9FT=5K!*!=U^DEM5<3<VOFC/9LN*)6:[1.8R>4MMV"7%)&HU&R; $DN
M"B@DVW Y1'4?=H=#9^@_C]R:=@-WF"/RMLX$8)"+<U 9D^Q?UF:[Q<4;KV<7
MI.0"*KGR_VRY+BDB4:G97@&27!106OVVEI*RNL<^#U.LB3U5@!T7IQV(T.LD
M5C_*[Q:[WQP[7Q(Q2^FH"P)R 8'<8=NME!1UJ-1LFP [+LH8-%OIZ"#VZK?2
MFG;(5LH!9#@.,A"H?R3F:Q7G-/-F%LP?#;W@4\>%&V<.NJ <#I3#W98ARTDA
MATK-MEE)#.&9(8J0+8? =E2TB3UU !>.@PL$ZEU:Y/-^G)HG:=J'2LUV#\3#
MO;;Q24HS5&JV3: 9CF=^2.)3GHY/K(D]=8 3CL,)Q.<T2==)?@QDB_R4>&*V
MI D>*C7[,P#JX8.V44K*-U1JMDW@&X[G>$BB='@Z2K$F]M2!63C.++LHY;4S
M(DW/4*G9I0# &N&T+0:08@N5FFT3L$7@R1F*2"R'J(;9D/N>_QQ!:]IQ3_J<
MU\>D "@1.)24,=GR-(^+-U[/3BI8E1(67L,Z<9H7M)6L+I!& -((/(G3:K&]
MPQAT!W(X>!ZKA^U<QQDYHR.Q"H B<$"!6#WO7(_+-5ZQ+O(O A!'M*U2"5**
MH5*S;0+%B.XK5>40V,\[VL2>.I")P,D$PK/I:1X7;KR"761F!%".P.M02*"2
M0@Z5FGTQ $".A^=N2"X'< YW5"YKK@>H:><XU7:V"4 8[YSZ$C__7(_K-5U"
M*C7;/;"/U[;JY)%R#96:;1.XQNN^ZE0.@6VI-4T00O4JE]V<4V_B3<_VN&KC
M)>PB->,!^7AXH0F)5%+&H5*S;0+C>'@:AR12#PM*ON,>GJAJVAW;3@%>O',*
M3Z)V6J0Y&"HUVR>0CM>VQN21D@R5FFT32,;KOL;D'=:.#C9.K(E]#1_0B3RG
MLB1:'NMQ\<;7]G61II' .!*O+ITXUDM2HJ%2L[T"T4@\F]-JL4^7E- F]E2!
M2N0Y)25Q]F$>EVN\3EVD7R0PC6Q;49*DV$*E9MNL7$K<?45)GJXHH4WLJ0.*
MR',J2J+%81X7;KR"7:1C)!"-;%M4DJ1 0Z5FVP2@D=T7E>3IHA+:Q)XZ0(H\
MIZ@DSC_"XWJ-%ZZ++(P/G..W+37YI Q#I6;;!(;QNR\U^8<EI.?QB3:QIPY(
MXI]38!)-C^^X:N/EZR(#XP/K^&WOCO))J89*S;8)5./CF1J2*-T-X6-1BC79
M3;U?N74QOV_T.D@?PCACD;HW?9R+@0GQ='<KYNZ)3M;%W8RS1.MD53Q<JF"A
MTKR!>?\^,1Q=/LEOD-S?$#OY#U!+ P04    " "@/ A9Z(A@1ST5  ![7 $
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M6H1J,:HEJ"90+46U#-4DJBE*TT\+;6ML@NRF-D&K8:@6H%J(:A&JQ:B6H)I
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M#L<BGL\*O@=%92W1J@\U^[6WY(NR*E$>12&_I=)/S!_("V$[ JX?90JFNXP
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M]'H$GA DQCTR5 2ODH(G33!4S_M*QIE,AK\W]U( F:7 @C-1Q(D >RHV[:L
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M=A7-U9SF0?!M??=DR86,=/UQ0^*4%)6!_'[%N7A]J#KH+DC-_P=02P,$%
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M]PSP+$DP^WY'8GJ8&] XWGB(=J'(;YB+V1[OR",1G_;W3([,"B6($I+RB*:
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M52F+LJU$K/:A)4)BWFAON Z'P][D<8F0?08OZS,D^Q0D)D=[YR>WW^UU'[T
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M2U8$[35 M1#5!*I)5%.HIBG-+*@F*]*S9T6,O0R<Z'[; F?UZ%P5S;-5^ZT
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M\U$M0+40U02J2513J*8IS2RN)F32MX=,_L(^2/W]?4W6,\.]@D)C(ZCFHUJ
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M4$VBFD(U36E&V8R; ,?XSZZ&4N?X-Z>W.C]UNCVWM567O9M#JPO5/%3S42U
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M'@_6K P1*E^@)ZM6/&;5&I,L&Y-L,1+9T1(DW1(D@[GW\4/B.?ZG[TWWA@H
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M&B#OKRD5CR=50/=#2? +4$L#!!0    ( * \"%FSY.IJ_P(  %()   9
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MJVEFG4J#.OQ0F@NE>5":#Z4%4%J(HNGR:QQ^QX;UK@[4QH?27"C-@])\*"V
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M;X&0+>DV%M^RW9^L[M"DB!=D,2]_P:XNZU@@V'*1)75EB2")TNI*G^J!:%7
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M-:,ARXL"\OLRR\3S0]% <U:]^ ]02P,$%     @ H#P(60)>^C25!   G!D
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MLO74#=PP=,;VN@5I4",->I&VISQ:",K,W+'@@@-P';B&-:[A.;C*,!X-:W@
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M.A=%>2M7#A1?%3=A,ZX4SXK7)= 8A%F@_Y]SKK8#8Z"^&YW^"U!+ P04
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M"TW1VI4X;&*P_ZJ=8G"/].(ZF:0%1FFA*5J[3H<=%Q[><KVP4XRZ6\-NI[C
M*+C$*#QC5$FVCT[.,I"!JR-++O?)92ZJ<Y%FM#D6_: / T_&[_#M$O>,!^H8
M59_4'?#5&>PGF:<DYRB%M9S*N9[(>%EUK%G="%KH<[LG*@3-].462 Q,&<CG
M:TK%\XV:H#E<7OP+4$L#!!0    ( * \"%G1*O_U<@,  &D0   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;+5876_;-A3]*X16#"VP1M]*G-D"$DO%
M,K1%D*#;P[ '6KJVB4JD1E)Q\^]'4HIJ1:H6=ZH?;(GB.5?G'$G4]?+ ^&>Q
M!Y#H2UE0L;+V4E:7MBVR/918G+$*J#JR9;S$4NWRG2TJ#C@WH+*P/<>)[!(3
M:L5+,W;+XR6K94$HW'(DZK+$_/$:"G986:[U-'!'=GNI!^QX6>$=W(/\5-UR
MM6=W+#DI@0K"*.*P75E7[F7J.AI@9OQ!X"".MI&6LF'LL]ZYR5>6H\\("LBD
MIL#JYP'64!2:29W'/RVIU=74P./M)_9W1KP2L\$"UJSXD^1RO[(N+)3#%M>%
MO&.'WZ 5%&J^C!7"?*-#,S=T+)350K*R!:LS* EM?O&7UH@C@.(9!W@MP'L.
M"+X!\%N _](*00L(7EHA; %&NMUH-\8E6.)XR=D!<3U;L>D-X[Y!*[\(U1?*
MO>3J*%$X&=^!D+S.9,T)W:&WZ"/F'.OLT.L$)":%>*-&/]TGZ/6K-TM;JI(:
M:&<M_75#[WV#WD<?&)5[@5*:0SZ"3Z;QT03>5E([O=Z3WFMODO#WFIXAW_D%
M>8X7C)S/^N5P?TS._ZN>?G?UGAE^%[YO^/P7A;]F0B),<Z2&@:LKX*_W:CZZ
MD5"*O\>B;\B#<7+]A+L4%<Y@9:E'F&&TXI]_<B/GUS'?YR1+YB1+9R+K)11T
M"053[/$M?E1/92F06A*0@ ?@F&9@4H*R*M@C -H A2V1*%/YB;&<)DN<FM.<
M9$E#%ADRO:0]Q&'HZ,_2?CB.8*:BO0C"+H)P,H+[[W0]'&AS77<QT+8>S@NB
MP!_,2YIY8<\K;\2K_^;KV1!U-D23-MR4%29<7XR(;1$6 L9E1X/RSP5' R&N
MXURX0\4C$Z-HZ& Z+#D@[$D^[R2?GR"Y8'3WME K8SZA?I+PU%OM?'AW+$;N
MCF3.HNE,9#W#+SK#+R8-O\HR7BM_WQ.\(061!$9-GB0YU>0YR9(YR=*9R'I)
M++HD%C_RS6 Q9T)SDB5SDJ4SD?42<IVO;^[.#UF8IFE/36=6MJ1EFU@^TKD*
M-J[;1ZU3"7QG>E:AS*NI;%ZDN]&N+[XRW>"S\6OW<NV.C">ZCS:MVE?ZI@G_
M@/F.4($*V*I2SMFY6NEXT]<V.Y)5IG';,*G:0+.Y!YP#UQ/4\2UC\FE'%^C^
M78C_!5!+ P04    " "@/ A9^").W3<#  #($P  #0   'AL+W-T>6QE<RYX
M;6S=6%U/VS 4_2N1&1-($VF;$9K15MHJ(4W:)B1XV!MR&Z>UY-B9X[)VOWZ^
M=II^X(L8#UN[5#3V/3[G'MLWQ#"HS4JPNSEC)EJ60M9#,C>F^A#']73.2EI?
MJ(I)BQ1*E]38KI[%=:49S6L@E2+N=3II7%(NR6@@%^5-:>IHJA;2#$G:AB)_
M^YP/23=]3R(O-U8Y&Y*'L[<_%LI<OXG\_>3=R4GGX?QZ/W[F@',2!T4O7R!Z
MT<%U+89)I[O2;OBI%?+$4XQV%:#9+!LF=#!R_T73>68VF' 6=+7ER1'C9B='
M@T+)S88FQ >L,BU9]$C%D(RIX!/-@570DHN5#_<@,%5"Z<C82K*INA"I?WFX
MZWM09(U.R:72+K?/X+\GS? ]8-T#@UR(UF"/^,!H4%%CF)8WMN,&N^ 3*&K:
M]ZO*.IQINNKV+LF&X&XVR43IG.DV39>L0Z.!8 78T7PVA[M150R@,:JTC9S3
MF9+4>5@SFH:5G3(A[N )_%[L:"^+K3WKP([)MFD--4TOXSN@OZWFM;=EDU?I
M1A5_5.;3PDY'NCX4&;O5K.!+UU\6K0%,O8NKTZH2JX^"SV3)_.1?G' TH&M>
M-%>:_[+9H%2F-L TB1Z9-GRZ'?FI:77/EF9=3LL"]]P[0L]_=YUG3#)-Q;9I
M6_N'O,JO=IQ<_2O+[K?*ON&@Q^:U>N@F+X_!9'H,)H^B)OO'8#([?)/)87J,
MFT/&UDEFYQS31B,X+P[)-SAYBDW2:++@PG#9].8\SYE\<IRQ\H9.[)\I._IV
M?,X*NA#FO@6'9-/^RG*^*+-VU"TL1#-JT_X"T^NF[6'5YN(R9TN6CYNNGDU<
M,[(-F[6Y@+"/W+@KC& <CX41P+ \F .,XUE8GO]I/GUT/A[#O/6#2!_E]%&.
M9X60L?M@><*<S%[AF699DJ0IMJ+C<=#!&%NW-(6?L!KF#1A8'LCT9VN-[S9>
M(<_7 ;:GSU4(-E.\$K&9XFL-2'C=@)%EX=W&\@ #VP6L=B!_. _45)B3)+"K
MF#?L"<:1+,,0J,5PC:8ILCHI?,+[@STE29)E802PL(,DP1!X&G$$<P >,"1)
MW'MP[WT4K]]3\>9_=Z/?4$L#!!0    ( * \"%F7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ H#P(61H%R8HQ!0
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MH\BJ460M4&0M4&0M4&0M_E/69VN7?QP_///6U-TAGPW_=IJ] 5!+ 0(4 Q0
M   ( * \"%D'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ H#P(62](X!;O    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ H#P(69E<
MG",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " "@/ A97,;(6,\%  #-'@  &               @($.
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ H#P(66<.
MRY<6!P  N"<  !@              ("!$PX  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( * \"%G..%YKP ,  (<-   8
M  " @5\5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "@
M/ A9Z)LV$"0'   ,'@  &               @(%5&0  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ H#P(65$>9!,U P  $@L  !@
M         ("!KR   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( * \"%G7;3%%7PL  #=C   8              " @1HD  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "@/ A9@F"OH] "   -"
M&               @(&O+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ H#P(6>4Q=2H:"   =2$  !@              ("!M3(  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( * \"%D^6?0KI0<
M "<3   8              " @04[  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "@/ A9-6<X6*L/  !$+   &0              @('@
M0@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( * \"%G<
M ^%GJ (  'H&   9              " @<)2  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ H#P(6>&3' 8B!0  2PP  !D
M     ("!H54  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M" "@/ A9X,Y,JW D  #B?   &0              @('Z6@  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( * \"%G7R[J(;20  !5]   9
M              " @:%_  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ H#P(62[**_"# P  #P@  !D              ("!1:0  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "@/ A9':K4I_X"
M  !"!P  &0              @('_IP  >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( * \"%GMWEJ]=0(  &P%   9              "
M@32K  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ H#P(
M68R&\T>Y @  $P8  !D              ("!X*T  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "@/ A9'[41$9 #   V"   &0
M        @('0L   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( * \"%FW3$ Q?@,  +H(   9              " @9>T  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ H#P(63,)4_Z%"P  1R
M !D              ("!3+@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "@/ A93PC)#%4$  #\"0  &0              @($(Q
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( * \"%D93BSA
M,!    HV   9              " @93(  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ H#P(69#4^F<@!@  &Q$  !D
M ("!^]@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "@
M/ A9M*1WZ#4"  #[!   &0              @(%2WP  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( * \"%DG!MJ(A@(  ,('   9
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M970S,"YX;6Q02P$"% ,4    " "@/ A9!H1#[K4%   X#@  &0
M    @(%W  $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M * \"%F.PM?<D@,   ,(   9              " @6,& 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ H#P(6:)-@D 4 P  / <  !D
M             ("!+ H! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "@/ A9G/6#4H("  !W!0  &0              @(%W#0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( * \"%EKB6;2G (
M *L%   9              " @3 0 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ H#P(6<U]?E U P  S0<  !D              ("!
M Q,! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "@/ A9
M6R>"$^0%  !$#P  &0              @(%O%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( * \"%DU3>4M? ,  (P)   9
M      " @8H< 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ H#P(62I-6/'$!   (!@  !D              ("!/2 ! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "@/ A9+"R"\DT#  "0#
M&0              @($X)0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( * \"%F$'D0 X 8  !P[   9              " @;PH 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ H#P(6>B(8$<]
M%0  >UP! !D              ("!TR\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "@/ A9Q?<]?:<%   L)0  &0
M@(%'10$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( * \
M"%G ;1]B7@0  +<:   9              " @25+ 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ H#P(67,&)LV9!   B!@  !D
M         ("!ND\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " "@/ A9"5_8S0L5   V0 $ &0              @(&*5 $ >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( * \"%FIKQ.HG00  ,\3
M   9              " @<QI 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ H#P(64LP$#KJ @  R0H  !D              ("!H&X!
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "@/ A9%S-*
M,<T#   T$0  &0              @('!<0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( * \"%FSY.IJ_P(  %()   9
M  " @<5U 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MH#P(62<)J(TP P  6PL  !D              ("!^W@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "@/ A9^PD!8C@#   V#0  &0
M            @(%B? $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( * \"%E.@#,>( ,  ,\)   9              " @=%_ 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ H#P(60>5Z18-!@
MH#$  !D              ("!*(,! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "@/ A9XNV'X]T'   '4   &0              @(%L
MB0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( * \"%FQ
M YI"V@,  &44   9              " @8"1 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ H#P(6>N2 *!&!0  MQX  !D
M     ("!D94! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( * \"%F @= ") 0  &@6   9              "
M@1VL 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ H#P(
M6=$J__5R P  :1   !D              ("!>+ ! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "@/ A9^").W3<#  #($P  #0
M        @ $AM $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( * \"%F7BKL<
MP    !,"   +              "  8.W 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( * \"%D:!<F*,04  '4I   /              "  6RX 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "@/ A9)V75I0P"  "$)0  &@
M    @ '*O0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "@/ A9[M7M&.8!  #U)   $P              @ $.P $ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     1P!' &@3   EP@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>264</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Collaboration, License, and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</Role>
      <ShortName>Collaboration, License, and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EarningsLossperShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/MarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Revenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Earnings (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EarningsLossperShareTables</Role>
      <ShortName>Earnings (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/EarningsLossperShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Inventory</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Goodwill</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/LongTermDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Restructuring</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails</Role>
      <ShortName>Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails</Role>
      <ShortName>Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Collaboration, License, and Supply Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails</Role>
      <ShortName>Collaboration, License, and Supply Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Earnings (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EarningsLossperShareDetails</Role>
      <ShortName>Earnings (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/EarningsLossperShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Goodwill - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Long-Term Debt -Schedule of Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails</Role>
      <ShortName>Long-Term Debt -Schedule of Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Long-Term Debt -Schedule of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt -Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockholdersDeficit</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails</Role>
      <ShortName>Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/IncomeTaxes</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Restructuring -Schedule of Restructuring and Related Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails</Role>
      <ShortName>Restructuring -Schedule of Restructuring and Related Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nvax-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="nvax-20240630.htm">nvax-20240630.htm</File>
    <File>nvax-20240630.xsd</File>
    <File>nvax-20240630_cal.xml</File>
    <File>nvax-20240630_def.xml</File>
    <File>nvax-20240630_lab.xml</File>
    <File>nvax-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nvax-20240630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="783">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nvax-20240630.htm": {
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "nvax-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "nvax-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nvax-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvax-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 261,
   "keyCustom": 39,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 44,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ecd/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 1
   },
   "contextCount": 264,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 595,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 783,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 24,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.novavax.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952153 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.novavax.com/role/OrganizationandBusiness",
     "longName": "9952158 - Disclosure - Organization and Business",
     "shortName": "Organization and Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.novavax.com/role/MarketableSecurities",
     "longName": "9952160 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.novavax.com/role/FairValueMeasurements",
     "longName": "9952161 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.novavax.com/role/Revenue",
     "longName": "9952162 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements",
     "longName": "9952163 - Disclosure - Collaboration, License, and Supply Agreements",
     "shortName": "Collaboration, License, and Supply Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://www.novavax.com/role/EarningsLossperShare",
     "longName": "9952164 - Disclosure - Earnings (Loss) per Share",
     "shortName": "Earnings (Loss) per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash",
     "longName": "9952165 - Disclosure - Cash, Cash Equivalents, and Restricted Cash",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.novavax.com/role/Inventory",
     "longName": "9952166 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.novavax.com/role/Goodwill",
     "longName": "9952167 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.novavax.com/role/LongTermDebt",
     "longName": "9952168 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.novavax.com/role/StockholdersDeficit",
     "longName": "9952169 - Disclosure - Stockholders' Deficit",
     "shortName": "Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.novavax.com/role/StockBasedCompensation",
     "longName": "9952170 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.novavax.com/role/IncomeTaxes",
     "longName": "9952171 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.novavax.com/role/CommitmentsandContingencies",
     "longName": "9952172 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.novavax.com/role/Restructuring",
     "longName": "9952173 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.novavax.com/role/SubsequentEvents",
     "longName": "9952174 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.novavax.com/role/MarketableSecuritiesTables",
     "longName": "9954472 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.novavax.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.novavax.com/role/RevenueTables",
     "longName": "9954474 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.novavax.com/role/EarningsLossperShareTables",
     "longName": "9954475 - Disclosure - Earnings (Loss) per Share (Tables)",
     "shortName": "Earnings (Loss) per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables",
     "longName": "9954476 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.novavax.com/role/InventoryTables",
     "longName": "9954477 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.novavax.com/role/GoodwillTables",
     "longName": "9954478 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.novavax.com/role/LongTermDebtTables",
     "longName": "9954479 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.novavax.com/role/StockBasedCompensationTables",
     "longName": "9954480 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.novavax.com/role/RestructuringTables",
     "longName": "9954481 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.novavax.com/role/MarketableSecuritiesDetails",
     "longName": "9954483 - Disclosure - Marketable Securities (Details)",
     "shortName": "Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.novavax.com/role/FairValueMeasurementsDetails",
     "longName": "9954484 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
     "longName": "9954486 - Disclosure - Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "shortName": "Revenue -Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
     "longName": "9954487 - Disclosure - Revenue - Schedule of Product Revenue (Details)",
     "shortName": "Revenue - Schedule of Product Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails",
     "longName": "9954488 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)",
     "shortName": "Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "nvax:AmountsChargedAgainstProductSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
     "longName": "9954489 - Disclosure - Collaboration, License, and Supply Agreements (Details)",
     "shortName": "Collaboration, License, and Supply Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "nvax:RoyaltyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "nvax:RoyaltyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.novavax.com/role/EarningsLossperShareDetails",
     "longName": "9954490 - Disclosure - Earnings (Loss) per Share (Details)",
     "shortName": "Earnings (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails",
     "longName": "9954491 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.novavax.com/role/InventoryDetails",
     "longName": "9954492 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails",
     "longName": "9954493 - Disclosure - Goodwill - Schedule of Goodwill (Details)",
     "shortName": "Goodwill - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reporting_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportingUnits",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reporting_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportingUnits",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails",
     "longName": "9954494 - Disclosure - Long-Term Debt -Schedule of Convertible Notes Payable (Details)",
     "shortName": "Long-Term Debt -Schedule of Convertible Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
     "longName": "9954495 - Disclosure - Long-Term Debt - Narrative (Details)",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-192",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails",
     "longName": "9954496 - Disclosure - Long-Term Debt -Schedule of Interest Expense (Details)",
     "shortName": "Long-Term Debt -Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.novavax.com/role/StockholdersDeficitDetails",
     "longName": "9954497 - Disclosure - Stockholders' Deficit (Details)",
     "shortName": "Stockholders' Deficit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-202",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails",
     "longName": "9954499 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
     "longName": "9954500 - Disclosure - Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "shortName": "Stock-Based Compensation -Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
     "longName": "9954501 - Disclosure - Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Stock Options and Appreciation Rights, Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-230",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
     "longName": "9954502 - Disclosure - Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share Based Compensation Restricted Stock Awards Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-241",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-241",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.novavax.com/role/IncomeTaxesDetails",
     "longName": "9954503 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.novavax.com/role/CommitmentandContingenciesDetails",
     "longName": "9954504 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-251",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "unitRef": "defendant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-251",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "unitRef": "defendant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
     "longName": "9954505 - Disclosure - Restructuring -Schedule of Restructuring and Related Costs (Details)",
     "shortName": "Restructuring -Schedule of Restructuring and Related Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.novavax.com/role/RestructuringNarrativeDetails",
     "longName": "9954506 - Disclosure - Restructuring - Narrative (Details)",
     "shortName": "Restructuring - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nvax:PaymentsForSeveranceAndEmployeeBenefitCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nvax:PaymentsForSeveranceAndEmployeeBenefitCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r732"
     ]
    },
    "nvax_AccountsReceivableAllowanceForCreditLossAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AccountsReceivableAllowanceForCreditLossAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions",
        "terseLabel": "Additions",
        "label": "Accounts Receivable, Allowance for Credit Loss, Additions",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableAllowanceForCreditLossDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AccountsReceivableAllowanceForCreditLossDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Accounts Receivable, Allowance for Credit Loss, Deductions",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Additions",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Deductions",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable:",
        "label": "Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accounts receivable, beginning balance",
        "periodEndLabel": "Accounts receivable, ending balance",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r241",
      "r242",
      "r986"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r670",
      "r752",
      "r985",
      "r986"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r62",
      "r160",
      "r548",
      "r574",
      "r575"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r16",
      "r443",
      "r446",
      "r494",
      "r570",
      "r571",
      "r864",
      "r865",
      "r866",
      "r874",
      "r875",
      "r876",
      "r878"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r732",
      "r1021"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r874",
      "r875",
      "r876",
      "r878",
      "r962",
      "r1022"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r372"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICITParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r86"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AdjuvantProductsThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AdjuvantProductsThereafterMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjuvant Products Thereafter",
        "label": "Adjuvant Products Thereafter [Member]",
        "documentation": "Adjuvant Products Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r778",
      "r788",
      "r820"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r781",
      "r791",
      "r823"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r816",
      "r824",
      "r828",
      "r836"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r407"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Allowance for credit losses, beginning balance",
        "negatedPeriodEndLabel": "Allowance for credit losses, end balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r243",
      "r262",
      "r263",
      "r264",
      "r986"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r704",
      "r705",
      "r870",
      "r971"
     ]
    },
    "nvax_AmountsChargedAgainstProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AmountsChargedAgainstProductSales",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts charged against product sales",
        "label": "Amounts Charged Against Product Sales",
        "documentation": "Amounts Charged Against Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from calculations of diluted net income (loss) per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "nvax_ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA",
        "label": "Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA [Member]",
        "documentation": "Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "terseLabel": "Impairment of assets",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r103",
      "r155",
      "r188",
      "r225",
      "r229",
      "r235",
      "r236",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r438",
      "r440",
      "r476",
      "r543",
      "r622",
      "r696",
      "r697",
      "r732",
      "r759",
      "r926",
      "r927",
      "r973"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r163",
      "r188",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r438",
      "r440",
      "r476",
      "r732",
      "r926",
      "r927",
      "r973"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_August2023SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "August2023SalesAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Sales Agreement",
        "label": "August 2023 Sales Agreement [Member]",
        "documentation": "August 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AustraliaRevenueAgencyMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AustraliaRevenueAgencyMemberMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia Revenue Agency Member",
        "label": "Australia Revenue Agency Member [Member]",
        "documentation": "Australia Revenue Agency Member"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AustralianAPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "AustralianAPAMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian APA",
        "label": "Australian APA [Member]",
        "documentation": "Australian APA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r988",
      "r989"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r278",
      "r988",
      "r989"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "nvax_BillMelindaGatesMedicalResearchInstituteArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "BillMelindaGatesMedicalResearchInstituteArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bill &amp; Melinda Gates Medical Research Institute Arrangement",
        "label": "Bill &amp; Melinda Gates Medical Research Institute Arrangement [Member]",
        "documentation": "Bill &amp; Melinda Gates Medical Research Institute Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BilledContractReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BilledContractReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billed contracts receivable",
        "label": "Billed Contracts Receivable",
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "nvax_CICProductRelatedDevelopmentAndLaunchMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CICProductRelatedDevelopmentAndLaunchMilestonesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIC Product-Related Development and Launch Milestones",
        "label": "CIC Product-Related Development and Launch Milestones [Member]",
        "documentation": "CIC Product-Related Development and Launch Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CanadaAdvancePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CanadaAdvancePurchaseAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada APA",
        "label": "Canada Advance Purchase Agreement [Member]",
        "documentation": "Canada Advance Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada Revenue Agency",
        "label": "Canada Revenue Agency [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capital expenditures included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, amortization",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r152",
      "r689"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r545"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r72",
      "r185"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r156",
      "r157",
      "r158",
      "r188",
      "r210",
      "r214",
      "r218",
      "r220",
      "r227",
      "r228",
      "r259",
      "r301",
      "r303",
      "r304",
      "r305",
      "r308",
      "r309",
      "r341",
      "r342",
      "r344",
      "r347",
      "r353",
      "r476",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r609",
      "r631",
      "r649",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r846",
      "r871",
      "r879"
     ]
    },
    "nvax_ClinicalMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ClinicalMilestoneMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Milestone",
        "label": "Clinical Milestone [Member]",
        "documentation": "Clinical Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "nvax_CollaborationAgreementInitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborationAgreementInitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial transaction price at inception",
        "label": "Collaboration Agreement Initial Transaction Price",
        "documentation": "Collaboration Agreement Initial Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborationAgreementUpfrontPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborationAgreementUpfrontPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement upfront payment amount",
        "label": "Collaboration Agreement Upfront Payment Amount",
        "documentation": "Collaboration Agreement Upfront Payment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborationAgreementUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborationAgreementUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Collaboration Agreement Upfront Payment Received",
        "documentation": "Collaboration Agreement Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborationAgreementVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborationAgreementVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "collaboration agreement variable consideration",
        "label": "Collaboration Agreement Variable Consideration",
        "documentation": "Collaboration Agreement Variable Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Abstract]",
        "documentation": "Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements",
      "http://www.novavax.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Collaboration, License, and Supply Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r116"
     ]
    },
    "nvax_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 15)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r95",
      "r544",
      "r608"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r291",
      "r292",
      "r672",
      "r915",
      "r921"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r750",
      "r751",
      "r753",
      "r754",
      "r755",
      "r756",
      "r874",
      "r875",
      "r878",
      "r962",
      "r1020",
      "r1022"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value per share (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance beginning (in shares)",
        "periodEndLabel": "Balance ending (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r609",
      "r628",
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.01 par value, 600,000,000 shares authorized at June\u00a030, 2024 and December\u00a031, 2023; 161,267,120 shares issued and 159,891,014 shares outstanding at June\u00a030, 2024 and 140,506,093 shares issued and 139,505,770 shares outstanding at December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r547",
      "r732"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "nvax_CompensationStockIssuedUnderIncentiveProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CompensationStockIssuedUnderIncentiveProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under incentive programs",
        "label": "Compensation stock issued under incentive program",
        "documentation": "Value of stock issued issued under incentive programs."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completion of the Technology Transfer of the Company\u2019s Manufacturing Process for the COVID-19 Vaccine",
        "label": "Completion of the Technology Transfer of the Company\u2019s Manufacturing Process for the COVID-19 Vaccine [Member]",
        "documentation": "Completion of the Technology Transfer of the Company\u2019s Manufacturing Process for the COVID-19 Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r169",
      "r171",
      "r176",
      "r539",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income (loss):",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerBasisOfPricingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerBasisOfPricingAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Basis of Pricing [Axis]",
        "label": "Contract with Customer, Basis of Pricing [Axis]",
        "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r930"
     ]
    },
    "us-gaap_ContractWithCustomerBasisOfPricingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerBasisOfPricingDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Basis of Pricing [Domain]",
        "label": "Contract with Customer, Basis of Pricing [Domain]",
        "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r930"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "periodStartLabel": "Deferred revenue, beginning balance",
        "periodEndLabel": "Deferred revenue, ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r359"
     ]
    },
    "nvax_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer, Liability, Additions",
        "documentation": "Contract With Customer, Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Current deferred revenue",
        "netLabel": "Contract with customer, liability, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r359"
     ]
    },
    "nvax_ContractWithCustomerLiabilityDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ContractWithCustomerLiabilityDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "terseLabel": "Contract with customer, liability, deductions",
        "label": "Contract With Customer, Liability, Deductions",
        "documentation": "Contract With Customer, Liability, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Noncurrent deferred revenue",
        "netLabel": "Contract with customer, liability, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r359"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "nvax_ContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability [Roll Forward]",
        "label": "Contract with Customer, Liability [Roll Forward]",
        "documentation": "Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Notes Payable",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "totalLabel": "Total convertible notes payable",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r716",
      "r722",
      "r733",
      "r747",
      "r1017"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r188",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r476",
      "r696",
      "r926"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CostReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "CostReimbursementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost reimbursement",
        "label": "Cost reimbursement [Member]",
        "documentation": "Cost reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal, state and local, income tax expense (benefit)",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer refund liability, current",
        "label": "Customer Refund Liability, Current",
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_DatabaseLockOfAnExistingPhase23ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "DatabaseLockOfAnExistingPhase23ClinicalTrialMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Database lock of an Existing Phase 2/3 clinical trial",
        "label": "Database lock of an Existing Phase 2/3 clinical trial [Member]",
        "documentation": "Database lock of an Existing Phase 2/3 clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r186",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r299",
      "r300",
      "r310",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r326",
      "r333",
      "r334",
      "r336",
      "r486"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r93",
      "r94",
      "r190",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r731",
      "r872",
      "r916",
      "r917",
      "r918",
      "r970",
      "r972"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount of notes issued",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r486",
      "r487",
      "r702",
      "r703",
      "r731"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r338",
      "r486",
      "r487",
      "r731"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r312"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r731",
      "r872",
      "r970",
      "r972"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r190",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r731",
      "r872",
      "r916",
      "r917",
      "r918",
      "r970",
      "r972"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r33",
      "r42",
      "r84",
      "r85",
      "r190",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r731",
      "r872",
      "r970",
      "r972"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r337",
      "r485",
      "r486",
      "r487",
      "r702",
      "r703",
      "r731"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/MarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost\u200b",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, number of positions",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Value\u200b",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of investments classified as available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue [Domain]",
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_DeferredRevenueIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "DeferredRevenueIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue Increase (Decrease) [Abstract]",
        "documentation": "Deferred Revenue Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r375",
      "r403",
      "r404",
      "r406",
      "r718"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r210",
      "r218",
      "r219",
      "r220",
      "r224",
      "r433",
      "r436",
      "r450",
      "r451",
      "r540",
      "r557",
      "r693"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r210",
      "r218",
      "r219",
      "r220",
      "r224",
      "r433",
      "r436",
      "r450",
      "r451",
      "r540",
      "r557",
      "r693"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (Loss) per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r221",
      "r222",
      "r223"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense:",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r148",
      "r172",
      "r173",
      "r174",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r226",
      "r260",
      "r261",
      "r271",
      "r354",
      "r423",
      "r424",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488",
      "r489",
      "r494",
      "r554",
      "r570",
      "r571",
      "r572",
      "r584",
      "r649"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r778",
      "r788",
      "r820"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r775",
      "r785",
      "r817"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value:",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r467",
      "r722"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r467",
      "r722"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468",
      "r725"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468",
      "r725"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r466",
      "r467",
      "r469",
      "r498",
      "r499",
      "r500",
      "r702",
      "r703",
      "r714",
      "r715",
      "r716",
      "r722",
      "r727"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r537",
      "r722",
      "r728"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r362",
      "r367",
      "r454",
      "r467",
      "r498",
      "r714",
      "r715",
      "r716",
      "r722"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r362",
      "r367",
      "r454",
      "r455",
      "r467",
      "r499",
      "r702",
      "r703",
      "r714",
      "r715",
      "r716",
      "r722"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r454",
      "r455",
      "r456",
      "r457",
      "r467",
      "r500",
      "r702",
      "r703",
      "r714",
      "r715",
      "r716",
      "r722",
      "r727"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r466",
      "r467",
      "r469",
      "r498",
      "r499",
      "r500",
      "r702",
      "r703",
      "r714",
      "r715",
      "r716",
      "r722",
      "r727"
     ]
    },
    "nvax_FilipDubovskyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "FilipDubovskyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filip Dubovsky [Member]",
        "documentation": "Filip Dubovsky"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance lease payments",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.00% Convertible notes due 2027",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964",
      "r966"
     ]
    },
    "nvax_FirstFourAdjuvantProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "FirstFourAdjuvantProductsMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Four Adjuvant Products",
        "label": "First Four Adjuvant Products [Member]",
        "documentation": "First Four Adjuvant Products"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_FivePointZeroConvertibleNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "FivePointZeroConvertibleNotesDue2027Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.00% Convertible notes due 2027",
        "label": "Five Point Zero Convertible Notes Due 2027 [Member]",
        "documentation": "Five Point Zero Convertible Notes Due 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "GaviAdvancePurchaseAgreementCOVAXFacilityMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gavi Advance Purchase Agreement- COVAX Facility",
        "label": "Gavi Advance Purchase Agreement- COVAX Facility [Member]",
        "documentation": "Gavi Advance Purchase Agreement- COVAX Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r633"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r269",
      "r538",
      "r697",
      "r699",
      "r724",
      "r732",
      "r904",
      "r911"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r914"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_GovernmentBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "GovernmentBackedSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-backed securities",
        "label": "Government Backed Securities [Member]",
        "documentation": "Represents the information pertaining to government backed securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants receivable",
        "label": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "nvax_GrantsUSGovernmentContractAndJointVentureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "GrantsUSGovernmentContractAndJointVentureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants, U.S. Government Contract and Joint Venture [Abstract]",
        "label": "Grants, U.S. Government Contract and Joint Venture [Abstract]",
        "documentation": "Grants, U.S. Government Contract and Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r78",
      "r723"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income tax expense (benefit)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r97",
      "r102",
      "r541",
      "r552",
      "r695",
      "r696",
      "r881",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278",
      "r283",
      "r459",
      "r463",
      "r468",
      "r567",
      "r569",
      "r634",
      "r684",
      "r726",
      "r990"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r283",
      "r459",
      "r463",
      "r468",
      "r567",
      "r569",
      "r634",
      "r684",
      "r726",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r412",
      "r413",
      "r417",
      "r421",
      "r721",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r412",
      "r413",
      "r417",
      "r421",
      "r721",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r410",
      "r412",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r425",
      "r427",
      "r428",
      "r429",
      "r583",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r203",
      "r204",
      "r225",
      "r233",
      "r236",
      "r411",
      "r412",
      "r426",
      "r558",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes, net of refunds",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r184",
      "r420",
      "r421"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses, and other liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (decrease) in contract with customer, liability",
        "negatedTerseLabel": "Reduction in product sales",
        "terseLabel": "Credits/deductions",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r869"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, prepaid expenses, and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r220",
      "r374"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r816",
      "r824",
      "r828",
      "r836"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r840"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r840"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r840"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense on convertible notes payable",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r330",
      "r339",
      "r704",
      "r705"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Coupon interest",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r331",
      "r704",
      "r705"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r867"
     ]
    },
    "nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "InterestExpenseRelatedToConvertibleNotesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Interest Expense",
        "label": "Interest Expense Related to Convertible Notes [Table Text Block]",
        "documentation": "Tabular disclosure of interest expense related to convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on convertible notes",
        "label": "Interest on Convertible Debt, Net of Tax",
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r215",
      "r220"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash interest payments, net of amounts capitalized",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r182",
      "r183"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm purchase commitment loss",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "nvax_InventoryFirmPurchaseCommitmentRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "InventoryFirmPurchaseCommitmentRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory, firm purchase commitment, recoveries",
        "label": "Inventory, Firm Purchase Commitment, Recoveries",
        "documentation": "Inventory, Firm Purchase Commitment, Recoveries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.novavax.com/role/InventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r690",
      "r732"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Semi-finished goods",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for excess and obsolete inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total cash equivalents and marketable securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964",
      "r966"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r118",
      "r244",
      "r246",
      "r474",
      "r475",
      "r982"
     ]
    },
    "nvax_JohnC.JacobsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "JohnC.JacobsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "John C. Jacobs [Member]",
        "documentation": "John C. Jacobs"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_JohnTrizzinoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "JohnTrizzinoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "John Trizzino [Member]",
        "documentation": "John Trizzino"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "JointCommitteeOnVaccinationAndImmunizationJCVIMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint Committee on Vaccination and Immunization (JCVI)",
        "label": "Joint Committee on Vaccination and Immunization (JCVI) [Member]",
        "documentation": "Joint Committee on Vaccination and Immunization (JCVI)"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_June2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "June2021SalesAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2021 Sales Agreement",
        "label": "June 2021 Sales Agreement [Member]",
        "documentation": "June 2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset, net",
        "label": "Lease, Right-Of-Use Asset",
        "documentation": "Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r46",
      "r48",
      "r49",
      "r50",
      "r51",
      "r188",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r439",
      "r440",
      "r441",
      "r476",
      "r607",
      "r694",
      "r759",
      "r926",
      "r973",
      "r974"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r96",
      "r550",
      "r732",
      "r873",
      "r899",
      "r967"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r151",
      "r188",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r439",
      "r440",
      "r441",
      "r476",
      "r732",
      "r926",
      "r973",
      "r974"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LicenseFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LicenseFeesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fees",
        "label": "License Fees [Member]",
        "documentation": "License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "nvax_LicensedCOVID19ProductsAndRoyaltyPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LicensedCOVID19ProductsAndRoyaltyPaymentsMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensed COVID-19 Products and Royalty Payments",
        "label": "Licensed COVID-19 Products And Royalty Payments [Member]",
        "documentation": "Licensed COVID-19 Products And Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LicensingRoyaltiesAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LicensingRoyaltiesAndOtherMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing, royalties, and other",
        "label": "Licensing, Royalties, and Other [Member]",
        "documentation": "Licensing, Royalties, and Other"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "label": "Liquidity and Going Concern [Policy Text Block]",
        "documentation": "Liquidity and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, expense",
        "label": "Litigation Settlement, Fee Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r31",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r298",
      "r408",
      "r700",
      "r922",
      "r923"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r298",
      "r408",
      "r700",
      "r922",
      "r923"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r847"
     ]
    },
    "nvax_LossContingencyExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LossContingencyExtensionPeriod",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency extension period",
        "label": "Loss Contingency, Extension Period",
        "documentation": "Loss Contingency, Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lawsuits filed",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923"
     ]
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfDefendants",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of defendants",
        "label": "Loss Contingency, Number of Defendants",
        "documentation": "Number of defendants named in a legal action."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923"
     ]
    },
    "nvax_LossContingencyPeriodToAnswer": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "LossContingencyPeriodToAnswer",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period to answer",
        "label": "Loss Contingency, Period To Answer",
        "documentation": "Loss Contingency, Period To Answer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "nvax_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities [Member]",
        "documentation": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_MatrixMAdjuvantSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "MatrixMAdjuvantSalesMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matrix-M Adjuvant Sales",
        "label": "Matrix-M Adjuvant Sales [Member]",
        "documentation": "Matrix-M Adjuvant Sales"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r146",
      "r147",
      "r294",
      "r295",
      "r296",
      "r297",
      "r368",
      "r408",
      "r457",
      "r503",
      "r566",
      "r568",
      "r576",
      "r599",
      "r600",
      "r654",
      "r656",
      "r658",
      "r659",
      "r661",
      "r682",
      "r683",
      "r698",
      "r706",
      "r717",
      "r727",
      "r728",
      "r729",
      "r730",
      "r743",
      "r928",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r146",
      "r147",
      "r294",
      "r295",
      "r296",
      "r297",
      "r368",
      "r408",
      "r457",
      "r503",
      "r566",
      "r568",
      "r576",
      "r599",
      "r600",
      "r654",
      "r656",
      "r658",
      "r659",
      "r661",
      "r682",
      "r683",
      "r698",
      "r706",
      "r717",
      "r727",
      "r728",
      "r729",
      "r743",
      "r928",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.novavax.com/role/OrganizationandBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "terseLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r74",
      "r98",
      "r149",
      "r167",
      "r170",
      "r174",
      "r188",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r216",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r433",
      "r436",
      "r451",
      "r476",
      "r553",
      "r630",
      "r647",
      "r648",
      "r757",
      "r926"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToParentDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToParentDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss), dilutive",
        "label": "Net Income (Loss) Attributable to Parent, Diluted",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss), basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r217",
      "r220",
      "r436"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NetProceedsFromTheExerciseOfStockBasedAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NetProceedsFromTheExerciseOfStockBasedAwards",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from the exercise of stock-based awards",
        "label": "Net Proceeds From The Exercise Of Stock-Based Awards",
        "documentation": "Net Proceeds From The Exercise Of Stock-Based Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NewZealandRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NewZealandRevenueAgencyMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New zealand Revenue Agency",
        "label": "New zealand Revenue Agency [Member]",
        "documentation": "New zealand Revenue Agency"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NewZealandTerminationOfTheAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NewZealandTerminationOfTheAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Zealand, termination of the agreement",
        "label": "New Zealand, termination of the agreement [Member]",
        "documentation": "New Zealand, termination of the agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets from new lease agreements",
        "label": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "documentation": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r816",
      "r824"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America",
        "label": "North America [Member]",
        "documentation": "Continent of North America."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "nvax_NumberOfDosesToBeDistributed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NumberOfDosesToBeDistributed",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of doses to be distributed",
        "label": "Number Of Doses, To Be Distributed",
        "documentation": "Number Of Doses, To Be Distributed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r882"
     ]
    },
    "nvax_NumberOfQuarterlyInstallmentPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "NumberOfQuarterlyInstallmentPayments",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of quarterly installment payments",
        "label": "Number Of Quarterly Installment Payments",
        "documentation": "Number Of Quarterly Installment Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.novavax.com/role/GoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting unit",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r695",
      "r881",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized loss on available-for-sale marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r554"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r90",
      "r168",
      "r171",
      "r200"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r732"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other items, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r780",
      "r790",
      "r822"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r783",
      "r793",
      "r825"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r783",
      "r793",
      "r825"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of costs related to issuance of 2027 Convertible notes",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForCapitalImprovements",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capital expenditures",
        "label": "Payments for Capital Improvements",
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "nvax_PaymentsForSeveranceAndEmployeeBenefitCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "PaymentsForSeveranceAndEmployeeBenefitCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for severance and employee benefit costs",
        "label": "Payments For Severance And Employee Benefit Costs",
        "documentation": "Payments For Severance And Employee Benefit Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Internal-use software",
        "label": "Payments for Software",
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of available-for-sale marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r179",
      "r245"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value per share (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r341"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r609"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r341"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r609",
      "r628",
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized at June\u00a030, 2024 and December\u00a031, 2023; no shares issued and outstanding at June\u00a030, 2024 and December\u00a031, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r546",
      "r732"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development, tech transfer, launch, and sales milestone payments",
        "label": "Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payments",
        "documentation": "Proceeds Development, Tech Transfer, Launch, And Sales Milestone Collaboration Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ProceedsFromCollaborationAndLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ProceedsFromCollaborationAndLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaboration and license agreement",
        "label": "Proceeds From Collaboration And License Agreement",
        "documentation": "Proceeds From Collaboration And License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sales of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service, Other",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "verboseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r144",
      "r237",
      "r506",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r687",
      "r707",
      "r742",
      "r743",
      "r744",
      "r746",
      "r748",
      "r856",
      "r924",
      "r925",
      "r930",
      "r987",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "nvax_ProductReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ProductReturnsMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Returns",
        "label": "Product Returns [Member]",
        "documentation": "Product Returns"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r144",
      "r237",
      "r506",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r687",
      "r707",
      "r742",
      "r743",
      "r744",
      "r746",
      "r748",
      "r856",
      "r924",
      "r925",
      "r930",
      "r987",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r493",
      "r542",
      "r551",
      "r732"
     ]
    },
    "nvax_ProvisionForExcessAndObsoleteInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ProvisionForExcessAndObsoleteInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for excess and obsolete inventory",
        "label": "Provision For Excess And Obsolete Inventory",
        "documentation": "Provision For Excess And Obsolete Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r146",
      "r147",
      "r294",
      "r295",
      "r296",
      "r297",
      "r361",
      "r368",
      "r398",
      "r399",
      "r400",
      "r408",
      "r457",
      "r501",
      "r502",
      "r503",
      "r566",
      "r568",
      "r576",
      "r599",
      "r600",
      "r654",
      "r656",
      "r658",
      "r659",
      "r661",
      "r682",
      "r683",
      "r698",
      "r706",
      "r717",
      "r727",
      "r728",
      "r729",
      "r730",
      "r743",
      "r751",
      "r919",
      "r928",
      "r965",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r146",
      "r147",
      "r294",
      "r295",
      "r296",
      "r297",
      "r361",
      "r368",
      "r398",
      "r399",
      "r400",
      "r408",
      "r457",
      "r501",
      "r502",
      "r503",
      "r566",
      "r568",
      "r576",
      "r599",
      "r600",
      "r654",
      "r656",
      "r658",
      "r659",
      "r661",
      "r682",
      "r683",
      "r698",
      "r706",
      "r717",
      "r727",
      "r728",
      "r729",
      "r730",
      "r743",
      "r751",
      "r919",
      "r928",
      "r965",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r775",
      "r785",
      "r817"
     ]
    },
    "nvax_RemainingPerformanceObligationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "RemainingPerformanceObligationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of transaction price not yet satisfied",
        "label": "Remaining Performance Obligation, Amount",
        "documentation": "Remaining Performance Obligation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of 2023 Convertible notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r684",
      "r696",
      "r981"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_RestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "RestOfTheWorldMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of the world",
        "label": "Rest of the World [Member]",
        "documentation": "Rest of the World"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r776",
      "r786",
      "r818"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r777",
      "r787",
      "r819"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r784",
      "r794",
      "r826"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, current",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r152",
      "r185"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash, non-current",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r105",
      "r185"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r282",
      "r285",
      "r290"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Restructuring charge",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r286",
      "r287",
      "r920"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r86",
      "r549",
      "r573",
      "r575",
      "r582",
      "r610",
      "r732"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r260",
      "r261",
      "r271",
      "r423",
      "r424",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r442",
      "r444",
      "r445",
      "r447",
      "r449",
      "r488",
      "r489",
      "r570",
      "r572",
      "r584",
      "r1022"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition services revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r225",
      "r230",
      "r231",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r357",
      "r358",
      "r506"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Revenue",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition, Licensing and Transition Services",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r686",
      "r691"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r175",
      "r188",
      "r225",
      "r230",
      "r231",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r259",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r476",
      "r541",
      "r696",
      "r926"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_RoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "RoyaltyPeriod",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty period",
        "label": "Royalty Period",
        "documentation": "Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "nvax_SaleOfStockAmountOfRemainingUnissuedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "SaleOfStockAmountOfRemainingUnissuedShares",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining unissued capital",
        "label": "Sale of Stock, Amount Of Remaining Unissued Shares",
        "documentation": "Sale of Stock, Amount Of Remaining Unissued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SanofiPasteurInc.APAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "SanofiPasteurInc.APAMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Inc. APA",
        "label": "Sanofi Pasteur Inc. APA [Member]",
        "documentation": "Sanofi Pasteur Inc. APA"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r851",
      "r877"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario, Unspecified [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r205",
      "r369",
      "r847",
      "r877"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/EarningsLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.novavax.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913"
     ]
    },
    "nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue",
        "label": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]",
        "documentation": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r91",
      "r984"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r79",
      "r80"
     ]
    },
    "nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Gross to Net Deductions Balances",
        "label": "Schedule Of Revenue Gross To Net Deductions Balances [Table Text Block]",
        "documentation": "Schedule Of Revenue Gross To Net Deductions Balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Based Compensation Restricted Stock Awards Activity",
        "label": "Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]",
        "documentation": "Schedule Of Share Based Compensation Restricted Stock Awards Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Option and Appreciation Rights Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Estimation of Fair Value of Stock",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "nvax_SecuritiesSubscriptionArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "SecuritiesSubscriptionArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Subscription Arrangement",
        "label": "Securities Subscription Arrangement [Member]",
        "documentation": "Securities Subscription Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r125",
      "r127",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r238",
      "r239",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r596",
      "r597",
      "r598",
      "r655",
      "r657",
      "r660",
      "r662",
      "r669",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r688",
      "r708",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r745",
      "r751",
      "r930",
      "r987",
      "r991",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement Agreement",
        "label": "Settlement Agreement [Member]",
        "documentation": "Settlement Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "SettlementPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement payment",
        "label": "Settlement Payment",
        "documentation": "Settlement Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and employee benefit costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Restricted stock units forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding and Unvested, beginning balance (in shares)",
        "periodEndLabel": "Outstanding and Unvested, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding and Unvested, beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding and Unvested, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per\u00a0Share Weighted- Average Fair\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription rate cap",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, stock options and vesting RSA's",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum grant price, percent of common stock fair value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent",
        "documentation": "The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average Black-Scholes fair value of stop options and SARs granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding (less than)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase of shares each anniversary",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ShareBasedCompensationStockIssuedUnderIncentiveProgram",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under incentive programs (in shares)",
        "label": "Share-Based Compensation Stock Issued Under Incentive Program",
        "documentation": "Number of shares issued in incentive program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationStockOptionsandAppreciationRightsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining term, exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining term, outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r156",
      "r157",
      "r158",
      "r188",
      "r210",
      "r214",
      "r218",
      "r220",
      "r227",
      "r228",
      "r259",
      "r301",
      "r303",
      "r304",
      "r305",
      "r308",
      "r309",
      "r341",
      "r342",
      "r344",
      "r347",
      "r353",
      "r476",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r609",
      "r631",
      "r649",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r846",
      "r871",
      "r879"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r56",
      "r57",
      "r148",
      "r172",
      "r173",
      "r174",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r226",
      "r260",
      "r261",
      "r271",
      "r354",
      "r423",
      "r424",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488",
      "r489",
      "r494",
      "r554",
      "r570",
      "r571",
      "r572",
      "r584",
      "r649"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r125",
      "r127",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r238",
      "r239",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r596",
      "r597",
      "r598",
      "r655",
      "r657",
      "r660",
      "r662",
      "r669",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r688",
      "r708",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r745",
      "r751",
      "r930",
      "r987",
      "r991",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r489",
      "r506",
      "r577",
      "r595",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r752"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionLocationActivityAccrualAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Axis]",
        "label": "Statement of Financial Position Location, Activity, Accrual [Axis]",
        "documentation": "Information by location in statement of financial position in which disaggregated accrual activity has been included."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r969"
     ]
    },
    "us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionLocationActivityAccrualDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Domain]",
        "label": "Statement of Financial Position Location, Activity, Accrual [Domain]",
        "documentation": "Location in statement of financial position in which disaggregated accrual activity has been included."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r969"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r205",
      "r369",
      "r847",
      "r848",
      "r877"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r241",
      "r489",
      "r506",
      "r577",
      "r595",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r752"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r779",
      "r789",
      "r821"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under the Sales Agreement not settled at quarter-end",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r53",
      "r86",
      "r578",
      "r649",
      "r664"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r53",
      "r86",
      "r384"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from shares sold, net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r53",
      "r86",
      "r584",
      "r649",
      "r664",
      "r758"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r77",
      "r611",
      "r628",
      "r650",
      "r651",
      "r732",
      "r759",
      "r873",
      "r899",
      "r967",
      "r1022"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Deficit",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r187",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r448",
      "r652",
      "r653",
      "r668"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r496"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r496"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r496"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r497"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "nvax_TakedaArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TakedaArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Arrangement",
        "label": "Takeda Arrangement [Member]",
        "documentation": "Takeda Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "ThreePointSeventyFiveConvertibleNotesDue2023Member",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes due 2023",
        "label": "Three Point Seventy Five Convertible Notes Due 2023 [Member]",
        "documentation": "Three Point Seventy Five Convertible Notes Due 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA",
        "label": "Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA [Member]",
        "documentation": "Transfer of Approval of Marketing Authorization for the COVID-19 Vaccine from the FDA"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TransferOfEMAApprovalOfTheCOVID19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TransferOfEMAApprovalOfTheCOVID19VaccineMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of EMA Approval of the COVID-19 Vaccine",
        "label": "Transfer of EMA Approval of the COVID-19 Vaccine [Member]",
        "documentation": "Transfer of EMA Approval of the COVID-19 Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TransferOfTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TransferOfTechnologyMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of Technology",
        "label": "Transfer of Technology [Member]",
        "documentation": "Transfer of Technology"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TransitionServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TransitionServicesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition Services",
        "label": "Transition Services [Member]",
        "documentation": "Transition Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction gain (loss)",
        "label": "Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax",
        "documentation": "Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r62",
      "r968"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, cost basis, 1,376,106 shares at June\u00a030, 2024 and 1,000,323 shares at December\u00a031, 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r56"
     ]
    },
    "nvax_TwoThousandFifteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015\u00a0Plan",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TwoThousandFiveStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TwoThousandFiveStockIncentivePlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2005\u00a0Plan",
        "label": "Two Thousand Five Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TwoThousandTwentyThreeStockInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "TwoThousandTwentyThreeStockInducementPlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofShareBasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement\u00a0Plan",
        "label": "Two Thousand Twenty Three Stock Inducement Plan [Member]",
        "documentation": "Two Thousand Twenty Three Stock Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r714",
      "r983"
     ]
    },
    "nvax_USGovernmentPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "USGovernmentPartnershipMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Partnership",
        "label": "US Government Partnership [Member]",
        "documentation": "US Government Partnership"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r714",
      "r716",
      "r722",
      "r983"
     ]
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled contracts receivable",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtNarrativeDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofConvertibleNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r108",
      "r110",
      "r111",
      "r112"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "\u200bWeighted average number of common shares outstanding, dilutive (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r220"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.novavax.com/role/EarningsLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "\u200bWeighted average number of common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r220"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/EarningsLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "\u200bWeighted average number of common shares outstanding:",
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "WholesaleDistributorFeesDiscountsAndChargebacksMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesale Distributor Fees, Discounts, and Chargebacks",
        "label": "Wholesale Distributor Fees, Discounts, and Chargebacks [Member]",
        "documentation": "Wholesale Distributor Fees, Discounts, and Chargebacks"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20240630",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001000694-24-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-24-000035-xbrl.zip
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M<[U>$LS9 %)5=-$?@P!^0LBW+_W)%'HAT9:] "G/)XAI_.EU<<D#>,4?]7Z
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M!WU+/.<6\C<N'@+?CJWH/NC#X-FQ8._%0:O6S&9)OTUN_?G#UB?.)S]_\0%
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M@0")(6 _ J@-@Y2! )DA8"\"#&IC*VP5.(T=8% ;O&&KP(D00&U4B*T")T(
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M]KVG" 83/)C%B;;9MU^1PV_% <YE&M:G-(E);1R&L?Q(Z[]);1AE)\L'8[0
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M- K[E PS%&+&/ YF\*%.0>=%462H:2!J1.$XL-'1 L5+8F'/O230G%DL^M<
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MB($+M6LB+VDZ+TJ;Q-CB+!Q])CL=I S349/B:(8I\H*XV<YG-IUL#L_19>Q
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MZ+AL.[CNJ^(MBS[E7@UW9,0@119 $,(KF/Q[Z\V(Z^0W9Q6!)(V).BWQ K9
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M)0Z1)O9'T0\0G-G.SI%LXWY*S&V@5UI=3:(@$X59O!59O MPY%R"5=*E4*/
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M,0'*A;"X!0Q#WXVCW;<L8<^"V!PL6ZXSDE5=LT:6?N+18FET@(C$2+05R8)
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M-R+Q?V)$Y*C#I4Q&-M((!I@IMH-_0X!T2"GRE.C<%$T.AZ42+B&6#0DK !?
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M[.3Q UOQG^)+I<XJ=7[%2ZID,HBW8HD6Z #N*AR3$.;Q(&A,%;R)OJ=*5VV
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M<B2AO@!&9.B*3O#@@*YI(WL"-4PW'DT/U\,'3=]GC ]>U:=S$W:!,UI1'.+
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MP#WQ'8)Y$MX878O4B>A)!/24>Q#H]_%#@R0&\O.BXY9PP2<&TZ=K]9*CZL.
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M%,ISL4&!@W#;_8Y:.*)C'TQL:[:5N&+#-$2"E+CJ0IGFN!G:7*6$<U16R._
M+?Q4'YYU*;LGQ2G69+?V,K-;^[&,@-!HH$%/BN\^\D:AV\DD5Q*FH.&8J+_0
M;179$JH#,/5M&!4FQ[?V3D^;(=?2I:)8.[>VB( YMFY)C+<]Q_7-8*'Z.3^:
M[D)#J@12@M-/V%RW9M()\)D9Y!>]>??]"WGAD B4=4R<AV7;C'.8,'$<)QW9
MS,792L0OF&NMM)\VNDAU3_NZ9,*T^E-WE]K=$K-E"0:)P_G. _<AA0NG8:>
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MB*7%I/Y M8]R9XVTC2KC(IQ!$,<G\5-N>]1H9L$,$PUO9:]XV(1B$HCX/WJ
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M:[R7[M)EEYB:AZD[*Q2C2O'TQ_>ENQ$-1D<*89S^L#& 56. ]Q^1$ _U]]*
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M@;>E&OKJ8(WOH%U5M>41#9<XP3C/'5N8ES/3-L%J-[0'QS&V&PS\0M)H-A5
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M,JTQ2G.),88E)KWX#>6;5NP;N.1&9(>%PEISR/OJ82=GT2,"G>4" 6*/@%:
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MNLD.;C*OBS9<L5>NZ-10?G8;^;G'U*$R2NG65W[V=B8_][W)#?(3$4Q:^6J
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M/:S0Y=Y+KNX]\YJFE T&, Z =ZSZ:E( ,V4[X(>5!QCT;J7MH#?8A:62>AS
M78=(CB$U;PI\8:V%&R;N+XQ^4EL#&"SV71@9E>RD.9)Q*LHC)\,3B6IM)4YT
MI'X@0S'EO53KHU+:7.-A[5-P ;I]"IS@=>@NK!<\@NP8-U\G8^''X5.K8+5>
MBN2+M]QWQ7IQ\O&/_WMZ'OS1Z0Z[>1).OBF_D% T;/?__O)+P8B*X^2X@[:3
M^A)=R9+#T^H[Z@[PM$_A/WWY%]EFCCJ=Y08>MOM%3)<>6GT 9K8Q]WVNXN7,
M^,;FN95DLFB;5JK8/M.O)C^O_L1GOI+D<M&)C,1RC6WSR,\< YN&W#:&NWIA
M@S/D! ZI^0'<]00^'(?)T<Q=%)+('[--JZ9ML3SGF!S,$Z 4LUZ(UG7+MM+R
ML* 1S]GTK_C6Q=8R<@NEWS$_:[U 3^ IL0L^!K#7E_IVTGD*:D>_MRY;+#O4
M^##6=]0_#Z^R&';0&W5>[]/T5(=- =OOI[]?FK?_,DW[F19 2.@O2NBX@,5*
MF.'ER]?R<9%-Y7 I GY:*6'_%P?'Y5-B"OTD+!$&:W>N.RK!.8'H"[#O]C(.
MHQAH#==,TV"C&(K=*(4-S$!ZEMSK4)!P3_6PNG3]8.99Y[^=:7%$(D#^_C.L
M4\"P*:V!_Z8^_]I8)JA[W\3*P@N*9"K/ O\'3U^*W&FL'GCY YP,Z)<HGN!-
MI" -!IO<"?!$Y,[$:FW++E*R*6B\\LSF5EL/:V85R>]A[W(B7'CXKD7!-[5H
M1I_5X@H?RI46SYR$Q*P.5#6Y\8&FK[T-\RU#H:8L7"9^)J-O:$^;\$.X6O.Y
MTT.ML/.AG!5;8\?49Q&T'<R9HB-)Z$AJ[Z029 ;@S<I^L\E"HQ40(ZZ.-12\
MRO28/!/NT9#F,P_%<GY/^+%T+S+4NB8>7K-:LCP:4M2FF.'E7<7\$Y,4^E=Q
M"DE46<;#-),XN3ILU>J+L.AXB=*E&%8A!+A,;^(MZ=@#GS6K;$(:T,)"A*@R
M:4(,)9_AXR1] ?E'I&@\^+"A+,!%4&M;T!?]4U3R9/A_$?CPS,SI"Z%UY<E_
MS_A-D69 NAGPYQOL$-RY^KEK_3->X,E>>>%4BF2^<EL?DE["A3^;Q\+_VT6W
M[972-;08O#C78D*Q@29@/1APDS^%QP 54$^/E_O\:^1TL($HP@KW0HDW!>?&
MCSRV>YM/P1Z7.N]5 %JE"'D+,(#J?HJ,C"ZD)5/ M4!YO00]D,/6>%)2S! E
M('-)LB,WI+]2AY)T/365E(D<819S6VA.7"+M?'K+N4AQ.*&CUP(WTN=W]ODL
M2JE]U+-N;7Z4I K\<ZJ"SW;&SV2;%JDV2,@(Y ZIB,H2H_#BMQK)(2!7>X06
MDYZ*^0%4%V]. 7=ZH+#[*JQ?2KXXPM-4]R(_RC8(MOECNP'&EWF9\[42$HF=
M)+DO;?MP!S[9;C;%#4#M(%/(QN7U9<=#IUIR/*\-F;5P5W!0$;_B@EH(HH'N
M^2WK5[4^>Y/!"(2)7:@]=$.PRJDL*=Q]S$UR@0JG;%_?A!CBD(<:J?>4;/9;
MD;6$%V[..)Y@V^N<Q>S-Y[G?%7T0%++(@VO+C>KZV5^II(?\ MB&S/Y>2JF"
MCX/Q#QR7^7TB,+-_X2<[^]M(B&^YW<SSRY::46XWQ+:Y06\*3[/HEZY7I+V1
M/R79 35(%M><6JS[$",CLKN%20Z[A+LA<0_S*"H J*^H_LGHW' Y7;"4ZEC(
MRQF(O(ZD7_7[\DV3XT=0ZE#>^>.CA@'70:ET)("EL\5P:6$741#_[I3<4&L:
M\(HREP(?W5520Y*MXJ4C37MIM + OA]J)LE32$5-R29;3ZV],Y1P+J[)121)
ME%]?4W&0;CB2G+""J?26@1()5JQ4:)F$Y/@3Y6.-6M:&<Y/MOLT\II0C,/2B
M;]+SA$U4*:6+!.[JQL5426 '$',HRC*I4J1*R1</7@MLW<TBE;IJSW4*51#1
MPPE?H[.F9+*YQ[E@^,24$[K-S@;<M$ +R+;606PQWQ*?P!%/N!DG2AEB*GC
M/'9@^LD#=J]/D ZAX PV.@0S_C68"6@OPEQ?SH"#\T83,5%=A:&;"I()TOC!
MD?(Z3**;D?:"SD#8X!3/\Q:5Z("4[E-0FS').5KCBYE8)'C@L,-TLMQ&MY#2
MQ8P]J;1IU_K%(TME$EF_2>/PC!/O4LK>+X9-J%V(Z)X "I49RV_#&)YDHQ##
M^#I_\JTQQA;K?HU!?C@"_UI$V>0>F,!G+X0R=GT05$J]O_&6IN6:&BB"*:+9
MFNTA4DMQ*2E?MQK&UHJD,CX3<S1E7=ZXF!P!["$M #-K.ZV*XQT;6Z$&]J#V
M_ ?XSYO)0R<^IG1%U4C9EM)&7R#R/&[ %_AU3&M$.N6=F8F3Q2ZUU'G [L&*
M<M<4XY 6(YEB68NR[#O!E3),\K/]G5"I89L;=F[6K9UU>^)C"-RV'9UCZ",)
M?Y184K@/W 2S.1@QNS!>4E9LVE"UR-E$42!Y9O"+Y"Q9L\5@RLIE$WHJL)NW
MD*+N4H3Q@AXX;Q6SQ_X"IG6MS[>KEO7;:FJX8BXN4O8$?_4W;R:LRXDGZ ']
M#<4<^B+5=WZ[-/R_&3Z  ;5GDP9+L>\D.#5,3OHZ2BSM:/A\?B&#YK@2K%:0
M>4$H(&[4A>>$H[(P,!=HPGE F"^DCP[.-HSYC;.T%]?HS1S(2)WR#&"V*>A"
M\)K!QQ![ HX<GS1O H_=VJ#>:.)B]4GHWNFW+DKL,B]-JP9%+T-/K) %E?_G
MM;:<Z 4CJDO+@9L8"$;'@\B+5^(&,090BHPAQ<GAQPJ)3UY#S7^@>MQ@5-N0
M<1G1!F>WP*3G)8B)OV#::.K)SNJ1AW]P?0&2#\VD.:A6TG)$W]@U6W"%+IZ\
MBREO+1MRQ*,<5.[3KEP5^2#0Z^RVY?LKKY@>SMRXR;TF#AJXH6"IB54^T4!V
M8KE2H=%"DB0OU[I<H"2N&8,A4@M:"+&28;E5J-4MH[2'70>&Z4^WI2\HV0/&
M(F'3/GY*.VV(9:DJ*M%M6" ;4Y0:$L\ROZ3?Y+M6/S6T!DRF8U,"2RLDI:&O
ME;1+=(E95-9&,GD&#SNHC=)E*OW*JDX/%-I;CV2-4DO)FF!S!'F9PL48G);V
ME_ZB$>](^[.B3;HC:PNN<ET9B@1Z#(&3HY7F]4WC&/&,>\9(-EUJCR2.)MCP
M9Y#2%KR]E*WCG*DW^ M\V7H/XB,((^VU8)EUYOLQH1!GTTW^K54G"O]SV$25
MAEFJ*LR64R9SMK:8='.:BYIWYF%J,:JX^&&Y@@]4X"VG[\E'_[[,&94%@ 1W
MA></QS<7;'TL@JFLMDR42'P&Z-2GP226J0ST!5U"=?GN7)HSJ&3*I\76*2>)
M0Q3(_.[NKA6)20OD+W^ ?^5SR+<%(KIE_0^8L5RA"O9U"-)#UJBZ4^G3D>\D
M&G[:5[%PI^)(W#Q_DE:,%OPU7"2&O462'4/>!5OZ0VQ.C2']CGW!H&D83AVR
MHMW)#3I0\>I:%F9DX>_F<T5_&Q-^2N@):0?6@ZH4R0UT\OK O7%(^3 I/P=[
M/BBV@C22=I. /1N'2%WV9F<'9BVXWR+V17&]IDZ_N;L1H &ML(P-B8 )[TY6
M0*_<;Y@1!9H,W+2K3%VF;9:/MUXD[O6TP!S$ ^1JD#(5UH#F,I@T5!% %F8J
M:2SQ:][!'#8L:(YFJI3R5+P]=^]:1#8SE@T63(@E1"7LQ+LDWX[T5I. X/<"
M7@#4/B5[JP'1_PT, @M #Y^%Z&R\U#M-95@B$$49>T&X>A"E,^OX@I1)P"V"
MWPV>D@Z1OD$[GQCA+G0Y\H)L(IY"E]E];C*I(F[C&SL227"1T%8Y,QKI7$GB
MV0*>9Z1$TBWN7$DTH0#319[?!$O82&,G04[.)1UVD@H]/@OPN9@-"[#18'#0
MI)/PVZ]G9Y^SZ65W@B-&,NF#"S^%3%I3 "4M"Z0<RFWIB&/#A8C;/\51B_:"
MXT4>Y7DP=Y-K0=I1*0IE9HG2#NZSPI48Y^=K-S#]%0<'\LJ:E50>S^<J> -*
M\9+YBO*Y*L%?@5,D7UG*K%MB0CR:RJ4A>)Z0?+M:I'!6UY40?JH6%,;&5#X?
MAV:)7WZHD;H ,57)H])/EOB1K]"C*NZH LMF+PNY4;0G(CND*>%P6IL7Z@?Z
M3&F=\'F?Z4I$D]"[,K_ MN5:S6_&A5AO!&UHHKPF>%D>L!^H9GH-2!%)2,D'
M];! )FR7 (^HO#7.1O]TBXXA<7<<(D^*!5<EOTYDK1LG S"Y!"N!^Z'HE/0C
M2EL?6>>#NPJ][Z<?#B^[[^O3K'G;FC+E>FM9GS)..3-92^=EK=%EMD+Q"NP=
MHM@5K$0L@SO!*4V@M3%T"SXLL&=0Z8$2!?N^,$<%/8@>9Q*S6QMD&BP)$XL7
MB]@/X'OP+9@W0)^;-YF+Y,)!9,/QR>3"Z10C:(IH;@0&C$$]$T<3^\4KR?G,
M9=P7CD>Y^UCR@::D%0=ZSN&M#S$ER[Q(R4?*_P "="(5K1G6BZ'6APY0O .J
M._4B\^Z%C])8:8T+S&./UA&:O1P8DP6I*RPP->8R7D/^):6*JA$P<RSP(ZD>
MR,P/7E]@[-]8!KX1<[(,9;VZKY+BT29*C ^/;=GT-(GGY4IP*KP,35&X"O[H
MP]G"H=(1!FC>$.'2*.3W"*TH !V='QJ=Q8B/.6C/N(NR6\-$;- [@G 9L,F4
M8;C(A05J&:<DFDHU2W(D,8OQAI0XXQ[4]K HPR-/*G.5"&4E!6< ^!,F#XJS
M7P53<LYS8B@QHFM-Q'P>XZN:&;B<I>K+/W]*;4D2'V,W%-4'P%+!D)[&%+A
MWX/38=?3')W+RA\3+X&1D!CNC1F[!#0ER$!)!_14W4AF$2S#YFOB ="V%MYJ
MQ<O5:5HJ7&OHGM<AY\=_ BL+G5+HD++>D37I3];6[QB23LVN5/AWOR<!9<E$
M*M!L2T\/9:A:5)YQ<<&.>W,#XKM'D53T1WUC%WWQ5!\R*=$XU[L8R!X40>L#
M6J\DV,]XR7J!R==L'=CZW:<(W+]ALFFP^#^)1?+[O_4<R8CXK7_2FS!AFT-F
M-W])5/#,I!_^^24SJW$4J<W13GAPZ]SUW:E+1?J1O#O**D1->8Z9ZKCTZ]AC
MNRN3 H#G#7OEQ)8_,3=3#?LIO 8--G.8?_[S4_Y8/DJ1#[;.K1?AOLZ#!1$0
MQ4$O2'(I\O/--#S\Y[\^MAP+60>3%&5<)B%XIE(C.$,$RBEIY#S&A($B@HZ7
MR JI0]/I61P_VO!(;R]1B@(#!R&:+ORD3N5I%,#.=@K@/K7/.Y$!_)/0AHHW
M$BW@E]_.S,AQNF[,4L&$5*T2NB&40V,FO7ZP;&)=E*NL,:ABOC-XAN<H0/L_
M@"R?9=QP<-!QPQK)C0^N0E:X(T1/P=X]^8XGI4AF(I?-Y:ZG9LV%*'0ZI7(U
MV+.M9;L(^6$CME3FEPH*YJ+\K-"3+UH7VA;4?!0J1"WK%P&7XDMD.=*UN&:$
M!J+R#P._1H ]*M^S9/]T/I3.P[^2*S$/H+!0(BF1*'"9N@5;H%)<BJ!.C:H9
M=?"<H*#=I.GSH/@K%2^@YU(K59B?KW)OT@FSDU0BBKJHK^XW,75YVHN+EO4[
MOK[H19D+$U?#'#\J/)Z_ H\,<]J-Q8-D=FL4(*B0 2X)RX+Y)S,G!AVP''S@
MP@$YUPU'\2QJ3$,Q &D>^@&&MG3&V*F^'#.PH+T!7,2V,2$JJ;(CJ 9-K+FD
M-#LUA=86C125TCEDFA 9D^AUS8TM;2R=E((AI))--(ZL1SNRI#<1EG7M2>>Q
M2MHM+0!UHRB8L+] 6RFJSHPC!F4I3@5$MAWYLJ&(H5GELLX3N&07]%9(#L$4
M5V!<C.]%>H4J.S397I):(2+#_&W\I;LC,W*.F7G3$M^()5NPQ#@=NXR2<"VA
M+K"@H&3G#7#]2V]).^::ODB97K)JC>-F23$R(6J'G+)!R1WX&T),&B0US09V
M?Q%:Q9$X3=,/#B>XN^$IZ0A\_AYEA,H#)Q=-<39SBM?<5$YS^3N2^CHG);A\
MW9B_^(T#=52>A]XV+B_M<JJXPLJ9!7B5.N\') ^E^B 9P17<%#@7=4K%@FI"
M[H0BQA2SYUR)G(QLE+JGE I8S9>.\W/IMQ?N'!6]Y '5R,+*[N>H,T./H](3
M^RL&O3%E6*Y46FU/LT=.:F67DJX4X&I#-U_3@&?["VHY_]M=+%];'Y"_0&OZ
ME=RSY#CB=O0\J\X</Q*^2/EMF!$(.\?T,V%4!==.?TF@82*%"ZT4/WTC*W+I
M>PIQ!$A5_?2W!G;614#5:D\0-$A,XI72C!2K2%B:!%P'>5=6>53BSRA5"5]2
M1P%R/@!*_^XME,&42/9$CUAAGI&0.-;7/A6D (>4Y2QF2]O9(49\2_YJVJ(L
M#B/)3<@_9G:W#GF3<D.N^PB+'VQ.T)DF8!EA[(,%+=.=*=E?I$)P:($(\8T6
M= 5S6.I9-IXME;J*N*Q"BM+K,+A;W63>)$$9.[G5)M5^* ]@:YCJDWVH.ML_
M5 _&'<5&@C6.ZG]-8EQ'%^!7@;TL#DA1G-<,]FD "B-25OHDX4M+#TL4>\KO
MET41*8&>F!7%[#B2R2K"51BX(&0FP$1<PA$M/1/<7Y823 7&5*E&%@,Q_)#.
MJ+X5F E8A3%]#^U>BPGVBW&1'\V+5-910M&'MN&2B#QU4%$1;D0P)?\;2#QT
M:5!65I*0SE$=E0;!\+433G'F&E:?PK#7^"5T3<P926-&18):.<4Q-&E241/(
M5<:$S@TMP]I8J[-0:6$J6"S#\48Q)&E_/F;MP0Z\B$MY2-S# SN5X1XR<]1$
M>GY<L.?#(:Y,W^.5.XGGH'>&<?34<852?-[B>[M<!EC!!,^?-0OC:["MPJF[
M5T-2UQ'.3G_^Y0\=O\1#Q3I/$&*GLD2<8LN49J%4;)6'H=]QVYHC19X2%+EE
M?$]J&@E!2"I@^N&Y50Z'3,:),LE6DD25UY=#J4M*1IUA?#Q=1:"6*&% )J@*
M$B@!E9>J] ,[EP<"]-A"6# B43TES08Z! 6'2,JRMDJ)BY2P FI^,%]'07@%
M ENN./6D3 *&%W6)UKWK6!98TV[0Q%BHE!8OQ,P/[U;GIYH<H/*5::3[TI5H
M;/J2.UW+7'D50U5>F+(W[$A>ANSV%)K? 89JLXEQI=H'6K[6-[%.92#)^E&)
M-J:RYR15Z:_BZ\%<K8I ;59D5L&<=/:I-%9B3HA5Y?08;U )/^JQ@"]S]:YZ
M7(QT:Y0K)I#2>61('IU.)>$XP):1)=W\AO";E1I31_89B'*^7BP1KV4J5/88
MNC2P:(2,1]*I<%+;^GHZ(0< #/X+_W,9+!,0+O* S=UHP0E)NFT1W,,BD)96
M G"&FT6>Q!YY'KG<TNE-*I>)T*ZXO%,F-4DO'ITX&%58X>Y%"U5; R,K4>O"
M#N]D]9YYMF@Q<ZV-5#0C2H+.96418L?5FNM8J<"=LR$]?Q(*,ZE5@UF5UC:K
M5!.>XU1OBN@#EG<*3**_H)!XDXEU-K4B/NVWEF(-A/%_8CI>3']YUED:?XI4
MJ$[U!3,KH]/N )TY$^FBZ')C!<UIA&DQ(@+RW9-/,843%2Z7ADP)H]9&&70E
M\/*-'F9^*KA KX_RR4G?RRG*G8P_KP1K G>XR2UH(\)PV4C6A&Q_G>CQ+^'#
M[(FKS<8<+PHS<X7II^\PG6R$MM$7J6;26KC$ZR0-^/+B0KHZ,U:?2GU,RCJY
MI%,7TRZQJL$ &%'K_O.?GZBRRNAR,//":&42!M?Y2@6LBB.5<V)48UXAH51!
MR,RGH?"Y[2\<Y53R[<5M@/7#%(<*8G2?Q5,W%WCU=-Y -Y\WX'('F-,F8<5,
M6!G6-6&E-E7M5!B=!*$>XV27F#[;Q2Q0NGK^QJ"!9$]?)"0O*P=<76G(_NB9
MR.WA\M_6E1=$#/T"W-:R,W@Q2;ZI6LY]PKYDN5@]%GH)6#S!N\Q9XDK'M52&
M7%]'DSG%/ ^:NR8-%-/,^0D@@'?2.;104KYVCFBAKHI9(H$O8XBW D_&1RU7
M1X]543[6=Z70?$CBX!'R@HV8#M* \6#AX5S-W<FW4R!Z:OVP\DYOA8]UWZE\
M)A.6()O+(_^M1;-+J1;B.[Q+$=IL"J#92";)>OJR2?LZR8/M-2X)W'B-K5JD
M:FJ!L%F[VM(E/CS)C?@#C46G#SO+)548.=IXB;\I4."*)U![_?*]3&E]2,\"
MEFF/*Q7X_>S1Z?]G1EH_)K+K9/U_:[L"\^JKY],_4[N#&VC-TGG0='N1OF,X
M0[RZ63'UL'[WG>&X6;)Y*XZ@!1,J26$T+[C+/8DSVN.^,L]Y\B*NHPS(*Q.\
M1#[)"E6Y %R2XJ,Z59/>LU2%"]@SDE63X#O%>(L6D)XXA87G<9_+4XUUJ;I0
M+T"E0LL*5''T(V#X%HA:UI876 %,5_]N55^3K!U9AN3(T2A@;$$QU](,,WB.
MMUUG2@K(\G,:RH.S6\97\*JKPDX=]Y_<!$&44AB5BUL&K3,+J($'PVF-]UU<
M?1>$WZ3/*>728,1XO'D&B)\1AJJW<.7;"Q1OOCUPO^L@QC0 ;9%J\'CE"$,/
M%@)8H2<]@!N4M<0HN230$WG5<#4<5#4 Y2+.&C>7B"NW)G.X3]59)P%RHQ;D
M14B=O"A4$4W4MU2V2Z1;0%"YE'HX9?=5I%596<SK4H]JMBG14Y+7=BH<&)&U
M3FOX+--3/\N4Q@-\D#^9G4*2U$R?D JH"+X@>X K2_.Q?S+?LF1D*]M,!8A4
M%I3'>5H+3*N1W1$T@*Y.=MY8;)IHD480BNK^:!'%1:BY.H5\Z4C!$";6/Z4A
MS>[58['48QUD.VCH4PD*3][ ORD'HJV>LDGA/?EB*GXO->D-(SN72%DU>?)'
MO5'9!\E;7%M1./FO$__6_4X=MMJ#;OO_73NMOY;7)PC!_U\G3ON_K?_N6!_>
MGO$OTSY!I]=>?G^=EC4%"=PT._]9NKX&/6?Y'?UDNPAT/LD#.][J?56=RQ2O
M\$,A ^XIIT^Q0QT6_.7RCW15 .5%*DP!'.^?_8\.^H XNPA;T%A Q"8WY9&^
M3+F0?NDI)FZXC>"O."%GM43RY<1"'#<!-#?141?Q)(BT%RM!,<8 TBE<"+GO
MS8AX_E'7H10&#U&PMR OLBR#BD5\S1IX!C%"+9P[$DB+-*FY,19,"D8B-Q,H
M*@.WVTUR5Q48.56,%K2=,E/$ HD&IW'@W'"^EKVP4NV?UJF,6@(PX5XWDH*T
MO:SQZJ6TNS<E .LFD$N6>/_^]>E<S%:O.ATJI+B'<TZ=T;X8YX7STN(6\_G_
MGF4RR#$U*NE")!3L[RITIX(:G4?6-ET'7UOGP6W 9XW$Q0"CNC>@_*V$L4PM
M09OCV8GMK28N:F'XVOJDZG?RMI#*=DY!KW.90#DYE-[_7B^;%*@7G?++/C<U
M"_)87UY<O+9^E2ZK#4$XCGGK!A+TW=\_7IR_>\^9;RPN=>$!7N39#+NDY,]P
MJS?TH%)PSH,0]!W.QE..U7,ED-XF&;&'MMNM0O5D-$H,RWR#M")54S5(TSU.
M$?0<GJZ)KL@B#P90#\'%R%<QZV&Y*WGF=':'[(=AY(YYJCDCK)-3XGR&YE0-
MB&5CXH(^@X;.B?ULT!D"#\HI0SK*3!=0P:BBV9(M",O%Q[.,\H[J&N6M*?>5
MF/CRN;KDGHOG_%PAB7Y)^X\NF0C+O?LUW79)6C&I=5VG^PJU;U $S"R2.T1P
M1A0Q;CH*KU.W.P*A0GFDC#(U,E"F%'IY1QG-K#-*X "TQE,Z<UJ ,/*9V0_)
M:.6,<"CLO%;1H-A7=T+:C0:_:EEOW97+($5Z;]RB7#6.E8@%"$*+H"R4K68T
M7528G(97SH1$TL#B9O=HH_5,ID&$V9GS2!)CC8:BG_6#4M!:E([_T+9<BEER
M%E_#FA+&0!#JF#Q98+O,9>)&TE,WJ??;V'E58OF)%>/^2J\UT.DR\"26N4Z;
M(H8;Z%?5<0C6'XOC%]PIAIY+JJ_EG%M9)$'Q#>(U:O9EPA52[JAZGF4%;Z2X
M5)<_)@VPC,?]19I]7VH%@+-Z40+<!4D*63'LT0NC5_M+6\*-L1*L.[O"EF%_
MJQO@3GRX5 1GD:1X*%\<LB)GVO%6)'P(]N%+-4V^1$@E+>9D_$=ZXRB-C)K'
M3L6IP&H$'GT2W) &!EMQ[$Z[G5P+(H:0ZP)+2[!Y3A(/3H>EN2'"W"@G7"?S
MRC^XACB"'2C0*%67*->@D1-E6!0_AHDS%#,34^T:@+T:/6)S2S+:J;I:!83C
M<.?KB$V-.:&;2&FN:CJIXD$F_2K#TH_I/!'$4YT+3:=0#Q)=54)3)G"4!@J.
M<4V85!3H6HPK6"AY)!,N[-!-JQZ"=_AF<)M-W7ZQH!$9GZ/1&GB;-(4C$=M\
M \5]G3D1*O$T)Y^2?>X/[0@V)ZN48"5D+!\JC,.^ GG&<1DW(^$,<<J>,=FM
M >@;O7I3;(OH%K14O/CX5N??J3Z 4@QI<%6NY\G&'76-@])7&4_8EKJ6?CEL
M!3[.W0M8L?F;E*JD0;D.8K*(1R@Y%SF6!(BA;*$0P>CE5+=BQO.A@JFUH>AQ
M,0"EH*4#%P7Q"KDXE"4Z?X^F#<4"]:9"M(EDJHTX$QLR;PZ*7/\$42IDMQ,$
M.^"CT6WN"M">.-B4PNVGAK6D?..7J<4P)QJXJJ6:<N)FNQYN0IIR"<A:PM^#
M_7Z+Z%.8&2_=T-R"CC(<E&<<Z(C*]#7Y48?;2K,J= 'I':!*(S37;ZFGBILX
M'(S,,:6%<5]"$ZR$7>@JS2C@ZKIP(7WQ[&51@)\SCSHV1/J]$W?SM6Z^EQHV
M%RA( *$]@FD2#-XLTUPM=T5MX7 3W&HFB9*HSA>D<,&+&"UEP2&GJ('FJ(P5
MHV,$+1$;5#.D=L)G&7M+5MKR_F4$\.SG=)B&C9AC,5S^2<$=-"USZ9I'9*NP
MU=MI]\FB-[,EY0M7K!2[FE&D86*X_I"?;O*'9^9ZNMR$+)-H,Q[W#'=!9/7;
MTF;13@-37Y>0(-,LI2;PWWT+J%)E41G^ 3 ?>,CT1VRKF_X1/P-K*!X$G0P+
M=S6Y4?D+20^H9 6'##NV5Z3<!';LC P,3U<6*8HD&8[2T;1),1<>I1FG9@C&
M&F1O$>7:\WM#I9-3;@*0 #T?&C^7(%04)&&HL!R0(R=A2#EV:#LN)I5JF%W9
MLO3-12PFEB"6)J*FP%E+=H5Z/M7I1Q>(J)@?/?ZDHRA 5:,FY^+";".)#I],
MB4FE&CL3E16'!G:8H 2/MJX^2F'*)-!8[HH1D!0FM5E\$X-U$O%G0-WR*-?+
M^+NL_%V&WD2HJI\U-9\C7$>MM[.;]Q2/81[<P;,28WKNU+OV5E9(CG?&03"P
M)AG#DI/ZV3E OIB^>E"T;RA7QHC?5++&Z"U.2*\<6%T?6&L(SK#/%7TF(67E
MFO161NQ93'.%G$_TBO6&6^R@_!GKC?8!GWD .?^ELH#[*-X*XT\R5S/E0:;^
MA;IT^7/+FKES])5AKW@T$P@M 5E#84"ACV]?%6/[/^YMRZ,KB>VD^=WCZZ/3
M7BAD?36;+#6P45"S(PE].*'@U+J4)(P2$U#U1"4?CBR[5XDGW&0YLLX1G -;
M=5 6BH_M'*G(P;;.;UQX&-^*13!!BW.B_X0+/$>-SK8^!'^[BRM$9["MCQZV
MD^<JS-^OL<->U9R6;9/+N[5.+O]%M7]$^Y0\[E&%YVA/KX]2<[!3+4XNEIR=
MXG/+9!,SDS$;V>.4I'6SYF\F'",=J!K81'5Z8931GJG?OC03S O<?4T/B[)D
MD7%=DT52F7^H5NTE[W-+ZB?G_>#U_AZG=**LTT/3_^3-.Q6AM?X%A@4&2+G)
M>M].M4APHRA>)$%4XTF3H6%/1HZSY9FY,HR\+TA'=(?M_DLS[=26%84<BN!T
MV(7[%W7=IF9*%+W#9G6,ZAK%5W])QRPUN?]\1AV<=9*TB;FKI46!IW(K4= 0
MW^.)[XO"-?BIWT87VWR.0CU>SL( XQ#N6F.7HFF,H>KOU+08[OJG8?(%!&E8
MF8GF,I>'Z+?ZN]A<_)-?_(9N%?$2?X+K3>XW[7=(%S^B N""Y7IC-K8@DS_Q
M3A@>%+.>"T5"-@N>B4UWX,WTN)C-X\W=+9*:JN4<HV^J-45QG<H]S3HRW3F2
MKAFY11<M14IOKAN.#(202B ##4O\*); P";YEXR\&GF'&>@6PQTIZS)N1 DN
MS/W>S:0@:B-9&HN2[$9O,CG8#,8#)5WR;\=)^'=)O0YD>0_R16D+ER>@S3J9
M/RK$2Z)H3FATUQPJ*^HUC2P;XN%C3$VBR%'-6Z.P[(M)/Y6EF*AP?B8,R4%*
MW<.DJ&G#IEX-FW-6;!ERQ#0&[8^Y6@/;34^+>SH>%9VTAWNG$UA",9V<)P66
MNGH[4V=IZ">IB"6!4F"?;\PVGP4@0#4(2)60PX$+1Y4X:K8"4;BW\CA(G2-D
M342WP^+>N7!E)^IKRH(RF[QP+Y>)8&!ABJ3)=C!^ LR''S)JQ'3NW1>"]=/Y
M=T?.6 <A@!D2A:%*TGU7N$0L33&8?JA[X*;LR&[O'\8'-6HL4*&\=/:ABSDF
M/=K6KY1&QA#.9](9+W.E-$[BK_3%I ,XRF8_2J1Y)+#^.M?IBO.NF/PYAQX=
M+ARVQ!<$ W;-V[\_TOLL,^O2S<Q\4S4N%U2R79&B*=*"%:%H K%5MU4"$F*?
MMR8>#K2$PEM<Q:$,R4G[(+$"LDYOSLJ5R;<ZP9"P6R+"2U:NL11J-N(!R;YZ
MH9BI-)KHQET*FU."28E136%0EJ8;:F'6(L.D^A)L]Q'Z2)W>J"3S4W6'JNCK
ME+PML9^N5"JT$9(K*R"HZUGEP2WQK"CM_0/M\E4CLO8ELBY-H$P$3TR!99KE
M"<W#LK];.E/X5NG.!]16,(N\F&Y!0>Z6K64/E\KAT%B/(HM-.:R"@UW''K7\
M;EGO6,IQLH+"A]1M72A\$B\)*F8BO"5)+B"N1BO>&P5]314:@96S7,G,+54-
M6(C](+4-4&RP+(.A)-]B_='OL#;KO1#6&9(!I7//K#,P8.>/><B;F]ZAK BY
MC^3RQ@T76#Q+G4ZP\LP7U\'*DZ5?1B<TB>?XL.K%PU(^?F6SD-6/J-$_]AK3
M8$_E I&CIF+B11)D4$*0)3X;QF%+YP;+4 ,\4S(1(('%8A3_!.)(@9[]*K"D
M:6U;%RM7-A3Z'( !-&V$5@W44+9[\IB=6B^-E&+Z[L.9JJJKJHLH8%USAAVZ
M3K?-(!S4.H/PDD)WE&6Y6!!$33#Y=ARU( 7(&^G&/_#WE7P=K(L(FV],T'6"
M!W*63B)4+>.2X;*?4UX^!3O@HHX=R1;2'@RNLY?F*C3:;[<9 L[(;[@.@RCB
MNFXQI7N)X&7G&T+_RH1OB<#L)?0TQ0M(]Z< XHW  +!TYY3N+TF23(Y$=XQQ
M4IM.?ENRY9;U-L%AD" 85#/^7:%O,'@.#L0;[K9M%;D25A3,IY;3:75TG#C9
ML@*H5EN60"G<5QA4G%7JJ#*90<YHE#I?NSRH_!SS.;OMNN9S;B5E]G1JB8]U
M@S"@_'H@R"**QZ]R-3Y![KASULIUHX&M)K#NW"A+[GTG1>T'5\)8TO?G@;*E
MF\B686N\C6CA@R=H[S*)5TG\#++2!S[";\-/@U:2%(,W:99-4.&^-TT<_DE_
M=9GARD  U,6JB,:ZLG.!3*G$4)8;W;!\YXJ4[I'01JI]%B8M(2Q"IK=?).#4
M.)P1Q5>)?\,M?. OS8_D'KHT-+W9KTOBU$F"HV@'/OG<@%%!V?L,LGS+:8'N
M1' 6X\ >C=IV;^1L($["QY?Y/S^U6VV'<JGH\UQ/2663^,V?'/ASV_@SY4!>
M7R->TTID]0M87DP3 K6VTO3*U?5@;/F<H27'S[&-1!11WB&.6&(=1\(-T_RJ
M9*,DQF!"92F[,FX#.<?.NC)EDZ:[H<K_2&9B@B6)/<!71>EBVZKGXUJKY^>J
MA?C9A*Q<O(O/V%;$DY+A=T8[?(=]D#%5Z#@X&TG/@!_CS.^D])]P;4#I]2>,
MU>;+I@4L^!A*#S^FJH>XESK7!9.5R%3L [=Z[#9/1HNP^0F;H"]BWXUA:#%]
MJ3M[N1.*S_MKO D_(#A[YOZD.D]AKQ#+P^=#\J?+5 5.'$"7A/+/NLG5 IO!
M*I;S)$G@=Q_G1X2MU2;TVH.[73ZC5*>.^R\$ZY$]%)%L5BW<;V#2*<JWN3AE
M:331_BN>7DMO B+>N%3C(C4PC*WCX2_P[/G]IF?5MN:>#H%+9$*N*Y!PVPAG
M)8ON.9)^;;[)5(B6A-"YAC(E'0MWILBK:%U4G2OM1ZT5&-!W_!TB'\H2X18K
M$R4Y3/(R)8<^.(GW)U405H,N8&'64-W,&2.T?*&)4.(CBKOEM$__K?W(,P\!
M#SG:SRJ9KC#O.DHC<R/9!$_#HEV^XTQ(7((*85T),)TE(IB&-%.'@*!FUSZS
M.U5W<(JS2OBAIJ:> G6\A;^EM:O?U*=M,\->:UC>EJ+A<!B11GSEK6#^R18N
M\R_RF+\DQVPGAT8G]34YXDMYQ =S&AN]IH0FI-"O#++2%6*$>X4\CP'3!1H"
M(*E3^%G!U5S"^.EG ;^CH.UD.GY41JJ,*J:@DPJ7P.QY=GEN#=H#^ZEKW$NI
MI_@$%?408Y[+2%3$W'ZNV@3J!+E]UN?+ TR\=CFTH"FYT":KLOMM69\QD5<6
M1R"S_,V0\W0$[&V4$I:-5[QN5R6$$<A)$JT@Y&>T_E'R>%.IML@&EI%9T.C2
M1RAF#VKO'\7?\])"KW!ZY6 'WJ,\$)J*9@,=_(H&Y4>36D=3_PDR@!'0AB#V
M6!VB9XK>PIC!DVYSLOIO$OB@XF.59C"9Q)P/=G<C> S$&PF1I_"-S10[,=Q
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MN?*O_&_.Z?]=GH2XR_DW,O/F"QSA;<5=_ZB1_PTGWVX\AN1:V),HZ+X),#D
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M+#( 3@"OVP]<^P@W/2OR(A5.((^8"@! *B=*3 6V ,?2QKB8"Q!GF8,#*!(
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MZ767 %H@$"ED,+H8!F&^+TD@?PCI#Z[AH.0D)N;KDC\ZI[<#%$4JW=E^ICB
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M-:E@:@LZQ7+*E==)-2:P4R>+7J\,/XK(V[73F%>-J22N;@-#^OE^Z$RLS7\
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ML,?UB>.U_P]Z(R/93M[>;6631Y8):C$\"\ O>%"Q["R_%)X\^5U:L.@[U1M
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M8<1LX! Y_.CPH\./'N./GN+,J7Y[N=?RY229WL#_7.;SZ.__#U!+ P04
M" "@/ A9@.Z:GW<2  #)Q@  $0   &YV87@M,C R-# V,S N>'-D[5U;<]LX
MLGZ?7X'5RV2K(M\SB5WC;,FZ.,JQ+1]+2:;V90LB00EK"M" H&S/KS\ 2(JD
M> $A2QONH:=J9BP2W4#WUV@ W0#X^S^>%RY8(>9A2BY;QP='+8"(16U,9I>M
M;Y-!^U/K'Y]_^>7WO[7;?UP]W( >M?P%(AQT&8(<V> )\SG@<P1^4/:(5Q#<
MNY [E"W:[<^*K$N7+PS/YAR<')V<1<6BM^P"?3BU3IRS\_;Y"3IOGWTZ^]0^
MMX[M]M$QM#]]=)"#CJ;O9Q>.?7[L3.%YVSK[=-0^@^=.>XK.SMK6IU/'^H@^
M3.')F6+Z[%UXUAPM(!"B$>_BV;MLS3E?7AP>/CT]'3R='E V.SPY.CH^_./V
M9JR*ML*R+B:/J=+/4^9&Y4\/Y>LI]%!4G*S@<ZHXH2LHGAU8='$HI3WZ[?0H
M*BQ9X1+FF'@<$FO-W.:LS5^6R,NG$:\/Y6M9STG[Z+1]>IRA/-:3'@D]MT\$
M*>2<X:G/T4!@UT,.]%U^V?+)GSYTL8.1+0S#11+Z5('$:P[9#/$[N$#>$EI(
MKYC/OP @X<*+)64<D RE [VI:K''N")K@0#:&VI!KBQ6EO1$425<IOPA<KDG
M?[7EKX-GSVX=5J_5]]HS")=&-2=I@MK#)R8M2-CI\?GY^>&S-+S\%N2:DBK?
MEG^VCT^$81A46V23U>L6O]H1W2[:$'<ZLS9$=*]L0VYG*;(%':7Z[;VV&>ON
M;MR,D-*H&8J1AZR#&5T=V@A7Z0Z;Q>4?)AT@Q019MDF=47'Y1TZ=D!#*%;U\
M$CY;+C%Q:/! /)*F<Q'9SP-R(@^>&1YR.JGZWP5D%J.NID<?+AE=(L8Q\I)#
MBV(P9\BY;,D!IAWYRW\M&3H0+8F*9"I(=P+Y6M2 /.&RE;PWL4 1"VD'ERU/
MX."B0$5UEM]&CJG\@@03_/]">A=.3:47),C]KQ?<@JZIX(+$\MUMK%Z23\1[
M@.W+5I>*F?$]G(GFR>??'H:%DQI5;5P^8AJQC>WP\Y'ZYQBTX[ET&RA*($E_
M/]PDV&#E>\@>D<_J[\WN'1*'14H(-Q14F2[=GW+)PH>1(LO4.[H;CVZ&O<ZD
MWQM/Q']O^W>3\6@PNN\_="9#\;:JWO6,2@ Y/_]P<OQ! C(6FD01(@F>(&8*
M1@,0LWT#:] =W=X_]+_T[\;#[_WAG?C9OQF-7XM<$5<MC"?584S5 8)*P#M9
MS=\;BNM5YZ9SU^V/O_3[DVT03--KL3HMPRKD!0)F;X!,QO>0":GFB&/1SM>B
MDV:FA>JL.E3@78IW4_M2RIM]Z=Q=]\?#N_%DU/V?+Z.;7O]AW.L/AMWAY+6.
MLHRU%M8/!MXRJ$CX29"LZE<05O8&<RD6K^V\V]6C-8#?=F< ;_T^"U1G_&5P
M,_KQZMG0FH\6T(\&@ JN0+%M$%0C-H,$_Z5: 8E]Y7N8(,^K"% 1M1:63W*Y
MASW+I9[/D/B1Y 0$*Q#Q:A 68W^Q@.R%.F,\(]@17H/PCF51GW!,9O?4Q19&
M5:&IR$R+U/DF4B%C0!V08 UBWB!BWB#H;B%[1!Q.731&EL\PKPY4+JD.EM^.
M-F&)V8"83X,0&$#,OD/71[<(2I5(?U\5@GQ:+0;'FQA(/D Q DE.#4+A :T0
M\:O&!Z/26DV?;&HZI&R09KO4=>&4LK 9%B(>$N/DV%\NW9?.C"$CBZ_*38O,
MZ28R*<[O0<C[O1K3 _8@YM\@_/J0$3$X>C?4\Y:(C>=B<5 1K%Q2+3)GF\A$
M;, [R>CO0+ "BE>#4.A";R[_[?_IXQ5TI0T*PWQ 'F?8XLB6[ZIVH2JLM"A]
MR/0?0?9>_1<D. ?])V:N"C0(MR$1_IY3]E(1G+B\%H'?-A%8TS9(O]>4VD_8
MK1J)61?7:O?CIG8CT@8I]X:2V03)36)37E'!*1*MDC.K:4G>EO1 ,FB0JL><
M6H]SZMJ(>3W!V,)5-9Y'J55\=G&<X/(K"/DT3?]74%!WZ6(I9GZJ/2809(EU
M*'S,K(45H[;B!)*L&@3$D BUH@E\KAR'2%)H59Y9^@;40)$W2,W"NA:8+\+)
M7Y>J !@B!G&Z,@Y:&#+KX@0W-6-,\6L0+FJF[%O<9T+ZRM&()(U6]YF5;XJ^
M0;H>^U,/_>D+ ?HK@Q!$ADRK\<R*-F8! AZ-TGJ5^/Y>D@85DP=G9]EAHGKR
M +R+_FI2YC0O&3"1/U^330@9:-'*C":Y.07P+N#7)%AR$P1&N)1QT *3&6H*
M$@U-A";,!!B!D:;1JC\S[H3T351W7BS:2/<E#+1 9(*EA2'M)D)3)2!M!)4!
M0RUTF2BK09R[B6"N@]!&B&U2:6')A&?7')JH]"@V;:3S#2*MRC/!VHA!$S6>
MC',;:3V'4*OY3+0V'29OHO[S0ZY&2)2RT&'RJ7+LMHGHI")*AC/<+*46B\QJ
M/<6EB0!4BX?TQ!H9N[N-L40\M:!E%NTF(9:PEB9!FA<@,0.PC(,6KLQ2OB#&
MTD!D<D,D9M"4LM!BDUGG%X99&HA.&//HV+;B"-TAD;<:J5:9@52%DQ:K3"@@
MBLFT0<P8)#@W&31YJ9/MNX@ZX2C@/2 +B36W\#K?R%2L/9 ]1FR%+217^#WD
M(,:0'5)OA>YNJM2:02:LL#:#J %R'(R: .(VO =1*T#4C"#V$+4D#O*]V0UU
M[AFUQ41P-Q:1STR+=296$7?Y)-@A]S?\DBH/'UPSZGF<WB'>0U))HC;O"KKR
M:BK#D?8U-6B1SH1(\I&.GJHZ := U KB:D%4;R--H.(.?S/4#9EJ@<Y$9(Q.
M#S02U[S\B1F(91QTB)UGXC4E*9@&HE,E96+8Y0PX:M'+1'B,LC -Q'.=#C$#
M+4.F1283QDDD8AJH]R@G$L\OHB=F0.CY:)')1&S6^9KT;"1.XS00KV0Z)M9U
MEPHC9AR+]=8=Y<B[AR]R[64&X5:LM:AF8CT;N:#4^C%1&5"U@;"ZQF-]!YF<
MJZU>@6F&A1:[3.QG$SNPYMEX@.(>,R0<";%X_UGFU';2"0M8:@',1&W*.E]4
M"0AK:22D.:>3#+-.Q0RT<&4"+[FGG)J+2R;YO8,@^1:,M3AFPBJ%N?:W(+H6
MX]@+YK]'V[C9G52EM8/\4XOY=I#TQ(7%4-,]<PED'<_S%TL5D/PF"F'2]S@.
M>A-UUOG*$-K=6LM656NLY\-1]1T[Z1Q,W!@@6P,P 7%[9(E$MC4RMC>+BF&5
M3T>! B&Q.TLAI(75JP?Y-1DOH>"=F-$6]6EM)WL>J,3S* ,(6Z "4LDV@* 1
M[U-V]68M.4.&C,5FWL>Q/47?>8+,]CJ66#)A;ACKVF,#M/:4W?Q4<213 >J<
M8HF89V!_0<- U+)&FECB9+AI&#1#J(4T$VY+GBQOI/KC,]V;!\1-DW<Z/EIP
M,E&SF&?VN'DCP4IMF4UFQQ./5?[&E5^+ZU+/- 7[B@JT\.9LJDIN &ZGD^_)
M5T&^2%4)5)UOX&\9&BWGH84P9T-4"L+FA$9_/TQ_R2KXG?K:E?S65?@1/X6?
M_,[.OX(]!T)9#_0%NG(W;H?8(SY'[!8MIHBU )P*E4*+7[:$9E%+?:_KLJ6G
M(UAN;I!?ZPGHU!<0+Y:(86I/U#=X;#_8^= "GB\JP=R7OZX9]9>7K: XYFC1
M L$G>]8?-KRPZ0)B,A3O)*/XZUY9Z9#\]H^<.X\<L0P3LV?$DQ(YT/5BD7(+
MZ\4(/G?'HU?38!^.:"^:RON8*LD6/%E0(HR4O520+'^>J69Q0[%&0/8W8B,F
M9A."2IC_/:,S!A>%LF_+;N<@!T\\V1RO@AIV(OS^1-ZP"(LA>W\F(5JXPO)+
MK@/*^L\6\E27G'K"3W"4N%*P0 M5R5\A_UY[Q!WB0@0+(=L;,+J8S%'_&3$+
M>VB4B"0&*YQ")9@QJ:TJ*)%[6,(IRH1!8=S!+D&![0 3V00CU[@]P[JJZ%K(
MP+UOXVOYZ34BW\G9O!1=6/U7B@G_+IZ)244GU$C10+@%HWTY32XG/96<YGK;
MX0IUQ 1)K&%D"9VH>KJ?+=D-_M/'PL6^"-U?"]W/!!:6@$6= 7N9H&=^Y8I.
M7#P%J$J_O\G-\06/JJDR#0C7*"-'#%1,]L >"OX_)/JC")W,401UZ%&OIWU7
M6S_U)C=\3_(W?!OK;@N>>YQ4F^AE8RM$-"[0S7U*%56R+;OZF<D6X5]CL]E!
M';51'"34P??0X\B74^V#SGVG?-U91E&'%6=R]IC:WB^<7KB_?[VEOVPJ;L"D
MKE.L'Y0]RB$4+C&77STK$':S6$T7W/'\[@I:CW(PBXXOEQNLGFZ?G;&RW0[D
M$E?.5O^)6,;O]GQT<G3RL5Q0$PZU$#GO9'NYB&44=7 ^UW"%._9*]H9[GUES
MF/ 3W='WSA\#:&%7C <:DS5E4PLXQXCSX-FZL9JAI)B@%@)U?-EJ%T.B'15S
MB];!(KN00!L6&5.Y4-5H:P'5'7KZ)Y+#D"VW]6*BZALYDWE560T8U '66RCF
MFL^W'?O?OD"'CZ&K=YW%%'60*!G N8>,$\2\.5Z6"Z4AJH5IAO/% =(AE%.P
M%@*H:*/*B$7Q@W(YBLO7P<[6GCJZ%T1N'P@'THH^OH2R#A+&KBRGH7K_ETM4
M![D>D"PH+ZU"3&T1%Z/2:.KB6; R6\B@5^$BIQKQ]DN?_6:6TFO0:$#ZMG08
ME8[O1<VARA5@PJ*N:H@GC&&#BX,UV9)U%2H;KKU"PD)1QW7IDVS @+*N:H$\
M\?X@8!0/9'"IT$]MS_!GIP_,FAX=&BG.)F[-KZXA'3.!XG#VCC249%C;-'Q6
MI-V9SSX-IQY:V<IF]FHM>^U0&WFPS6R:+B-;F?QG>]8H)_X#\WE73&3I K$;
M#*<JC*3O"57):VO^I0)4L/G*]'4U=+43(M@_S1$:D>_0LL(P1X?8P\7")_@O
M]?-K]_NP?+&P':]:+&9EEDZ%=7Y0YMKE8N:7K848/^;411YT40]+%S#U.64R
M<"#WXBK?+'#HSB&;H2FT'C4+]BV9U6%-N+[;C_N,:,3,+UL'*4J=2X49?W7Z
MGST,!2M,+[ FNS.#<LT5 J-"DL63#CUE75WO!#XB&R;V:VGB9T7%:^%YKD0C
M;I&+B0VO(9>Q/1M;T!6^$D%FS8<DJ!95%O<5#.O0=\.HK=T=?1_VCL]#BY0N
M,]B8_Q(&(*H%?ZNSJ8/L\H0L74%WY 2)6>$#.CZ?4Q:._L+MB-$S%"F8)*!P
M5^^@I\NH[81W';2DXN%BF3!R]JFO7==2+\WU;SNQ6)G65]5,-2YUD+P'.9R*
M!>2-/!7O=$C_64S-9/1:IF!/3KO"74HG.6$8NN72;\.I#AJ06^M<M,["3I U
M)]2ELY<83HF@* 7)BW<+B>_ \-B9VKWE>7EVKDEX[[7.6FAUV%U/@]4>SQY:
M(9<N5?2?V#?0)];\%HOI%!?S&\V8M26S.NAA@)G'!]1G43X\&G!U6ZPT9'60
M;;-MPB 9@@[7YC>U='60+M$5U]VSJO_/4M1!HL@%KWN*IM<5%:^%+-03S@ O
MIC[SJNPP*BI>!UFBB;>JM#BQG"ZUIP5V1%0E_>]+%8Z<'O60-Z%7<50'%4M1
M3F20.C60"1..9HCM*/T=)"-*1#1C4M=80K0S/3'42J\6^;A@S!6#;["_*W(1
M*=FCE:1V]_M.ZJBK(O/-82B/_LO9\/J Y3T3*W-#HRKD4N/T2)X<WZ%8%8CF
M=BGQL(VBEAGIHH#'?X,F4F<LY;;0*J+G$-5G3/A?'S(QGW-?9%0-NFYB@TS)
MD>Q*Q#][C%@?D!=S]$6T63F^+TAX=KE3%)=$F TXU-9Z)W/1[=0AD+',2/,7
M>2@D_RS(J6;6O 6G6@2H._[,][ALEAJ?*N[_UE'584+ZU2=2W<<F<I73U$&J
M^"3/6-1@,:QN5ZR</JA,7@M9H1O=8Q'DL^09Y'!CZC>"U:TGZG1IL9<R85'3
MDWR3)SJ94U_>\SEYDJY%^9K@XA=B^U:P;U.T1..A3-G4PCTE6CW #D<HO/%F
M?<V-B=Q:#K40.?^\=**+7KW$1:*MR#)?'<T\ GONK"!6P@PHDQ<$24LUO$]I
M1W7N9ZY3^<ZEK64+;[=5-Z;T(%]?K:-6)[?"A2S\Q;UX5+JS^C]2^:XUG##;
M95#'/O4<B@%G2&9<B"_OSP\V!.Y>K65UU4*+*7>U0J_R=F7DM7!U<MMK?"MI
M&!6<T [QGM(BIF^]*:?Z^>O'C0;VG[F\>Y 236Q41_;S!8O6K\*]RV4.D_Z]
M0^S^8NG2%X2N$$$.YNJ*T>)PF0F/VJX<O](YZ1Y\A1:=:I)@>27K,+F6[9HP
M_-=?F%"]!)LEZR#! +MXV?.G=.4]:I):N47_HS*H"TX]:RX6'Y]_^3]02P,$
M%     @ H#P(670,4[_!&   Q.4  !4   !N=F%X+3(P,C0P-C,P7V-A;"YX
M;6S=75MS%$>R?M]?H<-Y/6GJ?G&LO2&#\!*!$0%XO6\3=<F".1[-L-T]7,ZO
M/UDC"71'FJD6C1V[ DE#]Y>97V5E5F5E_?T?'X\6>^^QZ^>KY4\/^ _LP1XN
MTRK/EV]^>O#[ZR?@'OSCY[_][>__!?#O7UX^VWN\2NLC7 Y[CSH, ^:]#_/A
M[=[P%O?^6'5_SM^'O1>+,)15=P3P\^:?/5J]^]3-W[P=]@03ZO1CI[_M?D0M
MDRC*@Q?H03GEP">>@?&0G2U8D,7_>?-CR9Z7&#PDY1BHX M$5 J2DR59U#$(
MM7GH8K[\\\?Z)88>]TB\9;_Y]J<';X?AW8\/'W[X\.&'C[%;_+#JWCP4C,F'
MIY]^</+QCY<^_T%N/LV]]P\WO_W\T7Y^U0?IL?SAOW][]BJ]Q:, \V4_A&6J
M+^CG/_:;'SY;I3!LM/Y57'O7?J)^!Z<?@_HCX (D_^%CGQ_\_+>]O6-U=*L%
MOL2R5__\_>73<Z]<KMZ']^'C#VEU]+#^_N&CP^>O#I\]?;S_^N#QJ]?T];>#
MYZ]?'3XY?''P<O_U4_HMB;%Y[/#I'?[TH)\?O5O@Z<_>=EA^>K"D)T*U-S.2
M53#_?8NG/OP".(5%6B\V^GE&WY\\N\)KBQT_#KC,>*RKTY<O5NG<AQ;54JON
M]%\N0L3%YJ>S=0]O0G@W>X[#4QHU1_ALU?<SC%I(H02(I HHU(RHZA)8Y;4Q
MQ7COV'EU59%ZDFECW!+ZN+'PR=,?5CT^Q,70G_YDH]F-5J\$<*S([:7Y\J0G
MW>KHT6HYS)=K<@B'[[#;F*3_!6F$X_'G7H>/V!]\'+JPZLAMA.[3TP&/^N<K
M^NUR(*O0:]X\70[883_,K$5A<^& UG)0T@5P*"+(K$2(V>CB?&/=C"C.>4V?
M(>U^E_;HWV-'/O7!W@>L_N_$O1[+%KITB<WGA_;))Q[VZZ.CS3-A3D!._WTA
M45IQ<%A-T_['?"4]M"$T 3WX^ Z7/?Z"2RSS899M0N:$ &.T R5B(3 F@\XV
MR&"2%5Z,0L9+4&Y#)/&%2/!=,6DWQ3=CP:-5/_3[RWR"I9]%FIQ\5)IHJ!,H
MQ31X;ADDE(&5K'RTN;'Y+V+85::7V".IYBT]\C&^Q\7J70W.3IX^BR5Z$[@#
M'2,--HJ?P#D6@9&HJ(((JF!C 6\$-"5WN1,;+O*\G1F:LOVPO"0TRS7.LC="
M*)M!NH2@$OG>8 *-.L9SR%I88<T(5/\,X([^[?NQ_/9J;F;I7\FI=F%!$NWG
MH_ERW@]UEGZ/I_3+/@1GO0!6-,GH@@"?909K,_.F!">T;FS[KT"Z#1OD]\B&
MEJ9HQH^3L*T&89\G]1 92UP$R*H8<DE&0K1. 4?GZ"])9N<:<^(*&+O/?IMA
MU\]L+-8S'<&P*$#I0E$E,Q$R!2FRN,Q$2<TGNN-W3VE.V]72EZ>U+?0[7KQ&
M+]&N, \F*/*NQ03PS&K@0D6'DINLQIC$KH_7OG&<WMK<.RF\<;(V3O:)VEB&
M/$% E2GOH"#,1:G!">ZQ).%C:+TR<V^K#VTFAA(S2Y%3ME="H&Q/<,KVHJ2Y
M*G$?*)+5K/7ZS%<GAF_K5*?"QXNC=5?K-1RPQ]*<N T2=74*;995EJ6H!%9(
M#XJQ #%QDC(@_:=MSJYU['D#G$EY[ZGRJI4YV\6OPUOLSL(XULAI3,V*$"8Y
M#R@BS7@4JX,GB8$K[VB"8EJGUK'?S8BFE-U,E60-;7J!9W]_>-4&4N.ML$>'
MO[UX>?#/@^>OGO[KX.ES^O;@V>&KIOMBU[UBQ$VR6TG5:,=L0X!'JZ-W';XE
MDU.._(6JSW$X+,3%%ZMN,VR&H9O']1#B E^O7H0.ET0^Y)JIB""9=92ET]\\
M<0Z\B8Y'BQQU&&/4;P^YB1N\YO7[[\-\45_V9-6]"@M\A6G=S8<Y]OOY?]?]
M4%<C3R'.L+ABN,@@BV$TN*R$H*6C/$&'9#2+4K:>DUMAGU)<>)\,OM)]WC<7
MVD[H5Z GP&2XY:-U1PI*GUYW8=F'M%'@,F^^.S'V)3ENU'/$$(W.P$*A::IX
M1N&*0<"HM0L\IF3L/=%]% &GM+0^Q3'Q[5G5<$7LDG2?1[+BV;O"$GBK"T5C
MBJ(QJ3U823@M1R=2^\6Q:^'L*NGY+6B=-#,8%:0B$JA,>HY9&M"&I1*]C;ZY
M;#<4U'SK?<LV'+@X?+;7^.CSPFV]!TO1R9(]9.L#*!G(>T1GP$AOLZ-Q&D/S
M38V6,>&WWA8=AUCW:=7[R@5_V7^V__S1P:M_'AR\WCGK._^PQOG=#4@;97*O
MAE7Z\^UJ063M#_ZSG@^?9L$ESHS3X.GQ1)=J,D;$$3IHQJ4,/LK& _$RBEV]
MT7[.\ZKZL'@1YOGI\E%X-Q_"8E:B$]9Z#3HJ"2J9NL:J.5B?@Z$X1<K8NJCF
M&BA3FI9V9,%%I]%"^<WFI?V4UD=5M9AOX\QFDA7NC+00$B&E(%9!C)Q !JT%
MUYB*;\Z0NT&<TKS3FCDC&JME('^T6FXD_U=8K''F-<?,2@+!?03%>4U\<@$>
MHO0IR*1R;!^]G\,PI67KQIS82=W-C/X2AS!?8CX(W7*^?-.?8>IC+/,T'V;*
M2LR<>%AXS7\SBQ #^3@7E$LQ,<9MZZ6YKZ.Z#3'4]TF,QB9I1I77'89^W7W:
MB'O,WF/BIA(PD>8@%V9 U:)2QW0 3&@=HC<4(S<FR'58;D,+?5^;J8UYT43_
MS=CP;![B?+%9PCU>Q:H%]((5@X*D88)P6 9>R@PR6G1&*T90&O/@,HHF^?X5
MPO$0$E9IR%+5<HI#*$)"5LH+HQ&=XF/D\5^3\-M&V#NRX,JT?$?E-XR'ED,7
MTO#'?'C[:-T/%*1]QO;I%!D+2J0L!20C:.P)KR#$1)-V9BH''K1SK6EQ&UQ3
MBJ4;<Z2Y69H1YLE\6<_3/B,WC9<012$T-]$"(K%769$A9H^ 3BK-+&/)M':.
M-^&94F#=F"#-S- R5^_6F*^0D][-='1U,TDIXJGSX'DM9=*EE$B,]5&US\JO
M!C.ED+HQ)=H8H"4?5NOET+\(G^JJ\BD62NNYR1+!&%'7D8J!0($AA?912&.0
M"#H"&:Y <L<H^CMCPJZJ;T>#OL>AG\GH1>9%00[U@(^(&H+-#NJ>EG:B.!9+
M:[-OWMP&_ZD*4[+%%(T@O0V@/$G@A*,OD9(:SP*E-ZU+'L\!F%)8O(5E+Q%U
M:^6VW?H\QE&K+4\]ID6;'(V-7'RNY;8) D\2.%>1)2$89ZU7!:\$,J40MX&]
M=U=V,[N_Z&H%[/#IQ2(LAWKTYC_K^;N3&I29SCF&)!@8*2F <K+VR%&A;KTF
M;5&2 EJ?5KD)SY3BV 8L:*;ZG<E0MX=GFQCZ957=8?F]QXV ,\6,S[S6%I%3
MHNG7%2 79, ZI)PK25;8!4=_>:OYVJ=/*0C=P9YMM-?N-/9JE3_,%XL98[FP
M2 [$6F2@"D\0C2P0=.'9.6V,:7[L^N3=4PHJ&XS4K53:.'3\'!WH;+(N&1Q2
M_J*"L00A)$!)4X>(R0;7NK3AAM!K^WSH)2:<OZ]Q>75W@0P03%! \QQ)52N
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M&(L$2+K" ^E/R=;M;[8_''Y?\TYS!C10_BVGF9.?UR\Q]/CSW_X?4$L#!!0
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M"K23>"\5!W-:'^;U??$:%3TZ*T)E6%JXPQH"SP)8]+(D%*;$V+S4X"8DCX$
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M"<LWC[>=JGJ(&MV$:Y5"T0593_[M9E2'<67;:*\#)780?0^.ZRT(Z0W0W)<
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M.:27SLMHI6%%-*_]:05^;X4_^V7IM4WR(,H^ELJ@-Z,PKJD&B_@,N8^)Y2+
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MN:A(])&CKR6(/+K:>PH1O/ :,J^MP.E E<TO\F^!<_A*^(-Q9=*/SGJHZ-@
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M!NLBESJ(+/W>K<(^?*R#7GS>J@&ALD-'C@?::$"51,82_1V<XP$+VOJ_(]-
MQZ4]H$WM.*Z"^J#,1@-@#]68E^*B]+Z>?/HTQ31<_.AM7=WL4A5B^Q+,>SR\
MM[K+705Q/,66MA8",RQT(M8)3%)P<%QQ*"[J1?A/NZ,)B?UR?,66R3@7F=?
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M^$$+/CH)Q28CO-"%8/]6QKA7E Y7QMA%V.,L8XPFE1"M !.+J5>Z!802#+C
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M):GS_\UGB;:OK_-\FI$+EI2%&'BFD),^G%49F"I>)AD%VN8W7[8A[!7"I+U
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M,)H!$ #L8=OSEP/XZ[%G+Q/C/O;]!S@XF2>4'P+V[F%AV<O*\A,U\]40YNL
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MME<V;GS$KOFKG>V5KUW\OOJF.BR;1X:&;?RI J8N!,G4]^[I^S/,B7JIV0S
MZ6+!&#R=U#KZ&V>Y8](@W]MWXGP-H2[J)[X&^_KZJFP-#*GQU6[S:QI(QY]U
M]I.5C@^03A@8,@*-8>W'9BNWME\-S/0_CXR4*^H_E!DI!_QNL(P@'3#[%[!@
M6C:8YPTYU#C"O&_MOI-MU/F&$T>$UC^R2R[QX*&6U$!:O+8D?'Y*K0FZ#VXO
M <*W19>/%5[1'#MU<F7)2]^5U=10H"<UP?U,-*!M;Q=NZ^P^E?$0)PC!7Z;>
M),S',( 2!E"!+)X+0#214%+=$_QM,11;&*YW0DO^#5F'<@'9F$_+DB(7T$)I
M>27KNVL4V=5T(T2_>$=E]_K8CYU//3U^FR+3O85&'_+/]_N5]'<O,P  RQ>)
M4D@VZU=&#K]O&GU,SKA92VYZMPCE>6!+WH13S7QSJ@M7=V)L+F<^:>=N/E7Y
M9:+GVX7/TC?Z&<"M-5X&T#A/9 ]5R>!;#%0-?;L(&1M"G'12L@UY..^8_XHU
M(;Q= 5C'S:F+M#(!6KC6<Q*,:B918L&04G+HY(2^.7TTPCA]:]6QO%J=+4G7
M0N8RX,"2-\\:^M4:@4WY@A.AZDZMNC<&(@KP(?[ZDI+5A(S7#F$/MGK:!^W>
MSXEER-[G>4GEBM;9_>9MN+E.]<==POAF]UXE)J^@)E>-\<C/:UQPP^9 [6+_
M*8_ W6'R5)?QZ) )6^* !FS<[]Y(627;-?@U] KJ@QN6<U E3=XJED[O;8,2
M0FT7,<YR]UUD+G7/"3>>.*U^9#HA905\F^)EU>5.Z.S_C#RX&LQ[>U++?$M>
MWBQ?9<9'WB7X'M>5)K_YKOO22<>SR(D4;P;@,>PJ5 \09#(>LF&>#;6J%2FF
M;V+==-*:!:[G&IM+7+BN^BA4>?"DJAUEK 8W.^Q-NMI-SJ-(DXWQ]Q/R6[R(
M-4UJ]:?Z4E0&J.!3[V*^E@)=G#^T?8H,3@I>;M-TUR>1R6:3Z##L,;)?.G=U
M\5YF4CICZ.OB=/?KSDM9IV4^SZL[L.3\'?"68 (QE91)$&Z)$8:F@Q[;Z*&F
M/8(<L.2X<NN<$W+G76]'N#UQG@=O9*2&>(+*A-M8B&/VA-9L6A3M&2T*OWR-
MO9-B.0I>._)IPZ?8[P=NV],K-J?\O>@/DQ=KV6N5L&..>.>LW71;70'+-SYA
M B87V/XK(ZAM16TRA'-*;543#^(A)U\-M>HKBB?TNG@>,%"U_K+\6O)+/I*#
M$+B)'NF=5J3*\42+@F(Q)9!*3*G09$CH*L1E SPL'45S;FL%?Z'UOW:(GBO^
MD'W2]#JVIZ6QTZ .]1&A0F^W9R''$ WQN%#J,65DA/:I[QXJ(ELQ:H8U&MEU
MM9X>=R7"9T9[U/PD=E<Z-B 1$((Q65M&IV@Y$-ILYC.9:DC,6:R>B(@X#3L^
MX+0_1U^H[]/=*<L[Z;?O<'_SW"??2@>"@R$LVDH@209P&^DQIYG+ $KI0R3D
M5F>3MG,;Y1-]37W5C@&L;%!<#0@^^"_8?4.UIR"1#UCK-6+B/@Z=5DZ-"KB\
M\Z)C?U>KL:;1/H,>_$-U&6-^(W#9;)!MI7\(Q?53=>)YS0XA!<PM#*\UU8#8
M&CJ5(>!J+TP8"EW%UPP$FWC&2.\3>73FY71GDC/'B*D>1UQ"8J\U11/1B]W[
MD9:CO'H@V 2/BTH7J2?05G<-#GYJ-LKU>_;V#O9F:*[8,PGB3?]PIL?F?:!Z
M3%,R#I&5>/CA4JU>+0?7PM94;"/6315V[.V^A(T?LG[VF45V]L!#-A@G?=!>
MB(PDIAH1WS_1YAN&PPR+^^:_Z:%<\]L=7[>_"_C6LS#V$ODI80+%>EZ?7WKZ
M],2INGH*;D9Z,2?E1R F$N.8)CLU5SX9)2]6QXYO*40WB2GRXW!CUN?TSROH
MU.(T)J?CYV6!>; ) 4,R[$-(!E^.2]^^2'Z/UPKZK!%;^6Y)>)!'(&CZ[,$N
M(=+)Y3I/G]?G*1^4P%/3)-PYUV2A#$+8ZD:]&+*Q#D?+ZY^]3?H2 %E%YC,K
MMD7P40I,+4S9>/\B R"$<Z+)^E297+CM%_K R#PM;PH&D308*^VDO#H_L1TN
M#W&)G)U=7*=NCQ>Y659U\Y 4OWD$'\37N;1AA*A:A&TKHLKS@0<Q(--'KVNY
M:N+FD@.?ZG#YLA=IDW3-R984L1%R%WY<^QS1I;E;^'.U7G9>Q[N%^)NVY8U+
M9E)*0NS>]RYU?C[+2GWW7+V;!B%U$"HJ)S,X73&\".Y%>PB1/5QAWZN<96'1
M%TE+'M_],KLYWO)Y2+Y/:!\-R(=R, #W59Y&W,'"8/YI:-@N+/:!A]2-!,NO
MF6KK-C':EGX^H D?Z=NO8@]OQ(OY'_Y.<^NMHU8,P9J\D?Y(,G+YAV9W$.E.
M7ST7]00M^\&U&U;,!$!H#F1-050-WCEQA**SAE00NO/*@L,SH"78$FI,-:95
M&#='0:,]F:%?C/9:^VC;NU8>TOM46@;I"+.T-05/, MEA_O(R/I;1=%@MW<3
M=A,8F=WQGJR8(<6M7!-=P4%' 1-=0!"'Z-T5C(C4UJ""^[9LK=;*NAC (2N;
M"5O#;:=G/WCM>(I94:U5HHOUA\G]=$%,,XH37KJ"'(4,!V979).,U3HW:E]9
M7$LE^,W?/Q<:O:ERKB;*T#NK^M,N#T4WF(6LCT<*!9][/-:8(AQ.O>A+W-=F
M**J=D2OV-F_QFAR/-$$\($"=]=:TNH*_UPRNG&<%^FYQ"'DHV'J21] U,-55
M=%RHLIZG?Z4V(3LJ3_!(C"/6/'91P(,#F,]X$;DS;T$>]#4>U:0+59+47B#Q
MTJAFT C$K7>\RKHV0\TEI,;_WMIKOZ(-4]K'HB(/A%)A1CB]R9?(:5[\_?8G
M84I/$FE(,C Z0*>G W"9:3T7^JVVRJ39;'8VD4);8@#>&N*+G=OZ61@J?V:C
M6(R##C):5*%>_>MFTG=?*+>MZYK4F%S,36#.I$JB:\/C\/A[\<B-L8SA47>>
MD?"NJ:WYZ _XH(7FBI235H9RR><"#$&C L]+$OHXIHLN-TA]@^"G)"6#5OV;
M480[+> 0],+J.[?TH^6#Z9#S5]T>)4EQLH%.OG:1O?.X;6^5(@]BQ*^>A_8:
MAA"YBV"),!Z K<3$8,MIA<K/.Y(4AO9^?Y'_Q6>[R<^^,U\<\<D)L5S9.TL.
M)=E!S.H'D)/)]?+%A)#FQ:FG\\3$^M>^(LI'L\8Y=1XE<$#G.UV#/-J@NCL%
MLQFANZW/W@8;?(6!=?'MM9;O"C\;/'CU@XOWBY6'W9<]ZJ8-Q;C[&I;]]@H_
M:]%Q<E/#=AP6?G(.)&KG.M6RU041@-K:%.Q!:2E,G<RED>_-YTG-HE$/:J9S
MW/R2'X&;8$J&I>H3Y8]:D1S8QVBY#DMZ_1K96[8]94:KE#1%T LCS)/2B1$1
M5)4<G:R%BL?M#2[W]U_>'OF\&IV^\@4I2DC9S!@]-RU+55R+MMF.959AD(_(
M<K8J>B_%>!2,/HE51P[>NSK?-;&M=R[6*V7#;3$S6]3+#-LYYU.:X'XK,U+>
M=&^DW)N?@Z<?(H#H1>Y70#II06P':T^\73 SG.0,L0#Q%;V[4Y]@[N[D&'-K
M\3BIH>>'H<=8CSYH2G&XM!$I#.8DP.%!S:.*H<%.^7!1+.G4P7MJAH4W%3BE
M$\"1RV5IPPHZ_*$-#6T=S':R_CPH1@C"L]H314,Q@/WO(TX%0VI6[9&CM7$H
M33%A9V3-AL/ 4 [<A32B+4X.(Z!:0(1P6A;]$.@@LE&39+QZ#0.C->G.P]:-
M$[=+*WGZ1=;L(1^;+X'[$NK1U*2ZGOI CY%"3A G,]<MPP[#08VB\U':QUVU
M60? #IY?R4C]FC+7V;JF)QVWCX5)QST*35ML/Q4Y1$!3^0>G[3'DEY680PIE
MA9 &_]7W6B/]CB][EODZ'>%]&P)!-X-Q:GK3D3UD)\K]NU@Q BQ4.4.4>JJ8
MB,V>+,BI(I!R=Q-L#.Z*-(4Y\5;=R;9D):[+BMQ,@^UA  T7E!D "_4"L3=&
MBNPDOKO]M%P($XY76<Q<%VB6.G152*NT];W/0_. >UL<%ME;75W)LY7(]1\R
M*V68)9=@=J9O(9<PA^LE%K&* V!SIMUHL<7>I-&K?BFG6M^YC*Z*))E)XDI;
MK6VYJ;<<IX_5RK8PNV!;/$^K+6H?>:;]HZO&B^MN\:[O-+6*G9SC)88[[J9Z
M_V@S>6U9%RQ%JY\C0)HHBASDC(82>#SN:FWZQK54PZ$B9:1\MW]<9MQMUBN/
MTCX6?CY\6'U?+8LY.08VA8Y"32ORW>W^,&R<FSTQ&+T;/=_SR J91<N\M+ZG
M^-(^Z>= VP7YS(S!\_.KVI*I2&@ 'RFX(-EG63%64H)\;5IQ1!-*7 NGB^D3
M=D>[+"OZF?FM)K%Z,&N\X&S< <V'4/69Y/,H]+YZ(70!\BYZ3*<16<;^\/97
M$)XK\" ]XW[2J I5^V@<OE] 0XAW3.& 2.?QGL"]6@#Z1?['XM>W!OIMMORI
M]UO,<S8YY#)KN"[]=/'Z.:89$50)@G^S<3@"_!VL,UD':JD."W_OP,IB6:OZ
M3."TUPF^AU[EAF<.[T2&M?>XXU.V(.Q4;VU^,MLT PA'#F/<).6K2S[1!R@6
MO26T=/,$6.+'M8E2D?&JWL"YYDN^)]8;EGUW4LSBHXMZ"\=(/N1S4XIL5-_0
M:T-E,"XR[#)1]X6JI.*GB%7<[:=M!Y+VOU9W@:I@SV[XM!J@)2MIC[<N:Y\E
M3S<&MD67K0HWT@]]C# ;"+;6^G26EGYC@M?*?]ZK:4;X\_I8POI\!U636$M&
MDH*(L$9FZ08#N^\R4P\MCU18KY]8.;->(3$R-N39&BA*,B;#8!542R+TJ2\$
M&'.SYR-:Q'ADN=%%J@8, _(X! V$O XU!?>V]D0']!SVHH"O:3L)(VNZH.GU
M>N,#L^X,P#;>#?21HWL*'2[J$H&0640<[0_VV\[IMXCM8/:7A5E\0BQ?9(:C
M8U[??L2ZI2*9P !8Z1@B>RN.CRQUE?A!. 42ODE&;UUS?1"%TF8Y<N<Y)W@M
MX*GIF/G3MA#<*;5F7$5OF$JW)3[:+X-]M8S9%(F@M;NR3M><P!Z_L;_C9'.A
M^%-+OVF,@D]#0V$24\/G;AY$%S,B+\&-F>7/YBYX+@AKG%S:D!EKXN_LZR;-
MFLBF<*T?'.X1*T*X05>3^DM7<1N5[1 ?)-FG ^*Z-@*UH*6L*1_(^:Y7\V;Y
M:\>I,,IPEX/JS%C]>8^9G<Q;$D8'9D#7+VRCAJ4:D)R(,W _YF5$<4U=$BXW
M*F/="UUL!Q33[D=[8-H-#S^_WSY<\[%3SV"GA"UXBV* ^/J,.&W]+;WIMQK"
M7$S.A=N/.]=N5@],#*<[NKPJKGJXS_PBI+F[58MG$KV:AE\+PQXBE!<5$+*N
M$GDBJ<>'V'6)7)8Y/;]MZ+#,GVP-'M_7)ON<_9*:Q$F]6L(B)*K+>&AWW,33
M7/'K3H)UJ2BB.,2MV'AO SAN?U'RO;SRIZ/3I5S>6CXWEHU;)(_5$/V?E8?X
M7Y>#;1EVH.]SN9<'=XC7W/(3<6AQMLQ$>Q@Q@_^)AQ81$0_$<(+NN_>C<AKO
M^TKHS6D:WK4LZ))BU:4:"&;81U$@P3>*R;)$A]^(A=L1$9'[XAV3)+2*Z%]R
M[D3GSE(K*=F5>V+?^)@='["-K!$MW](NI94S "<H&YE]$I%: !<VOEP.99T8
M6Z ?_Q2K9N;G5!D6UI2$C]U&)4Z?.T,7YY$B8%;T_:=@DL$*A*_$!ZJKTV@N
M%)^^]SU.SC-WE )D@AMJB3$CH"OE, ; QDY<>Z9L+'H7Q'L,U28I011*U8JV
M@1^RHCW6/V\0]XW/UL7I/MX('_L ?( 2 MI'!C59; 2#/PY0_?$AHG:<ND0S
M7'5(RL2+DS\J]^LDFIMLAWLB?A@%5[4)&V6<7IO]'D!R,7R0+9\^1- D^9&M
M\^"6I#N8:CN0+69P]CND[%;JM3N^#B3W9Z+G.;WH4<<^!(#/7K>,)$"C0<50
MDH+&\<))'I%%K$;9$-@4*[RNL'JM9 1Z3G6X4OA6Y][GT(< ^W,?:QP7YEX_
M8?X:6=&5&<@C2!%4^5?EKOX,P'4'.@KRX(MVZ-"VZ%6CU8TA(U0>O:-_'TV.
MT!9=I(M^4W8L&]ADYE"4F*U;B5U 9 GKR8I5[H8JQYF*'_IB07VB\)?='5K:
M=C@JX)TS[4*[YX?D@]R&DG\+EIFJTVG"\#V BBQC>703F@,%TVIT3T6^7CO9
M@GI5>?!U&-[8JZ).7X?V/%B>8-D,X@N&Y+J/@IJ1AZS)PJ;?G3[6?W.,HLAE
M-MY.A'ZY/:>]W7KFPM69^^ASY!B*]R)=AO ^V@,L3VBZ1G!Y2G6+ CW=&O9E
MKW(OFX=?[I1#(6S!&;4^"1OFIV"D<8VAEK5GZ>K:7.L1,>!3LN&(!EI>1O&/
M2'4J SC709L#UZZ,8H+6O.(_>?G$9.\&^.W0L^JD-\4*$*V!9\AJ.?#M)@;
M7TC]S3=H.43*L%^JSZG"?6S'SFQE8?WRN;*DKDET^T2K? $YCAF'OA/9'R%
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M^3S$/L-A(X(NOLT S)DEWBD,?3GK#S-TWY(<O:\%"9G$M&NCC8M_?@+,'<0
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M1TJT:]MTTV592\ $F@8Z_O.Q^;\\.I^,AF?I$<IX>PO=2!J_*:DVQ]-GCUC
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MY/S\;)N1TAY)M*Y9LP7L59=)]9983=ST"<I)N"%=\$<=WF#KX/V5Y:'KV*7
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M;5Q,QJ8,<M:">4649?;6!PB5BL)BOE!P,,.=(2QJWZC<J#P6B8] J"*_)C*
M1%L074N?>F:MM7>7#[->X,  VO)H[CP, "*UC=[@^<^ORMT=!-$1^FO0.4EL
M\@:Z3O+@?PJCR=\A:M4ISD,#P6)WL^ZB QA N 1YA %<LJ2;WT.2MT"$)HP8
M9.$* ^@L1#$C5-:R%7)G!U2'?!D4".VIWX2K]NGUV6\P "Y-8BG]"9J:/\P
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MO/$[>?W[BO__E:VB%UL@6^+C" P;)=)$^^_;2I2,?0OK N7C'Z CY5H3#YW
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M8-1L"C([?!ZV5 17*5PF<+)^X C>:^*,2[)[85Y\_Z,C?U#K;2<B;[9E9'Y
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ML#AJ'XVBT2@:C:+1*!J-(IQ1M/7>'X;X'_OE>?\SO$F]7/]EE=5?(W0]\1]
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MA_#/P1\ 7]$U*U?W__&'7^[>P?P/__L__]?_^O?_"\+_^?'S!_!F33>/?-6
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M:A$@EI(PCR''\C\H"P)8Y"2#-$5!49 BRG*V:';?^X*OX"]?MJBU\.V!_\&
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MLU[5I5RI^W"C)&9RA1#R,* 0I2F!180%9'D@52FF82Y-(UV5:0#8L]JD0TP
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M<+91 PH_\[JI-K21=](VBO.9MU[MMN1EWZJ1\Y@5$4TA#UD$$4.1O"F*"+(
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M*;*.9H^>?,ARPH&\(U?\0:Y7/O/W[6"KC[QI$]H6(DLBB@,&<_4?E*$(YG%
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M %6:!<VFDB;%H]+Y!B'RT[2/:QPW9)NI&EN*S4+DHT39!<E/+SE?F'R4I(-
M^?B3%Q=-=FUCWM?UAK,%QYQ'@@K(**$0X32&)$TX+'*LAI&&(@N-LOS.P/%^
M_@^+(^NN+T[90F[+(KO?V-=#'K!,SWOH@!&F-L"P[K&#>04ZJ%X*'4^1Y;ZX
M\0#*:Q4TGB)UI(CQY./FY^';OS??KG^O6'W-_OIN95R:>.9UWTEB76?[-C^N
M!M?[&:!J\.6Z6:U-$L?.<6#Z6'1 O)GX:=#MH4AP@DRKD_+<FK,=E1-$#<_*
MJ4<M+LR_?/E)E06NU.;=XJI921EX*)_Z]HM)$632AB<P#51P+LQ#2!@/828H
M*>((4TZURF.F07F6TU^^@#UP,(!N<%D<9Y7&;=D9 \QD]2SM-ET[QYE@<&5V
MQ@R[.[/Y!V%V6]8B;_2Z/+["?/=E+4H.+LQZ;UBF&<CK]]"YN,CB (E")) Q
MQ%6W;@:Q"$,8IB3F(A4A"HSF6KP$X#M9H 4W2%LUS 1XR0X]<_T2(LV43T_?
MYVGZS(/U9XAP%8]_N?R\(?<SQ!U%U<\]9VZ OU_5I7SRKF*WZV5)2U[?5FMZ
MS=9/#6?OEOA>UQ2?7,BS3/7PP;;&88M%&]%2J'"V45?F'B-] WV:0].FNE/F
MF,FB(5_ ;PH=1Z:[-ME61OSTZK.9\]J$#@U[_9<LZV35/;V[H;_95'+ONPF+
MW<V]_>.+(8QLD=(D"[*"P#PD\EP-,%5-J O)]R2,&<)%%N>+%;]7O8OT3E9S
M)+1$H>A$88B*_C7V8(JNE=_,@K5Z9[0G=GTOG9V'4VP=UJ5:,\U5 :HY O-6
MFEHSZ*BDU'XEFZ0^O%J+\A;7#=]4[U?TS]>WU_VE,XT2EN=$0%X0!A%/""2)
M/"%2)(3(&>,4Z8?US\/Q;+1T@$$/6>7N_-EPUL@(BS2<$VX(-U0KIVFV\4N,
M$&^2_>6$"9:96X8?@&'&U21EX]E2YU^?,=-IDH;#+*7IQ^VLJ>,4)S4O,HU9
M'L;MO*,@@@C1'!:L]4MP$A"<92P+31P1)Z%X5D(GRFC-K*'3K-$S>"XFV$SY
MG$R#Q$)R;5"3*5S79&H1Z\@6.0UC5G-CE,R7%L7XP_:="/=3>#^4*_Z^X8_U
M F6X$ 4+880S!%',0XA#I@J0<BFZ,0X8TS(:)N!XEM>V0=X>+/A- 08M9,.2
MHG-\TA-=!]2;":\5X5;]_T;(<MCJ[Q24V;OZC9!ZJH'?V./FWL>/^)$S>56@
M&Y5F]TF(DDIYL$@$F%S(LTRV\,$. ;#%P"8C8)HITPY'I_PPD])I5GA($M"F
MU\K3.+WZ;)Y&;4*'GD;]EUYG1MZG35,W>*7\TV-SDU1?!='W""%1F(8XS&!!
M8Y74)PJ8DP!#GC&6"98D23[KN#QS$CQKI"T6T'!\VO>RP9K^TN]ZVU[/WSJ@
M:W*2GI>BZM?;F.]DOIX% ?]4H_;L-\CUU+T+,/'07;KW/Z(X1G&"4AC(&R9$
MN8A@H?Z)Y:&%@Y GA&L-PC: Z?E F:'3M);CVA-'S'3U5-?I:6^VV_;3I[RZ
M?IM0S^D(MF"!44/JBQS$==4LWFZJ]=/V\\UR7$2\H# ( @01#U)8,)S!)!6Y
M2 2- I[IB/[+A3W+=P=*3YJ/:!X7V4LH,9/+#HI#Z3N'^IB(R7<&XB7_M1>M
MH^5FD9]S1&R%Y.S?+6*V']<KU8/J,U^JS(P[>8C7:MB,/*??K:MWY4IYV#^H
MJO'/ZJC^)'ZINWXP"XS2* MI!"-42+%)DQP602B@"$B0,Y&G1:#5'>HB+'R?
MH0H:7 NXD4<$[KH;J6T"*_X[6+9M&_!V>OWYN(-#IH_+[6RL-/0PK5>0JLYV
M/4Y@B%3;4;-'"[1X78&.[9\$E+AU3:7FX*U!"'H.'ML%J'WRVBR8?2F/1D/=
MUHO/%PB_E/Z#,/G%BSDJT;W>- _KJOP'9PL2! 6A\K+$:!)(LREG$*=A!FD>
MYXAR*@IB%)P;@>59RY\LU<4[Z [+=0?LT[LT.6**F;X^5;8+]H ]5NX>4^>K
M>G< Z74K>(])GJSB/?&*G7C_B.NR_B3ZD+[*#E2)S=^Z_^[#5Q$)!28QA0RI
M,'P2A) 0E, DC@H1900G.#>1=#VPGH6^14(UX+J5#VV/63/QUF2?GJ2[9XJ9
MT._XL<?@JBL^^ 9^Z__7R_P^,\(=Z0--H+.J!C-&O-02AF_;*8Q/S0.OE->W
MX@]\59?/_/V*KA^Y2KMZ.2!P,#IP5WG^D4O;Y$[:,WD@>*'LAJA TGC($PH+
MFDOC(4&X2% 89J'6O O7B/E..^ -V*PJCI>M8;%4 QOD27L\6Q0\XNIOO&F[
M-=8[?,W4D[/-TE-@K[$%9BKNT\W[*Z QKO0*_(2ER?='A?F?=NF&.T1;'[)$
MU)T*=,TZ1TK2&5JSJE'7S'RI:)VO;Z>*7X3./FZ4(_"3>%,N-_*WG:$XB+0M
M\BR7)ER((0IBHC*?(XB#0OX'%RE-<5P4PBC 90C?=XYE!];^JF;*SHCD*<U%
M"+,@%1 Q^5,>QEC^D[&<X8P58;AH5-NLUV?G#@MM=O[KO^11$/_;+A$!]XD(
MJQ8M9272_L[<70[7P_0%IG!6F62S;8;> >61Q6;GT%%^Q\<=6_O+]D$Z2(^@
MN^/&DA&.3A53Z+,>'I:L>7E&V"YC7>I2;3C[4&)2+MO39AO93$44%B2&<9*%
M\N*>42CO\3',,"%9S%B$4R,K^QP@S\J]!PL&<(T+7DXS2$]QN"#;3$.<H-A#
MAL(47>XJ7$Z#F;O(9938$W4NX\_;>M17;>K>?Y?-PXVT"*7A6/57=Y7UI(;^
M?"WK19KA@.51!(NX4/,@DQSB-$&0TS3G-*&88L,>F#I@O?O9.R3 [Q(+L$7C
M"@Q<<2TJX#>%C&%MC"9C==WNKMEEZH%WPRD+C[P)X<Z<\UI 9_;3FS#BV&5O
M]+9Y(<[/JZ=2#>2Y*Q\Y4\,,Y7WT5[PT:0 TLH1G/?#SQ]OWPR%1+09=%><P
MC5HBHSMV9HHEXU+OD!MF8F[""*>-?C2HM2J\&5MWMI(;#>*&Q38ZC]LV],%-
MFQKT270A^A(O;]=UJ3;U@]H?E3;=C?C[UIH;>-F>46%""U&D HI<^19"S&$N
MCWV(@X3%)*(D(H51K8P='IZUP XK=9[M\ );Q, 6LZOMP,MOZJ<6.RL#P78W
M]"R&&7ALIEL\LM>BX<]%S''6]<<.BYE;_US$JN/^/Y<M9Z?X/JQ7]VK(C8JU
MW,DE6CE*LH(3(@0D4KE!E&(F+S<)AD&4ATS$24@BK3;%8T \JRP%$JJ)(FT4
MZ0HHL%:ZZ"2#]!3-I62;:1$;BHW5PQA)CF3_)(A9!7N,R)=2._JL]63R$V&J
MN_4@N:@;[5&K>PK=S:7E/(L++@661T6@AG%@2!#*(>=%RGB0!P'2*HZX$ _?
M<?F-O*"IK]1\,+D55_5$?09>F6D#E;[08=0'Q_?!<]"LP3!OL$>L<UE07X/*
M+V&/NVGE5EC,/;+\$E:=F%M^T7(7]$?MU^U&6RQ$4>2Q2 )(4<8A8HS"(DDS
M*###@8IX)Y%1%/88A.= :S>ZJAZ 5:'7,/LWP+@H:6E8K7F"17E!(Y'3 &(>
M%JKU>@ )"]6P",8C&K,HR8/%4]<5LL%5,P>C7H(S2%)<MK4+A-^7JU6YNK^8
M/2+GF/(PA5D8Q)(]<0)SH@9/!IS%\G=)QE'/GK<KDQZZ%S)G"\R8-;R-*%[,
M%]U;[R64FAT^W?KRDMHT54DVS?;4N<756%6S77?:DS2Y[#Y["&#^[K(G"3S9
M/?;TD[;1K]-3&O<^T'W:=!&&>1:C%*)$4(CR+(*$X@"F&0HP%VF<4F(6 M.&
M[=G:-)JH;L,ZG >DR)6Z9UFB$O;5--TTA"01*,TS5'"6+YYY1=:OS+PA#@;!
ML1TNRGWUH:2J)KP;A?UE\_2T_ :N#8LR;9BLIR$],<Y,=9Z=/3L,/KAM\G4!
M_<ZBBOJ09PXM&K/D.+YHOH1MB5!K5GQYX+S9.0Q;=UZ TRS""4P3IAIZLQ02
M$N602TU=$-71"QMUTCT'R+,NWII-+=R=4]S*J7>657J:P@4#S-2"?HA@RR77
MGK\IFIU5^YP!,W-]SSBQQQ4]$\_;2?3[E1037F][J7Q<K]9/ROFE$FD9P6$>
MQ!A&(I&&%XX*2 )*8):10B0HC*+<<)[("#2M#_N2P2%;V(!WP,W$>8Q/>A)]
M*>V6\X-ZHGNH5V (UYWH:A#G2'K'(,TJP!HDOY1AG5<LO6'T@;/-DG\2/ZW7
M[/=RN=R;IIRS**!Q!"..0M71*(-Y&.0PSW(1)BEAB&&C!(+SL'PG"?20U0FU
MA6WHVQCADZ:3PPWUAF?S"<*EB=XZ/;P8ZAI4NO)_C$":UQ$R3?*11T3C%3-Y
M9KQ<O%TU*O[.F/P@ZAM5OUM]6R1YPE 04TBC!$-41#&4=WH& YX7F.0B11G3
M$>)S #Q+;@<2]#"O0 ]53WC/,F5<8EV0:NB4-*126RRG2!E)SY.O=F(H?]A+
MW]D%9Q&Y*7*V<C;YG&T'T*>N#VG]2=RL5\^\:DJI255\75YD@QA%J10QR@E$
M<4:5GRR1G MHRB(4!V)G\]Z9-  ]"]+"\+VS\3+V"*@C1'X&,1B@ 51?=T/G
MV!@3]4[22WEBV?IS"U0Q8L@#!==EO\])XISU^3P/:>;^GI,D'_?UG'[%9O+<
MR9[$@^EWOZSD2N\E52OE,KNMUO<5?ERP7'"14PQYF*9JK$PJ#65>P#REHLAS
M+'*N=<9>@(-O UJ!!V4+'VP4 J#<8@">.A1J\TK=2Y@^KBMF8J6A-7ZNU7O'
MW@XGT"(%=EB!'BW_'#49GN>=LY9]"W<ET'U)>?_)R@_SZ'O]LZMQ>Q?Q8GP4
MG]W2,X[INXCVPQ%^ERUE&9>05R\%L*NSV@\CJQ<B0F%$@PPF#'.ITY& 4HM3
MF,C?IWE>D)@;Y1F?A>0[,M'"!;0';#_N[SRK- ,3+AA@IF][VF]VM'^>IMT\
M^#!%EZOHPUDX\X8?IL@]BC],ON"^B=BV.<[MNFK#'8-<G[MUE^FS2-*D2 II
MM"%&$$11F$ 2\DC>WUA.HBR/29:8)/U=B(^1&C#/$&RQ4^U6]NBI$['-P57]
MPPQ;JUS*?#V5,2-+S11+Q\T#S XSFJ^ 2G*69HC$4/4_K+J)/IYSSASQ:X:^
M7SK8?#?MO@Q89]+ERV19VQBM@B5!*.U;KN[YBG[[L!OWR:51$XDP@/)Z&D,4
ML R2*,0PX"1FB.4L,FOK,@K-LY73"Y\$#@;0+YB1.LXZ/?7EC"%FRND27EC$
M;S5H=!;!'8,U<PQ7@^SC**[.2Z\SB_$G^6!3OU_=MFGC/U52/RU2+B]!<9I*
MM9!1Y==6!>2"PC2E.. I(A$UZA[C 4?/:J6%>$D_0!_;HJ=\7IG9CAQC%C,0
M.\25QZ=#7?W&Z3AWCYS]3H88GL+PGVI*X0B+78\A' -E6]U02\-0]7W=]I?+
M21@RD0<P3=(0HB+(8$&" B8<%3E**$JQ4?7L$03/:E3!:WVR"J)I*OU+9NBI
MOXM(-%->6^I:8![ZZYTEQ5F&^\OU9\YC/T/><;;ZN0?MY.RV6K,-;?K/BE L
M>)!R*&+$("(9@CG)& SR.&-I@7&:&LVA.5C=LWSUL&SDZY )6<@BE@8$,LQR
MB').(<92[U 6)V%<1$E!([.*'VLV6-7T]- N88&>>K$FRTRU;#?6O5(Y28 C
MA7*X]JS*Y"19+Q7)Z8<LT@64%V=PE^M,@+OU]:K^77Y)(8L9"D0J[TNIO#Z1
M@D&,&(6QB(.$%ED61EH:91J4;_72 E,.2]R",XA$CW-H7-;<TFTF> KLT'MR
MU5\FP-T:7+ME@D'4W1DS[(+K%S#%+**N1>=HX'Q\A?GBXUJ4'(3!]=Z8V4FT
M[3Q^-'X.D9Q@C@(8,5I A B&.(D9S ,:A5$><90$L[B(SF'H635>.QCOYWY7
M/'N(7/!Z=O_0T7 $'Y,(O;'TM1U#9_'[YW +3;'7F5-H$I"EXL:J5J3-A?J(
M'^6/@]&M;]:/N)2&0T$$26@&&<WDU4W@".89E>J8(YZ)(B0L-_(138/TK%H5
M JVX=O-#%1)M0'V/!OBM0\2T@^LT,S45J%,6&6K$(7>F&6&NR;1I<Z6:I@'.
MJVNT&7"D//3?M!S4HD8ROW]\PF6E%,^-U#7WO%X4)(UPD&#(442D!I"7SB(+
M,(P9I5BP- I%8N:\.0W(NQ=G#U%]X4O5.W19/JOY40H?TZ$MIYF%BHSFN"@@
M96$FF25_RI,B@X2KJ1A,*/^ZT4R;BUEED_5PP"B'W-'3?Y?3;*;S6GA@0'0/
MT>$HFU&*7 VR.0UDWC$VHX0>#;$9?]I\[L3MJEY=L[_6MU7UY9G>U%OGJ^;,
MB3.O>W>#K>KVSK&;P5BK 2KK"GSAU7-).5 1"OU)$^>8,"Y\CN@W]$-KD>[0
M3:U!I=5DB7-KSC958H*HX42)J4?-"\3?]&Z_=V5-\;)S+;V3OZL7"4NR I$,
M4I*$$*$L@'F4QI!@>4XF8<IYH)7J,PK%LWQNX8(.\-8YV8+6KQ<_SZ-QN71&
MN9ED6A%M5#X^2915#?GY56<K))\D;%A-/OVP^2EXO5R^_<II.^7T!C?\?EWM
M9PIJ'H5C:_CV?2Z78 <;[('KGX"C#)@^!EW1;FB%GB';\>FG0YS5$3BZ\&SG
MH YYP\-0ZWGK+/FJ=>KA9=]YO'/>'>3C'[O[]L[ >H'#D.68)K H< Y1DH<0
MJUX0@J(X(SR(<6*4*7LY2IYE_ZT0G+:WSMV8YGHWI-P^%.)@*_2NKO,RV$S!
M#'#;S4+H0Q8OZH?>;'F_WXZ3$9 !VDXS_QVQT%UYP*4(S5U#X(B!)PH-7*WL
MKMUK[UI/LR(E24IABA&6JI))52EX"@67EXX0%5E!C"+&YT%Y5H'G6KY:Q21&
M&*:GT-RPP3 &8=[XU7F<8IINC\U?7R,N,4VP3@/8B^(0RAZ[>5"Z@MUR7OU4
MK3=/[U;[?HB:5Y>1)3R+;@\9*-"@A7TE;\SK1G6STK^]C+%@^O+BB'HSB1TC
MW''G=DT:K:XP8^O.=H/1(&YX@=%Y_(*L+C*=K$#.5+!\VC1U@]MY+__-R_N'
MAK/K9U[A>_Z9*RTA?[_MWK#!2S7%+UJD K,@%P4D@E#E+Y2G>!H36 2)H!%.
M.$Z,:H=?@0;/.F8'%Z@1?%=@O<>PO1]]X[BRRA2;>:?US(_O?/\,[1J'U8@#
MPJ[ EC30TP;V'\F .J#(<YR3]CI;XS)K;68*YL]K>YTM.IGY]DJH7) -4^]F
M8H9AG&5YPJ&\688089+ /& %Q)B@!*$\#Q.C.J[#Y7V[U+]\>7OWQ2*%HS:<
M"6I/E:&SO(7C96[G:1)<YFC4KS-E\S1A)W,RCI^:N3#@'2ZK7_%RPR4ZF\=.
M!:@A!53*_9ORN61\Q3[CAB^*E**<XA@&41)!%*8A+"+!H! ")6&,8QJ8&XP^
M,?8=K.Y!@6\E7Y[/0'^EW3(P^KZ7/9C=Q%-$@)8*,"#C"FP) ;LM5J1\!S4&
MIEQ_[9H#;7S_.6H03-GOK";!&+!]8I&:,K^(118*%DI5'_,"HERDL,A2!G.D
M^BWRB#"A/7%BN/!<Z4,*EGF^4$OZN-Z\A" S]:9'BU4:T!#QBS)_VH5F3_89
MHG\JO^?@[W;&E&I"_WXE[;)VP>WH)B5A79A6-2_FE6IC+&]%4EH03E' 84&H
MFD\K5!O2-(%92 3-HB*)S88L&4'W+5(2%U#ND+F2/_=3Q2J)SQ7@6XS TPXE
M,U/(C-=Z9HTW#AK*L&+>^P'S=B/9/K?,VR$#;J>99VQE6#'!D<5@!GO6T]^*
M+2]/<KM%+/I3G)OOJNDLT%K#8[#J[+AA#7>"!3,,&C&X9(I=+X:SS''4@D&7
MPM$N#).+S->(09>>@UX,VB_95<#\N!)-?<W^:A$[/_.ZY_-\6P;R(U]Q43;U
ML![$)H)^C@GC:LD1_6;*2(]T#S'T"4JMJV!.K3EK%<P(42^K8,8>-1>].]4]
MO[TJ/ZR7\I7/S>K7>A>7-Q9%S>4\BV:+!1B@ 3[S9E.MP*_U(-M#7S1UF30M
MJA[X8R:Z>JSQ(+J&E%N)LBZ,V43;D.BAJ)N^:ION?S!+61GC;[_2Y4:%+*\?
M52_^?W068,9XC"D.($6J/SXB!.99$L.DH)0&49QD:6Q63Z\+VD06K"KL;R0_
MUZO==?RBB>;G&:AWW?;!%#,%<3SK7"&A//D]&F"(A[?9YY.4^QF$?A[L:TY%
MGV3&Q(CTZ?=?)]GN[5=YLR]KE8*OF1\1+N(B4^V?&4SB.%3CBBC,$::P2 ,A
M1%IDE.5S)MM9T#!SLAW?8_AJR78V.ZVG,;_S_3-3OBZ3[0:$_9,FVUVP-=])
MLIT-!?]4R787;)'K9+M+4)DY4>CMWS=E\VWO]:[;R5AW#WC5T_*K/+LYV\Y1
M6.0T"%@8%A"EL6J>S!',J;S\9%& $LSC/.-T.T[=X-2; 74M57DXEMWTL).8
ME&V*2=UV?]NLE$/JN<7B%=J0FFZMP2'WO6S7:YUL'2V#*& -NM&#C21G?^YU
M%.U'WGP'R4:6N_#:.4>F:/]SI!Y9;H:S#"1;^%8AS[KYS,M'LI&7" 6K[R;"
M\C2+Y/T)TA )B +,81ZQ N8$BQCE\J3)B'8S_C- /%]RVA9;U1"L4?3S-%^T
M(L 74VL:^'U)Z'1O%8,OP23,>S'EMM%=[:TV#>N.4C01S3W][IQ!W%'L7\1N
MQY_]#A+E/Y?UW]Y5G \S0!8HRDD2\QB&,0HAX@6#>9'$,, BPR'+,I9K94_.
MAK%OUXX$"86$>9@\]HH9\R>WS;-1ZV,S9K=FSV7,*T* HN0PQ>T[L&)-V?[:
MYJLVOO\<=JLI^[VFS(\"-CM-ZJI9_(R_EH^;Q]XH"=(H"E*I]3$B 419F$$<
M9@*R&*6,DR OJ%;W_J.5/6OG'I:>-CXF>UQK7D2,F7;KP3CLX7<6^3$=(5\:
MZ ?YK[UN.%YO%AD^2\96ULX_8#O]M'-8_G?9/-QLZF;]R*L/)2;E4EXA%TF<
MH21F% 81B2%B108+'DN)$2$1!&4DP$;6T2@TS[+SA@M>5?*8K/@S7VT,39IQ
M/J52F11YE$,>Q43R*0KE33?F,$0,QXA@'"=H\=3>MK\TN&IFYM9+R-8\NP*$
MWY>K-JI#NCY'+MG(:8[#( YAD>6)5,M"0)*11(W'C),X3X-,)#T;WZXT_=".
MF;B%>P$+>=>5Q /_]*QB9QPQ=3-T8,'O$B[8 KX".] N1_AJ4.ALG.\8K)E'
M^VJ0?3SF5^<E\[3/S@FIK+K."MQ9=F]*(26"2XHL$K'-5O5\HO3A@ATV@VL6
MV.-CDZEMR+QQN??+-S,E8,HR#VFB=JRPRA8U!#5;TJ@="X:YHY8K6$08/O+?
M_U^NCDJF NKEJH7W2=P]\.M[>3T<>II)BD(<1) %<B-0ED4P#[($4A3S)"VX
MM,^T>EZ8@?6L8R0>H$?DJLVVZE%1/4";!P[P%AL#5[T^2S7"%5X89:94M'ED
M$]<P^/[T(QU>F&87^[C\ S,+B1B3/AHDT5]MOK"),84'@13SMRW[>%&ZWJR:
M^A9_4PE--QMY25DUBP+A.)#_!^,@E4HTHADD!<MAD.0811Q3D21&_;Q.@O&L
M-+= P5,'U;##UVG.Z%VN+J?73/?M2.T!7H$>I,/.7Z,DN>H =AK(O)W 1@D]
MZ@@V_O1%4EFN[F_7RY*6?-]I+DI8RCG*8(98)B63,U@@EL*,D2C+:4#"U,@7
M=Q[4/-*I?"!;R,8EYAK\,I+7"[E@);.F#+ 5W!':W KO*4"O(< C!)\1XK$W
M[ 3Y<^?MVW^.(@IH'E ",<T01"'AD&",8<JI((ERJ!.CQC,O ?C."^C _<5,
M/(^XH">4E]!F)HI;2%[D[QP9CJ3N:/E99>T<<2\E[.QSEAE!](&S33OQ^60H
MN9T#O4US/'9/U'?M-):=YRQ-@H"GREV 4@R1X%PU5H]@PN(D$$$A@LBLULLI
M>IYE>HNLNNH-< "_U%UV\]NZ*1]WE\%!.LEV$+IA5I#;K=-3):^W(6:*:+@7
M(SD]W?SY?2;Z"3^JU&4MTL"IY]0O/UTE\KA%;MZL'2^,/4K1\0/%O(5E?UWJ
MYGO^'XZKMROV1F7VX52$ J,$QI1+C<Q#!E6Z.(QS&N9)BD.$M33R&!#/>K4'
MNYT1JP #"1F\T4ZD'.70N.)S1;>9^K(BV:@AYA1-5LTQSRXZ6Z/,*;*&33,G
MGYTYR?J-1$3=GMY)BG[&U=]X<UN5E-_*;^1!/MM^K!D)LJS %%*<<HC2((!%
MRE,8QF$H=R)+T\)H5*=/9#VKA6W2&^LQF3.Q6F>K- VJ[V0##,VKR].IM_@#
M)<"@HP"T)%R!+1&.]-V<O'[M'&H=5/\YTJ<-F.XL<]H$IGG2]&<%_OIK62\2
M3@A235 2D2*(HK103<83&(8LRTF6%PQKJ?&#57U?;U4D5%YAE4'R,\?UIMJV
M,Y6P-?W,AUP8UY#6M!FJ,CNRC#*IC\BX((MZO]9L&=1'Z ^SIX__:-%.E*\_
MXD>NW3ZT>]SS]W[[]A-08 P:@O9DC'_7EA28?=63R)MU\3Q$UZYK9[_&?%TZ
M#Y$^Z,KYXD_F7^S']>JSO/>' 4E">:[<58^KAKU;XGO=;_CL KX3H-8KJ  #
M!1F&!P;;-D.":T[T&6?$M!0XX8&97.B1#WY36#A*D)RDTDJ<SJ\ZFX!-$C84
MN>F';?MATO4C_["N:V6SJ>SK<O7_<_>FS7'DQKKP7T&$X_K.1!"^M2_'GSB4
M-(>^DLB0-./P.Q\ZL!79=K.:KNKF#,^O?X%:>N\J)!HHRC?B'%N6JI"93W4F
M,H%<UO/RX>Y95(W75_\DBF4EVN>^D3]$_?Z/544D#?FMJ]?;E7BJ)7-,Y6TO
M%Y+20U\B-Z-9&/I$37=G*<61SW),PB#%E&9>(KPDY&$^6ZFVGWK!MD->059C
MP[&VVK0<H1\6DO<?$6VX1//V+U?D#R3:MH7H!]HVF 8V[W'Y$?7"\._DT\",
M6?]5/C9?I8FCMYRC+>O]!^N>;[B_0OO<;HJ7;38(=8ZIM9ZB[CB=N VI<\B/
M.Y>Z)VGDGRDG3RRO7QZ:QLSJ(.#Z:05PSTZ^/X%WUKCN\O_[QH]M _#]4[8G
M=4@!<M).HZ'EHUT,!-Q%NQP#J(LV**2IAW9ZT2D=M$&Q#ORSX6<=78;4YX[B
MFO]0\\RN2WXO?R J8'NW5'TA9TD4)8PGA?3&\@Q'$2M4=T6&6<@BGGEYPG*M
MLP273#HV%%WA5T,?_=:2!.9Z.ODTEBX]' ,.,T@MR(KH.-+V[R0N@&*JNP@3
M%K^O.X@+0 ;?/5Q""^X([4RT_R+84NZGK[<EAYRVGE_!M3,$.GP=$'3<R[$C
M(\RL[-!$/5$U)I&KH;:JM[>]\]MQ\8P\G(%E)_-QQD7;]7(TGC:<FCJOR<-#
MI1HB-_5E79KNQWDIF@!GEO/0%UG@89'D'$=YY$N?)<MPG$9%&!8133,?-"AU
MA*!CW>S(-3_<AW*N> "./AT#3,^3L D#3'WW*:L\TQZ3WQ1UU)"WZ"CH2FIK
MBND8N6D'EVH*?S2K5/<]^,;:Q$=-9_K%ZSV9\U_KF^57L6CFDG?WR.!V') U
M'2OX?JS=\8044^BE_DL3BI/R%?7<]5?G^OLU"+_Q'=P5=#"C8(B:@[8<)G@8
M.0$@0I.Y!2;B[SH*1N]?<$S9]3R GDY.TS-C>R!G<.2HU?KB0J',#QCM=4P<
M$.&RX\,I&RX,"''RL-!*ZX3;4@W_:$+C3>=2E8BW6"HUFP6!X%F8QI@7>2H]
M9T)PE@8I9C$G-$T9R;B #C(<(@CYX1F-+VP/LQFI'Y'X]WK^0A:*$R3#$O34
MY!PVY4;R%[*NI&,M:NA=ZB":NM>AMA""WFANZ.XU7-[2MGD]J2.CM1O&06(3
M7Q+J"'Y\SZ?UEF&?!LZ;&)(LU&9[6]Z0Y[E4DF[O2/TD+V(9-K.$$QS1D&*:
M<(J)H*GOASPF*0.U:ABBYG@SW=)NW$(\+U%''MBI81 Q/2VWA@/P//TL!!:W
M8Y",MOHV#-*:MG6#CMA'W1NT7C+3\ _S4K5G_2A]9['IAZFN_;MV0+&(8Y%D
M'DZ*5.[RD1]*]<XX]OTTI0$K2%R SL=&Z$W@,G>44-%R@A:*%;3H> 'OZV,
MZJF\15A@2M\11@WEG2ZU;1Z2[1Y+FF):TOLQ:I-JOJ;HA[JO^QH\QFVOM9X>
M[BO!5]53"4J3/OFRZRVZO>^=/S4=A21AT?;Q@Z1%GQ9Z/ B^6%[@5GQ65*LI
MT(-2&47'IU><+$8>%&@W4AY^T#"G9DUK&3A*K7S_(O]#W1AWV1>T$&&81@(G
M:9#CR ]"G#-!L9^&-$_"C":Q!TJ,.4?)L09NZ:*&L&;R!1 MO1W3"@8PK304
M'YY[,B::K022LW2FS0(9$_<HE6/T!3,%_BQ^WVF45BU+^4?6YH8T;=->V__<
M7G_D>9 &L?2&P^;RF'D4YQD7.*5>3+."B33DL",P* O.#\6^"-84A^_T\MOC
M"J;T8(3U;(%+U(!GV.+W\UA=M7T07]%OW7\[:5UD"H8EHP(F/ZFM,07GT 09
MKV/H6JS(JEG]9D'J^JYH^A<UM=IID@<LI"'V(R)-D)_Z.*=QA(5' ^IG6<AR
MK1%?HY1<WVLK<IN.:Z#B]7&0-#T*&Z+#S 5,:K@C,2:1+4?B+)UI'8DQ<8\<
MB=$7X,TDOLK]DE3SY8=E)1BI^Z[Y4<J3+,X2'(O$5VT8?4QY%.(L3H,B]F(1
M\%"WL\1I$HX5M">FWU#B#!+#RFA'/N 96$?'\IR^83$N:#5Q9N')^DX,"[;;
MA&+D2;/-\#VIU&2V^EY43<+VN_EBO1)\)KP\+Z*PP+Y/(AQEH9IQ3#.<ADP$
M?E@4>00ZJCY#Q[&>=530#_,2K6N.GD6%:D4>6+M[#B6]O=""[# =[ DB2;%M
M3Z5:435$[>V'(U)9V@W/49ET+QP1]7 G''O<8*+1X,2U=X*O65.%.DO3(.,%
M93@2D?1@BZ+ .8M]G+ \\(ND8(1[LU*EB@HU*T1KK)$F;:V?<][^G(\XT-?H
M#3W /!Y=]$)?>A \4&T0_ Q'82A=BB25-C!+\S @6>YED?8T*)NP79+BNCM!
MD6TF*"ZV=U/<):3#%M(54,# H<?H[V>F3$KKZ1(CP! H!UB9C8"R@QEL#!10
M^,$A4+IK33<""BC=W@ HZ+OP"\XN'QA24[?SBNM,!% 1W:XHP^;I BE@%JA/
MD;=7#7>";:,[R-UU)KMY/,'\[GWCJ7^&=Q-_7ZZD<C1M.*3FS%]4XTO2#^ZB
MU&,\\PD.HT1Z EF:X-Q+*<ZB.!>Y=*)BENMV%!\BY%@Q6M)HA[;J-DM&YWW!
MP!I6(IL0 ,,@0^E!/<9U1#/J,SZX\&2]QG7$V^TWKO6\<1>T2F7NO!/M?]^6
MPY/-N?"2R \)CH(BP%%*$YQY7HH)IWF4!BPLDA2:4P_BP/E]8L\/^H%W'/VH
M9K"P,9\?W+@,A+O'DX!R'N$BC'(9B,8"YR%/<.)')(FS@OJ< F)0E^!?'(Y^
MZ7TKA?MSM53_"]5D 2]H@&$<Q9Q3XF4XB8@,5]/"PT1$ H<I]6.?93[U09/!
M'/ZR38+62O#YJOX_T,C4%$V]8SR'&,'VM:W:O]M5^_U0_T1(9K7KG0D4]CK9
M@:A/W9W.!)H3'>>,EH%'=E]$W=_<O5N*^O-R]455;%6B;QX!KO#67]&Q'=EA
M!'')"2J7*U2UO&S:D>@'C@"DQN-*-R#!#,DN/HH))+E 7P[P<5"W#9?=*'8%
MD)DLM(6+OAOY&KQMF+VW5G>+=T77X+)\^"H>FH2<F9\48<&2 (>"2L^#^DQ&
MQC3&@@1!)$+AYS#/XRPEUV=&#5V5+D+7];P4=8WJCC(P#>\L5'INA14 8'J_
ME7U#%'T=$QZ>.S<FF*TDN;-TILV&&Q/W*.UM] 4SW;V7L H9<+>#^9H;R/JV
MKM>"S]*8J>QYAA-1%#B*>(@SFB0X)"1*.,UB+P&-+CU/RK'V;@BC6E&^:F_U
M:S1OB#?W_>W? "_Z![#3TV8[B,#4>0O&UQ:,EBQJZ=I3Z''9+&GT *%)57I<
MX$.=UGC#:N^U9K;F+!%A4) HQ2)E4JV#S,.$%G)CSCTF"I[QJ(@M]%UKB#G/
MV#G;<:PA#TQC'81-3Z-M@0'3:7,<;#5=VQ/0;<.UEM3WT&QM3VC-1FO[[UR8
MDWY7M$6J<[*X7]9-I7H_!7V644XI#WQ,6*B:Q 0$YS3,,,E8DGG$#Z-4*ST%
M0M2QNF]8:*:%]TR@G@OT6\^':?KZ$)YZ^F\;)9@=L "0>::[AL2VD]Z'2+Y-
M_KL&"&=3X77>M9T-^&6Y6'Q85JHF=^;SHLAB)J2#'S,<>4F$\R+-<!X3KXA(
M0O) R]\'475].3!VS(U^4\R@CAM-PP'#==AR.$,+9CJ^!Z!LI;89 G9A;IN[
MBQ0CB<T3VG87^TXRVD[(IY_2=NIE,\=+G:A6:[9:5_/RX;KD7\1"705?J]R%
MIH'-MOW73JFR%XG<)P'.A)K-0=(0YWX2XRP@61HG:>S#Z@1-F)C@ZF3#$LSW
M,H)4SQ=S#13\^F3#3=/:L.,';1G:Z>IG^2+%!B:6O#<C%B;UYBX!Z="[NV@M
M V_OFO]S_4+*U7V;7E)_>Q25((54ZJX(D(@BC;F7XX"HXQ\O+G 6B10+$E$O
M2TB:T4#;RQNCYMCN].113Q]M&0 X**.8:7AP-I& &98A$,;K*@W0 +AI-E$Q
M<\^,?B(PSTQ7R$&/;'21Z3PQ77GV/##MEPR/O$[.$)IY+*(LD,:,\51=4841
MS@AEF!5Q[$4\\>-0J[9[F(SKRV75&E'U/FYNIS!5Y!';H6]CBME%<\@<GE@I
M>K@AB+K)3[L3J-M>B J;]^T\7==CQFR?5)TF\AV,^CI[&C7\M'$R=COIM/N*
M/[4SD6<Y)R&-I>;2A'@X2OT DRR7BAS2D 1I) ,D4-WX&3J.]??6\M3G8YST
M=->"]##EW4Y/[M43_?#3F."&0Y//BF5UX/$QE3<85GQ6U-.#AL\_;IC-M2R7
M?9))2Z%;?G,50E*24RHB3+V4J8XJ'J:1%\C_Z:7$\WP6%:!==Y2B8P6^6TEG
MI1_>_D.GPS_^%S"S:Q0V/2VV"@9,GW=)]Z/1?^BH_^CD\DA;6%O97Z/TILT"
MTQ7_*!M,^T7#!!)!5[>E.KE07E@_??P+68GFMHK?BTHU)R0/8A:Q(O?"+,5%
MS$(<!8' &>,A9L+G$>,%BV/0* )]TJZ32R0CTBCTG%S)/[>\((F[N$)-<FW3
M):;C!YALH@^QGN%P QS,@C28W>Y@UK.!OC28M9R@^W',X(DI8/%MI:GH$YXV
M:04,R%$*"WP%PV$GB\7R=]5L_<.R>K=<TU6Q7G1-'FO5!G7^HK)FU#U.T5T5
M)BSUXRQ2E]/J4L63@7\>,0_G(A8\H6DDC0]H  J4 ]<GFST_2-)#O.,(D8XE
MX&04,+QZ%L<I:,!#T(XLVM*]0OL@MG6"Z..RKG7OLN&S54P1L35O!4Q_VADL
MIO <S64Q7LBTP?SS\Z(YD2*+&U(_?I#D;TNY]A/92Q*+$I^FS60V/Y.1$0T*
M3%,OPCSQ21 5<409L-V\%EW7>7<[7""^O:)<%NW,MD)R);VC#5O R$D77,T3
M3/N0 8\T=]%2'"#% MKAP4T>'DQN:XWL]:A.W-8>!,5QDWO8ZV8FY>.R?/@F
MJB?E9&T=J9\$41?%'^9_"+[K<,W"-$O3V*.8\5B&64PPG <APS3(\HPE12Q\
M4-8^C+SS$]2=R IF/( PZMD0=^# 3(GB RM&D.+D:B=N0ATSJ.%F$V;M/?)E
M"$RP?3'#Q)*9 1*?U-J8 7-H= Q7,>SC^_2\6+X*\554+W,F3M_Y?%XV\RT%
M;R;VU,V,UMU_OUG6J\_+U3_$2M43/Y3S_VDBPOF22Z>L^ROUG#]+&25>3 K,
M*8VE5R3]HRQE@0K6*/=2+V.^5I^XMV'?L>W[I:PV]/=N??O+I"M4;;E1QTV2
M16!#XFD_MYZ-_7X_HOT;[%8&U AQA1333?.$5[%"6[X;VRTY;X+5'=XM-F%^
M$\AM]7:>EOEI6T:_R8<YZD3]-EP8)#FJ-G$J3>;CDOWKKK@NW_\QKYMQ,(_R
M+X/P1KXW9V3QK9IOYO]FE":A4*YSW/1HC @F.9-;DL]R+\L)]856JH$A?==W
M%1U#2*6/JKB<E*AG"C5<H>#_A(AUC*&5X@R0$V@ ^/ N, &,P)L+$P1-TBL-
MH 0D7+J%U"P%T^Z/$Y:;:8['8+:FP;+3Y6^:R[R7T7G!,J;5-4V%] <IS:EZ
MGO=_L,6:JRSZNA;R__@WR606">X'88IY+A(<1>I8A+,,AUZ4!(0++PH*6'$-
MF ?'IOV;="6[\MVZW9AK&1 T7$(K;>#PZKGRCD&#&?*^\X%2BK-=#C<LH9XG
ME<5FL\S&&!%K539P#B8NLC&&Z+C&QGPI ^_S9]4\K53[X$^$_4OPKX*MJZ:6
MI]NOJ70O61XRS)O&22Q+I*\I;52<\IQ[09*E,=7V-<>H.38_6_*8-O2E%>H9
M '@]HYAIN(LVD8#9E"UEU))&6]HF/N H&@"/SR8J9O[=%_$L_U7U(D.K1[%[
M$:A.JU9DKN8;H=42/6QA//HM_<62PZ<+QZ![-[K(=,Z<KCQ[KIOV2X8]X]IC
MKEI&]#?D>;XBB]NGYTK2;#L91D*PF"0>3D0D?3(O2#%EPL="A"2,O3B,"V;0
MTGN8JM;/_.(.WAWA]FB6SU?K"MJ[>P0[/8?+ A1FO>,ZNFT^38?%+FF+[>.T
M1+350FZ8V+1MY+0$/VHEI_?6Q?VFVF3CZ[(Y$ZS$HY"QR8OH_K9/U. JYY=%
M B=Q3-5PN0B3E*8X87Z:)#RA+ <UC@32=YT-L]MD:8^-/F?>0A\J+9SUC(5#
M]( W)3: NZ0_%41\^ZVJM*B_5=<J"#0##:Q RYC6$LI@3W[RU[]+CT:\6_Y>
MSAC/6.%%,99QE70X1,!EO)5S7"1^PM,P5JDSL#+"0Q*.3<J]M-3S6CG,:F,5
M?S#58%JU"%G26BZY4DYUQQ*TH/ (+#VC<1D$,+NPH84:8IA+:C;+!\])8JUR
M\(C Q$6#YP0\KA<\^Z1)IY&C?-N?A/SYBMW<W#;G6J5<[TRP9''N!T2UHO1R
MAJ-82'6E7HR3("QREJ0L]V+HV%E39J8)&XP&@AKCJW&4XA0N>PG\+5,[>?P?
M]O/X#4>M&B,+Z7PR <*&'5&<(0ULFW(A0L/M5$P7G[#-RH7R[[=?N70QPUIQ
ML5(9THW_P@7_Z?676B4JWC8Y(NK$?=/F:I87K*!Y+,U\Z,N@D*4II@6A.!>>
MR#+N9UE2S%8JG43/2=,G#7+>-@QHZY-DI"V#6*MKI'G9^&KMY3;9\ "L)=>'
M5<^=<P,6S,(KG)IRB)X+1%_1#[^TH/V(-KSL],.S6&@.!L!6Q;D^X6E+S\&
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M.DMAFKNLCBAJJ"))%GJ+=8B+[OW5!=(:W5SI"VIP9W5&F MNJPY7G/B>ZHQ
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M:TT>4CO;M2MX 5:SCZ.JI^-6L8)I?0_3;RU%-T,DM>6SI-_C]";5>&WQ#VV
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MYPRED[O+5CZ+M^%>8UILW9I;E/=E;]>]QK2<W,)[%28,RXU'>AWH%!M?UY3
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M98R@S.J]?\5%S#97_78K5LN'.U9F!6T.O3ZS[\UOJC5U8Q1'H>S-E28 4LQ
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MBD@K?"U?!&E3G:-UCU8)F/G9]HHO^\@$G;LRRTGVA#:[GKW(3:#/<0Q<Y/H
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M1!9=A:<%/5XP+SR]<)7LQ=[K[XN2LTRLR/T*O:8\:M"%08S]1&S$A'/$B+F
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M9F9^M4*''=?JYTL]?PU868?YI ^H.^>$J>V5?J!IT L*&GC?/><K9\<[$.P
MR;WXV<$T#?MV=C(XO1"R'$**X>SD:'O3-9(X4A2[B,$+Z-PB\/"<W"Z.7[R
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M>4! PF(/A#&F(?4XBO3JV\^3FMD6N],S0=G9D5XYDKA1 X()E:GM2>PH0L]
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MZ(LXB^MADDG/(U>Y]@WQ#G+ZS6@]D_%41Q@-Z)_WZ_<N6+4L/!*@I8@VXM9
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M@!9Q]/!,E\DJ:I4F1@O4LTD8XBVSZ)/8;"-XKDV'!^!Q%E9GF7KG1]2QHF@
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M4B906KW[Z+&=_/Z[7CL=(H*J0.J_C+!JA[_C7MI7@>%9^P+NJ#"3GDEC62
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MQ/^\'4[OBW!QF1\?%>&^A# ?:&9"8)P1R\J<)25P)V?MB<?/DW>2F50[V^%
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MG#R,PGXU3W?8>JJ+.I1;H]KI[61\?073FT4;QR,TU*._KZ&EMA-425.5!V^
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M2*/@$JNEN.C17,ZN=#TI?7EP44%DY). 1)D-7++:<Y)VD--OW+Q?<!TCD9;
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M>M180+]%.6V88/TAHH'ML%SSAO3_N^S_A$0S%RQN:)]+5QB/5DD.)";'49>
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M[?@AK&\ 1*MY<H]2;A?Z-,6,G."BM 2198<IU-7!$L9T*+O,L^I=Q;;1TAZ
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M>S#M].<XNYC;[]_&WDY6.B-B()@2B9C/\P?SC9@FE"(( EV0B5.FBTR ?8Z
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MD &BIVXM49_YP&EU/>TET5EA]M:&R!<[G:7Q)[M8QJLY!.#_<?;I[*;$D?(
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MEX>O\[&=;+9'7:16<(5P5!1Q91UR'"<D7!(,_ W]),WF&43U_W8G5(D30=7
MK*^-K#>SG'BZ+K\"3?D:_;?I;#*[N+[3IJQ \+?L]'KQJYU>)8C*K^:9 _,9
M\'>QS73?=-R(TE(B E(N]PCG3"*'.49>V92B21*SK@/*AJ.R$UKEB:"U&7%6
MQ_6'-[<5R9/<V?!M_!$GL^^K1[:<!'XU]=]^'4_B8CF;WMXW1BM)T(HCPV6>
M(4<5LH(F^"7( YC/O+#= 'O(YSLA49T*$@<70&V(O1_/%\OWLZOY6?C?5S_L
M]*: ZV8O224?DW&(Y8&EL!^-G"<2169Q\)B)&+J!:<^'.L%&GPAL2C*U-D >
M;P'LZCS:!*O?; 8KB@T5(//<UUZ9@(R1>7H3#\ER C:U&T+V?:D31,R)0*0H
M6VMC9'.#F+NKW$QJ%YYH@CTRD5@X97V"N 1<2"$]UY&;)+CO!(HG2W>[>L4G
M H/C.-? <_-F QOB@V%@URQ%,3D.A@WXX'PRR(/%BS*&($WIUB(/".@&CA.X
MF#^>O;5MPLI77TT=OF''C7?DG)"P:T1T+L&4 '#M=4*1).V-L,"6;K?ISWVA
M&PA.Y8J\"!^; ,,Z<+L-YFZ2 [$0D8.S' U9#5DA2$N9D/>)6:8,3:9;OZKG
MO]$-$*=W'WT4+VM#XN;.Z39ZNIO/"(0ZC22WJP=PA0Q$[(@D103QS#C7,7K=
M_H%N8#B5Z^(27*R.A-D"PNOQI;N"Y>ZE#7NE(\X)$,Y+C+AE&#E#/7*:")ZP
M!1/7$0G;/] -":=RQ5N"BPWXDQO.W#'F?/GM-B:BSFB(G!G V %S/.=(YZHI
MB*(CA0-/>%XZA7$7/=T = *WKL69WP"0;H=^GJ?WXZF=^K&=?)JM/:G;M&&_
M'/\8+Z]7J9N;D:"64DI$U(B%_#ZK:)X/G#!2(5A.7?11=QJ3VJ<=P6&DUJTK
M:20Y\B7%?9JHONF)&E7"!IR!*&T$NZ!AHY3!+XE@7#GAB='U<=U"@<&+0.EX
M^!X@U]J>WO,E8H$+P[ +2- \:A/CB)RB%$F*/2.!8$E?H@JO)4P=(M]N]7A]
MF-V S7NVL")Y!A$O;(&1%/),37!UF :WA!,=-!4Z%+]M/*JB9;AZO!=%5U&Y
M-("O+U=N,0YC.[_.72O/TY?ES/^QJ2CC$FAUB(+W@;C,O9]C (O.L%&$Z<!T
M\3/S.6+JY".UZNT5$5D+V+LC_Z.]A)_>X]--31KV%MNH$'=$(YZ21(Y8B0@/
MSG--J$FN- CW4E7Y-"TC_L>@*BN+!M#U:3[^ 2?#IXGU]\]_*Z*UEH)I-H'G
M)I@86<W@9];@(+3%R9<^-[=34AE%A>7]Y#+E:.8W *$/8-$OXZV#<>M-9&6+
MQA-KG$4>2V"13@09HB521/+@&81!+!7&T0YRZJ1 -GI EA);NPC<:*B/D7D:
M(C(^Y1;CVB)'*4=4R%P.I%2@I5VTG035-6G%Q-X-3@?(H % ?8D3^*.+G^,T
MSNT$M/(L7(ZG>4C42B??_?4]IUS<5N_GJ"4JCRS$-/D(<,A)B)A%H#A9+ A_
MG$U[O/O5A\ F 7<(,!Y[8X-)J0$(%C@C?KF=+X-UXC9Q8&NB$,,+@O/\68-T
MHMXX2L"%*=T!M"3]=1+&&SVWJP&C]M7P3:GYJL']R!L1:>X8I@)H,I=*@ DQ
M&B5!K) A*,.Z)04]6+;VQ,-:HIT5X7-MA'R\RI;^/+V=@=G_.OOI;JYC#*,8
M2,Q=GN"0@?",Y_%:SDGXI8C$>1V#?3P+XQG [/I*[>F'+>"GF!1JP^G!3(C;
M%Y+?O@/CI\M-QXO/T4?@9ABQ1*+C 2,B,<V.C(&@';A'6$K:&<<%[M;8ML]7
MZS8_:@-N@TFI-OQ6A8HQ+.X5E.5TSIODSG5E64[$R8.T;K/['K#CIBT+<!>8
MZ8D#YY<!=QEPP! +OK!D04E.F8[=*E0+$E4W.:4-\-:2<6UL;U?:#]/Q<IQK
MS&]YG(?VQI&G5#$E5KFI,K<3 LYJI9'223B<:&"Z6ZE0K\_6?4YK Y_#R:E-
M!#X\-M;C"T<,*\YHLDA2 =NBR2!GP'L)#HX,Q23%HMMD@^[?K'M3W3+VCI90
MF\#[W<['^6K@#?!N#-)=_>E(&DN"3!%A@6%?08%Q#S8@B4'!@E><=FS>U..C
M=2];6H;>\3)JX%YQ,WMZ,0HF@6IP@5)T>/UZ:9+E2*CHG1-:!E+Z:>[FVW4J
M^9N!V%&B: ="N6_9MH&7[_[RDZN0.Y\M%A'^&[Z"1@6AG,/"(N%R:8#%&&D,
MMMI$GK370N,DAT%;'S+K] ]H%9B#";@!#+_=?':SU9&CQKKD+:(Q@!4W-B%C
M*4&>P2X<UTE+5AB?CTBHU+6@.? =(YD&@+5S!/";JWF6Q8A$1;65%@7P'1#'
M(2$G<@YL])9PH4.BN##:NM!5J3="<Q L+L/^N#1K7$[C<GA49MYN-J4LT\QR
M4#:='R8QL$Y'&B"0HA!0<.>D*_]0W(FT2BT;3@N;!TJR/CSM]_'23L;_$\/-
M_G*Q,D3W\^6F<^Y(:VLH#PX1XU9U"!@Y;RD2P$N:._5%77R6_7ZR*C6.: ^6
MA278P$E^/_EW\Z3YY1M(9?%AL;B*X</T'A='4F&N<L]F[[2!$"ZGSGF<$+$V
M9Q=)ZT-IP]F'ODHM+9J#Z6 R;0"O;V:7E[/I:F^?[/Q\ODJY"[_;R57\%.>K
M;8XLU>"I:(<<":OG=V ;,PH%%80G 0NA2\^GZT!6I38;S:&SM 0; .4]A5N]
M$=WN0TD(ZYBB2&(F$&>*(&V!6=9XE2QS$-Z5OA!ZCI9*33J:@U\1636 N9M'
M]7Q_E>UZ'N66DS=OE6O$B.'1\P#;4#A7V 1D->5Y:SXZQE-(I>^^]Q+5#86O
M]^%E&.DU]-KWD&]Q?CDB2L7D-$4AZ3RG&SAD,<1H21,5#)$ATD<PW/^\]^0K
MW7#U>E];RHJA-I[N6C9L7L!'Q$2G#+.Y4S1XJ8FP7$I/$;!#1DD]4Z+;@+,G
M2W=#SNM]#BG \-IPN0ER_M\K.X<E)]=Y6+N=3.[M9S&2% PJ%1;) -$XQ.(<
MV1@Y\LHE8W1R-'5#4)>O=<N0?KW/',.(I0&OZS-($@C(V8KWLADW15@CZ95@
M&H[KH"""!MP09,%W1!HSSDSRAMC2@>=.@KK!\/4_=9236C$(_M__ZXE,8*]_
MK/YH]2?Y7WV.Z?_,__O;YP\/UI_.?EC0L/_PL\OUZN_L?#J>7BQ^F2T6WS<!
MS=NXM./)XB'EBW$>*;//SNU:[G_=D?B8^,VJ3S!T.+GQKV6<AAC^K^.T]N9[
M-['>F5NL+F]'4M#@0/R()9=COL21#HRCQ+V.. 8E!2FLL,_1<JQE^AB7ZR+4
MS-2S'\#+G,7U=78OIO@VFX#&+WZRB[&_98%B.%$3)6A3U(@;E9!1/B'%\^ %
M%[QEI>]T#R2U;ME:$0P]-DPO(;0&3LV>VQQ)#?^A4B"!<P=!)V4N8(G(<!L<
MP5SQ5!F3=;'X(K Y#JJ]9-@ 1#],8:VX6)Y/W\RF/^)\.8;=O8UN"?L^3SGW
MBS*KP?=PB-& <U651U8D"*")<48*)4EQ4.XEJFXE9@T8EI53 \![R,3ENH9T
MS<=/*RF\'4]61:62!\=9A'UY;C+7<$X1RS.>7;!!&CAS2C=D[DI;W0K-^M:P
MD-0.1^,,XNHB:/SO.+[X!G2?@6K9B_CP^?C\:@D!_#0GQ3[DI&46^(49DIZF
MW%)'(R/SK75*."47.2:E^]$?1&A=<SF(!SF\P!JPD;TV.3)>>8$E*#+./7"B
M<:#7^:: 69H@T _"E\YR[D5@7=_Q!0!S#$1[2>]@: (E;E:N+]M\=6]E)YL3
M9[6QAX?"ZO=@@S'<U/3=NPX;N:"Y()0C:7._"(8S=X$%.$KKC=,FJ-*M38^G
MNJXQ?7D8O["<VS6[&]?F":M'24@=(:R#@RN:W/N$(.N"0SYB"@>9TD:43CCH
M26)=1[49TUM$@@UXJX\]JH>,XT9[4#B"),TOWCQ&Y*S#2!#"8TH4^^*3/G82
M5!=\@WB?Y030@+G;NID133D5D44$*D 1STF)6MF 0@*=U);[I$J'W5L):>OV
M^PA!=X%0+ZXW")V;Z!\["G]9.'!F8T#<,9-'X2A$K(H13OZD!C=!?:YH7BST
M'0X^AW"^ 0"=39?CD$D?_XA?HK^:K^:(K&N08UC7*%]^OUI+[#P],>;K#B%6
MPVD-!SB*/@$C:1#("DN1(]YJB867IG2/WB*$UVV2-<C)^/(";30UX8U=?,O_
M_^[?5^,?=I+C(' V/\?<+=&#IN8_.R)5H<_R)5(7#MY.H52&O/[9-#PBX1:R
M%"<O- Y(& 7GIA!@]G++(,,"8<YJ\.]+WR3LINCXHLFMJR_?V/G\&C1F53<R
MPLEQZ;E"T@@")PC+ Y^51%%&.$UX'CM7NLZB$V&5.^V6P\K32LC28FG@$'ZH
MQ?NWIU@*3!$/WHK4N?J8(P,6&[& A74)$VE+'[<]2:S<J7<X_ TIJB9NE?=M
M\%X1O &O.3F(D (7'G'C)-(,/%\7P)76,3(;2]O\[M15;MY;#X$'"J@!,[C%
MQ7FRV8>_<>]OCB*Q06.7D,6Y_MT2BBRU"<E$I0 E# &7'JIU%,&5&_0.>T2_
MC!B+W027C3P^3'_ *K/Y]1'AQ9,U2L00NPDK%"C<?62\\)/9XNI>8!N5\LHD
MELV0S8-O'3(ZY=LUEV1(PFE<NC/3#G*.?X#=+/W9_OFK!3LXMI/%2/N\&Y7?
MVG)6OPK@>^8T,,9(BL1% '/Y-]4MA-2>2U0&!4\?0X_E>0,'W>TF_GLV_^/#
M=%63NUB,<B88%1"U**E@%]PS,+H2=A$<8]1IYN5@R'E 25WO?7#H',[UEK#S
M/@_C^A;#S[-9@%U898(,#F$/&UB/7HB@!L%3QR@7-#R>WUX..P\HJ>MW#XZ=
MP[G>$G8^QN6()ZJE]PKYW'J'4V.08XZC"'OBA*OD7.ELM?O?K^O^#HZ3OAQN
M(*GASC[.Q\OX=O;G=,1$\!! 8B15E(!O')&5X)L[XZT-RHB ASN1;JBH.REB
M^-/H(&ZW9$W>C^>7GZ[F_IM=Q)RA-EZN1U'"X9IT!"7P!%GMP$ R"X>K5QH1
MZQ3P2R:)!SR6GB.K[OR'%SBCBLBC=G>%/?OY'/WL!_C_<3%BG#O!-+!):8ZX
M9A+!'@72T6#N@V=6=9M@T_F3=<<XE$;0@.PN>*==]I(F.W!_CB>3F_FCLW3S
M.T?<VNQ?M,0U3D_2"]WKW'SC;!H^ -73BUP EWO4+Q=;8)BD#9%BA4AVCSEA
M'&EG,**<:>>$H<J5+G#O1>#1U7.;C-;/\7ONP3J]^&TZ7H)J8$PMUP)YGS,W
ME(RP[0A1@=#8Q:@L*7[>;:>D[NW/<%AY4@]WO!P:<*5N^/5Y-IF\G\W_M/,P
MXM@S&9- AMJ >)0!?F8BDL[#5FP2#)?NZ;*%C+I702^'HV,ET!"(1I11(WS0
MR$0*<6<$3\^J:%$R6E":L.:V=%+*S;?;,#L'"_$94/3BZ,%(^+X:"?UE:>=E
MVK[?4 ^<B..+Z7JR@K]>=3F:K&3RLQU/5V%!Q,Y$)D%51"[PP*NVM\$#DY1,
MWFGIB\?YW:EKPP25QE1AJ;1D?QQU1J3<5<VP50HT'+Y4*?AE8DX)D2=[U+0_
M@]T^#V9_^G#T2/OS;AH&B[E^F4TO<D_0W#;C+GBYUT_CXVP9%Y_LM5WUUC@X
M##OH.R4BL^,W6"A8RP1L\9 ,80HK8\%# K/"*?P,0)@0B83[R(U+Q?LE;*?D
M^ %C;IF[.LZO5HW[,CM'6@EFK,=(L-SQPJF$M-($J6"<)YP(XDH?8EO(J.L!
M%9#[TXEAQ[&Z@9/IX1;._AHO1LER*IEU2"4,%E5PC9RR%GGC.1.>81Y*9Z(\
MI:(^5HX2[$Z@].9R<SCY:"_CV]DE>&.C9)(&51$H>=@")S17PC"#G,.1*>LI
M(Z5;<#U'2TN8Z2_CG9 YD.&UWRG>CW_$3[/Q=/G_Q?GL\5G_]BJ":-6O,5]3
MC9(FG%*6,TQBKB[--U*&<Y2BCKF/K")BKW/3\YLMX>50 <^&YW8#UB<[C\N-
M\_@5_LU*NZ@U- 7*D L)KV>O&VXQ\L)C:S3F\-_"EF<;'75C\-(GU=&<;A M
M&[V*>6"'CJNV16"-K8_(<A<0!F4(%H)(]O@IM#A>6CBGCI?P'L@<P.X&0//;
M=)%+@F/(V]A82:$%E3G_,<&/>0*P1#8IC:@07 3O<J928<1L(:,MN!PBW5E9
M5C> EH=F]Y?;COB>26D334 \9XAK.%R-)P'I)(,PVA*BA_6&;TFI>]TW; !U
M&+^;@\U[T)I-4P$6)9$>_+$8B<DC-Q32#G9$,&$^44HQ+^W+/$=+2U[Q@8+>
M"9X#N=X<>GZ;VO6,6["CXX7/&_HTCY?CJ\O52 WXJYL99GD<[B(GW6J;C' R
M("&H P5T%MB'&4H$8V>9UHF5?GPXDN26?.LAL#BL#(^8KGV1YW^6J5R]BT-O
MG@#NW_2/HA#!,"411*0YLQ<XJH6W2"4AO3!&T.(%^WM(:NGD+ .ZDC)H(!O_
M_E/2ISCW63P7\:=HY^/IQ?OQ7WF<\KHC_6> \<B9R*5/&F'O7"Z;S6F?)"%!
MHJ)&:6N*WV?WH[!NO<<0@!M00HVV5+J_XX]VOAZ@5>B=]LEZI=]C=Q,\[+NK
ME"QB+&,>#;'*'^+(T7Q;'C4FW$A!>>EV?"_W[LJB,$EBC21 '/'L:NJ47QBI
M2I88(0D)@WI<[;Z[]I%[EW?7/JQNSI=?W<%)';7Q&*-@B46<<84<!_L;?%1,
M.I=<\8[CI_#NVDNP^]]=^W"Y.9S<>R7"(1HE5X$  9_-.XG 4<,(!PW* SX<
M'-!_UW?77C+N^N[:A^&G].YJH[<Q!A2X,HA3B (<R0_5-'H=M.;^<8/XU_KN
MVDO A[Z[]N!V;1!]!7&O]_4EYOJWZ[S/[=MCF^T9PYVW)B&2+$;<$8HT(SB_
M"@CKHZ%)ZTY@ZO_MEJZ*2H!J8.XW<+1M?8ADN>&(M09I&7)W+>:1$QKV0'(J
M'N>)\%CX6#N-1_UCW*"C.=T@6C;ZQ1RCSA*%J,U-Z3$72'NJD(U*&2EQ"K;T
M*("3>=3O)>%NC_I]V-T :+:]-!O%393.(J,5!^<P]],SN<=1 &M,-8NV.&).
MY5&_EW0[/.KW874#:'GN)M19F32<G2B:P!#G1B"7F$' *:\-HU[H86]Q?FGW
M4;]<='X8OYN#S?V+[7<I19_O5>_NP$?1::RMC4@!_"$"<!Y9RREB"OXDL@@_
M#ILALH? EH*S R&Q$V8EY=, ^#['[^NA=HOSE#<Z(E0PEL,,:1G8<&\8LA@;
MT$^L>:(^:5D:7X]I:,EY+@.AH[C< $IZOL=9*VUTT2&K01&X!D6P1N?)GTPJ
MFWB2Q3LF#O!B^N)/],<@;$ )G<"+Z5U!Z,TNW_WU/8)'6;S2]9GUAZMP[;*A
M85]8B26>!2M1M#JM>U)9 C\H*ZE.4H'7/T0]WQ!-I1^QTBW7PYM 1<[6>50K
MJ8VP#BDHSE @.:]/T]Q=,F*PS@&44GLE4NFAIUUIJ^]>'8F0IZWU!A!*$^,^
M[E-_GMZ/IW;J85.K5+R<GK=)V%N,8H)(V<8\ H" ,58YC=0H"^PC6ABPQ[3\
MB+>.M-5WQ0K#;1"A-."A;5&CD3*)6PBO40@"G$P=''+ +10T(RXRY;TIG12^
MA8SZOM;P%JL7JQL=K?%E.?-_?)M-0!Z+MS&-_7AYA/>T8[42OE)78@MY1O<_
MER>J+*_S\]DMFI0R3@J*D<(&Y]:O&-F</L!HXI(ERJDOW4]N-T7'6I,O5VXQ
M#F,[OSZ?KU?_-2Z_S4)N9+I8QOC%3N)Y6M'PT_73OWSSU]97?,0ZZCS$&F8U
M=D:J@!PA#%'*F8^2<E%\8&Y)^NMZ7 61]]B.51-R \?E%Y!@S-'WFXE=+#:[
M7/=<B&#"N:<HV.!S@01'SC.,O R!,06^)BW=N_]98BI#KQH^'@.UB+ :0-U]
M^C=/9HIAK$*DR%G,P,TT 5F#%7)16.>]TE*7#C6?4E';Q!41[^.:E>-XW0):
M9I>7L^EJ YOW4&T]$T$;E'CN[$$A!#;>0(@B9#"&^@A[*@V6QT14'G][I%2?
M%#8=P^(&,')G=N]9XY7N1.^Q!H)15 0BG&AA#S%QA*,DRGKN%"V=IO L,75O
M$=HYQXH(JP74W9&?4Q7/TZK%*OBC(-&;_@[:4QI59E&(><H]**1/"9$0-#BF
M0>GB=P_[J6K%GSI*_(]!5586M9.&SZXNKA;+G)2:-[8XNYC'E6^P,<^8TT2!
M(V"/D\A]IS0H(LG-R#7&42NLTR-8/9,@O/L[E8%26*2S8?A;&RK_=37-V<MD
MZT:()#9109&R*:=A4 UV6C.D-#?1TR0U(YV LNLKE<^U 6%2C+<-G%:?YN,?
M$&%\FEA_?Q<&/$-!P5LT+(\$4\XAS<#3$Y(YSS71GI5.4MA.2=T+\H%05)#Y
M#4 HY[B>I[,YL.8BWI:)41XC\8H@%C 82VLD,E)A4(9(*)4ZAN*Q^U9"*@.H
M%??Z>"$U@+1[Y.?WR(^SJ;W[G7NJN;BQQ23&Y#5!(62&85 DXQ1#H$=:L1 M
M+9ZNUY/$NKY4 5 \?D$>4$*U7:HO.05_O!S'1594/Q]_7\OI=G^;/7FMDF5P
M[A.&P0.0GN1G<HF<=H1'DD"%NTT%[/C!NA@:5.*S@=G?@$W;&OC^<IOVJ%+$
M@7&*.,D=]#V5*%<;(F<D%58R:8KWX=U-4=U^.LV<IP7%5C4?:S%?KI]1/\?O
MF]F;G^:SB[F]/+L"QLYS][1U0S\RBC)QOJYV V^4>RZ04R*/I.*,@4^*)>_4
M%0&^>0^'\*L[#/8@I\'[J@/E/QM6%"T8N7MQU&9PXI=OP.=%;L&7LZ_O'12C
MP!S5A&A$@8DYK%)(QSQ3UCAM+(1&49>N4NY#7ROW]<5P-[B0V@+@&_!%QB"D
ME<@^1Q_'/V(X?[ Y&V0,W@<D#0%62LR1H4(@QC"64EL75.FD[EX$MA+3#@G!
MPF*J'CS<>]58V? \.C9?(*U'QZXT;*UM(T6,RE>%B+(\3A0\%.2BX2B EAEF
M&&;$=(L?.G^S%:>N&*"&Y'D#YNS>T_PG.S^?K[)$PN]V<I6K+5=[&AG/$I69
M3X1"&.]#1$;1@##FX"E(EY@OW_MU+UF=D"9."&E#B:0!E-WCT:?YV-_M(U <
M@DT$]J'RP&-LD [*(Q6("UYKYVCI]FC/T=()3_($\52$^0V "$(8'V-8O ?F
MW33</D_WM"5OR'O&-)(V<<2M\\CXS#2:L&/21\U*MV;<2U0G6*D3A%59<32
MKQ71ZPB%C+3G.<U;@$5=59H(#U$)PWGH)*/<$5*^P=7][W="C3Y!U!S,Y$;+
MH]<7A'81 R _%RJMA13"./^OG7R8IMG\<O6;QY;Y]/M*L?*?(S97JF#ZMK!L
M95]N"?D<)]DS6A45KDXTETG]M&D!<5N\ 0>;LA8'Y 7+N::"($V- M"!MQ1]
MP$P5'QE\%,5'&[)-5?OFUN6I .\]M/QT??=W-G2<Y:G?ZWMM:BT)1FID10!-
M-X8AHW4$!37,*29QHL5KBDH17[F$^^4P^\3$5A%_ P?XIXF=YN2:U=LSQ-D>
MAT214C$"[4$A:^"721OKX9PRZ7$*X_&^X+WO5WY3J .!QQ[BH?)H"$N;W*P\
M;Y%*F;606\2C,LA8G-,9G"<A4,U-Z33_AQ34Q=/ADGP&$@>PM?:]Z]<_9U^_
MS:X6=AJ^_@D\NUZU_EW[L]-PM<Z[R_O;9 \XD73RC"*+/>PM@8=K(\Y#$SUQ
MB03F)-[G]QWRX3:0<HB 9R_$[8:0]'Z<EC%.-_O*[:1RF[N[;3%JI:,DHNAC
M #^ 162PBHBPF$SN4.Y(MW';W;]9]U5R /R4Y'%%Z.1'_<_YU%X9864E\219
M%%ENZ.E<0(;XA)S5$(&[)+WH="#MR:"X_6#EM^JJ_LSAG&\!+C?);$0';K!%
MW@H'!C((V'-^,1 A"FTH3ZH88&H>1$<(Z[&X#^!<98'_.IZ.+Z\N-X3+:(EW
M2J.D/$&<>\!Z8O"#=QK,:J3&=4I:WB/R!Q^M+/1#1#8KP;_:@K=_W2,\)!:9
M4!A%DW.ZJ"7(<?#5+15:49R([E8QL4_P]S]:YX H)OB#^== K+H^WF[&"5A#
MF,P58P[GB6V62J03L" F)2U-5C-:O%3A/@&54XJ:N/DX7"(-P.EPQMUM>QH>
M.?*,*- ^ SN75B,N11YRD32B(C)OM$B@MJ5OD@?81^4*B<-A]?B.N+:,&\#Y
MN\OOD]GUYE)A8_DMIH3(Y) R4H"_F*\1G$N(2$V)LQ&X6KK6< L9E2^/JV-C
M5E90#6!M+T^?8^G=J[O6$,J 0X*LS"/EX><H]ZS(8P^X%HYSZN1+6]"]5%=.
M!VW"&7AAV9\RVA]6"YS]L.-)9O_[V?QG^+?+$<.Y), HI").H/6*(XN=1R09
MRH('YUP7[[8TT%X:M_&%,5E*)4H"I/8SP !,N,G#&V$<O,@)Z-Y+CGA@$3G)
M)6*:Y H;G=3C%G;/9?X/1V3E*^4Z&M"4Y%_147%;USABL&7X/X]2S)-6<H&X
MYD$B8BEAE@BA0^DQ<,4W4?D.Y74<#H=!HA6=</L9X!XSX-U?W\?K,K=/<3Z>
MA5'RSN!(+?+@GZ[KTJV GWF)0V JX2A+5^X4([YRZ-" #KPX!$[6(SI?=?!8
MK'S MWEBX%]Q[L>YZGWLX^919S.N:X0CT9H)A[#/72 Y4<APXI"..D@B'?8R
M#>L:]:"V<I';*?I(0V&AE8/A$)ZL?O@]+I;CZ<7:+I"1$B)Z)QFR"4N0C,[M
MYB!>RH/IM",R6=>,G[2%_LKE>@T<#S6 T( 2W-X&Q_D/T.CMK/@X6_?G66]X
M\36/]+G_YSG__N-L^:^X_!S][&*Z<A,53RH([!"C1N=![!2L 8^(81XUB3$R
M57J^S&";J5QV6%<]VH#(:]:5M>UX/YMO?BO_/3(R,@;.I$"2)I 9CF!) J%(
M,4U(@/\X/MCKV8OLL')9YBO5JN/!U("J'>NOWKBIBP^;R&W%N@_3Y7P\78S]
MJOW#"(.-L9Q&)(50$,QQBK3F'L60A+=&$V:+U^.]P+XZJ95YI6K5''!>@3*=
M7RT72SO-PVT?,8(;9[W$!GEE(.+#P2,C@T8Z&.$3_&AYZ181@VVFVQ,B_D=O
M!L1(*\IRR%WA4T;\=QQ??,N']X\XMQ?QML?5F]ET59=\92=Y=#H=Z8C! 8X1
M>9/S;$V^40^!(.6!=U0%'<,@R2@ON\UN"O:J'^D;QM4K4+W-V9W?<!_:(#+R
MB6EM'$56D8!X!",$LDS()^,$H1(3/TBJRR"[Z:9(K^VMOS&4O"Y]Z6A2R"AI
M8(-V&CEE/+B^6B,;A40F$B.2-2;@XIV<7GZ;W33L5:<,-(RKDWU8W3R4 2/.
MT]ET>I4#2S^/\-=&%@2F&5-(T]S=+:6$G# 821P()D[)8!]%4J7?49\GKILV
MO+;D@29$W<HI<P@+-E6 MQ>=]Z:#?+;+./)!:65RDP I, 2&QB)+<VDH5L')
M@ /(II7+@SU[Z:8AKRVSH"F$G+*FY/9FN0]V;O[YJYW_$9?KUK*;:1,Y[V+$
MHG"$<($D![%P(0/(QN8+%0K2LEAP7[RW[X#[Z:8Q_V0<#(R4D^H#>E. -$O;
M_SS^E7\:BW<&[?G=X7J%'L. -KJ'&JL BXHB(1+8<<VS^D# +2WFVA$%?U[Z
MS&^E>VBG!]^SR6I)^%F>B?#P27=%Z;J 3B@GI'4<444LXI8'9+@WB#$KO&?>
M&<U*'P9#;.2DNXKVP?+S745KP:(!?PDBHMEE7 UDR)S]9;/%53F^<22:7']/
MG,X=Z&)$AAJ! LG]].&$9<6?1':0TTK_T6I@F0TCN79!N"FT%\XD3R1#.K>]
MXB(ZY+06R!I"M?/).5_ZO-I)4%T@%A-[-S@=((,& )55[#RM9M#?=+Y20@2G
M5:Z;-8@;FI!S/"$)[AB-'@=O2]NR)T0T"9Q#!/QDO,\QW&X +I]!$D# M[-I
M>!M_Q,GL>^;0N[4G?]-!"Z>4VZXBR^)JL@-'FCN'%%4N"1[A=TN[>QW(JEMQ
M/!RD2DND 9!]B1/XHXN?XS3.[00V=A8NQ]-Q=F1S^];-WFXTB"O'B7 *69^+
MW CFR KP$;RC6,9$?'3%9QOW(;!N/>]PP!M.2@U L(SK>G?])B-1GD>"!"9Y
M'-(J!U,Y)(V6(9E@ J]27M)]"ZTT 6XEJ*B)D 849+.SS>C+)QO?:/_(>D^"
M411%'!3B(;?O]D$B*HQBBA 13.EW@&Z4U?4PJX+G<;_*\I(L.(O^96_JSQ:+
MJ\MU6LAO\)?&TW>+Y7@]Y&J6WMOQ?)5ZM;G0'O#F_B Z7N(F_W@&M7&SS[$A
M7+H$GH@!A8D:'!\K":(:O&&36%3QG[E@CY_SUH<FEU):10GRP$3$N2#(DFQU
M1!316Y<KAP>[S3^2^).^P>^#V>'F@O41?P-^RH/I15I%0;TE2&+K$:>*(Q-=
MYB U5FKCF2O=$N<US@7K!8%=<\'ZR*,A+-VTM>4&8R 288M]'G$;D6;2(I$;
M#JH0I,)#H:F%Z_7#);E[+E@?MM;.K>T[J2H$8R(5#%GM0'-HT,@PD9!Q6 OL
M)#5>[?,=3WXN6"\!'S,7K ^W&T+2OIE5(B7/M:6(&$US^VN/'"4&,8$E#3AQ
MF;HUL3K1N6 E\%.2QTU!YT=\=D^8"Z9-9$C(%!#7-.0Z<(&,%IY9997KV/RL
MXP?K7GP/ II"W&W ERF04LJ-#2;15?T+03Q$@9S'$DF2 C:>)V)*WVD?3W4K
MU]@U?? 7EOTIH_UI.?/GV63R?C;/?SBB6"2E<Y=EC<EZPISS.97$$QVQ$.&)
M.]=20XE[.SGYAO2]\#A<,XE#P?&Z5&3=BWD$YZH-U&G$<.2YB9-$3C*-1,))
M>"VI$R\^]JGO)DY4,0HB<SAE.0 F!^O)]]6KV9>EG2^;T)95A]K;KDT_SV>+
MQ0@3ATG@#&%CLU@805H9B;@/.OJH N7%$UG*;^-$)SNTJS''0J6%LV45-"T6
M5S&\O9K?MI]=;7NQ^L-'_<S"2',I&*,410M!%$^8(^=(1#:%J!V62HK2DRS[
M4WFBHQH&Q/JP@NX/9;.&\C1>Y!>V)DP_\#G%\?)J?M>U;\2C##Q0BXSU< 9*
MJ>!G>82+3%9@JH-J9[[;\]LXT:D-[9K^8Z'R*O3EJ<<8N<),&H(([ E,1IXL
M::E&4DI/4Y#2%7]XJQ-8M->"H5U=.0XF1P86[Z9MZ,J]7D8;)G"G,(]6(T]%
MOABQ'!E%X =KO;(0>D'PU9BN/-G$B884;=Q.'0>)5Z(7S[>C?# A)MNRM+%E
M'EO*K!4(2[!@'.. M#<."2-5C#(&V\XHN8-W>:(!3!N:-3"H6HC;7X9#(YGG
MMMH 8HNK*T ,4I3)(QT3TUPXS2P^35U[-??'@R"\CD+V@MOIW#@_^V"\]1YQ
M)X.$21C'B%&(N5F42@&9?"4?(N%"J^#XXTR1X?6QW/9.U)UL5"<KP>X43L=]
MK'DRO6,G=[##,GBO$8M$($XM1M99BYP2!,P6X4F_^/-0T1V>J#-ZHGHY'/A>
M@VINN7G=R1\KJ8]26&08!U$:L%J.")"LX5$83)30+YX+5WB/K^9V_R34<T@
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M,HBEK=H3(NK>\P\'I>.XW0!<'CBD>3<KIW01YS_BW6V0<H9Y*35*R><F!D;
M[H1%PCA%B'#:V=*E8UWHJMP?_(6<^N(2:@!U7V+N#CCU<<4C,I*:! \!-M";
M"\Q#I,AAPI&*!&PM8\D_OFXM<!(^(*&AFX@B,GYRY!W.\ ;P<K98Q.6'R^]V
M/,\&_,TW.[^(.;7#:AZP0UAJL+68,Z03CD@$&[QAAF@="L-F.R5U+='@Z"G
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M<X\6H07+OFGI9DI'O I4OM0] CT%V-\ B.XV<)Y^F4TO?AG_B&&UM<5_QDD
M,_O;(HZB)10'KI!W),+Q#S]HQ2/"/!D6F*=6%4\X[$)8W7JVP2%67CCUBTI6
M:R^B_X^+V8__%7U8+[^J#/TZO@1&WO4TWO^"\ !E]Q== \R'.UQM_T+/)X6#
MB2_TEK!W@.'BN0F&:QIS YUI^#2QTX_V\J;%3V$78@@22\2(8P\AS9?ES/_Q
MVW2\7'S^\MLF^!\@[GOV6VU/\CX"/5N#OGTL/]@:34H<?3<QPXK 0;"P[0MM
M#W(NB( =[*TC=[#7H_4V+E=V^NX:YM SY?D5"Y#XZ_3[."_Z%<Z.G^ /_RA"
MYM-5JUP6[)7%#9HZ<:2B'_V OKC\-@N%Y?5HS2H1^6'2VLZ-1F3U"3Z[G%].
MP_N)O2@BJ8<K5CGH#Y+35DXT(J6L\6^FBS O)Z9'2U8YC@^V?D]YT8B@_G/V
MYQU]92W@,TM7Z3)RD.!V\Z:R &_/U/%ES!<*V2_\W4Z.5K==ZU;I^M%+=!VX
MTH+B+=Y,9HOX=79+;GZK*ZA]>];O(D=57P6[<:E9>0XDQD[2TXU*KQ&A?9B&
M\8]QN,F[.T90CY:J&Y3MYOEL'P-JJ])D<D?78N_%3@<EVK9@-0D]P_-9-P8T
M\.1T=Y6T6VD.>HE\L';=8+F3%NUD2G%AO?AXKZV[>OP,/^2E9'VX/[@'/?^>
M]S;\9?.#[]3-;JQUY;R-U0W 847;V7?XO!^O6/%Y?/%MN?AR]OG+(+#8_[VZ
M28@O"(_.K*_MP&P[/>!$SSLL'PW<+-P%!F:PP_+@>. 17UH0W6_3,)]<7WR)
M_FJ^KLFZ7!XOMZVK=C+MN+[4=K&D!9&]^VON/\W'OH!^W2W523@-/*T]V7P+
M$OD93H#E6[N,[^UXOFY>?K1HMJS9248-/*@]SX[*PGJHV=>__K%<0>G-M^G%
M)W^<V=NS="?1U7UCZ\:<5I/R/DP78^#BU[D-N2[DGD_VD/(C,_-V?*9(>E[7
M;1R9HU?IZJD[@:OZB?^:?9N^^8__LG[FMM+W3/7)EG]6[XIRU_76K-->ZR0@
MW1+U=3[^G_\93V<]!?#HG]6[W>HC@.U[K2B ]^/)^/O;*S?[L?CCNH<$MOV[
M>ED>746P8[?ULO">6.0GA^B!;RC/+GL$L7?+_70-/#_^36[K@A6?$_;)XKY#
MLXL9E1W1.]*.?HQ[M%0UV>SD]E:IM/4,M\7E*N,3/;]P [+:\2RWER%_ZP?M
M09R5KCKT0D_9_[P4=X3BK\OYY&N<7R[.T]=Y /&5R6O:L6PUB/8[@O<SIOI!
MG*DJ\5[Q<*5JSG9?%VG+]EL1R=?Q\FCO]<%2U?*G#Q3* P94ELKGJTDDV F2
MG88P^[Z,QZ>Y/[=FM73I?G+:PY+* OLXFPXALQW+5DN5[B>V_8QIP@"NZ,J3
M#^RRA!%\L%RU9.A##.$V1C1D#+_.+Z?+LK;PWI+5$I\/-X5/&=*6)2PDL.=7
MK9:<<I0=;$YL-P'#_'(\M04MX>,5ZZ6E'&(-G^%'$[)Z]]?W\;RDJ!XM6"]'
MY1!);>=&$X)Z>[4FK("(;I>JEYQRB' ><Z )L=S+.+NX./MAQY-CD_%VK5LO
M)>40@>WD3:M)*>_FJVK,@;I$/5V]2 K*'J(+9)Y\CG[V(\ZOS].3;SU!PF'.
M=)</'*&NFU5O/G/\,^O6!:O=Q?>1SWU-W<66VA%;7-QTKLZG\=$O1MO6JR:O
MG7R?=6+"/V]YM83R3UGJ/X^-?:\S/L99":$\7*GI',EG-][0N1*7!>\J=BY<
MS:@=ZAET85-MDW=QL=QLZN@2J(=+57L+/E1:VUE163XW!$WMY'HQ7I3)L'AV
MT6I/Q4?ZWL^RI[+TOBS_^#3WY_.OB_F[Q7)\:=?USN5Z$';Z0+6'Y4.EVH=M
ME25\?K4$&S]=W>B4,Z7/KUKMM?E06>YE4#L'X,?9\E_Q]J2.I9KD=?E M:?I
M H?E7K95EO![6'0VC3<[+9'U]LR2U9ZM#Y7B;M:T);>W5_'K[-U?N0%%A'U.
MTVSN5Z[UL<:VSW>J/7(7DG 7)C8H]M_'L\F*S>?I/V>7\<WL:KJ<7_]B_QQ"
M]CL_5N_9O"0"NO"S01C CO]]92?C-/8;ZK_:OS;SQ([NX''0!^N]S9>$0U>^
MM@4),&,3.]T0_.'R>QZI#1M8S<J\+N.['?;%>CD!A4#1C[/M1& E7;P=R]9+
M(2@0A+7IZVTAL' <_7C93D)LZJYK/X\:>A68Q07$A9_COZ_&\UN[4L8H]_A,
M)R$W=?75GX>M9@%]^C%4!M##E8MD_^P@MD#FSR=[_?OB4YQ#M'69AYF63OSI
MLOX1>@W,.3[7YW:1:@^N/:1P7R,?[[[V@]!?T5\MQS_B&S 3%[/Y]=&I(]M7
MK">FQ_R>==Q\[8ODR>0Q>>-8*(GD^87K95_M%,6L'U\JB^Y3W-KGJ:^%BWW:
M/@V54[*?U[,=&Z^?Y ,D?2PBCL=KU>S%U4LHSS#AGUS%ESQI_LE/_"<_L9]L
MPO_^.EO%X\>JQ\.5JJ51[=*.K9NM+8#)Y):L,JKQ>+EZQ_I6=L^Z[+VV4"XN
MEJM6NM/%]'<+ROOEZO)R?6^U6$Z_NLG[V?SL^\1-_C4O(;/>7ZOIJ3TGL5D!
M]C4@]DPS;''QY8=_LU@6DN[616MZ=AV%N(L9M8.?TG(Z6$;#*-H^[L^ZL:(1
M*7V:SXL+ZO&:]?3I %D]PY#:MW3_7EZ?_3D/BTQB 5%M6Z]F9^,.9F\'"UH1
MSL#N2)_OU+O'VR&F;=(\&1_DP<;>_>4G%^!!??X^7X:G6RBMH=T^5Z](LZ?,
M>W.PLNC_-7\W#>_S#);S=+N)G^?33/B;'_/PKWE^2P_3B[-I^&WZ8[$,!0!P
M\$?;4/U^\IV58W9EK.3PZL-T0_]C2A_O!YR-?\U+G.>'?[4-HW$P6HYF=V6X
M_ X;O'B[W(IWV ?\\2WL"\"D_]>J.85EX'$P>]NQ(F>+\[39QGE:(?AV&X71
M<?!'JY5Y%K<A!S&[=AKS#>%K>J?AZ;FY-GSO)V&UMS>S:5B\G<-/2B&G$ G5
M"DO+X*BL("JCZNV/$!;G\_/EM_D[H'#Q*9Q/;W?S<9E__\_%YS3Q>5M?EY/,
M((C<BD&JQ/>K%;>6P5-!$=2>[!!MSHL[^BGS_CK5#IU=#YE;-EK[HG=#;9E<
MZ:>KU<NV."[]LK6RDS>S+W$2_3*&#8:.KCC9OF*]]__#Y+63+[73RX"4<)N+
M=9[2V,.Z[Z=E=&W_ZO5,X&&R[,ROVC8SQOG/\]G5]P^+Q55!B>Y:MYKO>Z@=
MW<^CVA;U6YZX%FX)+27%7>M6\S@/M:[[>51=%V=?9TL[*5&^]WBM:EU2#M:Y
MK;RH+Z$SO[RRD\GU)SL.A02U;<EJ_5 .E]<.SM3.J<I/[D#A*FHL9!J?6[-:
MFY,#!;>'-[7=SIN$_K,?%\5LX[.+UNM0<JB7N8<]#4EO1=D]"U%2B-O6KM=>
MI( L=S"K!5-Z2VIQ@_KLRO4:@QQC5_<QJGJ>S]5X>?V[G5RM60GAS>5Z<MHX
M 3$1=EM*NCT_5:]/R('B/HR5M</&1V;F]\7J$/GR#;CT;38!+G]>EHHD^WVJ
M7HN1@^_N#F%E<_+_&)<?IGYV6>@.O=,'ZG4:*2;KY]G6G(2?7#(/)>D='^HD
M\:;NC@Y@8^T!84_-3][YYO*KC-"[?J.3O%NZ?>K)O.:4_'SY+<X'UN_MW^@D
MZI8NKGHRK[966W<UL?-?QHMEP:?NYU?M),Z6KK/V,JBV )]:EJ-'-FY?LE.V
M0DN76;M94_WF_\;XEQ?@OK4[2;*EJZR.S*HHTJL%NK#V^^C6<?]EMMB5KY7L
MPJV(V/S#C20GR\7-[]R)=/O:G838R@763O94]W8>>=['JM_6!3N)JZ4+J%UL
MJ=VA-CM4>4>%!+9MO4[R:NG": =36KCB+S+5[/Y"G034TBW/-C94=T)F1Z=*
MWJS121XMW<$\VGP;:=Y'BZ-OOBIMZ9JDP335V?1G<%PVA+V-"S\?KYYA"N6I
M[E^^DQ!;N@#ISK+JYU(89[KLA&/ZXVYWI9Z?]ZW>2;(MW85T9ECM8VVZF/XT
M3<M<0E0L__B9-3O5!+1T*[*'.=4S".ZJO\JE"FQ?LY/H6KH&V<.<5J</?)@N
MQL#,KW.;YV5\FDW&?AP7G^8S_Y#R(T<1[/A,D;D$7;=18$C!\Y]Z@H\#N_[N
M7_^H_L2;Y</]I<_"[/LRAO<3>U&&^&=7K]@UM[/<'C8X[LBOZGVGM]'Y<;;<
MD%K&7'?_2K7ZR:)RWL&_X2WZY@_R#\XNXO_S?_S_4$L#!!0    ( * \"%E;
M&377$P@   DE   7    ;G9A>"TR,#(T,#8S,'AE>#,Q,2YH=&W-6MMRVS@2
M?=^OP,HUF;A*8D3=+,D:5WD<I=;SD.RXO#O[-@61H(@Q27  4K+VZ_<T0%TL
MR1/:FXJ<!\4"&XU&XW3W:5"3N$B3JTDL>'CUM\G?6RWV405E*K*"!5KP0H2L
M-#*;L]]"81Y8JU5)W:A\I>4\+EBGW>FQWY1^D ONGA>R2,356L_D@_L^^6 7
MF<Q4N+J:A'+!9/A30U[XP[X8!NU@$/5[W:$8^F$XZOJBTPE&W9FX^-UO8"K$
MW1Q3K!+Q4R.562L6M/[X8N2-.GEQN91A$8_]=ON'AA6]FD0J*[">QGSWIU-S
MJ(SK.?05*A]WO6X?NG(>AMATR^YPW/>&-%B(QZ+%$SG/QG:\X598:PE4HO3X
MK&W_7=*35L13F:S&/][+5!CV62S9G4IY]F/3\,RTC- R<H)&_E? =(^6L0/+
M:F_0E,A,K/?J=VAWT\=8SF3!NK[G/]W:\4VUO6&^MO:(/W8FK?>=B*C M$[G
MP!?5X(XO IRQT"=SQLWT[O[VT^W-]?WME\_LRR=V\X_;Z2<V_<_TYE_WM_^>
M8@A/IW<U'=5_C:?Z%C7?P06]HRZX;;)?5)RQ&X_]P@,U,TT6"%W(:,6*F!?O
MSOK#RSK;][U7[;X#&#Z%Q!^EH=5/YQ 6\X5@6BRD6"*#%;$T[->2:P U6;$[
MD2M=,)6Q3TJGS&^W?F4J8I_5@B_X8Y/=9H$'IXUJ.>V5P06G]0\SS<#K'?6D
M&Y)9B%@;M]K>J=#6A7-_Y@8NA?/2%7O(U#(1X5PTG8^U\VRHL&"F4$*@C<N,
M\6S%RJS0I8"]*"JVOL#EG*7XIB5/6,0##&FF4F2V0CFY X%,!,(8KE<DDO('
M@75W=!J,A3 &2R:V.&$-$@BD1C&"6(;IL"04FBUC&<3,E/2QG;\46E1*: .I
M- FJ%A7 I2QB;-#D(K &DMX<IJD0VUQ@6LAFJUTWO !"_FL#[RB&VOTW#:+!
M7X%(L$AF."8Z\>VQ-($@B..QWGDNLPCQRPL)/3(+DC*$3AS]SADT 1M),9_C
MY AT!,8DV:*J.E"SMS2 &TI2W"2),H$ H*1PWG8Y8^T)N(E9E*BE6>-,B[DT
MA>98B-.@LQM6-G?@8M;&'%A;&S&^[RA)+3@<3\YO!0V44NZ?N.[=V;#C7UR:
MZKRK4D8AJ*)(XJMUZBWC6MCCPW'(62+(S4P ,[-$FIC$22Q%^J$41-]#:8)$
MF1+S*#%IE;ASS+4*1(AAP][CV$(!'+BSF3X&,<_F@ETCYN_*!!)^E[?\_GMQ
M;J?Z_=!]<U\E4:',X8?T,TH,.[!RQTRVU%XH>K)0A(5HG_M@@P25O-JE_K4I
MIWOA71PCR*,Z*:?;H?)VLIS#S]=[/,7Z>[':\SKV #X* W\!!+80?1VA3:J1
M 2]-_2E4K&8":*M6<N5/E1H*D)$6TM@\!RF163U$&K<9<C?+:I%P"]^J_FTA
MV*PR,#V4R):PQ:A$AK:#-.7,R%!R+6D#TE5IF_<STE0:JIPVVHTMLS8K*B-@
M$'I'.RD'>9-!F7!*YMB6-6);@3'#U?-=&H*_9H($D6\Q7X0ORJ_[Z?59Z+]M
MY%-^G9T0^=U]Y'>]P> 0^;4SYT$ U,^YM>, L;.0(<&;&Y5Q*B[<(#2(/A+F
MN0[7^$-$2#Z3B2Q61 *.+4O1:*%J4>@"Z8GH#OVT->RQVE!>ZAQ18"QI"0*E
M0VN ):)SD8&+) @&/!$Y11F)@&0[P",:98XR\I(^YAM6A(&[1WGC<1&\I;A8
M5X3I@B>E39L$&A%%H*=R@>,V1VCFABO5* /NZW'F:<, $Y'"C>.W,U46SUM0
MIU#QC;0@\AY]O6-BLW5;8"-;.$_ 'HMB6N#[<YMZ_/F$0.X#R.$)@=Q_-L$[
MC!QBC6X#*KIKGQP%] O2.M$5%02E)D3M<(,C6E-E"HS3G25TF0"*_G3W0NS]
M,U,BA 82[IYT93A:0&$O,NB.(RLW=IT[JV)N-D2*4K4-)1':&F;]4=67%4OD
M@TBJ6XT]^>;_[:*OA\_Z-'%VEO@H8[O?L2-\"W%PN[Z>.%-%H=)Q>SN%ST#\
MRN)PRE<NY+<VU7LOT-N\%XCU-I[GHC6#6Q]:/()SQCQ9\I5I//?N8##P1H-O
M]>X "?Q(2SYX94;Q!Z3N9*6Q?\Y>UY7;F]=P'?K-;4JG"K,;?MOL3@'T OYW
MT'ML3./H/PJES89RV0&H3%-9%$+\1?V<*9 Z>AY*V&>5O$>0HEP9*H?XG[J@
M=681?Y82YMLL4F:!O1(Z?T'S_:HK8]2GX1$P==X^F$[9>>_SK*&]'FU<72<@
MWG"8!'CI"H4N8P(I@+:**FT:X"72"7$?1\0M^[$MA+VM7M\(O@C#5:_J+K".
ME  >8J(1FPKP+-ZKQ@-3 %KT!TU'P S8ERE30 YNLINI*N_1N]/O1:Z.@;?.
MZXX3@_<M-<\77L]2JVLPJ$@CNS4!)6$3,L!H7UA4J&TZ B*SA4H6@EA(AMKH
MWKOH*H>+-$_42N#I,E8N<?,G,0$,?Q.*YM5!5K_J?R8R1<^<%.  *4S^O=WQ
M_LCG#69T<##TE+SDCY>5OHJ5D(,75*C W"J$662YQU75[_=&^>/1WQCLEO;>
M?FD_\3O?CSAG6W#8=3E'U+!AT_X2X]V9/VA?'G[^O'+2I\-R^P<7UB%E*IMX
MQO8&AJ0:5^_.>H"4_=Q[F?W<CNJ]T1[MG]NPZUV<\-R>[JW>'GH'KWI.O(E_
MHK^7E)QM;;F)I8C8]%$$);4*[(OC@V^_U_C@?HKTP?X$ZG]02P,$%     @
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MT$*4"D0"U^*.W)$'"Z8\LN%$F[T\[GF>,YR(O"!\9;ZYPU/ G2Y%F8/KM#Y
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MU/Z2;[P@:9[UZYK7YC71OU!+ P04    " "@/ A9_(,A+(@%  #]$@  %P
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MSL_15]P5L274,F4ZZTAT/8VT,2"S[9+HFZ ?1B,).7D:LLA28AHRG>VWT<8
MRK9+HF]%D";<VF4CIK/]4FP,;FR[I+C[>8R,(E:,C9C.V=;SU1J#$-LN,?X@
MX+Q,'\1.V,_A)$XG389A)))I325BAP6\GG;:&+38=@FXCH,YM^R3/3L;,IWM
M-]?&X,2V3)I%W&.!1U7417-MW7 CIG.V]?2<%B^V$;GN^+Z@&HU;%K"!Q7\:
M,IW5Y7D-VFS+V[<F;U_K4!'W7=\@:]^-)94W8SIG*_&&],(D"4=P'WA066!J
M:/^, 59N5_G#Q_'!=80K>FT+F<R8SFJRC8+<.F^VZBC*QH JMTN4NW^F(IDZ
M-\&$QPF>4VLJ #LKSS4]F1H#J-PN<9YO')'UC! ^2#A<Y#RP*0JZ/;,:,9UU
M)+V6L65C@)9;*ND=[X]TPH($_FEEW>SIG&T[Z9<Q$,SMDO7'<,K\1-BTD1G3
M.=OV@F1C,)A;)L;+"+8??(8$G;9$V9#IG!]MN4]N##ISVP1\D/HL":.IE69S
MIG.^<I_QFIIK8Z"8VR7-S]P=!C"FP=1YCN!Y?1Y9L39G.N?;WFW5&$SF=HGU
M;:D!AA5H8Z9S_D-R7NT32]^'X$:U#B9ODT5#?H5(9+;?A15L0Z;S!<%6-[@X
M:9Z=H@R'L: ?1QS.4F+"W[X(+QF^:1T2+K+P0P55.\Q_PGIQZ*?)_$^DQ/WC
M;[UH9AS%_QU&^LYC-N 'O8BS3P>LG_#H#?-?V#0N/WX$VDA/_@AV)XQ]S<=N
MF78S!FVW;=KMD4]XD,*#,7"H*[DE#=I#%/9%(K_Y$,:VPMN0Z:SCS'S]Z:12
M<3<&D;=MXJZ[^U@7QICIG/^0S'VEXFP,(F_;Q#EK_6&EV9#IK"/--37.QJ#N
MMDV:[Y,ACS2NSGGFT<@*M1'3V0$3;0R\;MN$^G>1#(>ACY<[S^QS325@VP3Z
MAS3GJE2@C0':;9M RQZ: @[1C_B5IZ)EG=03U@DW8SKKB'=-[;4Q,+MM$^\/
M<*36/GA-M_^V2?/*F/C5F20L\\JZS"LMQ;QR>7]W?7/5O7N^Z7RX>?Z/T[F[
M<N[N[PZN;IXN/]P_?7SLUG2;[;+4U!'#9DQ*>+LP;)=AT!?X?M'#+;3<J*D8
M[*Q4UQ1P;DSF=WNEVC)Y&S*==82YEC!S8_*^VR7,W<\N'R>VHYTIT[G8]LXY
MQF1\MTN.56.-_W+/N1*QZX=Q&EG20R.FL_4B;4R^=[M$^I'_F8JH)-#62!LQ
MG8OVECO;QB1\MTNB']*>+URG$P1A&KC<4IX9,YUU)+J6-MJ8'.]V2?23*S 0
MU@>ISJA,;\,@=*2H,WNR-F8Z%RNS)=FN&QO,_;95[O>A\]R]>Z:4[[_N[G\_
M>'__NW/;>7[N/C[5=(-MF[RLS$=T44\GUR9]-V(2[U\"'L5#,:[IOM]9,8:S
M:@VEV"9Y-W-4C<*8NREQE&#1_BT30<(#ZB87]AU9+&@]6R.F<[$.Q5@-1=RF
M?C<BXA\#D;!HJF39>9K&"1_55 2V3:+7J?RMH43;)/!FC+:49*SV=;J?X=^Q
M-M]/Z7CL4\"9)#X*$^Y*_C$>4?@*?EE36=DVT?\AY80V6[RELO]!Q G\P'KF
M1DQG'6&N95K))HHW*<Q=+)F0>>*:"H"5YWK)LTT3;X;,6\1L/(["<20D[6_8
M=_X5A"\'[\.7FHK"EDEVZ["UY7ZW;;^Q$=&^@I$'L0R*J[Z6-T$?2?O);CN7
M/A.6>\N,Z;0.MQWF99MQ;$3("[7+SM.0H7375 2V3J)_2 \\VXUC&^EYB.J6
MPN/(OC6!I]D""S.FLY98UY1URQCXV;:)]1-/$M\&S8R9SGHVNI:R; P(;=MD
M&1MF@<]]$R0\XG%B2R%-FPZ,T#+J55]5<:2J*IX?.U?=V\[COVPMA4G364M*
M:AE=-L:;W:[ DPXIW[+HD[5X1DQG#5FN::;(&&]VNV3YD4\$/#'L.Q^$BSDC
M;[9FV J[:=-92]AKF3&RQ16;20O#HT3@W+&1;H'Z.^_%(K'G5C.FL_U6W-98
M;$2PE>UVDM!Y8D'8%S45@*V3YS6*(&MIJ&W=Q$;D^3EB'H?=\8D2P06S78)Q
M21-N\=B&36<MJ:]CH:2MK]@0A;U&?G0_C]&<6Z_<B.FL*,^],$G"$=P(GE1_
M1]W67&Q$QJ^9'XN^X)YSRSWAPHVLD!LQG36,=NN\V;))XTTEC8]5TOBQ^_#8
M?>K>/7>>;^[OGHB3[_?.XV/G[OFF:S/(1DRG=7AJ,\C6#'Y-UFD<\1B)/XB+
MEIS>WUD4L2 1,)JP[W29.W0>6&1;.9DQG35$O:8>KTTP5R3J=^&$3=CGF@K&
MULGY&BQ?M0Q9V]SRAJ)7$V3B3*SU-G ZK=:VMWNRB>7-2[4UU 9-I]7:=FX0
MFUO>B$@KYWLJRY88#"&JJ0ALG42O3 2R1C3-1J#7C4"?J CTS=U5]_;NYOKF
MDD+0$FUQ<_?T\;%S=]F5?WZXN;U1$>J:[KJM$Z)-=%0RR2S:D/2&V'0\/@HD
MZS1\6M/MO[O27--SJXTZ;TB:XS3"OC UW?A;)\=;#HFT0>4-U36,1)*1TUZQ
M$1M8P)09TVFU7D\(JSM<G#3/3E%\PUC0KR/NPVTF_.V+\)+AF]8A'1<+/U0X
MRL/\)ZP7AWZ:S/]$BML__M:+9L91_-]AI.\\AMUST(LX^W3 ^@F/WC#_A4WC
M\N-'H(?T[(^.FJAGUGRL[=_ZPX_LIYIII/MX*P_F^*^;.SJ9UU3 =DQ?E*-;
M-70![+E\,Z50/!JI0J?/8Q'9P[DQTUE#HFN:@;*'\XV)M @RMSX9BMCI#")N
M:QB-F<Y:LEW+P)L]L6\(,!+$_,^4!ZX$=Q9DO::BL'62?;'E5MM"P38BV;^R
MX%.4CA/78CJ-F$ZKO0X K(9R;/%?&Y'CIS2:B E<B]1^$X'=F&U(W8CIK"'1
M%@"VP6CRF8HFW]X\778_?.C<=>\_6GB7$=-IM=? 2%IXE[5ZF7#'L1@$-L!D
MRG36$.2:!IAL\'@S##I(=N?<LC]X&EETEQ'3:;5_2+]#&RS>-EDN<P,XO:GS
M@0^8[UR&:1!SOZ;BL,O274M+;0/&&Y'NNS 1KH5KFC&=5GL=:OD:"K&-%F_F
MW Q'9L\>FTV93JN]3B%%'8VQ)9?>4-6_F-A"?S.FLY80U]*CMNS1FTG=<I!A
MUA.^L,1:9DQG^^WQN17E38CR%8_=2(RQ$LYYSQG^RIZ4C9C.]EOG"RO2FQ#I
M[N=Q&"7.)=PQ"FWPVHCI_"!A;I]4"!@Y-$6<C_0ZF+Q/%@UYR>9Y%X*['2!2
M\@-[J:D [+(\?[V_7:D\&X, VS9Y_F<:B=@3+GXD2XI_XT'*Y3^?>#01+L>:
MI8<H='ELW7$CIK,+%MP8J-BV2?R5B,=IPIU'3@PRM@C1D.FTVC^$.J!2H38&
M,[9M0OW HWX8C9#=#R%CG7Y?^((E%FEBQG1:[1_20:92V38&,;9MLMT-$A%Q
MRP9BUG1:[?.M%VEC\&/;)M)(K#WF])9E;)RY21A98VW$=-:2[)HZXL8@RK9/
MLA,>C2.>6'H?8Z:S"Z;:&'39M@GT7>@\#T7DR=:-SB/>)';"R+GO^6(@&[C6
M5"YV6<QK:K>-09YMFYA?IU$RY)'3<:U$&S.=73#<Q@#/MDVBL6 :?7$PVU:<
MC9A.J[T&S68]Q;EM@6<;$N</+!BD;*"0*<\1/-.W9VQCIO,EV59WJ+[U#=Y:
M>'__:865/?S)L'XYK;-F:T6MN&D%>+90 3Y=ON]>??S0?7(Z=U=.]W_>W_QZ
M\_RT=%.L,9$%*S6_NT"#G)Y7NKNJW"C?;34+.^Y\O>WV^GU7M^;,%X/@C<O1
M@:MF)U_>?_C0^?7^D;HET6[^<'/9O7OJ.IUWC]WN;??N>?/;NN00G:Y);OI]
MW\4?:9R(_K3D;%59L?.,#3(N0]]G/66('!9XS@<!FR8N),N=/6JE\<O/Y^TV
M&M<?X)PMWE"%]'U%#B+Z'+ *K;?[#JS(B'G<X?T^=ZG>CE%G@ELV=5J'#:=]
MV#[&E>,&+%PW&^,52[@!J]= A!5NMAY/7C@/G"<6A'WA/+ XX6GDW 1NL^$P
M!SRDL=Z;831@ 3S*<U*0G<C!I?792RQ[O7#G*8&Y43]'L%@O+.(-9\B(D#KL
M]Y$QR/%#%R[Q')8X+>=*Q"X68DR=JPA6IN$\O8A^\@(71 WGH>.TSH_.#IV]
MZE^>7!HC7AJ^L;MPPB;L<V/S[PB6P_EW*A"/=Q^Y0Q9Y#><=$QACC'MI-&@X
MMU<@9N=GYR:\)K4N!KRGII:FPNMR.'.'H+"F('$.G(MX%,$B)Z$#B\E%X( Y
M$A/AI<SWIZC(F %:B[)%U:\G)JK@B;[4H')YS%#KN$ "\:F5+5%3K5$=W*\J
M7>''[N7-<^?#\F-<:9U:.^JFSJ]=&];N]_?=QV[GJ:)=CB-H9%I4H&8<^&&/
M^4Y/A&,P2B/F\C01+GSBAJ,Q"Z:@'<!Z#4%-\,]C#B(*SC2H6*0D96#'&H['
M08^$8_*M44?#[T8\<@6L_W^S]G7C*/12-XD=3T2@>J2V'K-D& YX(%QE:N-1
M#/=V_11?J//4>7PZN Q_.W#:%.-;Z7C:O%@K2FS>)CFJ?),<T2915O=;]@B8
M7S O8X[O7;E,\+T?%KJ5S]Q/;Y-&81LPIY?&,, X!C=,)+#?/"&]*MA"$^:Z
M^-T:&V35"(;=(*]O$'R=RF8[+R(>XNMPL_,WQS_[*H>N5$2CI!NX],!#O.(%
M=XS:&[FNF/?L&K2M7'#2/:IL>0'_F08"MA!TAU0_X/Q1RMZ)>>+T0QB"^K7,
M%,!%N[%1"N:FX51H<."-N"F\QR !=S-[8_PS=]/%W4W+>PN.5/IJ/$G!*_:X
MCSQ]^)?S!)]'@BY\2GN*+@ANFMVLN5(;E"UXU7?WOS><9WS?U_>/W4H=#!!2
M>.FQ@$-SH8$M'M7(&F#H!J,5 0M0U4<E@G/X ([2$7P%[U2J"*;?Y;Q(SVP5
M^ QT!5V/!YL^J*/P):9&1:MUPSE<+\E<O2_>T?V89#>FJ^[US=T-AJA7],[;
M/]P[KR8\? WGWG$:C<.8Q\LTCMPNZ'.X; Q.BD^Q'VE:7@0X,Z2*RE>..$/R
MD]7WV/=>\M*MU]R^9C!M&4/EH5:A^E!(Z^+L&,N 0$5*0$/E4:.A"A.I[5[0
MPZ#KGSAA))TZHA3.B!J*_</9*Q$9[:_D-E2A/K_D@I P5PEX,DB:3\P09TR>
M_?+S\=E;^,<)2 N+C9!IE&4IU7!F%Z%'9A&>XWC@48,8O R%.W3VV#XR@ZA@
MSU4>[&DXMRQ(^\Q-Z/(&7#5(?9:$T91 TQ,A/;C+[,S7P.#S+1W?_<(E^.E>
M;]_!0 ((*#5;Q2-?#VPM^\0#<NLH ]/ <,18,AN 98;?T07D<%)*P&5PCMS#
M(:/?"#?=;\@3A_(\\;9,'S"=*QV+>@Z=WU@DP.?<B_=Q&;+04QM^28=6>+R'
M:;[??GU\Z%SB T6"!\X@A;GDE]-KOKS_[>;JH'4![S5B<&7,?:4A1YPGN+1#
M[GMX#]P9RS6-U2L%O6(,4XA1>N5$ZY53JU?F](K4(;F^R/3(;FN<DQ5]FY4/
M$SN@@]J5]L!JFZF#<%$ZKHME%92O24 $6.15E<)MS^J@19(HBS9!CE&8,E8D
M_. I[?D2+,8;SKM.YP$_O+E^?&I@*"E.0=@?> 0JUDDQAM!7]^B+@ 6HA3".
M!2<B.AWIE7#Z43B2R@^>CO\M:PZZ-87*XD3&1]EX[ ON;2!J:<9AWQ@&$6,.
M^QWWSU1@,-L4A,C6GO6;)\?RJ'\Y9,& D%N*A_R5X[XQ2/(UZA2.3*M3.%LY
M+;\SOD15A"M&^Q*D"2-S_ =0>*@)P4+CUD&%P9PYY8&PT2(CQ)QS0>@()B<7
M:Q]D-0N_<GF/23;>&.H1@VR\(A&PQGV#@?R6M.YK,IB;'NHW0Z:-X1DQ1Z:]
M/](),Z%\1T7<;ED2B<\'MX;O9W-=LJJ8-TQVR=0F+P9HG5OA\S@!M>MT)]75
MK[6WQZJUEUJUP^9Q4YFUA6]@->-UWKSX&ER363)Z5&TCIZ-Y<@H3A/3HRT+Z
MP*85EID>;8^8'FU<3,]JB=\R!L!U9)IOZ%P+[GO&>(B4=Z AR9B$B)T@3)R/
M 9LPX;.>3ZA9%L=P+.+>(JR]$M*-4"J6C$XU/J"YNF>IB] &U7,D50\=:+TT
MXO%^P^&?LP(:WW>Z]!>\T_+.C!M.&OA86I.781!ZFE[^"P+KX0:]J2X9VQUO
MHUUMTZFY(X$9WD;I2$#,UB/N48SS7T'X<O ^?#'@,*#Q)Z#@]*ATJ-:7D I=
M #D;J8T5ZP7Z*&66";Q4P5?PRV>8>*9"$:E"E>8I*DW,"^,E.8B%ZULN7+EX
M=V3*O)Y/)LC4X5*9>N;N,( !#$S("DNI0J#3TJV<B5N#T%6WR#XBF!]_%^G#
M% I6FA: 9%H2B]6B$7MQ1MF#$9,EBL+6D$+:HRP-'#9Z?,C\/CYUV:@R@1[+
M<#$L/Q\7"Y'@+D_N$.PN>$_F^@^O9,5;TGU8HK@6*ZW&JF64:]>D&. %[KG[
MSB\_7[3>_N4O?X'_'KW=.15M4.LNLU5T-W8C<"^>X=T.>%1I/'0Q!+</!SLE
MR5K#):&NH'7V9*5FUBF0SGB(EA-]K+&G*FJJP(0C!)T0G(A3&EM68Z+*4+>:
M%CB2LJ5Z2L=C\(NR,CLD74H<G[,X(4M2$C+*KB-CP @!A?%RW2,=KP*)A1J3
M5YS9.(WB%'^*N+NL0!SNF14@+QTEG7O!U)1&U]"8X2K&_/IPE36<&[*&7\]8
M2UMOL-K1KRJD8NV.?KF;JM2A,6= %CA<*NAE@ED<O(;(HT(4L =EY]0RMD?=
MC@U0\/0!T.,Q[&*B).E-2P7I"]DJRH7'LAHBR8=!E<;$:X:*4FH(1<:2CD,)
M2 I=R:@@@0PPS=6MT^L,&G.5T:NZ/K7W?-K5]D&KF]0; _+_.D^]]MOUJ-HN
M7W7(AGY@:0"JU0RTPLZD0=LR%S&[^*MF0+\7Z5+EAJ0JP%P=#,F<9%8+4=@9
M)-'ZLOEM<;L5>S3(0I,-5=8DE-;.?AEY/#H@FKIQS-_H?[SU1#SVV?2-"&@]
MZ4=OE6)2C\/@W@3)#5WFJ]G2Q.77ZLE'S;,6/3N!B2>>?JX:5I.^^FOBS7]W
M 4[)X?*O#YNM[+N_TKWE_6$"\9@%?_\IWV7J!;UICS\[K?+;P;<X.P<Y_)^6
MQV_/9C7R!J F%RM%M]KEK90OQE_I?=6Q_<;7RD[U'3D,P1X9U"W/-.R1:GUA
M0#BZYD9U:>ZLW21. +*I<K%S@ T6]"HBTY4K3"P@OWR\K:QY7AV.MR66%.<]
M"SPD,*NR)\HNG'%/--@N>P^%"#(U(>SS:'<.NTI.JT( UT].%^P6*ZU66G]D
M:*IM0:W+0U-?E%;GP6=5L:SM0J#J.XIL/=D3VB;A8ZN7SM*15IVH##C2:H#!
MU'GEY(>8(8WYF9W#BF?"-=O[;HXKW$1[I@3&HA672\QC.&5^,B7DEREBTT#,
M-+9:3(,DFA[TI@?JG\6.K8OD"2]]5=YZ+!9QH\@]VN.PX\E 9N"9:Q'%28$^
MU'EBOL31O'IO41@S#13!$")@2>GF/F+/-6;/0Q".A,Q+I%#R @(S=?;:A_O.
ME+,H+G026#HLHA[\PLCHFN+@X'>(5N2?QZ+<@\-'\.5O(,V><^DS,9(3UUKJ
M@249LND2XPFQLR?V%0G22.=;\#<CEB22277$DZ%D>4WC^5H7/;C7U>3W#9"9
M@R07:O%&[!-QV:K^H-AK%TL1Z+.P#QX-?HIPVAA>>@/Y6WWY7>2(D::5_(JE
MW68_R1@J2?/\I%F,L &:O^;GE:4Y@-/FD<ZKSZ[ZRH%_Z^1].6AA@9G+@Q8U
M06#KXL&Y(U$YZ)(5[2I&]477JP*_1JU!V_=44?/C0-KG=607:1O#)FF>F2]N
M<NFY6XK)36;[3V<BDS?!@?*];8[_J^7;&&9),PP[";@N/C= FE7$1I;F8[QS
M' IIH*@4'VTTG5M#QP^Q"E&U2I @SC"(AV),_,DB2&5+%OY9Q,E\9P:XLVRO
MT*!_RVI3U7"!;#;>) K1YHM8_R$9!>0Q.585J-@\)0ST%:JD->_>T'0Z^K:Y
MT1ZP",EQ6*Q<"?HES;<T#M%WA*Q<#5\"ZEN5#THV-O<E_7.@_VHXHS B!NC
MZ8L^Z.DQC[!?J+-W<OB_]K.VV'^F KZ+\V:VZHLX[?V!*Z0&@/T $U^UO@X3
MK@FJLW8O\#/YZ! C-V&44UBS6,6XBFNJ"* PKA6-E;9K9$P Q;O*"%"$;PP;
M+%,,(V #*CQ-DV$(PY[N2XI=52@[#B6/U"MK0W&Z\ 7+AD-U$2TJPT 2!=#H
ML\(0Z*&R[!4;>H:^<-5J%1MT[+T,.;VW9!B%Z6"(KPN^P:V(5Q96.5(;+;^
MZ")XC(UIP2^D]PN>:2.[%#F2+&7P2IK=8C/G%'M= C)T'HHX&_5\;C?["IO]
MJ"JHHL&;W0<?!H^OMZ2TJ\(Y[<+1Y*+9/M0$I)TQ>6C$M[%J_-%2@<^$&X^J
M0C2:'&[$3"554]U/>!2EE?6S6*71&QPA1# )L=4#$=@XO=0;@+0K=LN9D!]Z
MO/@3)IM'3N=:1VIRF_FF\9KZ12?C]%-ETQ?P_8E>DPX \!!P])F/=Y^CD2G>
M:\X44U<XE]9>S8/.7/@\/61;PV=K^&I0PW=4WDJVAL_V1UMB@2U*>=X"!ZX
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M=5 I#WRW&%Z^@;(V0[)O)E675"]2%!2,T .S"+8?DGUK-]M[3,7H-3.Y(]^
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MB_0U6;I]T?SS'E0BZ_ !SFY7IS:?D-N,8]T=7A.4,H9J(-FU^HJ[,,BW6&%
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M&/:0Q00T''? ]E55,K%9\+5%6END]?='6I^6M](V(*TKAE4;0>-E1OK]M"K
MM,'I=RJ*3K@)_:_R^.$_GRYE;! /C$]IS]6C7!5ELM.[W$*1E^YR+(\>@Q-A
MP&ZO>6W 4KY)(J0[DL4!5]P51+"L0_<@V)9Q\JL38194O2 1IB5;,DV:4)Y>
M<\E^C6KR3,KU!T1,JU <U1CKEY"U:]BYSF^G)H&8#1!.:78+Q"0W <C R*B
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M*R;<7[0>$G.FC.R/F..7WD 9EYW#LN5KQV+'7M9X0S_P1<"U$Q%J(JGL]HH
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M$T\27T%B(S"R$J]954"\O3T!\5<R7^VS0]5;=?'BKT;*MPTL+UI 36D\8Z*
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M) -6K!&G@D]YD[R<,R_CI%H$-/(];(4(G_=%E)<^JXJUC/7H6G!_(66Y^9Y
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M:JK<CM.3V4XGO]C=^^Z?% G9G%"DEA<[FD__G@L  KQ(E&.'D,W:VNE8HD@
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MPE-=H-:L2!&O@IC _!*M"+_JP//3+:]NXCQ2-ZZ[12$\/X?;X2$LLC05B7>
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MVTTI_W!1:PJET'&A]/;I""5W"G:<$4KQ;8:8<$>%$J%;M-_4<DJ12VX^,PY
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M#_$]PM\/=F"G<JZIG&NW<JY7]EYZ"N5<^UF[Y5C,:^I8TER5+P).N$/XTHX
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M P+9P-!XYL,CBU:.#*XTLZZ<JE6CO,NJ)#)Z&<T%D@_]6\Y./3^&<67S1/9
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M._&]#^DBJ43ZGX D+95ZZN]/Z(;&%1J&ETCZ59).BF4;5NT:#NP$ YA@ /L
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MO2OP!XH%E\OK"#^A*ESVIK8>Y5=\E#LF.B."O[DH[X0D;=)]S2S EFQ.WKV
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MJB(<W/J9C&C7]F[=#T'D!9*S)-A]O3D\<M?M.ZF IA*WTEE080#*NV(84E>
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MO$/!-%S>B(WN4D:3=X/WHK=7Q49"#+(YU15M8HPFT>CN'IH:K$S"D(=DIF;
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M:"5+42NJFN1EEQ/1UDX;;,+M> C$B1>=,>+_/P$#;X>4TNIMT+VX$[7E#YO
M2Q:F(_.,]<G(V3W;];C(7>F@'JBIC :S5/2:S59M^^7#='[HDF,=O1Y8A!AC
M[>W:H$O X1385>#LRSU+7LON N5^_V@J2/Z^@N1-GN?W%"!/:+,);>8.VNRT
M >^:T&83VJS'F=\CGC$30L04I>=NQK31+^T$/MD()PO[U-VN7LA6Z+*)=]W=
M51<7-.^NOK!NWM,8O'5W$UXE:;_H<;[=/;RS*&8^S.WG*2"$@WUF1-'-N92F
MVZFERVA4[(U(5 C3%A,WPL6W59+%],O=&YC#P*O2GK@$_N%LBC!;"4WL"VNM
M^M7+[2?_)/>H-D2:O$$R< L[I,SCD#UUPVRQJ9F:D=T]-NLDZDJMV:_([U3\
M[:^OWOX,[XRW7ES*G,/3#/([75[KHEHZD6KIQU3E=Z((=U5+"K(VMBXZZ=1%
MF_&T@[3.F,+_/@*]3W[K%V4*\5VDM%RM_9'0O9C8IRFAMTZW,PT[R#;:MS.
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MY!$E220L7#74<K_4I+>QUDMV6['8I.T2SDSC1/H 5%'TT);_H"#$T WF?IS
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MV):>VE!0')R2%&8>ZIFSYV;GY.Z743<5I,[Z8J+6%I"U+*SU#OAFXEI$M6V
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M[<)N-#3;=>Y#JGX:C;%F1ER5 )K%G<C;W;%US7"I7Q[-2B)L339C;>IJV[.
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MH#/: 2RB:UT@&R^B=3;/6SJ;;@C]2\? ,7^0%F8-WFI_SEZP[[BA>@3,JT'
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M.&VC8:= %OK2=5!F@AG"ED+QD$VH7*<T2T!8C2H*@5#;V]H2\S4TZZ*&.R#
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M9GN$'FEOYCZ*M)NBG3FD:.M-X:1SMG!=PN8@]>Q&N).!0JI44T?&#]1@*AN
M,/)']FO_$23<*_CS-4.WJ]N@)P[UR'1*>.,,UTR93)W&@@3Y>S73M1-L1T^C
M$$ZF-C7U[D^RR3+ EIA&&X@4"7/C)._2%4;A<=4O".LE13YOD)SX9ZA;I*(>
M&K(&DCU2BKU?)''OD%X,H;$"ME-,4@8L-";4NA.+V:!@+^[76),<3HI;^,D'
MJ+?S>CNOM_.,#'1OY]EVGG#(SMM4OG(3'9=LLS9%1B%PP$QZ,B"C 343V*<:
MS$FZ;QLTW%XZ'4C-(*4:XX=ZRZJWK%RSK+J<,.@SX7TFO .9\-,^$^Y&)KP=
M'+D36<VF<^VXY3QWQG)^.SJ[W&0Y1RO!'[,W^X6[RH%"__7FQI6J3?8H.3XZ
M$PFLNPK@EBV;W J0^EMVX]J&Y5SWE5.18V6\=ZK$9TU7+D8<<ULN.OB# A4X
MSAA;- 9K?)G%7/8@Q%_;47@E3U81&.*/9CL^HQ:VJ@VBD?ILL&)6*:TNEE Y
M4WM(A>YW0UWI8.PQ'F>B&#ZM=]"EPU6LXX7YTB:NMF8-IG?[M9&_G]Y=&OEY
M:V45S\@GJX99G7ZU=OZ#)"^LY3L7%WA.52WJ[,LYZK$H.S%_W#K$_+&)D^B+
M:A'>:A'6-_L8WE']J14,T2"68"%ECQG8V$6\>[=PSD(EV65I>L:UMV:=+67R
MC,Q>GL\;HL=:1-?D/=<#:CH0J+K6)HTK*J3@+Q%(@Q E!SC@1BV:+?R>O?BJ
MY?H85V@P&M?'=*GZ:MS'OOM*F;8K93@G!(*2#3/N?C,L%S,^"=*GVTGG%>Q;
M]"VJKG;/:]NK0[)/JX5Y+4>N1]B_/,)^JR/7R'P)PMU/5T-E=;)79;7;K=T]
M2TXR#QXX%OY9CE$9C?ZJ>$W:@YG6^-"]/GAI?6!"V+8X#7U:M4^KNI-6/>O3
MJFZD5=U5=YU#VQ7U 5;&(8)G'9-5ZQW'331>D>^KD&7<E&%\'C6I@]-;!B2*
MK+ K/P:KP%_=>4?^X!CL* _N *^ I& ^@\=!70EB<,86N1)]M8&)3!8@;B0L
M8_O"GY)%5$C7VIDQD&UA2A/(U\RS!77KY7RTX$[B<%"?9[JMQ.$V,^YC)@WY
MZW)"3B.-UK2HK)=^W45,]$T\]N%"[*_%1P?[>VPOTMQO_]''Y3:*N=9P 3OT
M*G*E(\CV#8Z?HR/($VR05](P9'>1YGP_D?82Y(Z0W[I"3LKDM^NDUO^-LD1@
MY4<'4!?[998X1(6)6\\A9MQ-_6_*;J<3NO.;*<M+(%B0B AIS18IN[P2G*I=
M?/$#_''4#BS]L?HI2Q+-(!ZDF@A\%24<"6"0]+4!Y/4?V)(V[GN;!1RTH-P%
M%E@)KI2$*:>!:.B*CAB$/D8K[M019T6SB&ZCA%.)]=\;R@,U"OYXY4^_^[>J
MN-%*RQ@:$6X0@*,2X6T?:*C+E41XD [S8< YTH/OC0T25CC?TPPKP?('8:%R
M%"($>.1]G./4!8FW0K!ZBM9!!Z?--U^T=OMS>,OXI8R[V*16N(TH0B6?:$"H
MB6M?5>Z)T@\*+Z#'7SWFF@B1,58+5]F]E7*+O$&,;MLE;_CDIW'PX_C3H&X+
MK['4RSO4@[DOUA7H]5V[>VE7E580C5/:JM9)X_(#-<Z>J6IWZ\$=W/ FZ^'P
MXXKF,2IG5=090D=NG2"L%^J:\>.)H;V\0=03!MIDG#V&H<<P= ##<-YC&'H,
MP_I]<JKT[5E+&JJ(VMNL;UT)<+]8R^LGZEV9V5^MA!\_20E71)[;U[AVE=QV
M!_O9-DM5.S#8N%^^?;SY[;UW]8^_7US]Y'UZ_^[CS?5O;OL(C@2R76GB)F?A
M8^C](D(1YR1!KR5:W6UM)W>3,Z'I!KW9-T"B'/4K:]J.S[(8Q7L9K_5-Q,NA
MJ?QD\3;UN50_%&;;RT]BAE8Y=2(U.HTW) S9%:/7H I #2S'_H-ZGV<Q1=UG
M(IG&P00N#L(N$Y%<87P&64BVG8S!R'NO"R_$CQ7LGF11*B,*DBY.RC4ZBN \
MRS;,\MT'0R\4@4'8H>E(N'UK^%BWE_&K#?/;MZ9Y7K^HM3!DJ9AI&TWA<$"2
MG:9JY Z[#19E::-7L0*"M??<+I1H<V%NUCOT8]-E85"Z00,$,NW]C]4BXE(O
MN'_ @!E!J=E8,$]LRGB8!TSN)HRRQD1NB*.89&F9I%,#H)-IM!**,PM?4DX5
MW>,/_2=YFWF%);MA23;Y2^IPQD2#6$[C@)M\F_68\ .1LWMA[9PIN-V5V:>;
M9+:MSKQ?8O!S$R96 WVUR!)<[,<!)Y:=5U$;7[>@HEY7B2K*=5?"7=O(]8J(
M4JM2_'HK7&:%=*\*D6TERRLB4H:H7DO#[:#0UF]C2NX-HKF7P!U]W5<K@3D&
M\S)V=;.('DW#MHZL*\A %H\YG0"UC0F(]'UN,6M4&*[,W"[%)5Q>I/7<%$C!
MH\B/UZ0)AD)8%JG_<!0K$<-_EA11495$-2;U1L:]+1OK'-'#2I.3L^8S]'U&
M7 U+),R?>?<B3@).3\0BFL-O/00(G9[\U-K^[=16I<D:_S3@+:OF?NL(&HAZ
M/TU!@\(UDG85-%][0=PUUMI7'&0& MY=W;3^!61HK\5-TZF98ZT^(FV.>_S7
M3]<WJG<&DO(.%?*:Y4Q.<JV V%R"$V.E-PJA)8B@& \)B2#51X3W?$5 NH-S
MI2R@MVP!,4TJOM%@9+9>6_K?!34RJ9R1)GVG*@3)/(Z65#Q/=\#_2IO>H'O.
M+?N^YTU-B["\H7*(G65H/6B]:M9JVW62\%U5HZ"XS7.T 7*:>[/8GZ?:BJ &
M8_@,X]'4S\CT1HT>-9H/'$^=IOBF#:*>$XNI".ZE852B\(8'TP]6J3(/FG8L
MZ\N'-@5H7B8\4S:O2N$9-0U&NX568RY&;P7K:!CRRT^2($E1H")VG6C_94%,
M2*:WJF$H$LG[B7D\0H'MEWQ.@Q(,E(*__ BC6Y]D8,FC+GC;"HN>4*KLHFPP
M['MT;8^N[0*Z]J)'UU;%J%XZA]PNEN\M8_E^^>-?[[_\?OW[S7NW05D]G*\*
MSM<9+-]>+<=#L!/;@_+5)/+^]D\, I!5EE"&AG([W4Y5E!UUJ]<L%TXC"8KS
M>+;:5WT[DOF87Z, TXE@JH:<0,3"83$8Y"AZ1*M%"VQA#:;LD3]H$HA Z_MH
M4O?3&U5>/E1F.8P1GY_CX[3K#\;X4< WTM=_$8GP8RIJGWGOQ+U81"NJ:O^\
MP,9?,5P!E_C>-S&]"V&2;Q^];S%,(+:VQY\TS#TUU>SNR@P%_W6EME3+C!P2
M:2XT+K+[9ZHVSO>6I3.)#E:P _9#PRC%@ KZJ#@7%(#1$E,= 7 GTQC=SS(T
M]!J374L^+UT3MCM$1:7H0;)/%C]2[MCPT!S5-JP"R5'!^AK@!8F)"=^T BDW
MK$#)T2WKD!@%[M8PRH6I">O@B'>(>3=*[#!!0S$/*>/BV#$/ML44)D9M&YR'
M_<V!XI&5D \F"I7Q0SD_^YB;ZN?(7SM.;.6R6&\+T]6+=>ZO+J92#!?/[_ZE
MU9J3NB7)G&P?6%>".<&<QDPHDV_R.,P!2!8(#,$!:@#*W-N7,%TK,%I\W^U$
M5DO<R6Z$/%S".^$LL)_S%=0Q561IY>Q^#*37?,4@R*EK09!U\)(/*@75>M5^
M34]FE'/OYW-4T&"@OB,R5+,PD=)N(L$8?Y!@&OHO.DJ).DI3;><>I=1=NTVX
M&+[MKU_;:@=_:B# R(Z?IB;X&0:FV;:D$\ X,?A"DQ,B]UX<H!D SIV]7E\$
MAD>PORXNE<S=Y^4I>^8,<%<*2 WC6EACG13 %?YBHD/A9+6*J/V:P^QQ:R)(
MB^$CF-8.4BNZ8,0?F. "CWVW+?JB/9^:IW :13&\H^KM@9&)1 @9I=&@6_3F
M\W2_+&G0(.5:WWY#2-0N^EN#0U;RHM@GD*/3'#TPBR5PJ5S&C^[9&*K/[+8;
M?C?>W-V3LW[<;UGTM@:912WK'55)U,'(NP87=.X'BRS694;X2U3&1+  QT"=
M#4,SK[(8L:OF%5:E$8E!]R7>FG3/J2(PJ)PW4YI$BWN.VU1Q0:B8Q_'2_\XQ
MR1G8AE-_P2BK51Q-X33'HE"FU>FI&\M4V3OY[MXG>O>F)4R7AX)1/.U2$2G8
M-]HQ:;=J]$,1@IU;&PC[-CPK@LLOQ"T:'K.,XU.YP87!M;AP<$V!Y8*J7Z\X
M.E JTEG-1ZET:]/C-O!#Y8_[R7$HQ$S,I'_J3?PD(*RZ,F\-VO/<KAUZ#W<!
M.)AR7\IHM](5\P6WEY-:=!F$69IORJ406$5L;E+T.^!N]CCQ%,#M]$% UY>&
M[DPQ LZ[/_/NHFE[!^MO_^05HZ+"+$;H/\VLK]LYJV5[',I^- 9JF:^5G0Z5
MZ,EK<TR' NL$TB#-<&'UY[K78<T=N&[9J05KNWKD5%6/4(3&W/(&>Z3X3^9C
ME48>V(%UVRVNLZ6=X4::H*VZA_5I@EJ D=MI@[TE"?K:@+XV8+O:@#>'5QO0
MTVP_7;IWB7BT[41=3C&ZWT1=;"JSF:',G$K<X=O_^N5=6YD[D[N!B_MJ4P!R
MNF4F3X7V<4EJS08C3\!)@2W@S/CAYI_^G,UNA2Q[3'/8<ZI@S\8(P'E(,NJI
M'MGCJ(-+#V'0:;!@=X("&<H+@/6B-O1!,O&)/L1$?F$*) AE@A-_^4(9SI[6
MLT(.=RE5BGNESY4ZGBLU#_0K2T'V&<BVQ_V6)5K;<=@J0563@L2?;IF#Q$L.
M+ EYII.0E5/79R&?+PMYU<7HX+F3T<%/?IC-P:#FW@Y$N9-1G9+;T4$GZO'=
MM9'/^UA%^[&*9>EH)7RTW(M5?&H-95R,52#*&#GN4=%ER^VB%P599N1]<^]E
MUWB"?>^ZZ *'+$PVZ&;7<:Q#M<"9B05L-.S4C0DURH$:NP=,JC60RV2X"7 Y
M+.YQN+7U"3]-O\''$'U$,:/Z)"YF\L$8S%],IE9I>(%5W90WVRY,K.E;>D?Y
MZA0#2AX,7NJC_/?6Z$K?"APN65O,N2B;]]B<M34;95 ;'((#TC X].GEX._[
M+J<Y3#:Z\RZU@:'MXTB\Z/0I\:*T>!;<CZL</-[KW(4X0]4&KXDS?-H>Z_RI
M"'96M!.==I?/=:BA<O;Z4$,?:K#<OPLG0PWECBXJQM"B[R'Z&,.NFZR/,;0?
M8YB6SI1[P86;0X@M;&Q'U8!(KF&_SWJ(PDU3)_3F>7W07@Y:<K!+>(2;DOW8
MXN%,GN9>WG3)NSSPQC-O^1RTVGH&_*/R]JYS+F^V]BUOUJ2P#Q)MT3%,A?+X
M+K2W7+4;>F?YN9SEM]O&C-UPEM\XZ2SK)AQS$%P@E]QVE?MBG;Y8IZ5BG<N^
M6*<OUBD+]2X&IUJ4[>&S &"D#O.E#G,O-/7I^A!B4S4M>!M$I&KA#M>-X0[7
M-:$F/Y3UX&&VG, >@H_L>%,QW,2MU;<,47D?YQIL @-&FG79I%BQC%1,3LYG
MAM/DXQ5!5!$?(^Y<OFG>([GFGDUZ'JM%R58P4T3<ZB]$./-C[[\%_)]T.[%Y
MXO$TBV-$L^S8>U$O(K.UP]KX&6ATGY3\XM%<6-D^N43&DK\QXFA2"<UQW[M9
M4_SQ)D^C7E=YAK)+B#53$[C-4JSCJNFA.GN#ZKSI%E2GO(E:A%;4Q5)KL3G7
M78J>'CPVYXT3V)PJL5B#S;G>'IMS?7 U0)LTRM:Q1J\/-C9%YKSM8K#QTLE@
MXX> FA5UJ>:G;R10VEI]R*/]D,=<GB3W0AT?.A?IX+D,P+U5QH5VW.LA,A^:
M!BX^.!.WN/,IQC!<'XT8JL"&C$$8\"/F<D]2,O:9XA(K=.!EEY,L3BC9D?="
M,R8QCQ5\V'^HP$V<A?,&TR:8Q:4+,(L/'0^?'(:^[Q+NK+QCNHL[^]"ER,G!
MX\Z<%8C5@9,/6\=-/CP9=_:4 '$//&L<T+C4T:!*_=@#SYX->+8=L-*-4-"5
MDZ&@SWYJ<D.["3?K+</U.ZN+D:!#J\Q:\4%R+Q#TV95 D!'VJ>AF3/^F4!!>
M3DKP#OYO@1H1+",IIY3Y9'"(R&]0ZW*3CX''Z%%D?XDJ$!4:GU$74_K<-*;T
MN5'952$6E%.JT&=^OG,R&.<"QTQ#VH87I+'!]PIDXJF4B1V"%KS_ 9LZ]!>@
MAFD/M$H \C[?J=@E)0CO@U3(YN0&7[108RYO7V[&$ZQ(=,+AN<U 7!(K$_4D
MSQ)N/(]'O-1F!XY4WS^GKG^.M3C<9CZ$R9]1*R2Y4-A,7J^-L2B^FFMSJA5"
M;1[$2<I"D*-Z880GFF4R]>!1SXRC[/:.'H+73Z/CZ9T/&P.&LA ^W,,6?>CQ
MS.X5%Q/>S4?2J"F%J/$&<DQ/JS2H]V+[XH.^^&"?Q0=7]EXZA.*#70]/7X^P
MWOSH4+M)%,3N<Y#51><_=RDZ?_"XQBL7<(T5^[DZ.J]]S^TB])\/D73L2D>S
MJZ:OCV8_(^=8Y^'\'(=\ZU"$FZ9!XQN]3P+!/>UV8LE]-UG(E91@0^CZYJA,
ML]7F#X0)"3QIX$'%T2I&>EZE()7(RNET#8E%P21]3\N%I/O#_2B B3Y=$,)I
M+_3TO)?53N; P-TCQ4P.HW5_C)R9S7#)R?<?]5/PLL2'RS[#@.%UX0V648SQ
M!?#YX3B9#TF\1802).%GR%L0ZV^05,N?3@CA-25+;UF0E#;NH!27@25:^+@=
M0J*(QM7;L)LPZ@@_ID6;/,J0)HIH=/;A3C"A#W&@XJ8%U[]^W^"B'8T':P91
MV"$F)E %$%:\&TK;U3NR @H##KS:5Y%I2+'4PLFIL A!Y_ +8BCB%HOQZ&,S
M#%48 &VL(%QE*0=R\WE9\M*4K\G9O1%<DDWU$^L?(Z>7;\F=D0LO(V]%<UR"
M5^45CK"(MU$T0T,GO9,MD.$?X'7"3%$D8HJA9VJG!U??HD@9>;]'52OK%Y&0
MN'+AHSFRN^@??[^X^LD[\@>Z=!)N',,9C.(AO,@<=E9,/9W%<K6('D7.RJV>
M"%9ZQH(!I!K\$#=A*D+JY8QG75I=QF94C;W5+VC4^&Q8\2S4[\HWOQ.+V3"'
M^8@9C68F%OXC-A3'UL]'DX%"98*D%5-N'VT.9!Z@A@V(G9U-11)#V*J:AI5_
MQ&&YI6QQ#6)0=1Z'URC>2)V-XC2K!(&.JJ$(3)&\G/C0$^G8P.U2'R0+V6(=
M%'?7& >"'3D>*ZE7F&?8I+^#)?DN2*:+* &C<<#K!=-^-!UXLTCPFI&*I".=
MP<S$>"WJ%?][;HZ2()J(.W\Q+VS :I,_F48K43ZG6G/K)S7,T)SU&9J"M3@^
M<<5</)/SP/L!=QQK7>\72EPX8C3:V1@\_U+C'L%QP/]>@[!=4-<&N4L'6N8F
M>$10"Y$=F08):7M?9FJRA0^:4<9<^"Q(,9; D<'+8H'6)"8W8Y7"00F9VED%
M6S>0[KF+2+"V(52UONG%::TX]8[0;@)[Q0&@0O7I<P2[@(>">IZ0D<8['N?3
M2'7FF4[</^8O66DYD]#$=]-XAA;GE\ZE@8MHG'G46<<C,N02T'!"#"HRC+DP
MDM^%_E+D[H*4GS5BGX07V\.\^+FLJ\EV3L2<75EK$"K%B25 OGP8#CH69MH6
MK&04/K6#07LF6Z3!:F&[$;YW"R9C:#H?5.5C&#CL+?X'[X.)=960??"QZ9 V
M<:03B#^$H2W9K";/@5+^.M2@GDVK9SP%-0N":HJ?5\QK/J=#W4!)K6G"T0(*
MQMH.:1+QD*WAYKH G9@41YRD<$_E<>&"W((S<SLT=IHVXJX7H"]Q+C[Y(7B#
MO*$8Z:"V53+@ <DM !JN7N$E>GV++]W42.QMQ(*-^#+ QBUL1%Q97F,7C,,?
M4[%*2[F(3D? =!JB"(H:#.'0>]_N@GAF"+:2;"X=RW* P0@L3$#'Z"S0$5Y(
MTL5XBAO&46';.6 5<3[-@"(]8,#75&F^5Q@UPY#RE5%+M@3)4Z/WM:BNU_G%
M^'.N-&K4-&\"&<M*9,IU9NAIC@"(>_(.-FIL?$G/% D=T]7%\3^C?BYMB#6J
MU5C2+%R(1"8!BG<PO<NAO;2&M<;APLH;/$398H:!0QF"&U)4NLXW]:<H<<FN
M@Z>8TH//0^GN=U&][="#WGK06P= ;V][T)L;H+=VP&RY'"[U='7?T%P'VI!A
MLJ)%SPX?IA7NHU0P&OU1A44Q#4A6#'TW>:1<$NMAG5;$_/P]V*W1?%B9&-1Q
M#JX;R4(,C%)R$G\,DTQASF:5D >"'!F_3+'&%G[>)VD[<>SNOS+DKG'$UR/S
M^ %C^(6JI&%E%AQMCLI"MX I:KD:3X?-9]3VF;A?TKPVBC^9/*JX)KR)=^14
M1#,8Y06D+2P0IJ0%^2U@%2LT0ZS#EJE8"+0J89VH&"+V<.$BS_Y,K^R @DEH
M==*DLS%?@S;06Z/*!?CU\\UPHQ]$NX9N:O^@Y*D-B['-W"M@C$(08S*)@4ET
MUT)FN^RN^;B)4>#-3#Q&X4?5KAEY+[9O4H[)D:.B?HDY(/A?&)F)+_#EEG5H
MSS)RA3 E5<FP@/6$<>,"G5/NZL%XO9(S!?>F5':T,*,9,VY97K$XV0IVF 'K
M4*ZB=+RT"UB[:_[$&U3M")6AXSN!4 F,.#P.&#8M+ "N'>XU(NRJ=MQ4>9'4
M:?BU*@"3;-U9?)N7=39:!!@XNX.Y&+0/BHKFY-XI!8YJXT.28RN'T. KIH@=
M8("5]#YK#E%Y@QL9C0)X20%KF#BKC)N3=]+3A@YH+-)'E;TP$T^B@,;*$F'N
M!C'':""%(J8^?E>&9ATEZP=D%_+A=!:TBS&CA27J(1$[FD$O4S2RA1F4K[;"
M-KL"AUB'H:TP@Q !MEAP[>H"S':"#"%TD0QY1VKU^3S_*VJ5AT.GO='S6>1D
MC!.R9%*5Y2Q("T8(*[05RF*.LB>9JEHMFJ4V.LOGL*D-Q$*A]1=HP&06L*,)
MM\U"/PR64:;RMO\B)\V.Y"M\H/&+'! ZQUW "IN$:A!F:<Y0-RV)MR/!YI4V
M-ZAN%70$FG1D:,E[TG#S-R* #2H7&<\FA+/Y1!2P,8QMBIKE%BNIX^ ^@'^*
M 05+[^6;%=,9_")"4U3@U"NOL5PEI?27H3 P9EJCSHK ;WP)"E^2;6'"OO$?
M-$)X&&K+L S5_7I'L55S6R!6?4;P8]-.B+(T 7.8S0?+UFRRVKGKHAZ#JZ,>
M):T7>J*R;*B&):,=I1^P>%1V!(7X=60;+JRT9$NPYH@?PKC _X'[8(["3^$/
M W(@L=0?, L%-F* ^24R=^YB/]$B:":PY U.YE >QOP+OFGI"XI8Q\OBQQR+
MR'\=Q:5':+\%PQK\<_7KPBI1["( @0.V+8\W0;-CILN?\CTG'4_,8*AHR$'"
M]5%AVWA]K2:;%?^<C$Y[(\@NG1V?MZ2!2Y6SR@CZ&.9ADJ]W/GIDK9;'?C.\
MG!@VY6T(5[-^4JZ#WI"D9N99R(<L6H'L1J+6H0V\(CDMHTDEZ!6?57B#!>)/
M\ZE0$-$8%.&]#@NCV TQB%3ENJ'<\^^C8*8H(691-DG!/[-\3-)/6-:BDX?D
MGMQQX<(C<>V CF!3SD,C@_YM#4[7(YIODI,&%6,E.4O0QQM-$#3,/_ZC\M/K
MV5\9OCG\,_]6T3S;=U*?6C>"V5"?JUOI;U]9[>#XPC77YQ.;::VZ.WC2K6*?
M1[;VP$SS=<)!V9/X3<'S.2J8GF"Z#K1ARWG^!:%L#$XN0S!0 9G\^?'D\5A=
M*<EHOMG!0-LM4QB-BJ+\?,@TA!JY4[Z3PB+4!K7X6,]B?YYJ6\^<'4LRYJ4<
MRD3)B;KR*:J@B9OYCXD,H>>14W6%*C C,-;0\Y=8P:A6 1,*0[*'DVD<K%!0
M$2N2$;@!N\P/%D/ECEA\2:D9!;(D.)K%G%SRO460$+0)?;?<&V$3707PC8Q4
M+A,5RSRN>D)3/BM?@.0,^+KF EK>2!2B)4VSP[4#TJB<%8SJ999FQ%!D%7EI
MF(\=2(/9[,$2/5C"?;#$Y4D/EG #+.$$M361SQ?DY\=Y,>Y40(996DHFK-)<
MC(+LI.B'D44J7;1);UEZ1*G5B K  J+4).!K0$,;ZM)8&()@0DP-[YNKJTR3
MF[)"\V JE9D>7_Y3Z2GHU%^N3FC<Y737,0Q>=DHQ,VE%-33#^,-,YNG,&3,2
M0QL+!<+(F$D&:T@U3"L5)$DF+(I1GX"PR()H$9,6?0Q9J<_U!51?.I3DB3[;
M=D,/K)!@1O^"H2>(:B03 0O\PCD5K&%X93#422F/R5KL?C7*#I1.CTXL69ZC
M:B9<OD&2MX8!E84N5M&$FT73# ?"VR=5)1,P2;'@$>N)2HP4J5P'XGB,>3K(
M,,IGNV9653Q7/3<Q8*EA*LT'#@'F]M)0O@9-!;P+UH%3958:!]-48SRGHI@X
M-.*R_&(8$X9-BXFRF "^5/F%,Q;+NF,=N46=Z*>9/M8^:*XX%(_'TT6@Z(&S
M$'2;G*;9/:5883HX!!RM@C"@Q*X*4Z>2<;9A-*G/J17#26]<"R>]_['"\$&[
MO6.+;!X57!F8SH@>0D*+APDE ZA-]<PHB$1GU$X2V]D*K61RL9CJ[E64QU8W
MMXKRM6]FEGO(XDI#PE9<4*(^K4'%-.XZ>2CQ%6<Z4:IC\%L >R0OX\[WS+6B
M5F@_TURT \BYI=2QQ321YVN4T2%QH425IK.:>1F&39?T W4)):#RY-'FNRJR
M)ROQ<B0YQ=O/91L41OSZ#J2T*:V:#^Q.$KZ;:TET-H?:90=9>I;1#.NLT !;
M"FE%->N&E7/E<)T/%6*I+*(9P#>*MI8K66&KG8.MGH4D+^!+S(1A>5->'68B
M5"P57,&#]MP"#3O])'FN&C[1.YH-//2]L3 <X9F19"S$)*:1V$16)4LMP8^O
M\R#H;_Z#'+NH&#NJ539E"P_/98 LZDIJPZ$YOEQ7,N:L./.!E@_XU'=!LLI2
M.PYLIG3E]X-*86+%!O6M&*BADL;FS?B<HT3S5>])_FA(I8"<YU"?$%SD*]O*
M_Y5%\O.&2OFRBZV@Q\XT #KC:2BP5;K? [IW;LI[RIG6/Y<;::;?:=^<A/$O
M B0XB#&U#8]Y&V("= JBL/6\FPH'^-/O8?2P$+-;F6,O4I8,;=*]H8X6%9)Q
MGW*0,Q80270S:1Q\;XV7*Y(3%SV8@@6I92S,:3!7"'-U+TG*1T\1,Z,%,&7=
MDEP7HO^W] /2 THY=AN;4T/*J_K6@LY>0]ZV-S&S-Y/1-<'C2C?:S8+G?4X_
M#<?GUZ]M-L22-$!?LTF.-)U3D)R I+YU>#G_SF)#PFX#QOAHJ&-EI%\3E1(.
M1P-7E]I XWXO,NAKH/^M81GYVB..MFMKKGWWTAJIM$T=\# - 2MG6\?208 *
MBIZ5>7:Q+7;%OE F-U$JTQ;FI9*7$#X3C'SS&OG\8G6(@EB@^1_ZB\<D2'C-
M5ZLH9N"R2E17!LPJAR5W50@'K]1;"$9W1"9^$D7ALS>'W[)4L-UN3CB"BNF:
MRY1(@7^1"Z2&%DW%7^"333F?0C2V:I5H)7)"$[RKCK]&<2X'-&[:KJ RO%.7
M^F^YM6(2*RGS24U!OGU_O@H#HJT..3MX+CF)L#ZPK?LG>+S+$4P,\96YC^WJ
M&I6?1R P2A!QJS1+0.RK>3!*_K(*X\\.!T8#R7#AF%.5GDCLX8:18G?58ZX*
M/N47Z?)&@]=<EC>2YU4.,G;?<QF=V;Z+N?'0QJ ,]7*5<FY>A_L,*\T0Y@&S
M).GY'M:YH#W$KH?8=0!B-[;W4@^Q>_40N^U"9RP@T>$:&G"XC/D)JI2,-M'K
M_/08-&@L\R25KI(%=RJ3'>AF _))Y2X#7>TWMKN60YR'RBI._42X$78HI<[<
MCCGD88.*\LNN[YYSR1-K1?>^BA Y3-X3):3N7860JUF \Z#V&LR:E1.MCG#0
M:?^8BJ5WBGNS _T9UTS9Q>AT2%/&9F'E&^N=4Y&</<0]='$T&QP%@Z/Q@#=3
MZ:6I\R$3",^SF'9,WLVPH?<_=D QN^;\OTR1[_ZS!TWE2]LIAJULEI)6JTXK
MF%5=>>Z Y$#1\RQT 645I;#BS)P1<+\W$SB4FUHLARADKH'=-# 5D"XM@VWY
MY54-FWZINZO-2]W3HE#F135;A+R4P3S5J1?P):,'J@"D'$LLIB)8Y0!UFUQ+
M+]7&4=8OGSD]ABF@,T11W1.TK)\$7 =!E&+F0ZFC0?%&*EE1?=-9E.>;:W:;
M7DH9XB[F-I:;N"+VVTS!"2\&T7GNZM"UK6^?:(?5U_S8]3Z&>9M7^TR)_;)[
M_0_63^@%3^B'(#3@,0T)1:Y&;W<&QYVV:Q*\# - $Y/@=(-)4%B9'CG7!'G9
MVN8Z\@>.["P4EE?KMY:-DVT7!7>=:%((V[0B.[ >W(V>LO,B>+U?*+G!MX,L
M#NA'FXP4-YG>SYPV0,[6+M9IE0%",40P.=S?B>M?;GV,U$\,!I9!3C.4=XXG
M#P:?I-/"5.Y,&LQ"D1EQ\L9%,'OF'VJK2O0H:$M#E(I$WXXNW^ T6)8PU7<\
M2VF$LPOBSHI<CB[.G[(B>ZT@;7%!W%F1B]'9Z5-6Y.I SLB]0RM2)[70)'I-
MY\2=-;D<O;W:\I3T.)\>Y^,.SN>TQ_FX@?-I290:Y(H<]V7:Q$G.W:Y)FY!,
M.T,6$;#D/=5S!V1Q^Z"1T_]=C.FTR/NB>1!>NK=8*YN(8G\39V)_EZ.K#;$_
MJVC^F4-_6Q9@C-JLO7AZ''+/#6GZE.$3,UQ/#Z\Z',];_^H=#U:N?[GM@I52
MWKU8K/(P/$QWXC!]K/*P8I6=/Q\G+4<J2S;?TR*5KB)'VUO:UJ)K%2N[M>SK
M J5(:TOKSLKN$#<U9>AHW#URLJ-[ET2F?;">95SC<<,*F^T,FHO.GT7.83AD
MT9S56C3>FIX@!PA1N'<I SO>WJ[I\S]]_F>[_,]9G_]Y_OS/#NY?9]-!($#=
M2 A9@?[7F ]J$0P^=<;2W0P&O[GSPUO![/AA&D<+)V#A.6]"#P$OY2B&G7_O
M]=1#W4C![(,X@'D5\EI(U8<+#<R*>MJJ;D]249&)R^6-NM/CH^;.Q]VCZ=1#
M[WI*_.]$PJN  ZC&D N06T3"*+,0DR:207(:12O8DZDJR6?E@FQ><#J97IX_
MT[0B6.\KXFD ^SA)\<I;[BN:=\']XU\?WQV/W^INM$0N'_ P]"Q$7(HGAP%C
MH&[W<M#Z87D7WZ2Z9X4L()Y@/ZXT(%(R(D7QEUCB1\R$6#W['=-$5#.J0>X^
M-B#G:F1<.\V-7!*;?J)X]6=R#!W>P^/+T7AT2L@&ZCU>?-N!U2'-+IF4;&$S
M;Y7%22:;-G=\+DZUH*:RXB^Z7+N5%NQ/"<ZV'6@@ VGFC('$D=BUB)D274=?
MB]FAP-9)J_GLTG[C?/:Z_?8Q5 9@;X'W%OASO7?'(4)/X7PK0H1Z=V-K=R,Q
M_(WUX*C72 A H<2Q,XF4J]')F2. G?9"<J?.6 !/6XX]>Q+=7EDZ:&<'<M#V
MC55L;T7.#V9%WNSN6[<R_<BP<731UO2?[6'Z]R;9>BQ CP78#@MP?GA8@&VC
MB4UA3,]HL;=F(;YQQD*L1X<VQ*.U9B2ZH0 OW5: PV>'%+;%@5=H#V.!9\ A
MSF$REPZ 9*C#7S&V[P[5?FB2%AOU:UD88.0%HY-VT9JD03;Z.51UV>-K;+IA
M;LM8G H.C&7A ON;\S_38&%WCC17.TBL#K!N-7=+^.W^ V_7XA)K-F1L@IO"
M_Q2U=;%]2)D7'Q<@C#0__)02L@G<Z)'O-Z-4>=Z-2WZ1^M]A+^5[9O&('?VL
MK05GDVUB#AK6;0;Q8RI6:>6>RKO%SRE&Z"]%.*.T.\((5MP@E'^JD_Y?1"+\
MF-H (E'OO5A$*[KDYVQV*U+NW?Y-3.]"6)K;1^];#-..]-GR^US8:%IJ%P2*
M')V;<H5[,M1EZVU"[*X'Q+GI0B#Q"Z5E:25M?P!Y5'<2J5R&NBZ16EKT5O.I
MOT<IRDX$(.%;',@!D^<KSUF#F GZS/&KS!R_\DRJ1$XVS*/6&0I&)P)_ 3>:
M/1Z+'T%"?8$GTO0)R,P:L J/!1J3J+W%?(X/8#.=6J#X( D9Y:D;M2.Y!9D!
MU,35? 4&04J;7CYJ'L7*PI/Y<MTP <&:DX%M2E(OE<1NIH*W,-P-ZB?NH3);
M"=)H,'>3  &B467S)WSZ"L_.+(,YMEHPM*>)UJ'%.MF^RW@!932UJ"S!7O,3
M,4%?Z5IN#MPZ%>!+[XCVFMX@?"H=< .JQO]9C=(!9\ S2IV4TXCRVX&YP_XM
ML?8#'>AUI><,U1O-6(WXBO&C&(,E7O5+< S7J< (>N[4X*;%"2; ?:ZV;(V$
M^E*I(Z6-MICR(:^8U*5>49<J+]@*T#;T#9LV?WHE0(SQ:/RVM7K'4D4_SP.H
MC(FO8E'SO ==6Q#N4W(%5=?YI?\XY(9HVE8<HMV$0R8CT6J?"6<$/TMA*"2)
MI.4%6B::4H2-V\C![9)@$BP".D,ZNFO>B4Q0[DQJ?8XQMR3)X/YT3>EF09J(
MQ7SD7<.9R:<2'+YPNLC(J94@RR&=*_0$&5\H#Y]\-0P0^UD*$TF9XH7^(F\.
M)WZL JDU\<Q3#9-O=L>[P=3Z1)HOWC?XP;-WKFHMZC(>G9ZTIH_+!PNG 78
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M<WFE(S+U,_@:1-K-%B+-O2D[**DWX5YQ[[,X6@D_Y-)79OQ195?" R$##UK
M4&<&7XD"1S273J[(U*<(R7WLQUZ.KI>C-K!_'?J^+RSI"TMV+BQYTXW"DG6;
MO\_.'%9VIFV/KA5-\:[W<,LVRCL?SIJ?"&\13;\K<V]\>KR$*Q'W#"(G6'I^
MZ"\>DX#P)-,(3+W4&WM';X['8^]1^+$7+6;)0%W]^0[O=_J/OY]?_G3FW< S
M\7V];S$"7PFNJGUAC"<%<T10GYZ,WX8WT;^.+T[.7+'?CJ9R["D./1G=1O?F
MD'^_^79R<?[FZO+L355HJ?>!-Y[(#\$\?:Q$\C_%^WT-LNR]N[*LE?GXFDVQ
M9&V>$:N2X;WF$2L_S.;^-,UB=%@K6-$['+MO9\HY\%[G>57%W?L(UK8"LH]@
M[6;5@(L-IUP:)'-0,W?>T45Z-_!6X*1C1EJ&X3FH]#FXCU(P3@JVBKX<?Y-'
MF3[>Z-2?K'>%3R>/6%=#M;=W_F).Y-P4*!LR%8ZNKQGF]3>2SAC/S]=L(HM\
MD"-.I@C" .[LBC&$+,M</(0EUN__A'?/PC0N,O7TD:V]'?X_PKS:$3.=ZR-=
MX^U"795!$Q>*7]JI7:1*]V;0E2Y@LT\;8+/!FUOYC_0B^'9'XP$5XL(?"T6I
MF4N_:,KUAE.A2RV:P+%4W-_@/J\M86.&C:7_(UAFRZ9K0:0-Q>IB(^]@<+JY
M3ZK?9-6.<B B949JIQ/\<7CI#U$6:R&RP6([-TRVAI7+!]!M5U6YN4*_UJ#*
M[3<_"^$ .E+@MGVE%GZTX'=86Z/ENI1=7P$C>WQ(_DB7JF"*^Z?+A5>H878U
MM-<4;=D:KK19#[!@JT/;]977:U4?WT:E6K(JZQ"+LD[&XUW2?A<7C3/8V]SV
M?/RTQ/BZXI&.ED]M23GUHE5)XXMN5$^-JRS#DA O2HJ6"J=X4K<OG-ICD<X!
M1($:6FV'5.KDV#P72Y;Z+,;6:5X,(2'D4\13#*Q_]4'.6E%N3X67-X7<7S8?
M\BIV_K>':(LX\^EN<>;7&5;^MM9N5T%,JR.CZU[D^B#E:5UHV:N*+5<+ALUI
MMZJ*NW7,<XU+FUWBGCMWE7ON>O97=L\(_\WL<VV$)'NJM]WH.\^=Z5S4-:JW
MTQTCX=MQEE$E#DG5"5SPX *[$K4EDO+ 05:OTZ<%ES>P>FUX\<H@<3?7L-V(
M:]-5W'?$M<G&WB+L^HQ4JZW%74]';\9G.\5=1^.WSU!N<34Z>=NL+F*K<HNS
MT?GX"='<G@SKA<FP.A+./5T;SCV7D(]*,=06&=:.,5UGR;!:B;AL8S'U@=WG
MG>P^NOO4^>TQZCL!JC\@E-K"IE,S*O0(DVR2B/]DN%'?!4D:A%,C$%8.OW![
M!S1F$8#.'4MD9_.C8$!?_@)??A=B!1]Q-S%X$=4]:QJ%\T!U$=,$#[6&Y_/'
M5IMSUO@I5QS&$?9*FWD? K&8$2Z2FFN5)J_'JC]7#@%LK*ILP5FKN8*>JZ'G
M:MB.J^&R&UP->S\IQGI<](&*5QNH>(;:X1,4$3LSJ58= M<*GMLS(2LR<4&"
MF0?OS]"_]X,%IV#1# 0[4,:R2_8?9BJFPN(H9)*#1XR55AM254G (/3\Z11F
M&+N%.E"V2'3$Q#?1=NE/L\'61(+.1A<*G"U7\(M(!/:DY:X_AE?[1:RB.$V*
MU3MN5+0K0> NDT-'R)Y_[LF>J]A]MBSY)I*:L?<A6]37?>_#-7^6$O$N$TUW
MQC_M8 #0>0EV-7I#[31N6J$-.!2[[QGH+1I9>$UE6?O&WZ7<9[L)U3XZN&<
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M*$:6C?)&]YS<$%Y6V8C-A":-3U8C\HIQ8T*35Q0B/.M.B!!W1>)8A) 2'84
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MG7:O[[4/_+'EG!.8GW]7'7D;QF907]"LVF\Q-*0'2)4@2<#7\M$TOX] %AA
MMNI4GCP5<H$YHF5A2K"9*2VDNN-1%L+"@U\)%BM8O+-!C=PR>3NH;0UJ)6;M
M8R%04#L%+(OL]6$)1QX((U""$%YHR7L.44X"_0CT3M4%*LV;]\3#&=#?1I0P
M!">$;DR@&SME1U,Q#T+8W*AL>!^3\)V V2&!.1([!*+ASU6"C-1+#1W2Z"P3
M1&1'*"Y'XYPX5FE</H-R4@9*>M7??N!RK[N[Z$&@EFL[:%2&28'&SQ>2X'%R
MPQD*648US> O[9:'NVB9XR']Q$:A^NOV FL1&<.Y1\Z<!'Y!_S:W=,/L96/P
MS_-U,'\&9ZRID?TR)G:5+BF8V'(6OHA$^#%(*)0<[V#?+Z(5+?KG!4CDFRAI
MUYQNHS'Z(?AR;T;C#OER(EA.LC@A:<.:X6-X_/]@*EOUY*X3C>Q';8:R-$"/
MPC)>)G!Z"B"VS2<*5#>Z"%FL&Z:#94YR5&;6?:P!"-@M6Z!=GS+P%:Y3_4T;
M/U'C: NU!>Q.O@-+8SF!.YZ-A][IR>GYB)U',"#89_O5#S,T1/CK"]LAC-7*
MJ4F1I(#;L/BA+S>7G0JVF\20^<_0@$*P;@B+ ;IR3NZ27*.@A).KS.25./Z;
MS.[/V>Q6/'=N:5LC9I$E;1HNU^@%T#S_ 294G$D<.+K1:HW9%%8)%Q/L3QD;
MN:',RIRZ+@S:0B%3G7QT@F>0]93O #IGU#UJF]WE3R()3.]WPGYV@H(VRH51
M^1I?\?UM)T 3L9B/+&'DO"CNJ;%W-69.NV3,*)_;<=-ZNV/"D1KF/UU0<GT2
MQ3E]+#N:K)%5$&@*%Z)B%C]6C&Q.<CQA;)I\F++6WG?GT7-O%"RXO3W;-5N[
M)JA8,+55L$/+?+ #?&\F4C]8( MND(JE3'=PU$^&H?9F5 8<7\.XV_5\'BP"
MZI<E85^DP^QPHE0HJ$VX6GAF'I> ,@)QE-VRP?GKAQOJ>2FQ*]EJYJ?Y%?"M
MM.1AWBD:B?^EF/70C4!U@\G]R O3V2AV\U>TW:1RC:.,_L)__20*R4Q2H69_
M48@3+Y3)L;V9M'9O$JR#@\KA/(B7;#<;"1 3[]3D:7@?W.O:A])$Z$U-:-N@
MPS ^W@;$EXS;]Y";'G+3 <C-60^Y<0-RTTYEOXIM2#MDUB#9J OIMM QKZH1
M[)O6>K?7-(+]VS_7!D(U2<*';^]51 E6](\L/8[FQY^CZ7>1RL^KPE5,]1)*
M1X@5:@SCGPOVK]3//X%M$(-+EG2LKK*6M. ,,V14O2)?%T^&?LMFW4FWV_-N
MY 4OG<L+ZH: K4<J]LP \WQYY=,6@V27+F7\3G?.^#F^V"XJ2"<;&?_MG^^Y
M],H_J-)8J9P:6&F#(:MM56PB 63X1S /IF;'U;H4@X4*0]RHA)5J0&]#[UPS
M'5DHNKR7[*:\%E_?^3*B2[5VMF8;U&7T-UMN9K"PD'$N9)&J5]NXK+A7UE/K
MZ635#08&)O)5\]]JI'=3 $TO32UJMM:ZL9:<#29V^ML_RUL4P]#1 V^#XI[.
M=V;U=BQ<TRC':?Q>V^:-LYK==T.=I##_VS\_JO(&U?_RKRP.DEDP99([*GV\
ME76/7/&1LV(55O4+Z88DP#@DY_-,^JWU JD A"ZYPY6Z<#L!6P?Q,6"P?I($
M2$4Y+9.A;M5WMJDX=()+LJ-M9\\YK4\:F;(BI"5!J""[#%?I=-C<..> 5<W;
M]4"0@Z!;W$7Z*JF%E6BQ6")W\7[EL!\^5Y;LI9<["%Q9[U,05>>XWE)I)I%>
M&E6Q8U9<ZI3K!G[L J5*[>X9>I+&1)5#53F1K#!CE#$23@FWUX1<"<)LAXC#
M'.I2.4(X5CD_J,$K+,I21#J:I+!_F?9YYN%>5G]O;&^\86;T[S9-3>_?['2T
MA"LGZPEV;*N2=&^LB;UL5;)U$H%(4< HC';M(%*?5U*N3?AQX8-;$/ X0CK@
MYQ[5VC%0D0?,IJ*.G2G*VB9J /0LN7XD&:2^C:B^%>O<DS1:BKC$D%LK.O(2
MA/IPR?I2DI=3@$W?J:'^:RRA7BUE[-'<%8$X?CLZNWQ2: <UXK[#.YHD>]]B
MNH?T]9"^#D#ZSGM(GQN0/F=LZ.=UQ'/[4@IUA\U+M/%:-#&[;5[F-:Z=M2[[
MZ(IM2MXZ8TKN'J=^IBRA0=6TOT!J\S/Z<O&!=8'4/#7_8D>^^13U9WZG,W_G
MW)FOCNOO)^<.F\G<G'B2;A?1!/1FXL\%G.89V 6HE/&7FG'COW$0)8Z1JE]<
MU')?:AB\@K'4/#?/_U>P1W0ZL?QV=#JDS/+Z<"0*AGDP1VXX$*=$Z79Q\K\U
M-]L+[X,VI,HAAJD0Y]U1,@1WZ@F\ZRJ]W#,<- ;2]@P'V^ZYYV4XF/;4!4^C
M+BB( I=X"M87Q'MYK:GB**A^E^UJ4*OOX3@;HQN%?%>.%?)]$].[$!Y_:\"V
M6]? ?9'7CIO+I2*_CM)Z[LI?6='BB; -*I14>]#V151IE(&5/-JJA_>LA$U8
M"4?>1W,5-%ED_7+F)3'&:E7]G(KOK*8/-5RC&^[3+^0>Z"77',\Z+LEF\3(.
M7#^51;)NRU&%51?]Q(O16%5 T'MAWM^[U@4Z8-F^S]-NY:HV>][I>[)O>6'
MV/U/!O?#D!9UA*'0%BQYS+,-OUX;TJH(O1?C6->SOS+J"O,1>?*78H8ND[E$
M[Y-I'#UTC'=CS7+)TN;*]T[*+S[09<7ZBO+D4*>5O"CU8.=.EA;_0=3&_'+K
MN$IZ:%,/;7('VG310YN<A38YYGUV*/7@9-QCC16Z)OV@?=-MTPL<JT?*BSI/
M_'GCTO5OJX9/:F0MTW^'[0*8_BN5*EFS!,T=2ND(FGPP?<1_EXA__<9T*?2_
M T7QQA=[/F+B^D<_F86X_M8UX3"+?+C^)&V17=F>R7/C4K3! G"8F(BW#N5<
M:!H^^6$V]Z<I;_SVS8YZ]J"*D:X-D^ !L:_!^#?UX\464S]6BRA(64!@(";,
M&:YN/MYH-&)N7_QA?FCTNM1!!0U@5'V$JI[3 /S(30RYDW#>_E@'?A,5L0L*
M[9/Y&4;\S@Q:7*/3!R*R@\:)#%F47G7@R7S&!@QY>8X^Q/Y2/$3Q=ZMSZJ:Z
M!@6:W[2$9DO,)?5W76$G5(,F[[",QS>CL;(=O_*K&JU@<UR $>9^F2.=KY-U
MGO7'UH'&,ZN_44?::%<^?)Y3G8/7^T/]3(=Z,_BT^E##$U8PU# =;JP5*'BD
MMLT%#ZB,5)-7DKM10YM=FX0&^3(%>C"+35.>M[P!KOFPXI>E!U:((;('?>.*
M4!/S&1WK3%]+MOM-/?%#3-D4?<;Q%;KI]>Q4.UFAXQ-7S- S.0_EX]R^*=K3
M J^E!?X$8HPRI;EN>F:8[9:)?S&Z';6X@8;>"J;QN*X<:@I7T/REW"_@60B5
MJSBSE/$UU3EK"0K?;'NAI54^J?7>4Y7SM-9WLHRLRB=MLK1ZA^F9;:L2]F3'
M_:2L]@VKO'?3_8F[JC?8GV-3?8![3!=^'*2/0[/(O<)GK(0Y>8W!,QW6WI=@
MMXW&5+.-*_$Y#J@J\9JBQXU;SO3F<-D<?AFH\A;F\!=TMC+!>_R]%*><BX/S
M- _D[O\M2N!S1XQDD/I@*B;@T>D$KRGZR'/KX*E3(AM])CQV'X(0W%$08V ?
MAR(@')4IK,@?1GO(2%1-12 _7/F/9)QQSA&D)O68[^%7/?RJ _"K-SW\REGX
M53OM1UCP@003%)P<2C>5<_[@N6XI(.';B 'F5(R=^Y:QTH?P]4HJ0(G<B?('
ML*%O/S,'#^!]H@G,&5N?\%R)T'[T%J1'R9"-*+E.'",J5#R78V(')R^BMLME
M"F-I9(M=-=XZSIM0+X.WV\*$4N&I]N.(_ZZ(HFW**.2UTMA4LAQITW$A*S2Y
M1:<MZ;][,XRD-VE[72AQ@$LQ-I^1IXTGI/'C%:#%+G]A!(V1[:BN%E]#<0M_
MX]QI_$[%K!U6WA6CN;HQB4%?L3FRVW.<[$WNO4ROWRWDWF<_U<=UU&;=VS=-
M10)2+<'<H&(+^V04,/F>''"#8K::*$\%I)0$@.)!*4D*_E8-*@KS00GT[=;
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MR-*9U%ECPSU.(X&Y-R99^A#EGQ7E//1A+@D?I,'.N:'E"1+<WQ+>TC?KOI$
M/HM30BN5OG1G-%)2P (7MK7:VFR?6L,46FCK_^Q+4I $75$X=I9,Z.P 6:Q<
M?/+I9" )W+[489DCFE^HHP0CRMCY.J\E5[SH@KPE.>E^_#)*JVN)C:?-D@TX
MJ0$GU7^<U,\_##BI 2?E66)RU(1RP 3$"HI4)Y;-DWL+4/A=8^%S%4?(IV>2
M/::LR6K-4)HJ:NP^TBV"VDPH+>]E++W&&):B?$P-N7,AXVDZ3CT5'*Q]E19;
M:PV3]T..YQIE86].:ESK:9E3>+KK$_M8T_K*J6P@/]+K9,%SNH8Y2<NA_\N6
MHYN?LH/Y7%/8>VL]]Z4[K+&>&6U8R< P0>VJ%#ADMI+8VA5E57!;KKM(Y;=(
MF_6)12&O>5DJG<'!%6]&U74$ ]P!]S=8_ZW6?],)Q)V:+&>L]JNKJ6*::?JM
MFX)QI4\*S:JB%I@V( @D@W."25[E;-E1(/H;8V]%#VK@HT81(BP94<LW&5&=
MQZ4TPTJFEL$8:YL9N&K0RV$%:-VD\=FQ6R9R1[0ZG+;VFE3,["F[I!X8=-@Z
M35NG-:'!CB1'N1=>CQV8_],/IZX9%P83N#UQ5,31*G)*USUZ$'H,$=%'S%"A
M!0->+;A1<]+3E%('TV\1351)OA;F7>'"_)Y^%F&WQAC,0S7)L4K>D##J&SBH
M>R2YG]< ;&QO!O,LG:&@2FFG<U/9F3XEUHC:WCERVPHNEO)\3A04R7AN>[-Z
M8 /=W<W31X83J-"(YD^@;!#\=Y/9"KG65?/1KGO.\2A6#&J7QG3I:(>X_("^
MK1F(3]/=;)?P*GI\F\_0*(8=DL$)?&"S<K8CA_X6*>Q6R/EYKWMZ<=>+"/LZ
MA8WF9#0!!Y2#8J2=,+XUUDT=E^SXP<WD6=@=,ROSB;#M).DM=H_*^2_2((BG
M14N!L6Z*/5L$$C',;;#HOK%%9T7!+IY9,F>]J%^NNV"/:=H]@P(19E=%D(0&
MGH.<3,%DHVXQ@8+WQ&/:F8 1V8/=6'H4O"F<:B;;0$/3O,+]N&2M4L0V&(D[
M&HED<U&'7M\H<^$2@QDYF)&=FY&O-IJ16X)L!UZL)E/R:8B?=S E_72PFUF@
M1D=B)?A;DPX.S!QP0[<HAH,GH3HIS%IP-_D#]<5MD_IG2C3C5RN*9<(F*7-N
M0X4FQ=F7"9QS,\4<BG1:\B-T97=NL2;1##0-1P$Y=Y'?>T7*M6<=1#WHG7:U
MRB:?S7OVH(5:*$SP]DCGIE]%.?[[&30&/]+N\*46:*O%"BSY]J/?%?I'KX37
M:6.A:_RPN=O@D[1;02O3J00/T<3OJ;R(/JN:Q_),>FV0A@])\I)IC4B@KD1)
M58;$)=1:T2^T:8:LHKE7+Y)63+(,^UZ3UC-.6,.MO"81=UDN--LQRC79F]-&
MKY)" \B4$3?1#@39$MGFRE3*RO#/@D#"1'A YB?B3-E7M,84,=F2CS+%1+6P
M?HJXN X'<E[ I)8I7(*H\&F)ABIER33?B&N,3>81%H' O.CV.2!W1<"LH&8R
M\9WFT1W>*YJP1XIC9]AB^SB;LOAQ<!"/##B>IPC/Q46Y,%UXL('B)%L:AZK5
MK'2![VL.XO;:E %1-2"J^H.H.AH05;U%5'D.4E?],1#L<C[5'/0I>/SY>@84
MKU*T#1+0?U-B76'6C^L\\;!V/!O.BPD=?.8$K]!>3!22(#%P;"T-E%! -?98
M8&*E&HN&MH^=48&U4<ZEC$1WU?:XL!JB1?O8L73=0H(Z.L2U?-I"TBY;W?Q5
M,33[OW[K;?JC=5L1+=M]?\'7ZW5-:^@5/1=1!MQ//%DX%04X,YS*F!&RU3A$
ME.$ @6TAGVBL S?I(^S2Q38^N9*Z&[5H%.L#,,,TZ)?I-)DD7(INH+CP4\I+
M5M15D5%+C4P3_C4-+XK!/<$**.KQCCH0AW$'VH^/+9:$A'MQ8K0; PK$7D@_
MRM#56PD'=BT<+>]>4=ICY9QVNF,@:ODZ]V(1+2P!([[^6I^K2?_"!,#@[[)R
M'KNCU<2,[8=&GBW<N22@TR;*12<#$J)[)T#J=F:ST*T/!H]WB=5H^"T>%)*_
M7NGT&(&5V_@6G=FI90;L%&W)6;9UR>%W6<W(T>^GP=ENU_Z,IJ$I.-AI[S-,
M>,5QXM;)NP'::D!IST^=]6>.QW=9XQUH*?_DJM-:)M3-K=;I/.E^V!I*AX"P
M%XU:+.>1T4-5!/06*1,JG2OGDN*0# ;='C3JHIS/]-VCP,\.A&X0GNY"^<V8
M&N/NBV/ST-#\8? KTP)%LO)N0*VZ< XMC,B#:5&4ZJS0;J2ESWINJWD.YR!U
MC3:*!'L7$AMRGMTDXZ2Q"2K.^]]PAD^$J[F2$(2?8C0S;.:#-G;D!I-P3608
MC"&RP3"X"[;#LI5#!,Y[]5G;7: 02A6W6T8ATP=Q#==: MS0D#)GZ=Q35-BG
M'>P< 2"T<Z)(<9<VE"L%7L;V.T14_6*)EJRP9\5VIEKWA]67:!+#!\\,M+!!
MYAV^7<*N5+?!XTAWP[9IWE^ADZ<A)13?6@U$.4E]?C7VRV:!%(&:J)PR%0Z(
MI7XD'JRRF=,.#C>)^D)O6TA&XD;%>%"-:@FBJ1 [&'EL2F2Q]->FF?R3NL4O
MM]4O O<$IZEMZ+9+N'WB#)&-*0K\.(L3M0&#:.<Z=J9.CV6L5G=*I>[@/2/,
MEQ[</40#"UZ%-0/\:!:"$I;W#:\BY9^KZ$L0L<5CN>R\-BP)>'9+LEE 3RY7
M.ANG58-"M3%1-!6^B<,5J&,)^WD/"K?S-+["T>@F9'R0)"/>*&!W)78;M4T8
MR[,69XYEPHZ&V^C[^!N.2(O$Y%[IYJ%+82SA;H0)2PQM^UMQJ1OK?&U2W-'9
MZQF,*;[1O(7 LZ7"39UNK\#M=',%547HB<2Y$ =/4!Q (HC&YT0:,-OH@VZQ
MB&$"]^A\[+;G?7=FGZ8F8 =G]A,'UT_2-"MAI:DZN%-G]B.#N,::D]&GFP_E
MK--]Y+SVB"3]25&4B!!=1L0WM,SQE 5/#A,8CJE/_1CAY> :KHB.> ;8)*+M
MX2GBFPCU/BC] D2+]P<R]6*Y ]??2Q<&,)>BU2K"PS&04"+\LCOX7M7\H:,8
MKT(Z=CK.@Y,.USLX.$\34F.?:*$N9:' HV.V>)P]VZU= X_QE"-M@T<J:2@&
MI:LOM-ZN+6SZG'PG 9#]?KE-1OG>>QT"E&Y2NZ-P_W-"DA&ZHLQ),H57]#N&
M\GM+$4LH#KP8.&S_L_YFMBA'=5O-K=&]DA9&2HLRE7NN"=F%%/#1,3*P>59"
M9](0QS-%4() (]O'-'_7SK$V\%FI9"V^ES\&EVW8A^1%PF37T&0Q-,F;9&HB
M7'?83(J,NB>9L0$R-D#&]@ R=CQ QGH+&>O&Y^I&T[O%)5%=+XLFCISC_UMD
MA,C%+S!H.Z$P$Q=OD)LT5M5\D<F-[;<%LLZ"[$=5C^?I]*"HA\.YMEX%75W&
MLDM+=L<4,7":%N.E)<E9;1('WAQU*S1X^TCC[9UQL#TH%0ZUB*<3X*K4$!C"
MT5CSG1%#@(ZNM6U&WRR*$"$3%:M*&;43>5])6N1@?1_(2GEJSTJ@!875A](?
MF+@DBU$!-2R@I&#22@^%E=_Z<JPJRQ5S*3055<!(;DB_G90S.)#H]F\5*-\Q
MUAWNM(C<CA$UJ\TULK1BPQR0D5D&;S*-2'UG&!S-\F5&\2C#VX@Q)U-ZU1#1
MS](=Q+4A_1!7DZ$(AI J*MUAJ@ZMQ2<A1T-D>HVBHM71:4]SX<ANDZS$: NY
M(-O0P&G_YR:Z%9]#JF;6ZQF=/"&<EM8U!1>'$_2N&LO6BL0;,",BX.J\I'Q:
MGBM,TNH\U"(#J9B4\&FZ\N[65 #E.Y).B(K40@(K<L5>UQS=-R)?B# -RR2*
M]E"R@<4%5K:W=S^*C%[$A5SB6.45Z_>D*EC8:I])^DC]H2MGI?!.C<$KA'\<
M2+X7/J"_83<3H9_.!WW2!)_U',>IYA*XSC%^1[7SFNHSQF'%)<UNX0(91VL\
M8+W(30[P5FM=GX@G7?'MLF6ONK'$W?Q'=^F/IZECWR[]@;.P59RJRW3(=C)U
M-,!(-XM>9TUQ6D@4UJ5F'/'3W,CWG6;EKLU1).8Q:%"T3&!E#5$*!G/Q+'D;
MK2(OK(@?FH.ALL_XF# !3HO *^S6=!Y<>#>FDEHR_HE!@L^-]4]"!@.&M4B5
MP5*I_ 5;G$K<(#RRQHC4F:R*D%AUBDF>+/$/,=VB/$&.J[E:,9^5&(]@?V$U
M,M_M1<3,5'#=.,L^OPC *U^NE!"8P>2]@.,/K< #GKB8JXXQX,@)3[0<NO=6
M^ZXB+36%3\Y@"(? K,"%;S-/JZ#@_8Y^[)1_X6W]Q^7;4XX)28_%D/R!LA#F
MME@Q1Y@R.P>W-!GAB+<M1#W9 G=ON^*GM"J;MJ5%D C2Q-:^,+_  =X&B:6Z
MWQ,]4\]5=I:FX?$*T_'LX.-BXERF^(\P\-N@YQ^?3KFREE 50DS'6,*9X!CE
M(,@5J6#F@-"EFP@8]?G!,*A)41CDV\HP+.2[$(U=PZS?XU5RY4B,M\SF6*)5
M;&DE'?<@!MX3D^A83**>-<!>9Q(QWJ&X29:==O&TP]!!$=<LTJ%UHS-;#YU9
MF<0*'U#P#0H$#'$(#'?$W* \SUG:5\P%25178'20M?-!T;7!'UE)^^&,[(_"
ML=9@G#YB'K4JS.@]C F)4N<JGBF#;,^3<:F-.2?>H+M]HUDW5GA#,^)OTN6V
M)TT77W?61:^EZ>):AX$B*9=D>/;?7QTH_OQI P>@+Z+VYO#'-^M%C84,#3<L
M8.C4*Q6(((<>?41]4SW0%EV&I:*F#3&(\+N-T+MO'UCI2"4>'?[4"LW+O$EZ
MU8IP,Z7TSOG$[C#&$C1P',L9-G5<]^+##,<?!=LX/NQ)4,0B$<<;?MH3SZ(>
MQ.Z%8V'J*E61Y!)]X2*']N#[U"2K9-IQU7HPQ17#J ?SNR'5W9.)8\7?IWD;
M0(D#*'$/0(DO?5D:0(G?/2A14NBZZ+/U"&U!(5'6OODK36'O)# 0*^"D'4S.
MIAA9:XS.<J;0KAW;?3EYD&(_R>(>G#L8U&&^<H_SJ7) -M#;-D/3"&):7_W0
M O.<OIT<8'**Q)'# %$0.!1NP:-#1U5+AP-#U5&R[>'0*%1_AF^+& W\()DV
MOBF"6/!M"2'AT- TOI5.(\2EPY3=(/R8G:.]JGF:[.@JP6U!NF*,NA /P2'Y
M:.=?R-P%1%HNW<"D^GZZ^ISV1B0MT(G@BA['Z$+3Z @K]^DB*;?& E\F"4;W
M$N$['C.77JWZ%!P&Y\WS[2R_"37*[5NG,\Y48>=TBPEEP?SCZE3WR\ QM":'
MDG5J#)]8K'^DI0.HBA].&#%DB,/1,EDUQ26RBB]0G:2V6VPST(<LRCHQ9+36
M)N$19K5Y\EG-Z_+3-O.RCHD *(FH#ILVJ>:9EJ[ ]N5$Y89,TT<$ XT_%/\%
M#AJXQ$<*K#O>.'!C@9^54ZX?;L\90D(1I-F[4PAU%S&K-^NLFQHR6C>I5K?1
MG+D(,5$@TI9H)D'495^AM(86!ZTXY]!HR4W!K>IBROS3NA';4KTGE-'8NQ_P
M>H]JM<5#<<#3S7L@;-?9NL,28@0>],)$"]FFIK<P6UNU](PZ,W$#!&.F5(>_
M\=6U6F=:T;A@RDLD'>!T.ED+&#1S6X/8$#-FVPB8NH69HB_6I -K-7W[8ACE
M[,R9+F_:XC"E+E<&8@XC]'7USJJH-EF,O&J8L</@HH+ZYU)7X2[2:T@)3.3K
MJK %^!6M[?.#EI$8&-5W9^A[?8[\I=Q5PET@= L$NO*3+;-K?7"K^Y1<&_<H
MN?;#R_7)M;=>$LO@8S#WWCG^4U=!^M !V (6*Q!JT+S %Z,8[<:"&>29=,QT
M"9SE6;D,="R4JQO)CXRS)6;>#$N9H'RJ +]<S:+< ,8>#Y1D>B06JS(F:J\3
MPF_ K?"5J@2CX:ZH)8=URK[:I6U5=F)XOAS"*7&WJA1JAC,PFLUP/L"D,\,W
M[XRPO,6"(*NF:&VF4BSR47&MU&$]3F]HJKNFBLVIF.%%=CLJ2>A'\_YYI]2>
M8TX/7Q* @<MN77# :(_J%[[UX=3L7)Y<7I^?OC\+CHYA8[WY)?AT<GUV<1V<
M7+P-_G'Q\:\7OW_\*_AP<GU]=GG5ZS[L_2@O>IH*C^W+BS[>85/L[B"+ZR%9
MCR8F0T9TR(CNEA']\?EE1/<S_=DC/PW4]SZ5Z&G2R5[H^."DD94X--28.OP_
MQ^P!]F.ACI9X"[AHE:SFDFTD+T45TGJ+N:DIG8R%]_"3?X#G]^)WRG<R4G*:
MY,7*NA-8OY92]_.8O1-FV(&/D2(=_\&19?R7YB>[PWP$5;\[8;=KE2\PZ(07
MI?!N,/XINF_ZA7P>_Y,I<O12"U/)7V";:>KB@ND%C,50X,@R^VRF*NA!WEN_
M[$F>$(I5SWX/D@]/)W(<$90\Q&FF>_S9S)C4)L5ZZ=MFK8\K*B_7AP7=TE4;
M#JWJH=55$=4##BTA3>[WF:4LJO_/-+)8^W.3DPPU^_.S.=;D?;Z+4TW>=:\.
MM4>6MYW/M)8YZ^%R]N9$D^RTU\6DR3S0:Z%SV7]DL'K5;SESV/UD]VZ6M[4;
MAN+KFMW0H_+2378#[XG]-QN<'W#6_V]\L0?H\B>W&?1 U[O$%:M!/F%0:Y('
M5P1JP/0>3IB ^1 3<@/OQ6]K#9$'W8M4+=_M.9DL_IFP%Q;+HXGZUY@MS?/6
MOQ7MT7'J]#VQW4S68IHL<\X>YH]/F"0K..;\L: /@M_R*-5@ Y@0Q/6#OK@?
M>428!K<E??)4N_U&(MPBC0]DI)3FSX5N!LA-%\O4@8'CG6_4G(\"1LZ)MH_5
M/+K?DC_CD8VGKZE"[T>:]VD"+MNG>3_E&78$-]"C#Q&A0C7K>O?*94LQ>U3L
MP".)69<,,,=]RD=M8H!I.<J>,)K[W'A#7W;*S/*RF9G%Q%LX%'43W?*IAS$I
M-NGP(-(:25E]%#5'DD1<MB1R>K/WBWK<*2*XQGO&B& L,K),-F!1-\>HC*<9
MZ57\-OKI)S(X-K])#>>#0O+BF*2D"DZ)"L5ZJEAU-O?_]3_!)>T0 VWE>25?
ME:D3$5J\!W#,XU8XYC&<6F)+#S+RB#)2:)(6K$RYKV:Y=U/#+1'H)T#J.<J\
M-T=_;XR]'N5Q>2(ZW\ _[-T&_J%] W_U]DH6LR":K_Z__TH6T4S]_[!,?R]G
MH/7S2>TC'Q>[_/(0!.K13Z^77_YKDT7V<O_M[+UC0.1]:2I[WE'<GX2NEXF1
M9H>!LQ7FJ!HK70K*H0Q;B(LF*?P0N?+TP57=6AP+UOF*#15$&/ZJ7W*:+; Z
M57K\$)=?2R)V7'[K?E4[UA^I+R;^VMWR>UY#_'=YB]W6W."G_O(WRD\1D_ X
M,U?T("+_Q*==<WBOSZ==\[2UG':]2&6XFB<<R/J&TI0]*$WYZ?F5I@QD?5]9
MVYMGY>Q&-\4(@\]*+<UYZJ3[N(.<(BHC2I>OR0LY" C21=QJ-5>KS%>;9'<9
M8MC,/':2+:57!UZT@!M0%SZO*V3!+"I$7\$!1+>VW*V>'SS-Q_0TA1HM!Q50
M:$(ELT((J$EGA=C<A/4Q)'C^(N'Z>BPKE#F.BJ#(4* *(BKGS#=J)FQ_BKU0
MZ7'3!*D&D&$OAIN&;% +0XL6H>A!/73EM0P%#Z.!+*E,J UX>""FQQ.D291'
M&I?)\!GJ+J=R5Z]UZE"1\.SI3GZ-)I_+90]\YW,#P8>!@L@6&M+1$L+M00;F
M.:E,PIL1-5<:_%V"QQ\GDY51)L)--F&^)SP0$UX?TIY,(JC[5TV"<5D@\6(A
MVDT8NE3,&C=54Z&0K,<@3(3B8(@OU!B+T3CAE=#S2H< \LK,[PUQZK+,D2:+
MFBN<C/1\F[X.2VGWJ!.91$?:OA+4UN%7S+S V:2(!Q;;R=G>W^8'E]E]-(>C
MB["R.HO:>E_;]4$3U2%5#H,>@R2'PR]CDIUY5M )SEA)?8&!.UHZ1.Q1/8^2
MA4/2-BB(1U80-*N^=B#..\]<UJ:R8]KXF#[+_&=PT].JAN%<L%PIK><3-G_4
M+26,P71C;95F 5KO*/T@&CXIGFLC!2GV48]5%.,K&Q%=1O=L7.5B&-JMH9!!
M!PGM$(1[FR7Q>N$<'59RDBM#V6IBOG0E1U#I>$-,XQ@67^B0-X6!![%^=+$6
M;F#U94FP5RWE1..=WYNZ $_L*PXB\G\SH-N*?#1A_\\3(L7?:2FAU09#O&W%
M$X&),S58X>*,U1=]*6VY:(E-<!E #N=P*81E,'AF,,,+Z2T7RWEVK[B8@/D:
M)]BPC@;WA:TL[B#:<D>D+RZ:7V4SXFF0V,=2Q"MNT*J9Z!QA]<3TR5$(>X@Y
MZ%$-V": Z=H$4O_!S7W@F.MYY&"?<O#5B%+?D_ M>+%=L_!K-V'% D3SN"ER
M+>?A-PA<^R_Y))'KM1/2\T"L+,03QF$KR)5'#<,./5V'..QCQ&'UCMXV$+M.
M SQU7-&.YN.I"6(-T<0Z6FD,\Y^E.BPXPVI/F$E9-(HUANTA'^EBAM5U.38Z
M4U)H%U5O),OIG'3P=3))EGQL43,<<#21S"59+$&!HSJ=P*A"]&_@Z(KFI.JQ
MZ[K*)W!J)/^AO?,D <1-@MT6#_-/X1T"8KKVOX_QL $]-*"']@ ]]&I #PWH
M(4\D'A#']\.[WR:,OQX._+"P="7_L&-<6M[Z&82E[9NLB4JO7X#'C;(.()E*
MC1^&7G_LR/ZMU0!OSS5=!?9W6"5I=SL9P$T%D ?-"FJTSIMKKV( :]ML]&:*
M%[(4L:=8VW2-4*]5 X<TX$E6<.&):+PMR^&W/=7ZNQET'N*GOL0J-F^&TRQ;
M*FGT=&EB@:8TZ=PZWCW(301_XLE=E3GM>N$YI IN"^F*ODC\6)%XZZU"33?E
M;#%=Y_2M8E5,\F1)LU*4%$2DPYZ<2MD;W$)6>+L:9RQSOSA/I_-2I?^)G.(L
MW-)\&]S8^E:M0!NW*Z$E)JL$I4F!2%?AX" :F0;1"7GPX$(5"9Z ) .5%EA%
M,,,QI#H<O!45#\>YBM"T=6;CAF>*(D8%-B?$;EKU=H0A3:OZ$H'5@*'>>^VH
M4L0 7%S\&2@,<IVC^4$Q"K5=D:1E9(@(L5\4\\CR++HV065)W*^:%H6"W-FV
M*W(P'G$017<<YGZ'N?H;E*O3$[-])D,P=. W$Z;GXS;04S(4)<8N4ZD#";Y8
M2V!Z,L+6O_.(.W=.,NJPYC5,W+"6=.LU"V4(72N[REAKX$DE"]C+-&0V\/0D
MA$('0>-C<U::L>$1$O%/RP7%#&DIO<,P!H&8*2+;HS& 0IG?FT",[&!B.ER7
M >$+FC(@"3&3I<)20==MF@S73/;S(4O=V-*F#HJV1,B]Q$UI0DQ2P<L65%,,
M2;HL5R:_X+^B9$-\MX$,!G(=D'B07]$>_:%!&I(KI64ASLHQ");>B?!+:63+
MBH4":_G(U8)CY88%I:TVMBDD<DY8XC1+7Q2K:%524SY\P%SW2B;'H2A*Y:7Z
M-HDB$7N37JL(I"F>7;MM;3;'DS4.5\MTY0K,D\^%9N/,\?R,W;?&(!(,<D:1
MTPE.-VRI+*!3*)%?%1,X7T-L-9S$M.2RV:5#=,AA/)1#G(K57%@(R;&<3K&?
M83HA"O/8ZV49/>2U#X-WV7R>40M4$B X,/1105+MN<HM$JF/$T_;K]TKO0K8
M]Z:](;&YWF0);SD]J[#NDJ'9:G)9:L>D1RNJ@BQQ7-Q<[>#9UH)_WU/#NZ>!
M#VW/A/AG"F*=FR/KZKY8J47_L4$#.7DE.O*R,^;#!T1'WJHIF&-D470:$#F-
MEJ34D70<S8\B* M-A0Q^S'ZSBKUD3K'&#<[94#P%+(EYC(OBO+VE\_;C10L5
MI03#X?2AQ#TORSE#A*B1;"PF!'X# Y@F-L-[FI4Y<27KKM'@CYF\I?SD)$9S
MG9M#PU,QF8L^,S*?!V^"/THP_(Y_.#[F^$^!>9JDN.%;T<_-R-&0:QX / F,
MEG=JG)<X.\<_'+T,#C[^$9P&1Z]_"N'OPU>'^"$83X?!T<B-9;'S,2XP%(!'
M)3PIIKCR=IT5WAR^?CB%;X<AIY=]HMO:I&&:UIS[]7Y<KEY\+-D)_@N,3?"M
M[L#I 'F0;YC"^I(#/=*<@+?0V70*&N&PP].1N[K7,BSB&,K+<M2E_\JKO4.U
M(43<CJ=YM(;3;UU(&R-79 )'J6?PPE>@FH*,I 26O02'&Y2>GE\".N+ME-"<
M*VH>KE8:U=*F]3B2,\_BF1I:_ Y(B+XA(5X_/R3$ 'O8A8^LJ@3OY'A$_0@*
M\04J1(I=2BI?-QMY1 79T%NFFCYP+#'=BN+-2[QKHYUG;4$\/]!*#7[20]C-
M9N6L $;!^<S0N: &$\& XRHS<\CG-YW9;D%U,VY"1\PUQC*A@!FGTI3MCM8(
MN!#,)05UQ+!F;#N%6V7DUF*NWX.-B#UQ@]99$B^U+?%0DS#8PB8<>K$^V*GH
M43W=)J?BS,FAL;YQ/.NB4[_@?!JHQ#:[P40"]C$K- 08Z=*Q+@;Y&%@5P"O.
M'>V0(K9[BM%]?K^&C!5I='\*\$:5 ,-S\#Y>B??!;^0L^ZB2'M<3;;(=+N*:
M_IC>5QL1M9<A"4[-HK1IWN&#*1ZA!S^-@E]U1<-;L*T",K1TWD@ERY4Y,G@8
M]K@Q+<7L^0%G=X(J $=(B;O;*)G3*!0F+^2D]F0"U-XB*6S67$2'GEB1 FE%
MQD<0OYB<FI);11,"6S&9Q.5Z><2T$D$C<C?!M48,>07&&-;BQ")'MJK&Q7.5
MTR&,_K#SZ&D@AMNE9V@:9&V))>?L"_R[T+&0JQ(,8UIM$OL\6XDLGZ(+.D4[
M7G4*I/JKP55HIW!J8[WV^S-0XER'BPNGLI31'[KKBJ0V"28C'^$$*CV!'@BY
M\"9R:2=R8B>RJ  "[)TLB#'-[E!%"A;:ZE,QQZ?EJLP)IZ)R19@?X]B8VIRU
M<&U](Y %T()9?G_8,F5FMFB4/.R!4N,1*348R6_1+T;8P-,SDJ$/I@J(PB?2
M&I;E,9E.=%](:Y15<9R-W2(/+<*KO09_ WLLE25@D?B*L%C9F-#19-D8B:C6
M6VA\&?QW0?U#BZ18,5PO*GPGG0?H:BWTW*//QO 4W!7\3N8BP];/*&@"@XO%
M,D>1]$,JSG@-KLX9LT_6%=T3!$Y0UP2^9"5L[V)S9.Z-'JKBWJU!C]5Q:*TZ
M$#^C,Z!Y5S:X.P[(R2 [IW+.X-T^1/EG11Z5@.VXT!2G7-XBC18T6EVE6>G0
MC!^X/9D'F^UA-MO3(.%WM]G>PV[&1'DOV4VV-K9L%^E@+B]$MA!_]D(SBE2P
MJ)=J5L(7",1T.3FF;B<10][Y(,T0:M@S;?"557-H\Z''MQ+5Z2N[K76P4U[M
M/\BOA*/P7TD.]8UBA@'I/KSWD=.?R+O<[IQA=A5GU2_9OZ<R !/VV/8TDJH\
M>J (7;^58S^PA:]ZI @=/>C$)?H/+!Q(Q[:0LSYU6=Y<B8FAT*XI<B)1@AP<
M@!/T+LI-\4TUR,JGWVV2S6WR;O 4']53A%,M"JYODCQVBM0=&Z1B:IBP3F7E
MSE-==!&<Z(,1QBF6A_^$:(;E?X/3_]A+>:"BR0U6VP3==T0[=W9R#_IY2;9*
M4 0HA,;H!6-W?M^6H;)A5?JI^U:ZSLY+='%4 K,[1;E8H&DL7($@7(KJN4U.
MB<LH[8 29T?YV!*F*.SM\@:='RRF:UN_Z?YZPMS[JD_PY4W,O2[2@ ^6?O+U
M#FC5 :W:$5KUS8!6[0=:M4>NJ<.'76G]?5SK_'W\#1I_=WVP, GWT(;^D=O0
M/[Q/=SOE&_B;F S*[E).$QUD>35M)('JUD!W+;8]"IG>(@O&7*9/'-3@SV9S
M1B/7K H.MM*G TK@\5O%:(^?(@4^N-(+, 0'40^\FUHOKU,"[2=4@]D[S];0
M^8(($YE-7)GO:F1F3%E]?U4&>?]Z>0]JG6:L7!,ZP (]HWJ_N#89(PV)KG\P
M@7<.#E"Q$8KCZ!=:]A%A)!*/*MI /0N7VBD,2B*=P] >S)X&:Z#F%6Z, X-6
M:-"0H)<U5Y*5G+IXP7#ZM(7K+]*#3>LU[<R$*!YG-%D1KV"P9O@2GR*.ZH?Q
MO+?W+!SHWA^A>>17-HX<::R[3T#.$'>=/8E!^=TRH6O0$(O3AI(;RJS6J]4"
MFKC!ZX=%EA/%GXKR>:+@WRVTZ$Z_$)<77<LT<R6MDVKI.Y*C5@>SKKC1TS=7
M,RQ!R@.T]CANP6S#H59'FAAWH6*&]S<$3QTB*4OT,'; J7R.RIX4F]1A_S4[
MZ^\RGM&XS;X=PY#5K01TU[^DX>\"!0TBA$#;.1\'P_G[F/:F;,J)Z7V THY@
M%5W6N*:!+A)R!'<W&8J$VZ.3JD:J^0+CF:#P:#S-(KJ'HQ;),]OZ%.C<@5.;
M0?L9!K1F\ULP9X5]2F[/Q2(OG)*0<.M#I>J%-5H*;"5L&67_:6BJL[]-=7K;
M,.\KFI1M'8+XZN#!VNXG>^8+5][ANW&(-W6PV>#>[39M@X_W>*+97X?/= =K
M\OBV?9GGZQUL/0/]<!7T:GZ-K[#]HK<Z#BUZRJ.1WVP/UUN_-1C"'GEOU1+6
MAJWC1:VS@XWA_'6&<+6J:4M+>.MY?Q2S>&CS-< %^@,7^/GYP06>39NOGKBK
MR E[,.G*7:W1Z&[NJ(U-)_#@<3J7]@<XIEL.K?!$PY(J"FGWOR)J':7N*^:2
M0M[(@\Y#E\=[%[H\;L=8,"'Q\Y".,4C'VDC2*#0$<9ZO024#?MZ$@=5% $<M
MMA8)3M(5-BH)WB9@#6*9P7467)U<7KTXS?[YXEA(*AJO@E$2@0_Z$.P"+:/5
M30:741>]+)]%:5(L"K9ZB1AM.S;C-SM5-?6A4NX@Z4U,\N?#UZ]P&A+K)]^0
M!V+JTT4<N+.4V]98Q9[;89PM"@*ZF3:_-9'YW#DUFF_N!F? E=2RM*I)W$JD
MBYVJ CV&=;+5TH?N83'+'>*51.+W[:',^[,7R.!).ML,-8OG]>%//U8V0U6J
M'[8M>KPEZLFV)]X0>-WS5?3=27=-U?]T^/+X<50]_ZR/TERC1W31'R26FR$1
M<+^M U7+,B_*B!F_^F\\KJ7RZY-K\9Q0$7OC6FPC'9M=BU8NN+^S>H?J^HX*
M30]&WK]R@,Q-+6AC:L9M&7[O<XQ&V R.?^HF7MP!U6_9VXK&;FRT&HMKTV2[
MW&!PQ%B6&O J;9MUS(4(0C)7TD&9U\41BTASIG/#U:7I_-PF 4(00YT)D6&U
M1&<6/=;*T<;,034"H"W;YKQY'OP9!W%O3)+-B)A/NG,DG/W<@[=;& RK#Y/X
M,MJ-VHE%TIS<6KU-POILF.U?F2XY=?Y?.0:H+>L2$X?"Z'QK\^65222;LJT/
MP'Y/U([-A!S\#+A-)O>/"7:OKZJE:IG@9*MTAJ 4P_)19Q@D/$"6EPM/5^/G
MK)"GH).)_1&F/+EE[I<EMJ90W$@7%O(%C1R,L]6+68Z&;[;4EII_J;U""'#M
MMT5PP%1>1;_:IM(<P'!SI-OM4,WDZC91=V:B YY&_G1T&/QZ']Q%I!!-2_'$
M$OR@;^;97489;0*B1MA)=94GX.E,J'5)K=7* )=^5+CTLW(>J?09M=P@(X_J
M/)J(!M+68.##Y=&!O3TI<U#:B BJNUQZZ^.'#?C"0?FN4;XR3710#2+]J%7)
MTF]*&@ODB(O#L^YDN53PSU^S*(]#ZC^"YUH5,9D4+0VCIM1.?EBMQUVM+2,A
M+X>J$]_'5CWRL3?!>+2C<(7DRR0%G?K8S=E9RPS=GHMR4D\N.!_40N+P6D:F
M>"0:L\>. 2IF^0TQ7JAFF)P@\&ZN<!>H]@35 #(=0*:] 9G"L@XHT]ZB3+N)
MW5>:ZMUF\UM=MX'E3IT;2\\)1>@Z5]Z\^QP$6W.0V)*Z?O?P>59K".?^5L4]
M;M5BXA45&@*-*L)AM^K$+;-2VZJV_J!BC@Y?/\FR;]\HX$-#5\E_I-G=B]^S
MNU[RGO:"6+>/SM<QRU=G#0)JF,*>-P@X7M\@0 HF71IY3#!X75A5[%5NZWV#
MBO2/+,$40YY0_9[Y1E-J=US,C.]>W?D=+D.%-)W.#5TEO#MG>DVE[4*;;MC2
M'T*4WL-5[98KW5W<;P,UZ0G%^>N!XOP;'_7'PU'?1KC<M<1M'V<U'D<?3,QN
MN85WH1;>A1G(=<XJ779J;3;ADB;[W[5I:BNVQK@ADXF[$A;Z]>J\9Q^R-&L$
MS9LKT"W,4G(H'XN$IH7_TB#76CB6;)B\Q;+8A1JE_O-6=I1'X@9LA0VWD'NT
M4W:LH8]\) ([ARZC%>NJ%Z1Y,1Z?4>[E8QXYS[$AW5Y1S)W$?Y?4$:D7A\]?
M58A9BS+&4+6KD&MOX85$+7_06@5.D56\ZPZ:7#^XE?ENFSQET_FX[4&( Z=S
MJT)&66DI'C;W@&X]1G<^-ANUSU8:Y>>MFZ3V?-MW1M7Q -NS6<0[W?MG7R:*
M.AX'A5HA? >D"@1-(R&/C@]?[R$:TN @?=43.+IG1(W7]_PUQ_*:-4WLD$NP
M+=<L>F"LIG.TJQRG@PM_K/K>P@GQ,1^^%FM648,-_%@VL#9]]]_>'5 \ XJG
M1RB>(U^8!A1/CU \/3% CSLMY&S@BMN6VKQSD.GQ_AN?K21@+<:G:WN&>_^.
MZRS/;!]*1==QN+T^/":_$E^PV7 >A;U$2#=99B[8L H/>,;HIC<=9;[;T$UO
MI?0+:XPEX^"A#$_G4;+8@^3G@'.J25IG.*>&A'NO<4X_5'%.3&:.,8<47?,%
M$9'DP03W0G# 08&&7&$C94V_"BD/K:/;P22' DHF$A:5\WSBQ.994=!?(SY!
M\&"@V 11\'Q9SC-X13?YVMXOKZ$/"*NS(JQ T[CQ@,T'W"89A_/Q 5)B&SHQ
M*7,$XAT4R0F^6Z''Y ;%>X)WPDEO5^L]:,(AX2$'2K85GHWH#_(,D6C-;3-0
MQI8$6:-;5_9P"-_FW!R&H6R<R(D-7 TO;H.]65:B!+?[@N624TPK#PG'41P4
MY:QQ&)W@>KXFR=H3*-F;?8*27>I(-%E:\6!)[9LEM5<PLEK\O5.3JCE#LXTO
MNB92'S('TJV:9TN^'_?:O9?4DMLBR&TP8T@N4+>KU6K.OFO[\5CGN'$-#_D=
MT]3VRLB3@S'NDBF#CT,Y?==,L2HF$1M=S,\G_:)TLFX[]M\==%8O2B^%YMVV
MJ\*T'R:H,)GQ@NF]"$;BE?<A):4@R?RK&*W2?.6*;-(ETV7BC-,O/*)SWIV-
M%)D.ED3GTO0N\C>H!M@X=XDF&$2ES)/38]5)6+9Q@;K$-$@)1UPVV(+/['.\
MR5Q%,=,X2GY8P"ZFJYB?Z6T7P3YOX&F9HRKKU&.CI?5EQ5">>^MV<#)BVE2:
M<'\?5X66PX,@FB]\T219_A6<P'@!MO0T*N?T45)I>N>H;[:KDV*)2CXS^=YJ
M]\83)MJ%>X<DU1F<.Q60%,*JD'4TRZ5)7@4U=?B '>.2*XD?L2;*YC+OC>]I
M,G6$5";R#C>N#)0!8/(L?#GX:\%<IZ8MGMUZ 0]YKB@JKM\$1EU@&(-)=G(T
M*>*"E_S*-(PS,X-NC,J1K9[:]"&V0!65$[>  [P CXUT15),< ??PS&?@R6W
MK;\SV)]>)J\S!.E79/(Z-C]U?Z<'HS![:W^Z=H/^J6$"0%7+P;7\_L7X_H7\
M,QA'15*$+8$SK]I 8FW$Z=]2^X'3-R?F9CT.?#ZABNX=U6<&LF4RY]7^X[WW
MKD?;.[8O@E,YO[JM<940O!M&C>"$R5="_MNV3;2A1]:@<QX:\=01Y:36SVI-
M98UF(X=]MZ:PP^R7REE<XQ;W+C2(-Z\A!8(<#77CE.*+P2S+P R,4!&0:9QA
M%2^QU[NTC4:CL($D;A>'US5E/G+=3TP,77U9BI5,0.]B57 37CJO<2 4"9WF
M&=$!PTS!XJ;$3(TUW[CWI%.O,0&+QSZ"!P#= *#[%@"Z8U^8!@!=5P"Z;@YH
M5'Z6/:$)X%7L*3SHC4.T7(L#CQ".DY6SFSU^N7$%P&;>;;O2HKVW+SG[]7-G
MN>0Z@HBFX=Q)@U[=1&AB=9IUN*;Z!-L:R)2I.8&4,>V%9T6SWMIN(]SS-WO-
M;[:.AVM?T)WK7O,-OZ8#R*LJ\::8X8B:X0;8FHV0$QAS*PO'.(?[OZCOAH:X
MA<12;>K%.B-%$M?=D;9[FX JU0BE5)/DL0_IYYH.CP&V#J/1?U9JN6;43LB5
ML1<P-[KOWRI:E84&ALQRJ4AR7\D+KG*,G8,\2W1X!,2SQ,1"@GU(ILE<Q74,
M1R0V@H&HE$N"?Z@DETZ&_$-VIQ!&%M.HZKVQT@+#V^L7*K2__?IU:&)FZG/Z
MXR:[4[=]2'^L&D^46N%A&L'^4Y.D,)A EGQ3(*[#@11B-"&7L$UX*WO230_<
MW2B*W%!W*8DQAA($(%T(>F"1%$7U'AB_*\=_2T!QOQ7FT9$T%3&ACQ'&?%<X
M\S"C::R3)R10A:#6S5HBMLN:_[@;DK1:N2_P,Q=N9BH9X4>^ZJ X4\3:@9,]
M"(77+8Z25#=KPNI6OUD3K1AN8C_1Y?/,&$0BUJ5DG%5;YKBL7/\_S;";(;XS
MZ9VE;/%LNF7:Y<=NTBX]P90=_= 7L_JES,,I1>50]"Y-6.Y[0X\]1T88E+7>
M0/-?;T3FDQAVZL^]$_.TXKJ-J<>=;6G'A_+@T/7_S0:';IU#%[:8F^0$C%7
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M^._+7X9^P8^H?_K">+I-RAX>VAM'5*CT&ER*(IJST8_;3$G)!%<02.T!LTW
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MIA0,3)I,ME X3&+ZLK4N7ZD0%K[VW4M^!!33$-?W_SCSP$^Z3D(BC@>AG\#
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MS%MA&TYFXC%VL$$@(2FO8$#LPR0O1.E/_"SL3GD8IR@H(#YA++MS0]B2=/O
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M7)B@9;6(H10*<<D2W(0G[P.OOSYNPCGL09IJE@-U9)#I$!=8"#,6UI0CT&%
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M1Y8)(O?,&T&&\DUW^<B%+^T.D761V>/5S[;C4.M[V1LIA^A+G92-&V@/28N
M?IQ$@2UYGNU7<O=B]A7>"R!$;\&+O=,Y6+O:?C.9M&1E$76@WX($]0@I[AJO
MT5=*1:74E-Y&KMK(U:HB5R?+1ZYP6J'_7[]4R/@<_M*$<%>](:FWMG3*8CV_
M_'I^Z?QU?G=Y=GOK_,6H][4Z_1DK%VM!J4_8SV?6I-A$Q7Q82858]X*I2?B$
M-U5-^Z@T,3DQPZH0@WW[4ST9H'3>['1TNQW^WGK%Y_%^9W_W5?)S_Q \Y]U*
M\G.9QQYT.X?[QS6(9=C@7QI_>4\H6O'+K\*P>.VETV"6@$TZZ)0(ZH^W+H)$
MZLY;D3<^,I:LV%^Z_&;-;MOG9RK1TWA&]7F]"SQ<LF?_\S^ZASLE_UW;B=_$
M;6WH=NX?_2NE_SJ_QP^1<]IQ?O<&<3]=8H_7>8>K]F#6L]>7WCC(7N+%_E\F
M8K<D&O#ZIK:'VO\.(9M?G-NZ[ORF'(/LG6HJL6<]JV2=J&MP%@BIG>)BIP^(
MO:T)%IVKX3 <!$DUQ_>]1U= 3NR\]_#*&U #Z_#*"D)[X,6>XK[V1:'2H17*
M$N,;SY..JPO6G*PB6', EOHF1VOLTS>@YOGUQV]PS52_66,JK$MK!>8@<A,D
MGU<QSO\J%O ZM\9P[^ 8QH%/I:Z&MV:M>9)N]?6K9[5(XEW/DG3F<8#OQO2P
MW7[Z;_#DI\'8.=SI;GG;6P=$?HQX].KXXUG"?@1*3G%/ N'"O; 'A*J*M?.$
MK#H,1PJD&-Z.V,#X55,D/9PE49@^6*W"WFC$O!R39Y7,BRFK[EN(/8(Y>\OL
M'PH^YTRR^YR(YQ(P2F]*EHTK:%1&T'4>XB?LH'(-8K(U1JPW4^G0@<W9-<5>
M H7@HX86PE*FG<4^PKNR!!<<N1>=)?V5X\[Q\=O9<PO57K/4[1*^0E-DL24G
M]@Y6[ \U98Z]Z]ZJ7;VF3&UK7KIF>UT3;A6M=8'*%"T</F?^-K5Z=KU%,<L&
M<QJI>==ZA5>V#ZV]L'''T?8B=@[?Y#Q*6>ONWEJJ6LNG>?9/:.H%HR!!T2CP
M&7<(U#2-D_E.Z4^IN%9[V@<LISZK;$NK/UO]N<&>:_7H\NYN(TH!ZXA^5#Z>
MAV\D?/<[)V]L9)E#W#DYW%3;:.UMU8T(G&QF?F'GZ!TG& J& [*,O]*F6\7T
M6RO/LO*.2H(D53>LM?;6:^V]F3NS_*.;;4C6KK:7,"0/WI<AF:G96W^M5E-T
MWJ;;(R?5[9']C;5';J=(?7X?#K2BT^5)%3-4/S_WUABQC)&31<;(HMUJ+9'U
M6B*5SWV3S87,C"J#2FY8<F4)2^2X<063C0]PVM*KVWT7,5LC;U$Z/B^M$I?L
MTVCUGWV"%NJ__'ZT2J]5>A\BV;+7;82/W(1*?LG/=]>#.O4N?=L3*N9WI/7:
M^1(3+S@VI:W:Z6M57$'%G915OY=M1:O<6N7V,93;_BJ46W>OL[._*NUVO.),
MP]+J;8]:F%=^T@@.9_%9VVV$?JLTT 4:;C^CX;X%48!4G2#.^K%S[4T7.G,_
MMUFKUG6?NIW:[)P5:+O]!=JN=%M:M=>JO:75WIJN['%G_PUBI,>'_-A-4-5'
MC5/5ARN& \\\>N,JC2S9NUNM0'X#)ZGTQUWB^0%,Y4<EMW45$VT=6?MX+5#M
M9FM:?=[J\S?1YZ\H\?K8RGM_IPTBYX+()YTW0&K^"#'DW:,=\K!O00.PG'9Z
M28+"=G&B].>VJ%6_1OT>[92H7WL[VBQIJX'7Z%$O<5$W,4B]O]<JS\8X@)NL
M._>0KNCERF)UTNF\;';WT^G5G^=?/G5/0):G@9<,'D@U? %!/XHG)+:O1U[T
M-FJ]M1CDIL"Q*[$7JFU-:T"T!D1]+OP[+$EN>I]34S3'ANOY:IK^W6KUSS/_
M/IA6F?YNYZBYTR_'??XYH+M53+@U;8QI\TKCAD]H:]ZTYLW2YDU=EWFG<URG
MUR\,P*V]]6;VUC(KW(1HD,'+.VCK\5]A)^XC<[OWJ])Y""I"+-%#Y!-&YUOM
MT<89.:MF_/U )@T<BD6-<'//2FO)M)9,;8&:5M^_U4EK4ST;J=H/P#'M?H00
MT'<OF@V]P104 F@GB[0EHYTV'DSG;8RDU>)N?" CB:[7HKA/M6/9&DVMT=0:
M3>_/:%I[G*QF ^FPLP?B<$M+OSQ:BO/?P3,BEX[357/QO#NC$V1S[7BD.\T6
MDYECM^ML:?Z^GSQV;8G/:^VA5"0 &A:\*0M,H_F[1-^OL)M@-H&=V]I-K=WT
M:L3!947<FNJ$6MNN+5ENXUA6'.OH71<R"3&[;\4-XBAVKI/8GPVFI&*"9  *
M(?P_5L5?$V\</,7)CS:@]483;DTZ$19'I5;<ZT]L&^MJ;;:?L]G6>+E7'1IO
M:YV:$,;;Y%JG^HV5338CC]^U&:EUL5+#WP,_'(!*:LW%QFB4]VXN'B\.^LT]
MF:U9V)J%K5G8FH6M6?BJ42L$C!T<0&L7+FL7GJA.2>?WVU-LU@+QGX;]<$1:
MXHWVI[49Y,"<S.F>*]N+UDYH[82E[816![Z[LG E4/<[AVW/UZLTWI[2>#=?
MEE!Y+0G+:C1>>7%,Z5ZT*J]5>1NL\OSJ '>'JP"XJXO\LBE18$O([*.(KW+D
M-VZ2OW]?QD]KFUU6H[3VRY56V5ZT2JM56A]#:9VL0FF]BQ)'Y9-U.]W6)7N-
M2W:D7+*OK4>V=N567NA6MA6M;FMUV]*ZK2WI;V8P\RV.['%MC8LUJ^!F,'=6
M&.9<%7RL5/#U:U5PVSSX:A5<7CQ4MA6M"FY5<*N"WXD*;H+O6G](<P/TY@+7
MM7O<.=CRM[?"</L=5UA_]M*@#[K#Z27]<,I+X'P)TPE<8-11>)/A5VT@^HT-
M!>NTE1@,%7>IM2%:&^)#A*@/=E<1HEXQ9?9JW:2W.+$'R,^^4>K)D#/N,^[C
M>YRDAB!61,_7WG0AX><'THR\[XMPFW.+UNK 5@>^5@=N$._TP4'3DK3=&J"'
M\F2I1W54SG:/2(8_A&":.SWG/ KIGEXG09K"C1X%8+Q7C;2V_M,R6L(L>E$_
ME&]#JQU:[=!&6=LHZ\IUSVZ-3#U*#'Y&A #/N?6&(#R]Q/^Y-K]6QV1TS.<2
M'9-;[E:YM,JE52[PWW[L/\/_'J;CT:__'U!+ P04    " "@/ A9#L"Q4? F
M  #^]@  '    &YV87@M,C R-# V,S!X97AH:6)I=#$P-2YH=&WM/6MW&LF5
MW_=7U'IV,_(<Q(#>LB<^!TO85F(+!^%QYE-.0Q>BQDTWVP_)Y-?O?5155T&#
ML",);)/LQ@*ZZW'KUGT_?AOEX^C%;R,9A"_^Z[?_WMT5Y\F@&,LX%X-4!KD,
M19&I^%I\#&7V2>SNZJ?.DLDT5=>C7.PU]@[$QR3]I&X"_CU7>21?F'%^^Y4_
M__8K3?);/PFG+WX+U8U0X5^?J(/!B3P*#T^", P/AH>GP:D,#AM'LGDP.-[K
M]X__U7P"K\+C_$Z63R/YUR=C%>^.),[_[.BTWMR;Y,]O59B/GC4;C?]]XCV:
MR\_Y;A"IZ_@9+1A^'2:P/?WS((F2]-E/#?K/<_QE=QB,531]]G-/C64F+N6M
MZ";C(/ZYE@5QMIO)5 WYP4S]6SYK-F%R_H@C/E,Y3#;@;VYYB0<P<J1B:9;<
MW,-%MC^/5%_EHMFH'_[V*SY?L5%G]0, IDSU\@&.Z0O_K7D@!>DUP"E/)L].
MZXU#6.8$H R'N1O)(:SBN'[L?IGRVO2W<Q/S-RH.X=.SW49]#YZZ;UB>&%!J
MP!U7 NZLW>VU+B[%Q>6K3O==JW?1@;_/VY>]BU<7[7/Q\:+W1OSEI]/F\U]^
M^07^W7\NWK2NQ,MV^U*T_WGV]L,Y//2JVWDG>F\NKN"K-Q<O+WKP^UGKPU5;
MP)_P[<L.#+)S\51<=GH"YFAW+UIO1>OR'+Z$;^&)SBMXORUZ?[R'_WG3ZM&G
M;OOUQ56OV[J$C]UVJW<E8.;WW8O?8031Z8JSSN4K7FKK;7WAH3_:P55@4?4R
M]NO[<ZLX/*Z?^O/]662Y&D[O_8;MK886G<NK#V][%Y>O1>MUM]U^!V!>96]'
M]>8<B.?!NW]0/SFLW*X'W_W#^ND#7(PY$,R1E/U3  $A=!4<Q$X^4AG<BI.]
MO<;SUG4J)=)F^MQ\_E3 ;X0K0.Y5G"<BR$0R%.^"J=@[K3&)[T]%$(>B+_-;
M*6-A(/O()TW;O$QN@IO@<TU<Q(/Z(ZVD&N [&J)Z10:>-1&(09).DC3(51*+
M47"#/%3EF9BD*AZH21 !@(=J($60"]BE^$<!WTO120>C( UA;4%8$Z\#E8]D
MFO6+]+HFWIW#29P<GXCJ6462"GC:'/)9,IX$\=0>,1[>.@_ME8K41)P7_>0F
M^S3=B%-K?Y:#(E<WT@!I)9+<;/KD=S'!F*7'FT4PC@$2']^T@4U=U80%!>!J
M)E*9P7J!&"#2 $&0<9@)( NIS%4JQ3!-Q@+IB1Q/HF1*TN(M8"JAG\8[)"&(
M[^]Q+-QI371E)@/ ;\#0_9/GXES>R"B9T-MR.)0#FIXIS]^*6(K]AB8].PY:
MM^V3YR"=FH/[RT^'I\]7.KR]>G.ELSO]5L\N0.(>XFE-TN0&0 ^4*,Z**$<*
M!%/= -')Z&"#08[@#L(;E2'M2+SS&R91E-SB2WC2?/)T5LP% * Q_@C4#=^:
M/18X#GQPU2/Y[NZ3=Q, 8.49@1Z%=PB@31R7^2UQ9\N6X9AR.JYADNI;!4^.
MZ69X-*MY_#QSCY=.E8]S"D<6$??)1D!W[?4<.(L:R#0/5"P29#)B'.0P2Z;?
M@]$T0N0I $01'T/)P,P7Q/EJY'*U&W=(3VWTX5YV/J*0WVV#VM&NP<$1*."&
M:2X/IX/PFL ]49F^8_C%N,@+X/>#Y$;&@;Y @3GK3 #L)8^%AR%#1IY)D.9*
M\J\(=GP>;RM?RPQNV,E*!.]H7G*OO%L'FP[]9GV)R- <XG\?2'HY_E\??GM[
MI)2!QE'>O"M-6)>*H_>XRFH8E52&\(5X-I)\PIP _HP5$'I#\(&Z5%[ZU/!I
M1-30X=*$T"5?H7> U91,)?/(PPQ'^3D39R,E'1(F.B0"IU:@/6MW/'DU*V 5
M3)T !Q7,"A<I@ZLWA)^G-9PPE$@:\=Z@AN),U>ZPG)(#@&DE\"^]<2NC"/]U
M.:1'"!<15+O/60I9SMI'8YG,"!2I#+(D#OH1DN+_*V26\QKIC:K5B1W DXC9
M:#2M:6%^_^"Y02[Z\+0NJHX9SBG)I57/#AJ[APTQ2HH4WCHX?CX&W!FAAA#$
M(A@G!9P.DBN:?00JB)I;KTJU%"%30)0QK:;$\DL %:DT,?,N2\^ TP!X^RQU
MY&EA1!% (YPSQ3\'40% +W=!D+A%$R*,B(1OEQ:&*%I$$7\8TMJG^HA@3E"2
M\%& DSY%C\DF )4XR<6-2A!)?1YZA3 &@GU8,\2W#SA^6Q<]_123<H\ET[:
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M$Q=0FNG=1:  =,^"^ HW<^.E[J6>^,>^F"QUOYKSB_FXP]$CB.ASWB)&>4"
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M$380,)/$IN - $Y6*.=Y$A@D[G9Y1";<,B0$-L&4Z+0B.H$%C-#U;^L9>6&
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M',AQ'S[M-ZU;V]N7+VGYOZFR"9?=JW V>!N4C8)J)OU)G\#=2*!+/#HG'"E
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M.!MA2\W68-UU&+3D/LN\*T-JF!>:_D%<8P3C@G2]=9)CX%E=EH70M:#VH:A
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MZ5<8#'[%-![X9Y2/HQ?_#U!+ P04    " "@/ A9'W?N7$^$  "P\P, '
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ML03[ )P$V+1!,Y$1P:"'*=X!M^TI!LS&Q@FD X#VS[VD_.4]2\Y67*!?K)A
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MT7U^1.A1&B^P=&IG]*>V3)K=%)R<S&OXL'>"IM('P[B<!C5SK?)@7%0UU5W
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MI.?;Z=G1AZN3B_>7R)[ 82KX1QVEF8953&W#8#Y;,3B?Y@Q7,XP0E*<H2ND
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M>] E^%>:V?0N[!4F19BS=9Q47"S,VK9]#^XG-%?G\C\+!241,/"9'EH_&[/
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M:UYAS%0#'5-3>:S.E78Z^-IIIQ,UZ:72=+^6J))0#LT/JF# *F5=)8]@?N
MY@(?+BPJ,!"<1(J#: ZFSHKQ2F&OHYRXFZC$&N-OPNJD0&4/^U_!JVUO1<>D
MAKOU,*G 'FRW[F3@_#CZ<YCI(M&KT.I1@:\N]S#Q,H4%YT.))]*H7:7.!C3S
MD\OQ 4<9$B0C@";D'\ E:J2P6>>@-3U)6DVH79V[HCU$9Y<2X\%MM ^/RPJP
MXP^Q7X S%@2X> XJ.[CVI\%6KY;:-JLT<PM)R8<EQX$70GDM></0;C(;S.WG
M))ZT6?Z^*.NBO)D/A\)892VY'YP*Q9*TG_.%&22&N(J(+ \G6M%$TLZV[2<B
MJU-8J%#0=46._HVG12)7#97>[M;!6U0.1F#O?O!?_W+PZB=](_T<E =J45;Q
M[J*M(13-L\5^;P^%]YB?'5PH"HK %V +G14U7FKZW8*TUK3!1$<P$JTDA)>[
MB_;(FM3[1894W7-,/#V.7J%-11M&QDH[B[@F'-E/^%#!]F:^7L-5&*9E57ML
MC3VJCAN8]JM<L5.MZJ)_5G$DC%<3'BG(^Z1AJFS6%LZ+X9LQ[@^U/7U=U=A6
MF&+,,5) P&8>"==$J"-Y)%!\^Y ;X@T=.F4F'\V9KKOJ]E7AN0(M@K%!5,ND
M36WK.[T??"/>Z1]AG]A")O:3Y]V;7.OAK+35M:97)$OIGE.X_C]'^>>RF=3Q
MPCW9F4)H-3UA.10=Y]4YNGUU3VYRO_7C6IUI)_8&>B2C-K@35:=:EPW,--))
M3F&](@,[-IY22Q7LOIC0R1]Q#HJ_Y7YAS$ 4)<@;!<: WMSV%F1&Z[Q53?[P
M)DA.0?+GFR#YRFU-S*/6)<O]F$4[%^@Y;5+-7310N1JF%-Z.2S!P&<B.Q[SN
M/H2.4PEOH)1+'MF4M<;$T[X2GC5I!PA_%BDE>O$#]*XFPEFY*./$'9/X79Q&
M*Y*P[7A-UT@&*HU,",UP?[;XU=@$EB6L'4WA( <84DCEA>8L"#]-P +MK>@T
MZP):_),-[F,RR5Y$Q:,!&Q5TB,5FQC5^A*]%6K8Y=BPH06,^<E/A*$:2/*KE
M@&T/]T\U[1S'?VR\:!SEN6:!+;(,KS/<YBEV'ALV%3N[AOM5C/*YYFXWWZQ;
M:QJF6]L/S;==K9#-2V!O],?*$*'UZ0^0D?<-<0H?,;[H::5V3MNQ3P<CT=>L
ML\W/?O(ESIH*O3*8E#*EB^6@15^V[VNS+^!1X!4K'3EU:*@K:C=@]^Y$6 5Q
M\X(W*=L=Z9C+M%*))GUNW62;E/LX*C^K6GX">L_TTL6_45,D)1(WS[Z,AXFL
MB<Q3:6.W!ODB@0EISZ%_((5PD5 SRJ[GNC;0T+^8%KL@/'J"4S<H9SE,4N5W
MFW?Y)[UYH^ MWEW_"GV3,0EH)JS8N(0C=/[A/1 /6 2)BC5<8!)A9["BO(VP
M:Y>-,8V+Q*&#E(F.;8\QHR,I2N1GRG:6D-]:>=# WNZ240/[+W?V#O#E.6%+
MBWJ"R<ZI1/KN#R)XM7/P8&?0S'NU0KI@$CP<6^ 301*\W'E!8GL8QV4#"H%9
M\1\(&?HX<W@R/ZT^$V^ YP9EF<2ZU6I.3@#-:R71[4@FR.;>&!*L.8,-5$%G
M^RGB.3/E'U)GZ@FXB: 5E6[S(.$95.N$56#ZXXP-;[8;32I%,BADG-M!X5G7
M35IVVMOB"TK8?;;UJ7M!S'^3^1DBXS;0O'JOJ8NQ373JH<R=[T8W+!F_H'7#
MA0+C(-?-.;E=)IS3I]RHDX_EIZ0P/FI\T1V G)DU'1<F>>YDLCLN+'5+ ><X
M*RI[:1>P/&M.M674N05W&:BT^=P:C 4U$\=!)2_'V@&#2=I+WBHD21>Q:SMS
M'*ZQZ.96U!<TV+!&H_5DV>\TSJHI;ZC"98')[4G9X0O"2-2H@+_Z)]^TY>8R
M"3O64L06;' %-G@QYQ7%&;"U%>@/--1:=EK5:AP,HOCSLV:"8;VB3- 43I1>
M /@ WJRD\HNR(MT_ $<E1Y8,5*$&". A'6!T40?8,&N 85>ZJ(&,*/:^5J7@
M4A0Y>DEFT6'=R"?I27EU077A5W'=KHUF7G(N3&OF2]I=439'_ZY3+N5@DTM9
MN</VBC1XEA6WJ'P(NU!Q?]6H"FX5*$;LY>>&9^0" 0IQX#0M-<0L0IA9CJ )
M08SU'3"E<[0+M/?.ZV8>2URKJ4/'^SNO@JUW$74(.5;D[H;!.=(B13$,?91F
MW/OD,+E1>!J<W"C=7A5.+C@(JFW&V&GO_46P-:]!6>OJE\'6K$.B=24,L]72
ME@9AN]JVKG^-XYA#FMVZ?&\WV%K W6?0G/G17K#U'NP9>-LH5T53;2\<T%FK
M,I"]O56)Z'BK]?A&P*Q;M6R O74+VQQ(^N"L\-BI/QC;CII[O;O<D%@YG(XK
M0C6F\QUP](!VKG0LO;+-F5)3DHIG)E5M+];D]6O[A4I/)IU^B"91+#W$*FX"
M5[:;>\*E?BH@"?Z-I36<=ABH^E8)]%N'U6S7:,T@WU/I EYM57EAMAVG794X
M>2:CBMD-GABV!=ID[?#1L,F&>/SC5Z9[&,\:IAS2FKN78=BLDH..F>!-*W0T
M3X33;TY80&->(Y/1Z"M>FI7DC9A:OT['RBU]QG,TU'058/<@5X3+,=GSSAZ8
M5P)R60KO&>D,/?[ YHN<=!R?W;,R=>P5$RY&@_*_+7D7ZB:PU*^9K07N1O<,
MC$""U92C*)=D5]!_=0[W[KM:+D:H6:/',G*39.2*3X-6:A!\*8:F31J0JQA>
MN)P48A[Z\1++>>GDWK=#MPK>^OVRO3Q9=053;PBI^;"R)\M% 5A7L/7*XI<8
MDJ"X W?!>WS$_"JK_!7A+7PK6Z&*/C-2)8M*JB6"O:R^J+BI><OWZ@=/_QD-
MS\RI&6\CX2]-QQ0'8J]GH&Q+R$QI<)F4HZ!@">RE+D+> _:("5W=&*)/-DXK
M-YOLZ,JYV@@5!T<:!!V$<\ OZ)\GRP\WK:REN601UI9FM\*"U-:)*1YX6CF
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ME,-3>H]55VY+]];?K(:W/NMPDD;PB-R2.LDGI=!TN T=%XS)2:1,UR5S@II
M'FZM1*X0?.5$##4N$D,"X#-J.AZFCHNITLQI&,1^J;AM7EFTXU3I+ P[5=AV
MQ":CQ.V2CO>F4W>IHJK >K>IC##B<G#7S\/0953BY_(NQ##$+VHB?;.R29LH
MFE-QO;O<C?G\8.?@90\QRL\$*8Q37'NAN-V4Y6 J[=4FE;9RZO?D2ZPFU,#"
M4L28N-NL-,&,=(ANR>E2IIDXJO"I=!,+[3)^0[Q!S=Q+702Q9;E&*"]"OV!<
M^\#9<'SU=H>$N -E,D"'R R_<"CAG+P7GDAI+M"#=DIGHY =A;SD,E.CD$_
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M^3.[RV;:!Q0 2:O/P>4U;EM6?UL1[L*A+NEX4%6Y[:MY4CE6RY-% 7X2<U^
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M.Y?9> 9DW0Z$ RV?L0\*PJG<84G+ VRZF#-ZUXTKTE ZS^8)[!F9#\G?^AH
MOH!2QZ"(4!EQ!: [@$70\B:]YOU2XE2MH+KTTF. FXE++1!0YX)'_PDZQ$Y
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M[-?9CT82!U,/7=5YUGQ[TCF C&G9OH4TO7%GM,-E N?6F''3:TF],=/GDJ+
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M97]3?<=0'_1JD-AG>3%84"1I2P-\XT>2;V-5Q9+E&E'LV:U1A1DOQFNSLX\
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M(@//ALGX%OY<Y[/HW_\'4$L! A0#%     @ H#P(6;!7'[@[J@$ @843 !$
M             ( !     &YV87@M,C R-# V,S N:'1M4$L! A0#%     @
MH#P(68#NFI]W$@  R<8  !$              ( !:JH! &YV87@M,C R-# V
M,S N>'-D4$L! A0#%     @ H#P(670,4[_!&   Q.4  !4
M ( !$+T! &YV87@M,C R-# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( * \"%D>
MJY@%8&$   A3!  5              "  036 0!N=F%X+3(P,C0P-C,P7V1E
M9BYX;6Q02P$"% ,4    " "@/ A9LB;F<A2)  #KZ@  %
M@ &7-P( ;G9A>"TR,#(T,#8S,%]G,2YJ<&=02P$"% ,4    " "@/ A9HWDR
M>E % 0#.30H %0              @ '=P ( ;G9A>"TR,#(T,#8S,%]L86(N
M>&UL4$L! A0#%     @ H#P(65N^DS:6H@  TH0' !4              ( !
M8,8# &YV87@M,C R-# V,S!?<')E+GAM;%!+ 0(4 Q0    ( * \"%E;&377
M$P@   DE   7              "  2EI! !N=F%X+3(P,C0P-C,P>&5X,S$Q
M+FAT;5!+ 0(4 Q0    ( * \"%G@SD'M"@@  #\I   7              "
M 7%Q! !N=F%X+3(P,C0P-C,P>&5X,S$R+FAT;5!+ 0(4 Q0    ( * \"%EH
MT[80+P4  "T2   7              "  ;!Y! !N=F%X+3(P,C0P-C,P>&5X
M,S(Q+FAT;5!+ 0(4 Q0    ( * \"%G\@R$LB 4  /T2   7
M  "  11_! !N=F%X+3(P,C0P-C,P>&5X,S(R+FAT;5!+ 0(4 Q0    ( * \
M"%G F!Y8G!,"  ]4%P <              "  =&$! !N=F%X+3(P,C0P-C,P
M>&5X:&EB:70Q,#0N:'1M4$L! A0#%     @ H#P(60[ L5'P)@  _O8  !P
M             ( !IY@& &YV87@M,C R-# V,S!X97AH:6)I=#$P-2YH=&U0
M2P$"% ,4    " "@/ A9'W?N7$^$  "P\P, '               @ '1OP8
M;G9A>"TR,#(T,#8S,'AE>&AI8FET,3 V+FAT;5!+!08     #@ . +X#  !:
%1 <    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>nvax-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nvax="http://www.novavax.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nvax-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensingRoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nvax:GovernmentBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nvax:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nvax:AustraliaRevenueAgencyMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:NewZealandTerminationOfTheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nvax:NewZealandRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:NewZealandTerminationOfTheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:LicensedCOVID19ProductsAndRoyaltyPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:ApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfApprovalOfMarketingAuthorizationForTheCOVID19VaccineFromTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfEMAApprovalOfTheCOVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:DatabaseLockOfAnExistingPhase23ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CompletionOfTheTechnologyTransferOfTheCompanysManufacturingProcessForTheCOVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CICProductRelatedDevelopmentAndLaunchMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:FirstFourAdjuvantProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:AdjuvantProductsThereafterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:ClinicalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:CostReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransferOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:TransitionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SanofiPasteurInc.APAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:BillMelindaGatesMedicalResearchInstituteArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-04</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-05</startDate>
            <endDate>2024-08-05</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnC.JacobsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:JohnTrizzinoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nvax:segment</measure>
    </unit>
    <unit id="security">
        <measure>nvax:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="dose">
        <measure>nvax:dose</measure>
    </unit>
    <unit id="installment">
        <measure>nvax:installment</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>nvax:reporting_unit</measure>
    </unit>
    <unit id="defendant">
        <measure>nvax:defendant</measure>
    </unit>
    <unit id="lawsuit">
        <measure>nvax:lawsuit</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-28">0001000694</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-209" id="f-743">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ecd:TrdArrDuration contextRef="c-257" id="f-933">P246D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-263" id="f-934">P233D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-26770</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">NOVAVAX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">700 Quince Orchard Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-11">MD</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">268-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">160093639</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">19904000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">285163000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-32" unitRef="usd">102228000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-33" unitRef="usd">277706000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-3" id="f-34" unitRef="usd">395580000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-35" unitRef="usd">2184000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-36" unitRef="usd">407111000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-3" id="f-37" unitRef="usd">3213000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-38" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-39" unitRef="usd">137079000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-40" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-41" unitRef="usd">224458000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-42" unitRef="usd">415484000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-43" unitRef="usd">424426000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-44" unitRef="usd">509339000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-3" id="f-45" unitRef="usd">505377000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c-15" decimals="-3" id="f-46" unitRef="usd">46242000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-16" decimals="-3" id="f-47" unitRef="usd">55777000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-48" unitRef="usd">105451000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-17" decimals="-3" id="f-49" unitRef="usd">89863000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-50" unitRef="usd">106946000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-51" unitRef="usd">219475000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-52" unitRef="usd">199625000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-53" unitRef="usd">466576000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-54" unitRef="usd">101298000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-55" unitRef="usd">93717000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-56" unitRef="usd">188096000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-57" unitRef="usd">206249000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-3" id="f-58" unitRef="usd">254486000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-3" id="f-59" unitRef="usd">368969000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-60" unitRef="usd">493172000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-3" id="f-61" unitRef="usd">762688000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-62" unitRef="usd">160998000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-63" unitRef="usd">55457000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-64" unitRef="usd">16167000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-65" unitRef="usd">-257311000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-66" unitRef="usd">4143000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-16" decimals="-3" id="f-67" unitRef="usd">3124000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-68" unitRef="usd">8254000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-17" decimals="-3" id="f-69" unitRef="usd">7440000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-70" unitRef="usd">7731000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-71" unitRef="usd">5532000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-72" unitRef="usd">11385000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-73" unitRef="usd">29894000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-74" unitRef="usd">164586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-75" unitRef="usd">57865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-76" unitRef="usd">19298000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-77" unitRef="usd">-234857000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-78" unitRef="usd">2205000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-79" unitRef="usd">-143000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-80" unitRef="usd">4467000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-81" unitRef="usd">1040000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-82" unitRef="usd">162381000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-83" unitRef="usd">58008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">14831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-85" unitRef="usd">-235897000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-86"
      unitRef="usdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-87"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-88"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-89"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-90"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-91"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-92"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-93"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-94" unitRef="shares">148379000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-3" id="f-95" unitRef="shares">89362000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-96" unitRef="shares">144147000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-3" id="f-97" unitRef="shares">87769000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-98" unitRef="shares">165855000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-3" id="f-99" unitRef="shares">104065000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-100" unitRef="shares">145121000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-3" id="f-101" unitRef="shares">87769000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-102" unitRef="usd">162381000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-103" unitRef="usd">58008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">14831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-105" unitRef="usd">-235897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-106" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-107" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-109" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-110" unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-111" unitRef="usd">-5011000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">-13080000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-113" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-114" unitRef="usd">317000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-115" unitRef="usd">-5011000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-13230000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-117" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-118" unitRef="usd">162698000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-119" unitRef="usd">52997000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">1601000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-121" unitRef="usd">-237697000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-18" decimals="-3" id="f-122" unitRef="usd">680162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-123" unitRef="usd">568505000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-18" decimals="-3" id="f-124" unitRef="usd">369432000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-19" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-18" decimals="-3" id="f-126" unitRef="usd">10486000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-127" unitRef="usd">10424000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet contextRef="c-18" decimals="-3" id="f-128" unitRef="usd">32105000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-19" decimals="-3" id="f-129" unitRef="usd">297240000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-3" id="f-130" unitRef="usd">9172000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-3" id="f-131" unitRef="usd">41696000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-18" decimals="-3" id="f-132" unitRef="usd">102013000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-133" unitRef="usd">226023000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-18" decimals="-3" id="f-134" unitRef="usd">1203370000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-3" id="f-135" unitRef="usd">1143888000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-18" decimals="-3" id="f-136" unitRef="usd">288559000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-3" id="f-137" unitRef="usd">305771000</us-gaap:PropertyPlantAndEquipmentNet>
    <nvax:LeaseRightOfUseAsset contextRef="c-18" decimals="-3" id="f-138" unitRef="usd">169507000</nvax:LeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-139" unitRef="usd">185218000</nvax:LeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-18" decimals="-3" id="f-140" unitRef="usd">123377000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-19" decimals="-3" id="f-141" unitRef="usd">127454000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-18" decimals="-3" id="f-142" unitRef="usd">33833000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-3" id="f-143" unitRef="usd">35159000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-18" decimals="-3" id="f-144" unitRef="usd">1818646000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-19" decimals="-3" id="f-145" unitRef="usd">1797490000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-18" decimals="-3" id="f-146" unitRef="usd">79962000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-3" id="f-147" unitRef="usd">132610000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-18" decimals="-3" id="f-148" unitRef="usd">159221000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-149" unitRef="usd">394668000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-18" decimals="-3" id="f-150" unitRef="usd">666390000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-19" decimals="-3" id="f-151" unitRef="usd">241310000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-18" decimals="-3" id="f-152" unitRef="usd">9427000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-153" unitRef="usd">5142000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-3" id="f-154" unitRef="usd">242811000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-155" unitRef="usd">861408000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-18" decimals="-3" id="f-156" unitRef="usd">1157811000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-157" unitRef="usd">1635138000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-18" decimals="-3" id="f-158" unitRef="usd">533431000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-159" unitRef="usd">622210000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-18" decimals="-3" id="f-160" unitRef="usd">168848000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-19" decimals="-3" id="f-161" unitRef="usd">168016000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-18" decimals="-3" id="f-162" unitRef="usd">54970000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-163" unitRef="usd">55923000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-3" id="f-164" unitRef="usd">335292000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-3" id="f-165" unitRef="usd">33130000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-18" decimals="-3" id="f-166" unitRef="usd">2250352000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-19" decimals="-3" id="f-167" unitRef="usd">2514417000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-18" id="f-168" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-169" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-170"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="INF"
      id="f-171"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-172"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-18"
      decimals="INF"
      id="f-173"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-18"
      decimals="INF"
      id="f-174"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-175"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-176"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-177"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-18" decimals="-3" id="f-178" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="INF"
      id="f-180"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-181"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-182"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-18"
      decimals="INF"
      id="f-183"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-18"
      decimals="INF"
      id="f-184"
      unitRef="shares">161267120</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-185"
      unitRef="shares">159891014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-186"
      unitRef="shares">140506093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-187"
      unitRef="shares">139505770</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-18" decimals="-3" id="f-188" unitRef="usd">1613000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-3" id="f-189" unitRef="usd">1405000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-18" decimals="-3" id="f-190" unitRef="usd">4477748000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-3" id="f-191" unitRef="usd">4192164000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-18" decimals="-3" id="f-192" unitRef="usd">-4806120000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-3" id="f-193" unitRef="usd">-4820951000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-18"
      decimals="INF"
      id="f-194"
      unitRef="shares">1376106</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-19"
      decimals="INF"
      id="f-195"
      unitRef="shares">1000323</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-18" decimals="-3" id="f-196" unitRef="usd">94439000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-19" decimals="-3" id="f-197" unitRef="usd">92267000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-3" id="f-198" unitRef="usd">-10508000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-3" id="f-199" unitRef="usd">2722000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-200" unitRef="usd">-431706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-201" unitRef="usd">-716927000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-18" decimals="-3" id="f-202" unitRef="usd">1818646000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-3" id="f-203" unitRef="usd">1797490000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-204"
      unitRef="shares">141700972</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-205" unitRef="usd">1417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-206" unitRef="usd">4204775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-207" unitRef="usd">-4968501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-208" unitRef="usd">-93950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-209" unitRef="usd">-10825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-210" unitRef="usd">-867084000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-211" unitRef="usd">14099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-212" unitRef="usd">14099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-27"
      decimals="INF"
      id="f-213"
      unitRef="shares">472751</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-27" decimals="-3" id="f-214" unitRef="usd">5000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-26" decimals="-3" id="f-215" unitRef="usd">2656000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-28" decimals="-3" id="f-216" unitRef="usd">-489000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-15" decimals="-3" id="f-217" unitRef="usd">2172000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-15" decimals="-3" id="f-218" unitRef="usd">3830000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-27"
      decimals="INF"
      id="f-219"
      unitRef="shares">19093397</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-220" unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-221" unitRef="usd">256218000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-222" unitRef="usd">256409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-29" decimals="-3" id="f-223" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-224" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-29" decimals="-3" id="f-225" unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-226" unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-227" unitRef="usd">162381000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-228" unitRef="usd">162381000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-229"
      unitRef="shares">161267120</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-230" unitRef="usd">1613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-231" unitRef="usd">4477748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-232" unitRef="usd">-4806120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-233" unitRef="usd">-94439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-234" unitRef="usd">-10508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-235" unitRef="usd">-431706000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-236"
      unitRef="shares">87139831</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-237" unitRef="usd">871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-238" unitRef="usd">3767733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-239" unitRef="usd">-4569794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-240" unitRef="usd">-91226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-241" unitRef="usd">-3166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-242" unitRef="usd">-895582000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">20292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-244" unitRef="usd">20292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-43"
      decimals="INF"
      id="f-245"
      unitRef="shares">95965</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-43" decimals="-3" id="f-246" unitRef="usd">1000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-42" decimals="-3" id="f-247" unitRef="usd">-1000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-44" decimals="-3" id="f-248" unitRef="usd">-198000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-16" decimals="-3" id="f-249" unitRef="usd">-198000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-16" decimals="-3" id="f-250" unitRef="usd">861000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-43"
      decimals="INF"
      id="f-251"
      unitRef="shares">7947954</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-252" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-253" unitRef="usd">67892000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-254" unitRef="usd">67972000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-45" decimals="-3" id="f-255" unitRef="usd">-5011000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-256" unitRef="usd">-5011000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-257" unitRef="usd">58008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-258" unitRef="usd">58008000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-259"
      unitRef="shares">95183750</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-260" unitRef="usd">952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-261" unitRef="usd">3855916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-262" unitRef="usd">-4511786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-263" unitRef="usd">-91424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-264" unitRef="usd">-8177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-265" unitRef="usd">-754519000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-53"
      decimals="INF"
      id="f-266"
      unitRef="shares">140506093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-267" unitRef="usd">1405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-268" unitRef="usd">4192164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-269" unitRef="usd">-4820951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-270" unitRef="usd">-92267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-271" unitRef="usd">2722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-272" unitRef="usd">-716927000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-58" decimals="-3" id="f-273" unitRef="usd">25655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">25655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-59"
      decimals="INF"
      id="f-275"
      unitRef="shares">1667630</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-59" decimals="-3" id="f-276" unitRef="usd">17000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-58" decimals="-3" id="f-277" unitRef="usd">3711000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-60" decimals="-3" id="f-278" unitRef="usd">-2172000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">1556000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">3830000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-59"
      decimals="INF"
      id="f-281"
      unitRef="shares">19093397</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="-3" id="f-282" unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-58" decimals="-3" id="f-283" unitRef="usd">256218000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">256409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-61" decimals="-3" id="f-285" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-61" decimals="-3" id="f-287" unitRef="usd">-13080000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-13080000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-62" decimals="-3" id="f-289" unitRef="usd">14831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">14831000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-291"
      unitRef="shares">161267120</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-292" unitRef="usd">1613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-293" unitRef="usd">4477748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-294" unitRef="usd">-4806120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-295" unitRef="usd">-94439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-296" unitRef="usd">-10508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-297" unitRef="usd">-431706000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-298"
      unitRef="shares">86806554</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-299" unitRef="usd">868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-300" unitRef="usd">3737979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-301" unitRef="usd">-4275889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-66" decimals="-3" id="f-302" unitRef="usd">-90659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-3" id="f-303" unitRef="usd">-6377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-3" id="f-304" unitRef="usd">-634078000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-69" decimals="-3" id="f-305" unitRef="usd">48939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-306" unitRef="usd">48939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-70"
      decimals="INF"
      id="f-307"
      unitRef="shares">429242</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-70" decimals="-3" id="f-308" unitRef="usd">4000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-69" decimals="-3" id="f-309" unitRef="usd">1106000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-71" decimals="-3" id="f-310" unitRef="usd">-765000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-17" decimals="-3" id="f-311" unitRef="usd">345000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-17" decimals="-3" id="f-312" unitRef="usd">861000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-70"
      decimals="INF"
      id="f-313"
      unitRef="shares">7947954</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-70" decimals="-3" id="f-314" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-69" decimals="-3" id="f-315" unitRef="usd">67892000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-316" unitRef="usd">67972000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-72" decimals="-3" id="f-317" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-318" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-73" decimals="-3" id="f-319" unitRef="usd">-235897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-320" unitRef="usd">-235897000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-321"
      unitRef="shares">95183750</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-322" unitRef="usd">952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-323" unitRef="usd">3855916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-324" unitRef="usd">-4511786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-325" unitRef="usd">-91424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-326" unitRef="usd">-8177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-327" unitRef="usd">-754519000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">14831000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-329" unitRef="usd">-235897000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">23279000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-17" decimals="-3" id="f-331" unitRef="usd">19110000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">25655000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-333" unitRef="usd">48939000</us-gaap:ShareBasedCompensation>
    <nvax:ProvisionForExcessAndObsoleteInventory contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">18472000</nvax:ProvisionForExcessAndObsoleteInventory>
    <nvax:ProvisionForExcessAndObsoleteInventory contextRef="c-17" decimals="-3" id="f-335" unitRef="usd">31546000</nvax:ProvisionForExcessAndObsoleteInventory>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">1669000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-17" decimals="-3" id="f-337" unitRef="usd">10081000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">2687000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-3" id="f-339" unitRef="usd">89000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">-14176000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-3" id="f-341" unitRef="usd">19361000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">-390766000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-17" decimals="-3" id="f-343" unitRef="usd">266482000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-366484000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-17" decimals="-3" id="f-345" unitRef="usd">-443238000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">111037000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-17" decimals="-3" id="f-347" unitRef="usd">357860000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">230714000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-349" unitRef="usd">-497531000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">9753000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-17" decimals="-3" id="f-351" unitRef="usd">26774000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">369582000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsForSoftware contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">622000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware contextRef="c-17" decimals="-3" id="f-355" unitRef="usd">4563000</us-gaap:PaymentsForSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">-379957000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-357" unitRef="usd">-31337000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">263272000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-17" decimals="-3" id="f-359" unitRef="usd">61986000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">1556000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards contextRef="c-17" decimals="-3" id="f-361" unitRef="usd">345000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">726000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-17" decimals="-3" id="f-363" unitRef="usd">26784000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-17" decimals="-3" id="f-365" unitRef="usd">325000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c-17" decimals="-3" id="f-367" unitRef="usd">3591000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">264102000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-369" unitRef="usd">-293044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">-3111000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-3" id="f-371" unitRef="usd">-8992000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">111748000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-373" unitRef="usd">-830904000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-374" unitRef="usd">583810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-68" decimals="-3" id="f-375" unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-376" unitRef="usd">695558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-52" decimals="-3" id="f-377" unitRef="usd">517941000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-17" decimals="-3" id="f-379" unitRef="usd">5986000</us-gaap:StockIssued1>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">-8289000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset contextRef="c-17" decimals="-3" id="f-381" unitRef="usd">0</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">2137000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-17" decimals="-3" id="f-383" unitRef="usd">6591000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">7180000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-17" decimals="-3" id="f-385" unitRef="usd">11294000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">-649000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-17" decimals="-3" id="f-387" unitRef="usd">128000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-388">Organization and Business&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Novavax, Inc. (&#x201c;Novavax,&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is a global company that is advancing protein-based vaccines with its Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; adjuvant. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology, and patented Matrix-M&#x2122; adjuvant to enhance the immune response. In May 2024, Novavax entered into a collaboration and licensing agreement (the &#x201c;Collaboration and License Agreement&#x201d; or &#x201c; Sanofi CLA&#x201d;) with Sanofi Pasteur Inc. (&#x201c;Sanofi&#x201d;) to co-commercialize Novavax&#x2019;s current standalone COVID-19 vaccines (&#x201c;COVID-19 Vaccine&#x201d;), including Novavax&#x2019;s Nuvaxovid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, prototype COVID-19 vaccine (&#x201c;NVX-CoV2373,&#x201d; or &#x201c;prototype vaccine&#x201d;) and XBB COVID-19 vaccine  (&#x201c;NVX-CoV2601&#x201d;), and the Company&#x2019;s updated vaccine for the 2024-2025 vaccination season (&#x201c;NVX-CoV2705,&#x201d; or &#x201c;updated vaccine&#x201d; and, collectively with NVX-CoV2373 and NVX-CoV2601, the Company&#x2019;s &#x201c;COVID-19 Vaccine&#x201d; or &#x201c;COVID-19 Program&#x201d;). This agreement is discussed in greater detail in Note 6 of Novavax&#x2019;s consolidated financial statements. The partnership with Sanofi allows Novavax to broaden access to its vaccine and adjuvant and refocus on clinical-stage research and development and pipeline expansion beginning in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Through the end of the 2024-2025 vaccination season, Novavax will continue commercialization of its COVID-19 Vaccine.  Local regulatory authorities have also specified nomenclature for the labeling of NVX-CoV2373 and NVX-CoV2601 within their territories (e.g., &#x201c;Novavax COVID-19 Vaccine, Adjuvanted&#x201d;, &#x201c;Novavax COVID-19, Adjuvanted (2023-2024 Formula),&#x201d; respectively, for the U.S., and &#x201c;Nuvaxovid&#x2122;&#x201d; for ex-US territories) collectively referred to as the Company&#x2019;s &#x201c;COVID-19 Program,&#x201d; or &#x201c;COVID-19 Vaccine&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2024, the Company has submitted an amendment to the previously granted October 2023 Emergency Use Authorization (&#x201c;EUA&#x201d;) to the U.S. Food and Drug Administration (&#x201c;U.S. FDA&#x201d;), filed for a type II variation of the existing Marketing Authorization (&#x201c;MA&#x201d;) with the European Medicines Agency (&#x201c;EMA&#x201d;) and the United Kingdom's (&#x201c;U.K.&#x201d;) Medicines and Healthcare products Regulatory Agency (&#x201c;MHRA&#x201d;), and filed for authorization with Health Canada for the Company&#x2019;s updated vaccine. Currently, the Company significantly depends on its supply agreement with Serum Institute of India Pvt. Ltd. (&#x201c;SII&#x201d;) and its subsidiary, Serum Life Sciences Limited (&#x201c;SLS&#x201d; and together with SII, &#x201c;Serum&#x201d;), for co-formulation, filling, and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novavax is advancing development of other vaccine candidates, including its COVID-19-Influenza Combination (&#x201c;CIC&#x201d;) and stand-alone influenza vaccine candidates. In addition, Novavax&#x2019;s adjuvant is included in the University of Oxford and SII&#x2019;s R21/Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;malaria vaccine which has received authorizations in a number of countries with doses administered in 2024.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novavax&#x2019;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#x2019;s proprietary Matrix-M&#x2122; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-389">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive income (loss), changes in stockholders&#x2019; deficit, and cash flows for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were a $1.6&#160;million loss and a $6.7&#160;million loss, and a $0.2&#160;million loss and $16.1&#160;million gain for the three and six months ended June&#160;30, 2024 and 2023, respectively, which are reflected in Other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2023. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span id="id646a6b9d9154d26bde005a7bb4415f3_15397"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company entered into the Sanofi CLA and a securities subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with Sanofi as a result of which, the Company received a total of $568.8 million during the second quarter of 2024 (See Note 6).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had $680.2 million in cash and cash equivalents, $369.4 million in marketable securities, and working capital of $45.6 million. During the six months ended June&#160;30, 2024, the Company recognized net income of $14.8 million, and had net cash flows provided by operating activities of $230.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company evaluated its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Based on the Company&#x2019;s current cash and cash equivalents and marketable securities balances and its current cash flow forecast for the one-year going concern look forward period, the Company has concluded that it will have sufficient capital available to fund its operations for the one-year period from the date that these financial statements are issued. As of December 31, 2023, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to significant uncertainty related to its ability to successfully develop, manufacture, distribute, and market its updated vaccine and execute on certain cost-reduction initiatives as described in Note 16. The Sanofi CLA has alleviated the substantial doubt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition, Licensing and Transition Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Company&#x2019;s third-party licensing agreements may contain multiple performance obligations, including licenses and transition services. The Company evaluates licensing agreements under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;) to determine the distinct performance obligations. Prior to recognizing revenue, the Company estimates the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple performance obligation arrangements, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, the Company considers discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, the Company applies judgment in determining the forecasted revenue, expected margins, and the discount rate. These estimates are subjective and require the Company to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset. For performance obligations recognized over time, the Company recognizes revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, the Company considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, and indirect administrative costs. Estimating the total cost at completion of the Company&#x2019;s performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on the Company&#x2019;s contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. The Company has not experienced any material adjustments as a result of changes in estimates arising from this process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes restructuring charges when such costs are incurred. The Company&#x2019;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities, and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 16 for additional information on the severance and employee benefit costs for terminated employees and impairment of assets in connection with the Company&#x2019;s Restructuring Plan as defined in Note 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements are unaudited but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive income (loss), changes in stockholders&#x2019; deficit, and cash flows for the periods presented. Although the Company believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were a $1.6&#160;million loss and a $6.7&#160;million loss, and a $0.2&#160;million loss and $16.1&#160;million gain for the three and six months ended June&#160;30, 2024 and 2023, respectively, which are reflected in Other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2023. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire&#160;year. The Company operates in one business segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-15" decimals="-5" id="f-391" unitRef="usd">-1600000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-1" decimals="-5" id="f-392" unitRef="usd">-6700000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-16" decimals="-5" id="f-393" unitRef="usd">-200000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-17" decimals="-5" id="f-394" unitRef="usd">16100000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-395"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <nvax:LiquidityAndGoingConcernPolicyTextBlock contextRef="c-1" id="f-396">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span id="id646a6b9d9154d26bde005a7bb4415f3_15397"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company entered into the Sanofi CLA and a securities subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with Sanofi as a result of which, the Company received a total of $568.8 million during the second quarter of 2024 (See Note 6).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had $680.2 million in cash and cash equivalents, $369.4 million in marketable securities, and working capital of $45.6 million. During the six months ended June&#160;30, 2024, the Company recognized net income of $14.8 million, and had net cash flows provided by operating activities of $230.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company evaluated its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Based on the Company&#x2019;s current cash and cash equivalents and marketable securities balances and its current cash flow forecast for the one-year going concern look forward period, the Company has concluded that it will have sufficient capital available to fund its operations for the one-year period from the date that these financial statements are issued. As of December 31, 2023, the Company had concluded that there was substantial doubt about its ability to continue as a going concern primarily due to significant uncertainty related to its ability to successfully develop, manufacture, distribute, and market its updated vaccine and execute on certain cost-reduction initiatives as described in Note 16. The Sanofi CLA has alleviated the substantial doubt.&lt;/span&gt;&lt;/div&gt;</nvax:LiquidityAndGoingConcernPolicyTextBlock>
    <nvax:ProceedsFromCollaborationAndLicenseAgreement contextRef="c-74" decimals="-5" id="f-397" unitRef="usd">568800000</nvax:ProceedsFromCollaborationAndLicenseAgreement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-18" decimals="-5" id="f-398" unitRef="usd">680200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-18" decimals="-5" id="f-399" unitRef="usd">369400000</us-gaap:MarketableSecuritiesCurrent>
    <nvax:WorkingCapital contextRef="c-18" decimals="-5" id="f-400" unitRef="usd">45600000</nvax:WorkingCapital>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-401" unitRef="usd">14800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-402" unitRef="usd">230700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition, Licensing and Transition Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Company&#x2019;s third-party licensing agreements may contain multiple performance obligations, including licenses and transition services. The Company evaluates licensing agreements under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;) to determine the distinct performance obligations. Prior to recognizing revenue, the Company estimates the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, transition service fees, other payments based upon the achievement of specified milestones, and royalty payments based on product sales from licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple performance obligation arrangements, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined for each performance obligation based on the prices charged to customers, discounted cash flows, or using expected cost-plus margin. For standalone selling prices determined using discounted cash flows, the Company considers discounted, probability-weighted cash flows related to the performance obligation transferred. In developing such estimates, the Company applies judgment in determining the forecasted revenue, expected margins, and the discount rate. These estimates are subjective and require the Company to make assumptions about future cash flows. Revenue related to performance obligations satisfied at a point in time is recognized when the customer obtains control of the promised asset. For performance obligations recognized over time, the Company recognizes revenue using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Under this process, the Company considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, and indirect administrative costs. Estimating the total cost at completion of the Company&#x2019;s performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and may impact the timing of revenue recognition on the Company&#x2019;s contracts. Changes in estimates related to the process are recognized in the period when such changes are made on a cumulative catch-up basis. The Company has not experienced any material adjustments as a result of changes in estimates arising from this process.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-404">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="c-1" id="f-405">&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;The Company recognizes restructuring charges when such costs are incurred. The Company&#x2019;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities, and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable.</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-407">Marketable Securities &lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities were classified as available-for-sale as of June&#160;30, 2024 and comprised of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2024, investments in marketable securities, comprising corporate debt securities, were due to mature within one year. Based on the Company&#x2019;s policy under the expected credit loss model, including an assessment of unrealized losses on the portfolio as of June 30, 2024, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of June 30, 2024. Also, based on the scheduled maturities of the investments, the Company was more-likely-than-not to hold these investments for a period of time sufficient for a recovery of the Company&#x2019;s cost basis. As of June&#160;30, 2024, the Company held no securities that were in an unrealized loss position for more than 12 months.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities were classified as available-for-sale as of June&#160;30, 2024 and comprised of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-75" decimals="-3" id="f-409" unitRef="usd">369582000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-75" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-75" decimals="-3" id="f-411" unitRef="usd">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-75" decimals="-3" id="f-412" unitRef="usd">369432000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-76" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-76" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-76" decimals="-3" id="f-415" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-76" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-18" decimals="-3" id="f-417" unitRef="usd">369582000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-18" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-18" decimals="-3" id="f-419" unitRef="usd">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-18" decimals="-3" id="f-420" unitRef="usd">369432000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-19" decimals="-3" id="f-421" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-19" decimals="-3" id="f-422" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-19" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-19" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-18"
      decimals="INF"
      id="f-425"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-426">Fair Value Measurements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as cash and cash equivalents as of June 30, 2024 and December 31, 2023, respectively, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes $232.0 million classified as Cash and cash equivalents and $369.4&#160;million classified as marketable securities as of June&#160;30, 2024, on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#x2019;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics. Pricing of the Company&#x2019;s convertible notes has been estimated using observable inputs, including the price of the Company&#x2019;s common stock, implied volatility, interest rates, and credit spreads.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six&#160;months ended June&#160;30, 2024 and 2023, the Company did not have any transfers between levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount in the Company&#x2019;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="c-1" id="f-427">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as cash and cash equivalents as of June 30, 2024 and December 31, 2023, respectively, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;Includes $232.0 million classified as Cash and cash equivalents and $369.4&#160;million classified as marketable securities as of June&#160;30, 2024, on the consolidated balance sheets.</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-428" unitRef="usd">188086000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-429" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-431" unitRef="usd">171824000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-435" unitRef="usd">225000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-438" unitRef="usd">200000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-89" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-90" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-91" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-92" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-444" unitRef="usd">45622000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-447" unitRef="usd">601466000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-452" unitRef="usd">188086000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-453" unitRef="usd">826466000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-455" unitRef="usd">171824000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-456" unitRef="usd">245622000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-107" decimals="2" id="f-458" unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-108" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-109" decimals="-3" id="f-460" unitRef="usd">217587000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-110" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-111" decimals="-3" id="f-462" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-112" decimals="-3" id="f-463" unitRef="usd">100909000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-113" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-114" decimals="-5" id="f-465" unitRef="usd">232000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-115" decimals="-5" id="f-466" unitRef="usd">369400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-467">Revenue&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable included $29.8 million and $286.4 million related to amounts that were billed to customers and $2.3 million and $10.8 million related to amounts which had not yet been billed to customers as of June&#160;30, 2024 and December&#160;31, 2023, respectively. During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#x2019;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(937,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;There was no allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $6.2 million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $2.2&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $225.0&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties and constrained variable consideration, was approximately $2 billion, of which $1.2&#160;billion was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#x2019;s APAs may require the Company to refund portions of upfront and other payments or result in reduced future payments, which could adversely impact the Company&#x2019;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on the timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request the Company&#x2019;s updated vaccine under certain of the Company&#x2019;s APAs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under an APA with Gavi, the Vaccine Alliance (&#x201c;Gavi&#x201d;), entered into in May 2021 (the &#x201c;Gavi APA&#x201d;), the Company received upfront payments of $700&#160;million from Gavi (the &#x201c;Advance Payment Amount&#x201d;) to be applied against purchases of the Company&#x2019;s prototype vaccine by certain countries participating in the COVAX Facility. As of December&#160;31, 2023, the remaining Gavi Advance Payment Amount was $696.4&#160;million. In February 2024, the Company entered into a Termination and Settlement Agreement with Gavi (the &#x201c;Gavi Settlement Agreement&#x201d;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under, or otherwise in connection with the Gavi APA. On February 22, 2024, the claims and counterclaims were dismissed with prejudice. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid in February 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#x2019;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#x2019;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of the Company&#x2019;s vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In total, the Gavi settlement agreement is comprised of $700 million of potential consideration, consisting of the $75&#160;million initial settlement payment, deferred payments of up to $400&#160;million that may be reduced through annual vaccine credits, and the additional credit of up to $225&#160;million that may be applied for certain qualifying sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the $3.6&#160;million difference between the refund liability recorded as of December&#160;31, 2023 of $696.4&#160;million and the $700 million of total consideration under the arrangement as a reduction to revenue during the six months ended June&#160;30, 2024. As of June&#160;30, 2024, the remaining amounts included on the Company&#x2019;s consolidated balance sheet were  $225&#160;million in non-current Deferred revenue for the additional credit that may be applied against future qualifying sales, $90&#160;million in Other current liabilities, and $305&#160;million in Other non-current liabilities. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SII under the SII R21 Agreement (see Note 6), which will continue for the deferred payment term of the Gavi Settlement Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,645&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218,921&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#x201c;WAC&#x201d;). Product sales in the U.S. are recorded net of gross-to-net deductions. During the six months ended June&#160;30, 2024, product sales in North America includes $4.8&#160;million of gross-to-net deductions in excess of the WAC, primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales, partially offset by updates to estimated product returns. During the six months ended June&#160;30, 2024, product sales for the rest of the world includes a $3.6&#160;million reduction to revenue recognized pursuant to the Gavi Settlement Agreement as discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, changes in the Company&#x2019;s gross-to-net deductions balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Wholesale Distributor Fees, Discounts, and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts charged against product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits/deductions &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $4.0&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024 no gross-to-net deductions were included in Accounts receivable. As of December&#160;31, 2023, $2.6 million of gross-to-net deductions were included in Accounts receivable. As of June&#160;30, 2024 and December&#160;31, 2023, $55.5 million and $103.1 million of gross-to-net deductions were included in Accrued expenses, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an APA with the Commonwealth of Australia (&#x201c;Australia&#x201d;) for the purchase of doses of COVID-19 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vaccine (the &#x201c;Australia APA&#x201d;). In March 2024, the Company and Australia agreed to cancel the COVID-19 Vaccine doses previously scheduled for delivery in the fourth quarter of 2023. As a result of the cancellation, the total contract value was reduced by $54.0 million, including $6.0 million of deferred revenue related to the cancelled doses that will be applied as a credit towards future deliveries of doses. Australia is not required to purchase updated vaccine doses until the Company receives authorization from Therapeutic Goods Administration (&#x201c;TGA&#x201d;). The Company does not expect approval in time for product delivery in 2024 which could result in a loss or deferral of approximately $240 million of contract value. The Company plans to seek an amendment to the Australia APA which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $119.1 million was classified as current Deferred revenue and $14.7 million was classified as non-current Deferred revenue with respect to the Australia APA in the Company&#x2019;s consolidated balance sheet.  If the Company is unable to satisfy its obligations under the Australia APA, $92.5 million of deferred revenue may become refundable and approximately $225 million of remaining funds under the contract may no longer be available.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#x201c;Canadian government&#x201d;), for the purchase of doses of COVID-19 Vaccine (the &#x201c;Canada APA&#x201d;). The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre (&#x201c;BMC&#x201d;) Inc. on or before &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not anticipate achieving regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC on or before &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Therefore, the Company plans to seek an amendment to the Canada APA to address possible alternatives, which may not be achievable on acceptable terms or at all. As of June&#160;30, 2024, $452.1&#160;million was classified as current Deferred revenue and $136.1&#160;million was classified as non-current Deferred revenue with respect to the Canadian APA in the Company&#x2019;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024, the Pharmaceutical Management Agency (&#x201c;Pharmac&#x201d;), a New Zealand Crown entity, provided notice of its termination of its APA (the &#x201c;New Zealand APA&#x201d;). As of June&#160;30, 2024, $31.3&#160;million was classified as current Deferred revenue with respect to such agreement in the Company&#x2019;s consolidated balance sheet. New Zealand has requested a refund of certain advanced payments and the Company is in discussion with Pharmac on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;both, whether its termination of the New Zealand APA was appropriate under the New Zealand APA, and whether a refund of the advanced payments is appropriate under the New Zealand APA. Ap&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proximately $125&#160;million of the contract value related to future deliverables may no longer be available if the APA is terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing, Royalties, and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Licensing, royalties, and other includes Licensing payments, Transition Services revenue, and Technology Transfer revenue from the Company&#x2019;s Collaboration and License Agreement with Sanofi (&#x201c;Sanofi CLA&#x201d;); royalty milestone payments; sales-based royalties; and Matrix-M&#x2122; adjuvant sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2024, respectively, the Company recognized $386.3&#160;million and $390.3&#160;million in revenue related to license fees and $2.7&#160;million and $10.2&#160;million in revenue related to Matrix-M&#x2122; adjuvant sales, respectively. During the three and six months ended June&#160;30, 2024, the Company recognized $6.6&#160;million of Transition Services revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three and six months ended June&#160;30, 2023, the Company recognized $2.2&#160;million and $3.2&#160;million in revenue related to Matrix-M&#x2122; adjuvant sales. During the three and six months ended June&#160;30, 2023, the Company did not recognize revenue related to license fees or milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grants &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s U.S. government agreement consisted of a Project Agreement (the &#x201c;Project Agreement&#x201d;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#x201c;USG Agreement&#x201d;). As of December&#160;31, 2023, the Company recognized the full $1.8&#160;billion funding in revenue.Collaboration, License, and Supply Agreements &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, the Company&#x2019;s material collaborations, license and supply agreements were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Serum&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously granted SII exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, NVX-CoV2601, its updated vaccine, and its CIC vaccine candidate. SII agreed to purchase the Company's Matrix-M&#x2122; adjuvant and the Company granted SII a non-exclusive license to manufacture the antigen drug substance component of the Company&#x2019;s COVID-19 Vaccine in SII&#x2019;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SII equally split the revenue from SII&#x2019;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. In May 2024, the Company and SLS entered into a supply agreement (the &#x201c;SLS Supply Agreement&#x201d;) under which SLS will supply the Company with antigen drug substance and finished COVID-19 Vaccine doses. The SLS Supply Agreement includes the general terms and conditions of supply orders between the Company and SLS. The Company and SLS intend to execute statements of work and firm purchase orders to included specific quantities to be delivered under the SLS Supply Agreement. The Company will supply SLS with all Matrix-M&#x2122; adjuvant needed to manufacture  finished COVID-19 Vaccine doses. In March 2020, the Company entered into an agreement with SII that granted SII a non-exclusive license for the use of Matrix-M&#x2122; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#x2122; adjuvant (&#x201c;SII R21 Agreement&#x201d;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#x201c;R21/Matrix-M&#x2122;&#x201d;). In December 2023, R21/Matrix-M&#x2122; received prequalification by the World Health Organization (&#x201c;WHO&#x201d;). Under the SII R21 Agreement, SII purchases the Company's Matrix-M&#x2122; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#x2019;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#x2122; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#x2019;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company entered into the Sanofi CLA under which the Company granted and Sanofi received the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;i)&#160;&#160;&#160;&#160;A co-exclusive license to commercialize the Company&#x2019;s current stand-alone COVID-19 Vaccine, including the Company&#x2019;s prototype vaccine and updated vaccines, that address seasonal variants throughout the world (the &#x201c;COVID-19 Vaccine Products&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii)&#160;&#160;&#160;&#160;A sole license to develop and commercialize combination products containing a potential combination of the Company&#x2019;s COVID-19 Vaccine and Sanofi&#x2019;s seasonal influenza vaccine (&#x201c;COVID-19 and influenza Combination Products&#x201d; or &#x201c;CIC Products&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize combination products containing both the Company&#x2019;s COVID-19 Vaccine and one or more non-influenza vaccines (&#x201c;Other Combination Products&#x201d; and together with the COVID-19 Vaccine Products, CIC Products, and Other Combination Products, &#x201c;Licensed COVID-19 Products&#x201d;); and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv)&#160;&#160;&#160;&#160;A non-exclusive license to develop and commercialize other vaccine products selected by Sanofi that include the Company&#x2019;s Matrix-M&#x2122; adjuvant (as described below, the &#x201c;Adjuvant Products&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also responsible for performing services related to the technology transfer of its manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#x2122; components to Sanofi. Until the successful completion of such transfer, the Company will supply Sanofi with both COVID-19 Vaccine Products and Matrix-M&#x2122; intermediary components for Sanofi&#x2019;s use and is eligible for reimbursement of such costs from Sanofi. In addition, the Company is responsible for certain research and development and medical affairs services related to the COVID-19 Vaccine.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Sanofi CLA, the Company will continue to commercialize its updated vaccine. Beginning in 2025 and continuing during the term of the Sanofi CLA, Sanofi and the Company will commercialize the COVID-19 Vaccine Products worldwide in accordance with a commercialization plan agreed by the Company and Sanofi, under which the Company will continue to supply its existing APA customers and strategic partners, including Takeda and SII. Upon completion of the existing APAs, the Company and Sanofi will jointly agree on commercialization activities of each party in each jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Sanofi CLA, the Company received a non-refundable upfront payment of $500&#160;million in the second quarter of 2024. In addition, the Company will also be eligible to receive development, technology transfer, launch, and sales milestone payments totaling up to $700 million in the aggregate with respect to the COVID-19 Vaccine Products and royalty payments on Sanofi&#x2019;s sales of such licensed products. Milestone payments are comprised of a payment of $175&#160;million upon the approval of the marketing authorization for a COVID-19 Vaccine Product in a pre-filled syringe from the FDA, $25&#160;million upon the transfer of such approval to Sanofi, $25&#160;million upon the transfer of EMA approval of a COVID-19 Vaccine Product in a pre-filled syringe to Sanofi, $50&#160;million upon database lock of an existing Phase 2/3 clinical trial (identifier 2019nCoV-503), $75&#160;million upon the completion of the technology transfer of the Company&#x2019;s manufacturing process for the COVID-19 Vaccine Products to Sanofi, and up to $350&#160;million in CIC Product-related development and launch milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also eligible to receive development, launch, and sales milestone payments of up to $200 million for each of the first four Adjuvant Products and $210 million for each Adjuvant Product thereafter, and royalty payments on Sanofi&#x2019;s sales of all such licensed products. In&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addition, a portion of the technology transfer costs and research and development costs incurred by the Company will be reimbursed by Sanofi in accordance with agreed upon plans and budgets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed whether the Sanofi CLA fell within the scope of ASC 808,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;) based on whether the arrangement involved joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. The Company determined that the Sanofi CLA did not fall within the scope of ASC 808, as the Company does not share in the significant financial risks of Sanofi's development or commercialization activities. The Company then analyzed the arrangement pursuant to the provisions of ASC 606 and determined that the arrangement represents a contract with a customer and is therefore within the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following performance obligations in the Sanofi CLA and determined that they were within the scope of ASC 606: delivery of (i) the licenses described above (the COVID-19 Vaccine license, CIC Products license, Other Combination Product license, and Adjuvant Products license) (collectively the &#x201c;Sanofi CLA Licenses&#x2019;), (ii) research and development transition services that support further regulatory approval and development of the COVID-19 Vaccine, referred to as the Sanofi Transition Services, and (iii) technology transfer of the existing manufacturing process for the COVID-19 Vaccine Products and Matrix-M&#x2122; adjuvant, referred to as the &#x201c;Sanofi Technology Transfer&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Sanofi and therefore are not considered separate performance obligations within the Sanofi CLA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sanofi CLA Licenses performance obligations are considered functional intellectual property and distinct from other promises under the contract as Sanofi can benefit from the licenses on their own or together with other readily available resources. Also, the Sanofi Transition Services provide a distinct benefit to Sanofi within the context of the contract, separate from the licenses, as the services could be provided by Sanofi or another third party without the Company&#x2019;s assistance. The Sanofi Technology Transfer obligation is distinct as Sanofi can benefit from the Sanofi CLA Licenses transferred by the Company at the inception of the agreement with other readily available resources. Therefore, each represents a separate performance obligation within the contract with a customer under the scope of ASC 606 at contract inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price at inception of the Sanofi CLA to be $620.2&#160;million, consisting of (i) fixed consideration (the $500 million upfront nonrefundable fee), (ii) and $120.2&#160;million of variable consideration attributed to a $50.0&#160;million clinical milestone and $70.2&#160;million of estimated cost reimbursement related to Sanofi Transition Services and Sanofi Technology Transfer. Since the clinical milestone allocated to Sanofi Transition Services is entirely within the Company&#x2019;s control, and the cost reimbursement variable consideration allocated to Sanofi Transition Services and Sanofi Technology Transfer would be recognized as revenue only as the costs are incurred, the Company determined it is not probable that a significant reversal of cumulative revenue would occur. The Company utilized the expected value method to determine the amount of these payments. The Company excluded certain regulatory and technology transfer milestones from the transaction price that were determined to be inherently uncertain of achievement and are highly susceptible to factors outside of the Company&#x2019;s control. Sales-based royalties and launch milestones are related to the license of the intellectual property rights and the Company will recognize revenue for these in the period when subsequent sales are made or sale-based milestones are achieved pursuant to the sales-based royalty exception under ASC 606. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the fixed consideration (i.e., the $500 million nonrefundable upfront fee) to the performance obligations in the Sanofi CLA based on each performance obligation&#x2019;s relative standalone selling price, or SSP, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;$386.3&#160;million for the upfront transfer of the licenses; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;$110.2&#160;million for Transition Services; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;$3.5&#160;million for Technology Transfer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SSP for the licenses were determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. In developing such estimates, the Company applied judgment in determining the forecasted revenues, expected margins, and the discount rate. The SSP for the ongoing Transition Services and Technology Transfer were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue related to the licenses at a point in time upon transfer of the rights and control of the license to Sanofi during the second quarter 2024. The Sanofi Transition Services and Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Technology Transfer for the three and six month period ended June&#160;30, 2024 was $6.6&#160;million. The Company&#x2019;s consolidated balance sheet as of June&#160;30, 2024 includes a deferred revenue balance of $109.2&#160;million ($50.9&#160;million included in Deferred revenue, current portion and $58.3&#160;million included in Deferred revenue, non-current portion) related to Transition Services and Technology Transfer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized an asset for $35.0&#160;million of direct costs incurred to obtain the Sanofi CLA. These costs are amortized to expense over the expected period of the benefit in a manner that is consistent with the transfer of the related goods and services in the Sanofi CLA. The Company recognized $27.1&#160;million of amortization expense related to the asset in Selling, general, and administrative expense in the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, 6,880,481 shares of the Company&#x2019;s common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to the Company of $68.8 million. The opening price of the Company&#x2019;s common stock on the date of the sale approximated $10.00 per share and therefore all gross proceeds were allocated to stockholders&#x2019; deficit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Medical Research Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company entered into a three-year agreement with the Bill &amp;amp; Melinda Gates Medical Research &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Institute to provide the Company&#x2019;s Matrix-M&#x2122; adjuvant for use in preclinical vaccine research. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#x201c;FDBK&#x201d;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#x201c;FDBT&#x201d;) and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#x201c;FDBU&#x201d; and together with FDBK and FDBT, &#x201c;Fujifilm&#x201d;) entered into a Confidential Settlement Agreement and Release (the &#x201c;Settlement Agreement&#x201d;) to resolve disputes regarding amounts that Fujifilm claimed were due under a prior Confidential Settlement Agreement and Release effective September 30, 2022 (the &#x201c;CSAR&#x201d;) by and between the Company and Fujifilm.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the CSAR, the Company agreed to pay up to $185.0 million to Fujifilm in connection with the cancellation of manufacturing activity at FDBT. The final two quarterly installments due to Fujifilm in 2023 under the CSAR, totaling $68.6 million, were subject to Fujifilm&#x2019;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT. In October 2023, the Company sent Fujifilm a notice of breach and refused to pay the final two installments based on its contention that Fujifilm had not used commercially reasonable efforts to mitigate losses and should have offset some portion of the final two payments. In October 2023, Fujifilm filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#x201c;JAMS&#x201d;) seeking payment of the full amount (the &#x201c;Fujifilm Arbitration&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Settlement Agreement, in March 2024, the Company paid $42.0 million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the CSAR, and Fujifilm agreed to dismiss the Fujifilm Arbitration. This payment is less than amounts previously accrued for and reflected in Research and development expense, and accordingly, the Company recorded a benefit of $26.6 million as Research and development expense during the six months ended June&#160;30, 2024 upon the execution of the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Program, and in doing so, recognizes that significant costs may be incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BilledContractReceivables contextRef="c-18" decimals="-5" id="f-468" unitRef="usd">29800000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables contextRef="c-19" decimals="-5" id="f-469" unitRef="usd">286400000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable contextRef="c-18" decimals="-5" id="f-470" unitRef="usd">2300000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-19" decimals="-5" id="f-471" unitRef="usd">10800000</us-gaap:UnbilledContractsReceivable>
    <nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock contextRef="c-1" id="f-472">During the six months ended June&#160;30, 2024 and 2023, changes in the Company&#x2019;s accounts receivables, allowance for credit losses, and deferred revenue balances were as follows (in thousands):&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(937,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;There was no allowance for credit losses recorded during the six months ended June&#160;30, 2024 or 2023. During the six months ended June&#160;30, 2023, there was a $6.2 million reversal of a credit loss allowance due to the collection of a previously recognized allowance for credit losses. To estimate the allowance for credit losses, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;(2) Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. During the six months ended June&#160;30, 2024, deductions included a $2.2&#160;million reclassification of refundable upfront payments previously included in Deferred revenue to Other current liabilities. During the six months ended June&#160;30, 2024, additions included a $225.0&#160;million reclassification of refundable upfront payment from Other current liabilities to Deferred revenue related to the settlement with Gavi as discussed below. There were no such reclassifications during the six months ended June&#160;30, 2023.</nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-19" decimals="-3" id="f-473" unitRef="usd">304916000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions contextRef="c-1" decimals="-3" id="f-474" unitRef="usd">672326000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions contextRef="c-1" decimals="-3" id="f-475" unitRef="usd">937462000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross contextRef="c-18" decimals="-3" id="f-476" unitRef="usd">39780000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-68" decimals="-3" id="f-477" unitRef="usd">96210000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions contextRef="c-17" decimals="-3" id="f-478" unitRef="usd">793039000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions contextRef="c-17" decimals="-3" id="f-479" unitRef="usd">486684000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross contextRef="c-52" decimals="-3" id="f-480" unitRef="usd">402565000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-19" decimals="-3" id="f-481" unitRef="usd">7675000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-1" decimals="-3" id="f-482" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-1" decimals="-3" id="f-483" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-18" decimals="-3" id="f-484" unitRef="usd">7675000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-68" decimals="-3" id="f-485" unitRef="usd">13835000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-17" decimals="-3" id="f-486" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-17" decimals="-3" id="f-487" unitRef="usd">-6160000</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-52" decimals="-3" id="f-488" unitRef="usd">7675000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ContractWithCustomerLiability contextRef="c-19" decimals="-3" id="f-489" unitRef="usd">863520000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions contextRef="c-1" decimals="-3" id="f-490" unitRef="usd">365150000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions contextRef="c-1" decimals="-3" id="f-491" unitRef="usd">28849000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability contextRef="c-18" decimals="-3" id="f-492" unitRef="usd">1199821000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-68" decimals="-3" id="f-493" unitRef="usd">549551000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions contextRef="c-17" decimals="-3" id="f-494" unitRef="usd">414816000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions contextRef="c-17" decimals="-3" id="f-495" unitRef="usd">56957000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability contextRef="c-52" decimals="-3" id="f-496" unitRef="usd">907410000</us-gaap:ContractWithCustomerLiability>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-17" decimals="INF" id="f-497" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-16" decimals="INF" id="f-498" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-15" decimals="INF" id="f-499" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-1" decimals="INF" id="f-500" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-17" decimals="-5" id="f-501" unitRef="usd">-6200000</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <nvax:ContractWithCustomerLiabilityDeductions contextRef="c-116" decimals="-5" id="f-502" unitRef="usd">2200000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:GrantsReceivable contextRef="c-117" decimals="-5" id="f-503" unitRef="usd">225000000</us-gaap:GrantsReceivable>
    <nvax:RemainingPerformanceObligationAmount contextRef="c-18" decimals="-9" id="f-504" unitRef="usd">2000000000</nvax:RemainingPerformanceObligationAmount>
    <us-gaap:ContractWithCustomerLiability contextRef="c-18" decimals="-8" id="f-505" unitRef="usd">1200000000</us-gaap:ContractWithCustomerLiability>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-118" decimals="-6" id="f-506" unitRef="usd">700000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-119" decimals="-5" id="f-507" unitRef="usd">696400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-120" decimals="-6" id="f-508" unitRef="usd">75000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementExpense contextRef="c-120" decimals="-6" id="f-509" unitRef="usd">80000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-121" decimals="-6" id="f-510" unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GrantsReceivable contextRef="c-117" decimals="-5" id="f-511" unitRef="usd">225000000</us-gaap:GrantsReceivable>
    <us-gaap:LitigationSettlementExpense contextRef="c-120" decimals="-6" id="f-512" unitRef="usd">80000000</us-gaap:LitigationSettlementExpense>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-118" decimals="-6" id="f-513" unitRef="usd">700000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-120" decimals="-6" id="f-514" unitRef="usd">75000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementExpense contextRef="c-121" decimals="-6" id="f-515" unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GrantsReceivable contextRef="c-117" decimals="-5" id="f-516" unitRef="usd">225000000</us-gaap:GrantsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-517" unitRef="usd">-3600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-119" decimals="-5" id="f-518" unitRef="usd">696400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-118" decimals="-6" id="f-519" unitRef="usd">700000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:GrantsReceivable contextRef="c-122" decimals="-6" id="f-520" unitRef="usd">225000000</us-gaap:GrantsReceivable>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-122" decimals="-5" id="f-521" unitRef="usd">90000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-122" decimals="-5" id="f-522" unitRef="usd">305000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,645&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218,921&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c-123" decimals="-3" id="f-524" unitRef="usd">1607000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-124" decimals="-3" id="f-525" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-125" decimals="-3" id="f-526" unitRef="usd">-4755000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-126" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-127" decimals="-3" id="f-528" unitRef="usd">169000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-128" decimals="-3" id="f-529" unitRef="usd">1518000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-129" decimals="-3" id="f-530" unitRef="usd">90586000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-130" decimals="-3" id="f-531" unitRef="usd">58785000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-131" decimals="-3" id="f-532" unitRef="usd">18128000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-132" decimals="-3" id="f-533" unitRef="usd">283645000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-133" decimals="-3" id="f-534" unitRef="usd">16397000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-134" decimals="-3" id="f-535" unitRef="usd">218921000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-3" id="f-536" unitRef="usd">19904000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-537" unitRef="usd">285163000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-538" unitRef="usd">102228000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-539" unitRef="usd">277706000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-125" decimals="-5" id="f-540" unitRef="usd">-4800000</us-gaap:Revenues>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-541" unitRef="usd">-3600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, changes in the Company&#x2019;s gross-to-net deductions balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Wholesale Distributor Fees, Discounts, and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts charged against product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits/deductions &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Amounts charged against product sales include $4.0&#160;million of adjustments made to prior period product sales due primarily to changes in the estimate of product returns.</nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-135" decimals="-3" id="f-543" unitRef="usd">21072000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-136" decimals="-3" id="f-544" unitRef="usd">84616000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-137" decimals="-3" id="f-545" unitRef="usd">105688000</us-gaap:ContractWithCustomerLiability>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-138" decimals="-3" id="f-546" unitRef="usd">15436000</nvax:AmountsChargedAgainstProductSales>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-139" decimals="-3" id="f-547" unitRef="usd">21302000</nvax:AmountsChargedAgainstProductSales>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-5" decimals="-3" id="f-548" unitRef="usd">36738000</nvax:AmountsChargedAgainstProductSales>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-138" decimals="-3" id="f-549" unitRef="usd">-35621000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-139" decimals="-3" id="f-550" unitRef="usd">-51331000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-551" unitRef="usd">-86952000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-140" decimals="-3" id="f-552" unitRef="usd">887000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-141" decimals="-3" id="f-553" unitRef="usd">54587000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-142" decimals="-3" id="f-554" unitRef="usd">55474000</us-gaap:ContractWithCustomerLiability>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-15" decimals="-5" id="f-555" unitRef="usd">4000000</nvax:AmountsChargedAgainstProductSales>
    <us-gaap:ContractWithCustomerLiability contextRef="c-143" decimals="INF" id="f-556" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-144" decimals="-5" id="f-557" unitRef="usd">2600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-145" decimals="-5" id="f-558" unitRef="usd">55500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-146" decimals="-5" id="f-559" unitRef="usd">103100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-147" decimals="-5" id="f-560" unitRef="usd">-54000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <nvax:SettlementPayment contextRef="c-148" decimals="-5" id="f-561" unitRef="usd">6000000.0</nvax:SettlementPayment>
    <us-gaap:ContractWithCustomerLiability contextRef="c-149" decimals="-6" id="f-562" unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-150" decimals="-5" id="f-563" unitRef="usd">119100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-150" decimals="-5" id="f-564" unitRef="usd">14700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-151" decimals="-5" id="f-565" unitRef="usd">92500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-151" decimals="-6" id="f-566" unitRef="usd">225000000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-152" decimals="-5" id="f-567" unitRef="usd">452100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-152" decimals="-5" id="f-568" unitRef="usd">136100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-153" decimals="-5" id="f-569" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-153" decimals="-6" id="f-570" unitRef="usd">224000000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-154" decimals="-5" id="f-571" unitRef="usd">31300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-155" decimals="-6" id="f-572" unitRef="usd">125000000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:Revenues contextRef="c-156" decimals="-5" id="f-573" unitRef="usd">386300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-157" decimals="-5" id="f-574" unitRef="usd">390300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-158" decimals="-5" id="f-575" unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-159" decimals="-5" id="f-576" unitRef="usd">10200000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-160" decimals="-5" id="f-577" unitRef="usd">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-5" id="f-578" unitRef="usd">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-162" decimals="-5" id="f-579" unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-163" decimals="-5" id="f-580" unitRef="usd">3200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-164" decimals="-8" id="f-581" unitRef="usd">1800000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:RoyaltyPeriod contextRef="c-15" id="f-582">P15Y</nvax:RoyaltyPeriod>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-165" decimals="-6" id="f-583" unitRef="dose">150000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentReceived contextRef="c-74" decimals="-6" id="f-584" unitRef="usd">500000000</nvax:CollaborationAgreementUpfrontPaymentReceived>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-166" decimals="-6" id="f-585" unitRef="usd">700000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-167" decimals="-6" id="f-586" unitRef="usd">175000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-168" decimals="-6" id="f-587" unitRef="usd">25000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-169" decimals="-6" id="f-588" unitRef="usd">25000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-170" decimals="-6" id="f-589" unitRef="usd">50000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-171" decimals="-6" id="f-590" unitRef="usd">75000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-172" decimals="-6" id="f-591" unitRef="usd">350000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-173" decimals="-6" id="f-592" unitRef="usd">200000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments contextRef="c-174" decimals="-6" id="f-593" unitRef="usd">210000000</nvax:ProceedsDevelopmentTechTransferLaunchAndSalesMilestoneCollaborationPayments>
    <nvax:CollaborationAgreementInitialTransactionPrice contextRef="c-74" decimals="-5" id="f-594" unitRef="usd">620200000</nvax:CollaborationAgreementInitialTransactionPrice>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-175" decimals="-6" id="f-595" unitRef="usd">500000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementVariableConsideration contextRef="c-74" decimals="-5" id="f-596" unitRef="usd">120200000</nvax:CollaborationAgreementVariableConsideration>
    <us-gaap:Revenues contextRef="c-176" decimals="-5" id="f-597" unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-177" decimals="-5" id="f-598" unitRef="usd">70200000</us-gaap:Revenues>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-175" decimals="-6" id="f-599" unitRef="usd">500000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:Revenues contextRef="c-178" decimals="-5" id="f-600" unitRef="usd">386300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-179" decimals="-5" id="f-601" unitRef="usd">110200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-180" decimals="-5" id="f-602" unitRef="usd">3500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-160" decimals="-5" id="f-603" unitRef="usd">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-5" id="f-604" unitRef="usd">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue contextRef="c-18" decimals="-5" id="f-605" unitRef="usd">109200000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-181" decimals="-5" id="f-606" unitRef="usd">50900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-181" decimals="-5" id="f-607" unitRef="usd">58300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-182" decimals="-5" id="f-608" unitRef="usd">35000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-183" decimals="-5" id="f-609" unitRef="usd">27100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-184"
      decimals="INF"
      id="f-610"
      unitRef="shares">6880481</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-185"
      decimals="INF"
      id="f-611"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-185"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-184" decimals="-5" id="f-613" unitRef="usd">68800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-185"
      decimals="2"
      id="f-614"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <nvax:CollaborativeArrangementTerm contextRef="c-186" id="f-615">P3Y</nvax:CollaborativeArrangementTerm>
    <nvax:SettlementPayment contextRef="c-187" decimals="-5" id="f-616" unitRef="usd">185000000.0</nvax:SettlementPayment>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-122"
      decimals="INF"
      id="f-617"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:SettlementPayment contextRef="c-188" decimals="-5" id="f-618" unitRef="usd">68600000</nvax:SettlementPayment>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-122"
      decimals="INF"
      id="f-619"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-122"
      decimals="INF"
      id="f-620"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:SettlementPayment contextRef="c-189" decimals="-5" id="f-621" unitRef="usd">42000000.0</nvax:SettlementPayment>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-190" decimals="-5" id="f-622" unitRef="usd">26600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-623">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss), basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss), dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities excluded from calculations of diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-624">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net income (loss) per share were calculated as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss), basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss), dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities excluded from calculations of diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-625" unitRef="usd">162381000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-626" unitRef="usd">58008000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-627" unitRef="usd">14831000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-17" decimals="-3" id="f-628" unitRef="usd">-235897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-15" decimals="-3" id="f-629" unitRef="usd">2608000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-16" decimals="-3" id="f-630" unitRef="usd">2582000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-15" decimals="-3" id="f-631" unitRef="usd">164989000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-16" decimals="-3" id="f-632" unitRef="usd">60590000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-1" decimals="-3" id="f-633" unitRef="usd">14831000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-17" decimals="-3" id="f-634" unitRef="usd">-235897000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-635" unitRef="shares">148379000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-3" id="f-636" unitRef="shares">89362000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-637" unitRef="shares">144147000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-3" id="f-638" unitRef="shares">87769000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-15" decimals="-3" id="f-639" unitRef="shares">17476000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-16" decimals="-3" id="f-640" unitRef="shares">14703000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-641" unitRef="shares">974000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-17" decimals="-3" id="f-642" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-643" unitRef="shares">165855000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-3" id="f-644" unitRef="shares">104065000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-645" unitRef="shares">145121000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-3" id="f-646" unitRef="shares">87769000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-649"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-650"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-651"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-652"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-653"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-15" decimals="-3" id="f-655" unitRef="shares">4544000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="-3" id="f-656" unitRef="shares">6791000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-657" unitRef="shares">21654000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-17" decimals="-3" id="f-658" unitRef="shares">23447000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c-1" id="f-659">Cash, Cash Equivalents, and Restricted Cash&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as Other non-current assets as of June&#160;30, 2024 and December&#160;31, 2023, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-660">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sums to the total of such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Classified as Other non-current assets as of June&#160;30, 2024 and December&#160;31, 2023, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-18" decimals="-3" id="f-661" unitRef="usd">680162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-662" unitRef="usd">568505000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-18" decimals="-3" id="f-663" unitRef="usd">10486000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-664" unitRef="usd">10424000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-18" decimals="-3" id="f-665" unitRef="usd">4910000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-19" decimals="-3" id="f-666" unitRef="usd">4881000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-667" unitRef="usd">695558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-668" unitRef="usd">583810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-669">Inventory&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.555%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments, offset by recoveries of such commitments, are recorded as a component of cost of sales in the Company&#x2019;s consolidated statements of operations. For the three and six months ended June&#160;30, 2024, inventory write-downs were $9.7&#160;million and $18.5&#160;million, respectively, and losses on firm purchase commitments were $1.7&#160;million. For the three and six months ended June&#160;30, 2023, inventory write-downs were $19.1&#160;million and $31.5&#160;million, respectively, and losses on firm purchase commitments were $0.7&#160;million and $8.5&#160;million. In addition, for the three and six months ended June&#160;30, 2023 the Company recorded recoveries on firm purchase commitments of $17.9&#160;million and $18.8&#160;million, respectively, related primarily to negotiated reductions to previously recognized firm purchase commitments</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.555%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-18" decimals="-3" id="f-671" unitRef="usd">1406000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-19" decimals="-3" id="f-672" unitRef="usd">6614000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-18" decimals="-3" id="f-673" unitRef="usd">7587000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-19" decimals="-3" id="f-674" unitRef="usd">7392000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-18" decimals="-3" id="f-675" unitRef="usd">179000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-19" decimals="-3" id="f-676" unitRef="usd">27690000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-3" id="f-677" unitRef="usd">9172000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-3" id="f-678" unitRef="usd">41696000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c-15" decimals="-5" id="f-679" unitRef="usd">9700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-680" unitRef="usd">18500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-1" decimals="-5" id="f-681" unitRef="usd">1700000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-15" decimals="-5" id="f-682" unitRef="usd">1700000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown contextRef="c-16" decimals="-5" id="f-683" unitRef="usd">19100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-17" decimals="-5" id="f-684" unitRef="usd">31500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-16" decimals="-5" id="f-685" unitRef="usd">700000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-17" decimals="-5" id="f-686" unitRef="usd">8500000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <nvax:InventoryFirmPurchaseCommitmentRecoveries contextRef="c-16" decimals="-5" id="f-687" unitRef="usd">17900000</nvax:InventoryFirmPurchaseCommitmentRecoveries>
    <nvax:InventoryFirmPurchaseCommitmentRecoveries contextRef="c-17" decimals="-5" id="f-688" unitRef="usd">18800000</nvax:InventoryFirmPurchaseCommitmentRecoveries>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-689">Goodwill&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reporting unit, which has a negative carrying amount as of June&#160;30, 2024 and December&#160;31, 2023. The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2024 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-191"
      decimals="INF"
      id="f-690"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-691"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-692">The change in the carrying amounts of goodwill for the six months ended June&#160;30, 2024 was as follows (in thousands):&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-19" decimals="-3" id="f-693" unitRef="usd">127454000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-694" unitRef="usd">-4077000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-18" decimals="-3" id="f-695" unitRef="usd">123377000</us-gaap:Goodwill>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-696">Long-Term Debt&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate of the 2027 Convertible notes is 6.2%. During the six months ended June&#160;30, 2023, the Company repaid the outstanding principal amount of $325.0&#160;million on its 3.75% Convertible notes due in 2023, together with accrued &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;but unpaid interest on the maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense incurred in connection with the convertible notes payable&#160;consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon interest &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c-1" id="f-697">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-107"
      decimals="INF"
      id="f-698"
      unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-192" decimals="-3" id="f-699" unitRef="usd">175250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-193" decimals="-3" id="f-700" unitRef="usd">175250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-18" decimals="-3" id="f-701" unitRef="usd">6402000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-19" decimals="-3" id="f-702" unitRef="usd">7234000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-18" decimals="-3" id="f-703" unitRef="usd">168848000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-19" decimals="-3" id="f-704" unitRef="usd">168016000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-192" decimals="3" id="f-705" unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:RepaymentsOfDebt contextRef="c-194" decimals="-5" id="f-706" unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-195"
      decimals="INF"
      id="f-707"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock contextRef="c-1" id="f-708">&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense incurred in connection with the convertible notes payable&#160;consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon interest &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-15" decimals="-3" id="f-709" unitRef="usd">2192000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-16" decimals="-3" id="f-710" unitRef="usd">2191000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">4384000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-17" decimals="-3" id="f-712" unitRef="usd">5397000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-15" decimals="-3" id="f-713" unitRef="usd">416000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-16" decimals="-3" id="f-714" unitRef="usd">391000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-715" unitRef="usd">832000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-17" decimals="-3" id="f-716" unitRef="usd">900000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseDebt contextRef="c-15" decimals="-3" id="f-717" unitRef="usd">2608000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-16" decimals="-3" id="f-718" unitRef="usd">2582000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-719" unitRef="usd">5216000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-17" decimals="-3" id="f-720" unitRef="usd">6297000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-721">Stockholders&#x2019; Deficit&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;August 2023 Sales Agreement&#x201d;), which allows it to issue and sell up to $500&#160;million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#x201c;June 2021 Sales Agreement&#x201d;). During the three and six months ended June&#160;30, 2024, the Company sold $12&#160;million shares of its common stock resulting in net proceeds of approximately $188&#160;million, under the August 2023 Sales Agreement. As of June&#160;30, 2024, the remaining balance available under the August 2023 Sales Agreement was approximately $51&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2023, the Company sold &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; million shares of its common stock under its June 2021 Sales Agreement resulting in net proceeds of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$68&#160;million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of which $6&#160;million was included in prepaid expenses and other current assets as of June&#160;30, 2023 and received in cash in July 2023.&lt;/span&gt;&lt;/div&gt;In May 2024, the Company also entered into the Subscription Agreement, pursuant to which the Company sold and issued to Sanofi, in a private placement, 6,880,481 shares of the Company&#x2019;s common stock, par value $0.01 per share at a price of $10.00 per share for aggregate gross proceeds to the Company of $68.8&#160;million.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-196" decimals="-6" id="f-722" unitRef="usd">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-197"
      decimals="-5"
      id="f-723"
      unitRef="shares">12000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-198"
      decimals="-5"
      id="f-724"
      unitRef="shares">12000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-198" decimals="-6" id="f-725" unitRef="usd">188000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <nvax:SaleOfStockAmountOfRemainingUnissuedShares contextRef="c-199" decimals="-6" id="f-726" unitRef="usd">51000000</nvax:SaleOfStockAmountOfRemainingUnissuedShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-200"
      decimals="-5"
      id="f-727"
      unitRef="shares">7900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-201"
      decimals="-5"
      id="f-728"
      unitRef="shares">7900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-200" decimals="-6" id="f-729" unitRef="usd">68000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-201" decimals="-6" id="f-730" unitRef="usd">68000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssued1 contextRef="c-17" decimals="-6" id="f-731" unitRef="usd">6000000</us-gaap:StockIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-202"
      decimals="-3"
      id="f-732"
      unitRef="shares">6880481000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-203"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-203"
      decimals="2"
      id="f-734"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-202" decimals="-5" id="f-735" unitRef="usd">68800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-736">Stock-Based Compensation &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company established the 2023 Inducement Plan (the &#x201c;2023 Inducement Plan&#x201d;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved 1.0&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of June&#160;30, 2024, there were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares available for issuance under the 2023 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Stock Incentive Plan, as amended (&#x201c;2015 Plan&#x201d;), was approved at the Company&#x2019;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan authorizes the issuance of up to 27.5&#160;million shares of common stock under equity awards granted under the 2015 Plan. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on April&#160;18, 2034. As of June&#160;30, 2024, there were 9.4&#160;million shares available for issuance under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Plan&#x201d;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Inducement Plan and the 2015 Plan permit, and the 2005 Plan permitted, the grant of stock options (including incentive stock options), restricted stock, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock units (&#x201c;RSUs&#x201d;). In addition, under the 2023 Inducement Plan and the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#x2019;s common stock at the time of grant. Grants of share-based awards are generally subject to vesting over periods ranging from &lt;span style="-sec-ix-hidden:f-743"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.939%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2024 and 2023, there was no stock-based compensation expense capitalized into inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, there was approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$73&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately one year and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#x2019;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option&#160;and SAR holders exercised their stock options and SARs on June&#160;30, 2024. This amount is subject to change based on changes to the closing price of the Company's common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the six&#160;months ended June&#160;30, 2024 and 2023 was approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan, and 2005 Plan for the six&#160;months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 Inducement&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2005&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,787,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;703,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(329,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(518,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(57,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,076,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.939%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average Black-Scholes fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%-3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%-4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4%-131.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.3%-121.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.4%-140.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $12.3&#160;million and 7.0 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of June&#160;30, 2024 was $3.7&#160;million and 6.0 years, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 Inducement&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,714,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,441,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(921,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(605,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,629,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP was approved at the Company&#x2019;s annual meeting of stockholders in June 2013. The ESPP currently authorizes an aggregate of 2.2 million shares of common stock to be purchased, and the aggregate number of shares will continue to increase 5% on January 1 of each year up to a maximum of 3.5 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). As of June&#160;30, 2024, there were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-204"
      decimals="-5"
      id="f-737"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance
      contextRef="c-205"
      decimals="-5"
      id="f-738"
      unitRef="shares">200000</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-206"
      decimals="-5"
      id="f-739"
      unitRef="shares">27500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance
      contextRef="c-206"
      decimals="-5"
      id="f-740"
      unitRef="shares">9400000</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-207" id="f-741">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent contextRef="c-208" decimals="2" id="f-742" unitRef="number">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-210" id="f-744">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-745">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.939%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-3" id="f-746" unitRef="usd">1104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-3" id="f-747" unitRef="usd">998000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-3" id="f-748" unitRef="usd">1698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-3" id="f-749" unitRef="usd">1516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="-3" id="f-750" unitRef="usd">6177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-216" decimals="-3" id="f-751" unitRef="usd">9946000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-217" decimals="-3" id="f-752" unitRef="usd">11682000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-218" decimals="-3" id="f-753" unitRef="usd">23804000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-219" decimals="-3" id="f-754" unitRef="usd">6818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-220" decimals="-3" id="f-755" unitRef="usd">9348000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-221" decimals="-3" id="f-756" unitRef="usd">12275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-222" decimals="-3" id="f-757" unitRef="usd">23619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-758" unitRef="usd">14099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-3" id="f-759" unitRef="usd">20292000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-760" unitRef="usd">25655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-3" id="f-761" unitRef="usd">48939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-18" decimals="-6" id="f-762" unitRef="usd">73000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-763">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-15" decimals="-5" id="f-764" unitRef="usd">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-765" unitRef="usd">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-16" decimals="-5" id="f-766" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-17" decimals="-5" id="f-767" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-768">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan, and 2005 Plan for the six&#160;months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 Inducement&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2005&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,787,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;703,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(329,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(518,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(57,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,076,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-223"
      decimals="INF"
      id="f-769"
      unitRef="shares">422800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-223"
      decimals="2"
      id="f-770"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-224"
      decimals="INF"
      id="f-771"
      unitRef="shares">4787042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-224"
      decimals="2"
      id="f-772"
      unitRef="usdPerShare">38.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-225"
      decimals="INF"
      id="f-773"
      unitRef="shares">58275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-225"
      decimals="2"
      id="f-774"
      unitRef="usdPerShare">119.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-226"
      decimals="INF"
      id="f-775"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-226"
      decimals="2"
      id="f-776"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-227"
      decimals="INF"
      id="f-777"
      unitRef="shares">703777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-227"
      decimals="2"
      id="f-778"
      unitRef="usdPerShare">7.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-228"
      decimals="INF"
      id="f-779"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-228"
      decimals="2"
      id="f-780"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-226"
      decimals="INF"
      id="f-781"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-226"
      decimals="2"
      id="f-782"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-227"
      decimals="INF"
      id="f-783"
      unitRef="shares">329354</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-227"
      decimals="2"
      id="f-784"
      unitRef="usdPerShare">8.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-228"
      decimals="INF"
      id="f-785"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-228"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-226"
      decimals="INF"
      id="f-787"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-226"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-227"
      decimals="INF"
      id="f-789"
      unitRef="shares">518519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-227"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">46.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-228"
      decimals="INF"
      id="f-791"
      unitRef="shares">57831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-228"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">119.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-205"
      decimals="INF"
      id="f-793"
      unitRef="shares">422800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-205"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-206"
      decimals="INF"
      id="f-795"
      unitRef="shares">4642946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-206"
      decimals="2"
      id="f-796"
      unitRef="usdPerShare">34.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-229"
      decimals="INF"
      id="f-797"
      unitRef="shares">444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-229"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">108.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-205"
      decimals="INF"
      id="f-799"
      unitRef="shares">124174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-205"
      decimals="2"
      id="f-800"
      unitRef="usdPerShare">11.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-206"
      decimals="INF"
      id="f-801"
      unitRef="shares">3076820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-206"
      decimals="2"
      id="f-802"
      unitRef="usdPerShare">43.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-229"
      decimals="INF"
      id="f-803"
      unitRef="shares">444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-229"
      decimals="2"
      id="f-804"
      unitRef="usdPerShare">108.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-805">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.939%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average Black-Scholes fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%-3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%-4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4%-131.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.3%-121.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.4%-140.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-230"
      decimals="2"
      id="f-806"
      unitRef="usdPerShare">14.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-231"
      decimals="2"
      id="f-807"
      unitRef="usdPerShare">6.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-232"
      decimals="2"
      id="f-808"
      unitRef="usdPerShare">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-809"
      unitRef="usdPerShare">7.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-230" decimals="3" id="f-810" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-231" decimals="3" id="f-811" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-231" decimals="3" id="f-812" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-232" decimals="3" id="f-813" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-233" decimals="3" id="f-814" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-233" decimals="3" id="f-815" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-230"
      decimals="INF"
      id="f-816"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-231"
      decimals="INF"
      id="f-817"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-232"
      decimals="INF"
      id="f-818"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-233"
      decimals="INF"
      id="f-819"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-230" decimals="3" id="f-820" unitRef="number">1.218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-231" decimals="3" id="f-821" unitRef="number">1.204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-231" decimals="3" id="f-822" unitRef="number">1.313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-232" decimals="3" id="f-823" unitRef="number">1.143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-232" decimals="3" id="f-824" unitRef="number">1.218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-233" decimals="3" id="f-825" unitRef="number">1.204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-233" decimals="3" id="f-826" unitRef="number">1.403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-234" id="f-827">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-235" id="f-828">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-236" id="f-829">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-237" id="f-830">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-238" id="f-831">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-239" id="f-832">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-240" id="f-833">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-18" decimals="-5" id="f-834" unitRef="usd">12300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-835">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-206" decimals="-5" id="f-836" unitRef="usd">3700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-227" id="f-837">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock contextRef="c-1" id="f-838">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the six&#160;months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 Inducement&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per&#160;Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,714,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,441,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(921,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(605,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,629,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;/span&gt;&lt;/div&gt;</nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-241"
      decimals="INF"
      id="f-839"
      unitRef="shares">363990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-241"
      decimals="2"
      id="f-840"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-242"
      decimals="INF"
      id="f-841"
      unitRef="shares">3714870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-242"
      decimals="2"
      id="f-842"
      unitRef="usdPerShare">19.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-243"
      decimals="INF"
      id="f-843"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-243"
      decimals="2"
      id="f-844"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-244"
      decimals="INF"
      id="f-845"
      unitRef="shares">4441935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-244"
      decimals="2"
      id="f-846"
      unitRef="usdPerShare">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-243"
      decimals="INF"
      id="f-847"
      unitRef="shares">102797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-243"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-244"
      decimals="INF"
      id="f-849"
      unitRef="shares">921832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-244"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">24.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-243"
      decimals="INF"
      id="f-851"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-243"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-244"
      decimals="INF"
      id="f-853"
      unitRef="shares">605480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-244"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-245"
      decimals="INF"
      id="f-855"
      unitRef="shares">261193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-245"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">10.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-246"
      decimals="INF"
      id="f-857"
      unitRef="shares">6629493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-246"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-247"
      decimals="-5"
      id="f-859"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease contextRef="c-248" decimals="2" id="f-860" unitRef="number">0.05</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-248"
      decimals="-5"
      id="f-861"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-248" decimals="2" id="f-862" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="c-249" decimals="2" id="f-863" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-248"
      decimals="-5"
      id="f-864"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-865">Income Taxes&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. Significant pieces of objective evidence evaluated by the Company were the cumulative loss incurred over the three-year period ended June&#160;30, 2024 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June&#160;30, 2024, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent Net Operating Losses (&#x201c;NOLs&#x201d;) have been used to reduce taxable income. As of June&#160;30, 2024, the Company has $2.3&#160;billion of U.S. Federal NOLs carryforward, and all are subject to limitation in accordance with the 2017 Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;), which limits allowable NOL deductions to 80% of federal taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2024 and 2023, the Company recognized $2.2&#160;million and $(0.1)&#160;million of federal, state, and foreign income tax expense (benefit), respectively. During the six months ended June&#160;30, 2024 and 2023, the Company recognized $4.5&#160;million and $1.0&#160;million of federal, state, and foreign income tax expense, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-250" decimals="-8" id="f-866" unitRef="usd">2300000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-867" unitRef="usd">2200000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-868" unitRef="usd">-100000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-869" unitRef="usd">4500000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-870" unitRef="usd">1000000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-871">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stockholder Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#x201c;Maryland Court&#x201d;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#x201c;Sinnathurai Action&#x201d;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#x2019;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#x2019;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#x2019;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#x2019; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. The Company filed its opposition to the plaintiffs&#x2019; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#x201c;Proposed Settlement&#x201d;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#x2019;s terms, the Company agreed to pay $47&#160;million into a settlement fund, which will be funded by the Company&#x2019;s directors and officers&#x2019; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#x2019;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024. Ahead of the May 23 settlement hearing, on April 11, 2024, Plaintiffs filed a motion seeking the Maryland Court&#x2019;s final approval of the settlement. At the May 23 settlement hearing, the Maryland Court granted final approval of the settlement. The Maryland Court closed the Sinnathurai Action on May 24, 2024. Upon the Maryland Court&#x2019;s final approval, the Company relieved the $47&#160;million estimated settlement liability within Accrued expenses and the $47&#160;million estimated insurance recovery within Prepaid expenses and other current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#x201c;Meyer Action&#x201d;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#x201c;Yung Action&#x201d;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#x201c;Kirst Action&#x201d;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#x201c;Snyder Action&#x201d;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#x201c;Blackburn Action&#x201d;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#x201c;Mesa Action&#x201d;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#x201c;Acosta Action&#x201d;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#x201c;Needelman Action&#x201d;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst Action was filed in the Circuit Court for Montgomery County, Maryland, and shortly thereafter removed to the Maryland Court by the defendants. The Needleman Action was also filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#x201c;Delaware Court&#x201d;). The derivative lawsuits name members of the Company&#x2019;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#x201c;First Consolidated Derivative Action&#x201d;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#x201c;Second Consolidated Derivative Action&#x201d;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#x201c;SLC&#x201d;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#x2019;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#x2019; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order, and, on April 15, 2024, the court entered a further order extending the stay until June 6, 2024. On June 7, 2024, the court entered another order extending the stay until August 5, 2024. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint. On August 5, 2024, the parties agreed to a further 90-day extension to November 4, 2024, which remains subject to court approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#x2019;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#x2019; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#x2019; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 9, 2023, following the ruling on the motion to dismiss the Sinnathurai Action, the Delaware Court entered an order granting the Mesa Action parties&#x2019; request to set a briefing schedule in connection with a motion to stay by defendants. On February 28, 2023, the court granted the defendants&#x2019; motion and stayed the Mesa Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On August 31, 2023, the Mesa plaintiffs filed a motion to lift the stay in the Mesa Action. On October 6, 2023, the Company filed an opposition to plaintiff&#x2019;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#x2019; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#x2019;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#x2019; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#x2019; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#x2019;s investigation. On May 3, 2024, the plaintiffs filed a consolidated complaint. On May 14, 2024, the parties filed a stipulation staying the action until June 6, 2024. On July 12, 2024, the court entered an order staying the action until August 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial impact of the above derivative claims is not reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c-251"
      decimals="INF"
      id="f-872"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <nvax:LossContingencyPeriodToAnswer contextRef="c-251" id="f-873">P14D</nvax:LossContingencyPeriodToAnswer>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-252" decimals="-6" id="f-874" unitRef="usd">47000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-252" decimals="-6" id="f-875" unitRef="usd">47000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-18" decimals="-6" id="f-876" unitRef="usd">47000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-253"
      decimals="INF"
      id="f-877"
      unitRef="lawsuit">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <nvax:LossContingencyExtensionPeriod contextRef="c-254" id="f-878">P90D</nvax:LossContingencyExtensionPeriod>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-879">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring &lt;/span&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company announced a global restructuring and cost reduction plan (the &#x201c;2023 Restructuring Plan&#x201d;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#x2019;s global workforce, as well as the consolidation of facilities and infrastructure. In January 2024, the Company announced further reductions to its global workforce which supplemented the 2023 Restructuring Plan and both are jointly referred to as the &#x201c;Restructuring Plan.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following restructuring charge related to the Restructuring Plan in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Restructuring charge &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Restructuring charges of $0.5&#160;million, $0.3&#160;million and $0.3&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $1.9&#160;million and $4.8&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the six months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $2.7&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three and six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the reporting period and had no requirements for future service. The Company paid a total of $5.5&#160;million for the severance and employee benefit costs during the six months ended June&#160;30, 2024 and had no remaining liability as of June&#160;30, 2024 or December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The Company performed an impairment evaluation for the applicable long-lived assets, which is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the six months ended June&#160;30, 2024, the Company recorded an impairment charge of $1.7&#160;million related to the impairment of capitalized internal-use software. During the three and six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded an impairment charge of $10.1&#160;million related to the impairment of &lt;/span&gt;&lt;/div&gt;long-lived assets, including $5.9&#160;million related to ROU assets for facility leases. The Company did not recognize any impairment of assets related restructuring charges during the three months ended June&#160;30, 2024.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-880">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following restructuring charge related to the Restructuring Plan in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Restructuring charge &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Restructuring charges of $0.5&#160;million, $0.3&#160;million and $0.3&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $1.9&#160;million and $4.8&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the six months ended June&#160;30, 2024. Restructuring charges of $0.5&#160;million, $2.7&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the three and six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2023&lt;/span&gt;.</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-15" decimals="-3" id="f-881" unitRef="usd">1119000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-16" decimals="-3" id="f-882" unitRef="usd">4643000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-3" id="f-883" unitRef="usd">5520000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-17" decimals="-3" id="f-884" unitRef="usd">4643000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-15" decimals="-3" id="f-885" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-16" decimals="-3" id="f-886" unitRef="usd">10081000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-887" unitRef="usd">1669000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-17" decimals="-3" id="f-888" unitRef="usd">10081000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-3" id="f-889" unitRef="usd">1119000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-16" decimals="-3" id="f-890" unitRef="usd">14724000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-891" unitRef="usd">7189000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-17" decimals="-3" id="f-892" unitRef="usd">14724000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-211" decimals="-5" id="f-893" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-215" decimals="-5" id="f-894" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-219" decimals="-5" id="f-895" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-213" decimals="-5" id="f-896" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-217" decimals="-5" id="f-897" unitRef="usd">1900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-221" decimals="-5" id="f-898" unitRef="usd">4800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-212" decimals="-5" id="f-899" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-214" decimals="-5" id="f-900" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-216" decimals="-5" id="f-901" unitRef="usd">2700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-218" decimals="-5" id="f-902" unitRef="usd">2700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-220" decimals="-5" id="f-903" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-222" decimals="-5" id="f-904" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <nvax:PaymentsForSeveranceAndEmployeeBenefitCosts contextRef="c-1" decimals="-5" id="f-905" unitRef="usd">5500000</nvax:PaymentsForSeveranceAndEmployeeBenefitCosts>
    <us-gaap:SeveranceCosts1 contextRef="c-255" decimals="INF" id="f-906" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-5" id="f-907" unitRef="usd">1700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-16" decimals="-5" id="f-908" unitRef="usd">10100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-16" decimals="-5" id="f-909" unitRef="usd">5900000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-910">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2024, Pharmac provided notice of its termination of the New Zealand APA (see Note 5).&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-15" id="f-911">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-15" id="f-912">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-256" id="f-913">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;John C. Jacobs, President and Chief Executive Officer&lt;/span&gt;&lt;/div&gt;On May 28, 2024, John C. Jacobs, our President and Chief Executive Officer and a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Jacobs, acting through a broker, may sell up to an aggregate of 47,526 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 27, 2024 to April 30, 2025. The plan is scheduled to terminate on April 30, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Jacobs or the broker, or as otherwise provided in the plan.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-257" id="f-914">On May 28, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-257" id="f-915">John C. Jacobs</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-257" id="f-916">President and Chief Executive Officer and a member of our board of directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-257" id="f-917">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-258"
      decimals="INF"
      id="f-918"
      unitRef="shares">47526</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-257" id="f-919">April 30, 2025</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-259" id="f-920">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;John Trizzino, President and Chief Operating Officer&lt;/span&gt;&lt;/div&gt;On June 17, 2024, John Trizzino, our President and Chief Operating Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Trizzino, acting through a broker, may sell up to an aggregate of 218,669 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from September 16, 2024 to May 7, 2025. The plan is scheduled to terminate on May 7, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Trizzino or the broker, or as otherwise provided in the plan.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-260" id="f-921">On June 17, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-260" id="f-922">John Trizzino</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-260" id="f-923">President and Chief Operating Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-260" id="f-924">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-261"
      decimals="INF"
      id="f-925"
      unitRef="shares">218669</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-260" id="f-926">May 7, 2025</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-262" id="f-927">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Filip Dubovsky, MD, Former President, Research &amp;amp; Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2024 , Filip Dubovsky, MD, our former President, Research &amp;amp; Development, terminated a Rule 10b5-1 trading plan that he had originally adopted on December 12, 2023. The plan was for the sale of up to 13,365 shares of our common stock. Sales under the plan were scheduled to occur from March 15, 2024 to June 14, 2024.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrTerminationDate contextRef="c-263" id="f-928">May 10, 2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrIndName contextRef="c-263" id="f-929">Filip Dubovsky</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-263" id="f-930">MD, our former President</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-263" id="f-931">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-264"
      decimals="INF"
      id="f-932"
      unitRef="shares">13365</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
